Trial.source,Drug_1,canSAR_target_1,Drug_1_target_uniprots,InChI_1,InChIKey_1,SMILES_1,Drug_2,canSAR_target_2,Drug_2_target_uniprots,InChI_2,InChIKey_2,SMILES_2,Patient.population,Disease,Phase,PMID,Results,NCT.Number,Title,Acronym,URL
clinicaltrials.gov,cabozantinib,1081506,P08581,"InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)",ONIQOQHATWINJY-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5)cc3)c2cc1OC,13-cis-retinoic acid,,,,,,,advanced solid cancers,Phase 1,,,NCT03611595,Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors,,https://ClinicalTrials.gov/show/NCT03611595
clinicaltrials.gov,cabozantinib,1081506,P08581,"InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)",ONIQOQHATWINJY-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5)cc3)c2cc1OC,13-cis-retinoic acid,,,,,,,advanced solid cancers,Phase 1,,,NCT03611595,Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors,,https://ClinicalTrials.gov/show/NCT03611595
clinicaltrials.gov,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,177Lu-PSMA,,,,,,Metastatic Castration Resistant Prostate Cancer (mCRPC),,Phase 1,,,NCT03874884,,,
clinicaltrials.gov,AB154,,,,,,AB122,,,,,,,,Phase 1,,,NCT03628677,A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies,,https://ClinicalTrials.gov/show/NCT03628677
clinicaltrials.gov,AB154,,,,,,AB122,,,,,,,,Phase 1,,,NCT03628677,A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies,,https://ClinicalTrials.gov/show/NCT03628677
clinicaltrials.gov,AB928,,,,,,AB122,,,,,,,,Phase 1,,,NCT03629756,A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies,,https://ClinicalTrials.gov/show/NCT03629756
clinicaltrials.gov,AB928,,,,,,AB122,,,,,,,,Phase 1,,,NCT03629756,A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies,,https://ClinicalTrials.gov/show/NCT03629756
clinicaltrials.gov,SC-011,,,,,,ABBV-181,,,,,,,lung cancers,Phase 1,,,NCT03639194,A Study of SC-011 Alone and in Combination With ABBV-181 in Subjects With Relapsed or Refractory Small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT03639194
clinicaltrials.gov,SC-011,,,,,,ABBV-181,,,,,,,lung cancers,Phase 1,,,NCT03639194,A Study of SC-011 Alone and in Combination With ABBV-181 in Subjects With Relapsed or Refractory Small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT03639194
clinicaltrials.gov,necitumumab,,P00533,,,,abemaciclib,1211300,P11802;Q00534,"InChI=1S/C27H32F2N8/c1-5-35-8-10-36(11-9-35)16-19-6-7-24(30-14-19)33-27-31-15-22(29)25(34-27)20-12-21(28)26-23(13-20)37(17(2)3)18(4)32-26/h6-7,12-15,17H,5,8-11,16H2,1-4H3,(H,30,31,33,34)",UZWDCWONPYILKI-UHFFFAOYSA-N,CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)c4cc(F)c5nc(C)n(C(C)C)c5c4)nc2)CC1,,lung cancers,Phase 1,,,NCT02411591,A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC),,https://ClinicalTrials.gov/show/NCT02411591
clinicaltrials.gov,pembrolizumab,,Q15116,,,,abemaciclib,1211300,P11802;Q00534,"InChI=1S/C27H32F2N8/c1-5-35-8-10-36(11-9-35)16-19-6-7-24(30-14-19)33-27-31-15-22(29)25(34-27)20-12-21(28)26-23(13-20)37(17(2)3)18(4)32-26/h6-7,12-15,17H,5,8-11,16H2,1-4H3,(H,30,31,33,34)",UZWDCWONPYILKI-UHFFFAOYSA-N,CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)c4cc(F)c5nc(C)n(C(C)C)c5c4)nc2)CC1,,,,,,NCT03997448,Abemaciclib and pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149,,https://ClinicalTrials.gov/show/NCT03997448
clinicaltrials.gov,cabozantinib,1081506,P08581,"InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)",ONIQOQHATWINJY-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5)cc3)c2cc1OC,abiraterone,181093,P05093,"InChI=1S/C24H31NO/c1-23-11-9-18(26)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22,26H,6,8-12,14H2,1-2H3/t18-,19-,21-,22-,23-,24+/m0/s1",GZOSMCIZMLWJML-VJLLXTKPSA-N,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c5cccnc5,,prostate cancers,Phase 1,,,NCT01574937,XL-184+Abiraterone in Post-Chemo CRPC,,https://ClinicalTrials.gov/show/NCT01574937
clinicaltrials.gov,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,abiraterone,181093,P05093,"InChI=1S/C24H31NO/c1-23-11-9-18(26)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22,26H,6,8-12,14H2,1-2H3/t18-,19-,21-,22-,23-,24+/m0/s1",GZOSMCIZMLWJML-VJLLXTKPSA-N,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c5cccnc5,,prostate cancers,Phase 3,,,NCT03732820,Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer,,https://ClinicalTrials.gov/show/NCT03732820
clinicaltrials.gov,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,abiraterone,181093,P05093,"InChI=1S/C24H31NO/c1-23-11-9-18(26)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22,26H,6,8-12,14H2,1-2H3/t18-,19-,21-,22-,23-,24+/m0/s1",GZOSMCIZMLWJML-VJLLXTKPSA-N,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c5cccnc5,,prostate cancers,Phase 3,,,NCT03732820,Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer,,https://ClinicalTrials.gov/show/NCT03732820
clinicaltrials.gov,onapristone,319776,P06401,"InChI=1S/C29H39NO3/c1-28-18-25(19-5-8-21(9-6-19)30(2)3)27-23-12-10-22(32)17-20(23)7-11-24(27)26(28)13-15-29(28,33)14-4-16-31/h5-6,8-9,17,24-26,31,33H,4,7,10-16,18H2,1-3H3/t24-,25+,26-,28+,29+/m0/s1",IEXUMDBQLIVNHZ-YOUGDJEHSA-N,CN(C)c1ccc(cc1)[C@H]2C[C@]3(C)[C@@H](CC[C@]3(O)CCCO)[C@@H]4CCC5=CC(=O)CCC5=C24,abiraterone,181093,P05093,"InChI=1S/C24H31NO/c1-23-11-9-18(26)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22,26H,6,8-12,14H2,1-2H3/t18-,19-,21-,22-,23-,24+/m0/s1",GZOSMCIZMLWJML-VJLLXTKPSA-N,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c5cccnc5,,prostate cancers,Phase 1/2,,,NCT02049190,Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer,,https://ClinicalTrials.gov/show/NCT02049190
clinicaltrials.gov,sipuleucel-T,,,,,,abiraterone,181093,P05093,"InChI=1S/C24H31NO/c1-23-11-9-18(26)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22,26H,6,8-12,14H2,1-2H3/t18-,19-,21-,22-,23-,24+/m0/s1",GZOSMCIZMLWJML-VJLLXTKPSA-N,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c5cccnc5,,prostate cancers,Phase 2,,,NCT01487863,Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer,,https://ClinicalTrials.gov/show/NCT01487863
clinicaltrials.gov,AZD6738,,,,,,acalabrutinib,2014063,,"InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1",WDENQIQQYWYTPO-IBGZPJMESA-N,CC#CC(=O)N1CCC[C@H]1c2nc(c3ccc(cc3)C(=O)Nc4ccccn4)c5c(N)nccn25,,leukemia,Phase 1/2,,,NCT03328273,A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL),,https://ClinicalTrials.gov/show/NCT03328273
clinicaltrials.gov,pembrolizumab,,Q15116,,,,acalabrutinib,2014063,,"InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1",WDENQIQQYWYTPO-IBGZPJMESA-N,CC#CC(=O)N1CCC[C@H]1c2nc(c3ccc(cc3)C(=O)Nc4ccccn4)c5c(N)nccn25,,bladder cancers,Phase 2,,,NCT02351739,Study of the Combination of ACP-196 and pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer,KEYNOTE143,https://ClinicalTrials.gov/show/NCT02351739
clinicaltrials.gov,pembrolizumab,,Q15116,,,,acalabrutinib,2014063,,"InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1",WDENQIQQYWYTPO-IBGZPJMESA-N,CC#CC(=O)N1CCC[C@H]1c2nc(c3ccc(cc3)C(=O)Nc4ccccn4)c5c(N)nccn25,,lung cancers,Phase 2,,,NCT02448303,pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer,KEYNOTE166,https://ClinicalTrials.gov/show/NCT02448303
clinicaltrials.gov,acalabrutinib,2014063,,"InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1",WDENQIQQYWYTPO-IBGZPJMESA-N,CC#CC(=O)N1CCC[C@H]1c2nc(c3ccc(cc3)C(=O)Nc4ccccn4)c5c(N)nccn25,ACP-319,,,,,,,lymphoma;multiple myeloma,Phase 1/2,,,NCT02328014,"ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies",,https://ClinicalTrials.gov/show/NCT02328014
clinicaltrials.gov,BI 836845,,,,,,afatinib,755714,O14578;O14976;O15197;O43353;O94804;P00519;P00533;P04626;P06239;P08581;P08631;P12931;P15735;P21860;P30530;P36888;P42681;P42685;P45984;P49674;P51451;P51617;P53779;Q13163;Q13627;Q15303;Q16539;Q16816;Q52WX2;Q8NE63;Q92630;Q9BUB5;Q9H2G2;Q9HBH9;Q9UEE5;Q9UF33;Q9UK32;Q9Y463,"InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1",ULXXDDBFHOBEHA-CWDCEQMOSA-N,CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]4CCOC4,,lung cancers,Phase 1,,,NCT02191891,Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC),,https://ClinicalTrials.gov/show/NCT02191891
clinicaltrials.gov,cetuximab,9,P00533,,,,afatinib,755714,O14578;O14976;O15197;O43353;O94804;P00519;P00533;P04626;P06239;P08581;P08631;P12931;P15735;P21860;P30530;P36888;P42681;P42685;P45984;P49674;P51451;P51617;P53779;Q13163;Q13627;Q15303;Q16539;Q16816;Q52WX2;Q8NE63;Q92630;Q9BUB5;Q9H2G2;Q9HBH9;Q9UEE5;Q9UF33;Q9UK32;Q9Y463,"InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1",ULXXDDBFHOBEHA-CWDCEQMOSA-N,CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]4CCOC4,,advanced solid cancers,Phase 1,,,NCT02020577,Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours,,https://ClinicalTrials.gov/show/NCT02020577
clinicaltrials.gov,cetuximab,9,P00533,,,,afatinib,755714,O14578;O14976;O15197;O43353;O94804;P00519;P00533;P04626;P06239;P08581;P08631;P12931;P15735;P21860;P30530;P36888;P42681;P42685;P45984;P49674;P51451;P51617;P53779;Q13163;Q13627;Q15303;Q16539;Q16816;Q52WX2;Q8NE63;Q92630;Q9BUB5;Q9H2G2;Q9HBH9;Q9UEE5;Q9UF33;Q9UK32;Q9Y463,"InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1",ULXXDDBFHOBEHA-CWDCEQMOSA-N,CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]4CCOC4,,head and neck cancers,Phase 2,,,NCT02979977,Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck,,https://ClinicalTrials.gov/show/NCT02979977
literature,cetuximab,9,P00533,,,,afatinib,755714,O14578;O14976;O15197;O43353;O94804;P00519;P00533;P04626;P06239;P08581;P08631;P12931;P15735;P21860;P30530;P36888;P42681;P42685;P45984;P49674;P51451;P51617;P53779;Q13163;Q13627;Q15303;Q16539;Q16816;Q52WX2;Q8NE63;Q92630;Q9BUB5;Q9H2G2;Q9HBH9;Q9UEE5;Q9UF33;Q9UK32;Q9Y463,"InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1",ULXXDDBFHOBEHA-CWDCEQMOSA-N,CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]4CCOC4,Lung adenocarcinoma with leptomeningeal carcinomatosis,lung cancers,not specified,24999085,We report a patient with non-small cell lung cancer (NSCLC) developed leptomeningeal carcinomatosis (LMC) after 4 years of multiple treatments. High-dose tyrosine kinase inhibitor (TKI) was given for LMC at first but was not effective. She then received dual therapy combining of afatinib and cetuximab. Brain magnetic resonance imaging (MRI) showed a partial response of disease and the patient experienced a clinical benefit. Our case suggests that dual targeting of epidermal growth factor receptor (EGFR) by a combination of afatinib and cetuximab can be a potential novel treatment option in treating LMC when high-dose TKI failed.,,,,
literature,cetuximab,9,P00533,,,,afatinib,755714,O14578;O14976;O15197;O43353;O94804;P00519;P00533;P04626;P06239;P08581;P08631;P12931;P15735;P21860;P30530;P36888;P42681;P42685;P45984;P49674;P51451;P51617;P53779;Q13163;Q13627;Q15303;Q16539;Q16816;Q52WX2;Q8NE63;Q92630;Q9BUB5;Q9H2G2;Q9HBH9;Q9UEE5;Q9UF33;Q9UK32;Q9Y463,"InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1",ULXXDDBFHOBEHA-CWDCEQMOSA-N,CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]4CCOC4,EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors,lung cancers,not specified,26056478,"We present two patients who acquired resistance to first-generation TKI and who underwent combination treatment with afatinib plus cetuximab as third-line therapy. Both patients presented partial response, and the time duration of disease control was 8 months and 10 months.",,,,
literature,dasatinib,375,O00238;O00506;O14965;O14976;O15197;O15264;O43283;O43318;O43353;O60674;O94804;O95819;P00519;P00533;P04049;P04626;P06239;P06241;P07333;P07947;P07948;P07949;P08631;P08684;P09619;P09769;P0C1S8;P10721;P11274;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P21860;P22607;P27037;P29317;P29320;P29322;P29323;P29597;P30291;P35968;P36507;P36888;P36894;P36896;P36897;P37023;P37173;P41240;P42680;P42681;P42684;P42685;P43405;P49674;P51451;P51813;P51955;P52333;P53667;P53671;P53778;P54753;P54756;P54760;P54762;P54764;P57059;Q01538;Q02750;Q04771;Q06187;Q07912;Q08345;Q09013;Q12851;Q13043;Q13163;Q13705;Q13882;Q15303;Q15569;Q15759;Q16539;Q16832;Q52WX2;Q56UN5;Q59H18;Q5VT25;Q6DT37;Q6PHR2;Q86Y07;Q8IVH8;Q8N4C8;Q8NG66;Q8NI60;Q8TDR2;Q92918;Q96GD4;Q99640;Q99759;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K8;Q9H3Y6;Q9NRP7;Q9NYL2;Q9P289;Q9P2K8;Q9UBE8;Q9UF33;Q9UKE5;Q9UL54;Q9Y2K2;Q9Y2U5;Q9Y4K4;Q9Y5S2;Q9Y6R4,"InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)",ZBNZXTGUTAYRHI-UHFFFAOYSA-N,Cc1nc(Nc2ncc(s2)C(=O)Nc3c(C)cccc3Cl)cc(n1)N4CCN(CCO)CC4,afatinib,755714,O14578;O14976;O15197;O43353;O94804;P00519;P00533;P04626;P06239;P08581;P08631;P12931;P15735;P21860;P30530;P36888;P42681;P42685;P45984;P49674;P51451;P51617;P53779;Q13163;Q13627;Q15303;Q16539;Q16816;Q52WX2;Q8NE63;Q92630;Q9BUB5;Q9H2G2;Q9HBH9;Q9UEE5;Q9UF33;Q9UK32;Q9Y463,"InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1",ULXXDDBFHOBEHA-CWDCEQMOSA-N,CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]4CCOC4,Patients with resistant EGFR-mutant lung cance,lung cancers,Phase 1/2,30880334,"Patients were 72% Caucasian and received median of 2 prior lines of therapy. Maximum-tolerated dose was 30_mg afatinib with 100_mg dasatinib. New or increased pleural effusions were observed in 56% of patients. No radiologic responses were observed, although several EGFR-mutant TKI-resistant patients (26%) had prolonged stable disease over 6 months. The combination reduced the EGFR mutation and T790M variant allele frequency in cell-free DNA (p_<_.05). Nonetheless, the threshold for futility was met, based on 6-month progression-free survival. For EGFR TKI-resistant patients, median progression-free survival was 3.7 months (95% confidence interval (CI), 2.3-5.0) and overall survival was 14.7 months (95% CI, 8.5-20.9).",NCT01999985,,,
clinicaltrials.gov,nivolumab,,Q15116,,,,afatinib,755714,O14578;O14976;O15197;O43353;O94804;P00519;P00533;P04626;P06239;P08581;P08631;P12931;P15735;P21860;P30530;P36888;P42681;P42685;P45984;P49674;P51451;P51617;P53779;Q13163;Q13627;Q15303;Q16539;Q16816;Q52WX2;Q8NE63;Q92630;Q9BUB5;Q9H2G2;Q9HBH9;Q9UEE5;Q9UF33;Q9UK32;Q9Y463,"InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1",ULXXDDBFHOBEHA-CWDCEQMOSA-N,CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]4CCOC4,,head and neck cancers,Phase 1,,,NCT03652233,Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck,,https://ClinicalTrials.gov/show/NCT03652233
clinicaltrials.gov,nivolumab,,Q15116,,,,afatinib,755714,O14578;O14976;O15197;O43353;O94804;P00519;P00533;P04626;P06239;P08581;P08631;P12931;P15735;P21860;P30530;P36888;P42681;P42685;P45984;P49674;P51451;P51617;P53779;Q13163;Q13627;Q15303;Q16539;Q16816;Q52WX2;Q8NE63;Q92630;Q9BUB5;Q9H2G2;Q9HBH9;Q9UEE5;Q9UF33;Q9UK32;Q9Y463,"InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1",ULXXDDBFHOBEHA-CWDCEQMOSA-N,CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]4CCOC4,,head and neck cancers,Phase 1,,,NCT03652233,Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck,,https://ClinicalTrials.gov/show/NCT03652233
clinicaltrials.gov,trastuzumab,4,P04626,,,,afatinib,755714,O14578;O14976;O15197;O43353;O94804;P00519;P00533;P04626;P06239;P08581;P08631;P12931;P15735;P21860;P30530;P36888;P42681;P42685;P45984;P49674;P51451;P51617;P53779;Q13163;Q13627;Q15303;Q16539;Q16816;Q52WX2;Q8NE63;Q92630;Q9BUB5;Q9H2G2;Q9HBH9;Q9UEE5;Q9UF33;Q9UK32;Q9Y463,"InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1",ULXXDDBFHOBEHA-CWDCEQMOSA-N,CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]4CCOC4,,breast cancers,Phase 1,,,NCT00950742,Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin__ in Patients With HER2-positive Advanced Breast Cancer.,,https://ClinicalTrials.gov/show/NCT00950742
literature,trastuzumab,4,P04626,,,,afatinib,755714,O14578;O14976;O15197;O43353;O94804;P00519;P00533;P04626;P06239;P08581;P08631;P12931;P15735;P21860;P30530;P36888;P42681;P42685;P45984;P49674;P51451;P51617;P53779;Q13163;Q13627;Q15303;Q16539;Q16816;Q52WX2;Q8NE63;Q92630;Q9BUB5;Q9H2G2;Q9HBH9;Q9UEE5;Q9UF33;Q9UK32;Q9Y463,"InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1",ULXXDDBFHOBEHA-CWDCEQMOSA-N,CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]4CCOC4,Advanced or Metastatic HER2-Positive Breast Cancer,breast cancers,Phase 1,25370464,"Of 18 patients treated, 16 received daily afatinib 20 mg and two 30 mg. Overall, 4 of 13 and 2 of 2 patients receiving afatinib 20 mg and 30 mg, respectively, experienced dose-limiting toxicity (DLT; all CTCAE grade 3 diarrhea). Most frequent treatment-related adverse events were diarrhea (94%), rash (56%), and fatigue (56%). Overall, pharmacokinetic profiles of afatinib and trastuzumab in combination were consistent with the known characteristics of each alone. Overall, objective response and disease control rates were 11% and 39%, respectively, with median progression-free survival 111.0 days (95% confidence interval, 56.0-274.0).",,,,
literature,trastuzumab,4,P04626,,,,afatinib,755714,O14578;O14976;O15197;O43353;O94804;P00519;P00533;P04626;P06239;P08581;P08631;P12931;P15735;P21860;P30530;P36888;P42681;P42685;P45984;P49674;P51451;P51617;P53779;Q13163;Q13627;Q15303;Q16539;Q16816;Q52WX2;Q8NE63;Q92630;Q9BUB5;Q9H2G2;Q9HBH9;Q9UEE5;Q9UF33;Q9UK32;Q9Y463,"InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1",ULXXDDBFHOBEHA-CWDCEQMOSA-N,CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]4CCOC4,Locally Advanced or Operable Breast Cancer Receiving Taxane-Anthracycline Containing Chemotherapy-DAFNE (GBG-70),breast cancers,Phase 2,25825476,"pCR rate was 49.2% [90% confidence interval (CI), 38.5-60.1] in 65 treated patients. Patients with hormone receptor-negative (N = 19) or hormone receptor-positive (N = 46) tumors showed pCR rates of 63.2% and 43.5%, respectively (P = 0.153). Patients with (N = 9) or without (N = 56) lymphocyte predominant breast cancer (LPBC) showed pCR rates of 100% and 41.1%, respectively (P < 0.001). PCR rate was not different in patients with or without PIK3CA tumor mutations (P = 0.363). Clinical responses were seen in 96.3% of 54 evaluable patients, and breast conserving surgery was possible in 59.4% of 62 assessable patients. Most frequent nonhematologic grade 3-4 toxicities were diarrhea (7.7%), increased creatinine (4.6%), and infection (4.6%). One patient developed symptomatic congestive heart failure.",,,,
literature,ofatumumab,,,,,,afuresertib,1081472,P31751;Q9Y243;P31749,"InChI=1S/C18H17Cl2FN4OS/c1-25-16(14(19)9-23-25)13-7-15(27-17(13)20)18(26)24-12(8-22)6-10-3-2-4-11(21)5-10/h2-5,7,9,12H,6,8,22H2,1H3,(H,24,26)/t12-/m0/s1",AFJRDFWMXUECEW-LBPRGKRZSA-N,Cn1ncc(Cl)c1c2cc(sc2Cl)C(=O)N[C@H](CN)Cc3cccc(F)c3,previously treated patients with chronic lymphocytic leukemia,leukemia,Phase 2,29916761,"Treatment was generally well tolerated but respiratory infections were common, with 18% severe requiring hospitalization. Hematologic toxicities were manageable (grade 3-4 neutropenia 39%). At a median follow-up of 13.4 months, overall responses were 50% (complete responses 3.6%). Median progression-free survival was 8.5 months and overall survival 34.8 months. Combination therapy with ofatumumab and afuresertib is active and well tolerated, but does not appear to lead to durable responses and may not provide additional benefit over single-agent ofatumumab in relapsed/refractory CLL. Novel agent combinations are currently undergoing intense investigation.",,,,
clinicaltrials.gov,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,afuresertib,1081472,P31751;Q9Y243;P31749,"InChI=1S/C18H17Cl2FN4OS/c1-25-16(14(19)9-23-25)13-7-15(27-17(13)20)18(26)24-12(8-22)6-10-3-2-4-11(21)5-10/h2-5,7,9,12H,6,8,22H2,1H3,(H,24,26)/t12-/m0/s1",AFJRDFWMXUECEW-LBPRGKRZSA-N,Cn1ncc(Cl)c1c2cc(sc2Cl)C(=O)N[C@H](CN)Cc3cccc(F)c3,,multiple myeloma;advanced solid cancers,Phase 1,,,NCT01476137,A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers,,https://ClinicalTrials.gov/show/NCT01476137
clinicaltrials.gov,AG-120,,,,,,AG-221,,,,,,Acute Myeloid Leukemia|Myelodysplastic Syndrome With Excess Blasts-2,,Phase 3,,,NCT03839771,,,
clinicaltrials.gov,pentostatin,615,P00813,"InChI=1S/C11H16N4O4/c16-3-8-6(17)1-9(19-8)15-5-14-10-7(18)2-12-4-13-11(10)15/h4-9,16-18H,1-3H2,(H,12,13)/t6-,7+,8+,9+/m0/s1",FPVKHBSQESCIEP-JQCXWYLXSA-N,OC[C@H]1O[C@H](C[C@@H]1O)n2cnc3[C@H](O)CNC=Nc23,alemtuzumab,,P31358,,,,,lymphoma;leukemia,Phase 2,,,NCT00453193,Alemtuzumab and Pentostatin In T-cell Neoplasms,,https://ClinicalTrials.gov/show/NCT00453193
clinicaltrials.gov,rituximab,16,P11836,,,,alemtuzumab,,P31358,,,,,leukemia,Phase 1,,,NCT00330252,Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL,,https://ClinicalTrials.gov/show/NCT00330252
clinicaltrials.gov,IMG-7289,,,,,,all-trans retinoic acid,273,P10276;P10826;P13631,,,C\C(=C/C=C/C(=C/C(=O)O)/C)\C=C\C1=C(C)CCCC1(C)C,,leukemia,Phase 1,,,NCT02842827,"IMG-7289, With and Without ATRA, in Patients With Advanced Myeloid Malignancies",,https://ClinicalTrials.gov/show/NCT02842827
clinicaltrials.gov,pembrolizumab,,Q15116,,,,all-trans retinoic acid,273,P10276;P10826;P13631,,,C\C(=C/C=C/C(=C/C(=O)O)/C)\C=C\C1=C(C)CCCC1(C)C,,skin cancers,Phase 1/2,,,NCT03200847,pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma,,https://ClinicalTrials.gov/show/NCT03200847
clinicaltrials.gov,AEB071,367295,Q05513;Q04759;Q02156;O94806;P17252;Q05655;P05129;P05771;P24723;P41743;Q15139,"InChI=1S/C25H22N6O2/c1-30-10-12-31(13-11-30)25-27-19-9-5-3-7-16(19)22(28-25)21-20(23(32)29-24(21)33)17-14-26-18-8-4-2-6-15(17)18/h2-9,14,26H,10-13H2,1H3,(H,29,32,33)",OAVGBZOFDPFGPJ-UHFFFAOYSA-N,CN1CCN(CC1)c2nc(C3=C(C(=O)NC3=O)c4c[nH]c5ccccc45)c6ccccc6n2,alpelisib,,P42336,"InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1",STUWGJZDJHPWGZ-LBPRGKRZSA-N,Cc1nc(NC(=O)N2CCC[C@H]2C(=O)N)sc1c3ccnc(c3)C(C)(C)C(F)(F)F,,skin cancers,Phase 1,,,NCT02273219,Trial of AEB071 in Combination With BYL719 in Patients With Melanoma,,https://ClinicalTrials.gov/show/NCT02273219
clinicaltrials.gov,BGJ398,760906,P11362;P22455;P22607;P21802,,,,alpelisib,,P42336,"InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1",STUWGJZDJHPWGZ-LBPRGKRZSA-N,Cc1nc(NC(=O)N2CCC[C@H]2C(=O)N)sc1c3ccnc(c3)C(C)(C)C(F)(F)F,,advanced solid cancers,Phase 1,,,NCT01928459,Phase 1b Trial of BGJ398/BYL719 in Solid Tumors,,https://ClinicalTrials.gov/show/NCT01928459
clinicaltrials.gov,LGH447,,,,,,alpelisib,,P42336,"InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1",STUWGJZDJHPWGZ-LBPRGKRZSA-N,Cc1nc(NC(=O)N2CCC[C@H]2C(=O)N)sc1c3ccnc(c3)C(C)(C)C(F)(F)F,,multiple myeloma,Phase 1/2,,,NCT02144038,Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma,,https://ClinicalTrials.gov/show/NCT02144038
clinicaltrials.gov,NVP-AUY922,480574,,"InChI=1S/C26H31N3O5/c1-4-27-26(32)24-23(18-7-5-17(6-8-18)15-29-9-11-33-12-10-29)25(34-28-24)20-13-19(16(2)3)21(30)14-22(20)31/h5-8,13-14,16,30-31H,4,9-12,15H2,1-3H3,(H,27,32)",NDAZATDQFDPQBD-UHFFFAOYSA-N,CCNC(=O)c1noc(c2cc(C(C)C)c(O)cc2O)c1c3ccc(CN4CCOCC4)cc3,alpelisib,,P42336,"InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1",STUWGJZDJHPWGZ-LBPRGKRZSA-N,Cc1nc(NC(=O)N2CCC[C@H]2C(=O)N)sc1c3ccnc(c3)C(C)(C)C(F)(F)F,,stomach cancers;oesophageal cancers,Phase 1,,,NCT01613950,PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer,,https://ClinicalTrials.gov/show/NCT01613950
literature,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,alpelisib,,P42336,"InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1",STUWGJZDJHPWGZ-LBPRGKRZSA-N,Cc1nc(NC(=O)N2CCC[C@H]2C(=O)N)sc1c3ccnc(c3)C(C)(C)C(F)(F)F,epithelial ovarian cancer,ovarian cancers,Phase 1b,30880072,"Between Oct 3, 2014, and Dec 21, 2016, we enrolled 34 patients (28 in the dose-escalation cohort and six in the dose-expansion cohort); two in the dose-escalation cohort were ineligible at the day of scheduled study initiation. Maximum tolerated dose and recommended phase 2 dose were identified as alpelisib 200 mg once a day plus olaparib 200 mg twice a day (dose level 3). Considering all dose levels, the most common treatment-related grade 3-4 adverse events were hyperglycaemia (five [16%] of 32 patients), nausea (three [9%]), and increased alanine aminotransferase concentrations (three [9%]). No treatment-related deaths occurred. Dose-limiting toxic effects included hyperglycaemia and fever with decreased neutrophil count. Of the 28 patients with epithelial ovarian cancer, ten (36%) achieved a partial response and 14 (50%) had stable disease according to Response Evaluation Criteria in Solid Tumors 1.1.",NCT01623349,,,
clinicaltrials.gov,ETBX-011,,,,,,ALT-803,,,,,,,thyroid cancers;bowel cancers;ovarian cancers;breast cancers;lung cancers;pancreatic cancers,Phase 1/2,,,NCT03127098,"QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer",,https://ClinicalTrials.gov/show/NCT03127098
clinicaltrials.gov,venetoclax,1150189,P10415,"InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)",LQBVNQSMGBZMKD-UHFFFAOYSA-N,CC1(C)CCC(=C(C1)c2ccc(Cl)cc2)CN3CCN(CC3)c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c(c5)N(=O)=O)c(Oc7cnc8[nH]ccc8c7)c4,alvocidib,262723,P06493;P24941;P11802;Q00534;P50613;P50750,"InChI=1S/C21H20ClNO5/c1-23-7-6-12(17(27)10-23)19-14(24)8-15(25)20-16(26)9-18(28-21(19)20)11-4-2-3-5-13(11)22/h2-5,8-9,12,17,24-25,27H,6-7,10H2,1H3/t12-,17+/m0/s1",BIIVYFLTOXDAOV-YVEFUNNKSA-N,CN1CC[C@@H]([C@H](O)C1)c2c(O)cc(O)c3C(=O)C=C(Oc23)c4ccccc4Cl,,leukemia,Phase 1,,,NCT03441555,A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia,,https://ClinicalTrials.gov/show/NCT03441555
clinicaltrials.gov,ganitumab,,P08069,,,,AMG 655,,,,,,,bowel cancers;lung cancers;ovarian cancers;pancreatic cancers;soft tissue cancers,Phase 1/2,,,NCT00819169,"QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors",,https://ClinicalTrials.gov/show/NCT00819169
clinicaltrials.gov,TQB2450,,,,,,anlotinib,,,,,,Triple Negative Breast Cancer (TNBC),,Phase 1,,,NCT03855358,,,
clinicaltrials.gov,TQB2450,,,,,,anlotinib,,,,,,,,,,,NCT03983928,Study of TQB2450 Combined With anlotinib in the Treatment of Mutation Positive Lung Cancer,,https://ClinicalTrials.gov/show/NCT03983928
clinicaltrials.gov,sintilimab,,,,,,anlotinib Hydrochloride,,,,,,,lung cancers,Phase 2,,,NCT03765775,anlotinib Plus sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative,,https://ClinicalTrials.gov/show/NCT03765775
clinicaltrials.gov,sintilimab,,,,,,anlotinib Hydrochloride,,,,,,,lung cancers,Phase 2,,,NCT03765775,anlotinib Plus sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative,,https://ClinicalTrials.gov/show/NCT03765775
clinicaltrials.gov,JNJ-809,,,,,,apalutamide,,,,,,,prostate cancers,Phase 2,,,NCT02906605,"A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer",,https://ClinicalTrials.gov/show/NCT02906605
clinicaltrials.gov,fluzoparib,,,,,,apatinib,1384455,P35968,"InChI=1S/C24H23N5O.CH4O3S/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18;1-5(2,3)4/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30);1H3,(H,2,3,4)",FYJROXRIVQPKRY-UHFFFAOYSA-N,CS(=O)(=O)O.O=C(Nc1ccc(cc1)C2(CCCC2)C#N)c3cccnc3NCc4ccncc4,,ovarian cancers;breast cancers,Phase 1,,,NCT03075462,A Study of fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients,,https://ClinicalTrials.gov/show/NCT03075462
clinicaltrials.gov,fluzoparib,,,,,,apatinib,1384455,P35968,"InChI=1S/C24H23N5O.CH4O3S/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18;1-5(2,3)4/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30);1H3,(H,2,3,4)",FYJROXRIVQPKRY-UHFFFAOYSA-N,CS(=O)(=O)O.O=C(Nc1ccc(cc1)C2(CCCC2)C#N)c3cccnc3NCc4ccncc4,,advanced solid cancers,Phase 1,,,NCT03645200,Treatment of Carrying TP53 Harmful Mutations,,https://ClinicalTrials.gov/show/NCT03645200
clinicaltrials.gov,fluzoparib,,,,,,apatinib,1384455,P35968,"InChI=1S/C24H23N5O.CH4O3S/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18;1-5(2,3)4/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30);1H3,(H,2,3,4)",FYJROXRIVQPKRY-UHFFFAOYSA-N,CS(=O)(=O)O.O=C(Nc1ccc(cc1)C2(CCCC2)C#N)c3cccnc3NCc4ccncc4,,advanced solid cancers,Phase 1,,,NCT03645200,Treatment of Carrying TP53 Harmful Mutations,,https://ClinicalTrials.gov/show/NCT03645200
clinicaltrials.gov,HS-10241,,,,,,apatinib,1384455,P35968,"InChI=1S/C24H23N5O.CH4O3S/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18;1-5(2,3)4/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30);1H3,(H,2,3,4)",FYJROXRIVQPKRY-UHFFFAOYSA-N,CS(=O)(=O)O.O=C(Nc1ccc(cc1)C2(CCCC2)C#N)c3cccnc3NCc4ccncc4,,advanced solid cancers,Phase 1,,,NCT03243643,"Tolerability, Safety, Pharmacokinetics and Efficacy of HS-10241 Single Agent or Combined With Apatinib in Patients With Advanced Solid Tumors",HS:Hansoh;,https://ClinicalTrials.gov/show/NCT03243643
clinicaltrials.gov,JNJ-63723283,,,,,,apatinib,1384455,P35968,"InChI=1S/C24H23N5O.CH4O3S/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18;1-5(2,3)4/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30);1H3,(H,2,3,4)",FYJROXRIVQPKRY-UHFFFAOYSA-N,CS(=O)(=O)O.O=C(Nc1ccc(cc1)C2(CCCC2)C#N)c3cccnc3NCc4ccncc4,,prostate cancers,Phase 1,,,NCT03551782,"A Study of JNJ-63723283, a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer",,https://ClinicalTrials.gov/show/NCT03551782
clinicaltrials.gov,JNJ-63723283,,,,,,apatinib,1384455,P35968,"InChI=1S/C24H23N5O.CH4O3S/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18;1-5(2,3)4/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30);1H3,(H,2,3,4)",FYJROXRIVQPKRY-UHFFFAOYSA-N,CS(=O)(=O)O.O=C(Nc1ccc(cc1)C2(CCCC2)C#N)c3cccnc3NCc4ccncc4,,prostate cancers,Phase 1,,,NCT03551782,"A Study of JNJ-63723283, a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer",,https://ClinicalTrials.gov/show/NCT03551782
clinicaltrials.gov,SHR-1210,841778,,"InChI=1S/C23H27FN4O2/c1-4-27(5-2)10-11-28-9-8-19-21(23(28)30)14(3)20(25-19)13-17-16-12-15(24)6-7-18(16)26-22(17)29/h6-7,12-13,25H,4-5,8-11H2,1-3H3,(H,26,29)/b17-13-",GKEYKDOLBLYGRB-LGMDPLHJSA-N,CCN(CC)CCN1CCc2[nH]c(\C=C\3/C(=O)Nc4ccc(F)cc34)c(C)c2C1=O,apatinib,1384455,P35968,"InChI=1S/C24H23N5O.CH4O3S/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18;1-5(2,3)4/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30);1H3,(H,2,3,4)",FYJROXRIVQPKRY-UHFFFAOYSA-N,CS(=O)(=O)O.O=C(Nc1ccc(cc1)C2(CCCC2)C#N)c3cccnc3NCc4ccncc4,,breast cancers,Phase 1/2,,,NCT03394287,A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced TNBC,,https://ClinicalTrials.gov/show/NCT03394287
clinicaltrials.gov,SHR-1210,841778,,"InChI=1S/C23H27FN4O2/c1-4-27(5-2)10-11-28-9-8-19-21(23(28)30)14(3)20(25-19)13-17-16-12-15(24)6-7-18(16)26-22(17)29/h6-7,12-13,25H,4-5,8-11H2,1-3H3,(H,26,29)/b17-13-",GKEYKDOLBLYGRB-LGMDPLHJSA-N,CCN(CC)CCN1CCc2[nH]c(\C=C\3/C(=O)Nc4ccc(F)cc34)c(C)c2C1=O,apatinib,1384455,P35968,"InChI=1S/C24H23N5O.CH4O3S/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18;1-5(2,3)4/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30);1H3,(H,2,3,4)",FYJROXRIVQPKRY-UHFFFAOYSA-N,CS(=O)(=O)O.O=C(Nc1ccc(cc1)C2(CCCC2)C#N)c3cccnc3NCc4ccncc4,,liver cancers,Phase 2,,,NCT03463876,A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC,,https://ClinicalTrials.gov/show/NCT03463876
clinicaltrials.gov,SHR-1210,841778,,"InChI=1S/C23H27FN4O2/c1-4-27(5-2)10-11-28-9-8-19-21(23(28)30)14(3)20(25-19)13-17-16-12-15(24)6-7-18(16)26-22(17)29/h6-7,12-13,25H,4-5,8-11H2,1-3H3,(H,26,29)/b17-13-",GKEYKDOLBLYGRB-LGMDPLHJSA-N,CCN(CC)CCN1CCc2[nH]c(\C=C\3/C(=O)Nc4ccc(F)cc34)c(C)c2C1=O,apatinib,1384455,P35968,"InChI=1S/C24H23N5O.CH4O3S/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18;1-5(2,3)4/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30);1H3,(H,2,3,4)",FYJROXRIVQPKRY-UHFFFAOYSA-N,CS(=O)(=O)O.O=C(Nc1ccc(cc1)C2(CCCC2)C#N)c3cccnc3NCc4ccncc4,,lung cancers,Phase 2,,,NCT03083041,A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC),,https://ClinicalTrials.gov/show/NCT03083041
clinicaltrials.gov,SHR-1210,841778,,"InChI=1S/C23H27FN4O2/c1-4-27(5-2)10-11-28-9-8-19-21(23(28)30)14(3)20(25-19)13-17-16-12-15(24)6-7-18(16)26-22(17)29/h6-7,12-13,25H,4-5,8-11H2,1-3H3,(H,26,29)/b17-13-",GKEYKDOLBLYGRB-LGMDPLHJSA-N,CCN(CC)CCN1CCc2[nH]c(\C=C\3/C(=O)Nc4ccc(F)cc34)c(C)c2C1=O,apatinib,1384455,P35968,"InChI=1S/C24H23N5O.CH4O3S/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18;1-5(2,3)4/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30);1H3,(H,2,3,4)",FYJROXRIVQPKRY-UHFFFAOYSA-N,CS(=O)(=O)O.O=C(Nc1ccc(cc1)C2(CCCC2)C#N)c3cccnc3NCc4ccncc4,,lung cancers,Phase 2,,,NCT03417895,SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy,PASSION,https://ClinicalTrials.gov/show/NCT03417895
clinicaltrials.gov,SHR-1210,,,,,,apatinib,1384455,P35968,"InChI=1S/C24H23N5O.CH4O3S/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18;1-5(2,3)4/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30);1H3,(H,2,3,4)",FYJROXRIVQPKRY-UHFFFAOYSA-N,CS(=O)(=O)O.O=C(Nc1ccc(cc1)C2(CCCC2)C#N)c3cccnc3NCc4ccncc4,,,,,,NCT04014101,SHR-1210 Plus Apatinib in Patients With Advanced-Stage Hepatocellular Carcinoma,,https://ClinicalTrials.gov/show/NCT04014101
clinicaltrials.gov,SHR1210,,,,,,apatinib,1384455,P35968,"InChI=1S/C24H23N5O.CH4O3S/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18;1-5(2,3)4/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30);1H3,(H,2,3,4)",FYJROXRIVQPKRY-UHFFFAOYSA-N,CS(=O)(=O)O.O=C(Nc1ccc(cc1)C2(CCCC2)C#N)c3cccnc3NCc4ccncc4,,,,,,NCT03955354,PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma,,https://ClinicalTrials.gov/show/NCT03955354
clinicaltrials.gov,ondansetron,2228,P46098,"InChI=1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3",FELGMEQIXOGIFQ-UHFFFAOYSA-N,Cc1nccn1CC2CCc3c(C2=O)c4ccccc4n3C,aprepitant,471,P25103,"InChI=1S/C23H21F7N4O3/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)37-20-19(13-2-4-17(24)5-3-13)34(6-7-36-20)11-18-31-21(35)33-32-18/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H2,31,32,33,35)/t12-,19+,20-/m1/s1",ATALOFNDEOCMKK-OITMNORJSA-N,C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1c3ccc(F)cc3)c4cc(cc(c4)C(F)(F)F)C(F)(F)F,,leukemia,Phase 2,,,NCT00954941,Ondansetron Versus Aprepitant Plus Ondansetron for Emesis,,https://ClinicalTrials.gov/show/NCT00954941
clinicaltrials.gov,rivaroxaban,245079,P00742,"InChI=1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1",KGFYHTZWPPHNLQ-AWEZNQCLSA-N,Clc1ccc(s1)C(=O)NC[C@H]2CN(C(=O)O2)c3ccc(cc3)N4CCOCC4=O,ASA,,,,,,,multiple myeloma,Phase 2/3,,,NCT03428373,ASA vs. Rivaroxaban in Newly Diagnosed or Relapsed and Refractory Multiple Myeloma Patients Treated With Len-Dex Combination Therapy.,RithMM,https://ClinicalTrials.gov/show/NCT03428373
clinicaltrials.gov,bevacizumab,11,P15692,,,,atezolizumab,,Q9NZQ7,,,,,kidney cancers,Phase 2,,,NCT02724878,Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT02724878
clinicaltrials.gov,bevacizumab,11,P15692,,,,atezolizumab,,Q9NZQ7,,,,,female cancers,Phase 2,,,NCT03526432,Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer,,https://ClinicalTrials.gov/show/NCT03526432
clinicaltrials.gov,bevacizumab,11,P15692,,,,atezolizumab,,Q9NZQ7,,,,,female cancers,Phase 2,,,NCT03526432,Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer,,https://ClinicalTrials.gov/show/NCT03526432
clinicaltrials.gov,BL-8040,,P61073,,,,atezolizumab,,Q9NZQ7,,,,,leukemia,Phase 1/2,,,NCT03154827,"A Phase Ib/II, Multicenter, Single Arm, Open-Label Study, To Evaluate the Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab Combination for Maintenance Treatment in Subjects With Acute Myeloid Leukemia Who Are 60 Years or Older - The BATTLE Study",,https://ClinicalTrials.gov/show/NCT03154827
clinicaltrials.gov,cabozantinib,1081506,P08581,"InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)",ONIQOQHATWINJY-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5)cc3)c2cc1OC,atezolizumab,,Q9NZQ7,,,,,bladder cancers;kidney cancers;lung cancers;prostate cancers,Phase 1/2,,,NCT03170960,Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors,,https://ClinicalTrials.gov/show/NCT03170960
clinicaltrials.gov,CDX-1401,,,,,,atezolizumab,,Q9NZQ7,,,,,lung cancers,Phase 2,,,NCT02495636,"Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer",,https://ClinicalTrials.gov/show/NCT02495636
clinicaltrials.gov,CMB305,,,,,,atezolizumab,,Q9NZQ7,,,,,soft tissue cancers,Phase 2,,,NCT02609984,Trial of CMB305 and Atezolizumab in Patients With Sarcoma,IMDZ-C232,https://ClinicalTrials.gov/show/NCT02609984
clinicaltrials.gov,CV301,,,,,,atezolizumab,,Q9NZQ7,,,,,bladder cancers,Phase 2,,,NCT03628716,CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer,,https://ClinicalTrials.gov/show/NCT03628716
clinicaltrials.gov,CV301,,,,,,atezolizumab,,Q9NZQ7,,,,,bladder cancers,Phase 2,,,NCT03628716,CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer,,https://ClinicalTrials.gov/show/NCT03628716
clinicaltrials.gov,giltertinib,1211984,P36888; P30530,"InChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34)",GYQYAJJFPNQOOW-UHFFFAOYSA-N,CCc1nc(C(=O)N)c(Nc2ccc(N3CCC(CC3)N4CCN(C)CC4)c(OC)c2)nc1NC5CCOCC5,atezolizumab,,Q9NZQ7,,,,,leukemia,Phase 1/2,,,NCT03730012,A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML),,https://ClinicalTrials.gov/show/NCT03730012
clinicaltrials.gov,giltertinib,1211984,P36888; P30530,"InChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34)",GYQYAJJFPNQOOW-UHFFFAOYSA-N,CCc1nc(C(=O)N)c(Nc2ccc(N3CCC(CC3)N4CCN(C)CC4)c(OC)c2)nc1NC5CCOCC5,atezolizumab,,Q9NZQ7,,,,,leukemia,Phase 1/2,,,NCT03730012,A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML),,https://ClinicalTrials.gov/show/NCT03730012
clinicaltrials.gov,IMC-C103C,,,,,,atezolizumab,,Q9NZQ7,,,,,,,,,NCT03973333,Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab,,https://ClinicalTrials.gov/show/NCT03973333
clinicaltrials.gov,ipatasertib,1017408,P31751;Q9Y243;P31749,"InChI=1S/C24H32ClN5O2/c1-15(2)26-13-19(17-4-6-18(25)7-5-17)24(32)30-10-8-29(9-11-30)23-21-16(3)12-20(31)22(21)27-14-28-23/h4-7,14-16,19-20,26,31H,8-13H2,1-3H3/t16-,19-,20-/m1/s1",GRZXWCHAXNAUHY-NSISKUIASA-N,CC(C)NC[C@@H](C(=O)N1CCN(CC1)c2ncnc3[C@H](O)C[C@@H](C)c23)c4ccc(Cl)cc4,atezolizumab,,Q9NZQ7,,,,,advanced solid cancers;brain cancers;prostate cancers,Phase 1/2,,,NCT03673787,A Trial of Ipatasertib in Combination With Atezolizumab,IceCAP,https://ClinicalTrials.gov/show/NCT03673787
clinicaltrials.gov,ipatasertib,1017408,P31751;Q9Y243;P31749,"InChI=1S/C24H32ClN5O2/c1-15(2)26-13-19(17-4-6-18(25)7-5-17)24(32)30-10-8-29(9-11-30)23-21-16(3)12-20(31)22(21)27-14-28-23/h4-7,14-16,19-20,26,31H,8-13H2,1-3H3/t16-,19-,20-/m1/s1",GRZXWCHAXNAUHY-NSISKUIASA-N,CC(C)NC[C@@H](C(=O)N1CCN(CC1)c2ncnc3[C@H](O)C[C@@H](C)c23)c4ccc(Cl)cc4,atezolizumab,,Q9NZQ7,,,,,advanced solid cancers;brain cancers;prostate cancers,Phase 1/2,,,NCT03673787,A Trial of Ipatasertib in Combination With Atezolizumab,IceCAP,https://ClinicalTrials.gov/show/NCT03673787
clinicaltrials.gov,isatuximab,,,,,,atezolizumab,,Q9NZQ7,,,,,,Phase 1/2,,,NCT03637764,"Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies",,https://ClinicalTrials.gov/show/NCT03637764
clinicaltrials.gov,isatuximab,,,,,,atezolizumab,,Q9NZQ7,,,,,,Phase 1/2,,,NCT03637764,"Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies",,https://ClinicalTrials.gov/show/NCT03637764
clinicaltrials.gov,KY1044,,,,,,atezolizumab,,Q9NZQ7,,,,Squamous Cell Carcinoma of Head and Neck|Non-small Cell Lung Cancer|Hepatocellular Carcinoma|Esophageal Cancer|Gastric Cancer|Melanoma|Renal Cell Carcinoma|Pancreatic Cancer|Cervical Cancer|Triple Negative Breast Cancer|Advanced Cancer,,Phase 1/2,,,NCT03829501,,,
clinicaltrials.gov,MV-NIS,,,,,,atezolizumab,,Q9NZQ7,,,,,lung cancers,Phase 1,,,NCT02919449,Trial of Measles Virotherapy in Combination With Atezolizumab in Patients With Metastatic Non-Small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT02919449
clinicaltrials.gov,obinutuzumab,,P11836,,,,atezolizumab,,Q9NZQ7,,,,,lymphoma;leukemia,Phase 2,,,NCT02846623,Atezolizumab (PD-L1 mAb) in Combination With Obinutuzumab and Ibrutinib in Patients With Relapsed Refractory or High-Risk Untreated Chronic Lymphocytic Leukemia (CLL),,https://ClinicalTrials.gov/show/NCT02846623
clinicaltrials.gov,PRS-343,,,,,,atezolizumab,,Q9NZQ7,,,,,advanced solid cancers,Phase 1,,,NCT03650348,PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors,,https://ClinicalTrials.gov/show/NCT03650348
clinicaltrials.gov,PRS-343,,,,,,atezolizumab,,Q9NZQ7,,,,,advanced solid cancers,Phase 1,,,NCT03650348,PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors,,https://ClinicalTrials.gov/show/NCT03650348
clinicaltrials.gov,PVSRIPO,,,,,,atezolizumab,,Q9NZQ7,,,,,,,,,NCT03973879,Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma,,https://ClinicalTrials.gov/show/NCT03973879
clinicaltrials.gov,RO6874281,,,,,,atezolizumab,,Q9NZQ7,,,,,,Phase 2,,,NCT03386721,Study to Evaluate the Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors,,https://ClinicalTrials.gov/show/NCT03386721
clinicaltrials.gov,RO7198457,,,,,,atezolizumab,,Q9NZQ7,,,,,skin cancers;lung cancers;bladder cancers;colorectal cancers;breast cancers;kidney cancers;head and neck cancers,Phase 1,,,NCT03289962,A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors,,https://ClinicalTrials.gov/show/NCT03289962
clinicaltrials.gov,rociletinib,1271035,P00533,"InChI=1S/C27H28F3N7O3/c1-4-24(39)32-18-6-5-7-19(14-18)33-25-21(27(28,29)30)16-31-26(35-25)34-22-9-8-20(15-23(22)40-3)37-12-10-36(11-13-37)17(2)38/h4-9,14-16H,1,10-13H2,2-3H3,(H,32,39)(H2,31,33,34,35)",HUFOZJXAKZVRNJ-UHFFFAOYSA-N,COc1cc(ccc1Nc2ncc(c(Nc3cccc(NC(=O)C=C)c3)n2)C(F)(F)F)N4CCN(CC4)C(=O)C,atezolizumab,,Q9NZQ7,,,,,lung cancers,Phase 1/2,,,NCT02630186,A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC,,https://ClinicalTrials.gov/show/NCT02630186
clinicaltrials.gov,TJ004309,,,,,,atezolizumab,,Q9NZQ7,,,,Solid Tumor|Metastatic Cancer,,Phase 1,,,NCT03835949,,,
clinicaltrials.gov,avelumab,,Q9NZQ7,,,,AVB-S6-500,,,,,,,,,,,NCT04004442,Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma,COAXIN,https://ClinicalTrials.gov/show/NCT04004442
clinicaltrials.gov,Anti-OX40 Antibody PF-04518600,,,,,,avelumab,,Q9NZQ7,,,,,,,,,NCT03971409,"Avelumab With Binimetinib, Utomilumab, or Anti-OX40 Antibody PF-04518600 in Treating Triple Negative Breast Cancer",InCITe,https://ClinicalTrials.gov/show/NCT03971409
clinicaltrials.gov,axitinib,600224,P35968;P17948;P35916,"InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+",RITAVMQDGBJQJZ-FMIVXFBMSA-N,CNC(=O)c1ccccc1Sc2ccc3c(\C=C\c4ccccn4)n[nH]c3c2,avelumab,,Q9NZQ7,,,,,kidney cancers,Phase 2,,,NCT03341845,Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC,,https://ClinicalTrials.gov/show/NCT03341845
clinicaltrials.gov,Debio 1143,,,,,,avelumab,,Q9NZQ7,,,,,lung cancers,Phase 1,,,NCT03270176,A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy,,https://ClinicalTrials.gov/show/NCT03270176
clinicaltrials.gov,defactinib,1369032,Q05397;Q14289,"InChI=1S/C20H21F3N8O3S/c1-24-18(32)12-4-6-13(7-5-12)29-19-28-10-14(20(21,22)23)16(30-19)27-11-15-17(26-9-8-25-15)31(2)35(3,33)34/h4-10H,11H2,1-3H3,(H,24,32)(H2,27,28,29,30)",FWLMVFUGMHIOAA-UHFFFAOYSA-N,CNC(=O)c1ccc(Nc2ncc(c(NCc3nccnc3N(C)S(=O)(=O)C)n2)C(F)(F)F)cc1,avelumab,,Q9NZQ7,,,,,ovarian cancers,Phase 1,,,NCT02943317,"Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial ovarian Cancers",,https://ClinicalTrials.gov/show/NCT02943317
clinicaltrials.gov,eFT508,,,,,,avelumab,,Q9NZQ7,,,,,colorectal cancers,Phase 2,,,NCT03258398,A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer,,https://ClinicalTrials.gov/show/NCT03258398
clinicaltrials.gov,Hu5F9-G4,,,,,,avelumab,,Q9NZQ7,,,,,ovarian cancers,Phase 1,,,NCT03558139,A Trial of Hu5F9-G4 With Avelumab in Ovarian Cancer,,https://ClinicalTrials.gov/show/NCT03558139
clinicaltrials.gov,Hu5F9-G4,,,,,,avelumab,,Q9NZQ7,,,,,ovarian cancers,Phase 1,,,NCT03558139,A Trial of Hu5F9-G4 With Avelumab in Ovarian Cancer,,https://ClinicalTrials.gov/show/NCT03558139
clinicaltrials.gov,PT-112,,,,,,avelumab,,Q9NZQ7,,,,,lung cancers;bladder cancers;head and neck cancers;breast cancers;prostate cancers,Phase 1/2,,,NCT03409458,A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab,PAVE-1,https://ClinicalTrials.gov/show/NCT03409458
clinicaltrials.gov,Talazoparib,,,,,,avelumab,,Q9NZQ7,,,,,,,,,NCT03964532,TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer,,https://ClinicalTrials.gov/show/NCT03964532
clinicaltrials.gov,TG4001,,,,,,avelumab,,Q9NZQ7,,,,,head and neck cancers,Phase 1/2,,,NCT03260023,Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers and Expansion Cohort to Oropharyngeal SCCHN,,https://ClinicalTrials.gov/show/NCT03260023
clinicaltrials.gov,valporic acid,382,P51649,"InChI=1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)",NIJJYAXOARWZEE-UHFFFAOYSA-N,CCCC(CCC)C(=O)O,avelumab,,Q9NZQ7,,,,,cervical cancers;female cancers;male cancers;other,Phase 2,,,NCT03357757,Avelumab With Valproic Acid in Virus-associated Cancer,LATENT,https://ClinicalTrials.gov/show/NCT03357757
clinicaltrials.gov,VXM01,,,,,,avelumab,,Q9NZQ7,,,,,brain cancers,Phase 1/2,,,NCT03750071,VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma,,https://ClinicalTrials.gov/show/NCT03750071
clinicaltrials.gov,VXM01,,,,,,avelumab,,Q9NZQ7,,,,,brain cancers,Phase 1/2,,,NCT03750071,VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma,,https://ClinicalTrials.gov/show/NCT03750071
clinicaltrials.gov,avelumab,,Q9NZQ7,,,,axitinib,600224,P35968;P17948;P35916,"InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+",RITAVMQDGBJQJZ-FMIVXFBMSA-N,CNC(=O)c1ccccc1Sc2ccc3c(\C=C\c4ccccn4)n[nH]c3c2,,kidney cancers,Phase 1,,,NCT02493751,A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100),,https://ClinicalTrials.gov/show/NCT02493751
clinicaltrials.gov,avelumab,,Q9NZQ7,,,,axitinib,600224,P35968;P17948;P35916,"InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+",RITAVMQDGBJQJZ-FMIVXFBMSA-N,CNC(=O)c1ccccc1Sc2ccc3c(\C=C\c4ccccn4)n[nH]c3c2,,liver cancers,Phase 1,,,NCT03289533,A Study Of Avelumab In Combination With Axitinib In Advanced HCC,,https://ClinicalTrials.gov/show/NCT03289533
clinicaltrials.gov,avelumab,,Q9NZQ7,,,,axitinib,600224,P35968;P17948;P35916,"InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+",RITAVMQDGBJQJZ-FMIVXFBMSA-N,CNC(=O)c1ccccc1Sc2ccc3c(\C=C\c4ccccn4)n[nH]c3c2,Cervical Cancer,,Not Applicable,,,NCT03826589,,,
clinicaltrials.gov,avelumab,,Q9NZQ7,,,,axitinib,600224,P35968;P17948;P35916,"InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+",RITAVMQDGBJQJZ-FMIVXFBMSA-N,CNC(=O)c1ccccc1Sc2ccc3c(\C=C\c4ccccn4)n[nH]c3c2,,,,,,NCT03990571,Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma,,https://ClinicalTrials.gov/show/NCT03990571
clinicaltrials.gov,JS001(Toripalimab Injection),,,,,,axitinib,600224,P35968;P17948;P35916,"InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+",RITAVMQDGBJQJZ-FMIVXFBMSA-N,CNC(=O)c1ccccc1Sc2ccc3c(\C=C\c4ccccn4)n[nH]c3c2,,,,,,NCT03941795,Phase III Trial to Evaluate the Efficacy and Safety of JS001 Combined With Axitinib for Advanced Mucosal Melanoma,,https://ClinicalTrials.gov/show/NCT03941795
clinicaltrials.gov,nivolumab,,Q15116,,,,axitinib,600224,P35968;P17948;P35916,"InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+",RITAVMQDGBJQJZ-FMIVXFBMSA-N,CNC(=O)c1ccccc1Sc2ccc3c(\C=C\c4ccccn4)n[nH]c3c2,,kidney cancers,Phase 1/2,,,NCT03172754,Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT03172754
literature,pembrolizumab,,Q15116,,,,axitinib,600224,P35968;P17948;P35916,"InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+",RITAVMQDGBJQJZ-FMIVXFBMSA-N,CNC(=O)c1ccccc1Sc2ccc3c(\C=C\c4ccccn4)n[nH]c3c2,Advanced Renal-Cell Carcinoma,kidney cancers,Phase 3,30779529,"After a median follow-up of 12.8 months, the estimated percentage of patients who were alive at 12 months was 89.9% in the pembrolizumab-axitinib group and 78.3% in the sunitinib group (hazard ratio for death, 0.53; 95% confidence interval [CI], 0.38 to 0.74; P<0.0001). Median progression-free survival was 15.1 months in the pembrolizumab-axitinib group and 11.1 months in the sunitinib group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.57 to 0.84; P<0.001). The objective response rate was 59.3% (95% CI, 54.5 to 63.9) in the pembrolizumab-axitinib group and 35.7% (95% CI, 31.1 to 40.4) in the sunitinib group (P<0.001). The benefit of pembrolizumab plus axitinib was observed across the International Metastatic Renal Cell Carcinoma Database Consortium risk groups (i.e., favorable, intermediate, and poor risk) and regardless of programmed death ligand 1 expression. Grade 3 or higher adverse events of any cause occurred in 75.8% of patients in the pembrolizumab-axitinib group and in 70.6% in the sunitinib group.",NCT02853331,,,
clinicaltrials.gov,X4P-001,,,,,,axitinib,600224,P35968;P17948;P35916,"InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+",RITAVMQDGBJQJZ-FMIVXFBMSA-N,CNC(=O)c1ccccc1Sc2ccc3c(\C=C\c4ccccn4)n[nH]c3c2,,kidney cancers,Phase 1/2,,,NCT02667886,Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT02667886
clinicaltrials.gov,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,AZD-5363,,P31751;Q9Y243;P31749,"InChI=1S/C32H44F2N2O5S2/c1-4-36(32(37)19-23-5-9-29(10-6-23)42(2,38)39)28-13-16-35(17-14-28)18-15-31(25-20-26(33)22-27(34)21-25)24-7-11-30(12-8-24)43(3,40)41/h5-6,9-10,20-22,24,28,30-31H,4,7-8,11-19H2,1-3H3/t24?,30?,31-/m1/s1",AESXAJXKMUNYJP-ZWFIUULVSA-N,CCN(C1CCN(CC[C@H](C2CCC(CC2)S(=O)(=O)C)c3cc(F)cc(F)c3)CC1)C(=O)Cc4ccc(cc4)S(=O)(=O)C,,advanced solid cancers,Phase 1,,,NCT02338622,Trial of Olaparib in Combination With AZD5363 (ComPAKT),ComPAKT,https://ClinicalTrials.gov/show/NCT02338622
clinicaltrials.gov,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,AZD6738,,,,,,,prostate cancers,Phase 2,,,NCT03787680,Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial),,https://ClinicalTrials.gov/show/NCT03787680
clinicaltrials.gov,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,AZD6738,,,,,,,prostate cancers,Phase 2,,,NCT03787680,Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial),,https://ClinicalTrials.gov/show/NCT03787680
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,bavituximab,,,,,,,lung cancers,Phase 2,,,NCT02673814,Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT02673814
clinicaltrials.gov,pembrolizumab,,Q15116,,,,bavituximab,,,,,,,liver cancers,Phase 2,,,NCT03519997,A Study of pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma,,https://ClinicalTrials.gov/show/NCT03519997
clinicaltrials.gov,pembrolizumab,,Q15116,,,,bavituximab,,,,,,,liver cancers,Phase 2,,,NCT03519997,A Study of pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma,,https://ClinicalTrials.gov/show/NCT03519997
clinicaltrials.gov,amcasertib,1896288,,"InChI=1S/C31H33N5O2S/c1-5-36(6-2)15-14-32-30(38)28-19(3)26(33-20(28)4)17-24-23-16-22(12-13-25(23)34-29(24)37)27-18-39-31(35-27)21-10-8-7-9-11-21/h7-13,16-18,33H,5-6,14-15H2,1-4H3,(H,32,38)(H,34,37)/b24-17-",QDWKGEFGLQMDAM-ULJHMMPZSA-N,CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C\2/C(=O)Nc3ccc(cc23)c4csc(n4)c5ccccc5)c1C,BBI503,,,,,,,advanced solid cancers,Phase 1,,,NCT02432326,A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT02432326
clinicaltrials.gov,carfilzomib,134643,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436,"InChI=1S/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1",BLMPQMFVWMYDKT-NZTKNTHTSA-N,CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,belinostat,73864,Q9BY41;Q969S8;O15379;P56524;Q8WUI4;Q9UQL6;Q9UKV0;Q13547;Q92769;Q9UBN7;Q96DB2,"InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+",NCNRHFGMJRPRSK-MDZDMXLPSA-N,ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc2ccccc2,,lymphoma,Phase 1,,,NCT02142530,Carfilzomib Plus Belinostat in Relapsed/Refractory NHL,,https://ClinicalTrials.gov/show/NCT02142530
clinicaltrials.gov,abaloparatide,,,,,,bevacizumab,11,P15692,,,,,leukemia,Phase 1,,,NCT03746041,A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes,,https://ClinicalTrials.gov/show/NCT03746041
clinicaltrials.gov,abaloparatide,,,,,,bevacizumab,11,P15692,,,,,leukemia,Phase 1,,,NCT03746041,A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes,,https://ClinicalTrials.gov/show/NCT03746041
literature,afatinib,755714,O14578;O14976;O15197;O43353;O94804;P00519;P00533;P04626;P06239;P08581;P08631;P12931;P15735;P21860;P30530;P36888;P42681;P42685;P45984;P49674;P51451;P51617;P53779;Q13163;Q13627;Q15303;Q16539;Q16816;Q52WX2;Q8NE63;Q92630;Q9BUB5;Q9H2G2;Q9HBH9;Q9UEE5;Q9UF33;Q9UK32;Q9Y463,"InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1",ULXXDDBFHOBEHA-CWDCEQMOSA-N,CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]4CCOC4,bevacizumab,11,P15692,,,,Chemonaive Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations,lung cancers,Phase 1,30514667,"A daily 30 mg dose of afatinib and 15 mg/kg intravenous bevacizumab every 3 weeks was well tolerated and was defined as the recommended dose. We have initiated a randomized phase 2 trial comparing afatinib (30 mg daily) and bevacizumab (15 mg/kg every 3 weeks) with afatinib (40 mg daily) alone for nonsquamous NSCLC harboring EGFR common mutations as a first-line therapy. A total of 100 patients will be enrolled onto this study and randomized in a 1:1 ratio. Patients will continue to receive treatment until disease progression or unacceptable toxicity. The primary end point is PFS, and the secondary end points are overall survival, tumor response, and time to treatment failure. The power is greater than 50% under the assumptions of a median PFS of 12 months for the afatinib group and a hazard ratio of 0.6 for the combination group (2-sided _ = 0.05).",,,,
clinicaltrials.gov,alectinib,859887,Q9UM73;P07949,"InChI=1S/C30H34N4O2/c1-4-20-16-23-24(17-26(20)34-9-7-21(8-10-34)33-11-13-36-14-12-33)30(2,3)29-27(28(23)35)22-6-5-19(18-31)15-25(22)32-29/h5-6,15-17,21,32H,4,7-14H2,1-3H3",KDGFLJKFZUIJMX-UHFFFAOYSA-N,CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N5CCC(CC5)N6CCOCC6,bevacizumab,11,P15692,,,,,lung cancers,Phase 1/2,,,NCT02521051,"Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer",,https://ClinicalTrials.gov/show/NCT02521051
clinicaltrials.gov,alectinib,859887,Q9UM73;P07949,"InChI=1S/C30H34N4O2/c1-4-20-16-23-24(17-26(20)34-9-7-21(8-10-34)33-11-13-36-14-12-33)30(2,3)29-27(28(23)35)22-6-5-19(18-31)15-25(22)32-29/h5-6,15-17,21,32H,4,7-14H2,1-3H3",KDGFLJKFZUIJMX-UHFFFAOYSA-N,CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N5CCC(CC5)N6CCOCC6,bevacizumab,11,P15692,,,,,lung cancers,Phase 2,,,NCT03779191,Alectinib in Combination With Bevacizumab in ALK Positive NSCLC,,https://ClinicalTrials.gov/show/NCT03779191
clinicaltrials.gov,alectinib,859887,Q9UM73;P07949,"InChI=1S/C30H34N4O2/c1-4-20-16-23-24(17-26(20)34-9-7-21(8-10-34)33-11-13-36-14-12-33)30(2,3)29-27(28(23)35)22-6-5-19(18-31)15-25(22)32-29/h5-6,15-17,21,32H,4,7-14H2,1-3H3",KDGFLJKFZUIJMX-UHFFFAOYSA-N,CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N5CCC(CC5)N6CCOCC6,bevacizumab,11,P15692,,,,,lung cancers,Phase 2,,,NCT03779191,Alectinib in Combination With Bevacizumab in ALK Positive NSCLC,,https://ClinicalTrials.gov/show/NCT03779191
clinicaltrials.gov,AMG 386,,Q15389;O15123,,,,bevacizumab,11,P15692,,,,,brain cancers,Phase 1/2,,,NCT01290263,Amgen 386 for Recurrent Glioblastoma,,https://ClinicalTrials.gov/show/NCT01290263
clinicaltrials.gov,apatinib,1384455,P35968,"InChI=1S/C24H23N5O.CH4O3S/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18;1-5(2,3)4/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30);1H3,(H,2,3,4)",FYJROXRIVQPKRY-UHFFFAOYSA-N,CS(=O)(=O)O.O=C(Nc1ccc(cc1)C2(CCCC2)C#N)c3cccnc3NCc4ccncc4,bevacizumab,11,P15692,,,,,colorectal cancers,Phase 2,,,NCT03271255,Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C),,https://ClinicalTrials.gov/show/NCT03271255
clinicaltrials.gov,atezolizumab,,Q9NZQ7,,,,bevacizumab,11,P15692,,,,,bladder cancers,Phase 2,,,NCT03133390,Atezolizumab With or Without Bevacizumab in Cisplatin-ineligible Patients,,https://ClinicalTrials.gov/show/NCT03133390
clinicaltrials.gov,atezolizumab,,Q9NZQ7,,,,bevacizumab,11,P15692,,,,,bladder cancers,Phase 2,,,NCT03272217,Atezolizumab With or Without Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer,,https://ClinicalTrials.gov/show/NCT03272217
clinicaltrials.gov,atezolizumab,,Q9NZQ7,,,,bevacizumab,11,P15692,,,,,bowel cancers,Phase 2,,,NCT02982694,"Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer",,https://ClinicalTrials.gov/show/NCT02982694
clinicaltrials.gov,atezolizumab,,Q9NZQ7,,,,bevacizumab,11,P15692,,,,,lung cancers,Phase 2,,,NCT03616691,Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab for NSCLC,,https://ClinicalTrials.gov/show/NCT03616691
clinicaltrials.gov,atezolizumab,,Q9NZQ7,,,,bevacizumab,11,P15692,,,,,kidney cancers,Phase 3,,,NCT03693573,A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT03693573
clinicaltrials.gov,atezolizumab,,Q9NZQ7,,,,bevacizumab,11,P15692,,,,,lung cancers,Phase 2,,,NCT03616691,Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab for NSCLC,,https://ClinicalTrials.gov/show/NCT03616691
clinicaltrials.gov,atezolizumab,,Q9NZQ7,,,,bevacizumab,11,P15692,,,,,kidney cancers,Phase 3,,,NCT03693573,A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT03693573
clinicaltrials.gov,atezolizumab,,Q9NZQ7,,,,bevacizumab,11,P15692,,,,Non Small Cell Lung Cancer,,Phase 2,,,NCT03836066,,,
clinicaltrials.gov,BEVZ92,,,,,,bevacizumab,11,P15692,,,,,bowel cancers,Phase 1,,,NCT02069704,Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN__) in First-line Treatment mCRC Patients,,https://ClinicalTrials.gov/show/NCT02069704
literature,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,bevacizumab,11,P15692,,,,"advanced, refractory malignancies",advanced solid cancers,Phase 1,25373733,"Ninety-one patients were treated (median=6 prior treatments). The FDA-approved doses of both drugs were safely reached, and the recommended phase 2 dose (RP2D) is bevacizumab 15 mg/kg with bortezomib 1.3 mg/m(2). Four patients attained partial response (PR) and seven patients achieved stable disease (SD) _ 6 months (Total SD _ 6 months/PR=11 (12%)). The most common drug-related toxicities included thrombocytopenia (23%) and fatigue (19%). DCE-MRI analysis demonstrated no dose-dependent decreases in K(trans) although analysis was limited by small sample size (N=12).",,,,
literature,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,bevacizumab,11,P15692,,,,relapsed or refractory multiple myeloma,multiple myeloma,Phase 2,22811009,"The stratified hazard ratio of PFS for the bevacizumab-containing arm (n = 49) relative to the bortezomib monotherapy arm (n = 53) was 0.743 (95% confidence interval [CI], 0.43-1.28; P = .2804); the median PFS was 6.2 months (95% CI, 4.4-8.5 months) and 5.1 months (95% CI, 4.2-7.2 months), respectively; the overall response rates were 51% and 43.4% (P = .4029), respectively; and the median response duration was 6.9 months (95% CI, 4.73-11.83 months) and 6.0 months (95% CI, 4.86-8.31 months), respectively. Frequent adverse events occurred at similar rates across treatment arms, but hypertension, fatigue, and neuralgia occurred more frequently in the bevacizumab-containing arm.",,,,
clinicaltrials.gov,capmatinib,1278782,P08581,"InChI=1S/C23H17FN6O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20/h2-9,11-13H,10H2,1H3,(H,25,31)",LIOLIMKSCNQPLV-UHFFFAOYSA-N,CNC(=O)c1ccc(cc1F)c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2,bevacizumab,11,P15692,,,,,brain cancers;bowel cancers;kidney cancers,Phase 1,,,NCT02386826,INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme,,https://ClinicalTrials.gov/show/NCT02386826
clinicaltrials.gov,cetuximab,9,P00533,,,,bevacizumab,11,P15692,,,,,head and neck cancers,Phase 2,,,NCT00409565,A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer,,https://ClinicalTrials.gov/show/NCT00409565
clinicaltrials.gov,CRLX101,,,,,,bevacizumab,11,P15692,,,,,kidney cancers,Phase 1,,,NCT01625936,CRLX101 Plus Bevacizumab in Advanced RCC,,https://ClinicalTrials.gov/show/NCT01625936
clinicaltrials.gov,DSP-7888,,,,,,bevacizumab,11,P15692,,,,,brain cancers,Phase 2,,,NCT03149003,A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy,WIZARD201G,https://ClinicalTrials.gov/show/NCT03149003
clinicaltrials.gov,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,bevacizumab,11,P15692,,,,,bowel cancers,Phase 3,,,NCT00598156,Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- Tarceva,ACT,https://ClinicalTrials.gov/show/NCT00598156
clinicaltrials.gov,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,bevacizumab,11,P15692,,,,,kidney cancers,Phase 2,,,NCT00193154,OSI-774 and Bevacizumab in the Treatment of Patients With Metastatic Renal Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT00193154
clinicaltrials.gov,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,bevacizumab,11,P15692,,,,,lung cancers,Phase 2,,,NCT01562028,BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC),BELIEF,https://ClinicalTrials.gov/show/NCT01562028
clinicaltrials.gov,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,bevacizumab,11,P15692,,,,,lung cancers,Phase 2,,,NCT00367601,Erlotinib + Bevacizumab for PS 2 Chemotherapy Naêève Non-Small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT00367601
clinicaltrials.gov,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,bevacizumab,11,P15692,,,,,lung cancers,Phase 2,,,NCT00749567,Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT00749567
clinicaltrials.gov,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,bevacizumab,11,P15692,,,,,lung cancers,Phase 3,,,NCT02633189,Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer,BEVERLY,https://ClinicalTrials.gov/show/NCT02633189
clinicaltrials.gov,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,bevacizumab,11,P15692,,,,,mesothelioma,Phase 2,,,NCT00137826,Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma,,https://ClinicalTrials.gov/show/NCT00137826
clinicaltrials.gov,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,bevacizumab,11,P15692,,,,,oesophageal cancers,Phase 2,,,NCT00442507,Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction,OSI3650,https://ClinicalTrials.gov/show/NCT00442507
literature,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,bevacizumab,11,P15692,,,,advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations,lung cancers,Phase 2,25175099,"Between Feb 21, 2011, and March 5, 2012, 154 patients were enrolled. 77 were randomly assigned to receive erlotinib and bevacizumab and 77 to erlotinib alone, of whom 75 patients in the erlotinib plus bevacizumab group and 77 in the erlotinib alone group were included in the efficacy analyses. Median progression-free survival was 16à0 months (95% CI 13à9-18à1) with erlotinib plus bevacizumab and 9à7 months (5à7-11à1) with erlotinib alone (hazard ratio 0à54, 95% CI 0à36-0à79; log-rank test p=0à0015). The most common grade 3 or worse adverse events were rash (19 [25%] patients in the erlotinib plus bevacizumab group vs 15 [19%] patients in the erlotinib alone group), hypertension (45 [60%] vs eight [10%]), and proteinuria (six [8%] vs none). Serious adverse events occurred at a similar frequency in both groups (18 [24%] patients in the erlotinib plus bevacizumab group and 19 [25%] patients in the erlotinib alone group).",,,,
literature,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,bevacizumab,11,P15692,,,,previously treated patients with malignant pleural mesothelioma,mesothelioma,Phase 2,18543326,"Twenty-four eligible patients initiated therapy with erlotinib and bevacizumab between February 2004 and October 2006. There were no complete or partial responses, although 12 patients achieved stable disease for at least 2 cycles of treatment. The median time to progression was 2.2 months (95% confidence interval [CI], 1.4 months-5.9 months). The median survival was 5.8 months (95% CI, 2.8 months-10.1 months). The most common toxicities were rash and diarrhea. There were no treatment-related deaths, intracranial bleeding, or hemoptysis.",,,,
literature,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,bevacizumab,11,P15692,,,,patients with EGFR-positive advanced non-squamous non-small-cell lung cancer,lung cancers,Phase 3,30975627,"Between June 3, 2015, and Aug 31, 2016, 228 patients were randomly assigned to receive erlotinib plus bevacizumab (n=114) or erlotinib alone (n=114). 112 patients in each group were evaluable for efficacy, and safety was evaluated in 112 patients in the combination therapy group and 114 in the monotherapy group. Median follow-up was 12·4 months (IQR 7·0-15·7). At the time of interim analysis, median progression-free survival for patients in the erlotinib plus bevacizumab group was 16·9 months (95% CI 14·2-21·0) compared with 13·3 months (11·1-15·3) for patients in the erlotinib group (hazard ratio 0·605, 95% CI 0·417-0·877; p=0·016). 98 (88%) of 112 patients in the erlotinib plus bevacizumab group and 53 (46%) of 114 patients in the erlotinib alone group had grade 3 or worse adverse events. The most common grade 3-4 adverse event was rash (23 [21%] of 112 patients in the erlotinib plus bevacizumab group vs 24 [21%] of 114 patients in the erlotinib alone group). Nine (8%) of 112 patients in the erlotinib plus bevacizumab group and five (4%) of 114 patients in the erlotinib alone group had serious adverse events. The most common serious adverse events were grade 4 neutropenia (two [2%] of 112 patients in the erlotinib plus bevacizumab group) and grade 4 hepatic dysfunction (one [1%] of 112 patients in the erlotinib plus bevacizumab group and one [1%] of 114 patients in the erlotinib alone group). No treatment-related deaths occurred.",,,,
clinicaltrials.gov,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,bevacizumab,11,P15692,,,,,kidney cancers,Phase 2,,,NCT00651482,Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus),,https://ClinicalTrials.gov/show/NCT00651482
clinicaltrials.gov,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,bevacizumab,11,P15692,,,,,other;soft tissue cancers,Phase 2,,,NCT01661283,SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors,,https://ClinicalTrials.gov/show/NCT01661283
clinicaltrials.gov,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,bevacizumab,11,P15692,,,,,ovarian cancers;female cancers,Phase 2,,,NCT01031381,"Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer",RADBEV,https://ClinicalTrials.gov/show/NCT01031381
clinicaltrials.gov,EZN-2208,,,,,,bevacizumab,11,P15692,,,,,advanced solid cancers,Phase 1,,,NCT01251926,EZN-2208 (Pegylated SN-38) in Combination With Bevacizumab in Refractory Solid Tumors,,https://ClinicalTrials.gov/show/NCT01251926
literature,gefitinib,701,O14578;O14976;O15197;O43293;O43353;O75676;O94768;O94804;O96017;P00519;P00533;P04626;P06239;P07948;P07949;P08581;P08631;P09769;P10721;P12931;P15735;P21709;P21860;P29320;P29322;P29376;P30530;P31152;P36888;P42681;P42684;P42685;P45984;P48730;P49674;P50613;P51451;P51617;P53779;P54756;P54760;P54762;Q09013;Q13163;Q15139;Q15303;Q16659;Q16816;Q52WX2;Q56UN5;Q86V86;Q8N4C8;Q8NE63;Q8TBX8;Q99759;Q9BUB5;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NWZ3;Q9UBE8;Q9UEE5;Q9UF33;Q9UKE5;Q9UNQ0;Q9Y2U5;Q9Y616,"InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)",XGALLCVXEZPNRQ-UHFFFAOYSA-N,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN4CCOCC4,bevacizumab,11,P15692,,,,Patients with Epidermal Growth Factor Receptor Mutant Non-Squamous Non-Small-Cell Lung Cancer,lung cancers,Phase 2,30429415,"We planned a randomized phase 2 trial to assess the efficacy and safety of gefitinib plus bevacizumab in such patients. In this study, subjects will be assigned to receive monotherapy with gefitinib (GEF group) or combination therapy with gefitinib and beva cizumab (GEF+BEV group) as the initial treatment at a ratio of 1:1. EGFR gene mutations are frequently detected in Asian patients with non-small-cell lung cancer. This study may be significant for establishing a new standard treatment.",,,,
literature,gefitinib,701,O14578;O14976;O15197;O43293;O43353;O75676;O94768;O94804;O96017;P00519;P00533;P04626;P06239;P07948;P07949;P08581;P08631;P09769;P10721;P12931;P15735;P21709;P21860;P29320;P29322;P29376;P30530;P31152;P36888;P42681;P42684;P42685;P45984;P48730;P49674;P50613;P51451;P51617;P53779;P54756;P54760;P54762;Q09013;Q13163;Q15139;Q15303;Q16659;Q16816;Q52WX2;Q56UN5;Q86V86;Q8N4C8;Q8NE63;Q8TBX8;Q99759;Q9BUB5;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NWZ3;Q9UBE8;Q9UEE5;Q9UF33;Q9UKE5;Q9UNQ0;Q9Y2U5;Q9Y616,"InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)",XGALLCVXEZPNRQ-UHFFFAOYSA-N,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN4CCOCC4,bevacizumab,11,P15692,,,,Patients with Epidermal Growth Factor Receptor Mutant Non-Squamous Non-Small-Cell Lung Cancer,lung cancers,Phase 2,30429415,"We planned a randomized phase 2 trial to assess the efficacy and safety of gefitinib plus bevacizumab in such patients. In this study, subjects will be assigned to receive monotherapy with gefitinib (GEF group) or combination therapy with gefitinib and beva cizumab (GEF+BEV group) as the initial treatment at a ratio of 1:1. EGFR gene mutations are frequently detected in Asian patients with non-small-cell lung cancer. This study may be significant for establishing a new standard treatment.",,,,
clinicaltrials.gov,lapatinib,2195,O00750;O14733;O43353;O75747;O94804;P00533;P04626;P08684;P09619;P21860;Q13163;Q15303;Q9H2G2;Q9UBF8,"InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)",BCFGMOOMADDAQU-UHFFFAOYSA-N,CS(=O)(=O)CCNCc1oc(cc1)c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2,bevacizumab,11,P15692,,,,,breast cancers,Phase 2,,,NCT00444535,Lapatinib and Bevacizumab for Metastatic Breast Cancer,,https://ClinicalTrials.gov/show/NCT00444535
clinicaltrials.gov,LY01008,,,,,,bevacizumab,11,P15692,,,,,lung cancers,Phase 3,,,NCT03533127,A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Na√Øve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT03533127
clinicaltrials.gov,LY01008,,,,,,bevacizumab,11,P15692,,,,,lung cancers,Phase 3,,,NCT03533127,A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Na√Øve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT03533127
clinicaltrials.gov,MIL60,,,,,,bevacizumab,11,P15692,,,,,lung cancers,Phase 3,,,NCT03196986,MIL60 Versus Bevacizumab in Patients With Treatment-naêève Non-squamous Non-small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT03196986
clinicaltrials.gov,MINT1526A,,,,,,bevacizumab,11,P15692,,,,,,Phase 1,,,NCT01139723,"A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors",,https://ClinicalTrials.gov/show/NCT01139723
clinicaltrials.gov,Mirvetuximab Soravtansine,,,,,,bevacizumab,11,P15692,,,,Endometrial Cancer|Endometrial Adenocarcinoma|Endometrial Serous Adenocarcinoma|Endometrial Clear Cell Adenocarcinoma,,Phase 2,,,NCT03836157,,,
clinicaltrials.gov,MRZ,539795,,"InChI=1S/C6H13N3/c7-6(8)9-4-2-1-3-5-9/h1-5H2,(H3,7,8)",QUUYRYYUKNNNNS-UHFFFAOYSA-N,NC(=N)N1CCCCC1,bevacizumab,11,P15692,,,,,brain cancers,Phase 1/2,,,NCT02330562,Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab,,https://ClinicalTrials.gov/show/NCT02330562
clinicaltrials.gov,nintedanib,37936,P11362;P22455;P22607;P21802;P09619;P16234;P35968;P17948;P35916,"InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,32H,15-18,20H2,1-3H3,(H,33,38)/b29-28-",XZXHXSATPCNXJR-ZIADKAODSA-N,COC(=O)c1ccc2\C(=C(\Nc3ccc(cc3)N(C)C(=O)CN4CCN(C)CC4)/c5ccccc5)\C(=O)Nc2c1,bevacizumab,11,P15692,,,,,kidney cancers;bowel cancers;lung cancers;ovarian cancers;cervical cancers,Phase 1,,,NCT02835833,Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT02835833
literature,nintedanib,37936,P11362;P22455;P22607;P21802;P09619;P16234;P35968;P17948;P35916,"InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,32H,15-18,20H2,1-3H3,(H,33,38)/b29-28-",XZXHXSATPCNXJR-ZIADKAODSA-N,COC(=O)c1ccc2\C(=C(\Nc3ccc(cc3)N(C)C(=O)CN4CCN(C)CC4)/c5ccccc5)\C(=O)Nc2c1,bevacizumab,11,P15692,,,,patients with advanced solid tumors,advanced solid tumours,Phase 1b,30603797,"Eighteen patients with advanced tumors [lung (n_=_9), colon (n_=_8), and cervical (n_=_1)] previously treated with at least two lines of chemotherapy including bevacizumab (n_=_9, 50%) were enrolled. The highest dose of nintedanib was 200 mg twice a day with no observed dose-limiting toxicities (DLT). Common adverse events (AE) were fatigue (grade 1-3) and diarrhea (grade 1-2). Durable clinical response was observed in 55% patients pretreated with bevacizumab (1 complete and 4 stable response). Better disease control was correlated with higher than median baseline values for VEFGR2 and E-selectin, and lower levels for SDF-1_.",NCT02835833,,,
clinicaltrials.gov,niraparib,919241,Q9UGN5;P09874,"InChI=1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)/t14-/m1/s1",PCHKPVIQAHNQLW-CQSZACIVSA-N,NC(=O)c1cccc2cn(nc12)c3ccc(cc3)[C@@H]4CCCNC4,bevacizumab,11,P15692,,,,,ovarian cancers,Phase 1/2,,,NCT02354131,Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial ovarian Cancers,AVANOVA,https://ClinicalTrials.gov/show/NCT02354131
clinicaltrials.gov,niraparib,919241,Q9UGN5;P09874,"InChI=1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)/t14-/m1/s1",PCHKPVIQAHNQLW-CQSZACIVSA-N,NC(=O)c1cccc2cn(nc12)c3ccc(cc3)[C@@H]4CCCNC4,bevacizumab,11,P15692,,,,,ovarian cancers;female cancers,Phase 2,,,NCT03326193,"Phase 2, A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy",,https://ClinicalTrials.gov/show/NCT03326193
clinicaltrials.gov,nivolumab,,Q15116,,,,bevacizumab,11,P15692,,,,,liver cancers,Phase 1,,,NCT03382886,Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma,NUANCE,https://ClinicalTrials.gov/show/NCT03382886
clinicaltrials.gov,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,bevacizumab,11,P15692,,,,,advanced solid cancers,Phase 1,,,NCT00710268,Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid Tumours,,https://ClinicalTrials.gov/show/NCT00710268
clinicaltrials.gov,osimertinib,1371518,P00533;P04626;P21860;Q15303;P00533,"InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)",DUYJMQONPNNFPI-UHFFFAOYSA-N,COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2nccc(n2)c3cn(C)c4ccccc34,bevacizumab,11,P15692,,,,,lung cancers,Phase 1/2,,,NCT02803203,Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers,,https://ClinicalTrials.gov/show/NCT02803203
clinicaltrials.gov,panobinostat,523996,Q9BY41;Q969S8;O15379;P56524;Q8WUI4;Q9UQL6;Q9UKV0;Q13547;Q92769;Q9UBN7;Q96DB2,"InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+",FPOHNWQLNRZRFC-ZHACJKMWSA-N,Cc1[nH]c2ccccc2c1CCNCc3ccc(\C=C\C(=O)NO)cc3,bevacizumab,11,P15692,,,,,brain cancers,Phase 1/2,,,NCT00859222,LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma,,https://ClinicalTrials.gov/show/NCT00859222
literature,pazopanib,200268,O00238;O00444;O14965;O14976;O15197;O43353;O60331;O60674;O75716;O94804;O95819;P00519;P04049;P06239;P06241;P07332;P07333;P07947;P07948;P07949;P08581;P08631;P08922;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P16591;P17948;P19525;P21127;P21802;P22455;P22607;P27448;P29376;P29597;P33981;P35590;P35916;P35968;P36888;P37173;P42681;P42684;P42685;P43405;P45983;P45985;P51451;P51617;P51955;P52333;P52564;P53667;P53671;P53779;P57059;P80192;Q00536;Q02763;Q02779;Q08345;Q12851;Q12866;Q13163;Q13233;Q13470;Q13546;Q13705;Q13882;Q14012;Q16584;Q16832;Q2M2I8;Q56UN5;Q6P3R8;Q7L7X3;Q8IVH8;Q8TBX8;Q92918;Q96NX5;Q9BVS4;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K8;Q9H3Y6;Q9NRP7;Q9NSY1;Q9UBE8;Q9UBF8;Q9UKE5;Q9UL54;Q9UM73;Q9UQ88;Q9UQB9;Q9Y2U5;Q9Y4K4;Q9Y616,"InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)",CUIHSIWYWATEQL-UHFFFAOYSA-N,CN(c1ccc2c(C)n(C)nc2c1)c3ccnc(Nc4ccc(C)c(c4)S(=O)(=O)N)n3,bevacizumab,11,P15692,,,,Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors,kidney cancers;advanced solid cancers,Phase 1,24705975,"The apparent oral clearance (CL/F, mean value of 0.60 L/h) presented an inter-individual variability of 40 %, and an inter-occasion of 27 %. A modest but statistically significant decrease in CL/F was observed from Day 1 to Day 15 (-16.4, 95 % confidence interval of -8.5 to -27.2 %). However, trough pazopanib concentrations observed at Day 16 (24 h after the bevacizumab iv infusion) were not significantly higher than those observed just before the beginning of the bevacizumab iv infusion, suggesting that the pharmacokinetic change between Day 1 and Day 15 was not due to an interaction of bevacizumab. Overall, the mean observed concentrations at the maximum tolerated pazopanib dose (600 mg) at both Day 1 and Day 15 were higher than those observed at 800 mg once daily level (corresponding to the recommended dose when given alone) during the first-in-man phase 1 study of pazopanib in monochemotherapy. This first population pharmacokinetic analysis of pazopanib shows that inter-individual and inter-study pharmacokinetic variability emphasize the need for further evaluation of therapeutic drug monitoring for pazopanib as suggested for other tyrosine kinase inhibitors.",,,,
literature,plitidepsin,795485,,"InChI=1S/C57H87N7O15/c1-15-33(8)46-44(66)29-45(67)79-49(32(6)7)48(68)34(9)50(69)58-39(26-30(2)3)54(73)64-25-17-19-41(64)56(75)62(13)43(28-37-20-22-38(77-14)23-21-37)57(76)78-36(11)47(52(71)59-46)60-51(70)42(27-31(4)5)61(12)55(74)40-18-16-24-63(40)53(72)35(10)65/h20-23,30-34,36,39-44,46-47,49,66H,15-19,24-29H2,1-14H3,(H,58,69)(H,59,71)(H,60,70)/t33-,34-,36+,39-,40-,41-,42+,43-,44-,46+,47-,49-/m0/s1",UUSZLLQJYRSZIS-LXNNNBEUSA-N,CC[C@H](C)[C@H]1NC(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H]2CCCN2C(=O)C(=O)C)[C@@H](C)OC(=O)[C@H](Cc3ccc(OC)cc3)N(C)C(=O)[C@@H]4CCCN4C(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)C(=O)[C@@H](OC(=O)C[C@@H]1O)C(C)C,bevacizumab,11,P15692,,,,Patients with refractory solid tumors,advanced solid cancers,Phase 1,27610894,"Dose-limiting toxicities occurred in two out of six patients treated at the maximum dose tested (plitidepsin 4.8_mg/m and bevacizumab 10_mg/kg) and consisted of grade 3 fatigue, grade 3 myalgia, and two grade 2/3 alanine aminotransferase increases lasting for more than 7 days or leading to subsequent cycle delay greater than 2 weeks (n=1 each). The recommended dose for the combination of plitidepsin with bevacizumab was 3.8_mg/m for plitidepsin and 10_mg/kg for bevacizumab every 2 weeks. Most frequent treatment-related adverse events were nausea, vomiting, fatigue, epistaxis, and headache. Relevant hematological toxicity was minimal. Objective disease responses were not observed; however, stable disease (>3 months) was observed in four patients with colorectal cancer, renal cancer, and cervical cancer. Combining plitidepsin with bevacizumab combination is feasible. Stable disease was the best response obtained.",,,,
clinicaltrials.gov,ridaforolimus,1020194,P42345,"InChI=1S/C53H84NO14P/c1-32-18-14-13-15-19-33(2)44(63-8)30-40-23-21-38(7)53(61,67-40)50(58)51(59)54-25-17-16-20-41(54)52(60)66-45(35(4)28-39-22-24-43(46(29-39)64-9)68-69(11,12)62)31-42(55)34(3)27-37(6)48(57)49(65-10)47(56)36(5)26-32/h13-15,18-19,27,32,34-36,38-41,43-46,48-49,57,61H,16-17,20-26,28-31H2,1-12H3/b15-13+,18-14+,33-19+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",BUROJSBIWGDYCN-GAUTUEMISA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OP(=O)(C)C,bevacizumab,11,P15692,,,,,,Phase 1,,,NCT00781846,Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED),,https://ClinicalTrials.gov/show/NCT00781846
literature,RO4929097,,,,,,bevacizumab,11,P15692,,,,patients with recurrent malignant glioma,brain cancers,Phase 1,27826680,"Of the three subjects treated with the highest dose of RO4929097, one grade 3 toxicity and one grade 2 toxicity were observed. Definitive maximum tolerated dose of RO4929097 in combination with bevacizumab was not identified due to manufacturer's decision to halt drug production. 2 of 12 evaluable subjects demonstrated radiographic response; one subject experienced CR and the second PR. The median overall survival was 10.9_months with a median progression-free survival of 3.7_months. Two subjects remained free of disease progression at 6_months from treatment initiation. PK evaluation did not identify clinically significant drug-drug interactions. All analyzed tissue specimens revealed activation of notch signaling. Combination of RO4929097 and bevacizumab was well-tolerated. Given the compelling scientific rationale, additional studies of antiangiogenic and notch signaling inhibitors should be considered.",,,,
literature,S-1,,,,,,bevacizumab,11,P15692,,,,patients previously treated for advanced non-squamous non-small cell lung_cancer_(NSCLC),lung cancers,Phase 2,28455584,"We enrolled 30 patients. One patient had never received platinum-based therapy. Five patients had activating mutations of the epidermal growth factor receptor gene, of whom four had received tyrosine kinase inhibitors before this study. The RR was 6.7% [95% confidence interval (CI)_1.8-21.3%], and the disease control rate (DCR) was 80% (95% CI 62.7-90.5%). Median PFS was 4.8_months (95% CI 2.7-6.4_months], and median OS was 13.8_months (95% CI 8.4_months-not applicable). Patients did not experience any Grade 4 toxicity or treatment-related death. Grade 3 hematologic toxicity (anemia) occurred in one patient (3.3%). The main Grade 3 non-hematologic toxicities were anorexia (10%), infection (10%), and diarrhea (6.7%).",,,,
clinicaltrials.gov,sirolimus,344,P06730;P08183;P08684;P11712;P33261;P42345;P62942;Q13451;Q53EL6;Q9Y6L6,"InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1",QFJCIRLUMZQUOT-HPLJOQBZSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1O,bevacizumab,11,P15692,,,,,liver cancers,Phase 1,,,NCT00467194,Sirolimus and Bevacizumab in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery,,https://ClinicalTrials.gov/show/NCT00467194
literature,sirolimus,344,P06730;P08183;P08684;P11712;P33261;P42345;P62942;Q13451;Q53EL6;Q9Y6L6,"InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1",QFJCIRLUMZQUOT-HPLJOQBZSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1O,bevacizumab,11,P15692,,,,unresectable hepatocellular carcinoma,liver cancers,Phase 1,23265712,"Twenty-four participants were treated. There were two dose limiting toxicities with rapamycin 5mg: grade 3 thrombocytopenia and grade 3 mucositis. The maximally tolerated dose of rapamycin was 4 mg. Adverse events (grade 1-2) included hyperglycaemia (83%), thrombocytopenia (75%), fatigue (46%), mucositis (46%), anorexia (42%), diarrhoea (33%) and proteinuria (12.5%). Of 20 evaluable participants, one reached complete response that lasted 4.5 months, two reached partial response, 14 reached stable disease and three had progressive disease. Median overall survival was 9.4 months; progression-free survival was 5.5 months. Dose level and steady state area under the concentration time curve for hour zero to infinity of rapamycin correlated inversely with blood flow rate and change in permeability-surface area. After 22 days of treatment, there were significant reductions from baseline in blood flow rate, permeability-surface area and fractional intracellular blood volume.",,,,
literature,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,bevacizumab,11,P15692,,,,Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma,liver cancers,Phase 1/2,27943153,"Seventen patients were enrolled in the phase I component. Dose-limiting toxicities included grade 3 hand/foot skin reaction, fatigue, hypertension, alanine/aspartate aminotransferase increase, dehydration, hypophosphatemia, creatinine increase, hypoglycemia, nausea/vomiting, and grade 4 hyponatremia. Seven patients were enrolled in the phase II component at the MTD: sorafenib 200_mg BID days 1-28 and bevacizumab 2.5_mg/kg every other week; 57% (4/7) had grade 3 AEs at least possibly related to treatment. No responses were observed in the phase II portion. Estimated median time to progression and survival were 8.6_months (95% CI: 0.4-16.3) and 13.3_months (95% CI 4.4 - not estimable), respectively.",,,,
clinicaltrials.gov,sunitinib,1055,O00238;O00444;O00506;O14578;O14730;O14757;O14965;O14976;O15075;O15111;O15146;O15197;O15530;O43172;O43283;O43293;O43318;O60285;O60674;O75116;O75385;O75460;O75582;O75676;O75716;O75914;O94768;O94804;O94806;O94921;O95747;O95819;O95835;O96013;O96017;P00519;P04629;P06213;P06239;P06241;P07332;P07333;P07947;P07948;P07949;P08069;P08581;P08631;P09619;P09769;P0C264;P10721;P11362;P11802;P12931;P14616;P15735;P16234;P16591;P17252;P17948;P19525;P19784;P21802;P22455;P22607;P23443;P23458;P27448;P29320;P29376;P29597;P30291;P30530;P31751;P32298;P33981;P35590;P35916;P35968;P36507;P36888;P42679;P42684;P42685;P45984;P45985;P46734;P48729;P48730;P49674;P49759;P49760;P50613;P51451;P51617;P51812;P51955;P52333;P52564;P53355;P53779;P54646;P54756;P54760;P54762;P57058;P57059;P57078;P68400;P78356;P78362;P78368;P80192;P80370;Q00535;Q00536;Q00537;Q02750;Q04759;Q05397;Q06187;Q06418;Q07002;Q07912;Q08345;Q08881;Q12809;Q12851;Q12852;Q12866;Q13043;Q13131;Q13163;Q13164;Q13188;Q13464;Q13470;Q13523;Q13546;Q13554;Q13555;Q13557;Q13627;Q13873;Q13882;Q14012;Q14164;Q14289;Q14680;Q15139;Q15208;Q15349;Q15375;Q15418;Q15746;Q15831;Q15835;Q16288;Q16512;Q16513;Q16566;Q16584;Q16620;Q16816;Q16832;Q2M2I8;Q32MK0;Q52WX2;Q56UN5;Q5S007;Q6PHR2;Q6XUX3;Q6ZN16;Q7KZI7;Q7L7X3;Q86UE8;Q86V86;Q86YV6;Q86Z02;Q8IU85;Q8IVH8;Q8IWQ3;Q8IY84;Q8IYT8;Q8N4C8;Q8N568;Q8N5S9;Q8N752;Q8NE63;Q8NEV4;Q8NFD2;Q8TDC3;Q8TDR2;Q8TDX7;Q8WTQ7;Q8WXR4;Q92630;Q92772;Q92918;Q96BR1;Q96GD4;Q96L34;Q96NX5;Q96RR4;Q96SB4;Q99755;Q99759;Q9BRS2;Q9BUB5;Q9BVS4;Q9BXA7;Q9BYT3;Q9BZL6;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K2;Q9H2K8;Q9H2X6;Q9H422;Q9HAZ1;Q9HBH9;Q9HCP0;Q9NQU5;Q9NRH2;Q9NRM7;Q9NSY1;Q9NWZ3;Q9NYY3;Q9P0L2;Q9P1W9;Q9P286;Q9P289;Q9P2K8;Q9UEE5;Q9UEW8;Q9UF33;Q9UHD2;Q9UIK4;Q9UK32;Q9UKE5;Q9UKI8;Q9UM73;Q9UPE1;Q9UPZ9;Q9UQB9;Q9UQM7;Q9Y2H1;Q9Y2H9;Q9Y2U5;Q9Y463;Q9Y4K4;Q9Y616;Q9Y6E0;Q9Y6M4;Q9Y6R4,"InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-",WINHZLLDWRZWRT-ATVHPVEESA-N,CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C\2/C(=O)Nc3ccc(F)cc23)c1C,bevacizumab,11,P15692,,,,,kidney cancers,Phase 2,,,NCT00556205,Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT00556205
literature,temsirolimus,401,P42345,"InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1",CBPNZQVSJQDFBE-FUXHJELOSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO,bevacizumab,11,P15692,,,,advanced renal cell carcinoma,kidney cancers,Phase 2,21664867,"Between March 3, 2008 and May 6, 2009, 171 patients were randomly assigned: 88 to the experimental group (group A), 42 to group B, and 41 to group C. PFS at 48 weeks was 29.5% (26 of 88 patients, 95% CI 20.0-39.1) in group A, 35.7% (15 of 42, 21.2-50.2) in group B, and 61.0% (25 of 41, 46.0-75.9) in group C. Median PFS was 8.2 months (95% CI 7.0-9.6) in group A, 8.2 months (5.5-11.7) in group B, and 16.8 months (6.0-26.0) in group C. 45 (51%) of 88 patients in group A stopped treatment for reasons other than progression compared with five (12%) of 42 in group B and 15 (38%) of 40 in group C. Grade 3 or worse adverse events were reported in 68 (77%) of 88 patients in group A versus 25 (60%) of 42 in group B and 28 (70%) of 40 in group C. Serious adverse events were reported in 39 (44%) of 88, 13 (31%) of 42, and 18 (45%) of 40 patients in groups A, B, and C, respectively.",,,,
literature,temsirolimus,401,P42345,"InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1",CBPNZQVSJQDFBE-FUXHJELOSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO,bevacizumab,11,P15692,,,,advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors,kidney cancers,Phase 2,25556030,"Maximum tolerated dose was not reached at the maximum dose administered in 12 phase I patients. Forty evaluable patients were treated with the phase II recommended dose (temsirolimus 25_mg IV weekly and bevacizumab 10_mg/kg IV every 2_weeks). The 6-month progression-free rate was 40_% (16/40 pts). Median PFS was 5.9 (4-7.8) months, and median OS was 20.6 (11.5-23.7)_months. Partial response, stable disease, and progressive disease were seen in 23, 63, and 14_% of patients, respectively. Most common grade 3-4 AEs included fatigue (17.8_%), hypertriglyceridemia (11.1_%), stomatitis (8.9_%), proteinuria (8.9_%), abdominal pain (6.7_%), and anemia (6.7_%). Baseline levels of serum sFLT-1 and VEGF-A were inversely correlated with PFS and OS, respectively.",,,,
clinicaltrials.gov,TPI 287,,,,,,bevacizumab,11,P15692,,,,,brain cancers,Phase 1/2,,,NCT01933815,Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma,,https://ClinicalTrials.gov/show/NCT01933815
clinicaltrials.gov,TPI 287,,,,,,bevacizumab,11,P15692,,,,,brain cancers,Phase 2,,,NCT02047214,Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy,,https://ClinicalTrials.gov/show/NCT02047214
clinicaltrials.gov,TPI 287,,,,,,bevacizumab,11,P15692,,,,,brain cancers;central nervous system cancers,Phase 1/2,,,NCT01582152,Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma,,https://ClinicalTrials.gov/show/NCT01582152
clinicaltrials.gov,valporic acid,382,P51649,"InChI=1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10)",NIJJYAXOARWZEE-UHFFFAOYSA-N,CCCC(CCC)C(=O)O,bevacizumab,11,P15692,,,,,,Phase 1,,,NCT00530907,Valproic Acid and Bevacizumab in Patients With Advanced Cancer,,https://ClinicalTrials.gov/show/NCT00530907
clinicaltrials.gov,VGX-100,,,,,,bevacizumab,11,P15692,,,,,advanced solid cancers,Phase 1,,,NCT01514123,Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT01514123
clinicaltrials.gov,vorinostat,260,O15379;O75376;P56524;Q13547;Q8WUI4;Q92769;Q969S8;Q96DB2;Q9BY41;Q9UBN7;Q9UKV0;Q9UQL6;Q9Y618,"InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)",WAEXFXRVDQXREF-UHFFFAOYSA-N,ONC(=O)CCCCCCC(=O)Nc1ccccc1,bevacizumab,11,P15692,,,,,brain cancers,Phase 1/2,,,NCT01266031,Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma,,https://ClinicalTrials.gov/show/NCT01266031
clinicaltrials.gov,vorinostat,260,O15379;O75376;P56524;Q13547;Q8WUI4;Q92769;Q969S8;Q96DB2;Q9BY41;Q9UBN7;Q9UKV0;Q9UQL6;Q9Y618,"InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)",WAEXFXRVDQXREF-UHFFFAOYSA-N,ONC(=O)CCCCCCC(=O)Nc1ccccc1,bevacizumab,11,P15692,,,,,kidney cancers,Phase 1/2,,,NCT00324870,Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer,,https://ClinicalTrials.gov/show/NCT00324870
clinicaltrials.gov,BGB-A317,,,,,,BGB-290,,,,,,,advanced solid cancers,Phase 1,,,NCT02660034,"The Safety, Pharmacokinetics and Antitumor Activity of the BGB-A317 in Combination With the BGB-290 in Subjects With Advanced Solid Tumors",,https://ClinicalTrials.gov/show/NCT02660034
clinicaltrials.gov,BGB-3111,,,,,,BGB-A317,,,,,,,lymphoma;leukemia,Phase 1,,,NCT02795182,BGB-3111 in Combination With BGB-A317 in Subjects With B-cell Malignancies,,https://ClinicalTrials.gov/show/NCT02795182
clinicaltrials.gov,BGB-A333,,,,,,BGB-A317,,,,,,,advanced solid cancers,Phase 1/2,,,NCT03379259,Study of BGB-A333 Alone and in Combination With BGB-A317 in Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT03379259
clinicaltrials.gov,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,BGB324,,P30530,,,,,lung cancers,Phase 1/2,,,NCT02424617,A Study of BGB324 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT02424617
clinicaltrials.gov,BHQ880,,,,,,BHQ990,,,,,,,multiple myeloma,Phase 2,,,NCT01337752,Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency,,https://ClinicalTrials.gov/show/NCT01337752
clinicaltrials.gov,BI 754111,,,,,,BI 754091,,,,,,,lung cancers,Phase 1,,,NCT03156114,This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.,,https://ClinicalTrials.gov/show/NCT03156114
clinicaltrials.gov,BI 765063,,,,,,BI 754091,,,,,,,,,,,NCT03990233,A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours,,https://ClinicalTrials.gov/show/NCT03990233
clinicaltrials.gov,BI 836880,,,,,,BI 754091,,,,,,,lung cancers,Phase 1,,,NCT03468426,This Study Aims to Find the Best Doses of BI 836880 Combined With BI 754091 in Patients With a Certain Type of Advanced Lung Cancer (NSCLC),,https://ClinicalTrials.gov/show/NCT03468426
clinicaltrials.gov,BI 836880,,,,,,BI 754091,,,,,,,,,,,NCT03972150,A Study to Find the Best Dose of BI 836880 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer,,https://ClinicalTrials.gov/show/NCT03972150
clinicaltrials.gov,BI 891065,,,,,,BI 754091,,,,,,,lung cancers,Phase 1,,,NCT03166631,A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread,,https://ClinicalTrials.gov/show/NCT03166631
clinicaltrials.gov,BI 907828,,,,,,BI 754091,,,,,,,,,,,NCT03964233,A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With BI 754091 and 754111,,https://ClinicalTrials.gov/show/NCT03964233
clinicaltrials.gov,BI 754091,,,,,,BI 754111,,,,,,,,Phase 1,,,NCT03433898,This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer,,https://ClinicalTrials.gov/show/NCT03433898
clinicaltrials.gov,BI 754091,,,,,,BI 754111,,,,,,,advanced solid cancers,Phase 2,,,NCT03697304,Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 na√Øve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours.,,https://ClinicalTrials.gov/show/NCT03697304
clinicaltrials.gov,BI 754091,,,,,,BI 754111,,,,,,,advanced solid cancers,Phase 2,,,NCT03697304,Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 na√Øve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours.,,https://ClinicalTrials.gov/show/NCT03697304
clinicaltrials.gov,venetoclax,1150189,P10415,"InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)",LQBVNQSMGBZMKD-UHFFFAOYSA-N,CC1(C)CCC(=C(C1)c2ccc(Cl)cc2)CN3CCN(CC3)c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c(c5)N(=O)=O)c(Oc7cnc8[nH]ccc8c7)c4,BI 836826,,,,,,,leukemia,Phase 1,,,NCT03343678,This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax,,https://ClinicalTrials.gov/show/NCT03343678
clinicaltrials.gov,F16IL2,,P24821,,,,BI 836858,,,,,,,leukemia,Phase 1,,,NCT03207191,Trial to Find and Investigate a Safe Dose of F16IL2 and BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation,PHIBI,https://ClinicalTrials.gov/show/NCT03207191
clinicaltrials.gov,Ara-C,,,,,,BL-8040,,P61073,,,,,leukemia,Phase 2,,,NCT01838395,Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients,,https://ClinicalTrials.gov/show/NCT01838395
clinicaltrials.gov,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,BNC105P,,,,,,,kidney cancers,Phase 1/2,,,NCT01034631,BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT01034631
clinicaltrials.gov,alisertib,,O14965,"InChI=1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33)",ZLHFILGSQDJULK-UHFFFAOYSA-N,COc1cccc(F)c1C2=NCc3cnc(Nc4ccc(C(=O)O)c(OC)c4)nc3c5ccc(Cl)cc25,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,,multiple myeloma,Phase 1/2,,,NCT01034553,Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma,,https://ClinicalTrials.gov/show/NCT01034553
clinicaltrials.gov,AT7519M,,,,,,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,,multiple myeloma,Phase 1/2,,,NCT01183949,Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma,,https://ClinicalTrials.gov/show/NCT01183949
clinicaltrials.gov,bevacizumab,11,P15692,,,,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,,kidney cancers,Phase 1/2,,,NCT00184015,"Bortezomib and Bevacizumab (""BB-mib-mab"") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)",,https://ClinicalTrials.gov/show/NCT00184015
clinicaltrials.gov,bevacizumab,11,P15692,,,,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,,lung cancers,Phase 1/2,,,NCT00411593,Phase I-II for Patients With Recurrent or Refractory Non-small Cell Lung Cancer (NSCLC),,https://ClinicalTrials.gov/show/NCT00411593
clinicaltrials.gov,bevacizumab,11,P15692,,,,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,,lymphoma;multiple myeloma,Phase 1,,,NCT00428545,Bevacizumab and Bortezomib in Patients With Advanced Malignancy,,https://ClinicalTrials.gov/show/NCT00428545
literature,daratumumab,,,,,,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,Untreated Melanoma,skin cancers,Phase 3,29231133,"At a median follow-up of 16.5 months in a prespecified interim analysis, the 18-month progression-free survival rate was 71.6% (95% confidence interval [CI], 65.5 to 76.8) in the daratumumab group and 50.2% (95% CI, 43.2 to 56.7) in the control group (hazard ratio for disease progression or death, 0.50; 95% CI, 0.38 to 0.65; P<0.001). The overall response rate was 90.9% in the daratumumab group, as compared with 73.9% in the control group (P<0.001), and the rate of complete response or better (including stringent complete response) was 42.6%, versus 24.4% (P<0.001). In the daratumumab group, 22.3% of the patients were negative for minimal residual disease (at a threshold of_1_tumor cell per 105_white cells), as compared with 6.2% of those in the control group (P<0.001). The most common adverse events of grade 3 or 4 were hematologic: neutropenia (in 39.9% of the patients in the daratumumab group and in 38.7% of those in the control group), thrombocytopenia (in 34.4% and 37.6%, respectively), and anemia (in 15.9% and 19.8%, respectively). The rate of grade 3 or 4 infections was 23.1% in the daratumumab group and 14.7% in the control group; the rate of treatment discontinuation due to infections was 0.9% and_1.4%, respectively. Daratumumab-associated infusion-related reactions occurred in 27.7% of the patients.",,,,
clinicaltrials.gov,DFMO,1226,P11926,"InChI=1S/C6H12F2N2O2.ClH.H2O/c7-4(8)6(10,5(11)12)2-1-3-9;;/h4H,1-3,9-10H2,(H,11,12);1H;1H2",FJPAMFNRCFEGSD-UHFFFAOYSA-N,O.Cl.NCCCC(N)(C(F)F)C(=O)O,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,,neuroblastoma,Phase 1/2,,,NCT02139397,Study of DFMO in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma,,https://ClinicalTrials.gov/show/NCT02139397
clinicaltrials.gov,erismodegib,1024199,Q99835,"InChI=1S/C26H26F3N3O3/c1-16-14-32(15-17(2)34-16)24-12-9-20(13-30-24)31-25(33)23-6-4-5-22(18(23)3)19-7-10-21(11-8-19)35-26(27,28)29/h4-13,16-17H,14-15H2,1-3H3,(H,31,33)/t16-,17+",VZZJRYRQSPEMTK-CALCHBBNSA-N,C[C@@H]1CN(C[C@H](C)O1)c2ccc(NC(=O)c3cccc(c3C)c4ccc(OC(F)(F)F)cc4)cn2,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,,multiple myeloma,Phase 2,,,NCT02254551,Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma,,https://ClinicalTrials.gov/show/NCT02254551
clinicaltrials.gov,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,,,Phase 1,,,NCT00895687,Study of Erlotinib in Combination With Bortezomib,,https://ClinicalTrials.gov/show/NCT00895687
clinicaltrials.gov,GO-203-2C,,,,,,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,,multiple myeloma,Phase 1,,,NCT02658396,GO-203-2C + Bortezomib For Relapsed Or Refractory MM,,https://ClinicalTrials.gov/show/NCT02658396
clinicaltrials.gov,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,,lymphoma,Phase 1/2,,,NCT02356458,Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma,,https://ClinicalTrials.gov/show/NCT02356458
clinicaltrials.gov,KW-2478,,,,,,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,,multiple myeloma,Phase 1/2,,,NCT01063907,A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma,,https://ClinicalTrials.gov/show/NCT01063907
literature,KW-2478,,,,,,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,patients with relapsed/refractory multiple myeloma,multiple myeloma,Phase 1/2,28873084,"The maximum tolerated dose was not reached during_phase_I and the RP2D was KW-2478 175_mg_m-2_plus BTZ_1.3_mg_m-2_on days_1, 4, 8, and 11 every 3 weeks. In the efficacy evaluable_phase_I/II population treated at the RP2D (n=79), the objective response rate was 39.2% (95% confidence interval: 28.4-50.9%), clinical benefit rate 51.9% (40.4-63.3%), median progression-free survival 6.7 (5.9-not reached (NR)) months, and median duration of response 5.5 (4.9-NR) months. In the_phase_I/II safety population (n=95), the most frequently observed treatment-related grade 3/4 adverse events were diarrhoea, fatigue, and neutropenia (each in 7.4% of patients), and nausea and thrombocytopenia (each in 5.3%).",,,,
clinicaltrials.gov,lenalidomide,718,O14920,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,Nc1cccc2C(=O)N(Cc12)C3CCC(=O)NC3=O,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,,multiple myeloma,Phase 3,,,NCT01191060,Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years,IFM/DFCI2009,https://ClinicalTrials.gov/show/NCT01191060
literature,NVP-AUY922,480574,,"InChI=1S/C26H31N3O5/c1-4-27-26(32)24-23(18-7-5-17(6-8-18)15-29-9-11-33-12-10-29)25(34-28-24)20-13-19(16(2)3)21(30)14-22(20)31/h5-8,13-14,16,30-31H,4,9-12,15H2,1-3H3,(H,27,32)",NDAZATDQFDPQBD-UHFFFAOYSA-N,CCNC(=O)c1noc(c2cc(C(C)C)c(O)cc2O)c1c3ccc(CN4CCOCC4)cc3,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,relapsed or refractory multiple myeloma,multiple myeloma,Phase 1/1b,25809731,"Twenty-four patients received NVP-AUY922 monotherapy at doses of 8 to 70 mg/m(2) . One dose-limiting toxicity (DLT) was observed (grade 3 blurred vision at 70 mg/m(2) ); no MTD was reached. The recommended phase 2 dose was 70 mg/m(2) . The most frequent drug-related adverse events (AEs) were diarrhea, nausea, and ocular toxicities. Grade 3/4 AEs were uncommon (<10%). Eight patients discontinued treatment because of AEs; 5 had ocular toxicities (_45 mg/m(2) ). The best response was stable disease in 66.7% of the patients. There were no partial or complete responses. Five patients received NVP-AUY922 (which was started at 50 mg/m(2) ) plus bortezomib (1.3 mg/m(2) ). Three of these patients experienced DLT. No further dose escalation was performed; the MTD for NVP-AUY922 plus bortezomib was not established.",,,,
literature,palbociclib,149415,P11802;P20248;P24385;P24941;P30279;P30281;P36888;P50750;P52333;Q00534,"InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)",AHJRHEGDXFFMBM-UHFFFAOYSA-N,CC(=O)C1=C(C)c2cnc(Nc3ccc(cn3)N4CCNCC4)nc2N(C5CCCC5)C1=O,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,previously treated mantle cell lymphoma,lymphoma,Phase 1,31120355,"Two subjects experienced dose limiting toxicity (DLT): thrombocytopenia (dose level 1) and neutropenia (dose level 3). Although no DLTs were seen at dose level 4, all patients required dose delays during cycle 2 due to cytopenias, and the study team decided to stop the trial. Four of 19 patients achieved a clinical response, including one patient with a complete response. Three patients received treatment for more than one year, including one patient receiving single-agent palbociclib for more than 6 years. The combination of palbociclib 125_mg on days 1-12 plus bortezomib 1.0_mg/m2 on days 8, 11, 15, and 18 of a 21-day cycle is feasible and active in previously treated MCL, with the primary toxicity being myelosuppression.",NCT01111188,,,
clinicaltrials.gov,panobinostat,523996,Q9BY41;Q969S8;O15379;P56524;Q8WUI4;Q9UQL6;Q9UKV0;Q13547;Q92769;Q9UBN7;Q96DB2,"InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+",FPOHNWQLNRZRFC-ZHACJKMWSA-N,Cc1[nH]c2ccccc2c1CCNCc3ccc(\C=C\C(=O)NO)cc3,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,,lymphoma,Phase 1,,,NCT01504776,Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL),BUS48T,https://ClinicalTrials.gov/show/NCT01504776
literature,rituximab,16,P11836,,,,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,relapsed or refractory mantle cell and follicular lymphoma,lymphoma,Phase 2,24048792,"R-bortezomib resulted in a statistically significant improvement in overall survival in Hu-MCL-SCID mice. In the clinical trial, the overall response rate was 40% in all 25 patients, 55% in patients with follicular lymphoma, and 29% in patients with MCL. The estimated 2-year progression-free survival (PFS) rate was 24% (95% confidence interval [CI], 10%-53%) in all patients and 60% (95% CI, 20%-85%) in responding patients. Thirteen patients (52%) developed grade 3 neurotoxicity, which consisted of constipation/ileus, sensory or motor neuropathy, or orthostatic hypotension. Patients who were heterozygous for the CD32a (Fc_ receptor IIa) 131 histidine (H) to arginine (R) polymorphism had a significantly decreased PFS (P = .009) after R-bortezomib compared with HH and RR homozygotes.",,,,
clinicaltrials.gov,SCIO-469,,Q16539,,,,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,,multiple myeloma,Phase 2,,,NCT00095680,"Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma",,https://ClinicalTrials.gov/show/NCT00095680
literature,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,advanced malignancies,advanced solid cancers,Phase 1,23887852,"Fourteen patients (7 males, median age 65, range 24-74), with renal (3), lung (3), pancreas (2), and breast, adrenal gland, melanoma, spindle cell tumor, chronic lymphocytic leukemia and multiple myeloma (1 each) were enrolled. All patients are off treatment, 10 due to disease progression. DLT was seen in two patients (one grade 3 abdominal pain and grade 4 lipase elevation; one with grade 3 vomiting) at sorafenib 200 mg twice daily and bortezomib 1.3 mg/m(2), establishing the MTD. No grade 4 hematologic or grade 5 toxicities were seen. One patient with renal cell cancer had a partial response and 5 patients attained stable disease.",,,,
clinicaltrials.gov,tanespimycin,51720,P04626;P07900;P08238;Q12931,"InChI=1S/C31H43N3O8/c1-8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30(38)34-22(28(21)37)16-23(26)35/h8-11,15-17,19,24-25,27,29,33,36H,1,12-14H2,2-7H3,(H2,32,39)(H,34,38)/b11-9-,18-10+,20-15+/t17-,19+,24+,25+,27-,29+/m1/s1",AYUNIORJHRXIBJ-TXHRRWQRSA-N,CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(=C\C=C/[C@H](OC)[C@@H](OC(=O)N)\C(=C\[C@H](C)[C@H]1O)\C)\C)C2=O,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,,leukemia,Phase 1,,,NCT00103272,17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer,,https://ClinicalTrials.gov/show/NCT00103272
literature,tanespimycin,51720,P04626;P07900;P08238;Q12931,"InChI=1S/C31H43N3O8/c1-8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30(38)34-22(28(21)37)16-23(26)35/h8-11,15-17,19,24-25,27,29,33,36H,1,12-14H2,2-7H3,(H2,32,39)(H,34,38)/b11-9-,18-10+,20-15+/t17-,19+,24+,25+,27-,29+/m1/s1",AYUNIORJHRXIBJ-TXHRRWQRSA-N,CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(=C\C=C/[C@H](OC)[C@@H](OC(=O)N)\C(=C\[C@H](C)[C@H]1O)\C)\C)C2=O,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,relapsed or relapsed and refractory multiple myeloma,multiple myeloma,Phase 1/2,21534941,"Tanespimycin in combination with bortezomib was well tolerated; few patients experienced significant neutropenia, constipation and anorexia (<10%), and no patients developed severe peripheral neuropathy. Among 67 efficacy-evaluable patients, there were 2 (3%) complete responses and 8 (12%) partial responses, for an objective response rate (ORR) of 27%, including 8 (12%) minimal responses. Response rates were highest among bortezomib-naive patients and proved durable in all patient subgroups, including those with bortezomib-refractory disease. Pharmacodynamic analyses indicated that tanespimycin plus bortezomib effectively inhibited the proteasome, as evidenced by decreased 20S proteasome activity, and inhibited HSP90, as reflected by increased HSP70 expression. The results of this study support additional studies of this combination approach in MM.",,,,
clinicaltrials.gov,temsirolimus,401,P42345,"InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1",CBPNZQVSJQDFBE-FUXHJELOSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,,multiple myeloma,Phase 1/2,,,NCT00483262,Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma,,https://ClinicalTrials.gov/show/NCT00483262
literature,temsirolimus,401,P42345,"InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1",CBPNZQVSJQDFBE-FUXHJELOSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,relapsed or refractory B-cell non-Hodgkin lymphoma,lymphoma,Phase 2,26079295,"Of 39 patients who received treatment, 3 achieved a complete response (7.7%; 95% confidence interval [CI], 1.6%-21%), and 9 had a partial response (PR) (23%; 95% CI, 11%-39%). Thus, the overall response rate (12 of 39 patients) was 31% (95% CI, 17%-48%), and the median progression-free survival was 4.7 months (95% CI, 2.1-7.8 months; 2 months for patients with diffuse large B-cell lymphoma [n = 18], 7.5 months for those with mantle cell lymphoma [n = 7], and 16.5 months for those with follicular lymphoma [n = 9]). Two extensively treated patients with diffuse large B-cell lymphoma achieved a complete response. There were no unexpected toxicities from the combination.",,,,
clinicaltrials.gov,vorinostat,260,O15379;O75376;P56524;Q13547;Q8WUI4;Q92769;Q969S8;Q96DB2;Q9BY41;Q9UBN7;Q9UKV0;Q9UQL6;Q9Y618,"InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)",WAEXFXRVDQXREF-UHFFFAOYSA-N,ONC(=O)CCCCCCC(=O)Nc1ccccc1,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,,multiple myeloma,Phase 1,,,NCT00111813,Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1)),,https://ClinicalTrials.gov/show/NCT00111813
literature,vorinostat,260,O15379;O75376;P56524;Q13547;Q8WUI4;Q92769;Q969S8;Q96DB2;Q9BY41;Q9UBN7;Q9UKV0;Q9UQL6;Q9Y618,"InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)",WAEXFXRVDQXREF-UHFFFAOYSA-N,ONC(=O)CCCCCCC(=O)Nc1ccccc1,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,children with refractory or recurrent solid tumors,advanced solid cancers,Phase 1,22887890,"Twenty-three eligible patients [17 male, median age 12 years (range: 1-20)] were enrolled of whom 17 were fully evaluable for toxicity. Cycle 1 DLTs that occurred in 2/6 patients at dose level 3 (vorinostat 300_mg/m(2) /day) were Grade 2 sensory neuropathy that progressed to Grade 4 (n_=_1) and Grade 3 nausea and anorexia (n_=_1). No objective responses were observed. There was wide interpatient variability in vorinostat PK parameters. Bortezomib disposition was best described by a three-compartment model that demonstrated rapid distribution followed by prolonged elimination. We did not observe a decrease in nuclear factor-_B activity or Grp78 induction after bortezomib treatment in peripheral blood mononuclear cells from solid tumor patients.",,,,
literature,vorinostat,260,O15379;O75376;P56524;Q13547;Q8WUI4;Q92769;Q969S8;Q96DB2;Q9BY41;Q9UBN7;Q9UKV0;Q9UQL6;Q9Y618,"InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)",WAEXFXRVDQXREF-UHFFFAOYSA-N,ONC(=O)CCCCCCC(=O)Nc1ccccc1,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,relapsed or refractory multiple myeloma,multiple myeloma,Phase 3,24055414,"Between Dec 24, 2008, and Sept 8, 2011, we randomly allocated 317 eligible patients to the vorinostat group (315 of whom received at least one dose) and 320 to the placebo group (all of whom received at least one dose). Median PFS was 7à63 months (95% CI 6à87-8à40) in the vorinostat group and 6à83 months (5à67-7à73) in the placebo group (hazard ratio [HR] 0à77, 95% CI 0à64-0à94; p=0à0100). 312 (99%) of 315 patients in the vorinostat group and 315 (98%) of 320 patients in the placebo group had adverse events (300 [95%] adverse events in the vorinostat group and 282 [88%] in the control group were regarded as related to treatment). The most common grade 3-4 adverse events were thrombocytopenia (143 [45%] patients in the vorinostat group vs 77 [24%] patients in the placebo group), neutropenia (89 [28%] vs 80 [25%]), and anaemia (53 [17%] vs 40 [13%]).",,,,
clinicaltrials.gov,axitinib,600224,P35968;P17948;P35916,"InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+",RITAVMQDGBJQJZ-FMIVXFBMSA-N,CNC(=O)c1ccccc1Sc2ccc3c(\C=C\c4ccccn4)n[nH]c3c2,bosutinib,121888,O00506;O14578;O14730;O14733;O14757;O14936;O14976;O15197;O43283;O43318;O43353;O60285;O60674;O75116;O75385;O75914;O94804;O94806;O94921;O95819;O96017;P00519;P00533;P04626;P04629;P06239;P06241;P06748;P07332;P07333;P07947;P07948;P07949;P08581;P08631;P09619;P09769;P0C1S8;P10721;P11274;P12931;P15735;P16234;P16591;P21709;P21860;P23443;P29317;P29320;P29322;P29323;P29376;P29597;P30291;P30530;P32298;P35590;P36507;P36888;P41240;P42679;P42680;P42681;P42684;P42685;P43403;P43405;P45985;P46734;P48729;P48730;P49674;P49759;P49760;P49761;P50613;P51451;P51617;P51812;P51813;P51955;P52333;P52564;P53350;P54753;P54756;P54760;P54762;P54764;P57058;P57059;P80192;Q00536;Q02156;Q02750;Q02763;Q04759;Q04912;Q05397;Q05655;Q06187;Q06418;Q07912;Q08345;Q08881;Q09013;Q12851;Q12852;Q12866;Q13043;Q13131;Q13153;Q13163;Q13164;Q13177;Q13188;Q13233;Q13464;Q13555;Q13873;Q14164;Q14289;Q15303;Q15349;Q15746;Q16288;Q16512;Q16513;Q16584;Q16620;Q16816;Q16832;Q2M2I8;Q56UN5;Q59H18;Q5S007;Q6PHR2;Q6XUX3;Q7L7X3;Q86UE8;Q86Y07;Q86Z02;Q8IU85;Q8IVH8;Q8IY84;Q8IYT8;Q8N4C8;Q8N752;Q8NE63;Q8NEV4;Q8NFD2;Q8NG66;Q8TDR2;Q8WTQ7;Q8WU08;Q8WXR4;Q92918;Q96Q40;Q96RR4;Q99640;Q99755;Q99759;Q9BQI3;Q9BRS2;Q9BXA7;Q9BYT3;Q9C098;Q9H093;Q9H0K1;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HAZ1;Q9NRP7;Q9NSY1;Q9NWZ3;Q9NYL2;Q9NYY3;Q9P289;Q9P2K8;Q9UBE8;Q9UEW8;Q9UF33;Q9UHD2;Q9UK32;Q9UKE5;Q9UKI8;Q9UL54;Q9UM73;Q9UPE1;Q9UQM7;Q9Y2H9;Q9Y2K2;Q9Y2U5;Q9Y4K4;Q9Y6E0;Q9Y6R4,"InChI=1S/C26H29Cl2N5O3/c1-32-6-8-33(9-7-32)5-4-10-36-25-13-21-18(11-24(25)35-3)26(17(15-29)16-30-21)31-22-14-23(34-2)20(28)12-19(22)27/h11-14,16H,4-10H2,1-3H3,(H,30,31)",UBPYILGKFZZVDX-UHFFFAOYSA-N,COc1cc(Nc2c(cnc3cc(OCCCN4CCN(C)CC4)c(OC)cc23)C#N)c(Cl)cc1Cl,,leukemia,Phase 1/2,,,NCT02782403,"Axitinib and Bosutinib for Patients With Chronic Myeloid Leukemia in Chronic, Accelerated or Blastic Phases",,https://ClinicalTrials.gov/show/NCT02782403
clinicaltrials.gov,SHR-1210,841778,,"InChI=1S/C23H27FN4O2/c1-4-27(5-2)10-11-28-9-8-19-21(23(28)30)14(3)20(25-19)13-17-16-12-15(24)6-7-18(16)26-22(17)29/h6-7,12-13,25H,4-5,8-11H2,1-3H3,(H,26,29)/b17-13-",GKEYKDOLBLYGRB-LGMDPLHJSA-N,CCN(CC)CCN1CCc2[nH]c(\C=C\3/C(=O)Nc4ccc(F)cc34)c(C)c2C1=O,BP102,,,,,,,lung cancers,Phase 2,,,NCT03666728,A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC,,https://ClinicalTrials.gov/show/NCT03666728
clinicaltrials.gov,SHR-1210,841778,,"InChI=1S/C23H27FN4O2/c1-4-27(5-2)10-11-28-9-8-19-21(23(28)30)14(3)20(25-19)13-17-16-12-15(24)6-7-18(16)26-22(17)29/h6-7,12-13,25H,4-5,8-11H2,1-3H3,(H,26,29)/b17-13-",GKEYKDOLBLYGRB-LGMDPLHJSA-N,CCN(CC)CCN1CCc2[nH]c(\C=C\3/C(=O)Nc4ccc(F)cc34)c(C)c2C1=O,BP102,,,,,,,lung cancers,Phase 2,,,NCT03666728,A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC,,https://ClinicalTrials.gov/show/NCT03666728
clinicaltrials.gov,lenalidomide,718,O14920,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,Nc1cccc2C(=O)N(Cc12)C3CCC(=O)NC3=O,brentuximab,,Q13748;P68366;Q9H4B7;P04350;Q3ZCM7;P07437;Q71U36;P68371;Q13509;P68363;Q13885;Q6PEY2;Q9BQE3;Q9BUF5;Q9BVA1;P28908,,,,,lymphoma,Phase 1,,,NCT03302728,Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma,EpiBrentlen,https://ClinicalTrials.gov/show/NCT03302728
clinicaltrials.gov,binimetinib,1222391,Q02750;P36507,"InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)",ACWZRVQXLIRSDF-UHFFFAOYSA-N,Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO,brigatinib,,,,,,,,,,,NCT04005144,brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT04005144
clinicaltrials.gov,cetuximab,9,P00533,,,,brivanib,418047,P11362;P22455;P22607;P21802;P35968;P17948;P35916,"InChI=1S/C19H19FN4O3/c1-10-6-13-14(23-10)4-5-15(17(13)20)27-19-18-12(3)16(26-8-11(2)25)7-24(18)22-9-21-19/h4-7,9,11,23,25H,8H2,1-3H3/t11-/m1/s1",WCWUXEGQKLTGDX-LLVKDONJSA-N,C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C,,bowel cancers,Phase 3,,,NCT00640471,Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer,,https://ClinicalTrials.gov/show/NCT00640471
literature,cetuximab,9,P00533,,,,brivanib,418047,P11362;P22455;P22607;P21802;P35968;P17948;P35916,"InChI=1S/C19H19FN4O3/c1-10-6-13-14(23-10)4-5-15(17(13)20)27-19-18-12(3)16(26-8-11(2)25)7-24(18)22-9-21-19/h4-7,9,11,23,25H,8H2,1-3H3/t11-/m1/s1",WCWUXEGQKLTGDX-LLVKDONJSA-N,C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C,advanced gastrointestinal malignancies who have failed prior therapy,bowel cancers,Phase 1,21629245,"Toxicities observed were manageable; the most common treatment-related toxicities (>10% of patients) were fatigue, diarrhoea, anorexia, increase in aspartate aminotransferase and alanine aminotransferase, acneiform dermatitis, headache, mucosal inflammation, nausea, dry skin, vomiting, hypertension, pruritus, proteinuria and weight loss. Of 62 patients, 6 (9.7%) had objective radiographic partial responses, with an overall response rate of 10%. Median duration of response was 9.2 months; median progression-free survival was 3.9 months.",,,,
literature,cetuximab,9,P00533,,,,brivanib,418047,P11362;P22455;P22607;P21802;P35968;P17948;P35916,"InChI=1S/C19H19FN4O3/c1-10-6-13-14(23-10)4-5-15(17(13)20)27-19-18-12(3)16(26-8-11(2)25)7-24(18)22-9-21-19/h4-7,9,11,23,25H,8H2,1-3H3/t11-/m1/s1",WCWUXEGQKLTGDX-LLVKDONJSA-N,C[C@@H](O)COc1cn2ncnc(Oc3ccc4[nH]c(C)cc4c3F)c2c1C,"K-RAS wild-type, chemotherapy-refractory, metastatic colorectal cancer",bowel cancers,Phase 3,24127364,"Of 750 randomized patients, 721 (358 of whom received CET/BRIV) were assessable for QoL. QoL compliance and baseline PF and GHS scores did not differ by treatment arm. The median time to deterioration was 1.6 months versus 1.1 months for GHS (P =.02) and 5.6 months versus 1.7 months for PF (P <.0001) favoring CET/placebo. Secondary analysis favored CET/placebo for QOL response on the PF, Cognitive Function, Fatigue, Nausea, Appetite, and Diarrhea scales. A greater percentage of patients on the CET/BRIV arm had PF worsening at 6 weeks (31% vs 17%). Clinical adverse events of _ grade 3 were more common with CET/BRIV than with CET/placebo, including fatigue (25% vs 11%), hypertension, rash, diarrhea, abdominal pain, dehydration, and anorexia.",,,,
literature,abiraterone,181093,P05093,"InChI=1S/C24H31NO/c1-23-11-9-18(26)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22,26H,6,8-12,14H2,1-2H3/t18-,19-,21-,22-,23-,24+/m0/s1",GZOSMCIZMLWJML-VJLLXTKPSA-N,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c5cccnc5,buparlisib,962639,O00329;O00459;P27986;P42336;P42338;P48736;Q8WYR1;Q92569,"InChI=1S/C18H21F3N6O2/c19-18(20,21)13-9-15(22)23-11-12(13)14-10-16(26-1-5-28-6-2-26)25-17(24-14)27-3-7-29-8-4-27/h9-11H,1-8H2,(H2,22,23)",CWHUFRVAEUJCEF-UHFFFAOYSA-N,Nc1cc(c(cn1)c2cc(nc(n2)N3CCOCC3)N4CCOCC4)C(F)(F)F,castration-resistant prostate cancer,male cancers,Phase 1b,28282611,"In buparlisib_+_AA arm, 25 patients received buparlisib_+_AA (median age, 67 years; Eastern Cooperative Oncology Group performance status (ECOG PS) of 0/1/2 for 7/17/1 patients, respectively). At 100_mg qd; two patients experienced dose-limiting toxicities (DLTs) (grade 3 hyperglycaemia; grade 2 asthenia), and this was the maximum buparlisib dose explored. Buparlisib_+_AA showed a 26% lower median area under the curve from time zero to 24çh (AUC0-24) and 48% lower median maximum serum concentration (Cmax) versus the single-agent buparlisib assessed in first-in-human study. No objective response and few PSA decreases were reported. In dactolisib_+_AA arm, 18 patients (median age, 71 years; ECOG PS of 0/1 for 6/12 patients, respectively) received dactolisib_+_AA at the first dose level (200_mg bid). Five patients had 9 DLTs (grades 2&3 stomatitis; grade 3 hyperglycaemia; grades 2& 3 diarrhoea; grades 1& 2 pyrexia, grade 2 vomiting, and grade 2 chills).",,,,
clinicaltrials.gov,alpelisib,,P42336,"InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1",STUWGJZDJHPWGZ-LBPRGKRZSA-N,Cc1nc(NC(=O)N2CCC[C@H]2C(=O)N)sc1c3ccnc(c3)C(C)(C)C(F)(F)F,buparlisib,962639,O00329;O00459;P27986;P42336;P42338;P48736;Q8WYR1;Q92569,"InChI=1S/C18H21F3N6O2/c19-18(20,21)13-9-15(22)23-11-12(13)14-10-16(26-1-5-28-6-2-26)25-17(24-14)27-3-7-29-8-4-27/h9-11H,1-8H2,(H2,22,23)",CWHUFRVAEUJCEF-UHFFFAOYSA-N,Nc1cc(c(cn1)c2cc(nc(n2)N3CCOCC3)N4CCOCC4)C(F)(F)F,,breast cancers,Phase 1,,,NCT02058381,A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer,B-YOND,https://ClinicalTrials.gov/show/NCT02058381
clinicaltrials.gov,bevacizumab,11,P15692,,,,buparlisib,962639,O00329;O00459;P27986;P42336;P42338;P48736;Q8WYR1;Q92569,"InChI=1S/C18H21F3N6O2/c19-18(20,21)13-9-15(22)23-11-12(13)14-10-16(26-1-5-28-6-2-26)25-17(24-14)27-3-7-29-8-4-27/h9-11H,1-8H2,(H2,22,23)",CWHUFRVAEUJCEF-UHFFFAOYSA-N,Nc1cc(c(cn1)c2cc(nc(n2)N3CCOCC3)N4CCOCC4)C(F)(F)F,,brain cancers,Phase 1/2,,,NCT01349660,Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme,,https://ClinicalTrials.gov/show/NCT01349660
clinicaltrials.gov,erismodegib,1024199,Q99835,"InChI=1S/C26H26F3N3O3/c1-16-14-32(15-17(2)34-16)24-12-9-20(13-30-24)31-25(33)23-6-4-5-22(18(23)3)19-7-10-21(11-8-19)35-26(27,28)29/h4-13,16-17H,14-15H2,1-3H3,(H,31,33)/t16-,17+",VZZJRYRQSPEMTK-CALCHBBNSA-N,C[C@@H]1CN(C[C@H](C)O1)c2ccc(NC(=O)c3cccc(c3C)c4ccc(OC(F)(F)F)cc4)cn2,buparlisib,962639,O00329;O00459;P27986;P42336;P42338;P48736;Q8WYR1;Q92569,"InChI=1S/C18H21F3N6O2/c19-18(20,21)13-9-15(22)23-11-12(13)14-10-16(26-1-5-28-6-2-26)25-17(24-14)27-3-7-29-8-4-27/h9-11H,1-8H2,(H2,22,23)",CWHUFRVAEUJCEF-UHFFFAOYSA-N,Nc1cc(c(cn1)c2cc(nc(n2)N3CCOCC3)N4CCOCC4)C(F)(F)F,,advanced solid cancers;breast cancers;pancreatic cancers;bowel cancers;brain cancers;stomach cancers;oesophageal cancers;breast cancers,Phase 1,,,NCT01576666,"Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors",,https://ClinicalTrials.gov/show/NCT01576666
clinicaltrials.gov,avelumab,,Q9NZQ7,,,,cabozantinib,1081506,P08581,"InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)",ONIQOQHATWINJY-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5)cc3)c2cc1OC,,kidney cancers,Phase 1,,,NCT03200587,Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC),,https://ClinicalTrials.gov/show/NCT03200587
literature,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,cabozantinib,1081506,P08581,"InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)",ONIQOQHATWINJY-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5)cc3)c2cc1OC,patients with EGFR wild-type advanced non-small-cell lung cancer,lung cancers,Phase 2,27825638,"Between Feb 7, 2013, and July 1, 2014, we enrolled and randomly assigned 42 patients to erlotinib treatment, 40 patients to cabozantinib treatment, and 43 patients to erlotinib plus cabozantinib treatment, of whom 111 (89%) in total were included in the primary analysis (erlotinib [n=38], cabozantinib [n=38], erlotinib plus cabozantinib [n=35]). Compared with erlotinib alone (median 1à8 months [95% CI 1à7-2à2]), progression-free survival was significantly improved in the cabozantinib group (4à3 months [3à6-7à4]; hazard ratio [HR] 0à39, 80% CI 0à27-0à55; one-sided p=0à0003) and in the erlotinib plus cabozantinib group (4à7 months [2à4-7à4]; HR 0à37, 0à25-0à53; one-sided p=0à0003). Among participants included in the safety analysis of the erlotinib (n=40), cabozantinib (n=40), and erlotinib plus cabozantinib (n=39) groups, the most common grade 3 or 4 adverse events were diarrhoea (three [8%] cases in the erlotinib group vs three [8%] in the cabozantinib group vs 11 [28%] in the erlotinib plus cabozantinib group), hypertension (none vs ten [25%] vs one [3%]), fatigue (five [13%] vs six [15%] vs six [15%]), oral mucositis (none vs four [10%] vs one [3%]), and thromboembolic event (none vs three [8%] vs two [5%]). One death due to respiratory failure occurred in the cabozantinib group, deemed possibly related to either drug, and one death due to pneumonitis occurred in the erlotinib plus cabozantinib group, deemed related to either drug or the combination.",,,,
clinicaltrials.gov,niraparib,919241,Q9UGN5;P09874,"InChI=1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)/t14-/m1/s1",PCHKPVIQAHNQLW-CQSZACIVSA-N,NC(=O)c1cccc2cn(nc12)c3ccc(cc3)[C@@H]4CCCNC4,cabozantinib,1081506,P08581,"InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)",ONIQOQHATWINJY-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5)cc3)c2cc1OC,,bladder cancers,Phase 1/2,,,NCT03425201,Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer,,https://ClinicalTrials.gov/show/NCT03425201
clinicaltrials.gov,nivolumab,,Q15116,,,,cabozantinib,1081506,P08581,"InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)",ONIQOQHATWINJY-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5)cc3)c2cc1OC,,breast cancers,Phase 2,,,NCT03316586,A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer,,https://ClinicalTrials.gov/show/NCT03316586
clinicaltrials.gov,panitumumab,1238534,P00533,,,,cabozantinib,1081506,P08581,"InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)",ONIQOQHATWINJY-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5)cc3)c2cc1OC,,bowel cancers,Phase 1,,,NCT02008383,Cabozantinib and panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer,CaboMAb,https://ClinicalTrials.gov/show/NCT02008383
clinicaltrials.gov,rosiglitazone,1830,P37231,"InChI=1S/C18H19N3O3S/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15/h2-9,15H,10-12H2,1H3,(H,20,22,23)",YASAKCUCGLMORW-UHFFFAOYSA-N,CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c3ccccn3,cabozantinib,1081506,P08581,"InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)",ONIQOQHATWINJY-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5)cc3)c2cc1OC,,thyroid cancers;kidney cancers,Phase 1,,,NCT01100619,A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors,,https://ClinicalTrials.gov/show/NCT01100619
clinicaltrials.gov,nivolumab,,Q15116,,,,cabrilizumab,,,,,,,other,Phase 2,,,NCT03768531,Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer,,https://ClinicalTrials.gov/show/NCT03768531
clinicaltrials.gov,nivolumab,,Q15116,,,,cabrilizumab,,,,,,,other,Phase 2,,,NCT03768531,Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer,,https://ClinicalTrials.gov/show/NCT03768531
clinicaltrials.gov,SHR-1702,,,,,,camrelizumab,,,,,,Advanced Solid Tumor,,Phase 1,,,NCT03871855,,,
clinicaltrials.gov,afuresertib,1081472,P31751;Q9Y243;P31749,"InChI=1S/C18H17Cl2FN4OS/c1-25-16(14(19)9-23-25)13-7-15(27-17(13)20)18(26)24-12(8-22)6-10-3-2-4-11(21)5-10/h2-5,7,9,12H,6,8,22H2,1H3,(H,24,26)/t12-/m0/s1",AFJRDFWMXUECEW-LBPRGKRZSA-N,Cn1ncc(Cl)c1c2cc(sc2Cl)C(=O)N[C@H](CN)Cc3cccc(F)c3,carfilzomib,134643,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436,"InChI=1S/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1",BLMPQMFVWMYDKT-NZTKNTHTSA-N,CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,,multiple myeloma,Phase 1,,,NCT02235740,"A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)",,https://ClinicalTrials.gov/show/NCT02235740
clinicaltrials.gov,isatuximab,,,,,,carfilzomib,134643,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436,"InChI=1S/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1",BLMPQMFVWMYDKT-NZTKNTHTSA-N,CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,,multiple myeloma,Phase 1,,,NCT02332850,SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma,,https://ClinicalTrials.gov/show/NCT02332850
clinicaltrials.gov,Zoladex,,,,,,casodex,,,,,,,,,,,NCT03971110,A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy.,,https://ClinicalTrials.gov/show/NCT03971110
clinicaltrials.gov,enzalutamide,679762,P10275,"InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)",WXCXUHSOUPDCQV-UHFFFAOYSA-N,CNC(=O)c1ccc(cc1F)N2C(=S)N(C(=O)C2(C)C)c3ccc(C#N)c(c3)C(F)(F)F,CC-115,,P78527;P42345,,,,,prostate cancers,Phase 1,,,NCT02833883,"Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer",,https://ClinicalTrials.gov/show/NCT02833883
clinicaltrials.gov,obinutuzumab,,P11836,,,,CC-122,,,,,,,lymphoma,Phase 1,,,NCT02417285,A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.,,https://ClinicalTrials.gov/show/NCT02417285
clinicaltrials.gov,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,CC-5013,,,,,,,multiple myeloma,Phase 1,,,NCT00153933,Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma,,https://ClinicalTrials.gov/show/NCT00153933
clinicaltrials.gov,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,,CDX-3379,,,,,,,skin cancers,Phase 1/2,,,NCT03580382,"Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma",,https://ClinicalTrials.gov/show/NCT03580382
clinicaltrials.gov,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,,CDX-3379,,,,,,,skin cancers,Phase 1/2,,,NCT03580382,"Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma",,https://ClinicalTrials.gov/show/NCT03580382
clinicaltrials.gov,bevacizumab,11,P15692,,,,cediranib,106760,O00444;O14976;O15197;O43353;O75460;O94804;O95819;P00519;P00533;P04626;P06239;P06241;P07333;P07947;P07948;P07949;P08581;P08631;P09619;P09769;P10721;P11362;P12931;P16234;P17948;P21709;P21802;P21860;P22455;P22607;P29320;P29322;P29376;P30530;P35590;P35916;P35968;P36507;P36888;P36896;P36897;P42684;P42685;P49674;P51451;P54760;Q02763;Q04771;Q04912;Q06187;Q06418;Q08345;Q12851;Q12866;Q13043;Q13163;Q13882;Q15303;Q15375;Q16832;Q56UN5;Q8IVH8;Q8N4C8;Q8TDR2;Q92918;Q96GD4;Q9BQI3;Q9BYT3;Q9H0K1;Q9H2G2;Q9H2K8;Q9P289;Q9UF33;Q9UKE5;Q9UL54;Q9UM73;Q9UQB9;Q9Y4K4,"InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3",XXJWYDDUDKYVKI-UHFFFAOYSA-N,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN5CCCC5,,lymphoma,Phase 1,,,NCT00458731,"Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma",,https://ClinicalTrials.gov/show/NCT00458731
clinicaltrials.gov,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,cediranib,106760,O00444;O14976;O15197;O43353;O75460;O94804;O95819;P00519;P00533;P04626;P06239;P06241;P07333;P07947;P07948;P07949;P08581;P08631;P09619;P09769;P10721;P11362;P12931;P16234;P17948;P21709;P21802;P21860;P22455;P22607;P29320;P29322;P29376;P30530;P35590;P35916;P35968;P36507;P36888;P36896;P36897;P42684;P42685;P49674;P51451;P54760;Q02763;Q04771;Q04912;Q06187;Q06418;Q08345;Q12851;Q12866;Q13043;Q13163;Q13882;Q15303;Q15375;Q16832;Q56UN5;Q8IVH8;Q8N4C8;Q8TDR2;Q92918;Q96GD4;Q9BQI3;Q9BYT3;Q9H0K1;Q9H2G2;Q9H2K8;Q9P289;Q9UF33;Q9UKE5;Q9UL54;Q9UM73;Q9UQB9;Q9Y4K4,"InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3",XXJWYDDUDKYVKI-UHFFFAOYSA-N,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN5CCCC5,,ovarian cancers,Phase 2,,,NCT02340611,A Study of Cediranib and Olaparib at the Time ovarian Cancers Worsens on Olaparib,,https://ClinicalTrials.gov/show/NCT02340611
clinicaltrials.gov,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,cediranib,106760,O00444;O14976;O15197;O43353;O75460;O94804;O95819;P00519;P00533;P04626;P06239;P06241;P07333;P07947;P07948;P07949;P08581;P08631;P09619;P09769;P10721;P11362;P12931;P16234;P17948;P21709;P21802;P21860;P22455;P22607;P29320;P29322;P29376;P30530;P35590;P35916;P35968;P36507;P36888;P36896;P36897;P42684;P42685;P49674;P51451;P54760;Q02763;Q04771;Q04912;Q06187;Q06418;Q08345;Q12851;Q12866;Q13043;Q13163;Q13882;Q15303;Q15375;Q16832;Q56UN5;Q8IVH8;Q8N4C8;Q8TDR2;Q92918;Q96GD4;Q9BQI3;Q9BYT3;Q9H0K1;Q9H2G2;Q9H2K8;Q9P289;Q9UF33;Q9UKE5;Q9UL54;Q9UM73;Q9UQB9;Q9Y4K4,"InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3",XXJWYDDUDKYVKI-UHFFFAOYSA-N,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN5CCCC5,,ovarian cancers,Phase 3,,,NCT03278717,Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients,ICON9,https://ClinicalTrials.gov/show/NCT03278717
literature,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,cediranib,106760,O00444;O14976;O15197;O43353;O75460;O94804;O95819;P00519;P00533;P04626;P06239;P06241;P07333;P07947;P07948;P07949;P08581;P08631;P09619;P09769;P10721;P11362;P12931;P16234;P17948;P21709;P21802;P21860;P22455;P22607;P29320;P29322;P29376;P30530;P35590;P35916;P35968;P36507;P36888;P36896;P36897;P42684;P42685;P49674;P51451;P54760;Q02763;Q04771;Q04912;Q06187;Q06418;Q08345;Q12851;Q12866;Q13043;Q13163;Q13882;Q15303;Q15375;Q16832;Q56UN5;Q8IVH8;Q8N4C8;Q8TDR2;Q92918;Q96GD4;Q9BQI3;Q9BYT3;Q9H0K1;Q9H2G2;Q9H2K8;Q9P289;Q9UF33;Q9UKE5;Q9UL54;Q9UM73;Q9UQB9;Q9Y4K4,"InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3",XXJWYDDUDKYVKI-UHFFFAOYSA-N,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN5CCCC5,recurrent epithelial ovarian or triple-negative breast_cancer,advanced solid cancers,Phase 1,23810467,"28 patients (20 ovarian, 8 breast) enrolled to 4 dose levels. 2 dose limiting toxicities (DLTs) (1 grade 4 neutropenia _ 4 days; 1 grade 4 thrombocytopenia) occurred at the highest dose level (cediranib 30 mg daily; olaparib 400 mg twice daily [BID]). The RP2D was cediranib 30 mg daily and olaparib 200 mg BID. Grade 3 or higher toxicities occurred in 75% of patients, and included grade 3 hypertension (25%) and grade 3 fatigue (18%). One grade 3 bowel obstruction occurred. The overall response rate (ORR) in the 18 RECIST-evaluable ovarian cancer patients was 44%, with a clinical benefit rate (ORR plus stable disease (SD) > 24 weeks) of 61%. None of the seven evaluable breast cancer patients achieved clinical response; two patients had stable disease for > 24 weeks.",,,,
literature,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,cediranib,106760,O00444;O14976;O15197;O43353;O75460;O94804;O95819;P00519;P00533;P04626;P06239;P06241;P07333;P07947;P07948;P07949;P08581;P08631;P09619;P09769;P10721;P11362;P12931;P16234;P17948;P21709;P21802;P21860;P22455;P22607;P29320;P29322;P29376;P30530;P35590;P35916;P35968;P36507;P36888;P36896;P36897;P42684;P42685;P49674;P51451;P54760;Q02763;Q04771;Q04912;Q06187;Q06418;Q08345;Q12851;Q12866;Q13043;Q13163;Q13882;Q15303;Q15375;Q16832;Q56UN5;Q8IVH8;Q8N4C8;Q8TDR2;Q92918;Q96GD4;Q9BQI3;Q9BYT3;Q9H0K1;Q9H2G2;Q9H2K8;Q9P289;Q9UF33;Q9UKE5;Q9UL54;Q9UM73;Q9UQB9;Q9Y4K4,"InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3",XXJWYDDUDKYVKI-UHFFFAOYSA-N,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN5CCCC5,relapsed platinum-sensitive ovarian cancer,ovarian cancers,Phase 2,30753272,"In this updated analysis, median PFS remained significantly longer with cediranib/olaparib compared to olaparib alone (16.5 vs. 8.2 mos, HR 0.50; p_=_0.007). Subset analyses within stratum defined by BRCA status demonstrated statistically significant improvement in PFS (23.7 vs 5.7 mos, p_=_0.002) and OS (37.8 vs 23.0 mos, p_=_0.047) in gBRCA wild-type/unknown patients, although OS was not statistically different in the overall study population (44.2 vs. 33.3 mos, HR 0.64; p_=_0.11). PFS and OS appeared similar between the two arms in gBRCAm patients. The most common grade 3/4 adverse events with cediranib/olaparib remained fatigue, diarrhea, and hypertension.",,,,
clinicaltrials.gov,selumetinib,646570,Q02750;P36507,"InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)",CYOHGALHFOKKQC-UHFFFAOYSA-N,Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO,cediranib,106760,O00444;O14976;O15197;O43353;O75460;O94804;O95819;P00519;P00533;P04626;P06239;P06241;P07333;P07947;P07948;P07949;P08581;P08631;P09619;P09769;P10721;P11362;P12931;P16234;P17948;P21709;P21802;P21860;P22455;P22607;P29320;P29322;P29376;P30530;P35590;P35916;P35968;P36507;P36888;P36896;P36897;P42684;P42685;P49674;P51451;P54760;Q02763;Q04771;Q04912;Q06187;Q06418;Q08345;Q12851;Q12866;Q13043;Q13163;Q13882;Q15303;Q15375;Q16832;Q56UN5;Q8IVH8;Q8N4C8;Q8TDR2;Q92918;Q96GD4;Q9BQI3;Q9BYT3;Q9H0K1;Q9H2G2;Q9H2K8;Q9P289;Q9UF33;Q9UKE5;Q9UL54;Q9UM73;Q9UQB9;Q9Y4K4,"InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3",XXJWYDDUDKYVKI-UHFFFAOYSA-N,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN5CCCC5,,bowel cancers,Phase 1,,,NCT01160926,Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial,DREAMtherapy,https://ClinicalTrials.gov/show/NCT01160926
clinicaltrials.gov,temsirolimus,401,P42345,"InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1",CBPNZQVSJQDFBE-FUXHJELOSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO,cediranib,106760,O00444;O14976;O15197;O43353;O75460;O94804;O95819;P00519;P00533;P04626;P06239;P06241;P07333;P07947;P07948;P07949;P08581;P08631;P09619;P09769;P10721;P11362;P12931;P16234;P17948;P21709;P21802;P21860;P22455;P22607;P29320;P29322;P29376;P30530;P35590;P35916;P35968;P36507;P36888;P36896;P36897;P42684;P42685;P49674;P51451;P54760;Q02763;Q04771;Q04912;Q06187;Q06418;Q08345;Q12851;Q12866;Q13043;Q13163;Q13882;Q15303;Q15375;Q16832;Q56UN5;Q8IVH8;Q8N4C8;Q8TDR2;Q92918;Q96GD4;Q9BQI3;Q9BYT3;Q9H0K1;Q9H2G2;Q9H2K8;Q9P289;Q9UF33;Q9UKE5;Q9UL54;Q9UM73;Q9UQB9;Q9Y4K4,"InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3",XXJWYDDUDKYVKI-UHFFFAOYSA-N,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN5CCCC5,,female cancers;ovarian cancers;cervical cancers;other,Phase 1,,,NCT01065662,AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies,,https://ClinicalTrials.gov/show/NCT01065662
clinicaltrials.gov,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,celecoxib,646,O43570;P00918;P10635;P18089;P22748;P23280;P23975;P31645;P35218;P35354;P43166;Q01959;Q16539;Q16790;Q8N1Q1;Q9ULX7;Q9Y2D0,"InChI=1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)",RZEKVGVHFLEQIL-UHFFFAOYSA-N,Cc1ccc(cc1)c2cc(nn2c3ccc(cc3)S(=O)(=O)N)C(F)(F)F,,head and neck cancers,Phase 1,,,NCT00400374,"Secondary Primary Tumor Prevention With EGFR, OSI-774, and Cyclooxygenase-2",,https://ClinicalTrials.gov/show/NCT00400374
literature,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,celecoxib,646,O43570;P00918;P10635;P18089;P22748;P23280;P23975;P31645;P35218;P35354;P43166;Q01959;Q16539;Q16790;Q8N1Q1;Q9ULX7;Q9Y2D0,"InChI=1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)",RZEKVGVHFLEQIL-UHFFFAOYSA-N,Cc1ccc(cc1)c2cc(nn2c3ccc(cc3)S(=O)(=O)N)C(F)(F)F,advanced non-small cell lung cancer,lung cancers,Phase 2,26033830,"A total of 107 patients were enrolled with comparable baseline characteristics. Among the patients treated with celecoxib, those with wild-type EGFR were found to have an increased PFS (3.2 months vs 1.8 months; P_=_.03). PFS was numerically improved among patients in the intent-to-treat group who received erlotinib and celecoxib compared with those treated with erlotinib and placebo (5.4 months vs 3.5 months; P_=_.33) and was increased in patients in the erlotinib and celecoxib arm with elevated baseline PGEM (5.4 months vs 2.2 months; P_=_.15). Adverse events were similar in both treatment arms.",,,,
clinicaltrials.gov,isatuximab,,,,,,cemiplimab,,,,,,,lymphoma,Phase 1/2,,,NCT03769181,A Study of Isatuximab-based Therapy in Participants With Lymphoma,,https://ClinicalTrials.gov/show/NCT03769181
clinicaltrials.gov,REGN4018,,,,,,cemiplimab,,,,,,,ovarian cancers,Phase 1/2,,,NCT03564340,Study of REGN4018 Administered Alone or in Combination With cemiplimab in Patients With Platinum-Resistant Ovarian Cancer,,https://ClinicalTrials.gov/show/NCT03564340
clinicaltrials.gov,REGN4018,,,,,,cemiplimab,,,,,,,ovarian cancers,Phase 1/2,,,NCT03564340,Study of REGN4018 Administered Alone or in Combination With cemiplimab in Patients With Platinum-Resistant Ovarian Cancer,,https://ClinicalTrials.gov/show/NCT03564340
clinicaltrials.gov,REGN4659,,,,,,cemiplimab,,,,,,,lung cancers,Phase 1,,,NCT03580694,Study of REGN4659 in Combination With cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC),,https://ClinicalTrials.gov/show/NCT03580694
clinicaltrials.gov,REGN4659,,,,,,cemiplimab,,,,,,,lung cancers,Phase 1,,,NCT03580694,Study of REGN4659 in Combination With cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC),,https://ClinicalTrials.gov/show/NCT03580694
clinicaltrials.gov,REGN5678,,,,,,cemiplimab,,,,,,,,,,,NCT03972657,Study of REGN5678 (Anti-PSMAxCD28) With cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer,,https://ClinicalTrials.gov/show/NCT03972657
clinicaltrials.gov,SAR441000,,,,,,cemiplimab,,,,,,Metastatic Neoplasm,,Phase 1,,,NCT03871348,,,
clinicaltrials.gov,isatuximab,,,,,,cemiplimab REGN2810,,,,,,,lymphoma,Phase 1/2,,,NCT03769181,A Study of Isatuximab-based Therapy in Participants With Lymphoma,,https://ClinicalTrials.gov/show/NCT03769181
clinicaltrials.gov,ribociclib,,P11802;Q00534,"InChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28)",RHXHGRAEPCAFML-UHFFFAOYSA-N,CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N4CCNCC4)nc2n1C5CCCC5,ceritinib,1135147,O60674;O75116;P00519;P00533;P04629;P06213;P06239;P07948;P07949;P08069;P08581;P08922;P09769;P10721;P11802;P12931;P16234;P21802;P22455;P22607;P23458;P24941;P35968;P36888;P41212;P43403;P43405;P52333;Q06187;Q16620;Q9BXA7;Q9HBH9;Q9UM73,"InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34)",VERWOWGGCGHDQE-UHFFFAOYSA-N,CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)C(C)C)n3,,lung cancers,Phase 1/2,,,NCT02292550,Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.,,https://ClinicalTrials.gov/show/NCT02292550
clinicaltrials.gov,afatinib,755714,O14578;O14976;O15197;O43353;O94804;P00519;P00533;P04626;P06239;P08581;P08631;P12931;P15735;P21860;P30530;P36888;P42681;P42685;P45984;P49674;P51451;P51617;P53779;Q13163;Q13627;Q15303;Q16539;Q16816;Q52WX2;Q8NE63;Q92630;Q9BUB5;Q9H2G2;Q9HBH9;Q9UEE5;Q9UF33;Q9UK32;Q9Y463,"InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1",ULXXDDBFHOBEHA-CWDCEQMOSA-N,CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]4CCOC4,cetuximab,9,P00533,,,,,bowel cancers,Phase 2,,,NCT01919879,Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer,,https://ClinicalTrials.gov/show/NCT01919879
clinicaltrials.gov,afatinib,755714,O14578;O14976;O15197;O43353;O94804;P00519;P00533;P04626;P06239;P08581;P08631;P12931;P15735;P21860;P30530;P36888;P42681;P42685;P45984;P49674;P51451;P51617;P53779;Q13163;Q13627;Q15303;Q16539;Q16816;Q52WX2;Q8NE63;Q92630;Q9BUB5;Q9H2G2;Q9HBH9;Q9UEE5;Q9UF33;Q9UK32;Q9Y463,"InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1",ULXXDDBFHOBEHA-CWDCEQMOSA-N,CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]4CCOC4,cetuximab,9,P00533,,,,,lung cancers,Phase 2,,,NCT02716311,Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer,ACE-Lung,https://ClinicalTrials.gov/show/NCT02716311
clinicaltrials.gov,afatinib,755714,O14578;O14976;O15197;O43353;O94804;P00519;P00533;P04626;P06239;P08581;P08631;P12931;P15735;P21860;P30530;P36888;P42681;P42685;P45984;P49674;P51451;P51617;P53779;Q13163;Q13627;Q15303;Q16539;Q16816;Q52WX2;Q8NE63;Q92630;Q9BUB5;Q9H2G2;Q9HBH9;Q9UEE5;Q9UF33;Q9UK32;Q9Y463,"InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1",ULXXDDBFHOBEHA-CWDCEQMOSA-N,CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]4CCOC4,cetuximab,9,P00533,,,,,lung cancers,Phase 2,,,NCT03727724,Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer,AFACET,https://ClinicalTrials.gov/show/NCT03727724
clinicaltrials.gov,afatinib,755714,O14578;O14976;O15197;O43353;O94804;P00519;P00533;P04626;P06239;P08581;P08631;P12931;P15735;P21860;P30530;P36888;P42681;P42685;P45984;P49674;P51451;P51617;P53779;Q13163;Q13627;Q15303;Q16539;Q16816;Q52WX2;Q8NE63;Q92630;Q9BUB5;Q9H2G2;Q9HBH9;Q9UEE5;Q9UF33;Q9UK32;Q9Y463,"InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1",ULXXDDBFHOBEHA-CWDCEQMOSA-N,CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]4CCOC4,cetuximab,9,P00533,,,,,lung cancers,Phase 2,,,NCT03727724,Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer,AFACET,https://ClinicalTrials.gov/show/NCT03727724
literature,afatinib,755714,O14578;O14976;O15197;O43353;O94804;P00519;P00533;P04626;P06239;P08581;P08631;P12931;P15735;P21860;P30530;P36888;P42681;P42685;P45984;P49674;P51451;P51617;P53779;Q13163;Q13627;Q15303;Q16539;Q16816;Q52WX2;Q8NE63;Q92630;Q9BUB5;Q9H2G2;Q9HBH9;Q9UEE5;Q9UF33;Q9UK32;Q9Y463,"InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1",ULXXDDBFHOBEHA-CWDCEQMOSA-N,CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]4CCOC4,cetuximab,9,P00533,,,,"heavily pretreated patients with unselected/EGFR wild-type, advanced solid tumours",advanced solid tumours,Phase 1b,30278378,"The most common treatment-related adverse events (AEs) across all 58 patients were diarrhoea (63.8%) and acneiform dermatitis (43.1%). Overall, the best confirmed response was stable disease (SD; 53.4%); mean duration of disease control was 4.5 months; median progression-free survival was 2.6 months. In Part B, 55.1% of patients had SD (squamous NSCLC, 75.0%; HNSCC, 66.7%; other tumours; 36.4%). In conclusion, the recommended phase 2 dose was determined as afatinib 40 mg/day plus cetuximab 250 mg/m2/week. AEs were predictable and manageable, and anti-tumour activity was observed in some patients, particularly in those with squamous NSCLC and HNSCC",NCT02020577,,,
literature,afatinib,755714,O14578;O14976;O15197;O43353;O94804;P00519;P00533;P04626;P06239;P08581;P08631;P12931;P15735;P21860;P30530;P36888;P42681;P42685;P45984;P49674;P51451;P51617;P53779;Q13163;Q13627;Q15303;Q16539;Q16816;Q52WX2;Q8NE63;Q92630;Q9BUB5;Q9H2G2;Q9HBH9;Q9UEE5;Q9UF33;Q9UK32;Q9Y463,"InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1",ULXXDDBFHOBEHA-CWDCEQMOSA-N,CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]4CCOC4,cetuximab,9,P00533,,,,"heavily pretreated patients with unselected/EGFR wild-type, advanced solid tumours",advanced solid tumours,Phase 1b,30278378,"The most common treatment-related adverse events (AEs) across all 58 patients were diarrhoea (63.8%) and acneiform dermatitis (43.1%). Overall, the best confirmed response was stable disease (SD; 53.4%); mean duration of disease control was 4.5 months; median progression-free survival was 2.6 months. In Part B, 55.1% of patients had SD (squamous NSCLC, 75.0%; HNSCC, 66.7%; other tumours; 36.4%). In conclusion, the recommended phase 2 dose was determined as afatinib 40 mg/day plus cetuximab 250 mg/m2/week. AEs were predictable and manageable, and anti-tumour activity was observed in some patients, particularly in those with squamous NSCLC and HNSCC",NCT02020577,,,
clinicaltrials.gov,avelumab,,Q9NZQ7,,,,cetuximab,9,P00533,,,,,,,,,NCT03944941,Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer,,https://ClinicalTrials.gov/show/NCT03944941
clinicaltrials.gov,avelumab,,Q9NZQ7,,,,cetuximab,9,P00533,,,,,,,,,NCT03944252,"Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS)",CARACAS,https://ClinicalTrials.gov/show/NCT03944252
literature,bevacizumab,11,P15692,,,,cetuximab,9,P00533,,,,Pancreatic Carcinoma,pancreatic cancers,Phase 2,27082562,"The primary end-point for this study was the overall response rate. Secondary end-points were progression-free survival and the safety profiles of the combined therapy. The median time-to-progression and overall survival were 3 and 7 months, respectively, in the conventional treatment group as well as 11 and 13 months, respectively, in the targeted medications treatment group. The most common adverse events in both treatment groups were nausea and vomiting. Moderate (Grade 2) nausea and vomiting were more common in the conventional group than the targeted group but severe (Grade 3) nausea and vomiting were more common in the targeted group",,,,
clinicaltrials.gov,BMS-754807,,P06213;P08069,"InChI=1S/C23H24FN9O/c1-23(21(34)26-15-7-8-18(24)25-13-15)9-3-10-32(23)22-28-20(17-4-2-11-33(17)31-22)27-19-12-16(29-30-19)14-5-6-14/h2,4,7-8,11-14H,3,5-6,9-10H2,1H3,(H,26,34)(H2,27,28,29,30,31)/t23-/m0/s1",LQVXSNNAFNGRAH-QHCPKHFHSA-N,C[C@]1(CCCN1c2nc(Nc3cc([nH]n3)C4CC4)c5cccn5n2)C(=O)Nc6ccc(F)nc6,cetuximab,9,P00533,,,,,bowel cancers;head and neck cancers,Phase 1/2,,,NCT00908024,Combination Study of BMS-754807 and Erbitux__ in Subjects With Advanced or Metastatic Solid Tumors,,https://ClinicalTrials.gov/show/NCT00908024
clinicaltrials.gov,cabozantinib,1081506,P08581,"InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)",ONIQOQHATWINJY-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5)cc3)c2cc1OC,cetuximab,9,P00533,,,,,head and neck cancers,Phase 1,,,NCT03667482,Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer,,https://ClinicalTrials.gov/show/NCT03667482
clinicaltrials.gov,cabozantinib,1081506,P08581,"InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)",ONIQOQHATWINJY-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5)cc3)c2cc1OC,cetuximab,9,P00533,,,,,head and neck cancers,Phase 1,,,NCT03667482,Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer,,https://ClinicalTrials.gov/show/NCT03667482
clinicaltrials.gov,capmatinib,1278782,P08581,"InChI=1S/C23H17FN6O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20/h2-9,11-13H,10H2,1H3,(H,25,31)",LIOLIMKSCNQPLV-UHFFFAOYSA-N,CNC(=O)c1ccc(cc1F)c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2,cetuximab,9,P00533,,,,,head and neck cancers;bowel cancers,Phase 1,,,NCT02205398,"Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or panitumumab Therapy",,https://ClinicalTrials.gov/show/NCT02205398
clinicaltrials.gov,CC-95251,,,,,,cetuximab,9,P00533,,,,,advanced solid cancers,Phase 1,,,NCT03783403,"A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPŒ±, With Cetuximab in Subjects With Advanced Solid Cancers",,https://ClinicalTrials.gov/show/NCT03783403
clinicaltrials.gov,CC-95251,,,,,,cetuximab,9,P00533,,,,,advanced solid cancers,Phase 1,,,NCT03783403,"A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPŒ±, With Cetuximab in Subjects With Advanced Solid Cancers",,https://ClinicalTrials.gov/show/NCT03783403
clinicaltrials.gov,CDX-3379,,,,,,cetuximab,9,P00533,,,,,head and neck cancers,Phase 2,,,NCT03254927,A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT03254927
clinicaltrials.gov,cixutumumab,,P08069,,,,cetuximab,9,P00533,,,,,bowel cancers,Phase 2,,,NCT00503685,Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Patients With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFr Therapy,,https://ClinicalTrials.gov/show/NCT00503685
clinicaltrials.gov,cixutumumab,,P08069,,,,cetuximab,9,P00533,,,,,head and neck cancers,Phase 2,,,NCT00617734,"Study of IMC-A12, Alone or in Combination With Cetuximab, in Patients With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck",,https://ClinicalTrials.gov/show/NCT00617734
clinicaltrials.gov,dasatinib,375,O00238;O00506;O14965;O14976;O15197;O15264;O43283;O43318;O43353;O60674;O94804;O95819;P00519;P00533;P04049;P04626;P06239;P06241;P07333;P07947;P07948;P07949;P08631;P08684;P09619;P09769;P0C1S8;P10721;P11274;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P21860;P22607;P27037;P29317;P29320;P29322;P29323;P29597;P30291;P35968;P36507;P36888;P36894;P36896;P36897;P37023;P37173;P41240;P42680;P42681;P42684;P42685;P43405;P49674;P51451;P51813;P51955;P52333;P53667;P53671;P53778;P54753;P54756;P54760;P54762;P54764;P57059;Q01538;Q02750;Q04771;Q06187;Q07912;Q08345;Q09013;Q12851;Q13043;Q13163;Q13705;Q13882;Q15303;Q15569;Q15759;Q16539;Q16832;Q52WX2;Q56UN5;Q59H18;Q5VT25;Q6DT37;Q6PHR2;Q86Y07;Q8IVH8;Q8N4C8;Q8NG66;Q8NI60;Q8TDR2;Q92918;Q96GD4;Q99640;Q99759;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K8;Q9H3Y6;Q9NRP7;Q9NYL2;Q9P289;Q9P2K8;Q9UBE8;Q9UF33;Q9UKE5;Q9UL54;Q9Y2K2;Q9Y2U5;Q9Y4K4;Q9Y5S2;Q9Y6R4,"InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)",ZBNZXTGUTAYRHI-UHFFFAOYSA-N,Cc1nc(Nc2ncc(s2)C(=O)Nc3c(C)cccc3Cl)cc(n1)N4CCN(CCO)CC4,cetuximab,9,P00533,,,,,advanced solid cancers,Phase 1,,,NCT00388427,Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies,,https://ClinicalTrials.gov/show/NCT00388427
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,cetuximab,9,P00533,,,,,head and neck cancers,Phase 2,,,NCT03691714,Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT03691714
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,cetuximab,9,P00533,,,,,head and neck cancers,Phase 2,,,NCT03691714,Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT03691714
clinicaltrials.gov,E7050,1378212,P08581,"InChI=1S/C33H37F2N7O4/c1-40-16-18-41(19-17-40)24-9-14-42(15-10-24)32(45)39-29-21-26(8-13-36-29)46-25-6-7-28(27(35)20-25)38-31(44)33(11-12-33)30(43)37-23-4-2-22(34)3-5-23/h2-8,13,20-21,24H,9-12,14-19H2,1H3,(H,37,43)(H,38,44)(H,36,39,45)",UQRCJCNVNUFYDX-UHFFFAOYSA-N,CN1CCN(CC1)C2CCN(CC2)C(=O)Nc3cc(Oc4ccc(NC(=O)C5(CC5)C(=O)Nc6ccc(F)cc6)c(F)c4)ccn3,cetuximab,9,P00533,,,,,head and neck cancers,Phase 1/2,,,NCT01332266,E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck,,https://ClinicalTrials.gov/show/NCT01332266
literature,EMD 1201081,,,,,,cetuximab,9,P00533,,,,second-line cetuximab-na_ve patients with recurrent or metastatic squamous cell carcinoma of the head and neck,head and neck cancers,Phase 2,24894651,"Objective response rate in both arms was 5.7% (95% CI 1.2-15.7%) by independent assessment. Disease control was 37.7% for patients on combination (24.8-52.1%) and 43.4% on control (29.8-57.7%). Neither independent nor investigator assessments showed significant differences between study arms. Median progression-free survival was 1.5 months (1.3-2.6) for patients on combination, and 1.9 months (1.5-2.9) on control. The most frequent adverse events in the combination arm were rash (29.6%), acneiform dermatitis (22.2%), and injection site reactions (20.4%). Grade 3/4 dyspnea and hypokalemia were more frequent with cetuximab monotherapy (7.5% and 5.7% vs 1.9% each, respectively), and grade 3/4 respiratory failure and disease progression were more frequent with combination (5.6% each vs 1.9% each).",,,,
clinicaltrials.gov,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,cetuximab,9,P00533,,,,,,Phase 1,,,NCT00895362,Erlotinib in Combination With Cetuximab,,https://ClinicalTrials.gov/show/NCT00895362
literature,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,cetuximab,9,P00533,,,,advanced cancer,advanced solid cancers,Phase 1,24108668,"Everolimus and cetuximab were tolerable at full doses, with an expected toxicity profile. Dose-limiting toxicities in the everolimus 70 mg group included grade 3 skin toxicity in 2 patients, and mucositis in 1 patient. Of 16 patients evaluable for response, 5 had stable disease lasting 4 to 19 months. Mean change in maximum standardized uptake value (SUV(max)) for those treated initially with everolimus was -24% (2% to -54%), and with cetuximab was -5% (-23 to 36%). The K(trans) measured by DCE-MRI did not decrease, regardless of run-in drug.",,,,
clinicaltrials.gov,ficlatuzumab,,P14210,,,,cetuximab,9,P00533,,,,,head and neck cancers,Phase 1,,,NCT02277197,Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC),,https://ClinicalTrials.gov/show/NCT02277197
clinicaltrials.gov,Hu5F9-G4,,,,,,cetuximab,9,P00533,,,,,bowel cancers,Phase 1/2,,,NCT02953782,Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer,,https://ClinicalTrials.gov/show/NCT02953782
clinicaltrials.gov,lenalidomide,718,O14920,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,Nc1cccc2C(=O)N(Cc12)C3CCC(=O)NC3=O,cetuximab,9,P00533,,,,,advanced solid cancers,Phase 1/2,,,NCT01166035,Lenalidomide and Cetuximab in Patients With Advanced Solid Tumors,TEXO,https://ClinicalTrials.gov/show/NCT01166035
clinicaltrials.gov,lenvatinib,802872,P35968;P17948;P35916,"InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)",WOSKHXYHFSIKNG-UHFFFAOYSA-N,,cetuximab,9,P00533,,,,,head and neck cancers,Phase 1,,,NCT03524326,Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT03524326
clinicaltrials.gov,lenvatinib,802872,P35968;P17948;P35916,"InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)",WOSKHXYHFSIKNG-UHFFFAOYSA-N,,cetuximab,9,P00533,,,,,head and neck cancers,Phase 1,,,NCT03524326,Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT03524326
clinicaltrials.gov,LJM716,,,,,,cetuximab,9,P00533,,,,,head and neck cancers,Phase 1/2,,,NCT02143622,Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients,,https://ClinicalTrials.gov/show/NCT02143622
literature,motolimod,1211396,,"InChI=1S/C28H34N4O2/c1-3-13-31(14-4-2)28(34)24-17-23-12-11-22(18-25(23)30-26(29)19-24)20-7-9-21(10-8-20)27(33)32-15-5-6-16-32/h7-12,17-18H,3-6,13-16,19H2,1-2H3,(H2,29,30)",QSPOQCXMGPDIHI-UHFFFAOYSA-N,CCCN(CCC)C(=O)C1=Cc2ccc(cc2N=C(N)C1)c3ccc(cc3)C(=O)N4CCCC4,cetuximab,9,P00533,,,,Patients with Recurrent or Metastatic squamous cell carcinoma of the head and neck,head and neck cancers,Phase 1b,27810904,"There were no protocol-defined dose-limiting toxicities, drug-related deaths, or evidence of synergistic toxicities between motolimod and cetuximab. Clinical tolerability at the 3.5 mg/m2 dose level was not optimal for repeated dosing and 3.0 mg/m2 was identified as the MTD. Two patients achieved partial responses for an overall response rate of 15%. Five patients had disease stabilization equating to a disease control rate of 54%. Statistically significant increases in plasma cytokines and in the frequency and activation of circulating NK cells were observed.",,,,
clinicaltrials.gov,nivolumab,,Q15116,,,,cetuximab,9,P00533,,,,,nasopharyngeal cancers,Phase 1/2,,,NCT03370276,Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT03370276
clinicaltrials.gov,NVP-AUY922,480574,,"InChI=1S/C26H31N3O5/c1-4-27-26(32)24-23(18-7-5-17(6-8-18)15-29-9-11-33-12-10-29)25(34-28-24)20-13-19(16(2)3)21(30)14-22(20)31/h5-8,13-14,16,30-31H,4,9-12,15H2,1-3H3,(H,27,32)",NDAZATDQFDPQBD-UHFFFAOYSA-N,CCNC(=O)c1noc(c2cc(C(C)C)c(O)cc2O)c1c3ccc(CN4CCOCC4)cc3,cetuximab,9,P00533,,,,,bowel cancers,Phase 1,,,NCT01294826,Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer,,https://ClinicalTrials.gov/show/NCT01294826
clinicaltrials.gov,pazopanib,200268,O00238;O00444;O14965;O14976;O15197;O43353;O60331;O60674;O75716;O94804;O95819;P00519;P04049;P06239;P06241;P07332;P07333;P07947;P07948;P07949;P08581;P08631;P08922;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P16591;P17948;P19525;P21127;P21802;P22455;P22607;P27448;P29376;P29597;P33981;P35590;P35916;P35968;P36888;P37173;P42681;P42684;P42685;P43405;P45983;P45985;P51451;P51617;P51955;P52333;P52564;P53667;P53671;P53779;P57059;P80192;Q00536;Q02763;Q02779;Q08345;Q12851;Q12866;Q13163;Q13233;Q13470;Q13546;Q13705;Q13882;Q14012;Q16584;Q16832;Q2M2I8;Q56UN5;Q6P3R8;Q7L7X3;Q8IVH8;Q8TBX8;Q92918;Q96NX5;Q9BVS4;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K8;Q9H3Y6;Q9NRP7;Q9NSY1;Q9UBE8;Q9UBF8;Q9UKE5;Q9UL54;Q9UM73;Q9UQ88;Q9UQB9;Q9Y2U5;Q9Y4K4;Q9Y616,"InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)",CUIHSIWYWATEQL-UHFFFAOYSA-N,CN(c1ccc2c(C)n(C)nc2c1)c3ccnc(Nc4ccc(C)c(c4)S(=O)(=O)N)n3,cetuximab,9,P00533,,,,,head and neck cancers,Phase 1,,,NCT01716416,Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC),HNSCC,https://ClinicalTrials.gov/show/NCT01716416
clinicaltrials.gov,pembrolizumab,,Q15116,,,,cetuximab,9,P00533,,,,,skin cancers,Phase 2,,,NCT03666325,Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary Resistance,I-Tackle,https://ClinicalTrials.gov/show/NCT03666325
clinicaltrials.gov,pembrolizumab,,Q15116,,,,cetuximab,9,P00533,,,,,skin cancers,Phase 2,,,NCT03666325,Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary Resistance,I-Tackle,https://ClinicalTrials.gov/show/NCT03666325
literature,pembrolizumab,,Q15116,,,,cetuximab,9,P00533,,,,"Patients with head-and-neck squamous cell carcinoma that progressed during or after platinum-containing treatment for recurrent or metastatic disease (or both), or whose disease recurred or progressed within 3-6 months of previous multimodal therapy containing platinum for locally advanced disease",head and neck cancers,Phase 3,30509740,"Between Dec 24, 2014, and May 13, 2016, 247 patients were randomly allocated to pembrolizumab and 248 were randomly allocated to standard of care. As of May 15, 2017, 181 (73%) of 247 patients in the pembrolizumab group and 207 (83%) of 248 patients in the standard-of-care group had died. Median overall survival in the intention-to-treat population was 8·4 months (95% CI 6·4-9·4) with pembrolizumab and 6·9 months (5·9-8·0) with standard of care (hazard ratio 0·80, 0·65-0·98; nominal p=0·0161). Fewer patients treated with pembrolizumab than with standard of care had grade 3 or worse treatment-related adverse events (33 [13%] of 246 vs 85 [36%] of 234). The most common treatment-related adverse event was hypothyroidism with pembrolizumab (in 33 [13%] patients) and fatigue with standard of care (in 43 [18%]). Treatment-related death occurred in four patients treated with pembrolizumab (unspecified cause, large intestine perforation, malignant neoplasm progression, and Stevens-Johnson syndrome) and two patients treated with standard of care (malignant neoplasm progression and pneumonia).",NCT02252042,,,
literature,pembrolizumab,,Q15116,,,,cetuximab,9,P00533,,,,"Patients with head-and-neck squamous cell carcinoma that progressed during or after platinum-containing treatment for recurrent or metastatic disease (or both), or whose disease recurred or progressed within 3-6 months of previous multimodal therapy containing platinum for locally advanced disease",head and neck cancers,Phase 3,30509740,"Between Dec 24, 2014, and May 13, 2016, 247 patients were randomly allocated to pembrolizumab and 248 were randomly allocated to standard of care. As of May 15, 2017, 181 (73%) of 247 patients in the pembrolizumab group and 207 (83%) of 248 patients in the standard-of-care group had died. Median overall survival in the intention-to-treat population was 8·4 months (95% CI 6·4-9·4) with pembrolizumab and 6·9 months (5·9-8·0) with standard of care (hazard ratio 0·80, 0·65-0·98; nominal p=0·0161). Fewer patients treated with pembrolizumab than with standard of care had grade 3 or worse treatment-related adverse events (33 [13%] of 246 vs 85 [36%] of 234). The most common treatment-related adverse event was hypothyroidism with pembrolizumab (in 33 [13%] patients) and fatigue with standard of care (in 43 [18%]). Treatment-related death occurred in four patients treated with pembrolizumab (unspecified cause, large intestine perforation, malignant neoplasm progression, and Stevens-Johnson syndrome) and two patients treated with standard of care (malignant neoplasm progression and pneumonia).",NCT02252042,,,
literature,PX-866,398788,O00329;O00459;P27986;P42336;P42338;P48736;Q8WYR1;Q92569,"InChI=1S/C29H35NO8/c1-7-11-30(12-8-2)14-17-23-26(34)25(33)22-18-9-10-20(32)28(18,4)13-19(37-16(3)31)24(22)29(23,5)21(15-36-6)38-27(17)35/h7-8,14,18-19,21,34H,1-2,9-13,15H2,3-6H3/b17-14+/t18-,19+,21+,28-,29-/m0/s1",QIUASFSNWYMDFS-NILGECQDSA-N,COC[C@H]1OC(=O)\C(=C\N(CC=C)CC=C)\C2=C(O)C(=O)C3=C([C@@H](C[C@@]4(C)[C@H]3CCC4=O)OC(=O)C)[C@@]12C,cetuximab,9,P00533,,,,metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck,head and neck cancers,Phase 1,24916771,"Eleven patients were enrolled. The most frequent treatment-emergent adverse event was diarrhea (90.1%), followed by hypomagnesemia (72.2%), vomiting (72.2%), fatigue (54.5%), nausea (54.5%), rash (45.5%) and peripheral edema (40%). No dose limiting toxicities were observed. The RP2D was 8 mg, the same as the single-agent PX-866 MTD. Best responses in 9 evaluable patients were: 4 partial responses (44.4%), 4 stable disease (44.4%), and 1 disease progression (11.1%). The median progression free survival was 106 days (range: 1-271).",,,,
clinicaltrials.gov,regorafenib,998226,P15056;P34913,"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)",FNHKPVJBJVTLMP-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1,cetuximab,9,P00533,,,,,,Phase 1,,,NCT01973868,Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination,,https://ClinicalTrials.gov/show/NCT01973868
literature,seribantumab,,,,,,cetuximab,9,P00533,,,, patients with EGFR-dependent cancers,advanced solid cancers,Phase 1,27853996,"34 patients were enrolled in Part I (seribantumab/cetuximab) and 14 patients were enrolled in Part II (seribantumab/cetuximab/irinotecan). Common toxicities of seribantumab/cetuximab included acneiform rash, diarrhea, stomatitis, and paronychia. The MTD of Part I was seribantumab 40_mg/kg bolus, then 20_mg/kg weekly combined with cetuximab 400_mg/m2 bolus, then 250_mg/m2 IV weekly. Common toxicities reported in the seribantumab/cetuximab/irinotecan combination were similar to the Part I portion. However, toxicities were more frequent and severe with the triplet combination. There was one treatment-related death in Part II secondary to Grade 4 neutropenia and grade 3 diarrhea. Other dose-limiting toxicities in Part II were Grade 3 mucositis and Grade 3 diarrhea. A cholangiocarcinoma patient, previously untreated with EGFR-directed therapy, had a confirmed partial response (PR). One colorectal cancer patient, previously treated with EGFR-directed therapy, had an unconfirmed PR.",,,,
clinicaltrials.gov,sirolimus,344,P06730;P08183;P08684;P11712;P33261;P42345;P62942;Q13451;Q53EL6;Q9Y6L6,"InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1",QFJCIRLUMZQUOT-HPLJOQBZSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1O,cetuximab,9,P00533,,,,,,Phase 1,,,NCT00940381,Sirolimus and Cetuximab in Advanced Malignancies,,https://ClinicalTrials.gov/show/NCT00940381
clinicaltrials.gov,temsirolimus,401,P42345,"InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1",CBPNZQVSJQDFBE-FUXHJELOSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO,cetuximab,9,P00533,,,,,bowel cancers,Phase 1,,,NCT00593060,"Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer",,https://ClinicalTrials.gov/show/NCT00593060
literature,temsirolimus,401,P42345,"InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1",CBPNZQVSJQDFBE-FUXHJELOSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO,cetuximab,9,P00533,,,,advanced solid tumors,advanced solid cancers,Phase 1,28618305,"Among 39 patients enrolled, three experienced dose-limiting toxicities (DLTs): pulmonary embolism (C200_+_T20), stomatitis (C250_+_T20) and acneiform rash (C250_+_T25). The weekly C 250_mg/m2_and T 25_mg dose level was selected as the MTD. The most common treatment-related adverse events were: acneiform rash (97%), oral mucositis (82%), fatigue (59%), nausea (41%) and diarrhoea (36%). The median progression-free survival (PFS) and overall survival (OS) were respectively 2.0_months [95% CI:_1.8, 3.5] and 7.5_months [95% CI: 5.5, 11.9]. Among all patients, partial responses (PRs) and stable diseases (SDs) were observed in 2 (5.1%) and 18 patients (46.2%), respectively. The objective response rate (ORR) in patients with a molecular aberration was 2/14 (14%), versus 0/24 in those without molecular aberration.",,,,
literature,tivantinib,1026778,P08581,"InChI=1S/C23H19N3O2/c27-22-19(16-11-24-18-9-2-1-7-14(16)18)20(23(28)25-22)17-12-26-10-4-6-13-5-3-8-15(17)21(13)26/h1-3,5,7-9,11-12,19-20,24H,4,6,10H2,(H,25,27,28)/t19-,20-/m0/s1",UCEQXRCJXIVODC-PMACEKPBSA-N,O=C1NC(=O)[C@H]([C@@H]1c2c[nH]c3ccccc23)c4cn5CCCc6cccc4c56,cetuximab,9,P00533,,,,Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression,colorectal cancers,Phase 2,30846365,"In total, 41 patients were evaluated, 4 patients (9.8%) achieved an objective response, the median progression-free survival was 2.6 months (95% confidence interval, 1.9-4.2 months), and the median overall survival was 9.2 months (95% confidence interval, 7.1-15.1 months). Among 13 patients with tested MET amplification, 2 responding patients had MET amplification compared with none of the nonresponding patients. The most common grade ≥ 3 treatment-emergent adverse events were neutropenia (14.6%), skin toxicity (12.2%), and fatigue (9.8%).",,,,
clinicaltrials.gov,urelumab,,Q07011,,,,cetuximab,9,P00533,,,,,bowel cancers;head and neck cancers,Phase 1,,,NCT02110082,Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer,,https://ClinicalTrials.gov/show/NCT02110082
literature,vatalanib,535503,O14578;P00533;P07333;P07949;P09619;P10721;P16234;P17948;P35916;P35968;P42685;P49336;Q08345;Q13882;Q56UN5;Q9BWU1;Q9NYL2,"InChI=1S/C20H15ClN4/c21-15-5-7-16(8-6-15)23-20-18-4-2-1-3-17(18)19(24-25-20)13-14-9-11-22-12-10-14/h1-12H,13H2,(H,23,25)",YCOYDOIWSSHVCK-UHFFFAOYSA-N,Clc1ccc(Nc2nnc(Cc3ccncc3)c4ccccc24)cc1,cetuximab,9,P00533,,,,advanced solid tumors,advanced solid cancers,Phase 1,20126478,"Safety and tolerability was evaluated in 16 patients. The most frequently reported adverse events were acne, dry skin, fatigue, nausea, dizziness, vomiting, headache, and diarrhea. One dose-limiting toxicity occurred in cohort 3 consisting of a grade 3 transaminitis. Pharmacokinetic analysis revealed no significant changes in PTK/ZK exposure on coadministration with cetuximab and in bioavailability at equivalent total daily doses. Biomarker analysis showed no significant change in the number of CE(P)Cs during treatment. One of 14 evaluable patients showed a partial response for at least 11.5 months, and 7 patients (50%) stable disease for at least 2 months.",,,,
clinicaltrials.gov,tofacitinib,,,,,,chidamide,,,,,,,lymphoma,Phase 2,,,NCT03598959,Tofacitinib Combined With Chidamide in R/R ENKTCL,,https://ClinicalTrials.gov/show/NCT03598959
clinicaltrials.gov,tofacitinib,,,,,,chidamide,,,,,,,lymphoma,Phase 2,,,NCT03598959,Tofacitinib Combined With Chidamide in R/R ENKTCL,,https://ClinicalTrials.gov/show/NCT03598959
clinicaltrials.gov,alectinib,859887,Q9UM73;P07949,"InChI=1S/C30H34N4O2/c1-4-20-16-23-24(17-26(20)34-9-7-21(8-10-34)33-11-13-36-14-12-33)30(2,3)29-27(28(23)35)22-6-5-19(18-31)15-25(22)32-29/h5-6,15-17,21,32H,4,7-14H2,1-3H3",KDGFLJKFZUIJMX-UHFFFAOYSA-N,CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N5CCC(CC5)N6CCOCC6,cobimetinib,1055500,Q02750;P36507,"InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1",BSMCAPRUBJMWDF-KRWDZBQOSA-N,OC1(CN(C1)C(=O)c2ccc(F)c(F)c2Nc3ccc(I)cc3F)[C@@H]4CCCCN4,,lung cancers,Phase 1/2,,,NCT03202940,A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC,,https://ClinicalTrials.gov/show/NCT03202940
clinicaltrials.gov,atezolizumab,,Q9NZQ7,,,,cobimetinib,1055500,Q02750;P36507,"InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1",BSMCAPRUBJMWDF-KRWDZBQOSA-N,OC1(CN(C1)C(=O)c2ccc(F)c(F)c2Nc3ccc(I)cc3F)[C@@H]4CCCCN4,,advanced solid cancers,Phase 1,,,NCT01988896,Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors,,https://ClinicalTrials.gov/show/NCT01988896
clinicaltrials.gov,atezolizumab,,Q9NZQ7,,,,cobimetinib,1055500,Q02750;P36507,"InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1",BSMCAPRUBJMWDF-KRWDZBQOSA-N,OC1(CN(C1)C(=O)c2ccc(F)c(F)c2Nc3ccc(I)cc3F)[C@@H]4CCCCN4,,colorectal cancers,Phase 2,,,NCT03340558,Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer,ATELIER,https://ClinicalTrials.gov/show/NCT03340558
literature,atezolizumab,,Q9NZQ7,,,,cobimetinib,1055500,Q02750;P36507,"InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1",BSMCAPRUBJMWDF-KRWDZBQOSA-N,OC1(CN(C1)C(=O)c2ccc(F)c(F)c2Nc3ccc(I)cc3F)[C@@H]4CCCCN4,previously treated metastatic colorectal cancer,colorectal cancers,Phase 3,31003911,"Between July 27, 2016, and Jan 19, 2017, 363 patients were enrolled (183 patients in the atezolizumab plus cobimetinib group, 90 in the atezolizumab group, and 90 in the regorafenib group). At data cutoff (March 9, 2018), median follow-up was 7·3 months (IQR 3·7-13·6). Median overall survival was 8·87 months (95% CI 7·00-10·61) with atezolizumab plus cobimetinib, 7·10 months (6·05-10·05) with atezolizumab, and 8·51 months (6·41-10·71) with regorafenib; the hazard ratio was 1·00 (95% CI 0·73-1·38; p=0·99) for the combination versus regorafenib and 1·19 (0·83-1·71; p=0·34) for atezolizumab versus regorafenib. Grade 3-4 adverse events were reported in 109 (61%) of 179 patients in the atezolizumab plus cobimetinib group, 28 (31%) of 90 in the atezolizumab group, and 46 (58%) of 80 in the regorafenib group. The most common all-cause grade 3-4 adverse events in the combination group were diarrhoea (20 [11%] of 179), anaemia (ten [6%]), increased blood creatine phosphokinase (12 [7%]), and fatigue (eight [4%]). Serious adverse events were reported in 71 (40%) of 179 patients in the combination group, 15 (17%) of 90 in the atezolizumab group, and 18 (23%) of 80 in the regorafenib group. Two treatment-related deaths occurred in the combination group (sepsis) and one in the regorafenib group (intestinal perforation).",NCT02788279,,,
clinicaltrials.gov,ipatasertib,1017408,P31751;Q9Y243;P31749,"InChI=1S/C24H32ClN5O2/c1-15(2)26-13-19(17-4-6-18(25)7-5-17)24(32)30-10-8-29(9-11-30)23-21-16(3)12-20(31)22(21)27-14-28-23/h4-7,14-16,19-20,26,31H,8-13H2,1-3H3/t16-,19-,20-/m1/s1",GRZXWCHAXNAUHY-NSISKUIASA-N,CC(C)NC[C@@H](C(=O)N1CCN(CC1)c2ncnc3[C@H](O)C[C@@H](C)c23)c4ccc(Cl)cc4,cobimetinib,1055500,Q02750;P36507,"InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1",BSMCAPRUBJMWDF-KRWDZBQOSA-N,OC1(CN(C1)C(=O)c2ccc(F)c(F)c2Nc3ccc(I)cc3F)[C@@H]4CCCCN4,,advanced solid cancers,Phase 1,,,NCT01562275,"A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors",,https://ClinicalTrials.gov/show/NCT01562275
clinicaltrials.gov,RMC-4630,,,,,,cobimetinib,1055500,Q02750;P36507,"InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1",BSMCAPRUBJMWDF-KRWDZBQOSA-N,OC1(CN(C1)C(=O)c2ccc(F)c(F)c2Nc3ccc(I)cc3F)[C@@H]4CCCCN4,,,,,,NCT03989115,Dose-Escalation and Dose-Expansion of RMC-4630 and Cobimetinib in Relapsed/Refractory Solid Tumors,,https://ClinicalTrials.gov/show/NCT03989115
clinicaltrials.gov,vemurafenib,754991,P15056,"InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)",GPXBXXGIAQBQNI-UHFFFAOYSA-N,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)c4ccc(Cl)cc4)c1F,cobimetinib,1055500,Q02750;P36507,"InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1",BSMCAPRUBJMWDF-KRWDZBQOSA-N,OC1(CN(C1)C(=O)c2ccc(F)c(F)c2Nc3ccc(I)cc3F)[C@@H]4CCCCN4,,skin cancers,Phase 2,,,NCT03430947,Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases,RadioCoBRIM,https://ClinicalTrials.gov/show/NCT03430947
clinicaltrials.gov,vemurafenib,754991,P15056,"InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)",GPXBXXGIAQBQNI-UHFFFAOYSA-N,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)c4ccc(Cl)cc4)c1F,cobimetinib,1055500,Q02750;P36507,"InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1",BSMCAPRUBJMWDF-KRWDZBQOSA-N,OC1(CN(C1)C(=O)c2ccc(F)c(F)c2Nc3ccc(I)cc3F)[C@@H]4CCCCN4,,skin cancers,Phase 2,,,NCT03224208,Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients,VECODUE,https://ClinicalTrials.gov/show/NCT03224208
clinicaltrials.gov,vemurafenib,754991,P15056,"InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)",GPXBXXGIAQBQNI-UHFFFAOYSA-N,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)c4ccc(Cl)cc4)c1F,cobimetinib,1055500,Q02750;P36507,"InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1",BSMCAPRUBJMWDF-KRWDZBQOSA-N,OC1(CN(C1)C(=O)c2ccc(F)c(F)c2Nc3ccc(I)cc3F)[C@@H]4CCCCN4,,skin cancers,Phase 2,,,NCT03005639,ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma,,https://ClinicalTrials.gov/show/NCT03005639
literature,vemurafenib,754991,P15056,"InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)",GPXBXXGIAQBQNI-UHFFFAOYSA-N,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)c4ccc(Cl)cc4)c1F,cobimetinib,1055500,Q02750;P36507,"InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1",BSMCAPRUBJMWDF-KRWDZBQOSA-N,OC1(CN(C1)C(=O)c2ccc(F)c(F)c2Nc3ccc(I)cc3F)[C@@H]4CCCCN4,BRAF-mutated melanoma,skin cancers,Phase 3,25265494,"The median progression-free survival was 9.9 months in the combination group and 6.2 months in the control group (hazard ratio for death or disease progression, 0.51; 95% confidence interval [CI], 0.39 to 0.68; P<0.001). The rate of complete or partial response in the combination group was 68%, as compared with 45% in the control group (P<0.001), including rates of complete response of 10% in the combination group and 4% in the control group. Progression-free survival as assessed by independent review was similar to investigator-assessed progression-free survival. Interim analyses of overall survival showed 9-month survival rates of 81% (95% CI, 75 to 87) in the combination group and 73% (95% CI, 65 to 80) in the control group. Vemurafenib and cobimetinib was associated with a nonsignificantly higher incidence of adverse events of grade 3 or higher, as compared with vemurafenib and placebo (65% vs. 59%), and there was no significant difference in the rate of study-drug discontinuation. The number of secondary cutaneous cancers decreased with the combination therapy.",,,,
clinicaltrials.gov,birinapant,1106473,Q13490;Q13489,"InChI=1S/C42H56F2N8O6/c1-7-33(49-39(55)21(3)45-5)41(57)51-19-27(53)15-25(51)17-31-29-11-9-23(43)13-35(29)47-37(31)38-32(30-12-10-24(44)14-36(30)48-38)18-26-16-28(54)20-52(26)42(58)34(8-2)50-40(56)22(4)46-6/h9-14,21-22,25-28,33-34,45-48,53-54H,7-8,15-20H2,1-6H3,(H,49,55)(H,50,56)/t21-,22-,25-,26-,27-,28-,33-,34-/m0/s1",PKWRMUKBEYJEIX-DXXQBUJASA-N,CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc2c([nH]c3cc(F)ccc23)c4[nH]c5cc(F)ccc5c4C[C@@H]6C[C@H](O)CN6C(=O)[C@H](CC)NC(=O)[C@H](C)NC,conatumumab,,O14763,,,,,ovarian cancers;female cancers;other,Phase 1,,,NCT01940172,Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed ovarian Cancers,,https://ClinicalTrials.gov/show/NCT01940172
clinicaltrials.gov,panitumumab,1238534,P00533,,,,conatumumab,,O14763,,,,,bowel cancers,Phase 1/2,,,NCT00630786,Conatumumab/panitumumab Combination Metastatic Colorectal Cancer Study,,https://ClinicalTrials.gov/show/NCT00630786
clinicaltrials.gov,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,copanlisib,1212464,O00329;O00459;P27986;P42336;P42338;P48736;Q8WYR1;Q92569,"InChI=1S/C23H28N8O4/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15/h3-4,13-14H,2,5-12H2,1H3,(H2,24,26,27)(H,28,29,32)",PZBCKZWLPGJMAO-UHFFFAOYSA-N,COc1c(OCCCN2CCOCC2)ccc3C4=NCCN4C(=Nc13)NC(=O)c5cnc(N)nc5,,lymphoma,Phase 1/2,,,NCT03581942,Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL),,https://ClinicalTrials.gov/show/NCT03581942
clinicaltrials.gov,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,copanlisib,1212464,O00329;O00459;P27986;P42336;P42338;P48736;Q8WYR1;Q92569,"InChI=1S/C23H28N8O4/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15/h3-4,13-14H,2,5-12H2,1H3,(H2,24,26,27)(H,28,29,32)",PZBCKZWLPGJMAO-UHFFFAOYSA-N,COc1c(OCCCN2CCOCC2)ccc3C4=NCCN4C(=Nc13)NC(=O)c5cnc(N)nc5,,lymphoma,Phase 1/2,,,NCT03581942,Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL),,https://ClinicalTrials.gov/show/NCT03581942
clinicaltrials.gov,rituximab,16,P11836,,,,copanlisib,1212464,O00329;O00459;P27986;P42336;P42338;P48736;Q8WYR1;Q92569,"InChI=1S/C23H28N8O4/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15/h3-4,13-14H,2,5-12H2,1H3,(H2,24,26,27)(H,28,29,32)",PZBCKZWLPGJMAO-UHFFFAOYSA-N,COc1c(OCCCN2CCOCC2)ccc3C4=NCCN4C(=Nc13)NC(=O)c5cnc(N)nc5,,lymphoma,Phase 2,,,NCT03789240,Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma,,https://ClinicalTrials.gov/show/NCT03789240
clinicaltrials.gov,rituximab,16,P11836,,,,copanlisib,1212464,O00329;O00459;P27986;P42336;P42338;P48736;Q8WYR1;Q92569,"InChI=1S/C23H28N8O4/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15/h3-4,13-14H,2,5-12H2,1H3,(H2,24,26,27)(H,28,29,32)",PZBCKZWLPGJMAO-UHFFFAOYSA-N,COc1c(OCCCN2CCOCC2)ccc3C4=NCCN4C(=Nc13)NC(=O)c5cnc(N)nc5,,lymphoma,Phase 2,,,NCT03789240,Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma,,https://ClinicalTrials.gov/show/NCT03789240
clinicaltrials.gov,Rogaratinib,,,,,,copanlisib,1212464,O00329;O00459;P27986;P42336;P42338;P48736;Q8WYR1;Q92569,"InChI=1S/C23H28N8O4/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15/h3-4,13-14H,2,5-12H2,1H3,(H2,24,26,27)(H,28,29,32)",PZBCKZWLPGJMAO-UHFFFAOYSA-N,COc1c(OCCCN2CCOCC2)ccc3C4=NCCN4C(=Nc13)NC(=O)c5cnc(N)nc5,,advanced solid cancers,Phase 1,,,NCT03517956,"Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors",ROCOCO,https://ClinicalTrials.gov/show/NCT03517956
clinicaltrials.gov,Rogaratinib,,,,,,copanlisib,1212464,O00329;O00459;P27986;P42336;P42338;P48736;Q8WYR1;Q92569,"InChI=1S/C23H28N8O4/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15/h3-4,13-14H,2,5-12H2,1H3,(H2,24,26,27)(H,28,29,32)",PZBCKZWLPGJMAO-UHFFFAOYSA-N,COc1c(OCCCN2CCOCC2)ccc3C4=NCCN4C(=Nc13)NC(=O)c5cnc(N)nc5,,advanced solid cancers,Phase 1,,,NCT03517956,"Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors",ROCOCO,https://ClinicalTrials.gov/show/NCT03517956
clinicaltrials.gov,palbociclib,149415,P11802;P20248;P24385;P24941;P30279;P30281;P36888;P50750;P52333;Q00534,"InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)",AHJRHEGDXFFMBM-UHFFFAOYSA-N,CC(=O)C1=C(C)c2cnc(Nc3ccc(cn3)N4CCNCC4)nc2N(C5CCCC5)C1=O,CPX-351,,,,,,Acute Myeloid Leukemia|AML,,Phase 2,,,NCT03844997,,,
clinicaltrials.gov,ruxolitinib,974392,O00238;O00444;O00506;O14730;O14920;O14936;O14976;O15075;O15197;O43293;O43318;O60674;O75116;O75385;O75460;O75582;O75676;O75716;O94768;O95747;O96013;P00519;P04629;P07949;P0C264;P10721;P15056;P15735;P19784;P23458;P29320;P29376;P29597;P32298;P33981;P36507;P45983;P45985;P46734;P48729;P49760;P50613;P51617;P51956;P52333;P53350;P53355;P57078;P68400;Q02156;Q02750;Q07912;Q09013;Q12851;Q13233;Q13237;Q13464;Q13554;Q13555;Q13557;Q13627;Q13873;Q14012;Q14164;Q14680;Q15349;Q15418;Q15746;Q15835;Q16288;Q16620;Q16816;Q2M2I8;Q52WX2;Q56UN5;Q5S007;Q6PHR2;Q6ZN16;Q7KZI7;Q7L7X3;Q86Y07;Q86Z02;Q8IU85;Q8IYT8;Q8N568;Q8NFD2;Q8TDX7;Q8WTQ7;Q92630;Q96NX5;Q96SB4;Q99759;Q9BRS2;Q9BVS4;Q9C098;Q9H093;Q9H2K8;Q9H2X6;Q9H422;Q9H4B4;Q9HAZ1;Q9HBH9;Q9NQU5;Q9NSY1;Q9NYY3;Q9P286;Q9P289;Q9UBF8;Q9UEE5;Q9UEW8;Q9UHD2;Q9UIK4;Q9UK32;Q9UL54;Q9UM73;Q9UPE1;Q9UQB9;Q9UQM7;Q9Y2H9;Q9Y2K2;Q9Y2U5,"InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1",HFNKQEVNSGCOJV-OAHLLOKOSA-N,N#CC[C@H](C1CCCC1)n2cc(cn2)c3ncnc4[nH]ccc34,CPX-351,,,,,,Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia,,Phase 1/2,,,NCT03878199,,,
clinicaltrials.gov,AT13387,,,,,,crizotinib,652583,O00238;O00444;O14730;O14920;O14936;O14965;O15075;O15146;O15197;O43283;O43318;O43353;O60674;O75116;O75385;O94804;O94806;P00519;P00533;P04629;P06213;P06239;P06241;P06748;P07332;P07333;P07947;P07948;P07949;P08069;P08581;P08922;P09769;P0C264;P10721;P12931;P14616;P16591;P17948;P19525;P21127;P21709;P22607;P23443;P23458;P29317;P29320;P29322;P29376;P29597;P30530;P32298;P35590;P36888;P36896;P36897;P42681;P42684;P42685;P43403;P43405;P46734;P50613;P51451;P51617;P51813;P52333;P53667;P53671;P54756;P54760;P54762;P54764;P57078;Q02763;Q04771;Q04912;Q05397;Q06187;Q06418;Q07912;Q08345;Q08881;Q09013;Q12851;Q12852;Q12866;Q13043;Q13131;Q13164;Q13188;Q13233;Q13464;Q13470;Q13546;Q14164;Q14289;Q15139;Q15375;Q15569;Q16288;Q16620;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q6PHR2;Q6XUX3;Q6ZN16;Q7L7X3;Q8IVH8;Q8IY84;Q8IYT8;Q8N4C8;Q8N568;Q8NE63;Q8NFD2;Q8TD19;Q8TDR2;Q8TDX7;Q92630;Q92772;Q92918;Q96D53;Q96GD4;Q96RR4;Q96SB4;Q99755;Q99759;Q9BRS2;Q9H093;Q9H0K1;Q9H2G2;Q9H2K8;Q9NSY1;Q9NWZ3;Q9P289;Q9UF33;Q9UHD2;Q9UL54;Q9UM73;Q9UPE1;Q9UQ88;Q9UQB9;Q9Y2U5;Q9Y4K4;Q9Y616,"InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1",KTEIFNKAUNYNJU-GFCCVEGCSA-N,C[C@@H](Oc1cc(cnc1N)c2cnn(c2)C3CCNCC3)c4c(Cl)ccc(F)c4Cl,,lung cancers,Phase 1/2,,,NCT01712217,A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib,,https://ClinicalTrials.gov/show/NCT01712217
clinicaltrials.gov,enzalutamide,679762,P10275,"InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)",WXCXUHSOUPDCQV-UHFFFAOYSA-N,CNC(=O)c1ccc(cc1F)N2C(=S)N(C(=O)C2(C)C)c3ccc(C#N)c(c3)C(F)(F)F,CRLX101,,,,,,,prostate cancers,Phase 2,,,NCT03531827,"Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment",,https://ClinicalTrials.gov/show/NCT03531827
clinicaltrials.gov,enzalutamide,679762,P10275,"InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)",WXCXUHSOUPDCQV-UHFFFAOYSA-N,CNC(=O)c1ccc(cc1F)N2C(=S)N(C(=O)C2(C)C)c3ccc(C#N)c(c3)C(F)(F)F,CRLX101,,,,,,,prostate cancers,Phase 2,,,NCT03531827,"Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment",,https://ClinicalTrials.gov/show/NCT03531827
clinicaltrials.gov,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,CVM-1118,,,,,,,liver cancers,Phase 2,,,NCT03582618,CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma,,https://ClinicalTrials.gov/show/NCT03582618
clinicaltrials.gov,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,CVM-1118,,,,,,,liver cancers,Phase 2,,,NCT03582618,CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma,,https://ClinicalTrials.gov/show/NCT03582618
clinicaltrials.gov,pembrolizumab,,Q15116,,,,CXD101,,,,,,Diffuse Large B Cell Lymphoma,,Phase 1/2,,,NCT03873025,,,
clinicaltrials.gov,APR-246,,,,,,dabrafenib,1929355,P15056,"InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)",BFSMGDJOXZAERB-UHFFFAOYSA-N,CC(C)(C)c1nc(c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(s1)c4ccnc(N)n4,,skin cancers,Phase 1/2,,,NCT03391050,A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma,,https://ClinicalTrials.gov/show/NCT03391050
clinicaltrials.gov,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,dabrafenib,1929355,P15056,"InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)",BFSMGDJOXZAERB-UHFFFAOYSA-N,CC(C)(C)c1nc(c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(s1)c4ccnc(N)n4,,central nervous system cancers,Phase 1,,,NCT02124772,"Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations",,https://ClinicalTrials.gov/show/NCT02124772
clinicaltrials.gov,crizotinib,652583,O00238;O00444;O14730;O14920;O14936;O14965;O15075;O15146;O15197;O43283;O43318;O43353;O60674;O75116;O75385;O94804;O94806;P00519;P00533;P04629;P06213;P06239;P06241;P06748;P07332;P07333;P07947;P07948;P07949;P08069;P08581;P08922;P09769;P0C264;P10721;P12931;P14616;P16591;P17948;P19525;P21127;P21709;P22607;P23443;P23458;P29317;P29320;P29322;P29376;P29597;P30530;P32298;P35590;P36888;P36896;P36897;P42681;P42684;P42685;P43403;P43405;P46734;P50613;P51451;P51617;P51813;P52333;P53667;P53671;P54756;P54760;P54762;P54764;P57078;Q02763;Q04771;Q04912;Q05397;Q06187;Q06418;Q07912;Q08345;Q08881;Q09013;Q12851;Q12852;Q12866;Q13043;Q13131;Q13164;Q13188;Q13233;Q13464;Q13470;Q13546;Q14164;Q14289;Q15139;Q15375;Q15569;Q16288;Q16620;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q6PHR2;Q6XUX3;Q6ZN16;Q7L7X3;Q8IVH8;Q8IY84;Q8IYT8;Q8N4C8;Q8N568;Q8NE63;Q8NFD2;Q8TD19;Q8TDR2;Q8TDX7;Q92630;Q92772;Q92918;Q96D53;Q96GD4;Q96RR4;Q96SB4;Q99755;Q99759;Q9BRS2;Q9H093;Q9H0K1;Q9H2G2;Q9H2K8;Q9NSY1;Q9NWZ3;Q9P289;Q9UF33;Q9UHD2;Q9UL54;Q9UM73;Q9UPE1;Q9UQ88;Q9UQB9;Q9Y2U5;Q9Y4K4;Q9Y616,"InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1",KTEIFNKAUNYNJU-GFCCVEGCSA-N,C[C@@H](Oc1cc(cnc1N)c2cnn(c2)C3CCNCC3)c4c(Cl)ccc(F)c4Cl,dacomitinib,1055487,P00533;P04626;P21860;Q15303;P00533;P04626;Q15303,"InChI=1S/C24H25ClFN5O2/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29)/b6-5+",LVXJQMNHJWSHET-AATRIKPKSA-N,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN4CCCCC4,,lung cancers,Phase 1,,,NCT01441128,-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT01441128
literature,abiraterone,181093,P05093,"InChI=1S/C24H31NO/c1-23-11-9-18(26)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22,26H,6,8-12,14H2,1-2H3/t18-,19-,21-,22-,23-,24+/m0/s1",GZOSMCIZMLWJML-VJLLXTKPSA-N,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c5cccnc5,dactolisib,1081384,O00329;O00459;P27986;P42336;P42338;P48736;Q8WYR1;Q92569;P42345,"InChI=1S/C30H23N5O/c1-30(2,18-31)22-9-11-23(12-10-22)35-28-24-15-19(21-14-20-6-4-5-7-25(20)32-16-21)8-13-26(24)33-17-27(28)34(3)29(35)36/h4-17H,1-3H3",JOGKUKXHTYWRGZ-UHFFFAOYSA-N,CN1C(=O)N(c2ccc(cc2)C(C)(C)C#N)c3c1cnc4ccc(cc34)c5cnc6ccccc6c5,castration-resistant prostate cancer,male cancers,Phase 1b,28282611,"In buparlisib_+_AA arm, 25 patients received buparlisib_+_AA (median age, 67 years; Eastern Cooperative Oncology Group performance status (ECOG PS) of 0/1/2 for 7/17/1 patients, respectively). At 100_mg qd; two patients experienced dose-limiting toxicities (DLTs) (grade 3 hyperglycaemia; grade 2 asthenia), and this was the maximum buparlisib dose explored. Buparlisib_+_AA showed a 26% lower median area under the curve from time zero to 24çh (AUC0-24) and 48% lower median maximum serum concentration (Cmax) versus the single-agent buparlisib assessed in first-in-human study. No objective response and few PSA decreases were reported. In dactolisib_+_AA arm, 18 patients (median age, 71 years; ECOG PS of 0/1 for 6/12 patients, respectively) received dactolisib_+_AA at the first dose level (200_mg bid). Five patients had 9 DLTs (grades 2&3 stomatitis; grade 3 hyperglycaemia; grades 2& 3 diarrhoea; grades 1& 2 pyrexia, grade 2 vomiting, and grade 2 chills).",,,,
literature,ridaforolimus,1020194,P42345,"InChI=1S/C53H84NO14P/c1-32-18-14-13-15-19-33(2)44(63-8)30-40-23-21-38(7)53(61,67-40)50(58)51(59)54-25-17-16-20-41(54)52(60)66-45(35(4)28-39-22-24-43(46(29-39)64-9)68-69(11,12)62)31-42(55)34(3)27-37(6)48(57)49(65-10)47(56)36(5)26-32/h13-15,18-19,27,32,34-36,38-41,43-46,48-49,57,61H,16-17,20-26,28-31H2,1-12H3/b15-13+,18-14+,33-19+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",BUROJSBIWGDYCN-GAUTUEMISA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OP(=O)(C)C,dalotuzumab,,P08069,,,,patients with estrogen receptor-positive breast cancer,breast cancers,Phase 2,28324268,"Median PFS was 21.4_weeks for ridaforolimus 30_mg qd___5_days/week plus dalotuzumab 10_mg/kg (n_=_29) and 24.3_weeks for exemestane (n_=_33; hazard ratio_=_1.00; P_=_0.5). Overall survival and objective response rates were similar between treatment arms. The incidence of drug-related, nonserious, and serious adverse events was higher with ridaforolimus/dalotuzumab (any ridaforolimus dose) than with exemestane. Lowering the ridaforolimus dose reduced the incidence of grade 3 stomatitis, but overall toxicity remained higher than acceptable at all doses without improved efficacy.",,,,
clinicaltrials.gov,atezolizumab,,Q9NZQ7,,,,daratumumab,,P28907,,,,,lung cancers,Phase 2,,,NCT03023423,A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer,DARZALEX,https://ClinicalTrials.gov/show/NCT03023423
clinicaltrials.gov,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,daratumumab,,P28907,,,,,leukemia,Phase 2,,,NCT03734198,Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction,IDA53,https://ClinicalTrials.gov/show/NCT03734198
clinicaltrials.gov,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,daratumumab,,P28907,,,,,lymphoma,Phase 2,,,NCT03679624,Daratumumab Plus Ibrutinib in Patients With Waldenstr”ßm's Macroglobulinemia,,https://ClinicalTrials.gov/show/NCT03679624
clinicaltrials.gov,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,daratumumab,,P28907,,,,,leukemia,Phase 2,,,NCT03734198,Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction,IDA53,https://ClinicalTrials.gov/show/NCT03734198
clinicaltrials.gov,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,daratumumab,,P28907,,,,,lymphoma,Phase 2,,,NCT03679624,Daratumumab Plus Ibrutinib in Patients With Waldenstr”ßm's Macroglobulinemia,,https://ClinicalTrials.gov/show/NCT03679624
clinicaltrials.gov,INCB001158,,,,,,daratumumab,,P28907,,,,Relapsed or Refractory Multiple Myeloma,,Phase 1/2,,,NCT03837509,,,
clinicaltrials.gov,ixazomib,1069383,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C14H19BCl2N2O4/c1-8(2)5-12(15(22)23)19-13(20)7-18-14(21)10-6-9(16)3-4-11(10)17/h3-4,6,8,12,22-23H,5,7H2,1-2H3,(H,18,21)(H,19,20)/t12-/m0/s1",MXAYKZJJDUDWDS-LBPRGKRZSA-N,CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,daratumumab,,P28907,,,,,multiple myeloma,Phase 2,,,NCT03757221,Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma,IDARA,https://ClinicalTrials.gov/show/NCT03757221
clinicaltrials.gov,ixazomib,1069383,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C14H19BCl2N2O4/c1-8(2)5-12(15(22)23)19-13(20)7-18-14(21)10-6-9(16)3-4-11(10)17/h3-4,6,8,12,22-23H,5,7H2,1-2H3,(H,18,21)(H,19,20)/t12-/m0/s1",MXAYKZJJDUDWDS-LBPRGKRZSA-N,CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,daratumumab,,P28907,,,,,multiple myeloma,Phase 2,,,NCT03757221,Ixazomib -Daratumumab Without Dexamethasone (IDara) in Elderly Relapse Refractory Multiple Myeloma,IDARA,https://ClinicalTrials.gov/show/NCT03757221
clinicaltrials.gov,nivolumab,,Q15116,,,,daratumumab,,P28907,,,,,advanced solid cancers,Phase 1/2,,,NCT03098550,A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Advanced Solid Tumors or Tumors That Have Spread,,https://ClinicalTrials.gov/show/NCT03098550
clinicaltrials.gov,pembrolizumab,,Q15116,,,,daratumumab,,P28907,,,,,multiple myeloma,Phase 2,,,NCT03221634,Efficacy and Safety Study of pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668),,https://ClinicalTrials.gov/show/NCT03221634
clinicaltrials.gov,RO6870810,,,,,,daratumumab,,P28907,,,,,multiple myeloma,Phase 1,,,NCT03068351,Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma,,https://ClinicalTrials.gov/show/NCT03068351
clinicaltrials.gov,bevacizumab,11,P15692,,,,dasatinib,375,O00238;O00506;O14965;O14976;O15197;O15264;O43283;O43318;O43353;O60674;O94804;O95819;P00519;P00533;P04049;P04626;P06239;P06241;P07333;P07947;P07948;P07949;P08631;P08684;P09619;P09769;P0C1S8;P10721;P11274;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P21860;P22607;P27037;P29317;P29320;P29322;P29323;P29597;P30291;P35968;P36507;P36888;P36894;P36896;P36897;P37023;P37173;P41240;P42680;P42681;P42684;P42685;P43405;P49674;P51451;P51813;P51955;P52333;P53667;P53671;P53778;P54753;P54756;P54760;P54762;P54764;P57059;Q01538;Q02750;Q04771;Q06187;Q07912;Q08345;Q09013;Q12851;Q13043;Q13163;Q13705;Q13882;Q15303;Q15569;Q15759;Q16539;Q16832;Q52WX2;Q56UN5;Q59H18;Q5VT25;Q6DT37;Q6PHR2;Q86Y07;Q8IVH8;Q8N4C8;Q8NG66;Q8NI60;Q8TDR2;Q92918;Q96GD4;Q99640;Q99759;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K8;Q9H3Y6;Q9NRP7;Q9NYL2;Q9P289;Q9P2K8;Q9UBE8;Q9UF33;Q9UKE5;Q9UL54;Q9Y2K2;Q9Y2U5;Q9Y4K4;Q9Y5S2;Q9Y6R4,"InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)",ZBNZXTGUTAYRHI-UHFFFAOYSA-N,Cc1nc(Nc2ncc(s2)C(=O)Nc3c(C)cccc3Cl)cc(n1)N4CCN(CCO)CC4,,advanced solid cancers,Phase 1,,,NCT01445509,Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT01445509
clinicaltrials.gov,crizotinib,652583,O00238;O00444;O14730;O14920;O14936;O14965;O15075;O15146;O15197;O43283;O43318;O43353;O60674;O75116;O75385;O94804;O94806;P00519;P00533;P04629;P06213;P06239;P06241;P06748;P07332;P07333;P07947;P07948;P07949;P08069;P08581;P08922;P09769;P0C264;P10721;P12931;P14616;P16591;P17948;P19525;P21127;P21709;P22607;P23443;P23458;P29317;P29320;P29322;P29376;P29597;P30530;P32298;P35590;P36888;P36896;P36897;P42681;P42684;P42685;P43403;P43405;P46734;P50613;P51451;P51617;P51813;P52333;P53667;P53671;P54756;P54760;P54762;P54764;P57078;Q02763;Q04771;Q04912;Q05397;Q06187;Q06418;Q07912;Q08345;Q08881;Q09013;Q12851;Q12852;Q12866;Q13043;Q13131;Q13164;Q13188;Q13233;Q13464;Q13470;Q13546;Q14164;Q14289;Q15139;Q15375;Q15569;Q16288;Q16620;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q6PHR2;Q6XUX3;Q6ZN16;Q7L7X3;Q8IVH8;Q8IY84;Q8IYT8;Q8N4C8;Q8N568;Q8NE63;Q8NFD2;Q8TD19;Q8TDR2;Q8TDX7;Q92630;Q92772;Q92918;Q96D53;Q96GD4;Q96RR4;Q96SB4;Q99755;Q99759;Q9BRS2;Q9H093;Q9H0K1;Q9H2G2;Q9H2K8;Q9NSY1;Q9NWZ3;Q9P289;Q9UF33;Q9UHD2;Q9UL54;Q9UM73;Q9UPE1;Q9UQ88;Q9UQB9;Q9Y2U5;Q9Y4K4;Q9Y616,"InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1",KTEIFNKAUNYNJU-GFCCVEGCSA-N,C[C@@H](Oc1cc(cnc1N)c2cnn(c2)C3CCNCC3)c4c(Cl)ccc(F)c4Cl,dasatinib,375,O00238;O00506;O14965;O14976;O15197;O15264;O43283;O43318;O43353;O60674;O94804;O95819;P00519;P00533;P04049;P04626;P06239;P06241;P07333;P07947;P07948;P07949;P08631;P08684;P09619;P09769;P0C1S8;P10721;P11274;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P21860;P22607;P27037;P29317;P29320;P29322;P29323;P29597;P30291;P35968;P36507;P36888;P36894;P36896;P36897;P37023;P37173;P41240;P42680;P42681;P42684;P42685;P43405;P49674;P51451;P51813;P51955;P52333;P53667;P53671;P53778;P54753;P54756;P54760;P54762;P54764;P57059;Q01538;Q02750;Q04771;Q06187;Q07912;Q08345;Q09013;Q12851;Q13043;Q13163;Q13705;Q13882;Q15303;Q15569;Q15759;Q16539;Q16832;Q52WX2;Q56UN5;Q59H18;Q5VT25;Q6DT37;Q6PHR2;Q86Y07;Q8IVH8;Q8N4C8;Q8NG66;Q8NI60;Q8TDR2;Q92918;Q96GD4;Q99640;Q99759;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K8;Q9H3Y6;Q9NRP7;Q9NYL2;Q9P289;Q9P2K8;Q9UBE8;Q9UF33;Q9UKE5;Q9UL54;Q9Y2K2;Q9Y2U5;Q9Y4K4;Q9Y5S2;Q9Y6R4,"InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)",ZBNZXTGUTAYRHI-UHFFFAOYSA-N,Cc1nc(Nc2ncc(s2)C(=O)Nc3c(C)cccc3Cl)cc(n1)N4CCN(CCO)CC4,,brain cancers,Phase 1,,,NCT01644773,Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG),,https://ClinicalTrials.gov/show/NCT01644773
clinicaltrials.gov,crizotinib,652583,O00238;O00444;O14730;O14920;O14936;O14965;O15075;O15146;O15197;O43283;O43318;O43353;O60674;O75116;O75385;O94804;O94806;P00519;P00533;P04629;P06213;P06239;P06241;P06748;P07332;P07333;P07947;P07948;P07949;P08069;P08581;P08922;P09769;P0C264;P10721;P12931;P14616;P16591;P17948;P19525;P21127;P21709;P22607;P23443;P23458;P29317;P29320;P29322;P29376;P29597;P30530;P32298;P35590;P36888;P36896;P36897;P42681;P42684;P42685;P43403;P43405;P46734;P50613;P51451;P51617;P51813;P52333;P53667;P53671;P54756;P54760;P54762;P54764;P57078;Q02763;Q04771;Q04912;Q05397;Q06187;Q06418;Q07912;Q08345;Q08881;Q09013;Q12851;Q12852;Q12866;Q13043;Q13131;Q13164;Q13188;Q13233;Q13464;Q13470;Q13546;Q14164;Q14289;Q15139;Q15375;Q15569;Q16288;Q16620;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q6PHR2;Q6XUX3;Q6ZN16;Q7L7X3;Q8IVH8;Q8IY84;Q8IYT8;Q8N4C8;Q8N568;Q8NE63;Q8NFD2;Q8TD19;Q8TDR2;Q8TDX7;Q92630;Q92772;Q92918;Q96D53;Q96GD4;Q96RR4;Q96SB4;Q99755;Q99759;Q9BRS2;Q9H093;Q9H0K1;Q9H2G2;Q9H2K8;Q9NSY1;Q9NWZ3;Q9P289;Q9UF33;Q9UHD2;Q9UL54;Q9UM73;Q9UPE1;Q9UQ88;Q9UQB9;Q9Y2U5;Q9Y4K4;Q9Y616,"InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1",KTEIFNKAUNYNJU-GFCCVEGCSA-N,C[C@@H](Oc1cc(cnc1N)c2cnn(c2)C3CCNCC3)c4c(Cl)ccc(F)c4Cl,dasatinib,375,O00238;O00506;O14965;O14976;O15197;O15264;O43283;O43318;O43353;O60674;O94804;O95819;P00519;P00533;P04049;P04626;P06239;P06241;P07333;P07947;P07948;P07949;P08631;P08684;P09619;P09769;P0C1S8;P10721;P11274;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P21860;P22607;P27037;P29317;P29320;P29322;P29323;P29597;P30291;P35968;P36507;P36888;P36894;P36896;P36897;P37023;P37173;P41240;P42680;P42681;P42684;P42685;P43405;P49674;P51451;P51813;P51955;P52333;P53667;P53671;P53778;P54753;P54756;P54760;P54762;P54764;P57059;Q01538;Q02750;Q04771;Q06187;Q07912;Q08345;Q09013;Q12851;Q13043;Q13163;Q13705;Q13882;Q15303;Q15569;Q15759;Q16539;Q16832;Q52WX2;Q56UN5;Q59H18;Q5VT25;Q6DT37;Q6PHR2;Q86Y07;Q8IVH8;Q8N4C8;Q8NG66;Q8NI60;Q8TDR2;Q92918;Q96GD4;Q99640;Q99759;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K8;Q9H3Y6;Q9NRP7;Q9NYL2;Q9P289;Q9P2K8;Q9UBE8;Q9UF33;Q9UKE5;Q9UL54;Q9Y2K2;Q9Y2U5;Q9Y4K4;Q9Y5S2;Q9Y6R4,"InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)",ZBNZXTGUTAYRHI-UHFFFAOYSA-N,Cc1nc(Nc2ncc(s2)C(=O)Nc3c(C)cccc3Cl)cc(n1)N4CCN(CCO)CC4,,,Phase 1,,,NCT01744652,Dasatinib and Crizotinib in Advanced Cancer,,https://ClinicalTrials.gov/show/NCT01744652
clinicaltrials.gov,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,dasatinib,375,O00238;O00506;O14965;O14976;O15197;O15264;O43283;O43318;O43353;O60674;O94804;O95819;P00519;P00533;P04049;P04626;P06239;P06241;P07333;P07947;P07948;P07949;P08631;P08684;P09619;P09769;P0C1S8;P10721;P11274;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P21860;P22607;P27037;P29317;P29320;P29322;P29323;P29597;P30291;P35968;P36507;P36888;P36894;P36896;P36897;P37023;P37173;P41240;P42680;P42681;P42684;P42685;P43405;P49674;P51451;P51813;P51955;P52333;P53667;P53671;P53778;P54753;P54756;P54760;P54762;P54764;P57059;Q01538;Q02750;Q04771;Q06187;Q07912;Q08345;Q09013;Q12851;Q13043;Q13163;Q13705;Q13882;Q15303;Q15569;Q15759;Q16539;Q16832;Q52WX2;Q56UN5;Q59H18;Q5VT25;Q6DT37;Q6PHR2;Q86Y07;Q8IVH8;Q8N4C8;Q8NG66;Q8NI60;Q8TDR2;Q92918;Q96GD4;Q99640;Q99759;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K8;Q9H3Y6;Q9NRP7;Q9NYL2;Q9P289;Q9P2K8;Q9UBE8;Q9UF33;Q9UKE5;Q9UL54;Q9Y2K2;Q9Y2U5;Q9Y4K4;Q9Y5S2;Q9Y6R4,"InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)",ZBNZXTGUTAYRHI-UHFFFAOYSA-N,Cc1nc(Nc2ncc(s2)C(=O)Nc3c(C)cccc3Cl)cc(n1)N4CCN(CCO)CC4,,,Phase 1,,,NCT00895128,Study of Erlotinib in Combination With Dasatinib,,https://ClinicalTrials.gov/show/NCT00895128
clinicaltrials.gov,ETC-1907206,,,,,,dasatinib,375,O00238;O00506;O14965;O14976;O15197;O15264;O43283;O43318;O43353;O60674;O94804;O95819;P00519;P00533;P04049;P04626;P06239;P06241;P07333;P07947;P07948;P07949;P08631;P08684;P09619;P09769;P0C1S8;P10721;P11274;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P21860;P22607;P27037;P29317;P29320;P29322;P29323;P29597;P30291;P35968;P36507;P36888;P36894;P36896;P36897;P37023;P37173;P41240;P42680;P42681;P42684;P42685;P43405;P49674;P51451;P51813;P51955;P52333;P53667;P53671;P53778;P54753;P54756;P54760;P54762;P54764;P57059;Q01538;Q02750;Q04771;Q06187;Q07912;Q08345;Q09013;Q12851;Q13043;Q13163;Q13705;Q13882;Q15303;Q15569;Q15759;Q16539;Q16832;Q52WX2;Q56UN5;Q59H18;Q5VT25;Q6DT37;Q6PHR2;Q86Y07;Q8IVH8;Q8N4C8;Q8NG66;Q8NI60;Q8TDR2;Q92918;Q96GD4;Q99640;Q99759;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K8;Q9H3Y6;Q9NRP7;Q9NYL2;Q9P289;Q9P2K8;Q9UBE8;Q9UF33;Q9UKE5;Q9UL54;Q9Y2K2;Q9Y2U5;Q9Y4K4;Q9Y5S2;Q9Y6R4,"InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)",ZBNZXTGUTAYRHI-UHFFFAOYSA-N,Cc1nc(Nc2ncc(s2)C(=O)Nc3c(C)cccc3Cl)cc(n1)N4CCN(CCO)CC4,,leukemia,Phase 1,,,NCT03414450,Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies,,https://ClinicalTrials.gov/show/NCT03414450
clinicaltrials.gov,nilutamide,813,P10275,"InChI=1S/C12H10F3N3O4/c1-11(2)9(19)17(10(20)16-11)6-3-4-8(18(21)22)7(5-6)12(13,14)15/h3-5H,1-2H3,(H,16,20)",XWXYUMMDTVBTOU-UHFFFAOYSA-N,CC1(C)NC(=O)N(C1=O)c2ccc(c(c2)C(F)(F)F)[N+](=O)[O-],dasatinib,375,O00238;O00506;O14965;O14976;O15197;O15264;O43283;O43318;O43353;O60674;O94804;O95819;P00519;P00533;P04049;P04626;P06239;P06241;P07333;P07947;P07948;P07949;P08631;P08684;P09619;P09769;P0C1S8;P10721;P11274;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P21860;P22607;P27037;P29317;P29320;P29322;P29323;P29597;P30291;P35968;P36507;P36888;P36894;P36896;P36897;P37023;P37173;P41240;P42680;P42681;P42684;P42685;P43405;P49674;P51451;P51813;P51955;P52333;P53667;P53671;P53778;P54753;P54756;P54760;P54762;P54764;P57059;Q01538;Q02750;Q04771;Q06187;Q07912;Q08345;Q09013;Q12851;Q13043;Q13163;Q13705;Q13882;Q15303;Q15569;Q15759;Q16539;Q16832;Q52WX2;Q56UN5;Q59H18;Q5VT25;Q6DT37;Q6PHR2;Q86Y07;Q8IVH8;Q8N4C8;Q8NG66;Q8NI60;Q8TDR2;Q92918;Q96GD4;Q99640;Q99759;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K8;Q9H3Y6;Q9NRP7;Q9NYL2;Q9P289;Q9P2K8;Q9UBE8;Q9UF33;Q9UKE5;Q9UL54;Q9Y2K2;Q9Y2U5;Q9Y4K4;Q9Y5S2;Q9Y6R4,"InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)",ZBNZXTGUTAYRHI-UHFFFAOYSA-N,Cc1nc(Nc2ncc(s2)C(=O)Nc3c(C)cccc3Cl)cc(n1)N4CCN(CCO)CC4,,prostate cancers,Phase 2,,,NCT00918385,Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer,ARS,https://ClinicalTrials.gov/show/NCT00918385
clinicaltrials.gov,pembrolizumab,,Q15116,,,,DEBIO1143,,,,,,Adenocarcinoma of the Pancreas|Adenocarcinoma of the Colon|Adenocarcinoma of the Rectum,,Phase 1,,,NCT03871959,,,
clinicaltrials.gov,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,degarelix,10866,P30968,"InChI=1S/C82H103ClN18O16/c1-45(2)35-60(72(107)92-59(16-9-10-33-87-46(3)4)80(115)101-34-12-17-68(101)79(114)88-47(5)70(84)105)93-74(109)63(38-51-23-30-58(31-24-51)91-81(85)116)95-76(111)64(39-50-21-28-57(29-22-50)90-71(106)66-42-69(104)100-82(117)99-66)97-78(113)67(44-102)98-77(112)65(41-53-13-11-32-86-43-53)96-75(110)62(37-49-19-26-56(83)27-20-49)94-73(108)61(89-48(6)103)40-52-18-25-54-14-7-8-15-55(54)36-52/h7-8,11,13-15,18-32,36,43,45-47,59-68,87,102H,9-10,12,16-17,33-35,37-42,44H2,1-6H3,(H2,84,105)(H,88,114)(H,89,103)(H,90,106)(H,92,107)(H,93,109)(H,94,108)(H,95,111)(H,96,110)(H,97,113)(H,98,112)(H3,85,91,116)(H2,99,100,104,117)/t47-,59+,60+,61-,62-,63-,64+,65-,66+,67+,68+/m1/s1",MEUCPCLKGZSHTA-XYAYPHGZSA-N,CC(C)C[C@H](NC(=O)[C@@H](Cc1ccc(NC(=O)N)cc1)NC(=O)[C@H](Cc2ccc(NC(=O)[C@@H]3CC(=O)NC(=O)N3)cc2)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc4cccnc4)NC(=O)[C@@H](Cc5ccc(Cl)cc5)NC(=O)[C@@H](Cc6ccc7ccccc7c6)NC(=O)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N8CCC[C@H]8C(=O)N[C@H](C)C(=O)N,,prostate cancers,Phase 1,,,NCT02324998,Studying the Effects of Olaparib (_± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Radical Prostatectomy,CaNCaP03,https://ClinicalTrials.gov/show/NCT02324998
clinicaltrials.gov,lenvatinib,802872,P35968;P17948;P35916,"InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)",WOSKHXYHFSIKNG-UHFFFAOYSA-N,,denosumab,,,,,,,thyroid cancers,Phase 2,,,NCT03732495,Study of the Efficacy of Lenvatinib Combined With denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas,LENVOS,https://ClinicalTrials.gov/show/NCT03732495
clinicaltrials.gov,lenvatinib,802872,P35968;P17948;P35916,"InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)",WOSKHXYHFSIKNG-UHFFFAOYSA-N,,denosumab,,,,,,,thyroid cancers,Phase 2,,,NCT03732495,Study of the Efficacy of Lenvatinib Combined With denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas,LENVOS,https://ClinicalTrials.gov/show/NCT03732495
clinicaltrials.gov,ATRA-IV,,,,,,depakote,1393986,P51649,"InChI=1S/2C8H16O2.Na/c2*1-3-5-7(6-4-2)8(9)10;/h2*7H,3-6H2,1-2H3,(H,9,10);/q;;+1/p-1",MSRILKIQRXUYCT-UHFFFAOYSA-M,[Na+].CCCC(CCC)C(=O)O.CCCC(CCC)C(=O)[O-],,advanced solid cancers,Phase 1,,,NCT00195156,Treatment With ATRA-IV and Depakote in Patients With Advanced Solid Tumor Malignancies,,https://ClinicalTrials.gov/show/NCT00195156
clinicaltrials.gov,AMXT1501,,,,,,DFMO,,,,,,,,Phase 1,,,NCT03536728,Oral AMXT 1501 Dicaprate in Combination With DFMO,,https://ClinicalTrials.gov/show/NCT03536728
clinicaltrials.gov,pembrolizumab,,Q15116,,,,dinaciclib,1656221,P06493;P24941;Q00535;P50750,"InChI=1S/C21H28N6O2/c1-2-17-14-23-27-19(22-13-16-6-5-9-25(29)15-16)12-20(24-21(17)27)26-10-4-3-7-18(26)8-11-28/h5-6,9,12,14-15,18,22,28H,2-4,7-8,10-11,13H2,1H3/t18-/m0/s1",PIMQWRZWLQKKBJ-SFHVURJKSA-N,CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N4CCCC[C@H]4CCO,,multiple myeloma;lymphoma,Phase 1,,,NCT02684617,Study of pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155),KEYNOTE-155,https://ClinicalTrials.gov/show/NCT02684617
clinicaltrials.gov,DOS2W,,,,,,DOS3W,,,,,,,stomach cancers;oesophageal cancers,Phase 1,,,NCT01928524,Chemotherapy for Patients With Cancer of the Stomach,DOS,https://ClinicalTrials.gov/show/NCT01928524
clinicaltrials.gov,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,dovitinib,31361,O00444;O00506;O14578;O14730;O14757;O14976;O15111;O15146;O15197;O43283;O43293;O43318;O60285;O60331;O60674;O75116;O75385;O75582;O75676;O75716;O75914;O94768;O94804;O95819;O95835;P00519;P00533;P04629;P06239;P06241;P07333;P07947;P07948;P07949;P08631;P09619;P09769;P10721;P11362;P11802;P12931;P15735;P16234;P17948;P19525;P19784;P21802;P22455;P22607;P23443;P23458;P27448;P29597;P30291;P30530;P32298;P35590;P35916;P35968;P36507;P36888;P42685;P49759;P49760;P49841;P50613;P51451;P51617;P51812;P51955;P51957;P52333;P54646;P57058;P68400;P78356;P78362;P80192;Q00536;Q00537;Q02750;Q04759;Q06418;Q07002;Q08345;Q08881;Q12851;Q12852;Q12866;Q13043;Q13131;Q13163;Q13188;Q13464;Q13523;Q13546;Q13873;Q14164;Q14680;Q15208;Q15349;Q15418;Q15746;Q15831;Q15835;Q16288;Q16512;Q16513;Q16584;Q16620;Q16816;Q16832;Q2M2I8;Q32MK0;Q52WX2;Q56UN5;Q5S007;Q6P3R8;Q6PHR2;Q7KZI7;Q86UE8;Q86YV6;Q86Z02;Q8IVH8;Q8IY84;Q8IYT8;Q8N4C8;Q8N5S9;Q8NFD2;Q8TD19;Q8TDX7;Q8WTQ7;Q92630;Q92772;Q92918;Q96BR1;Q96GD4;Q96L34;Q96SB4;Q99755;Q9BRS2;Q9BVS4;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2X6;Q9H422;Q9HAZ1;Q9HC98;Q9NRM7;Q9NSY1;Q9NWZ3;Q9NYY3;Q9P0L2;Q9P289;Q9P2K8;Q9UEE5;Q9UEW8;Q9UHD2;Q9UK32;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2H9;Q9Y2U5;Q9Y4K4;Q9Y6E0;Q9Y6R4,"InChI=1S/C21H21FN6O/c1-27-7-9-28(10-8-27)12-5-6-14-16(11-12)25-20(24-14)18-19(23)17-13(22)3-2-4-15(17)26-21(18)29/h2-6,11H,7-10H2,1H3,(H,24,25)(H3,23,26,29)",PIQCTGMSNWUMAF-UHFFFAOYSA-N,CN1CCN(CC1)c2ccc3nc([nH]c3c2)C4=C(N)c5c(F)cccc5NC4=O,,lung cancers,Phase 1,,,NCT01515969,Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC),,https://ClinicalTrials.gov/show/NCT01515969
clinicaltrials.gov,ADXS11-001,,,,,,durvalumab,,Q9NZQ7,,,,,cervical cancers;head and neck cancers,Phase 1/2,,,NCT02291055,Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head & Neck Cancer,,https://ClinicalTrials.gov/show/NCT02291055
clinicaltrials.gov,AZD1775,,,,,,durvalumab,,Q9NZQ7,,,,,advanced solid cancers,Phase 1,,,NCT02617277,"Safety, Tolerability and Pharmacokinetics of AZD1775 Plus MEDI4736 in Patients With Advanced Solid Tumours",,https://ClinicalTrials.gov/show/NCT02617277
clinicaltrials.gov,AZD4635,,,,,,durvalumab,,Q9NZQ7,,,,,advanced solid cancers;lung cancers,Phase 1,,,NCT02740985,A Phase 1 Clinical Study of AZD4635 and Durvalumab in Patients With Advanced Solid Malignancies,,https://ClinicalTrials.gov/show/NCT02740985
clinicaltrials.gov,AZD6738,,,,,,durvalumab,,Q9NZQ7,,,,,stomach cancers;skin cancers,Phase 2,,,NCT03780608,This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO),,https://ClinicalTrials.gov/show/NCT03780608
clinicaltrials.gov,AZD6738,,,,,,durvalumab,,Q9NZQ7,,,,,stomach cancers;skin cancers,Phase 2,,,NCT03780608,This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO),,https://ClinicalTrials.gov/show/NCT03780608
clinicaltrials.gov,AZD9150,,,,,,durvalumab,,Q9NZQ7,,,,,advanced solid cancers,Phase 1,,,NCT03394144,Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies,,https://ClinicalTrials.gov/show/NCT03394144
clinicaltrials.gov,AZD9150,,,,,,durvalumab,,Q9NZQ7,,,,,pancreatic cancers;bowel cancers;lung cancers,Phase 2,,,NCT02983578,"AZD9150 With MEDI4736 in Patients With Advanced Pancreatic, Non-Small Lung and Colorectal Cancer",,https://ClinicalTrials.gov/show/NCT02983578
clinicaltrials.gov,cabozantinib,1081506,P08581,"InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)",ONIQOQHATWINJY-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5)cc3)c2cc1OC,durvalumab,,Q9NZQ7,,,,,stomach cancers;oesophageal cancers;liver cancers;colorectal cancers,Phase 1,,,NCT03539822,Cabozantinib in Combination With Durvalumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA),,https://ClinicalTrials.gov/show/NCT03539822
clinicaltrials.gov,cabozantinib,1081506,P08581,"InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)",ONIQOQHATWINJY-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5)cc3)c2cc1OC,durvalumab,,Q9NZQ7,,,,,stomach cancers;oesophageal cancers;liver cancers;colorectal cancers,Phase 1,,,NCT03539822,Cabozantinib in Combination With Durvalumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA),,https://ClinicalTrials.gov/show/NCT03539822
clinicaltrials.gov,ensartinib,,,,,,durvalumab,,Q9NZQ7,,,,,lung cancers,Phase 1/2,,,NCT02898116,"A Study of ALK Inhibitor, Ensartinib, and Anti-PD-L1, Durvalumab, in Subjects With ALK-rearranged Non-small Cell Lung Cancer",,https://ClinicalTrials.gov/show/NCT02898116
clinicaltrials.gov,galunisertib,1096122,P36897,"InChI=1S/C22H19N5O/c1-13-4-2-5-18(25-13)21-20(19-6-3-11-27(19)26-21)15-9-10-24-17-8-7-14(22(23)28)12-16(15)17/h2,4-5,7-10,12H,3,6,11H2,1H3,(H2,23,28)",IVRXNBXKWIJUQB-UHFFFAOYSA-N,Cc1cccc(n1)c2nn3CCCc3c2c4ccnc5ccc(cc45)C(=O)N,durvalumab,,Q9NZQ7,,,,,pancreatic cancers,Phase 1,,,NCT02734160,A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer,,https://ClinicalTrials.gov/show/NCT02734160
clinicaltrials.gov,gefitinib,701,O14578;O14976;O15197;O43293;O43353;O75676;O94768;O94804;O96017;P00519;P00533;P04626;P06239;P07948;P07949;P08581;P08631;P09769;P10721;P12931;P15735;P21709;P21860;P29320;P29322;P29376;P30530;P31152;P36888;P42681;P42684;P42685;P45984;P48730;P49674;P50613;P51451;P51617;P53779;P54756;P54760;P54762;Q09013;Q13163;Q15139;Q15303;Q16659;Q16816;Q52WX2;Q56UN5;Q86V86;Q8N4C8;Q8NE63;Q8TBX8;Q99759;Q9BUB5;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NWZ3;Q9UBE8;Q9UEE5;Q9UF33;Q9UKE5;Q9UNQ0;Q9Y2U5;Q9Y616,"InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)",XGALLCVXEZPNRQ-UHFFFAOYSA-N,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN4CCOCC4,durvalumab,,Q9NZQ7,,,,,lung cancers,Phase 1,,,NCT02088112,MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC),,https://ClinicalTrials.gov/show/NCT02088112
clinicaltrials.gov,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,durvalumab,,Q9NZQ7,,,,,lung cancers,Phase 1/2,,,NCT02403271,A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors,,https://ClinicalTrials.gov/show/NCT02403271
literature,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,,durvalumab,,Q9NZQ7,,,,"previously treated patients with stage III/IV pancreatic adenocarcinoma, breast cancer, or non-small cell lung cancer (NSCLC)",pancreatic cancers;breast cancers;lung cancers,Phase 1b/2,31230047,"The RP2D was identified as ibrutinib 560 mg p.o. daily and durvalumab 10 mg/kg i.v. every 2 weeks, with 122 patients treated at the RP2D. Median age was 61 years, and the majority of patients (94%) had stage IV disease. Overall response rates (complete or partial responses) were 2% for pancreatic cancer, 3% for breast cancer, and 0% for NSCLC. Median progression-free survival was 1.7, 1.7, and 2.0 months in the pancreatic cancer, breast cancer, and NSCLC cohorts, respectively. Median overall survival was 4.2, 4.2, and 7.9 months in the pancreatic cancer, breast cancer, and NSCLC cohorts, respectively. The safety profiles observed across tumor types were consistent with the known safety profiles for ibrutinib and durvalumab. Grade ≥3 adverse events in ≥5% of all patients were hyponatremia (10%), dyspnea (7%), maculopapular rash (7%), pneumonia (7%), anemia (6%), and diarrhea (6%).",,,,
clinicaltrials.gov,IPH5401,,,,,,durvalumab,,Q9NZQ7,,,,,advanced solid cancers,Phase 1,,,NCT03665129,IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors,STELLAR-001,https://ClinicalTrials.gov/show/NCT03665129
clinicaltrials.gov,IPH5401,,,,,,durvalumab,,Q9NZQ7,,,,,advanced solid cancers,Phase 1,,,NCT03665129,IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors,STELLAR-001,https://ClinicalTrials.gov/show/NCT03665129
clinicaltrials.gov,JCAR017,,,,,,durvalumab,,Q9NZQ7,,,,,lymphoma,Phase 1/2,,,NCT03310619,A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM),PLATFORM,https://ClinicalTrials.gov/show/NCT03310619
clinicaltrials.gov,LN-145,,,,,,durvalumab,,Q9NZQ7,,,,,lung cancers,Phase 2,,,NCT03419559,Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) Alone and In Combo With Durvalumab in Non-Small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT03419559
clinicaltrials.gov,Loncastuximab Tesirine,,,,,,durvalumab,,Q9NZQ7,,,,,lymphoma,Phase 1,,,NCT03685344,"Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma",,https://ClinicalTrials.gov/show/NCT03685344
clinicaltrials.gov,Loncastuximab Tesirine,,,,,,durvalumab,,Q9NZQ7,,,,,lymphoma,Phase 1,,,NCT03685344,"Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma",,https://ClinicalTrials.gov/show/NCT03685344
clinicaltrials.gov,LY2510924,,,,,,durvalumab,,Q9NZQ7,,,,,,Phase 1,,,NCT02737072,A Study of LY2510924 and Durvalumab in Participants With Solid Tumors,,https://ClinicalTrials.gov/show/NCT02737072
clinicaltrials.gov,MEDI0457,,,,,,durvalumab,,Q9NZQ7,,,,,,,,,NCT04001413,Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients,,https://ClinicalTrials.gov/show/NCT04001413
clinicaltrials.gov,MEDI1191,,,,,,durvalumab,,Q9NZQ7,,,,,,,,,NCT03946800,A Study of MEDI1191 Alone and in Combination With Durvalumab in Subjects With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT03946800
clinicaltrials.gov,MEDI5083,,,,,,durvalumab,,Q9NZQ7,,,,,advanced solid cancers,Phase 1,,,NCT03089645,MEDI5083 Alone and in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT03089645
clinicaltrials.gov,MEDI6383,,,,,,durvalumab,,Q9NZQ7,,,,,advanced solid cancers,Phase 1,,,NCT02221960,A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT02221960
clinicaltrials.gov,MEDI9447,,,,,,durvalumab,,Q9NZQ7,,,,,advanced solid cancers,Phase 1,,,NCT02503774,MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT02503774
clinicaltrials.gov,mocetinostat,592058,Q13547;Q96DB2;Q92769;O15379;Q9BY41,"InChI=1S/C23H20N6O/c24-19-5-1-2-6-21(19)28-22(30)17-9-7-16(8-10-17)14-27-23-26-13-11-20(29-23)18-4-3-12-25-15-18/h1-13,15H,14,24H2,(H,28,30)(H,26,27,29)",HRNLUBSXIHFDHP-UHFFFAOYSA-N,Nc1ccccc1NC(=O)c2ccc(CNc3nccc(n3)c4cccnc4)cc2,durvalumab,,Q9NZQ7,,,,,advanced solid cancers;lung cancers,Phase 1/2,,,NCT02805660,Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC,,https://ClinicalTrials.gov/show/NCT02805660
clinicaltrials.gov,Naptumomab estafenatox ,,,,,,durvalumab,,Q9NZQ7,,,,,,,,,NCT03983954,Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors,,https://ClinicalTrials.gov/show/NCT03983954
clinicaltrials.gov,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,durvalumab,,Q9NZQ7,,,,,breast cancers,Phase 2,,,NCT03167619,Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA),DORA,https://ClinicalTrials.gov/show/NCT03167619
clinicaltrials.gov,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,durvalumab,,Q9NZQ7,,,,,ovarian cancers;breast cancers;lung cancers;stomach cancers,Phase 1/2,,,NCT02734004,A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.,MEDIOLA,https://ClinicalTrials.gov/show/NCT02734004
clinicaltrials.gov,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,durvalumab,,Q9NZQ7,,,,,breast cancers,Phase 1/2,,,NCT03594396,Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer,,https://ClinicalTrials.gov/show/NCT03594396
clinicaltrials.gov,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,durvalumab,,Q9NZQ7,,,,,breast cancers,Phase 1/2,,,NCT03594396,Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer,,https://ClinicalTrials.gov/show/NCT03594396
clinicaltrials.gov,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,durvalumab,,Q9NZQ7,,,,,,,,,NCT03991832,Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors,,https://ClinicalTrials.gov/show/NCT03991832
clinicaltrials.gov,ONCOS-102,,,,,,durvalumab,,Q9NZQ7,,,,,bowel cancers;ovarian cancers,Phase 1/2,,,NCT02963831,"A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies",,https://ClinicalTrials.gov/show/NCT02963831
clinicaltrials.gov,osimertinib,1371518,P00533;P04626;P21860;Q15303;P00533,"InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)",DUYJMQONPNNFPI-UHFFFAOYSA-N,COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2nccc(n2)c3cn(C)c4ccccc34,durvalumab,,Q9NZQ7,,,,,lung cancers,Phase 3,,,NCT02454933,Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours,CAURAL,https://ClinicalTrials.gov/show/NCT02454933
clinicaltrials.gov,pexidartinib,,,,,,durvalumab,,Q9NZQ7,,,,,bowel cancers;pancreatic cancers,Phase 1,,,NCT02777710,Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers,MEDIPLEX,https://ClinicalTrials.gov/show/NCT02777710
clinicaltrials.gov,TEW-7197,,,,,,durvalumab,,Q9NZQ7,,,,,lung cancers,Phase 1/2,,,NCT03732274,Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC,,https://ClinicalTrials.gov/show/NCT03732274
clinicaltrials.gov,TEW-7197,,,,,,durvalumab,,Q9NZQ7,,,,,lung cancers,Phase 1/2,,,NCT03732274,Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC,,https://ClinicalTrials.gov/show/NCT03732274
clinicaltrials.gov,tivozanib,,P35968;P17948;P35916,"InChI=1S/C22H19ClN4O5/c1-12-8-21(27-32-12)26-22(28)25-16-5-4-13(9-15(16)23)31-18-6-7-24-17-11-20(30-3)19(29-2)10-14(17)18/h4-11H,1-3H3,(H2,25,26,27,28)",SPMVMDHWKHCIDT-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,durvalumab,,Q9NZQ7,,,,,,,,,NCT03970616,A Study of Tivozanib in Combination With Durvalumab in Subjects With Untreated Advanced Hepatocellular Carcinoma,,https://ClinicalTrials.gov/show/NCT03970616
clinicaltrials.gov,tremelimumab,,P16410,,,,durvalumab,,Q9NZQ7,,,,,advanced solid cancers;mesothelioma,Phase 1,,,NCT02141347,"Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma",,https://ClinicalTrials.gov/show/NCT02141347
clinicaltrials.gov,tremelimumab,,P16410,,,,durvalumab,,Q9NZQ7,,,,,female cancers,Phase 2,,,NCT03026062,Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial ovarian Cancers,,https://ClinicalTrials.gov/show/NCT03026062
clinicaltrials.gov,tremelimumab,,P16410,,,,durvalumab,,Q9NZQ7,,,,,mesothelioma,Phase 2,,,NCT03075527,A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma,,https://ClinicalTrials.gov/show/NCT03075527
clinicaltrials.gov,tremelimumab,,P16410,,,,durvalumab,,Q9NZQ7,,,,,,,,,NCT03982173,Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors,MATILDA,https://ClinicalTrials.gov/show/NCT03982173
clinicaltrials.gov,STA9090,,,,,,dutasteride,,,"InChI=1S/C27H30F6N2O2/c1-24-11-9-17-15(4-8-21-25(17,2)12-10-22(36)35-21)16(24)6-7-19(24)23(37)34-20-13-14(26(28,29)30)3-5-18(20)27(31,32)33/h3,5,10,12-13,15-17,19,21H,4,6-9,11H2,1-2H3,(H,34,37)(H,35,36)/t15-,16-,17-,19+,21+,24-,25+/m0/s1",JWJOTENAMICLJG-QWBYCMEYSA-N,C[C@]12CC[C@H]3[C@@H](CC[C@H]4NC(=O)C=C[C@]34C)[C@@H]1CC[C@@H]2C(=O)Nc5cc(ccc5C(F)(F)F)C(F)(F)F,,prostate cancers,Phase 2,,,NCT01368003,STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor Pathway Signaling,,https://ClinicalTrials.gov/show/NCT01368003
clinicaltrials.gov,pembrolizumab,,,,,,EDP1503,,,,,,,skin cancers,Phase 2,,,NCT03595683,pembrolizumab and EDP1503 in Advanced Melanoma,,https://ClinicalTrials.gov/show/NCT03595683
clinicaltrials.gov,pembrolizumab,,Q15116,,,,EDP1503,,,,,,,skin cancers,Phase 2,,,NCT03595683,pembrolizumab and EDP1503 in Advanced Melanoma,,https://ClinicalTrials.gov/show/NCT03595683
clinicaltrials.gov,capmatinib,1278782,P08581,"InChI=1S/C23H17FN6O/c1-25-22(31)18-6-5-16(11-19(18)24)21-13-28-23-27-12-17(30(23)29-21)10-14-4-7-20-15(9-14)3-2-8-26-20/h2-9,11-13H,10H2,1H3,(H,25,31)",LIOLIMKSCNQPLV-UHFFFAOYSA-N,CNC(=O)c1ccc(cc1F)c2cnc3ncc(Cc4ccc5ncccc5c4)n3n2,EGF816,,P00533,,,,,lung cancers,Phase 1/2,,,NCT02335944,Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Non-small Cell Lung Cancer Patients With EGFR Mutation.,,https://ClinicalTrials.gov/show/NCT02335944
clinicaltrials.gov,atezolizumab,,Q9NZQ7,,,,emactuzumab,,,,,,,advanced solid cancers,Phase 1,,,NCT02323191,A Study of Emactuzumab and Atezolimumab Administered in Combination in Participants With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT02323191
clinicaltrials.gov,atezolizumab,,Q9NZQ7,,,,emactuzumab,,,,,,,head and neck cancers,Phase 2,,,NCT03708224,Phase II Study of Perioperative Immunotherapy in Patients With Advanced Non-Virally Associated Squamous Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT03708224
clinicaltrials.gov,atezolizumab,,Q9NZQ7,,,,emactuzumab,,,,,,,head and neck cancers,Phase 2,,,NCT03708224,Phase II Study of Perioperative Immunotherapy in Patients With Advanced Non-Virally Associated Squamous Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT03708224
clinicaltrials.gov,cetuximab,9,P00533,,,,EMD 1201081,,,,,,,head and neck cancers,Phase 2,,,NCT01040832,EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naêève Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,,https://ClinicalTrials.gov/show/NCT01040832
literature,ramucirumab,,P35968,,,,emibetuzumab,,,,,,solid tumors,advanced solid cancers,Phase 1b/2,31142504,"97 solid tumor patients (6 phase 1b, 16 GEJ, 45 HCC, 15 RCC, and 15 NSCLC) received emibetuzumab at 750 or 2000 mg flat dosing plus ramucirumab at 8mg/kg Q2W. No DLTs were observed. Common AEs were primarily mild or moderate and included fatigue (36.1%), peripheral edema (28.9%), and nausea (14.4%). Emibetuzumab exposures were similar as in previous studies with no apparent drug-drug interactions. Five partial responses (5.2%) were observed across all tumor types. The greatest anti-tumor activity was noted in HCC with a 6.7% ORR, 60% DCR, and 5.42 months (95% CI: 1.64-8.12) PFS. HCC with high MET expression showed improved PFS with approximately threefold increase in PFS (8.1 vs. 2.8 months) relative to low MET expression.",,,,
clinicaltrials.gov,binimetinib,1222391,Q02750;P36507,"InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)",ACWZRVQXLIRSDF-UHFFFAOYSA-N,Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO,encorafenib,,,,,,Advanced BRAF Mutant Cancers,,Phase 1/2,,,NCT03843775,,,
clinicaltrials.gov,binimetinib,1222391,Q02750;P36507,"InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)",ACWZRVQXLIRSDF-UHFFFAOYSA-N,Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO,encorafenib,,,,,,Melanoma,,Phase 1,,,NCT03878719,,,
clinicaltrials.gov,nivolumab,,Q15116,,,,entinostat,,,,,,CNS Tumor|Solid Tumor,,Phase 1/2,,,NCT03838042,,,
clinicaltrials.gov,pembrolizumab,,Q15116,,,,entinostat,,,,,,,,,,,NCT03978624,Window of Opportunity Study of pembrolizumab Alone and in Combinations in Bladder Cancer,,https://ClinicalTrials.gov/show/NCT03978624
clinicaltrials.gov,alpelisib,,P42336,"InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1",STUWGJZDJHPWGZ-LBPRGKRZSA-N,Cc1nc(NC(=O)N2CCC[C@H]2C(=O)N)sc1c3ccnc(c3)C(C)(C)C(F)(F)F,enzalutamide,679762,P10275,"InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)",WXCXUHSOUPDCQV-UHFFFAOYSA-N,CNC(=O)c1ccc(cc1F)N2C(=S)N(C(=O)C2(C)C)c3ccc(C#N)c(c3)C(F)(F)F,,breast cancers,Phase 1,,,NCT03207529,Study of BYL719 (Alpelisib) in Combination With Androgen Receptor Inhibitor (Enzalutamide) in Patients With Androgen Receptor (AR)-Positive and PTEN Positive Metastatic Breast Cancer,,https://ClinicalTrials.gov/show/NCT03207529
clinicaltrials.gov,atezolizumab,,Q9NZQ7,,,,enzalutamide,679762,P10275,"InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)",WXCXUHSOUPDCQV-UHFFFAOYSA-N,CNC(=O)c1ccc(cc1F)N2C(=S)N(C(=O)C2(C)C)c3ccc(C#N)c(c3)C(F)(F)F,,prostate cancers,Phase 3,,,NCT03016312,"IMbassador250: A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen",,https://ClinicalTrials.gov/show/NCT03016312
clinicaltrials.gov,AZD-5363,,P31751;Q9Y243;P31749,"InChI=1S/C32H44F2N2O5S2/c1-4-36(32(37)19-23-5-9-29(10-6-23)42(2,38)39)28-13-16-35(17-14-28)18-15-31(25-20-26(33)22-27(34)21-25)24-7-11-30(12-8-24)43(3,40)41/h5-6,9-10,20-22,24,28,30-31H,4,7-8,11-19H2,1-3H3/t24?,30?,31-/m1/s1",AESXAJXKMUNYJP-ZWFIUULVSA-N,CCN(C1CCN(CC[C@H](C2CCC(CC2)S(=O)(=O)C)c3cc(F)cc(F)c3)CC1)C(=O)Cc4ccc(cc4)S(=O)(=O)C,enzalutamide,679762,P10275,"InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)",WXCXUHSOUPDCQV-UHFFFAOYSA-N,CNC(=O)c1ccc(cc1F)N2C(=S)N(C(=O)C2(C)C)c3ccc(C#N)c(c3)C(F)(F)F,,prostate cancers,Phase 2,,,NCT02525068,A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC,RE-AKT,https://ClinicalTrials.gov/show/NCT02525068
clinicaltrials.gov,AZD5069,,,,,,enzalutamide,679762,P10275,"InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)",WXCXUHSOUPDCQV-UHFFFAOYSA-N,CNC(=O)c1ccc(cc1F)N2C(=S)N(C(=O)C2(C)C)c3ccc(C#N)c(c3)C(F)(F)F,,prostate cancers,Phase 1/2,,,NCT03177187,Combination Study of AZD5069 and Enzalutamide.,ACE,https://ClinicalTrials.gov/show/NCT03177187
clinicaltrials.gov,crizotinib,652583,O00238;O00444;O14730;O14920;O14936;O14965;O15075;O15146;O15197;O43283;O43318;O43353;O60674;O75116;O75385;O94804;O94806;P00519;P00533;P04629;P06213;P06239;P06241;P06748;P07332;P07333;P07947;P07948;P07949;P08069;P08581;P08922;P09769;P0C264;P10721;P12931;P14616;P16591;P17948;P19525;P21127;P21709;P22607;P23443;P23458;P29317;P29320;P29322;P29376;P29597;P30530;P32298;P35590;P36888;P36896;P36897;P42681;P42684;P42685;P43403;P43405;P46734;P50613;P51451;P51617;P51813;P52333;P53667;P53671;P54756;P54760;P54762;P54764;P57078;Q02763;Q04771;Q04912;Q05397;Q06187;Q06418;Q07912;Q08345;Q08881;Q09013;Q12851;Q12852;Q12866;Q13043;Q13131;Q13164;Q13188;Q13233;Q13464;Q13470;Q13546;Q14164;Q14289;Q15139;Q15375;Q15569;Q16288;Q16620;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q6PHR2;Q6XUX3;Q6ZN16;Q7L7X3;Q8IVH8;Q8IY84;Q8IYT8;Q8N4C8;Q8N568;Q8NE63;Q8NFD2;Q8TD19;Q8TDR2;Q8TDX7;Q92630;Q92772;Q92918;Q96D53;Q96GD4;Q96RR4;Q96SB4;Q99755;Q99759;Q9BRS2;Q9H093;Q9H0K1;Q9H2G2;Q9H2K8;Q9NSY1;Q9NWZ3;Q9P289;Q9UF33;Q9UHD2;Q9UL54;Q9UM73;Q9UPE1;Q9UQ88;Q9UQB9;Q9Y2U5;Q9Y4K4;Q9Y616,"InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1",KTEIFNKAUNYNJU-GFCCVEGCSA-N,C[C@@H](Oc1cc(cnc1N)c2cnn(c2)C3CCNCC3)c4c(Cl)ccc(F)c4Cl,enzalutamide,679762,P10275,"InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)",WXCXUHSOUPDCQV-UHFFFAOYSA-N,CNC(=O)c1ccc(cc1F)N2C(=S)N(C(=O)C2(C)C)c3ccc(C#N)c(c3)C(F)(F)F,,prostate cancers,Phase 1,,,NCT02207504,Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer,,https://ClinicalTrials.gov/show/NCT02207504
clinicaltrials.gov,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,enzalutamide,679762,P10275,"InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)",WXCXUHSOUPDCQV-UHFFFAOYSA-N,CNC(=O)c1ccc(cc1F)N2C(=S)N(C(=O)C2(C)C)c3ccc(C#N)c(c3)C(F)(F)F,,prostate cancers,Phase 1,,,NCT02125084,Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer,,https://ClinicalTrials.gov/show/NCT02125084
clinicaltrials.gov,GS-5829,,,,,,enzalutamide,679762,P10275,"InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)",WXCXUHSOUPDCQV-UHFFFAOYSA-N,CNC(=O)c1ccc(cc1F)N2C(=S)N(C(=O)C2(C)C)c3ccc(C#N)c(c3)C(F)(F)F,,prostate cancers,Phase 1/2,,,NCT02607228,"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer",,https://ClinicalTrials.gov/show/NCT02607228
clinicaltrials.gov,GSK2636771,1268958,,"InChI=1S/C22H22F3N3O3/c1-13-15(4-3-5-18(13)22(23,24)25)12-28-14(2)26-20-17(21(29)30)10-16(11-19(20)28)27-6-8-31-9-7-27/h3-5,10-11H,6-9,12H2,1-2H3,(H,29,30)",XTKLTGBKIDQGQL-UHFFFAOYSA-N,Cc1c(Cn2c(C)nc3c(cc(cc23)N4CCOCC4)C(=O)O)cccc1C(F)(F)F,enzalutamide,679762,P10275,"InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)",WXCXUHSOUPDCQV-UHFFFAOYSA-N,CNC(=O)c1ccc(cc1F)N2C(=S)N(C(=O)C2(C)C)c3ccc(C#N)c(c3)C(F)(F)F,,prostate cancers,Phase 1,,,NCT02215096,Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer,,https://ClinicalTrials.gov/show/NCT02215096
clinicaltrials.gov,KPG-121,,,,,,enzalutamide,679762,P10275,"InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)",WXCXUHSOUPDCQV-UHFFFAOYSA-N,CNC(=O)c1ccc(cc1F)N2C(=S)N(C(=O)C2(C)C)c3ccc(C#N)c(c3)C(F)(F)F,,prostate cancers,Phase 1,,,NCT03569280,"Safety, Tolerability, PK and Antitumor Activity of KPG-121 Plus Enzalutamide in mCRPC Patients",,https://ClinicalTrials.gov/show/NCT03569280
clinicaltrials.gov,pembrolizumab,,Q15116,,,,enzalutamide,679762,P10275,"InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)",WXCXUHSOUPDCQV-UHFFFAOYSA-N,CNC(=O)c1ccc(cc1F)N2C(=S)N(C(=O)C2(C)C)c3ccc(C#N)c(c3)C(F)(F)F,,prostate cancers,Phase 2,,,NCT02787005,Study of pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199),,https://ClinicalTrials.gov/show/NCT02787005
clinicaltrials.gov,tivozanib,,P35968;P17948;P35916,"InChI=1S/C22H19ClN4O5/c1-12-8-21(27-32-12)26-22(28)25-16-5-4-13(9-15(16)23)31-18-6-7-24-17-11-20(30-3)19(29-2)10-14(17)18/h4-11H,1-3H3,(H2,25,26,27,28)",SPMVMDHWKHCIDT-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,enzalutamide,679762,P10275,"InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)",WXCXUHSOUPDCQV-UHFFFAOYSA-N,CNC(=O)c1ccc(cc1F)N2C(=S)N(C(=O)C2(C)C)c3ccc(C#N)c(c3)C(F)(F)F,,prostate cancers,Phase 2,,,NCT01885949,Tivozanib + Enzalutamide in Adv Prostate Cancer,,https://ClinicalTrials.gov/show/NCT01885949
clinicaltrials.gov,ZEN003694,,,,,,enzalutamide,679762,P10275,"InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)",WXCXUHSOUPDCQV-UHFFFAOYSA-N,CNC(=O)c1ccc(cc1F)N2C(=S)N(C(=O)C2(C)C)c3ccc(C#N)c(c3)C(F)(F)F,,prostate cancers,Phase 1,,,NCT02711956,A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer,,https://ClinicalTrials.gov/show/NCT02711956
clinicaltrials.gov,bicalutamide,308,P10275,"InChI=1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)",LKJPYSCBVHEWIU-UHFFFAOYSA-N,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc2ccc(C#N)c(c2)C(F)(F)F,enzastaurin,139138,P05771,"InChI=1S/C32H29N5O2/c1-35-19-25(23-9-2-4-11-27(23)35)29-30(32(39)34-31(29)38)26-20-37(28-12-5-3-10-24(26)28)22-13-16-36(17-14-22)18-21-8-6-7-15-33-21/h2-12,15,19-20,22H,13-14,16-18H2,1H3,(H,34,38,39)",AXRCEOKUDYDWLF-UHFFFAOYSA-N,Cn1cc(C2=C(C(=O)NC2=O)c3cn(C4CCN(Cc5ccccn5)CC4)c6ccccc36)c7ccccc17,,prostate cancers,Phase 2,,,NCT00685633,Bicalutamide With or Without Enzastaurin in Treating Patients With Prostate Cancer,,https://ClinicalTrials.gov/show/NCT00685633
clinicaltrials.gov,atezolizumab,,Q9NZQ7,,,,epacadostat,1265058,P14902,"InChI=1S/C11H13BrFN7O4S/c12-7-5-6(1-2-8(7)13)17-11(18-21)9-10(20-24-19-9)15-3-4-16-25(14,22)23/h1-2,5,16,21H,3-4H2,(H,15,20)(H,17,18)(H2,14,22,23)",FBKMWOJEPMPVTQ-UHFFFAOYSA-N,NS(=O)(=O)NCCNc1nonc1\C(=N\O)\Nc2ccc(F)c(Br)c2,,lung cancers;bladder cancers,Phase 1,,,NCT02298153,A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110),,https://ClinicalTrials.gov/show/NCT02298153
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,epacadostat,1265058,P14902,"InChI=1S/C11H13BrFN7O4S/c12-7-5-6(1-2-8(7)13)17-11(18-21)9-10(20-24-19-9)15-3-4-16-25(14,22)23/h1-2,5,16,21H,3-4H2,(H,15,20)(H,17,18)(H2,14,22,23)",FBKMWOJEPMPVTQ-UHFFFAOYSA-N,NS(=O)(=O)NCCNc1nonc1\C(=N\O)\Nc2ccc(F)c(Br)c2,,lung cancers;skin cancers;head and neck cancers;stomach cancers;bladder cancers;breast cancers,Phase 1/2,,,NCT02318277,A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203),,https://ClinicalTrials.gov/show/NCT02318277
clinicaltrials.gov,MK-3475,,,,,,epacadostat,1265058,P14902,"InChI=1S/C11H13BrFN7O4S/c12-7-5-6(1-2-8(7)13)17-11(18-21)9-10(20-24-19-9)15-3-4-16-25(14,22)23/h1-2,5,16,21H,3-4H2,(H,15,20)(H,17,18)(H2,14,22,23)",FBKMWOJEPMPVTQ-UHFFFAOYSA-N,NS(=O)(=O)NCCNc1nonc1\C(=N\O)\Nc2ccc(F)c(Br)c2,,lymphoma;lung cancers;bladder cancers;breast cancers;head and neck cancers;ovarian cancers;female cancers;kidney cancers;bowel cancers;stomach cancers;liver cancers,Phase 1/2,,,NCT02178722,"A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037/ ECHO-202)",,https://ClinicalTrials.gov/show/NCT02178722
clinicaltrials.gov,pembrolizumab,,Q15116,,,,epacadostat,1265058,P14902,"InChI=1S/C11H13BrFN7O4S/c12-7-5-6(1-2-8(7)13)17-11(18-21)9-10(20-24-19-9)15-3-4-16-25(14,22)23/h1-2,5,16,21H,3-4H2,(H,15,20)(H,17,18)(H2,14,22,23)",FBKMWOJEPMPVTQ-UHFFFAOYSA-N,NS(=O)(=O)NCCNc1nonc1\C(=N\O)\Nc2ccc(F)c(Br)c2,,head and neck cancers,Phase 2,,,NCT03238638,"A Study of Epacadostat + pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy",,https://ClinicalTrials.gov/show/NCT03238638
clinicaltrials.gov,pembrolizumab,,Q15116,,,,epacadostat,1265058,P14902,"InChI=1S/C11H13BrFN7O4S/c12-7-5-6(1-2-8(7)13)17-11(18-21)9-10(20-24-19-9)15-3-4-16-25(14,22)23/h1-2,5,16,21H,3-4H2,(H,15,20)(H,17,18)(H2,14,22,23)",FBKMWOJEPMPVTQ-UHFFFAOYSA-N,NS(=O)(=O)NCCNc1nonc1\C(=N\O)\Nc2ccc(F)c(Br)c2,,head and neck cancers,Phase 2,,,NCT03463161,Epacadostat and pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy,ORKA,https://ClinicalTrials.gov/show/NCT03463161
clinicaltrials.gov,pembrolizumab,,Q15116,,,,epacadostat,1265058,P14902,"InChI=1S/C11H13BrFN7O4S/c12-7-5-6(1-2-8(7)13)17-11(18-21)9-10(20-24-19-9)15-3-4-16-25(14,22)23/h1-2,5,16,21H,3-4H2,(H,15,20)(H,17,18)(H2,14,22,23)",FBKMWOJEPMPVTQ-UHFFFAOYSA-N,NS(=O)(=O)NCCNc1nonc1\C(=N\O)\Nc2ccc(F)c(Br)c2,,head and neck cancers,Phase 2,,,NCT03325465,Neoadjuvant pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck,,https://ClinicalTrials.gov/show/NCT03325465
clinicaltrials.gov,pembrolizumab,,Q15116,,,,epacadostat,1265058,P14902,"InChI=1S/C11H13BrFN7O4S/c12-7-5-6(1-2-8(7)13)17-11(18-21)9-10(20-24-19-9)15-3-4-16-25(14,22)23/h1-2,5,16,21H,3-4H2,(H,15,20)(H,17,18)(H2,14,22,23)",FBKMWOJEPMPVTQ-UHFFFAOYSA-N,NS(=O)(=O)NCCNc1nonc1\C(=N\O)\Nc2ccc(F)c(Br)c2,,other,Phase 2,,,NCT03291054,Epacadostat and pembrolizumab in Patients With GIST,,https://ClinicalTrials.gov/show/NCT03291054
clinicaltrials.gov,pembrolizumab,,Q15116,,,,epacadostat,1265058,P14902,"InChI=1S/C11H13BrFN7O4S/c12-7-5-6(1-2-8(7)13)17-11(18-21)9-10(20-24-19-9)15-3-4-16-25(14,22)23/h1-2,5,16,21H,3-4H2,(H,15,20)(H,17,18)(H2,14,22,23)",FBKMWOJEPMPVTQ-UHFFFAOYSA-N,NS(=O)(=O)NCCNc1nonc1\C(=N\O)\Nc2ccc(F)c(Br)c2,,pancreatic cancers,Phase 2,,,NCT03432676,Study of IDO-1 Inhibitor Epacadostat in Combination With pembrolizumab in Advanced Pancreatic Cancer With Chromosomal Instability/ Homologous Recombination Repair Deficiency (HRD),,https://ClinicalTrials.gov/show/NCT03432676
clinicaltrials.gov,pembrolizumab,,Q15116,,,,epacadostat,1265058,P14902,"InChI=1S/C11H13BrFN7O4S/c12-7-5-6(1-2-8(7)13)17-11(18-21)9-10(20-24-19-9)15-3-4-16-25(14,22)23/h1-2,5,16,21H,3-4H2,(H,15,20)(H,17,18)(H2,14,22,23)",FBKMWOJEPMPVTQ-UHFFFAOYSA-N,NS(=O)(=O)NCCNc1nonc1\C(=N\O)\Nc2ccc(F)c(Br)c2,Muscle-invasive Bladder Cancer,,Phase 2,,,NCT03832673,,,
clinicaltrials.gov,JNJ-63723283,,,,,,erdafitinib,,,,,,,advanced solid cancers,Phase 1,,,NCT03547037,"A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers",,https://ClinicalTrials.gov/show/NCT03547037
clinicaltrials.gov,JNJ-63723283,,,,,,erdafitinib,,,,,,,advanced solid cancers,Phase 1,,,NCT03547037,"A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers",,https://ClinicalTrials.gov/show/NCT03547037
clinicaltrials.gov,agatolimod,,Q9NR96,"InChI=1S/C236H303N70O133P23S23/c1-91-47-287(223(333)269-193(91)309)157-23-105(308)130(394-157)62-370-440(347,463)418-107-25-158(283-19-15-153(237)253-219(283)329)395-131(107)63-372-457(364,480)434-123-41-175(301-85-247-181-187(301)257-213(241)263-207(181)323)412-148(123)80-388-452(359,475)429-118-36-170(296-56-100(10)202(318)278-232(296)342)400-136(118)68-376-442(349,465)419-109-27-160(285-21-17-155(239)255-221(285)331)397-133(109)65-374-459(366,482)436-125-43-177(303-87-249-183-189(303)259-215(243)265-209(183)325)413-149(125)81-389-455(362,478)432-121-39-173(299-59-103(13)205(321)281-235(299)345)407-143(121)75-383-447(354,470)424-114-32-166(292-52-96(6)198(314)274-228(292)338)403-139(114)71-379-445(352,468)422-113-31-165(291-51-95(5)197(313)273-227(291)337)406-142(113)74-382-450(357,473)427-117-35-169(295-55-99(9)201(317)277-231(295)341)410-146(117)78-386-462(369,485)439-128-46-180(306-90-252-186-192(306)262-218(246)268-212(186)328)416-152(128)84-392-454(361,477)431-120-38-172(298-58-102(12)204(320)280-234(298)344)402-138(120)70-378-444(351,467)421-110-28-161(286-22-18-156(240)256-222(286)332)398-134(110)66-375-460(367,483)437-126-44-178(304-88-250-184-190(304)260-216(244)266-210(184)326)414-150(126)82-390-456(363,479)433-122-40-174(300-60-104(14)206(322)282-236(300)346)408-144(122)76-384-448(355,471)425-115-33-167(293-53-97(7)199(315)275-229(293)339)404-140(115)72-380-446(353,469)423-112-30-164(290-50-94(4)196(312)272-226(290)336)405-141(112)73-381-449(356,472)426-116-34-168(294-54-98(8)200(316)276-230(294)340)409-145(116)77-385-461(368,484)438-127-45-179(305-89-251-185-191(305)261-217(245)267-211(185)327)415-151(127)83-391-453(360,476)430-119-37-171(297-57-101(11)203(319)279-233(297)343)401-137(119)69-377-443(350,466)420-108-26-159(284-20-16-154(238)254-220(284)330)396-132(108)64-373-458(365,481)435-124-42-176(302-86-248-182-188(302)258-214(242)264-208(182)324)411-147(124)79-387-451(358,474)428-111-29-163(289-49-93(3)195(311)271-225(289)335)399-135(111)67-371-441(348,464)417-106-24-162(393-129(106)61-307)288-48-92(2)194(310)270-224(288)334/h15-22,47-60,85-90,105-152,157-180,307-308H,23-46,61-84H2,1-14H3,(H,347,463)(H,348,464)(H,349,465)(H,350,466)(H,351,467)(H,352,468)(H,353,469)(H,354,470)(H,355,471)(H,356,472)(H,357,473)(H,358,474)(H,359,475)(H,360,476)(H,361,477)(H,362,478)(H,363,479)(H,364,480)(H,365,481)(H,366,482)(H,367,483)(H,368,484)(H,369,485)(H2,237,253,329)(H2,238,254,330)(H2,239,255,331)(H2,240,256,332)(H,269,309,333)(H,270,310,334)(H,271,311,335)(H,272,312,336)(H,273,313,337)(H,274,314,338)(H,275,315,339)(H,276,316,340)(H,277,317,341)(H,278,318,342)(H,279,319,343)(H,280,320,344)(H,281,321,345)(H,282,322,346)(H3,241,257,263,323)(H3,242,258,264,324)(H3,243,259,265,325)(H3,244,260,266,326)(H3,245,261,267,327)(H3,246,262,268,328)/t105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129+,130+,131+,132+,133+,134+,135+,136+,137+,138+,139+,140+,141+,142+,143+,144+,145+,146+,147+,148+,149+,150+,151+,152+,157+,158+,159+,160+,161+,162+,163+,164+,165+,166+,167+,168+,169+,170+,171+,172+,173+,174+,175+,176+,177+,178+,179+,180+,440?,441?,442?,443?,444?,445?,446?,447?,448?,449?,450?,451?,452?,453?,454?,455?,456?,457?,458?,459?,460?,461?,462?/m0/s1",OKYYOKGIPDRZJA-CPSXWDTOSA-N,CC1=CN([C@H]2C[C@H](O)[C@@H](COP(=S)(O)O[C@H]3C[C@@H](O[C@@H]3COP(=S)(O)O[C@H]4C[C@@H](O[C@@H]4COP(=S)(O)O[C@H]5C[C@@H](O[C@@H]5COP(=S)(O)O[C@H]6C[C@@H](O[C@@H]6COP(=S)(O)O[C@H]7C[C@@H](O[C@@H]7COP(=S)(O)O[C@H]8C[C@@H](O[C@@H]8COP(=S)(O)O[C@H]9C[C@@H](O[C@@H]9COP(=S)(O)O[C@H]%10C[C@@H](O[C@@H]%10COP(=S)(O)O[C@H]%11C[C@@H](O[C@@H]%11COP(=S)(O)O[C@H]%12C[C@@H](O[C@@H]%12COP(=S)(O)O[C@H]%13C[C@@H](O[C@@H]%13COP(=S)(O)O[C@H]%14C[C@@H](O[C@@H]%14COP(=S)(O)O[C@H]%15C[C@@H](O[C@@H]%15COP(=S)(O)O[C@H]%16C[C@@H](O[C@@H]%16COP(=S)(O)O[C@H]%17C[C@@H](O[C@@H]%17COP(=S)(O)O[C@H]%18C[C@@H](O[C@@H]%18COP(=S)(O)O[C@H]%19C[C@@H](O[C@@H]%19COP(=S)(O)O[C@H]%20C[C@@H](O[C@@H]%20COP(=S)(O)O[C@H]%21C[C@@H](O[C@@H]%21COP(=S)(O)O[C@H]%22C[C@@H](O[C@@H]%22COP(=S)(O)O[C@H]%23C[C@@H](O[C@@H]%23COP(=S)(O)O[C@H]%24C[C@@H](O[C@@H]%24COP(=S)(O)O[C@H]%25C[C@@H](O[C@@H]%25CO)N%26C=C(C)C(=O)NC%26=O)N%27C=C(C)C(=O)NC%27=O)n%28cnc%29C(=O)NC(=Nc%28%29)N)N%30C=CC(=NC%30=O)N)N%31C=C(C)C(=O)NC%31=O)n%32cnc%33C(=O)NC(=Nc%32%33)N)N%34C=C(C)C(=O)NC%34=O)N%35C=C(C)C(=O)NC%35=O)N%36C=C(C)C(=O)NC%36=O)N%37C=C(C)C(=O)NC%37=O)n%38cnc%39C(=O)NC(=Nc%38%39)N)N%40C=CC(=NC%40=O)N)N%41C=C(C)C(=O)NC%41=O)n%42cnc%43C(=O)NC(=Nc%42%43)N)N%44C=C(C)C(=O)NC%44=O)N%45C=C(C)C(=O)NC%45=O)N%46C=C(C)C(=O)NC%46=O)N%47C=C(C)C(=O)NC%47=O)n%48cnc%49C(=O)NC(=Nc%48%49)N)N%50C=CC(=NC%50=O)N)N%51C=C(C)C(=O)NC%51=O)n%52cnc%53C(=O)NC(=Nc%52%53)N)N%54C=CC(=NC%54=O)N)O2)C(=O)NC1=O,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers,Phase 2,,,NCT00321815,Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT00321815
clinicaltrials.gov,apricoxib,968251,P35354,"InChI=1S/C19H20N2O3S/c1-3-24-17-8-4-15(5-9-17)19-12-14(2)13-21(19)16-6-10-18(11-7-16)25(20,22)23/h4-13H,3H2,1-2H3,(H2,20,22,23)",JTMITOKKUMVWRT-UHFFFAOYSA-N,CCOc1ccc(cc1)c2cc(C)cn2c3ccc(cc3)S(=O)(=O)N,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers,Phase 2,,,NCT00652340,APRiCOT-L: Study to Evaluate Efficacy and Safety of Apricoxib With Erlotinib in Patients With Non-small Cell Lung Cancer,TP2001-201,https://ClinicalTrials.gov/show/NCT00652340
literature,apricoxib,968251,P35354,"InChI=1S/C19H20N2O3S/c1-3-24-17-8-4-15(5-9-17)19-12-14(2)13-21(19)16-6-10-18(11-7-16)25(20,22)23/h4-13H,3H2,1-2H3,(H2,20,22,23)",JTMITOKKUMVWRT-UHFFFAOYSA-N,CCOc1ccc(cc1)c2cc(C)cn2c3ccc(cc3)S(=O)(=O)N,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,advanced non-small-cell lung cancer,lung cancers,Phase 2,24736085,"The primary endpoint was time to progression (TTP). A decrease of 50% or more from baseline urinary prostaglandin E2 metabolite after a 5-day, open-label, run-in period was used to select eligible patients. One hundred twenty patients (median age 64 years) were randomized (78 to AP/E and 42 to P/E). Overall median TTP was 1.8 months in the AP/E group and 2.1 months in the P/E group, with a 12% objective response rate in both groups (intent-to-treat analysis). A subgroup analysis in patients aged 65 years or younger demonstrated a statistically significant TTP benefit for AP/E (hazard ratio 0.5 [95% confidence interval: not applicable-0.9]; p=0.018) and overall survival advantage at minimum 1-year follow-up (median 12.2 versus 4.0 months; hazard ratio=0.5; p=0.021). The most common adverse events were rash, diarrhea, fatigue, and nausea. Toxicity contributed to early discontinuations in patients aged more than 65 years treated with AP/E. This is the first randomized placebo-controlled study of a COX-2 inhibitor in NSCLC to use a prospective patient-selection strategy. Although AP/E seemed to improve TTP and overall survival in a subset of patients aged 65 years or younger, the primary endpoint of the trial was not met.",,,,
clinicaltrials.gov,bevacizumab,11,P15692,,,,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,kidney cancers,Phase 2,,,NCT01130519,A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer,,https://ClinicalTrials.gov/show/NCT01130519
clinicaltrials.gov,bevacizumab,11,P15692,,,,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,liver cancers,Phase 2,,,NCT01180959,Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy,,https://ClinicalTrials.gov/show/NCT01180959
clinicaltrials.gov,bevacizumab,11,P15692,,,,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,liver cancers,Phase 2,,,NCT00242502,Efficacy and Safety Study of Bevacizumab and Erlotinib to Treat Primary Liver Cancer That Cannot be Removed By Surgery,,https://ClinicalTrials.gov/show/NCT00242502
clinicaltrials.gov,bevacizumab,11,P15692,,,,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,liver cancers,Phase 2,,,NCT00605722,A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.,,https://ClinicalTrials.gov/show/NCT00605722
clinicaltrials.gov,bevacizumab,11,P15692,,,,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers,Phase 1/2,,,NCT00043823,Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT00043823
clinicaltrials.gov,bevacizumab,11,P15692,,,,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers,Phase 2,,,NCT00095225,A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer),,https://ClinicalTrials.gov/show/NCT00095225
clinicaltrials.gov,bevacizumab,11,P15692,,,,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers,Phase 2,,,NCT00553800,Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer,NSCLC,https://ClinicalTrials.gov/show/NCT00553800
clinicaltrials.gov,bevacizumab,11,P15692,,,,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers,Phase 2,,,NCT02655536,"Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial",BRILLIANT,https://ClinicalTrials.gov/show/NCT02655536
clinicaltrials.gov,bevacizumab,11,P15692,,,,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers,Phase 2,,,NCT03126799,A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+),AvaTa,https://ClinicalTrials.gov/show/NCT03126799
clinicaltrials.gov,bevacizumab,11,P15692,,,,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers,Phase 2,,,NCT00436332,S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma,,https://ClinicalTrials.gov/show/NCT00436332
clinicaltrials.gov,bevacizumab,11,P15692,,,,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers,Phase 2,,,NCT00445848,S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT00445848
clinicaltrials.gov,bevacizumab,11,P15692,,,,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,other,Phase 2,,,NCT00369889,A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer,,https://ClinicalTrials.gov/show/NCT00369889
clinicaltrials.gov,bevacizumab,11,P15692,,,,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,ovarian cancers,Phase 2,,,NCT00130520,Bevacizumab and Erlotinib Study in Advanced ovarian Cancers,,https://ClinicalTrials.gov/show/NCT00130520
clinicaltrials.gov,bevacizumab,11,P15692,,,,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,,Phase 2,,,NCT00193622,Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site,,https://ClinicalTrials.gov/show/NCT00193622
literature,bevacizumab,11,P15692,,,,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,metastatic colorectal cancer,bowel cancers,Phase 3,26474518,"Between Jan 1, 2007, and Oct 13, 2011, 700 eligible patients were enrolled; following induction treatment, patients without disease progression were randomly assigned to bevacizumab (n=228) or bevacizumab plus erlotinib (n=224). At the final analysis, median follow-up was 51à0 months (IQR 36à0-60à0) in the bevacizumab group and 48à3 months (31à5-61à0) in the bevacizumab plus erlotinib group. In the primary analysis (after 231 progression-free survival events), median progression-free survival from randomisation was 5à1 months (95% CI 4à1-5à9) in the bevacizumab plus erlotinib group compared with 6à0 months (4à6-7à9) in the bevacizumab group (stratified hazard ratio [HR] 0à79 [95% CI 0à60-1à06]; p=0à11; unstratified HR 0à76 [0à59-0à99]; p=0à043). In the final analysis, median progression-free survival from randomisation was 5à4 months (95% CI 4à3-6à2) in the bevacizumab plus erlotinib group compared with 4à9 months (4à1-5à7) in the bevacizumab group (stratified HR 0à81 [95% CI 0à66-1à01], p=0à059; unstratified HR 0à78 [0à68-0à96], p=0à019). At the final analysis, median overall survival from maintenance was 24à9 months (95% CI 21à4-28à9) in the bevacizumab plus erlotinib group and 22à1 months (19à6-26à7) in the bevacizumab group (stratified HR 0à79 [95% CI 0à63-0à99], p=0à036; unstratified HR 0à79 [0à64-0à98], p=0à035). The most frequent grade 3-4 adverse events were skin rash (47 [21%] of 220 patients in the bevacizumab plus erlotinib group vs none of 224 patients in the bevacizumab alone group), diarrhoea (21 [10%] vs two [<1%]), and asthenia (12 [5%] vs two [<1%]).",,,,
literature,bevacizumab,11,P15692,,,,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,recurrent malignant glioma,brain cancers,Phase 2,20716591,"Fifty-seven patients (n = 25, glioblastoma [GBM]; n = 32, anaplastic glioma [AG]) were enrolled. The primary endpoint was 6-month progression-free survival (PFS-6). Overall survival (OS), radiographic response, pharmacokinetics, and correlative biomarkers were the secondary endpoints. Patients were stratified based on the concurrent use of enzyme-inducing antiepileptic drugs (EIAEDs). Bevacizumab (10 mg/kg) was given intravenously every 2 weeks. Erlotinib was orally administered daily at 200 mg/day for patients not on EIAEDs and 500 mg/day for patients on EIAEDs. PFS-6 and median OS were 28% and 42 weeks for GBM patients and 44% and 71 weeks for AG patients, respectively. Twelve (48%) GBM patients and 10 (31%) AG patients achieved a radiographic response. Erlotinib pharmacokinetic exposures were comparable between EIAED and non-EIAED groups. Rash, mucositis, diarrhea, and fatigue were common but mostly grades 1 and 2. Among GBM patients, grade 3 rash, observed in 32%, was associated with survival benefit, whereas elevated hypoxia-inducible factor-2 alpha and VEGF receptor-2 levels were associated with poor survival. Bevacizumab plus erlotinib was adequately tolerated in recurrent MG patients. However, this regimen was associated with similar PFS benefit and radiographic response when compared with other historical bevacizumab-containing regimens.",,,,
literature,bevacizumab,11,P15692,,,,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,advanced non-small-cell lung_cancer_after failure of standard first-line chemotherapy,lung cancers,Phase 1/2,21621716,"Overall survival did not differ between 317 controls and 319 patients in the bevacizumab group (hazard ratio [HR] 0à97, 95% CI 0à80-1à18, p=0à7583). Median overall survival was 9à3 months (IQR 4à1-21à6) for patients in the bevacizumab group compared with 9à2 months (3à8-20à2) for controls. Progression-free survival seemed to be longer in the bevacizumab group (3à4 months [1à4-8à4]) than in the control group (1à7 months [1à3-4à1]; HR 0à62, 95% CI 0à52-0à75) and objective response rate suggested some clinical activity of bevacizumab and erlotinib. However, these secondary endpoint differences could not be defined as significant because the study prespecified that the primary endpoint had to be significant before testing of secondary endpoints could be done, to control type I error rate. In the bevacizumab group, 130 (42%) of 313 patients with safety data had a serious adverse event, compared with 114 (36%) controls. There were 20 (6%) grade 5 adverse events, including two arterial thromboembolic events, in the bevacizumab group, and 14 (4%) in the control group.",,,,
clinicaltrials.gov,binimetinib,1222391,Q02750;P36507,"InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)",ACWZRVQXLIRSDF-UHFFFAOYSA-N,Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers,Phase 1,,,NCT01859026,A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation,,https://ClinicalTrials.gov/show/NCT01859026
clinicaltrials.gov,cabozantinib,1081506,P08581,"InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)",ONIQOQHATWINJY-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5)cc3)c2cc1OC,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers,Phase 1/2,,,NCT00596648,A Study of XL184 (Cabozantinib) With or Without Erlotinib in Adults With Non-Small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT00596648
clinicaltrials.gov,cabozantinib,1081506,P08581,"InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)",ONIQOQHATWINJY-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5)cc3)c2cc1OC,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers,Phase 2,,,NCT01708954,Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT01708954
clinicaltrials.gov,cetuximab,9,P00533,,,,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,bowel cancers,Phase 2,,,NCT00784667,Dual Inhibition of EGFR Signalling Using the Combination of Cetuximab and Erlotinib,Dux,https://ClinicalTrials.gov/show/NCT00784667
clinicaltrials.gov,cetuximab,9,P00533,,,,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers,Phase 1/2,,,NCT00408499,Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT00408499
clinicaltrials.gov,CS-7017,,P37231,,,,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers,Phase 1,,,NCT01199068,CS-7017 in Combination With Erlotinib in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC),,https://ClinicalTrials.gov/show/NCT01199068
clinicaltrials.gov,dalotuzumab,,P08069,,,,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers,Phase 2,,,NCT00654420,A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007),,https://ClinicalTrials.gov/show/NCT00654420
clinicaltrials.gov,dasatinib,375,O00238;O00506;O14965;O14976;O15197;O15264;O43283;O43318;O43353;O60674;O94804;O95819;P00519;P00533;P04049;P04626;P06239;P06241;P07333;P07947;P07948;P07949;P08631;P08684;P09619;P09769;P0C1S8;P10721;P11274;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P21860;P22607;P27037;P29317;P29320;P29322;P29323;P29597;P30291;P35968;P36507;P36888;P36894;P36896;P36897;P37023;P37173;P41240;P42680;P42681;P42684;P42685;P43405;P49674;P51451;P51813;P51955;P52333;P53667;P53671;P53778;P54753;P54756;P54760;P54762;P54764;P57059;Q01538;Q02750;Q04771;Q06187;Q07912;Q08345;Q09013;Q12851;Q13043;Q13163;Q13705;Q13882;Q15303;Q15569;Q15759;Q16539;Q16832;Q52WX2;Q56UN5;Q59H18;Q5VT25;Q6DT37;Q6PHR2;Q86Y07;Q8IVH8;Q8N4C8;Q8NG66;Q8NI60;Q8TDR2;Q92918;Q96GD4;Q99640;Q99759;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K8;Q9H3Y6;Q9NRP7;Q9NYL2;Q9P289;Q9P2K8;Q9UBE8;Q9UF33;Q9UKE5;Q9UL54;Q9Y2K2;Q9Y2U5;Q9Y4K4;Q9Y5S2;Q9Y6R4,"InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)",ZBNZXTGUTAYRHI-UHFFFAOYSA-N,Cc1nc(Nc2ncc(s2)C(=O)Nc3c(C)cccc3Cl)cc(n1)N4CCN(CCO)CC4,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers,Phase 1/2,,,NCT00826449,Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC),,https://ClinicalTrials.gov/show/NCT00826449
literature,dasatinib,375,O00238;O00506;O14965;O14976;O15197;O15264;O43283;O43318;O43353;O60674;O94804;O95819;P00519;P00533;P04049;P04626;P06239;P06241;P07333;P07947;P07948;P07949;P08631;P08684;P09619;P09769;P0C1S8;P10721;P11274;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P21860;P22607;P27037;P29317;P29320;P29322;P29323;P29597;P30291;P35968;P36507;P36888;P36894;P36896;P36897;P37023;P37173;P41240;P42680;P42681;P42684;P42685;P43405;P49674;P51451;P51813;P51955;P52333;P53667;P53671;P53778;P54753;P54756;P54760;P54762;P54764;P57059;Q01538;Q02750;Q04771;Q06187;Q07912;Q08345;Q09013;Q12851;Q13043;Q13163;Q13705;Q13882;Q15303;Q15569;Q15759;Q16539;Q16832;Q52WX2;Q56UN5;Q59H18;Q5VT25;Q6DT37;Q6PHR2;Q86Y07;Q8IVH8;Q8N4C8;Q8NG66;Q8NI60;Q8TDR2;Q92918;Q96GD4;Q99640;Q99759;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K8;Q9H3Y6;Q9NRP7;Q9NYL2;Q9P289;Q9P2K8;Q9UBE8;Q9UF33;Q9UKE5;Q9UL54;Q9Y2K2;Q9Y2U5;Q9Y4K4;Q9Y5S2;Q9Y6R4,"InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)",ZBNZXTGUTAYRHI-UHFFFAOYSA-N,Cc1nc(Nc2ncc(s2)C(=O)Nc3c(C)cccc3Cl)cc(n1)N4CCN(CCO)CC4,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,Recurrent malignant glioma,brain cancers,Phase 1,22407177,"The most common DLTs were diarrhea and fatigue, while most adverse events were grade 2. Pharmacokinetic data suggests that dasatinib exposure increased with increased dasatinib dose and concurrent erlotinib administration, while concurrent EIAED use diminished dasatinib exposure. No radiographic responses were observed, and only one patient (2 %) remained progression-free at 6 months.",,,,
literature,dasatinib,375,O00238;O00506;O14965;O14976;O15197;O15264;O43283;O43318;O43353;O60674;O94804;O95819;P00519;P00533;P04049;P04626;P06239;P06241;P07333;P07947;P07948;P07949;P08631;P08684;P09619;P09769;P0C1S8;P10721;P11274;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P21860;P22607;P27037;P29317;P29320;P29322;P29323;P29597;P30291;P35968;P36507;P36888;P36894;P36896;P36897;P37023;P37173;P41240;P42680;P42681;P42684;P42685;P43405;P49674;P51451;P51813;P51955;P52333;P53667;P53671;P53778;P54753;P54756;P54760;P54762;P54764;P57059;Q01538;Q02750;Q04771;Q06187;Q07912;Q08345;Q09013;Q12851;Q13043;Q13163;Q13705;Q13882;Q15303;Q15569;Q15759;Q16539;Q16832;Q52WX2;Q56UN5;Q59H18;Q5VT25;Q6DT37;Q6PHR2;Q86Y07;Q8IVH8;Q8N4C8;Q8NG66;Q8NI60;Q8TDR2;Q92918;Q96GD4;Q99640;Q99759;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K8;Q9H3Y6;Q9NRP7;Q9NYL2;Q9P289;Q9P2K8;Q9UBE8;Q9UF33;Q9UKE5;Q9UL54;Q9Y2K2;Q9Y2U5;Q9Y4K4;Q9Y5S2;Q9Y6R4,"InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)",ZBNZXTGUTAYRHI-UHFFFAOYSA-N,Cc1nc(Nc2ncc(s2)C(=O)Nc3c(C)cccc3Cl)cc(n1)N4CCN(CCO)CC4,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,Advanced non-small-cell lung cancer,lung cancers,Phase 1/2,20142592,"Thirty-four patients were enrolled. The average duration of treatment was 73 days. The main adverse events include GI (diarrhea, anorexia, and nausea), skin rash, cytopenias, pleural effusions, and fatigue. No effect of escalating doses of dasatinib was observed on erlotinib pharmacokinetics. Two partial responses and one bone response were observed, and the disease control rate was 63%. Reductions in plasma VEGF and bFGF were observed, and reductions in VEGF correlated with disease control.",,,,
literature,dasatinib,375,O00238;O00506;O14965;O14976;O15197;O15264;O43283;O43318;O43353;O60674;O94804;O95819;P00519;P00533;P04049;P04626;P06239;P06241;P07333;P07947;P07948;P07949;P08631;P08684;P09619;P09769;P0C1S8;P10721;P11274;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P21860;P22607;P27037;P29317;P29320;P29322;P29323;P29597;P30291;P35968;P36507;P36888;P36894;P36896;P36897;P37023;P37173;P41240;P42680;P42681;P42684;P42685;P43405;P49674;P51451;P51813;P51955;P52333;P53667;P53671;P53778;P54753;P54756;P54760;P54762;P54764;P57059;Q01538;Q02750;Q04771;Q06187;Q07912;Q08345;Q09013;Q12851;Q13043;Q13163;Q13705;Q13882;Q15303;Q15569;Q15759;Q16539;Q16832;Q52WX2;Q56UN5;Q59H18;Q5VT25;Q6DT37;Q6PHR2;Q86Y07;Q8IVH8;Q8N4C8;Q8NG66;Q8NI60;Q8TDR2;Q92918;Q96GD4;Q99640;Q99759;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K8;Q9H3Y6;Q9NRP7;Q9NYL2;Q9P289;Q9P2K8;Q9UBE8;Q9UF33;Q9UKE5;Q9UL54;Q9Y2K2;Q9Y2U5;Q9Y4K4;Q9Y5S2;Q9Y6R4,"InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)",ZBNZXTGUTAYRHI-UHFFFAOYSA-N,Cc1nc(Nc2ncc(s2)C(=O)Nc3c(C)cccc3Cl)cc(n1)N4CCN(CCO)CC4,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,Non-Small Cell Lung Cancer,lung cancers,Phase 1/2,25170013,MTD was 150 mg of erlotinib and 70 mg of dasatinib daily based on 12 patients treated in the phase I portion. No responses were observed in phase I. The 35 NSCLC patients treated in phase II had an overall disease control rate of 59% at 6 weeks. Five patients (15%) had partial responses; all had activating EGFR mutations. Median PFS was 3.3 months. Epithelial-mesenchymal transition markers did not correlate with outcomes.,,,,
literature,dovitinib,31361,O00444;O00506;O14578;O14730;O14757;O14976;O15111;O15146;O15197;O43283;O43293;O43318;O60285;O60331;O60674;O75116;O75385;O75582;O75676;O75716;O75914;O94768;O94804;O95819;O95835;P00519;P00533;P04629;P06239;P06241;P07333;P07947;P07948;P07949;P08631;P09619;P09769;P10721;P11362;P11802;P12931;P15735;P16234;P17948;P19525;P19784;P21802;P22455;P22607;P23443;P23458;P27448;P29597;P30291;P30530;P32298;P35590;P35916;P35968;P36507;P36888;P42685;P49759;P49760;P49841;P50613;P51451;P51617;P51812;P51955;P51957;P52333;P54646;P57058;P68400;P78356;P78362;P80192;Q00536;Q00537;Q02750;Q04759;Q06418;Q07002;Q08345;Q08881;Q12851;Q12852;Q12866;Q13043;Q13131;Q13163;Q13188;Q13464;Q13523;Q13546;Q13873;Q14164;Q14680;Q15208;Q15349;Q15418;Q15746;Q15831;Q15835;Q16288;Q16512;Q16513;Q16584;Q16620;Q16816;Q16832;Q2M2I8;Q32MK0;Q52WX2;Q56UN5;Q5S007;Q6P3R8;Q6PHR2;Q7KZI7;Q86UE8;Q86YV6;Q86Z02;Q8IVH8;Q8IY84;Q8IYT8;Q8N4C8;Q8N5S9;Q8NFD2;Q8TD19;Q8TDX7;Q8WTQ7;Q92630;Q92772;Q92918;Q96BR1;Q96GD4;Q96L34;Q96SB4;Q99755;Q9BRS2;Q9BVS4;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2X6;Q9H422;Q9HAZ1;Q9HC98;Q9NRM7;Q9NSY1;Q9NWZ3;Q9NYY3;Q9P0L2;Q9P289;Q9P2K8;Q9UEE5;Q9UEW8;Q9UHD2;Q9UK32;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2H9;Q9Y2U5;Q9Y4K4;Q9Y6E0;Q9Y6R4,"InChI=1S/C21H21FN6O/c1-27-7-9-28(10-8-27)12-5-6-14-16(11-12)25-20(24-14)18-19(23)17-13(22)3-2-4-15(17)26-21(18)29/h2-6,11H,7-10H2,1H3,(H,24,25)(H3,23,26,29)",PIQCTGMSNWUMAF-UHFFFAOYSA-N,CN1CCN(CC1)c2ccc3nc([nH]c3c2)C4=C(N)c5c(F)cccc5NC4=O,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,metastatic non-small cell lungcancer,lung cancers,Phase 1,26149476,"Two of three patients in cohort 1 had a DLT (grade 3 transaminitis and grade 3 syncope). Two of 6 patients in cohort -1 had a DLT (grade 3 pulmonary embolism and grade 3 fatigue); thus, the study was terminated. Erlotinib exposure (average Cmax 2308±698 ng/ml and AUC 0-24 41,030±15,577 ng_h/ml) approximated previous reports in the six patients with pharmacokinetic analysis. However, erlotinib Cmax and AUC0-24 decreased significantly by 93% (p=0.02) and 97% (p<0.01), respectively, during dovitinib co-administration.",,,,
clinicaltrials.gov,emibetuzumab,,,,,,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers,Phase 2,,,NCT01897480,A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations,Balise,https://ClinicalTrials.gov/show/NCT01897480
clinicaltrials.gov,emibetuzumab,,,,,,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers,Phase 2,,,NCT01900652,A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants,Chime,https://ClinicalTrials.gov/show/NCT01900652
clinicaltrials.gov,entinostat,312087,Q96DB2;Q9UBN7;Q92769;Q13547;Q9UKV0;Q9UQL6;Q8WUI4;P56524;O15379;Q969S8;Q9BY41,"InChI=1S/C21H20N4O3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-24-21(27)28-14-16-4-3-11-23-12-16/h1-12H,13-14,22H2,(H,24,27)(H,25,26)",INVTYAOGFAGBOE-UHFFFAOYSA-N,Nc1ccccc1NC(=O)c2ccc(CNC(=O)OCc3cccnc3)cc2,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers,Phase 2,,,NCT00750698,A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Patients With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib,,https://ClinicalTrials.gov/show/NCT00750698
clinicaltrials.gov,enzastaurin,139138,P05771,"InChI=1S/C32H29N5O2/c1-35-19-25(23-9-2-4-11-27(23)35)29-30(32(39)34-31(29)38)26-20-37(28-12-5-3-10-24(26)28)22-13-16-36(17-14-22)18-21-8-6-7-15-33-21/h2-12,15,19-20,22H,13-14,16-18H2,1H3,(H,34,38,39)",AXRCEOKUDYDWLF-UHFFFAOYSA-N,Cn1cc(C2=C(C(=O)NC2=O)c3cn(C4CCN(Cc5ccccn5)CC4)c6ccccc36)c7ccccc17,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers,Phase 1/2,,,NCT00452413,A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer,,https://ClinicalTrials.gov/show/NCT00452413
clinicaltrials.gov,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers,Phase 1,,,NCT00456833,Combination of RAD001 and Erlotinib in Patients With Advanced Non Small Cell Lung Cancer Previously Treated Only With Chemotherapy,,https://ClinicalTrials.gov/show/NCT00456833
clinicaltrials.gov,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,other,Phase 2,,,NCT00843531,RAD001 and Erlotinib in Patients With Neuroendocrine Tumors,,https://ClinicalTrials.gov/show/NCT00843531
clinicaltrials.gov,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,pancreatic cancers,Phase 2,,,NCT00640978,Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer,,https://ClinicalTrials.gov/show/NCT00640978
clinicaltrials.gov,ficlatuzumab,,P14210,,,,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,advanced solid cancers;lymphoma;multiple myeloma,Phase 1,,,NCT00725634,"A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma",P05538,https://ClinicalTrials.gov/show/NCT00725634
clinicaltrials.gov,foretinib,753913,P08581;P09619;P16234;P10721;Q02763;P36888;P35968;P17948;P35916,"InChI=1S/C34H34F2N4O6/c1-43-30-20-25-27(21-31(30)45-16-2-13-40-14-17-44-18-15-40)37-12-9-28(25)46-29-8-7-24(19-26(29)36)39-33(42)34(10-11-34)32(41)38-23-5-3-22(35)4-6-23/h3-9,12,19-21H,2,10-11,13-18H2,1H3,(H,38,41)(H,39,42)",CXQHYVUVSFXTMY-UHFFFAOYSA-N,COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5)cc3F)ccnc2cc1OCCCN6CCOCC6,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers,Phase 2,,,NCT02034097,A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT02034097
clinicaltrials.gov,giltertinib,1211984,P36888; P30530,"InChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34)",GYQYAJJFPNQOOW-UHFFFAOYSA-N,CCc1nc(C(=O)N)c(Nc2ccc(N3CCC(CC3)N4CCN(C)CC4)c(OC)c2)nc1NC5CCOCC5,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers,Phase 1/2,,,NCT02495233,A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI),,https://ClinicalTrials.gov/show/NCT02495233
clinicaltrials.gov,IRX4204,,,,,,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers,Phase 1,,,NCT02991651,Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC,,https://ClinicalTrials.gov/show/NCT02991651
clinicaltrials.gov,ixazomib citrate,1301621,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C14H19BCl2N2O4/c1-8(2)5-12(15(22)23)19-13(20)7-18-14(21)10-6-9(16)3-4-11(10)17/h3-4,6,8,12,22-23H,5,7H2,1-2H3,(H,18,21)(H,19,20)/t12-/m0/s1",MXAYKZJJDUDWDS-LBPRGKRZSA-N,CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,advanced solid cancers;lung cancers;pancreatic cancers,Phase 1,,,NCT02942095,Study of Ixazomib and Erlotinib in Solid Tumors,,https://ClinicalTrials.gov/show/NCT02942095
clinicaltrials.gov,linifanib,162800,P07333;P09619;P16234;P36888;P35968;P17948;P35916,"InChI=1S/C21H18FN5O/c1-12-5-10-16(22)18(11-12)25-21(28)24-14-8-6-13(7-9-14)15-3-2-4-17-19(15)20(23)27-26-17/h2-11H,1H3,(H3,23,26,27)(H2,24,25,28)",MPVGZUGXCQEXTM-UHFFFAOYSA-N,Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)c3cccc4[nH]nc(N)c34)c1,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,,Phase 1,,,NCT00754104,Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors,,https://ClinicalTrials.gov/show/NCT00754104
literature,linsitinib,678359,P06213;P08069,"InChI=1S/C26H23N5O/c1-26(32)14-19(15-26)25-30-22(23-24(27)28-11-12-31(23)25)18-8-7-17-9-10-20(29-21(17)13-18)16-5-3-2-4-6-16/h2-13,19,32H,14-15H2,1H3,(H2,27,28)/t19-,26+",PKCDDUHJAFVJJB-VLZXCDOPSA-N,C[C@@]1(O)C[C@@H](C1)c2nc(c3ccc4ccc(nc4c3)c5ccccc5)c6c(N)nccn26,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,advanced non-small cell lung cancer,lung cancers,Phase 2,28772281,"The study was unblinded early due to linsitinib non-superiority. No difference was found between the two treatment groups in median PFS of 125 days linsitinib vs 129 days placebo (P=0.601); no difference in overall survival (OS) was observed. Tolerability was similar, although in the linsitinib group, treatment-related adverse events and discontinuations were more frequent. No drug-drug interaction was implicated.",,,,
clinicaltrials.gov,metformin,1855,P43304;P03923;O95299;O00217;P03901;P56556;P03886;O95139;O00483;Q86Y39;P17568;P03891;O75306;P03915;P51970;O43674;P03905;P03897;O14561;O15239;O43181;O43676;O43677;O43678;O43920;O75251;O75380;O75438;O75489;O95167;O95168;O95169;O95178;O95182;O95298;O96000;P19404;P28331;P49821;P56181;Q16718;Q16795;Q8N183;Q9BU61;Q9NRX3;Q9NX14;Q9P032;Q9P0J0;Q9UI09;Q9Y375;Q9Y6M9,"InChI=1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)",XZWYZXLIPXDOLR-UHFFFAOYSA-N,CN(C)C(=N)NC(=N)N,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,breast cancers,Phase 1,,,NCT01650506,Study of Erlotinib and Metformin in Triple Negative Breast Cancer,,https://ClinicalTrials.gov/show/NCT01650506
literature,MK-2206,,P31751;Q9Y243;P31749,"InChI=1S/C25H21N5O/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31)",ULDXWLCXEDXJGE-UHFFFAOYSA-N,NC1(CCC1)c2ccc(cc2)c3nc4C=CN5C(=O)NN=C5c4cc3c6ccccc6,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,Advanced solid tumours,advanced solid cancers,Phase 1,24387695,"MTD of MK-2206 (N_=_72) was 45 mg QOD or 200 mg Q3W (arm 1); MAD was 200 mg Q3W (arm 2) and 135 mg QW (arm 3). DLTs included skin rash (arms 1, 3), febrile neutropenia (QOD, arms 1, 2), tinnitus (Q3W, arm 2), and stomatitis (QOD, arm 3). Common drug-related toxicities included fatigue (68%), nausea (49%), and rash (47%). Two patients with squamous cell carcinoma of the head and neck (arm 1; Q3W) demonstrated a complete and partial response (PR); additional PRs were observed in patients (1 each) with melanoma, endometrial, neuroendocrine prostate, NSCLC, and cervical cancers. Six patients had stable disease _6 months.",,,,
clinicaltrials.gov,MM-121,,P21860,,,,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers,Phase 1/2,,,NCT00994123,A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT00994123
literature,OSI-930,646574,P10721;P35968;P17948;P35916,"InChI=1S/C22H16F3N3O2S/c23-22(24,25)30-16-7-5-15(6-8-16)28-21(29)20-19(10-12-31-20)27-13-14-9-11-26-18-4-2-1-3-17(14)18/h1-12,27H,13H2,(H,28,29)",FGTCROZDHDSNIO-UHFFFAOYSA-N,FC(F)(F)Oc1ccc(NC(=O)c2sccc2NCc3ccnc4ccccc34)cc1,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,Advanced solid tumours,advanced solid cancers,Phase 1,23099006,"Twenty one patients were enrolled to 1 of 3 cohorts: 200 mg OSI-930 BID+100 mg erlotinib QD; 200 mg OSI-930 BID+150 mg erlotinib QD; 300 mg OSI-930 BID+150 mg erlotinib QD. The most common adverse events were anorexia (85%), diarrhoea (75%), rash (70%) and lethargy (65%). The MTD was not reached but the onset of cumulative toxicity necessitating dose modification after the 28-d DLT assessment period was common at the highest dose level. A PK interaction was identified with co-administration of both agents resulting in a two-fold increase in OSI-930 exposure. Pharmacodynamic activity was observed with a decline in sVEGFR levels detected in all patients. Ten patients had disease stabilization (median duration 119 d).",,,,
clinicaltrials.gov,pacritinib,1894124,P36888;O60674,"InChI=1S/C28H32N4O3/c1-2-13-32(12-1)14-17-35-27-9-8-25-19-24(27)21-34-16-4-3-15-33-20-22-6-5-7-23(18-22)26-10-11-29-28(30-25)31-26/h3-11,18-19H,1-2,12-17,20-21H2,(H,29,30,31)/b4-3+",HWXVIOGONBBTBY-ONEGZZNKSA-N,C(CN1CCCC1)Oc2ccc3Nc4nccc(n4)c5cccc(COC\C=C\COCc2c3)c5,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers,Phase 1/2,,,NCT02342353,Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI),,https://ClinicalTrials.gov/show/NCT02342353
clinicaltrials.gov,panobinostat,523996,Q9BY41;Q969S8;O15379;P56524;Q8WUI4;Q9UQL6;Q9UKV0;Q13547;Q92769;Q9UBN7;Q96DB2,"InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+",FPOHNWQLNRZRFC-ZHACJKMWSA-N,Cc1[nH]c2ccccc2c1CCNCc3ccc(\C=C\C(=O)NO)cc3,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers;head and neck cancers,Phase 1,,,NCT00738751,Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers,,https://ClinicalTrials.gov/show/NCT00738751
clinicaltrials.gov,pazopanib,200268,O00238;O00444;O14965;O14976;O15197;O43353;O60331;O60674;O75716;O94804;O95819;P00519;P04049;P06239;P06241;P07332;P07333;P07947;P07948;P07949;P08581;P08631;P08922;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P16591;P17948;P19525;P21127;P21802;P22455;P22607;P27448;P29376;P29597;P33981;P35590;P35916;P35968;P36888;P37173;P42681;P42684;P42685;P43405;P45983;P45985;P51451;P51617;P51955;P52333;P52564;P53667;P53671;P53779;P57059;P80192;Q00536;Q02763;Q02779;Q08345;Q12851;Q12866;Q13163;Q13233;Q13470;Q13546;Q13705;Q13882;Q14012;Q16584;Q16832;Q2M2I8;Q56UN5;Q6P3R8;Q7L7X3;Q8IVH8;Q8TBX8;Q92918;Q96NX5;Q9BVS4;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K8;Q9H3Y6;Q9NRP7;Q9NSY1;Q9UBE8;Q9UBF8;Q9UKE5;Q9UL54;Q9UM73;Q9UQ88;Q9UQB9;Q9Y2U5;Q9Y4K4;Q9Y616,"InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)",CUIHSIWYWATEQL-UHFFFAOYSA-N,CN(c1ccc2c(C)n(C)nc2c1)c3ccnc(Nc4ccc(C)c(c4)S(=O)(=O)N)n3,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers,Phase 2,,,NCT01027598,"Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer",,https://ClinicalTrials.gov/show/NCT01027598
literature,pembrolizumab,,Q15116,,,,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,Adults with previously untreated stage IIIB/IV EGFR-mutant NSCLC,lung cancers,Phase 1/2,30529597,"Twelve patients enrolled to receive pembrolizumab plus erlotinib and seven to receive pembrolizumab plus gefitinib. No dose-limiting toxicities or grade 5 events occurred. pembrolizumab plus erlotinib was feasible, with adverse events similar to those expected for monotherapy. However, pembrolizumab plus gefitinib was not feasible due to grade 3/4 liver toxicity in five of seven patients (71.4%), leading to permanent treatment discontinuation in four patients. The most frequently occurring treatment-related adverse events with pembrolizumab plus erlotinib were rash (50.0%), dermatitis acneiform, diarrhea, hypothyroidism, and pruritus (33.3% each). The objective response rate was 41.7%, including response in all four patients with programmed death ligand 1 expression 50% or greater.",NCT02039674,,,
clinicaltrials.gov,pertuzumab,1238538,P04626,,,,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers,Phase 2,,,NCT00855894,A Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer,PENGUIN,https://ClinicalTrials.gov/show/NCT00855894
clinicaltrials.gov,pictilisib,70473,O00329;O00459;P27986;P42336;P42338;P48736;Q8WYR1;Q92569,"InChI=1S/C23H27N7O3S2/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4,13-14H,5-12,15H2,1H3,(H,24,27)",LHNIIDJUOCFXAP-UHFFFAOYSA-N,CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)c5cccc6[nH]ncc56)CC1,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers,Phase 1,,,NCT00975182,A Study of the Safety and Pharmacology of GDC-0941 in Combination With Erlotinib in Patients With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT00975182
clinicaltrials.gov,pilaralisib,1348813,Q92569;Q8WYR1;P48736;P42338;P42336;P27986;O00459;O00329,"InChI=1S/C25H25ClN6O4S/c1-25(2,27)24(33)28-15-7-6-8-17(13-15)37(34,35)32-23-22(29-19-9-4-5-10-20(19)30-23)31-21-14-16(36-3)11-12-18(21)26/h4-14H,27H2,1-3H3,(H,28,33)(H,29,31)(H,30,32)",QINPEPAQOBZPOF-UHFFFAOYSA-N,COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c4cccc(NC(=O)C(C)(C)N)c4)c1,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers,Phase 1,,,NCT00692640,Safety Study of XL147 (SAR245408) in Combination With Erlotinib in Adults With Solid Tumors,,https://ClinicalTrials.gov/show/NCT00692640
clinicaltrials.gov,PM02734,,,,,,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,advanced solid cancers,Phase 1,,,NCT00884845,Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors,,https://ClinicalTrials.gov/show/NCT00884845
clinicaltrials.gov,RG1507,,,,,,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers,Phase 2,,,NCT00773383,A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy.,,https://ClinicalTrials.gov/show/NCT00773383
literature,rilotumumab,,P14210,,,,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,advanced non-small cell lung cancer,lung cancers,Phase 1/2,28472537,"Without indications for de-escalation, the recommended_phase_2 dose was dose level 0. Overall, 45 response-evaluable patients were enrolled (13 with squamous carcinoma, 32 with adenocarcinoma; 2 had confirmed EGFR mutations, 33 had confirmed wild-type [WT] EGFR, and 7 had KRAS mutations). The DCR for all patients was 60% (90% confidence interval [CI], 47.1%-71.3%). Median progression-free survival was 2.6 months (90% CI,_1.4-2.7 months), and median overall survival was 6.6 months (90% CI, 5.6-8.9 months). Among patients with WT EGFR, the DCR was 60.6% (90% CI, 46.3%-73.3%), median progression-free survival was 2.6 months (90% CI,_1.4-2.7 months), and median overall survival was 7.0 months (90% CI, 5.6-13.4 months). Elevated baseline levels of neuregulin_1_were associated with longer progression-free survival (hazard ratio, 0.41; 95% CI, 0.19-0.87), whereas elevated amphiregulin levels were associated with more rapid progression (hazard ratio, 2.14; 95% CI,_1.48-3.08).",,,,
clinicaltrials.gov,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers,Phase 2,,,NCT00609804,Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,,https://ClinicalTrials.gov/show/NCT00609804
clinicaltrials.gov,theophylline,1307,P30542;P29274;P29275;P0DMS8;Q13370;Q14432;Q08493;Q07343;P27815;Q08499,"InChI=1S/C7H8N4O2/c1-10-5-4(8-3-9-5)6(12)11(2)7(10)13/h3H,1-2H3,(H,8,9)",ZFXYFBGIUFBOJW-UHFFFAOYSA-N,CN1C(=O)N(C)c2nc[nH]c2C1=O,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,advanced solid cancers;lung cancers,Phase 1,,,NCT02080078,A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline,,https://ClinicalTrials.gov/show/NCT02080078
literature,tivantinib,1026778,P08581,"InChI=1S/C23H19N3O2/c27-22-19(16-11-24-18-9-2-1-7-14(16)18)20(23(28)25-22)17-12-26-10-4-6-13-5-3-8-15(17)21(13)26/h1-3,5,7-9,11-12,19-20,24H,4,6,10H2,(H,25,27,28)/t19-,20-/m0/s1",UCEQXRCJXIVODC-PMACEKPBSA-N,O=C1NC(=O)[C@H]([C@@H]1c2c[nH]c3ccccc23)c4cn5CCCc6cccc4c56,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,advanced solid malignancies,advanced solid cancers,Phase 1,22605616,"Thirty-two patients received combination treatment. Tivantinib serum concentrations were not dose-proportional. The most common (_ 20%) adverse events (AEs) regardless of causality included rash (n = 17), fatigue (n = 12), nausea (n = 10), abdominal pain (n = 10), diarrhea (n = 9), bradycardia (n = 9), and anemia (n = 7). AEs considered related to study treatment occurred in 28 patients (87.5%), and 5 patients (15.6%) had treatment-related serious AEs, including neutropenia, leukopenia, syncope, sinus bradycardia, and sick sinus syndrome. Fifteen of 32 patients (46.8%) had a partial response (n = 1) or stable disease (n = 14) as assessed by Response Evaluation Criteria in Solid Tumors. Six of 8 patients with nonsmall cell lung cancer achieved stable disease. The recommended phase 2 dose is tivantinib 360 mg BID plus erlotinib 150 mg QD.",,,,
clinicaltrials.gov,tosedostat,1027852,P15144;P55786;Q9H4A4;P53582;Q9UIQ6;Q9ULA0;Q07075;Q9NQW7;P28838;P50579;O43895;Q6P179;Q9NZ08;Q6Q4G3;Q8N6M6;Q6UB28;Q8NDH3;Q9HAU8;Q9NQH7,"InChI=1S/C21H30N2O6/c1-13(2)12-16(18(24)20(26)23-28)19(25)22-17(14-8-4-3-5-9-14)21(27)29-15-10-6-7-11-15/h3-5,8-9,13,15-18,24,28H,6-7,10-12H2,1-2H3,(H,22,25)(H,23,26)/t16-,17+,18+/m1/s1",FWFGIHPGRQZWIW-SQNIBIBYSA-N,CC(C)C[C@H]([C@H](O)C(=O)NO)C(=O)N[C@H](C(=O)OC1CCCC1)c2ccccc2,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers,Phase 1/2,,,NCT00522938,Clinical Trial of the Safety and Effectiveness of CHR-2797 With Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT00522938
clinicaltrials.gov,trastuzumab,4,P04626,,,,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,breast cancers,Phase 1/2,,,NCT00033514,Trastuzumab and Erlotinib as First-Line Therapy in Treating Women With Metastatic Breast Cancer Associated With HER2/Neu Overexpression,,https://ClinicalTrials.gov/show/NCT00033514
clinicaltrials.gov,U3-1287,,,,,,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers,Phase 1/2,,,NCT01211483,Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT01211483
clinicaltrials.gov,volociximab,,P08648;P05556,,,,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers,Phase 2,,,NCT00278187,Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT00278187
clinicaltrials.gov,voxtalisib,1279426,O00329;O00459;P27986;P42336;P42338;P48736;Q8WYR1;Q92569;P42345,"InChI=1S/C13H14N6O/c1-3-19-11-8(7(2)16-13(14)17-11)6-9(12(19)20)10-4-5-15-18-10/h4-6H,3H2,1-2H3,(H,15,18)(H2,14,16,17)",RGHYDLZMTYDBDT-UHFFFAOYSA-N,CCN1C(=O)C(=Cc2c(C)nc(N)nc12)c3cc[nH]n3,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,,lung cancers,Phase 1,,,NCT00777699,Safety Study of XL765 (SAR245409) in Combination With Erlotinib in Adults With Solid Tumors,,https://ClinicalTrials.gov/show/NCT00777699
clinicaltrials.gov,AEE788,52431,P00533;P04626;P17948;P35968,"InChI=1S/C27H32N6/c1-3-32-13-15-33(16-14-32)18-21-9-11-23(12-10-21)25-17-24-26(28-19-29-27(24)31-25)30-20(2)22-7-5-4-6-8-22/h4-12,17,19-20H,3,13-16,18H2,1-2H3,(H2,28,29,30,31)/t20-/m1/s1",OONFNUWBHFSNBT-HXUWFJFHSA-N,CCN1CCN(Cc2ccc(cc2)c3cc4c(N[C@H](C)c5ccccc5)ncnc4[nH]3)CC1,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,,brain cancers;central nervous system cancers,Phase 1/2,,,NCT00107237,AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme,,https://ClinicalTrials.gov/show/NCT00107237
clinicaltrials.gov,apalutamide,,,,,,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,,prostate cancers,Phase 1,,,NCT02106507,ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate,,https://ClinicalTrials.gov/show/NCT02106507
literature,axitinib,600224,P35968;P17948;P35916,"InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+",RITAVMQDGBJQJZ-FMIVXFBMSA-N,CNC(=O)c1ccccc1Sc2ccc3c(\C=C\c4ccccn4)n[nH]c3c2,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,Patients (pts) with advanced cancers were enrolled in an escalation_phase_I study to investigate the safety of the_combination. Pharmacokinetic profile and functional vascular imaging were performed. An extension to pts with naive metastatic renal cell carcinoma (MRCC) was explored.,advanced solid cancers;kidney cancers,Phase 1,28886476,"15 pts were included over three different dose levels (DLs); DL 0: AX 3_mg BID (twice daily)/EV 5_mg OD (once daily); DL_1: AX 5_mg BID/EV 5_mg OD and DL 2: AX 5_mg BID/EV 10_mg OD for 28 d. One dose-limiting toxicity (DLT) was reported at DL 0: grade (Gr) III diarrhoea and one DLT at DL 2: Gr_III asthenia. Three severe adverse events (AEs) in two pts were unexpected: jaw osteonecrosis, recurrent renal failure and cardiomyopathy. Maximum tolerated dose (MTD) was level 2. After 1st cycle, Gr_III or Gr_II AEs of interest were mainly asthenia, diarrhoea and anorexia. All pts but one showed tumour shrinkage. Partial responses (PRs) were seen in one pt with bladder carcinoma and in one pt in 1st line MRCC in the escalating_phase. In the extension_phase_in naive MRCC treated at MTD, five pts had a PR and one pt had a prolonged stable disease.",,,,
clinicaltrials.gov,bevacizumab,11,P15692,,,,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,,advanced solid cancers;central nervous system cancers,Phase 1,,,NCT00756340,A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors,,https://ClinicalTrials.gov/show/NCT00756340
clinicaltrials.gov,bevacizumab,11,P15692,,,,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,,bowel cancers,Phase 2,,,NCT00597506,Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus,BEV/EV,https://ClinicalTrials.gov/show/NCT00597506
clinicaltrials.gov,bevacizumab,11,P15692,,,,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,,kidney cancers,Phase 2,,,NCT00323739,Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma,,https://ClinicalTrials.gov/show/NCT00323739
literature,bevacizumab,11,P15692,,,,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,metastatic melanoma,skin cancers,Phase 2,20564157,"Fifty-seven patients with metastatic melanoma received a median of 4 treatment cycles (range, 1-14+ cycles). Seven patients (12%) achieved major responses, whereas 33 patients (58%) were found to have stable disease at the time of first evaluation. The median progression-free and overall survivals were 4 months and 8.6 months, respectively. Approximately 43% of patients were alive after 12 months of follow-up. The treatment regimen was well tolerated by the majority of patients.",,,,
literature,bevacizumab,11,P15692,,,,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,"women with recurrent or persistent ovarian, fallopian tube or primary peritoneal cancer",female cancers;ovarian cancers,Phase 2,30177462,"150 patients were randomized to BV with (n_=_75) and without (n_=_75) EV. Arms were well-balanced for age (median 63: range 28-92), PS (0: 73%, 1-2: 27%), prior regimens (1: 37%, 2: 47%, 3: 16%), prior BV (11%), PFI (<6mos: 65%) and measurable disease (81%). The BV_+_EV vs BV median PFS was 5.9 vs 4.5_months (hazard ratio [HR] 0.95 (95% CI, 0.66-1.37, p_=_0.39)). Median OS was 16.6 vs 17.3_months (HR 1.16 (95% CI, 0.72-1.87, p_=_0.55). Objective measurable responses were higher with BV_+_EV (22% vs 12%). Study removal due to toxicity was higher with BV_+_EV (29% vs 12%). Toxicity (≥grade 3) from BV_+_EV were ""other GI (mucositis)"" (23 vs 1%) and ""metabolic/nutrition"" (19 vs. 7%); common ≥_grade 2 toxicities with BV_+_EV were cytopenia, nausea, fatigue and rash",,,,
literature,bevacizumab,11,P15692,,,,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,"women with recurrent or persistent ovarian, fallopian tube or primary peritoneal cancer",female cancers;ovarian cancers,Phase 2,30177462,"150 patients were randomized to BV with (n_=_75) and without (n_=_75) EV. Arms were well-balanced for age (median 63: range 28-92), PS (0: 73%, 1-2: 27%), prior regimens (1: 37%, 2: 47%, 3: 16%), prior BV (11%), PFI (<6mos: 65%) and measurable disease (81%). The BV_+_EV vs BV median PFS was 5.9 vs 4.5_months (hazard ratio [HR] 0.95 (95% CI, 0.66-1.37, p_=_0.39)). Median OS was 16.6 vs 17.3_months (HR 1.16 (95% CI, 0.72-1.87, p_=_0.55). Objective measurable responses were higher with BV_+_EV (22% vs 12%). Study removal due to toxicity was higher with BV_+_EV (29% vs 12%). Toxicity (≥grade 3) from BV_+_EV were ""other GI (mucositis)"" (23 vs 1%) and ""metabolic/nutrition"" (19 vs. 7%); common ≥_grade 2 toxicities with BV_+_EV were cytopenia, nausea, fatigue and rash",,,,
clinicaltrials.gov,BEZ235,10990,O00329;O00459;P27986;P42336;P42338;P48736;Q8WYR1;Q92569;P42345,"InChI=1S/C7H6O2/c8-7(9)6-4-2-1-3-5-6/h1-5H,(H,8,9)",WPYMKLBDIGXBTP-UHFFFAOYSA-N,OC(=O)c1ccccc1,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,,advanced solid cancers,Phase 1/2,,,NCT01508104,Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT01508104
clinicaltrials.gov,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,,leukemia;lymphoma,Phase 1,,,NCT00671112,Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma,,https://ClinicalTrials.gov/show/NCT00671112
clinicaltrials.gov,buparlisib,962639,O00329;O00459;P27986;P42336;P42338;P48736;Q8WYR1;Q92569,"InChI=1S/C18H21F3N6O2/c19-18(20,21)13-9-15(22)23-11-12(13)14-10-16(26-1-5-28-6-2-26)25-17(24-14)27-3-7-29-8-4-27/h9-11H,1-8H2,(H2,22,23)",CWHUFRVAEUJCEF-UHFFFAOYSA-N,Nc1cc(c(cn1)c2cc(nc(n2)N3CCOCC3)N4CCOCC4)C(F)(F)F,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,,lung cancers,Phase 1,,,NCT01470209,A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies,,https://ClinicalTrials.gov/show/NCT01470209
clinicaltrials.gov,CB-839,,,,,,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,,kidney cancers,Phase 2,,,NCT03163667,CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC,,https://ClinicalTrials.gov/show/NCT03163667
literature,dactolisib,1081384,O00329;O00459;P27986;P42336;P42338;P48736;Q8WYR1;Q92569;P42345,"InChI=1S/C30H23N5O/c1-30(2,18-31)22-9-11-23(12-10-22)35-28-24-15-19(21-14-20-6-4-5-7-25(20)32-16-21)8-13-26(24)33-17-27(28)34(3)29(35)36/h4-17H,1-3H3",JOGKUKXHTYWRGZ-UHFFFAOYSA-N,CN1C(=O)N(c2ccc(cc2)C(C)(C)C#N)c3c1cnc4ccc(cc34)c5cnc6ccccc6c5,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,Patients with Advanced Solid Malignancies,advanced solid cancers,Phase 1b,28357727,"Common toxicities observed included fatigue, diarrhea, nausea, mucositis, and elevated liver enzymes. No confirmed responses were observed. BEZ235 pharmacokinetics exhibited dose-proportional increases in Cmax_and AUC0-24_over the three doses, with high inter-individual variability. Non-compartmental and population pharmacokinetic-based simulations indicated significant increases in everolimus Cmax_and AUC0-24_on day 28 and decreased clearance to 13.41_L/hr.",,,,
clinicaltrials.gov,dasatinib,375,O00238;O00506;O14965;O14976;O15197;O15264;O43283;O43318;O43353;O60674;O94804;O95819;P00519;P00533;P04049;P04626;P06239;P06241;P07333;P07947;P07948;P07949;P08631;P08684;P09619;P09769;P0C1S8;P10721;P11274;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P21860;P22607;P27037;P29317;P29320;P29322;P29323;P29597;P30291;P35968;P36507;P36888;P36894;P36896;P36897;P37023;P37173;P41240;P42680;P42681;P42684;P42685;P43405;P49674;P51451;P51813;P51955;P52333;P53667;P53671;P53778;P54753;P54756;P54760;P54762;P54764;P57059;Q01538;Q02750;Q04771;Q06187;Q07912;Q08345;Q09013;Q12851;Q13043;Q13163;Q13705;Q13882;Q15303;Q15569;Q15759;Q16539;Q16832;Q52WX2;Q56UN5;Q59H18;Q5VT25;Q6DT37;Q6PHR2;Q86Y07;Q8IVH8;Q8N4C8;Q8NG66;Q8NI60;Q8TDR2;Q92918;Q96GD4;Q99640;Q99759;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K8;Q9H3Y6;Q9NRP7;Q9NYL2;Q9P289;Q9P2K8;Q9UBE8;Q9UF33;Q9UKE5;Q9UL54;Q9Y2K2;Q9Y2U5;Q9Y4K4;Q9Y5S2;Q9Y6R4,"InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)",ZBNZXTGUTAYRHI-UHFFFAOYSA-N,Cc1nc(Nc2ncc(s2)C(=O)Nc3c(C)cccc3Cl)cc(n1)N4CCN(CCO)CC4,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,,brain cancers,Phase 2,,,NCT03352427,Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring PDGFR/FGFR Alterations,,https://ClinicalTrials.gov/show/NCT03352427
clinicaltrials.gov,dovitinib,31361,O00444;O00506;O14578;O14730;O14757;O14976;O15111;O15146;O15197;O43283;O43293;O43318;O60285;O60331;O60674;O75116;O75385;O75582;O75676;O75716;O75914;O94768;O94804;O95819;O95835;P00519;P00533;P04629;P06239;P06241;P07333;P07947;P07948;P07949;P08631;P09619;P09769;P10721;P11362;P11802;P12931;P15735;P16234;P17948;P19525;P19784;P21802;P22455;P22607;P23443;P23458;P27448;P29597;P30291;P30530;P32298;P35590;P35916;P35968;P36507;P36888;P42685;P49759;P49760;P49841;P50613;P51451;P51617;P51812;P51955;P51957;P52333;P54646;P57058;P68400;P78356;P78362;P80192;Q00536;Q00537;Q02750;Q04759;Q06418;Q07002;Q08345;Q08881;Q12851;Q12852;Q12866;Q13043;Q13131;Q13163;Q13188;Q13464;Q13523;Q13546;Q13873;Q14164;Q14680;Q15208;Q15349;Q15418;Q15746;Q15831;Q15835;Q16288;Q16512;Q16513;Q16584;Q16620;Q16816;Q16832;Q2M2I8;Q32MK0;Q52WX2;Q56UN5;Q5S007;Q6P3R8;Q6PHR2;Q7KZI7;Q86UE8;Q86YV6;Q86Z02;Q8IVH8;Q8IY84;Q8IYT8;Q8N4C8;Q8N5S9;Q8NFD2;Q8TD19;Q8TDX7;Q8WTQ7;Q92630;Q92772;Q92918;Q96BR1;Q96GD4;Q96L34;Q96SB4;Q99755;Q9BRS2;Q9BVS4;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2X6;Q9H422;Q9HAZ1;Q9HC98;Q9NRM7;Q9NSY1;Q9NWZ3;Q9NYY3;Q9P0L2;Q9P289;Q9P2K8;Q9UEE5;Q9UEW8;Q9UHD2;Q9UK32;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2H9;Q9Y2U5;Q9Y4K4;Q9Y6E0;Q9Y6R4,"InChI=1S/C21H21FN6O/c1-27-7-9-28(10-8-27)12-5-6-14-16(11-12)25-20(24-14)18-19(23)17-13(22)3-2-4-15(17)26-21(18)29/h2-6,11H,7-10H2,1H3,(H,24,25)(H3,23,26,29)",PIQCTGMSNWUMAF-UHFFFAOYSA-N,CN1CCN(CC1)c2ccc3nc([nH]c3c2)C4=C(N)c5c(F)cccc5NC4=O,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,,kidney cancers,Phase 1,,,NCT01714765,Dose Escalation Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal Cancer,DEVELOP,https://ClinicalTrials.gov/show/NCT01714765
clinicaltrials.gov,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,,breast cancers,Phase 1,,,NCT00574366,Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer,,https://ClinicalTrials.gov/show/NCT00574366
clinicaltrials.gov,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,,head and neck cancers,Phase 2,,,NCT00942734,Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT00942734
clinicaltrials.gov,IPI-504,747696,P07900;P08238,"InChI=1S/C31H45N3O8/c1-8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30(38)34-22(28(21)37)16-23(26)35/h8-11,15-17,19,24-25,27,29,33,35-37H,1,12-14H2,2-7H3,(H2,32,39)(H,34,38)/b11-9-,18-10+,20-15+/t17-,19+,24+,25+,27-,29+/m1/s1",OAKGNIRUXAZDQF-TXHRRWQRSA-N,CO[C@H]1C[C@H](C)Cc2c(O)c(NC(=O)\C(=C\C=C/[C@H](OC)[C@@H](OC(=O)N)\C(=C\[C@H](C)[C@H]1O)\C)\C)cc(O)c2NCC=C,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,,lung cancers,Phase 1/2,,,NCT01427946,Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT01427946
clinicaltrials.gov,itacitinib,1947652,P23458,"InChI=1S/C26H23F4N9O/c27-20-18(1-7-32-22(20)26(28,29)30)24(40)37-9-3-17(4-10-37)38-13-25(14-38,5-6-31)39-12-16(11-36-39)21-19-2-8-33-23(19)35-15-34-21/h1-2,7-8,11-12,15,17H,3-5,9-10,13-14H2,(H,33,34,35)",KTBSXLIQKWEBRB-UHFFFAOYSA-N,Fc1c(ccnc1C(F)(F)F)C(=O)N2CCC(CC2)N3CC(CC#N)(C3)n4cc(cn4)c5ncnc6[nH]ccc56,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,,lymphoma,Phase 1/2,,,NCT03697408,Itacitinib + Everolimus in Hodgkin Lymphoma,,https://ClinicalTrials.gov/show/NCT03697408
clinicaltrials.gov,itacitinib,1947652,P23458,"InChI=1S/C26H23F4N9O/c27-20-18(1-7-32-22(20)26(28,29)30)24(40)37-9-3-17(4-10-37)38-13-25(14-38,5-6-31)39-12-16(11-36-39)21-19-2-8-33-23(19)35-15-34-21/h1-2,7-8,11-12,15,17H,3-5,9-10,13-14H2,(H,33,34,35)",KTBSXLIQKWEBRB-UHFFFAOYSA-N,Fc1c(ccnc1C(F)(F)F)C(=O)N2CCC(CC2)N3CC(CC#N)(C3)n4cc(cn4)c5ncnc6[nH]ccc56,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,,lymphoma,Phase 1/2,,,NCT03697408,Itacitinib + Everolimus in Hodgkin Lymphoma,,https://ClinicalTrials.gov/show/NCT03697408
clinicaltrials.gov,lenalidomide,718,O14920,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,Nc1cccc2C(=O)N(Cc12)C3CCC(=O)NC3=O,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,,other,Phase 1,,,NCT01218555,Study of Everolimus (RAD001) in Combination With Lenalidomide,,https://ClinicalTrials.gov/show/NCT01218555
clinicaltrials.gov,lenvatinib,802872,P35968;P17948;P35916,"InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)",WOSKHXYHFSIKNG-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(=O)N,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,,advanced solid cancers;central nervous system cancers,Phase 1/2,,,NCT03245151,"Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors",,https://ClinicalTrials.gov/show/NCT03245151
clinicaltrials.gov,lenvatinib,802872,P35968;P17948;P35916,"InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)",WOSKHXYHFSIKNG-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(=O)N,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,,kidney cancers,Phase 2,,,NCT03173560,Trial to Assess Safety and Efficacy of Lenvatinib in Combination With Everolimus in Participants With Renal Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT03173560
literature,lenvatinib,802872,P35968;P17948;P35916,"InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)",WOSKHXYHFSIKNG-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(=O)N,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,metastatic renal cell carcinoma,liver cancers,Phase 2,26482279,"Between March 16, 2012, and June 19, 2013, 153 patients were randomly allocated to receive either the combination of lenvatinib plus everolimus (n=51), single-agent lenvatinib (n=52), or single-agent everolimus (n=50). Lenvatinib plus everolimus significantly prolonged progression-free survival compared with everolimus alone (median 14à6 months [95% CI 5à9-20à1] vs 5à5 months [3à5-7à1]; hazard ratio [HR] 0à40, 95% CI 0à24-0à68; p=0à0005), but not compared with lenvatinib alone (7à4 months [95% CI 5à6-10à2]; HR 0à66, 95% CI 0à30-1à10; p=0à12). Single-agent lenvatinib significantly prolonged progression-free survival compared with everolimus alone (HR 0à61, 95% CI 0à38-0à98; p=0à048). Grade 3 and 4 events occurred in fewer patients allocated single-agent everolimus (25 [50%]) compared with those assigned lenvatinib alone (41 [79%]) or lenvatinib plus everolimus (36 [71%]). The most common grade 3 or 4 treatment-emergent adverse event in patients allocated lenvatinib plus everolimus was diarrhoea (ten [20%]), in those assigned single-agent lenvatinib it was proteinuria (ten [19%]), and in those assigned single-agent everolimus it was anaemia (six [12%]). Two deaths were deemed related to study drug, one cerebral haemorrhage in the lenvatinib plus everolimus group and one myocardial infarction with single-agent lenvatinib.",,,,
clinicaltrials.gov,linsitinib,678359,P06213;P08069,"InChI=1S/C26H23N5O/c1-26(32)14-19(15-26)25-30-22(23-24(27)28-11-12-31(23)25)18-8-7-17-9-10-20(29-21(17)13-18)16-5-3-2-4-6-16/h2-13,19,32H,14-15H2,1H3,(H2,27,28)/t19-,26+",PKCDDUHJAFVJJB-VLZXCDOPSA-N,C[C@@]1(O)C[C@@H](C1)c2nc(c3ccc4ccc(nc4c3)c5ccccc5)c6c(N)nccn26,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,,bowel cancers,Phase 1,,,NCT01154335,Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer,,https://ClinicalTrials.gov/show/NCT01154335
clinicaltrials.gov,niraparib,919241,Q9UGN5;P09874,"InChI=1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)/t14-/m1/s1",PCHKPVIQAHNQLW-CQSZACIVSA-N,NC(=O)c1cccc2cn(nc12)c3ccc(cc3)[C@@H]4CCCNC4,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,,breast cancers;ovarian cancers,Phase 1,,,NCT03154281,Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Ovarian and Breast,,https://ClinicalTrials.gov/show/NCT03154281
clinicaltrials.gov,panobinostat,523996,Q9BY41;Q969S8;O15379;P56524;Q8WUI4;Q9UQL6;Q9UKV0;Q13547;Q92769;Q9UBN7;Q96DB2,"InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+",FPOHNWQLNRZRFC-ZHACJKMWSA-N,Cc1[nH]c2ccccc2c1CCNCc3ccc(\C=C\C(=O)NO)cc3,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,,brain cancers,Phase 2,,,NCT03632317,A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas,,https://ClinicalTrials.gov/show/NCT03632317
clinicaltrials.gov,panobinostat,523996,Q9BY41;Q969S8;O15379;P56524;Q8WUI4;Q9UQL6;Q9UKV0;Q13547;Q92769;Q9UBN7;Q96DB2,"InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+",FPOHNWQLNRZRFC-ZHACJKMWSA-N,Cc1[nH]c2ccccc2c1CCNCc3ccc(\C=C\C(=O)NO)cc3,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,,brain cancers,Phase 2,,,NCT03632317,A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas,,https://ClinicalTrials.gov/show/NCT03632317
clinicaltrials.gov,pazopanib,200268,O00238;O00444;O14965;O14976;O15197;O43353;O60331;O60674;O75716;O94804;O95819;P00519;P04049;P06239;P06241;P07332;P07333;P07947;P07948;P07949;P08581;P08631;P08922;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P16591;P17948;P19525;P21127;P21802;P22455;P22607;P27448;P29376;P29597;P33981;P35590;P35916;P35968;P36888;P37173;P42681;P42684;P42685;P43405;P45983;P45985;P51451;P51617;P51955;P52333;P52564;P53667;P53671;P53779;P57059;P80192;Q00536;Q02763;Q02779;Q08345;Q12851;Q12866;Q13163;Q13233;Q13470;Q13546;Q13705;Q13882;Q14012;Q16584;Q16832;Q2M2I8;Q56UN5;Q6P3R8;Q7L7X3;Q8IVH8;Q8TBX8;Q92918;Q96NX5;Q9BVS4;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K8;Q9H3Y6;Q9NRP7;Q9NSY1;Q9UBE8;Q9UBF8;Q9UKE5;Q9UL54;Q9UM73;Q9UQ88;Q9UQB9;Q9Y2U5;Q9Y4K4;Q9Y616,"InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)",CUIHSIWYWATEQL-UHFFFAOYSA-N,CN(c1ccc2c(C)n(C)nc2c1)c3ccnc(Nc4ccc(C)c(c4)S(=O)(=O)N)n3,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,,advanced solid cancers,Phase 1,,,NCT01430572,Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients,,https://ClinicalTrials.gov/show/NCT01430572
clinicaltrials.gov,pazopanib,200268,O00238;O00444;O14965;O14976;O15197;O43353;O60331;O60674;O75716;O94804;O95819;P00519;P04049;P06239;P06241;P07332;P07333;P07947;P07948;P07949;P08581;P08631;P08922;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P16591;P17948;P19525;P21127;P21802;P22455;P22607;P27448;P29376;P29597;P33981;P35590;P35916;P35968;P36888;P37173;P42681;P42684;P42685;P43405;P45983;P45985;P51451;P51617;P51955;P52333;P52564;P53667;P53671;P53779;P57059;P80192;Q00536;Q02763;Q02779;Q08345;Q12851;Q12866;Q13163;Q13233;Q13470;Q13546;Q13705;Q13882;Q14012;Q16584;Q16832;Q2M2I8;Q56UN5;Q6P3R8;Q7L7X3;Q8IVH8;Q8TBX8;Q92918;Q96NX5;Q9BVS4;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K8;Q9H3Y6;Q9NRP7;Q9NSY1;Q9UBE8;Q9UBF8;Q9UKE5;Q9UL54;Q9UM73;Q9UQ88;Q9UQB9;Q9Y2U5;Q9Y4K4;Q9Y616,"InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)",CUIHSIWYWATEQL-UHFFFAOYSA-N,CN(c1ccc2c(C)n(C)nc2c1)c3ccnc(Nc4ccc(C)c(c4)S(=O)(=O)N)n3,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,,kidney cancers,Phase 1,,,NCT01184326,Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer,,https://ClinicalTrials.gov/show/NCT01184326
clinicaltrials.gov,ribociclib,,P11802;Q00534,"InChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28)",RHXHGRAEPCAFML-UHFFFAOYSA-N,CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N4CCNCC4)nc2n1C5CCCC5,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,,brain cancers,Phase 1,,,NCT03355794,A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG),,https://ClinicalTrials.gov/show/NCT03355794
clinicaltrials.gov,ribociclib,,P11802;Q00534,"InChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28)",RHXHGRAEPCAFML-UHFFFAOYSA-N,CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N4CCNCC4)nc2n1C5CCCC5,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,,other,Phase 2,,,NCT03070301,A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors,,https://ClinicalTrials.gov/show/NCT03070301
clinicaltrials.gov,ribociclib,,P11802;Q00534,"InChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28)",RHXHGRAEPCAFML-UHFFFAOYSA-N,CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N4CCNCC4)nc2n1C5CCCC5,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,,soft tissue cancers,Phase 2,,,NCT03114527,Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS),,https://ClinicalTrials.gov/show/NCT03114527
clinicaltrials.gov,ribociclib,,P11802;Q00534,"InChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28)",RHXHGRAEPCAFML-UHFFFAOYSA-N,CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N4CCNCC4)nc2n1C5CCCC5,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,Glioblastoma Multiforme|Glioma of Brain,,Early Phase 1,,,NCT03834740,,,
clinicaltrials.gov,RX-0201,,,,,,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,,kidney cancers,Phase 1/2,,,NCT02089334,"Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer",,https://ClinicalTrials.gov/show/NCT02089334
clinicaltrials.gov,SOM230,1054651,P30872;P30874;P32745;P35346,"InChI=1S/C58H66N10O9/c59-27-13-12-22-46-52(69)64-47(30-38-23-25-42(26-24-38)76-36-39-16-6-2-7-17-39)53(70)66-49(31-37-14-4-1-5-15-37)57(74)68-35-43(77-58(75)61-29-28-60)33-50(68)55(72)67-51(40-18-8-3-9-19-40)56(73)65-48(54(71)63-46)32-41-34-62-45-21-11-10-20-44(41)45/h1-11,14-21,23-26,34,43,46-51,62H,12-13,22,27-33,35-36,59-60H2,(H,61,75)(H,63,71)(H,64,69)(H,65,73)(H,66,70)(H,67,72)/t43-,46+,47-,48-,49-,50+,51-/m0/s1",,,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,,other,Phase 1,,,NCT00804336,Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors,,https://ClinicalTrials.gov/show/NCT00804336
clinicaltrials.gov,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,,kidney cancers,Phase 1/2,,,NCT00392821,Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer,,https://ClinicalTrials.gov/show/NCT00392821
clinicaltrials.gov,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,,other,Phase 1,,,NCT00942682,Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors,,https://ClinicalTrials.gov/show/NCT00942682
literature,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,unresectable high-grade osteosarcoma,bone cancers,Phase 2,25498219,"We enrolled 38 patients between June 16, 2011, and June 4, 2013. 17 (45%; 95% CI 28-61) of 38 patients were progression free at 6 months. Toxic effects led to dose reductions, or short interruptions, or both in 25 (66%) of 38 patients and permanent discontinuation for two (5%) patients. The most common grade 3-4 adverse events were lymphopenia and hypophosphataemia each in six (16%) patients, hand and foot syndrome in five (13%), thrombocytopenia in four (11%), and fatigue, oral mucositis, diarrhoea, and anaemia each in two (5%). One patient (3%) had a grade 3 pneumothorax that required trans-thoracic drainage, and that recurred at the time of disease progression. This was reported as a serious adverse event related to the study drugs in both instances. No other serious adverse events were reported during the trial. There were no treatment-related deaths.",,,,
literature,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,Metastatic clear cell renal cell carcinoma,kidney cancers,Phase 1,21387258,"Twenty patients with a median age of 65 years received therapy in 3 cohorts. Dose level 1 was comprised of everolimus at a dose of 2.5 mg daily and sorafenib at a dose of 400 mg twice daily (6 patients), dose level 2 was comprised of everolimus at a dose of 5 mg daily and sorafenib at a dose of 400 mg twice daily (8 patients), and dose level 3 was comprised of everolimus at a dose of 10 mg daily and sorafenib at a dose of 200 mg twice daily (6 patients). DLTs included grade 4 (according to National Cancer Institute Common Terminology Criteria for Adverse Events [version 3.0]) hyperuricemia with grade 2 gout and grade 3 lipase associated with grade 2 pancreatitis at dose level 2, and grade 3 rash in 2 patients at dose level 3. Dose level 2 (everolimus at a dose of 5 mg daily and sorafenib at a dose of 400 mg twice daily) was established as the maximum tolerated dose. Treatment-related adverse events occurring in >20% of patients included diarrhea, hand-foot syndrome, hypertension, hypophosphatemia, hypothyroidism, and rash. Five of 20 patients achieved Response Evaluation Criteria In Solid Tumors (RECIST)-defined partial responses, all of which occurred in patients without a history of prior systemic therapy. Seven of 8 patients treated at dose level 2 experienced a partial response or stable disease. Pharmacokinetic analysis revealed no interaction between everolimus and sorafenib.",,,,
literature,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,Advanced renal cell cancer,kidney cancers,Phase 1,22169794,"In cohort 1, 2 of 6 patients experienced dose-limited toxicity (DLT) of thrombocytopenia/leukopenia and pneumonitis. In cohort 2, 1 of 6 patients experienced a DLT of pulmonary embolism, and the 3 patients in cohort 3 experienced no DLTs. The MTD was 10 mg/400 mg. Common adverse events included grade 1/2 hand-foot syndrome. Using Response Evaluation Criteria in Solid Tumors (RECIST), 1 patient achieved a pathologic complete response (CR), 1 patient achieved a radiographic CR, and 1 patient achieved a surgical CR. Seven patients achieved stable disease; 10 patients had decreased fluorine-18 fluorodeoxyglucose uptake. Median progressive-free survival was 5.6 months; overall survival was 7.9 months.",,,,
literature,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,Advanced hepatocellular carcinoma,liver cancers,Phase 1,23928403,"Thirty patients were enrolled; 25 were evaluable for MTD determination. One out of 12 patients treated with everolimus 2.5mg once daily and 6 out of 13 patients treated with everolimus 5.0mg once daily experienced a dose-limiting toxicity, most commonly thrombocytopenia (n=5). All patients experienced 1 adverse event, most commonly diarrhea (66.7%), hand-foot skin reaction (66.7%), and thrombocytopenia (50.0%). Best overall response was stable disease (62.5% and 42.9% in the 2.5-mg and 5.0-mg cohorts, respectively). Median time to progression and overall survival in the 2.5-mg cohort were 4.5 months and 7.4 months, respectively, and 1.8 months and 11.7 months, respectively, in the 5.0-mg cohort.",,,,
literature,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,Advanced neuroendocrine tumors ,other,Phase 1,23475104,"One patient in Cohort 1 experienced DLT (grade 3 skin rash); the cohort was expanded to 6 patients with no further DLTs. All 3 patients in Cohort 2 experienced DLT, consisting of thrombocytopenia, hand-foot skin reaction, and rash/allergic reaction. Sorafenib 200 mg twice daily in combination with everolimus 10 mg daily was established as the MTD. Independently reviewed best objective responses revealed that 62 % of patients had some degree of tumor shrinkage. By RECIST, we observed partial response in 1 patient, stable disease in 13 patients, and progressive disease in 3 patients.",,,,
clinicaltrials.gov,trastuzumab,4,P04626,,,,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,,breast cancers,Phase 1/2,,,NCT00317720,Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer,,https://ClinicalTrials.gov/show/NCT00317720
clinicaltrials.gov,vandetanib,551660,O00238;O00444;O14578;O14976;O15197;O43353;O75116;O94804;O95819;P00519;P00533;P04626;P06239;P06241;P07333;P07947;P07948;P07949;P08581;P08631;P09619;P09769;P10721;P11362;P12931;P15735;P16234;P17948;P21709;P21802;P21860;P22455;P22607;P23443;P29317;P29320;P29322;P29323;P29376;P30530;P35590;P35916;P35968;P36507;P36888;P37023;P41240;P42681;P42684;P42685;P49674;P50613;P51451;P51617;P54756;P54760;P54762;P54764;P57058;P57059;P57078;Q02750;Q02763;Q04771;Q04912;Q06187;Q06418;Q08345;Q12851;Q12866;Q13131;Q13163;Q13882;Q15303;Q15375;Q15418;Q15569;Q16659;Q16816;Q16832;Q56UN5;Q59H18;Q5VT25;Q6DT37;Q6PHR2;Q8IVH8;Q8N4C8;Q8NI60;Q8TDR2;Q8WU08;Q92918;Q96D53;Q9BUB5;Q9BYT3;Q9H0K1;Q9H2G2;Q9H3Y6;Q9HBH9;Q9NWZ3;Q9NYL2;Q9UF33;Q9UK32;Q9UKE5;Q9UM73;Q9UQB9;Q9Y2K2;Q9Y4K4;Q9Y5S2;Q9Y6R4,"InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)",UHTHHESEBZOYNR-UHFFFAOYSA-N,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC4CCN(C)CC4,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,,,Phase 1,,,NCT01582191,"A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer",,https://ClinicalTrials.gov/show/NCT01582191
clinicaltrials.gov,SHR-1210,841778,,"InChI=1S/C23H27FN4O2/c1-4-27(5-2)10-11-28-9-8-19-21(23(28)30)14(3)20(25-19)13-17-16-12-15(24)6-7-18(16)26-22(17)29/h6-7,12-13,25H,4-5,8-11H2,1-3H3,(H,26,29)/b17-13-",GKEYKDOLBLYGRB-LGMDPLHJSA-N,CCN(CC)CCN1CCc2[nH]c(\C=C\3/C(=O)Nc4ccc(F)cc34)c(C)c2C1=O,famitinib,,,,,,Renal Cell Carcinoma|Urothelial Carcinoma|Cervical Cancer|Ovarian Cancer Recurrent|Endometrial Cancer,,Phase 2,,,NCT03827837,,,
literature,dacomitinib,1055487,P00533;P04626;P21860;Q15303;P00533;P04626;Q15303,"InChI=1S/C24H25ClFN5O2/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29)/b6-5+",LVXJQMNHJWSHET-AATRIKPKSA-N,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN4CCCCC4,figitumumab,,P08069,,,,advanced solid tumors,advanced solid cancers,Phase 1,27733479,"Of the 74 patients enrolled, the most common malignancies were non-small cell lung cancer (24.3%) and colorectal cancer (14.9%). The most common treatment-related adverse events in the 71 patients who received treatment across five dose levels were diarrhea (59.2%), mucosal inflammation (47.9%), and fatigue and acneiform dermatitis (45.1% each). The most common dose-limiting toxicity was mucosal inflammation. Dosing schedules of dacomitinib 10 or 15 mg daily plus figitumumab 20 mg/kg every 3 weeks after a figitumumab loading dose were tolerated by patients over multiple cycles and considered recommended doses for further evaluation. Objective responses were seen in patients with adenoid cystic carcinoma, ovarian carcinoma, and salivary gland cancer. Pharmacokinetic analysis did not show any significant drug-drug interaction. In the adenoid cystic carcinoma xenograft model, figitumumab exerted significant antitumor activity, whereas dacomitinib did not. Figitumumab-sensitive tumors showed downregulation of genes in the insulin-like growth factor receptor 1 pathway.",,,,
clinicaltrials.gov,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,figitumumab,,P08069,,,,,soft tissue cancers,Phase 1,,,NCT00927966,"RAD001 in Combination With CP-751,871 in Patients Wtih Advanced Sarcomas and Other Malignant Neoplasms",,https://ClinicalTrials.gov/show/NCT00927966
literature,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,figitumumab,,P08069,,,,advanced sarcomas and other solid tumors,soft tissue cancers;advanced solid cancers,Phase 1,21177764,"No DLTs were observed in the initial cohort during cycle one, therefore full dose figitumumab and everolimus was declared the RP2D. In total, 21 patients were enrolled on study. Most toxicities were grade 1 or 2, and were similar to reported toxicities of the single agents. Mucositis was the most frequently observed grade 3 toxicity. Median time on study was 104 days (range 17-300). Of 18 patients evaluable for response, best response was partial response in 1 patient with malignant solitary fibrous tumor and, stable disease in 15 patients. There were no apparent pharmacokinetic interactions between everolimus and figitumumab.",,,,
clinicaltrials.gov,GB226,,,,,,Fruquintinib,,,,,,,,,,,NCT03977090,Genolimzumab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer,,https://ClinicalTrials.gov/show/NCT03977090
clinicaltrials.gov,GB226,,,,,,Fruquintinib,,,,,,,,,,,NCT03976856,Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib in the Treatment of Relapsed or Metastatic NSCLC With EGFR-sensitive Mutation,,https://ClinicalTrials.gov/show/NCT03976856
clinicaltrials.gov,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,GA101,,P11836,,,,,lymphoma,Phase 2,,,NCT02689869,Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma,Alternative,https://ClinicalTrials.gov/show/NCT02689869
clinicaltrials.gov,alpelisib,,P42336,"InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1",STUWGJZDJHPWGZ-LBPRGKRZSA-N,Cc1nc(NC(=O)N2CCC[C@H]2C(=O)N)sc1c3ccnc(c3)C(C)(C)C(F)(F)F,ganitumab,,P08069,,,,,,Phase 1/2,,,NCT01708161,A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors,,https://ClinicalTrials.gov/show/NCT01708161
clinicaltrials.gov,binimetinib,1222391,Q02750;P36507,"InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)",ACWZRVQXLIRSDF-UHFFFAOYSA-N,Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO,ganitumab,,P08069,,,,,pancreatic cancers;skin cancers,Phase 2,,,NCT01562899,A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors,,https://ClinicalTrials.gov/show/NCT01562899
clinicaltrials.gov,dasatinib,375,O00238;O00506;O14965;O14976;O15197;O15264;O43283;O43318;O43353;O60674;O94804;O95819;P00519;P00533;P04049;P04626;P06239;P06241;P07333;P07947;P07948;P07949;P08631;P08684;P09619;P09769;P0C1S8;P10721;P11274;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P21860;P22607;P27037;P29317;P29320;P29322;P29323;P29597;P30291;P35968;P36507;P36888;P36894;P36896;P36897;P37023;P37173;P41240;P42680;P42681;P42684;P42685;P43405;P49674;P51451;P51813;P51955;P52333;P53667;P53671;P53778;P54753;P54756;P54760;P54762;P54764;P57059;Q01538;Q02750;Q04771;Q06187;Q07912;Q08345;Q09013;Q12851;Q13043;Q13163;Q13705;Q13882;Q15303;Q15569;Q15759;Q16539;Q16832;Q52WX2;Q56UN5;Q59H18;Q5VT25;Q6DT37;Q6PHR2;Q86Y07;Q8IVH8;Q8N4C8;Q8NG66;Q8NI60;Q8TDR2;Q92918;Q96GD4;Q99640;Q99759;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K8;Q9H3Y6;Q9NRP7;Q9NYL2;Q9P289;Q9P2K8;Q9UBE8;Q9UF33;Q9UKE5;Q9UL54;Q9Y2K2;Q9Y2U5;Q9Y4K4;Q9Y5S2;Q9Y6R4,"InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)",ZBNZXTGUTAYRHI-UHFFFAOYSA-N,Cc1nc(Nc2ncc(s2)C(=O)Nc3c(C)cccc3Cl)cc(n1)N4CCN(CCO)CC4,ganitumab,,P08069,,,,,soft tissue cancers,Phase 1/2,,,NCT03041701,Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma,,https://ClinicalTrials.gov/show/NCT03041701
clinicaltrials.gov,cobimetinib,1055500,Q02750;P36507,"InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1",BSMCAPRUBJMWDF-KRWDZBQOSA-N,OC1(CN(C1)C(=O)c2ccc(F)c(F)c2Nc3ccc(I)cc3F)[C@@H]4CCCCN4,GD0-994,,,,,,,lung cancers;bowel cancers;lung cancers;skin cancers,Phase 1,,,NCT02457793,"A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors",,https://ClinicalTrials.gov/show/NCT02457793
clinicaltrials.gov,trastuzumab,4,P04626,,,,GDC-0084,,,,,,,breast cancers,Phase 2,,,NCT03765983,GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases,,https://ClinicalTrials.gov/show/NCT03765983
clinicaltrials.gov,trastuzumab,4,P04626,,,,GDC-0084,,,,,,,breast cancers,Phase 2,,,NCT03765983,GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases,,https://ClinicalTrials.gov/show/NCT03765983
clinicaltrials.gov,atezolizumab,,Q9NZQ7,,,,GDC-0919,,,,,,,advanced solid cancers,Phase 1,,,NCT02471846,A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors,,https://ClinicalTrials.gov/show/NCT02471846
clinicaltrials.gov,palbociclib,149415,P11802;P20248;P24385;P24941;P30279;P30281;P36888;P50750;P52333;Q00534,"InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)",AHJRHEGDXFFMBM-UHFFFAOYSA-N,CC(=O)C1=C(C)c2cnc(Nc3ccc(cn3)N4CCNCC4)nc2N(C5CCCC5)C1=O,gedatolisib,648770,P42345;Q92569;Q8WYR1;P48736;P42338;P42336;P27986;O00459;O00329,"InChI=1S/C32H41N9O4/c1-38(2)27-11-13-39(14-12-27)29(42)24-5-9-26(10-6-24)34-32(43)33-25-7-3-23(4-8-25)28-35-30(40-15-19-44-20-16-40)37-31(36-28)41-17-21-45-22-18-41/h3-10,27H,11-22H2,1-2H3,(H2,33,34,43)",DWZAEMINVBZMHQ-UHFFFAOYSA-N,CN(C)C1CCN(CC1)C(=O)c2ccc(NC(=O)Nc3ccc(cc3)c4nc(nc(n4)N5CCOCC5)N6CCOCC6)cc2,,lung cancers;head and neck cancers;pancreatic cancers,Phase 1,,,NCT03065062,"Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors",,https://ClinicalTrials.gov/show/NCT03065062
clinicaltrials.gov,cediranib,106760,O00444;O14976;O15197;O43353;O75460;O94804;O95819;P00519;P00533;P04626;P06239;P06241;P07333;P07947;P07948;P07949;P08581;P08631;P09619;P09769;P10721;P11362;P12931;P16234;P17948;P21709;P21802;P21860;P22455;P22607;P29320;P29322;P29376;P30530;P35590;P35916;P35968;P36507;P36888;P36896;P36897;P42684;P42685;P49674;P51451;P54760;Q02763;Q04771;Q04912;Q06187;Q06418;Q08345;Q12851;Q12866;Q13043;Q13163;Q13882;Q15303;Q15375;Q16832;Q56UN5;Q8IVH8;Q8N4C8;Q8TDR2;Q92918;Q96GD4;Q9BQI3;Q9BYT3;Q9H0K1;Q9H2G2;Q9H2K8;Q9P289;Q9UF33;Q9UKE5;Q9UL54;Q9UM73;Q9UQB9;Q9Y4K4,"InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3",XXJWYDDUDKYVKI-UHFFFAOYSA-N,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN5CCCC5,gefitinib,701,O14578;O14976;O15197;O43293;O43353;O75676;O94768;O94804;O96017;P00519;P00533;P04626;P06239;P07948;P07949;P08581;P08631;P09769;P10721;P12931;P15735;P21709;P21860;P29320;P29322;P29376;P30530;P31152;P36888;P42681;P42684;P42685;P45984;P48730;P49674;P50613;P51451;P51617;P53779;P54756;P54760;P54762;Q09013;Q13163;Q15139;Q15303;Q16659;Q16816;Q52WX2;Q56UN5;Q86V86;Q8N4C8;Q8NE63;Q8TBX8;Q99759;Q9BUB5;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NWZ3;Q9UBE8;Q9UEE5;Q9UF33;Q9UKE5;Q9UNQ0;Q9Y2U5;Q9Y616,"InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)",XGALLCVXEZPNRQ-UHFFFAOYSA-N,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN4CCOCC4,,,Phase 1,,,NCT00502060,Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer,,https://ClinicalTrials.gov/show/NCT00502060
literature,cediranib,106760,O00444;O14976;O15197;O43353;O75460;O94804;O95819;P00519;P00533;P04626;P06239;P06241;P07333;P07947;P07948;P07949;P08581;P08631;P09619;P09769;P10721;P11362;P12931;P16234;P17948;P21709;P21802;P21860;P22455;P22607;P29320;P29322;P29376;P30530;P35590;P35916;P35968;P36507;P36888;P36896;P36897;P42684;P42685;P49674;P51451;P54760;Q02763;Q04771;Q04912;Q06187;Q06418;Q08345;Q12851;Q12866;Q13043;Q13163;Q13882;Q15303;Q15375;Q16832;Q56UN5;Q8IVH8;Q8N4C8;Q8TDR2;Q92918;Q96GD4;Q9BQI3;Q9BYT3;Q9H0K1;Q9H2G2;Q9H2K8;Q9P289;Q9UF33;Q9UKE5;Q9UL54;Q9UM73;Q9UQB9;Q9Y4K4,"InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3",XXJWYDDUDKYVKI-UHFFFAOYSA-N,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN5CCCC5,gefitinib,701,O14578;O14976;O15197;O43293;O43353;O75676;O94768;O94804;O96017;P00519;P00533;P04626;P06239;P07948;P07949;P08581;P08631;P09769;P10721;P12931;P15735;P21709;P21860;P29320;P29322;P29376;P30530;P31152;P36888;P42681;P42684;P42685;P45984;P48730;P49674;P50613;P51451;P51617;P53779;P54756;P54760;P54762;Q09013;Q13163;Q15139;Q15303;Q16659;Q16816;Q52WX2;Q56UN5;Q86V86;Q8N4C8;Q8NE63;Q8TBX8;Q99759;Q9BUB5;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NWZ3;Q9UBE8;Q9UEE5;Q9UF33;Q9UKE5;Q9UNQ0;Q9Y2U5;Q9Y616,"InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)",XGALLCVXEZPNRQ-UHFFFAOYSA-N,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN4CCOCC4,advanced tumours,advanced solid cancers,Phase 1,20061136,"Combination treatment was generally well tolerated; the protocol-defined maximum-tolerated dose of cediranib was 30mg/day with gefitinib 250mg/day (part A1) and cediranib 45mg/day was the maximum dose investigated with gefitinib 500mg/day (part B1). The most common adverse events were diarrhoea (84 [93%]), anorexia (63 [70%]) and fatigue (60 [67%]). Cediranib pharmacokinetic parameters were not substantially different when given alone or in combination with gefitinib. Gefitinib pharmacokinetic parameters were similar to those seen previously with gefitinib monotherapy. Efficacy results included eight (9%) confirmed partial responses (6 renal; 1 lung; 1 osteosarcoma) and 38 (42%) patients with stable disease. Pharmacodynamic assessments demonstrated changes in levels of VEGF and soluble VEGFR-2 following treatment.",,,,
clinicaltrials.gov,celecoxib,646,O43570;P00918;P10635;P18089;P22748;P23280;P23975;P31645;P35218;P35354;P43166;Q01959;Q16539;Q16790;Q8N1Q1;Q9ULX7;Q9Y2D0,"InChI=1S/C17H14F3N3O2S/c1-11-2-4-12(5-3-11)15-10-16(17(18,19)20)22-23(15)13-6-8-14(9-7-13)26(21,24)25/h2-10H,1H3,(H2,21,24,25)",RZEKVGVHFLEQIL-UHFFFAOYSA-N,Cc1ccc(cc1)c2cc(nn2c3ccc(cc3)S(=O)(=O)N)C(F)(F)F,gefitinib,701,O14578;O14976;O15197;O43293;O43353;O75676;O94768;O94804;O96017;P00519;P00533;P04626;P06239;P07948;P07949;P08581;P08631;P09769;P10721;P12931;P15735;P21709;P21860;P29320;P29322;P29376;P30530;P31152;P36888;P42681;P42684;P42685;P45984;P48730;P49674;P50613;P51451;P51617;P53779;P54756;P54760;P54762;Q09013;Q13163;Q15139;Q15303;Q16659;Q16816;Q52WX2;Q56UN5;Q86V86;Q8N4C8;Q8NE63;Q8TBX8;Q99759;Q9BUB5;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NWZ3;Q9UBE8;Q9UEE5;Q9UF33;Q9UKE5;Q9UNQ0;Q9Y2U5;Q9Y616,"InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)",XGALLCVXEZPNRQ-UHFFFAOYSA-N,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN4CCOCC4,,lung cancers,Phase 2,,,NCT00068653,Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT00068653
clinicaltrials.gov,CT053PTSA,,,,,,gefitinib,701,O14578;O14976;O15197;O43293;O43353;O75676;O94768;O94804;O96017;P00519;P00533;P04626;P06239;P07948;P07949;P08581;P08631;P09769;P10721;P12931;P15735;P21709;P21860;P29320;P29322;P29376;P30530;P31152;P36888;P42681;P42684;P42685;P45984;P48730;P49674;P50613;P51451;P51617;P53779;P54756;P54760;P54762;Q09013;Q13163;Q15139;Q15303;Q16659;Q16816;Q52WX2;Q56UN5;Q86V86;Q8N4C8;Q8NE63;Q8TBX8;Q99759;Q9BUB5;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NWZ3;Q9UBE8;Q9UEE5;Q9UF33;Q9UKE5;Q9UNQ0;Q9Y2U5;Q9Y616,"InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)",XGALLCVXEZPNRQ-UHFFFAOYSA-N,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN4CCOCC4,,lung cancers,Phase 1/2,,,NCT03758287,Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative,,https://ClinicalTrials.gov/show/NCT03758287
clinicaltrials.gov,CT053PTSA,,,,,,gefitinib,701,O14578;O14976;O15197;O43293;O43353;O75676;O94768;O94804;O96017;P00519;P00533;P04626;P06239;P07948;P07949;P08581;P08631;P09769;P10721;P12931;P15735;P21709;P21860;P29320;P29322;P29376;P30530;P31152;P36888;P42681;P42684;P42685;P45984;P48730;P49674;P50613;P51451;P51617;P53779;P54756;P54760;P54762;Q09013;Q13163;Q15139;Q15303;Q16659;Q16816;Q52WX2;Q56UN5;Q86V86;Q8N4C8;Q8NE63;Q8TBX8;Q99759;Q9BUB5;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NWZ3;Q9UBE8;Q9UEE5;Q9UF33;Q9UKE5;Q9UNQ0;Q9Y2U5;Q9Y616,"InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)",XGALLCVXEZPNRQ-UHFFFAOYSA-N,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN4CCOCC4,,lung cancers,Phase 1/2,,,NCT03758287,Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative,,https://ClinicalTrials.gov/show/NCT03758287
clinicaltrials.gov,DS-1205c,,,,,,gefitinib,701,O14578;O14976;O15197;O43293;O43353;O75676;O94768;O94804;O96017;P00519;P00533;P04626;P06239;P07948;P07949;P08581;P08631;P09769;P10721;P12931;P15735;P21709;P21860;P29320;P29322;P29376;P30530;P31152;P36888;P42681;P42684;P42685;P45984;P48730;P49674;P50613;P51451;P51617;P53779;P54756;P54760;P54762;Q09013;Q13163;Q15139;Q15303;Q16659;Q16816;Q52WX2;Q56UN5;Q86V86;Q8N4C8;Q8NE63;Q8TBX8;Q99759;Q9BUB5;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NWZ3;Q9UBE8;Q9UEE5;Q9UF33;Q9UKE5;Q9UNQ0;Q9Y2U5;Q9Y616,"InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)",XGALLCVXEZPNRQ-UHFFFAOYSA-N,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN4CCOCC4,,lung cancers,Phase 1,,,NCT03599518,DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT03599518
clinicaltrials.gov,DS-1205c,,,,,,gefitinib,701,O14578;O14976;O15197;O43293;O43353;O75676;O94768;O94804;O96017;P00519;P00533;P04626;P06239;P07948;P07949;P08581;P08631;P09769;P10721;P12931;P15735;P21709;P21860;P29320;P29322;P29376;P30530;P31152;P36888;P42681;P42684;P42685;P45984;P48730;P49674;P50613;P51451;P51617;P53779;P54756;P54760;P54762;Q09013;Q13163;Q15139;Q15303;Q16659;Q16816;Q52WX2;Q56UN5;Q86V86;Q8N4C8;Q8NE63;Q8TBX8;Q99759;Q9BUB5;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NWZ3;Q9UBE8;Q9UEE5;Q9UF33;Q9UKE5;Q9UNQ0;Q9Y2U5;Q9Y616,"InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)",XGALLCVXEZPNRQ-UHFFFAOYSA-N,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN4CCOCC4,,lung cancers,Phase 1,,,NCT03599518,DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT03599518
clinicaltrials.gov,EGF816,,P00533,,,,gefitinib,701,O14578;O14976;O15197;O43293;O43353;O75676;O94768;O94804;O96017;P00519;P00533;P04626;P06239;P07948;P07949;P08581;P08631;P09769;P10721;P12931;P15735;P21709;P21860;P29320;P29322;P29376;P30530;P31152;P36888;P42681;P42684;P42685;P45984;P48730;P49674;P50613;P51451;P51617;P53779;P54756;P54760;P54762;Q09013;Q13163;Q15139;Q15303;Q16659;Q16816;Q52WX2;Q56UN5;Q86V86;Q8N4C8;Q8NE63;Q8TBX8;Q99759;Q9BUB5;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NWZ3;Q9UBE8;Q9UEE5;Q9UF33;Q9UKE5;Q9UNQ0;Q9Y2U5;Q9Y616,"InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)",XGALLCVXEZPNRQ-UHFFFAOYSA-N,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN4CCOCC4,,lung cancers,Phase 2,,,NCT03292133,A Study of EGF816 and Gefitinib in TKI-naêève EGFR-mutant Non-Small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT03292133
clinicaltrials.gov,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,gefitinib,701,O14578;O14976;O15197;O43293;O43353;O75676;O94768;O94804;O96017;P00519;P00533;P04626;P06239;P07948;P07949;P08581;P08631;P09769;P10721;P12931;P15735;P21709;P21860;P29320;P29322;P29376;P30530;P31152;P36888;P42681;P42684;P42685;P45984;P48730;P49674;P50613;P51451;P51617;P53779;P54756;P54760;P54762;Q09013;Q13163;Q15139;Q15303;Q16659;Q16816;Q52WX2;Q56UN5;Q86V86;Q8N4C8;Q8NE63;Q8TBX8;Q99759;Q9BUB5;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NWZ3;Q9UBE8;Q9UEE5;Q9UF33;Q9UKE5;Q9UNQ0;Q9Y2U5;Q9Y616,"InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)",XGALLCVXEZPNRQ-UHFFFAOYSA-N,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN4CCOCC4,,brain cancers;central nervous system cancers;prostate cancers,Phase 1/2,,,NCT00085566,Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer,,https://ClinicalTrials.gov/show/NCT00085566
literature,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,gefitinib,701,O14578;O14976;O15197;O43293;O43353;O75676;O94768;O94804;O96017;P00519;P00533;P04626;P06239;P07948;P07949;P08581;P08631;P09769;P10721;P12931;P15735;P21709;P21860;P29320;P29322;P29376;P30530;P31152;P36888;P42681;P42684;P42685;P45984;P48730;P49674;P50613;P51451;P51617;P53779;P54756;P54760;P54762;Q09013;Q13163;Q15139;Q15303;Q16659;Q16816;Q52WX2;Q56UN5;Q86V86;Q8N4C8;Q8NE63;Q8TBX8;Q99759;Q9BUB5;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NWZ3;Q9UBE8;Q9UEE5;Q9UF33;Q9UKE5;Q9UNQ0;Q9Y2U5;Q9Y616,"InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)",XGALLCVXEZPNRQ-UHFFFAOYSA-N,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN4CCOCC4,advanced nonsmall-cell lung_cancer,lung cancers,Phase 1,17577220,"Ten patients were enrolled. The maximum tolerated dose of everolimus was 5 mg when administered daily with gefitinib 250 mg. Two patients who were treated at the 10 mg dose level of everolimus experienced dose-limiting toxicity, including grade 5 hypotension and grade 3 stomatitis. Pharmacokinetic studies demonstrated no consistent, significant interaction on the t(max), C(max), and AUC(0-8h) of either agent. Two partial radiographic responses were identified among the 8 response-evaluable patients.",,,,
literature,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,gefitinib,701,O14578;O14976;O15197;O43293;O43353;O75676;O94768;O94804;O96017;P00519;P00533;P04626;P06239;P07948;P07949;P08581;P08631;P09769;P10721;P12931;P15735;P21709;P21860;P29320;P29322;P29376;P30530;P31152;P36888;P42681;P42684;P42685;P45984;P48730;P49674;P50613;P51451;P51617;P53779;P54756;P54760;P54762;Q09013;Q13163;Q15139;Q15303;Q16659;Q16816;Q52WX2;Q56UN5;Q86V86;Q8N4C8;Q8NE63;Q8TBX8;Q99759;Q9BUB5;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NWZ3;Q9UBE8;Q9UEE5;Q9UF33;Q9UKE5;Q9UNQ0;Q9Y2U5;Q9Y616,"InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)",XGALLCVXEZPNRQ-UHFFFAOYSA-N,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN4CCOCC4,metastatic castration-resistant prostate_cancer,male cancers,Phase 1/2,26178426,"Phase 1 revealed no pharmacokinetic interactions and no dose-limiting toxicities. In phase 2, 18 of 27 patients (67%) discontinued treatment before the 12-week evaluation because of progression as evidenced by prostate-specific antigen (PSA) levels (n_=_6) or imaging (n_=_5) or because of a grade 2 or higher toxicity (n_=_7). Thirteen of the 37 CRPC patients (35%) exhibited a rapidly rising PSA level after they had begun treatment, and this declined upon discontinuation. Fluorodeoxyglucose positron emission tomography 24 to 72 hours after the initiation of treatment showed a decrease in the standardized uptake value consistent with mTOR inhibition in 27 of the 33 evaluable patients (82%); there was a corresponding rise in PSA in 20 of these 27 patients (74%).",,,,
clinicaltrials.gov,ficlatuzumab,,P14210,,,,gefitinib,701,O14578;O14976;O15197;O43293;O43353;O75676;O94768;O94804;O96017;P00519;P00533;P04626;P06239;P07948;P07949;P08581;P08631;P09769;P10721;P12931;P15735;P21709;P21860;P29320;P29322;P29376;P30530;P31152;P36888;P42681;P42684;P42685;P45984;P48730;P49674;P50613;P51451;P51617;P53779;P54756;P54760;P54762;Q09013;Q13163;Q15139;Q15303;Q16659;Q16816;Q52WX2;Q56UN5;Q86V86;Q8N4C8;Q8NE63;Q8TBX8;Q99759;Q9BUB5;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NWZ3;Q9UBE8;Q9UEE5;Q9UF33;Q9UKE5;Q9UNQ0;Q9Y2U5;Q9Y616,"InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)",XGALLCVXEZPNRQ-UHFFFAOYSA-N,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN4CCOCC4,,lung cancers,Phase 1/2,,,NCT01039948,A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT01039948
clinicaltrials.gov,fruquintinib,,P35968;P17948;P35916,,,,gefitinib,701,O14578;O14976;O15197;O43293;O43353;O75676;O94768;O94804;O96017;P00519;P00533;P04626;P06239;P07948;P07949;P08581;P08631;P09769;P10721;P12931;P15735;P21709;P21860;P29320;P29322;P29376;P30530;P31152;P36888;P42681;P42684;P42685;P45984;P48730;P49674;P50613;P51451;P51617;P53779;P54756;P54760;P54762;Q09013;Q13163;Q15139;Q15303;Q16659;Q16816;Q52WX2;Q56UN5;Q86V86;Q8N4C8;Q8NE63;Q8TBX8;Q99759;Q9BUB5;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NWZ3;Q9UBE8;Q9UEE5;Q9UF33;Q9UKE5;Q9UNQ0;Q9Y2U5;Q9Y616,"InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)",XGALLCVXEZPNRQ-UHFFFAOYSA-N,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN4CCOCC4,,lung cancers,Phase 2,,,NCT02976116,A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT02976116
clinicaltrials.gov,metformin,1855,P43304;P03923;O95299;O00217;P03901;P56556;P03886;O95139;O00483;Q86Y39;P17568;P03891;O75306;P03915;P51970;O43674;P03905;P03897;O14561;O15239;O43181;O43676;O43677;O43678;O43920;O75251;O75380;O75438;O75489;O95167;O95168;O95169;O95178;O95182;O95298;O96000;P19404;P28331;P49821;P56181;Q16718;Q16795;Q8N183;Q9BU61;Q9NRX3;Q9NX14;Q9P032;Q9P0J0;Q9UI09;Q9Y375;Q9Y6M9,"InChI=1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)",XZWYZXLIPXDOLR-UHFFFAOYSA-N,CN(C)C(=N)NC(=N)N,gefitinib,701,O14578;O14976;O15197;O43293;O43353;O75676;O94768;O94804;O96017;P00519;P00533;P04626;P06239;P07948;P07949;P08581;P08631;P09769;P10721;P12931;P15735;P21709;P21860;P29320;P29322;P29376;P30530;P31152;P36888;P42681;P42684;P42685;P45984;P48730;P49674;P50613;P51451;P51617;P53779;P54756;P54760;P54762;Q09013;Q13163;Q15139;Q15303;Q16659;Q16816;Q52WX2;Q56UN5;Q86V86;Q8N4C8;Q8NE63;Q8TBX8;Q99759;Q9BUB5;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NWZ3;Q9UBE8;Q9UEE5;Q9UF33;Q9UKE5;Q9UNQ0;Q9Y2U5;Q9Y616,"InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)",XGALLCVXEZPNRQ-UHFFFAOYSA-N,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN4CCOCC4,,lung cancers,Phase 2,,,NCT01864681,Combination of Metformin With Gefitinib to Treat NSCLC,CGMT,https://ClinicalTrials.gov/show/NCT01864681
clinicaltrials.gov,nimotuzumab,,,,,,gefitinib,701,O14578;O14976;O15197;O43293;O43353;O75676;O94768;O94804;O96017;P00519;P00533;P04626;P06239;P07948;P07949;P08581;P08631;P09769;P10721;P12931;P15735;P21709;P21860;P29320;P29322;P29376;P30530;P31152;P36888;P42681;P42684;P42685;P45984;P48730;P49674;P50613;P51451;P51617;P53779;P54756;P54760;P54762;Q09013;Q13163;Q15139;Q15303;Q16659;Q16816;Q52WX2;Q56UN5;Q86V86;Q8N4C8;Q8NE63;Q8TBX8;Q99759;Q9BUB5;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NWZ3;Q9UBE8;Q9UEE5;Q9UF33;Q9UKE5;Q9UNQ0;Q9Y2U5;Q9Y616,"InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)",XGALLCVXEZPNRQ-UHFFFAOYSA-N,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN4CCOCC4,,lung cancers,Phase 2,,,NCT01498562,Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer,DATE,https://ClinicalTrials.gov/show/NCT01498562
clinicaltrials.gov,simvastatin,370,P04035,"InChI=1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1",RYMZZMVNJRMUDD-HGQWONQESA-N,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12,gefitinib,701,O14578;O14976;O15197;O43293;O43353;O75676;O94768;O94804;O96017;P00519;P00533;P04626;P06239;P07948;P07949;P08581;P08631;P09769;P10721;P12931;P15735;P21709;P21860;P29320;P29322;P29376;P30530;P31152;P36888;P42681;P42684;P42685;P45984;P48730;P49674;P50613;P51451;P51617;P53779;P54756;P54760;P54762;Q09013;Q13163;Q15139;Q15303;Q16659;Q16816;Q52WX2;Q56UN5;Q86V86;Q8N4C8;Q8NE63;Q8TBX8;Q99759;Q9BUB5;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NWZ3;Q9UBE8;Q9UEE5;Q9UF33;Q9UKE5;Q9UNQ0;Q9Y2U5;Q9Y616,"InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)",XGALLCVXEZPNRQ-UHFFFAOYSA-N,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN4CCOCC4,,lung cancers,Phase 2,,,NCT00452244,Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer (NSCLC),,https://ClinicalTrials.gov/show/NCT00452244
clinicaltrials.gov,CPX-351,,,,,,Gemtuzumab Ozogamicin,,,,,,Acute Myeloid Leukemia,,Phase 1,,,NCT03878927,,,
clinicaltrials.gov,venetoclax,1150189,P10415,"InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)",LQBVNQSMGBZMKD-UHFFFAOYSA-N,CC1(C)CCC(=C(C1)c2ccc(Cl)cc2)CN3CCN(CC3)c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c(c5)N(=O)=O)c(Oc7cnc8[nH]ccc8c7)c4,giltertinib,1211984,P36888; P30530,"InChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34)",GYQYAJJFPNQOOW-UHFFFAOYSA-N,CCc1nc(C(=O)N)c(Nc2ccc(N3CCC(CC3)N4CCN(C)CC4)c(OC)c2)nc1NC5CCOCC5,,leukemia,Phase 1,,,NCT03625505,A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Subjects With Relapsed/Refractory Acute Myeloid Leukemia,,https://ClinicalTrials.gov/show/NCT03625505
clinicaltrials.gov,venetoclax,1150189,P10415,"InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)",LQBVNQSMGBZMKD-UHFFFAOYSA-N,CC1(C)CCC(=C(C1)c2ccc(Cl)cc2)CN3CCN(CC3)c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c(c5)N(=O)=O)c(Oc7cnc8[nH]ccc8c7)c4,giltertinib,1211984,P36888; P30530,"InChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34)",GYQYAJJFPNQOOW-UHFFFAOYSA-N,CCc1nc(C(=O)N)c(Nc2ccc(N3CCC(CC3)N4CCN(C)CC4)c(OC)c2)nc1NC5CCOCC5,,leukemia,Phase 1,,,NCT03625505,A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Subjects With Relapsed/Refractory Acute Myeloid Leukemia,,https://ClinicalTrials.gov/show/NCT03625505
clinicaltrials.gov,GSK1795091,,,,,,GSK3174998,,,,,,,,Phase 1,,,NCT03447314,Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT03447314
clinicaltrials.gov,nanoxel,,,,,,herzuma,,,,,,,head and neck cancers,Phase 2,,,NCT03614364,Combination of Nanoxel and Herzuma in Salivary Duct Carcinoma,,https://ClinicalTrials.gov/show/NCT03614364
clinicaltrials.gov,nanoxel,,,,,,herzuma,,,,,,,head and neck cancers,Phase 2,,,NCT03614364,Combination of Nanoxel and Herzuma in Salivary Duct Carcinoma,,https://ClinicalTrials.gov/show/NCT03614364
clinicaltrials.gov,nivolumab,,Q15116,,,,HF10,,,,,,,skin cancers,Phase 2,,,NCT03259425,"Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma",,https://ClinicalTrials.gov/show/NCT03259425
clinicaltrials.gov,HLX10+,,,,,,HLX04,,,,,,,,,,,NCT03973112,A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients With Disease Progression or Intolerant Toxicity After Standard Treatment,,https://ClinicalTrials.gov/show/NCT03973112
clinicaltrials.gov,HLX04,,,,,,HLX10,,,,,,,advanced solid cancers,Phase 1,,,NCT03757936,"A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid Tumors",,https://ClinicalTrials.gov/show/NCT03757936
clinicaltrials.gov,HLX04,,,,,,HLX10,,,,,,,advanced solid cancers,Phase 1,,,NCT03757936,"A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid Tumors",,https://ClinicalTrials.gov/show/NCT03757936
clinicaltrials.gov,ipilimumab,1238537,P16410,,,,HSPPC-96,,,,,,,skin cancers,Phase 1/2,,,NCT02452281,Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma,,https://ClinicalTrials.gov/show/NCT02452281
clinicaltrials.gov,imatinib,1561,O00444;O14976;O15244;O43570;P00519;P00533;P00915;P00918;P04049;P06239;P06241;P07333;P07451;P07948;P09619;P09769;P10721;P11274;P15056;P16083;P16234;P22748;P23280;P24557;P25021;P28223;P29322;P29597;P31645;P36888;P42684;P42685;P43166;P43405;P45983;P45984;P49759;P51451;P51617;P53779;Q08345;Q14680;Q15046;Q16790;Q16832;Q59H18;Q86VL8;Q8NE63;Q8TBX8;Q96FL8;Q9BWU1;Q9HAZ1;Q9NYL2;Q9UEE5;Q9ULX7;Q9UNQ0,"InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)",KTUFNOKKBVMGRW-UHFFFAOYSA-N,CN1CCN(Cc2ccc(cc2)C(=O)Nc3ccc(C)c(Nc4nccc(n4)c5cccnc5)c3)CC1,hydroxyurea,185,P31350,"InChI=1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)",VSNHCAURESNICA-UHFFFAOYSA-N,NC(=O)NO,,brain cancers,Phase 3,,,NCT00154375,Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma,,https://ClinicalTrials.gov/show/NCT00154375
clinicaltrials.gov,abexinostat,,,,,,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,,,,,,NCT03939182,abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma,,https://ClinicalTrials.gov/show/NCT03939182
clinicaltrials.gov,AZD-2014,,P42345,"InChI=1S/C25H31N5O4/c1-16-13-30(14-17(2)34-16)25-27-23-20(24(28-25)29-8-10-33-11-9-29)5-6-21(26-23)18-4-7-22(32-3)19(12-18)15-31/h4-7,12,16-17,31H,8-11,13-15H2,1-3H3/t16-,17+",RFSMUFRPPYDYRD-CALCHBBNSA-N,COc1ccc(cc1CO)c2ccc3c(nc(nc3n2)N4C[C@@H](C)O[C@@H](C)C4)N5CCOCC5,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,,lymphoma,Phase 1,,,NCT02780830,AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma,INHIBITOR,https://ClinicalTrials.gov/show/NCT02780830
clinicaltrials.gov,BNC105P,,,,,,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,,leukemia,Phase 1,,,NCT03454165,A Study of BNC105P Combined With Ibrutinib,,https://ClinicalTrials.gov/show/NCT03454165
clinicaltrials.gov,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,,lymphoma,Phase 2,,,NCT03617484,Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma,,https://ClinicalTrials.gov/show/NCT03617484
clinicaltrials.gov,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,,lymphoma,Phase 2,,,NCT03617484,Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma,,https://ClinicalTrials.gov/show/NCT03617484
clinicaltrials.gov,buparlisib,962639,O00329;O00459;P27986;P42336;P42338;P48736;Q8WYR1;Q92569,"InChI=1S/C18H21F3N6O2/c19-18(20,21)13-9-15(22)23-11-12(13)14-10-16(26-1-5-28-6-2-26)25-17(24-14)27-3-7-29-8-4-27/h9-11H,1-8H2,(H2,22,23)",CWHUFRVAEUJCEF-UHFFFAOYSA-N,Nc1cc(c(cn1)c2cc(nc(n2)N3CCOCC3)N4CCOCC4)C(F)(F)F,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,,lymphoma,Phase 1,,,NCT02756247,A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma,,https://ClinicalTrials.gov/show/NCT02756247
clinicaltrials.gov,copanlisib,1212464,O00329;O00459;P27986;P42336;P42338;P48736;Q8WYR1;Q92569,"InChI=1S/C23H28N8O4/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15/h3-4,13-14H,2,5-12H2,1H3,(H2,24,26,27)(H,28,29,32)",PZBCKZWLPGJMAO-UHFFFAOYSA-N,COc1c(OCCCN2CCOCC2)ccc3C4=NCCN4C(=Nc13)NC(=O)c5cnc(N)nc5,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,Mantle Cell Lymphoma (MCL),,Phase 1/2,,,NCT03877055,,,
clinicaltrials.gov,duvortuxizumab,,,,,,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,,leukemia;lymphoma,Phase 1,,,NCT02743546,"Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma",,https://ClinicalTrials.gov/show/NCT02743546
clinicaltrials.gov,GA101,,P11836,,,,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,,leukemia,Phase 1/2,,,NCT02315768,Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.,,https://ClinicalTrials.gov/show/NCT02315768
clinicaltrials.gov,ixazomib,1069383,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C14H19BCl2N2O4/c1-8(2)5-12(15(22)23)19-13(20)7-18-14(21)10-6-9(16)3-4-11(10)17/h3-4,6,8,12,22-23H,5,7H2,1-2H3,(H,18,21)(H,19,20)/t12-/m0/s1",MXAYKZJJDUDWDS-LBPRGKRZSA-N,CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,,lymphoma,Phase 1/2,,,NCT03323151,A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma,PrE0404,https://ClinicalTrials.gov/show/NCT03323151
clinicaltrials.gov,Loncastuximab Tesirine,,,,,,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,,lymphoma,Phase 1,,,NCT03684694,Safety and Antitumor Activity Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma,,https://ClinicalTrials.gov/show/NCT03684694
clinicaltrials.gov,Loncastuximab Tesirine,,,,,,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,,lymphoma,Phase 1,,,NCT03684694,Safety and Antitumor Activity Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma,,https://ClinicalTrials.gov/show/NCT03684694
clinicaltrials.gov,nivolumab,,Q15116,,,,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,,leukemia,Phase 2,,,NCT02420912,"Nivolumab With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)",,https://ClinicalTrials.gov/show/NCT02420912
clinicaltrials.gov,obinutuzumab,,P11836,,,,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,,leukemia,Phase 1,,,NCT02537613,A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,,https://ClinicalTrials.gov/show/NCT02537613
clinicaltrials.gov,pacritinib,1894124,P36888;O60674,"InChI=1S/C28H32N4O3/c1-2-13-32(12-1)14-17-35-27-9-8-25-19-24(27)21-34-16-4-3-15-33-20-22-6-5-7-23(18-22)26-10-11-29-28(30-25)31-26/h3-11,18-19H,1-2,12-17,20-21H2,(H,29,30,31)/b4-3+",HWXVIOGONBBTBY-ONEGZZNKSA-N,C(CN1CCCC1)Oc2ccc3Nc4nccc(n4)c5cccc(COC\C=C\COCc2c3)c5,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,,leukemia;lymphoma,Phase 1/2,,,NCT02677948,Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL),,https://ClinicalTrials.gov/show/NCT02677948
clinicaltrials.gov,pembrolizumab,,Q15116,,,,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,,colorectal cancers,Phase 1/2,,,NCT03332498,"pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers",,https://ClinicalTrials.gov/show/NCT03332498
clinicaltrials.gov,TGR-1202,,O00329,,,,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,,leukemia;lymphoma,Phase 1,,,NCT02268851,A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL,,https://ClinicalTrials.gov/show/NCT02268851
clinicaltrials.gov,Tisagenlecleucel,,,,,,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,Diffuse Large B-cell Lymphoma,,Phase 1,,,NCT03876028,,,
clinicaltrials.gov,TP-0903,,,,,,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,,lymphoma;leukemia,Phase 1/2,,,NCT03572634,Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL,,https://ClinicalTrials.gov/show/NCT03572634
clinicaltrials.gov,TP-0903,,,,,,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,,lymphoma;leukemia,Phase 1/2,,,NCT03572634,Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL,,https://ClinicalTrials.gov/show/NCT03572634
clinicaltrials.gov,ublituximab,,P11836,,,,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,,leukemia;lymphoma,Phase 1/2,,,NCT02013128,Ublituximab + Ibrutinib in Select B-cell Malignancies,,https://ClinicalTrials.gov/show/NCT02013128
literature,ublituximab,,P11836,,,,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,relapsed and/or refractory chronic lymphocytic leukaemia,leukemia,Phase 2,27982425,"Forty-one of 45 enrolled patients were evaluable for efficacy. Safety was consistent with prior experience for each drug, with infusion reactions the most prevalent adverse event. Combination therapy resulted in an overall response rate (ORR) of 88% at 6_months. In the 20 patients with high-risk features (17p or 11q deletions or TP53 mutation) and evaluable for efficacy, the ORR was 95%, with three patients (15%) achieving negative minimal residual disease. Median time to response was 8_weeks. Ublituximab in combination with ibrutinib resulted in rapid and high response rates.",,,,
clinicaltrials.gov,ulocuplumab,,,,,,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,,lymphoma,Phase 1/2,,,NCT03225716,A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia,,https://ClinicalTrials.gov/show/NCT03225716
literature,umbralisib,,,,,,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4, relapsed or refractory chronic lymphocytic leukaemia and mantle cell lymphoma,leukemia;lymphoma,Phase 1/1b,30558987,"Between Dec 5, 2014, and March 7, 2018, we enrolled 44 patients, of which 42 were given at least one dose of study drug (chronic lymphocytic leukaemia, n=21; mantle cell lymphoma, n=21). Patients had a median age of 68 years (range 48-85) and had a median of two (IQR 1-3) previous therapies. No dose-limiting toxicities were observed and the maximum-tolerated dose of umbralisib was not reached. The recommended phase 2 dose of umbralisib when given in combination with ibrutinib was 800 mg once daily. The most frequent adverse events included diarrhoea (22 [52%] patients, 10% of whom had grade 3), infection (21 [50%], 17% grade 3-4), and transaminitis (ten [24%], 2% grade 3). Serious adverse events occurred in 12 (29%) patients and included lipase elevation, atrial fibrillation, hypophosphataemia, adrenal insufficiency, transaminitis, and infections",NCT02268851,,,
literature,umbralisib,,,,,,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4, relapsed or refractory chronic lymphocytic leukaemia and mantle cell lymphoma,leukemia;lymphoma,Phase 1/1b,30558987,"Between Dec 5, 2014, and March 7, 2018, we enrolled 44 patients, of which 42 were given at least one dose of study drug (chronic lymphocytic leukaemia, n=21; mantle cell lymphoma, n=21). Patients had a median age of 68 years (range 48-85) and had a median of two (IQR 1-3) previous therapies. No dose-limiting toxicities were observed and the maximum-tolerated dose of umbralisib was not reached. The recommended phase 2 dose of umbralisib when given in combination with ibrutinib was 800 mg once daily. The most frequent adverse events included diarrhoea (22 [52%] patients, 10% of whom had grade 3), infection (21 [50%], 17% grade 3-4), and transaminitis (ten [24%], 2% grade 3). Serious adverse events occurred in 12 (29%) patients and included lipase elevation, atrial fibrillation, hypophosphataemia, adrenal insufficiency, transaminitis, and infections",NCT02268851,,,
literature,umbralisib,,,,,,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma,lymphoma;leukemia,Phase 1b,30558987,"Between Dec 5, 2014, and March 7, 2018, we enrolled 44 patients, of which 42 were given at least one dose of study drug (chronic lymphocytic leukaemia, n=21; mantle cell lymphoma, n=21). Patients had a median age of 68 years (range 48-85) and had a median of two (IQR 1-3) previous therapies. No dose-limiting toxicities were observed and the maximum-tolerated dose of umbralisib was not reached. The recommended phase 2 dose of umbralisib when given in combination with ibrutinib was 800 mg once daily. The most frequent adverse events included diarrhoea (22 [52%] patients, 10% of whom had grade 3), infection (21 [50%], 17% grade 3-4), and transaminitis (ten [24%], 2% grade 3). Serious adverse events occurred in 12 (29%) patients and included lipase elevation, atrial fibrillation, hypophosphataemia, adrenal insufficiency, transaminitis, and infections.",NCT02268851,,,
clinicaltrials.gov,VAY736,,,,,,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,,leukemia,Phase 1,,,NCT03400176,VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib,,https://ClinicalTrials.gov/show/NCT03400176
clinicaltrials.gov,venetoclax,1150189,P10415,"InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)",LQBVNQSMGBZMKD-UHFFFAOYSA-N,CC1(C)CCC(=C(C1)c2ccc(Cl)cc2)CN3CCN(CC3)c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c(c5)N(=O)=O)c(Oc7cnc8[nH]ccc8c7)c4,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,,leukemia;lymphoma,Phase 1,,,NCT03422393,Venetoclax With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib,,https://ClinicalTrials.gov/show/NCT03422393
clinicaltrials.gov,entospletinib,1148059,P43405,"InChI=1S/C23H21N7O/c1-2-17-14-25-28-20(17)13-16(1)21-15-30-8-7-24-23(30)22(27-21)26-18-3-5-19(6-4-18)29-9-11-31-12-10-29/h1-8,13-15H,9-12H2,(H,25,28)(H,26,27)",XSMSNFMDVXXHGJ-UHFFFAOYSA-N,C1CN(CCO1)c2ccc(Nc3nc(cn4ccnc34)c5ccc6cn[nH]c6c5)cc2,idelalisib,1059065,O00329,"InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1",IFSDAJWBUCMOAH-HNNXBMFYSA-N,CC[C@H](Nc1ncnc2[nH]cnc12)C3=Nc4cccc(F)c4C(=O)N3c5ccccc5,,leukemia;lymphoma,Phase 2,,,NCT01796470,Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies,,https://ClinicalTrials.gov/show/NCT01796470
clinicaltrials.gov,pembrolizumab,,Q15116,,,,idelalisib,1059065,O00329,"InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1",IFSDAJWBUCMOAH-HNNXBMFYSA-N,CC[C@H](Nc1ncnc2[nH]cnc12)C3=Nc4cccc(F)c4C(=O)N3c5ccccc5,,lung cancers,Phase 1/2,,,NCT03257722,pembrolizumab + Idelalisib for Lung Cancer Study,PIL,https://ClinicalTrials.gov/show/NCT03257722
clinicaltrials.gov,BGJ398,760906,P11362;P22455;P22607;P21802,,,,imatinib,1561,O00444;O14976;O15244;O43570;P00519;P00533;P00915;P00918;P04049;P06239;P06241;P07333;P07451;P07948;P09619;P09769;P10721;P11274;P15056;P16083;P16234;P22748;P23280;P24557;P25021;P28223;P29322;P29597;P31645;P36888;P42684;P42685;P43166;P43405;P45983;P45984;P49759;P51451;P51617;P53779;Q08345;Q14680;Q15046;Q16790;Q16832;Q59H18;Q86VL8;Q8NE63;Q8TBX8;Q96FL8;Q9BWU1;Q9HAZ1;Q9NYL2;Q9UEE5;Q9ULX7;Q9UNQ0,"InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)",KTUFNOKKBVMGRW-UHFFFAOYSA-N,CN1CCN(Cc2ccc(cc2)C(=O)Nc3ccc(C)c(Nc4nccc(n4)c5cccnc5)c3)CC1,,soft tissue cancers,Phase 1/2,,,NCT02257541,BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST),,https://ClinicalTrials.gov/show/NCT02257541
clinicaltrials.gov,Entacapone,,,,,,imatinib,1561,O00444;O14976;O15244;O43570;P00519;P00533;P00915;P00918;P04049;P06239;P06241;P07333;P07451;P07948;P09619;P09769;P10721;P11274;P15056;P16083;P16234;P22748;P23280;P24557;P25021;P28223;P29322;P29597;P31645;P36888;P42684;P42685;P43166;P43405;P45983;P45984;P49759;P51451;P51617;P53779;Q08345;Q14680;Q15046;Q16790;Q16832;Q59H18;Q86VL8;Q8NE63;Q8TBX8;Q96FL8;Q9BWU1;Q9HAZ1;Q9NYL2;Q9UEE5;Q9ULX7;Q9UNQ0,"InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)",KTUFNOKKBVMGRW-UHFFFAOYSA-N,CN1CCN(Cc2ccc(cc2)C(=O)Nc3ccc(C)c(Nc4nccc(n4)c5cccnc5)c3)CC1,,,,,,NCT04006769,Entacapone Combination With Imatinib for Treatment of GIST,,https://ClinicalTrials.gov/show/NCT04006769
clinicaltrials.gov,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,imatinib,1561,O00444;O14976;O15244;O43570;P00519;P00533;P00915;P00918;P04049;P06239;P06241;P07333;P07451;P07948;P09619;P09769;P10721;P11274;P15056;P16083;P16234;P22748;P23280;P24557;P25021;P28223;P29322;P29597;P31645;P36888;P42684;P42685;P43166;P43405;P45983;P45984;P49759;P51451;P51617;P53779;Q08345;Q14680;Q15046;Q16790;Q16832;Q59H18;Q86VL8;Q8NE63;Q8TBX8;Q96FL8;Q9BWU1;Q9HAZ1;Q9NYL2;Q9UEE5;Q9ULX7;Q9UNQ0,"InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)",KTUFNOKKBVMGRW-UHFFFAOYSA-N,CN1CCN(Cc2ccc(cc2)C(=O)Nc3ccc(C)c(Nc4nccc(n4)c5cccnc5)c3)CC1,,kidney cancers,Phase 2,,,NCT00331409,Everolimus and Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney Cancer,,https://ClinicalTrials.gov/show/NCT00331409
clinicaltrials.gov,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,imatinib,1561,O00444;O14976;O15244;O43570;P00519;P00533;P00915;P00918;P04049;P06239;P06241;P07333;P07451;P07948;P09619;P09769;P10721;P11274;P15056;P16083;P16234;P22748;P23280;P24557;P25021;P28223;P29322;P29597;P31645;P36888;P42684;P42685;P43166;P43405;P45983;P45984;P49759;P51451;P51617;P53779;Q08345;Q14680;Q15046;Q16790;Q16832;Q59H18;Q86VL8;Q8NE63;Q8TBX8;Q96FL8;Q9BWU1;Q9HAZ1;Q9NYL2;Q9UEE5;Q9ULX7;Q9UNQ0,"InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)",KTUFNOKKBVMGRW-UHFFFAOYSA-N,CN1CCN(Cc2ccc(cc2)C(=O)Nc3ccc(C)c(Nc4nccc(n4)c5cccnc5)c3)CC1,,leukemia,Phase 1/2,,,NCT00093639,Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate,,https://ClinicalTrials.gov/show/NCT00093639
clinicaltrials.gov,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,imatinib,1561,O00444;O14976;O15244;O43570;P00519;P00533;P00915;P00918;P04049;P06239;P06241;P07333;P07451;P07948;P09619;P09769;P10721;P11274;P15056;P16083;P16234;P22748;P23280;P24557;P25021;P28223;P29322;P29597;P31645;P36888;P42684;P42685;P43166;P43405;P45983;P45984;P49759;P51451;P51617;P53779;Q08345;Q14680;Q15046;Q16790;Q16832;Q59H18;Q86VL8;Q8NE63;Q8TBX8;Q96FL8;Q9BWU1;Q9HAZ1;Q9NYL2;Q9UEE5;Q9ULX7;Q9UNQ0,"InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)",KTUFNOKKBVMGRW-UHFFFAOYSA-N,CN1CCN(Cc2ccc(cc2)C(=O)Nc3ccc(C)c(Nc4nccc(n4)c5cccnc5)c3)CC1,,leukemia,Phase 1/2,,,NCT01188889,RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.,,https://ClinicalTrials.gov/show/NCT01188889
clinicaltrials.gov,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,imatinib,1561,O00444;O14976;O15244;O43570;P00519;P00533;P00915;P00918;P04049;P06239;P06241;P07333;P07451;P07948;P09619;P09769;P10721;P11274;P15056;P16083;P16234;P22748;P23280;P24557;P25021;P28223;P29322;P29597;P31645;P36888;P42684;P42685;P43166;P43405;P45983;P45984;P49759;P51451;P51617;P53779;Q08345;Q14680;Q15046;Q16790;Q16832;Q59H18;Q86VL8;Q8NE63;Q8TBX8;Q96FL8;Q9BWU1;Q9HAZ1;Q9NYL2;Q9UEE5;Q9ULX7;Q9UNQ0,"InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)",KTUFNOKKBVMGRW-UHFFFAOYSA-N,CN1CCN(Cc2ccc(cc2)C(=O)Nc3ccc(C)c(Nc4nccc(n4)c5cccnc5)c3)CC1,,skin cancers,Phase 2,,,NCT00402662,A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma,,https://ClinicalTrials.gov/show/NCT00402662
clinicaltrials.gov,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,imatinib,1561,O00444;O14976;O15244;O43570;P00519;P00533;P00915;P00918;P04049;P06239;P06241;P07333;P07451;P07948;P09619;P09769;P10721;P11274;P15056;P16083;P16234;P22748;P23280;P24557;P25021;P28223;P29322;P29597;P31645;P36888;P42684;P42685;P43166;P43405;P45983;P45984;P49759;P51451;P51617;P53779;Q08345;Q14680;Q15046;Q16790;Q16832;Q59H18;Q86VL8;Q8NE63;Q8TBX8;Q96FL8;Q9BWU1;Q9HAZ1;Q9NYL2;Q9UEE5;Q9ULX7;Q9UNQ0,"InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)",KTUFNOKKBVMGRW-UHFFFAOYSA-N,CN1CCN(Cc2ccc(cc2)C(=O)Nc3ccc(C)c(Nc4nccc(n4)c5cccnc5)c3)CC1,,soft tissue cancers,Phase 1/2,,,NCT01275222,Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors,,https://ClinicalTrials.gov/show/NCT01275222
clinicaltrials.gov,ipilimumab,1238537,P16410,,,,imatinib,1561,O00444;O14976;O15244;O43570;P00519;P00533;P00915;P00918;P04049;P06239;P06241;P07333;P07451;P07948;P09619;P09769;P10721;P11274;P15056;P16083;P16234;P22748;P23280;P24557;P25021;P28223;P29322;P29597;P31645;P36888;P42684;P42685;P43166;P43405;P45983;P45984;P49759;P51451;P51617;P53779;Q08345;Q14680;Q15046;Q16790;Q16832;Q59H18;Q86VL8;Q8NE63;Q8TBX8;Q96FL8;Q9BWU1;Q9HAZ1;Q9NYL2;Q9UEE5;Q9ULX7;Q9UNQ0,"InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)",KTUFNOKKBVMGRW-UHFFFAOYSA-N,CN1CCN(Cc2ccc(cc2)C(=O)Nc3ccc(C)c(Nc4nccc(n4)c5cccnc5)c3)CC1,,,Phase 1,,,NCT01738139,Ipilimumab and Imatinib Mesylate in Advanced Cancer,,https://ClinicalTrials.gov/show/NCT01738139
literature,lonafarnib,278325,P49356;P49354,"InChI=1S/C27H31Br2ClN4O2/c28-20-12-19-2-1-18-13-21(30)14-22(29)24(18)25(26(19)32-15-20)17-5-9-33(10-6-17)23(35)11-16-3-7-34(8-4-16)27(31)36/h12-17,25H,1-11H2,(H2,31,36)/t25-/m1/s1",DHMTURDWPRKSOA-RUZDIDTESA-N,NC(=O)N1CCC(CC(=O)N2CCC(CC2)[C@H]3c4ncc(Br)cc4CCc5cc(Cl)cc(Br)c35)CC1,imatinib,1561,O00444;O14976;O15244;O43570;P00519;P00533;P00915;P00918;P04049;P06239;P06241;P07333;P07451;P07948;P09619;P09769;P10721;P11274;P15056;P16083;P16234;P22748;P23280;P24557;P25021;P28223;P29322;P29597;P31645;P36888;P42684;P42685;P43166;P43405;P45983;P45984;P49759;P51451;P51617;P53779;Q08345;Q14680;Q15046;Q16790;Q16832;Q59H18;Q86VL8;Q8NE63;Q8TBX8;Q96FL8;Q9BWU1;Q9HAZ1;Q9NYL2;Q9UEE5;Q9ULX7;Q9UNQ0,"InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)",KTUFNOKKBVMGRW-UHFFFAOYSA-N,CN1CCN(Cc2ccc(cc2)C(=O)Nc3ccc(C)c(Nc4nccc(n4)c5cccnc5)c3)CC1,chronic myeloid leukemia who have failed prior single-agent therapy with imatinib,leukemia,Phase 1,17623836,"A total of 23 patients were treated (9 with CP, 11 with AP, and 3 with BP) for a median of 25 weeks (range, 4-102 weeks). Of those with CP disease, 2 patients had grade 3 (according to the National Cancer Institute Common Toxicity Criteria [version 2.0]) dose-limiting toxicities (DLTs) at the 400 + 125-mg dose, including diarrhea (2 patients), vomiting (1 patient), and fatigue (1 patient). In patients with AP/BP disease, DLTs were observed at the 600 + 125-mg dose and was comprised of diarrhea (1 patient) and hypokalemia (1 patient). Eight patients (35%) responded; 3 with CP disease achieved a complete hematologic response (CHR) (2 patients) and a complete cytogenetic response (1 patient). Three patients with AP disease responded (2 CHR, 1 partial cytogenetic response), and 2 patients with BP disease demonstrated hematologic improvement. Pharmacokinetics data suggest no apparent increase in exposure or changes in the pharmacokinetics of either lonafarnib or imatinib when they are coadministered.",,,,
clinicaltrials.gov,nilotinib,457827,O15197;O43570;O94804;P00519;P00915;P00918;P04049;P06239;P06241;P07333;P07451;P07947;P07948;P07949;P08631;P09619;P09769;P10721;P11274;P12931;P15056;P16234;P21709;P22748;P23280;P29317;P29320;P29322;P29323;P35218;P35590;P41240;P42684;P42685;P43166;P45983;P45984;P49759;P51451;P53779;P54753;P54756;P54760;P54762;P54764;Q02763;Q08345;Q13163;Q15759;Q16288;Q16539;Q16620;Q16790;Q16832;Q59H18;Q7L7X3;Q8TBX8;Q92918;Q9H2K8;Q9HAZ1;Q9NYL2;Q9UF33;Q9ULX7;Q9Y5S2,"InChI=1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)",HHZIURLSWUIHRB-UHFFFAOYSA-N,Cc1cn(cn1)c2cc(NC(=O)c3ccc(C)c(Nc4nccc(n4)c5cccnc5)c3)cc(c2)C(F)(F)F,imatinib,1561,O00444;O14976;O15244;O43570;P00519;P00533;P00915;P00918;P04049;P06239;P06241;P07333;P07451;P07948;P09619;P09769;P10721;P11274;P15056;P16083;P16234;P22748;P23280;P24557;P25021;P28223;P29322;P29597;P31645;P36888;P42684;P42685;P43166;P43405;P45983;P45984;P49759;P51451;P51617;P53779;Q08345;Q14680;Q15046;Q16790;Q16832;Q59H18;Q86VL8;Q8NE63;Q8TBX8;Q96FL8;Q9BWU1;Q9HAZ1;Q9NYL2;Q9UEE5;Q9ULX7;Q9UNQ0,"InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)",KTUFNOKKBVMGRW-UHFFFAOYSA-N,CN1CCN(Cc2ccc(cc2)C(=O)Nc3ccc(C)c(Nc4nccc(n4)c5cccnc5)c3)CC1,,stomach cancers,Phase 2,,,NCT01089595,Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST),,https://ClinicalTrials.gov/show/NCT01089595
clinicaltrials.gov,tipifarnib,197794,P49356;P49354,"InChI=1S/C27H22Cl2N4O/c1-32-16-31-15-25(32)27(30,18-6-9-20(28)10-7-18)19-8-11-24-23(13-19)22(14-26(34)33(24)2)17-4-3-5-21(29)12-17/h3-16H,30H2,1-2H3/t27-/m1/s1",PLHJCIYEEKOWNM-HHHXNRCGSA-N,CN1C(=O)C=C(c2cccc(Cl)c2)c3cc(ccc13)[C@](N)(c4ccc(Cl)cc4)c5cncn5C,imatinib,1561,O00444;O14976;O15244;O43570;P00519;P00533;P00915;P00918;P04049;P06239;P06241;P07333;P07451;P07948;P09619;P09769;P10721;P11274;P15056;P16083;P16234;P22748;P23280;P24557;P25021;P28223;P29322;P29597;P31645;P36888;P42684;P42685;P43166;P43405;P45983;P45984;P49759;P51451;P51617;P53779;Q08345;Q14680;Q15046;Q16790;Q16832;Q59H18;Q86VL8;Q8NE63;Q8TBX8;Q96FL8;Q9BWU1;Q9HAZ1;Q9NYL2;Q9UEE5;Q9ULX7;Q9UNQ0,"InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)",KTUFNOKKBVMGRW-UHFFFAOYSA-N,CN1CCN(Cc2ccc(cc2)C(=O)Nc3ccc(C)c(Nc4nccc(n4)c5cccnc5)c3)CC1,,leukemia,Phase 1,,,NCT00040105,Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia,,https://ClinicalTrials.gov/show/NCT00040105
clinicaltrials.gov,pembrolizumab,,Q15116,,,,IMGN853,,,,,,Endometrial Cancer,,Phase 2,,,NCT03835819,,,
clinicaltrials.gov,ipilimumab,1238537,P16410,,,,IMO-2125,,,,,,,skin cancers,Phase 3,,,NCT03445533,A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE 301),illuminate 301,https://ClinicalTrials.gov/show/NCT03445533
clinicaltrials.gov,PDR001,,,,,,INC280,127878,P08581,"InChI=1S/C19H24Cl2N2O4S/c1-13-9-16(4-6-19(13)23-28(2,25)26)27-12-15(24)11-22-8-7-14-3-5-17(20)18(21)10-14/h3-6,9-10,15,22-24H,7-8,11-12H2,1-2H3/t15-/m0/s1",VWBZRYYMWZMKLF-HNNXBMFYSA-N,Cc1cc(OC[C@@H](O)CNCCc2ccc(Cl)c(Cl)c2)ccc1NS(=O)(=O)C,,liver cancers,Phase 1/2,,,NCT02795429,Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC,,https://ClinicalTrials.gov/show/NCT02795429
clinicaltrials.gov,INCB053914,,,,,,INCB050465,,,,,,,lymphoma,Phase 1,,,NCT03688152,A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma,,https://ClinicalTrials.gov/show/NCT03688152
clinicaltrials.gov,INCB053914,,,,,,INCB050465,,,,,,,lymphoma,Phase 1,,,NCT03688152,A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma,,https://ClinicalTrials.gov/show/NCT03688152
clinicaltrials.gov,enzalutamide,679762,P10275,"InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)",WXCXUHSOUPDCQV-UHFFFAOYSA-N,CNC(=O)c1ccc(cc1F)N2C(=S)N(C(=O)C2(C)C)c3ccc(C#N)c(c3)C(F)(F)F,indomethacin,725,P23219;P35354,"InChI=1S/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)",CGIGDMFJXJATDK-UHFFFAOYSA-N,COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c3ccc(Cl)cc3,,prostate cancers,Phase 1/2,,,NCT02935205,Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer,,https://ClinicalTrials.gov/show/NCT02935205
literature,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,infliximab,13,P01375,,,,advanced renal cell carcinoma,kidney cancers,Phase 1/2,20842130,"Acceptable safety was reported for the first three patients (infliximab 5_mg_kg__) in phase 1. Sorafenib 400_mg twice daily and infliximab 10_mg_kg__ were administered to a total of 13 patients (three in phase 1 and 10 in phase 2). Adverse events included grade 3 hand-foot syndrome (31%), rash (25%), fatigue (19%) and infection (19%). Although manageable, toxicity resulted in 75% of the patients requiring at least one dose reduction and 81% requiring at least one dose delay of sorafenib. Four patients were progression-free at 6 months (PFS_ 31%); median PFS and overall survival were 6 and 14 months, respectively.",,,,
clinicaltrials.gov,anti-OX40,,,,,,ipilimumab,1238537,P16410,,,,,skin cancers,Phase 1/2,,,NCT01689870,Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma,,https://ClinicalTrials.gov/show/NCT01689870
clinicaltrials.gov,CPI-1205,,,,,,ipilimumab,1238537,P16410,,,,,advanced solid cancers,Phase 1/2,,,NCT03525795,ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT03525795
clinicaltrials.gov,CPI-1205,,,,,,ipilimumab,1238537,P16410,,,,,advanced solid cancers,Phase 1/2,,,NCT03525795,ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT03525795
clinicaltrials.gov,CVA21,,,,,,ipilimumab,1238537,P16410,,,,,skin cancers,Phase 1,,,NCT03408587,CAVATAKÔÎ and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER),CLEVER,https://ClinicalTrials.gov/show/NCT03408587
clinicaltrials.gov,Evofosfamide,,,"InChI=1S/C9H16Br2N5O4P/c1-15-8(6-12-9(15)16(17)18)7-20-21(19,13-4-2-10)14-5-3-11/h6H,2-5,7H2,1H3,(H2,13,14,19)",UGJWRPJDTDGERK-UHFFFAOYSA-N,Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+](=O)[O-],ipilimumab,1238537,P16410,,,,,pancreatic cancers;skin cancers;head and neck cancers;prostate cancers,Phase 1,,,NCT03098160,Immunotherapy Study of Evofosfamide in Combination With Ipilimumab,,https://ClinicalTrials.gov/show/NCT03098160
clinicaltrials.gov,lirilumab,,P43626;P43627;P43628,,,,ipilimumab,1238537,P16410,,,,,,Phase 1,,,NCT01750580,Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor,,https://ClinicalTrials.gov/show/NCT01750580
clinicaltrials.gov,MGN1703,,,,,,ipilimumab,1238537,P16410,,,,,advanced solid cancers;skin cancers,Phase 1,,,NCT02668770,Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies,,https://ClinicalTrials.gov/show/NCT02668770
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,advanced solid cancers,Phase 1,,,NCT03195478,Study of Nivolumab in Combination With Ipilimumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors,,https://ClinicalTrials.gov/show/NCT03195478
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,advanced solid cancers,Phase 2,,,NCT03461952,Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe),NIMBLe,https://ClinicalTrials.gov/show/NCT03461952
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,bladder cancers,Phase 2,,,NCT03219775,Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma,TITAN-TCC,https://ClinicalTrials.gov/show/NCT03219775
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,bladder cancers;skin cancers,Phase 2,,,NCT02553642,Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260),,https://ClinicalTrials.gov/show/NCT02553642
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,breast cancers;ovarian cancers;oesophageal cancers;stomach cancers,Phase 2,,,NCT03342417,"Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients",,https://ClinicalTrials.gov/show/NCT03342417
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,central nervous system cancers,Phase 2,,,NCT03130959,An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies,CheckMate 908,https://ClinicalTrials.gov/show/NCT03130959
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,head and neck cancers,Phase 1/2,,,NCT03003637,ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma,IMCISION,https://ClinicalTrials.gov/show/NCT03003637
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,head and neck cancers,Phase 2,,,NCT03406247,"Immunotherapy in Head and Neck Squamous Cell Carcinoma : Phase 2 Trial Evaluating the Efficacy and the Toxicity of Nivolumab Alone, and of the Combination Nivolumab and Ipilimumab",ADJORL1,https://ClinicalTrials.gov/show/NCT03406247
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,kidney cancers,Phase 2,,,NCT03177239,UNISoN: anzUp Nivo Then Ipi+Nivo in Sequential Non-clear Cell.,UNISoN,https://ClinicalTrials.gov/show/NCT03177239
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,kidney cancers,Phase 4,,,NCT02982954,A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer,CHECKMATE 920,https://ClinicalTrials.gov/show/NCT02982954
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,kidney cancers,Phase 2,,,NCT03297593,Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT03297593
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,kidney cancers,Phase 2,,,NCT03274258,Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma,,https://ClinicalTrials.gov/show/NCT03274258
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,leukemia,Phase 1,,,NCT02846376,Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant,CPIT-002,https://ClinicalTrials.gov/show/NCT02846376
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,liver cancers,Phase 1,,,NCT03203304,Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer,,https://ClinicalTrials.gov/show/NCT03203304
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,lung cancers,Phase 2,,,NCT03001882,An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC),CheckMate 592,https://ClinicalTrials.gov/show/NCT03001882
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,lung cancers,Phase 2,,,NCT02259621,"Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC",NA_00092076,https://ClinicalTrials.gov/show/NCT02259621
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,lung cancers,Phase 2,,,NCT03083691,BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer,,https://ClinicalTrials.gov/show/NCT03083691
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,lung cancers,Phase 3,,,NCT03048136,A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer,CheckMate 955,https://ClinicalTrials.gov/show/NCT03048136
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,lung cancers,Phase 2,,,NCT03285321,Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC),,https://ClinicalTrials.gov/show/NCT03285321
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,lung cancers,Phase 2,,,NCT03262779,Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.,,https://ClinicalTrials.gov/show/NCT03262779
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,oesophageal cancers;stomach cancers,Phase 2,,,NCT03416244,A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer,RAMONA,https://ClinicalTrials.gov/show/NCT03416244
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,oesophageal cancers;stomach cancers,Phase 2,,,NCT03409848,Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma,INTEGA,https://ClinicalTrials.gov/show/NCT03409848
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,other,Phase 2,,,NCT03420521,Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors,,https://ClinicalTrials.gov/show/NCT03420521
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,ovarian cancers;female cancers;kidney cancers,Phase 2,,,NCT03355976,BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas,,https://ClinicalTrials.gov/show/NCT03355976
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,prostate cancers,Phase 2,,,NCT03061539,Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature,,https://ClinicalTrials.gov/show/NCT03061539
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,skin cancers,Phase 1,,,NCT01024231,Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma,,https://ClinicalTrials.gov/show/NCT01024231
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,skin cancers,Phase 1/2,,,NCT02736123,Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone,,https://ClinicalTrials.gov/show/NCT02736123
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,skin cancers,Phase 2,,,NCT02978443,A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab,,https://ClinicalTrials.gov/show/NCT02978443
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,skin cancers,Phase 2,,,NCT02939300,Ipilimumab and Nivolumab in Leptomeningeal Metastases From Melanoma,,https://ClinicalTrials.gov/show/NCT02939300
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,skin cancers,Phase 2,,,NCT01585194,Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma,,https://ClinicalTrials.gov/show/NCT01585194
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,thyroid cancers,Phase 2,,,NCT03246958,Nivolumab Plus Ipilimumab in Thyroid Cancer,,https://ClinicalTrials.gov/show/NCT03246958
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,breast cancers,Phase 2,,,NCT03789110,NIMBUS: A Phase II Study of Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer,,https://ClinicalTrials.gov/show/NCT03789110
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,other,Phase 2,,,NCT03591731,"A GCO Trial Exploring the Efficacy and Safety of Nivolumab Monotherapy or Nivolumab Plus Ipilimumab in Pre-treated Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)",NIPINEC,https://ClinicalTrials.gov/show/NCT03591731
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,advanced solid cancers,Phase 2,,,NCT03651271,Treatment With Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumoral CD8 Cells in Advanced Metastatic Cancer,,https://ClinicalTrials.gov/show/NCT03651271
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,skin cancers,Phase 2,,,NCT03521830,Nivolumab Alone or Plus Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT03521830
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,prostate cancers,Phase 2,,,NCT03570619,Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations,IMPACT,https://ClinicalTrials.gov/show/NCT03570619
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,skin cancers,Phase 2,,,NCT03528408,Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma,,https://ClinicalTrials.gov/show/NCT03528408
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,skin cancers,Phase 2,,,NCT03728465,Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma,,https://ClinicalTrials.gov/show/NCT03728465
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,,Phase 2,,,NCT03668119,A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H),CheckMate 848,https://ClinicalTrials.gov/show/NCT03668119
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,breast cancers,Phase 2,,,NCT03789110,NIMBUS: A Phase II Study of Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer,,https://ClinicalTrials.gov/show/NCT03789110
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,other,Phase 2,,,NCT03591731,"A GCO Trial Exploring the Efficacy and Safety of Nivolumab Monotherapy or Nivolumab Plus Ipilimumab in Pre-treated Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)",NIPINEC,https://ClinicalTrials.gov/show/NCT03591731
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,advanced solid cancers,Phase 2,,,NCT03651271,Treatment With Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumoral CD8 Cells in Advanced Metastatic Cancer,,https://ClinicalTrials.gov/show/NCT03651271
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,skin cancers,Phase 2,,,NCT03521830,Nivolumab Alone or Plus Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT03521830
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,prostate cancers,Phase 2,,,NCT03570619,Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations,IMPACT,https://ClinicalTrials.gov/show/NCT03570619
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,skin cancers,Phase 2,,,NCT03528408,Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma,,https://ClinicalTrials.gov/show/NCT03528408
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,skin cancers,Phase 2,,,NCT03728465,Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma,,https://ClinicalTrials.gov/show/NCT03728465
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,,Phase 2,,,NCT03668119,A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H),CheckMate 848,https://ClinicalTrials.gov/show/NCT03668119
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,Urinary Bladder Cancer|Invasive Bladder Cancer,,Phase 1/2,,,NCT03844256,,,
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,,,,,NCT04013854,Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab,,https://ClinicalTrials.gov/show/NCT04013854
clinicaltrials.gov,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,,,,,,NCT04006262,"Peri-operative Association of Immunotherapy (Pre-operative Association of Nivolumab and Ipilimumab, Post-operative Nivolumab Alone) in Localized Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR) Oeso-gastric Adenocarcinoma",NEONIPIGA,https://ClinicalTrials.gov/show/NCT04006262
literature,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,patients with metastatic renal cell carcinoma,kidney cancers,Phase 1,28678668,"All patients in the N3I3 arm (n = 6) were censored at the time of analysis as a result of dose-limiting toxicity or other reasons. Forty-seven patients were treated in both the N3I1 and the N1I3 arm, and baseline patient characteristics were balanced between arms. Grade 3 to 4 treatment-related adverse events were reported in 38.3% and 61.7% of the patients in the N3I1 and N1I3 arms, respectively. At a median follow-up of 22.3 months, the confirmed objective response rate was 40.4% in both arms, with ongoing responses in 42.1% and 36.8% of patients in the N3I1 and N1I3 arms, respectively. The 2-year OS was 67.3% and 69.6% in the N3I1 and N1I3 arms, respectively. Conclusion Nivolumab plus ipilimumab therapy demonstrated manageable safety, notable antitumor activity, and durable responses with promising OS in patients with mRCC.",,,,
literature,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,untreated melanoma,skin cancers,Phase 1,25891304,"Among patients with BRAF wild-type tumors, the rate of confirmed objective response was 61% (44 of 72 patients) in the group that received both ipilimumab and nivolumab (combination group) versus 11% (4 of 37 patients) in the group that received ipilimumab and placebo (ipilimumab-monotherapy group) (P<0.001), with complete responses reported in 16 patients (22%) in the combination group and no patients in the ipilimumab-monotherapy group. The median duration of response was not reached in either group. The median progression-free survival was not reached with the combination therapy and was 4.4 months with ipilimumab monotherapy (hazard ratio associated with combination therapy as compared with ipilimumab monotherapy for disease progression or death, 0.40; 95% confidence interval, 0.23 to 0.68; P<0.001). Similar results for response rate and progression-free survival were observed in 33 patients with BRAF mutation-positive tumors. Drug-related adverse events of grade 3 or 4 were reported in 54% of the patients who received the combination therapy as compared with 24% of the patients who received ipilimumab monotherapy. Select adverse events with potential immunologic causes were consistent with those in a phase 1 study, and most of these events resolved with immune-modulating medication.",,,,
literature,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,Untreated Melanoma,skin cancers,Phase 3,26027431,"The median progression-free survival was 11.5 months (95% confidence interval [CI], 8.9 to 16.7) with nivolumab plus ipilimumab, as compared with 2.9 months (95% CI, 2.8 to 3.4) with ipilimumab (hazard ratio for death or disease progression, 0.42; 99.5% CI, 0.31 to 0.57; P<0.001), and 6.9 months (95% CI, 4.3 to 9.5) with nivolumab (hazard ratio for the comparison with ipilimumab, 0.57; 99.5% CI, 0.43 to 0.76; P<0.001). In patients with tumors positive for the PD-1 ligand (PD-L1), the median progression-free survival was 14.0 months in the nivolumab-plus-ipilimumab group and in the nivolumab group, but in patients with PD-L1-negative tumors, progression-free survival was longer with the combination therapy than with nivolumab alone (11.2 months [95% CI, 8.0 to not reached] vs. 5.3 months [95% CI, 2.8 to 7.1]). Treatment-related adverse events of grade 3 or 4 occurred in 16.3% of the patients in the nivolumab group, 55.0% of those in the nivolumab-plus-ipilimumab group, and 27.3% of those in the ipilimumab group.",,,,
literature,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,patients with advanced melanoma,skin cancers,Phase 1/2,27622997,"Between Sept 16, 2013, and Feb 6, 2014, we screened 179 patients and enrolled 142, randomly assigning 95 patients to nivolumab plus ipilimumab and 47 to ipilimumab alone. In each treatment group, one patient no longer met the study criteria following randomisation and thus did not receive study drug. At a median follow-up of 24à5 months (IQR 9à1-25à7), 2-year overall survival was 63à8% (95% CI 53à3-72à6) for those assigned to nivolumab plus ipilimumab and 53à6% (95% CI 38à1-66à8) for those assigned to ipilimumab alone; median overall survival had not been reached in either group (hazard ratio 0à74, 95% CI 0à43-1à26; p=0à26). Treatment-related grade 3-4 adverse events were reported in 51 (54%) of 94 patients who received nivolumab plus ipilimumab compared with nine (20%) of 46 patients who received ipilimumab alone. The most common treatment-related grade 3-4 adverse events were colitis (12 [13%] of 94 patients) and increased alanine aminotransferase (ten [11%]) in the combination group and diarrhoea (five [11%] of 46 patients) and hypophysitis (two [4%]) in the ipilimumab alone group. Serious grade 3-4 treatment-related adverse events were reported in 34 (36%) of 94 patients who received nivolumab plus ipilimumab (including colitis in ten [11%] of 94 patients, and diarrhoea in five [5%]) compared with four (9%) of 46 patients who received ipilimumab alone (including diarrhoea in two [4%] of 46 patients, colitis in one [2%], and hypophysitis in one [2%]). No new types of treatment-related adverse events or treatment-related deaths occurred in this updated analysis.",,,,
literature,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,patients with advanced melanoma,skin cancers,Phase 1b,28729151,"Between Jan 13, 2015, and Sept 17, 2015, we enrolled and treated 153 patients. As of the Oct 17, 2016, cutoff date, median follow-up was 17à0 months (IQR 14à8-18à8). 110 (72%) of 153 patients received all four pembrolizumab plus ipilimumab doses; 64 (42%) remained on pembrolizumab monotherapy. 110 grade 3-4 treatment-related adverse events occurred in 69 (45%) patients. No treatment-related deaths occurred. Treatment-related adverse events led to discontinuation of pembrolizumab and ipilimumab in 22 (14%) patients, including 17 (11%) who discontinued both treatments for the same event and five (3%) who discontinued ipilimumab for one event and later discontinued pembrolizumab for another. 12 (8%) patients discontinued ipilimumab only and 14 (9%) discontinued pembrolizumab only because of treatment-related adverse events. 158 immune-mediated adverse events of any grade occurred in 92 (60%) patients, and 50 immune-mediated adverse events of grade 3-4 occurred in 42 (27%) patients; the most common immune-mediated adverse events were hypothyroidism (25 [16%]) and hyperthyroidism (17 [11%]). 93 (61% [95% CI 53-69]) patients achieved an objective response. Estimated_1year progression-free survival was 69% (95% CI 60-75), and estimated_1_year overall survival was 89% (95% CI 83-93).",,,,
literature,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,advanced melanoma,skin cancers,Phase 3,28889792,"At a minimum follow-up of 36 months, the median overall survival had not been reached in the nivolumab-plus-ipilimumab group and was 37.6 months in the nivolumab group, as compared with 19.9 months in the ipilimumab group (hazard ratio for death with nivolumab plus ipilimumab vs. ipilimumab, 0.55 [P<0.001]; hazard ratio for death with nivolumab vs. ipilimumab, 0.65 [P<0.001]). The overall survival rate at 3 years was 58% in the nivolumab-plus-ipilimumab group and 52% in the nivolumab group, as compared with 34% in the ipilimumab group. The safety profile was unchanged from the initial report. Treatment-related adverse events of grade 3 or 4 occurred in 59% of the patients in the nivolumab-plus-ipilimumab group, in 21% of those in the nivolumab group, and in 28% of those in the ipilimumab group.",,,,
literature,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,"patients were aged 18 years or older with previously untreated, unresectable, stage III or stage IV melanoma, known BRAFV600 mutation status, and an Eastern Cooperative Oncology Group performance status of 0 or 1",skin cancers,Phase 3,30361170,"Between July 3, 2013, and March 31, 2014, 945 patients were enrolled and randomly assigned to nivolumab plus ipilimumab (n=314), nivolumab (n=316), or ipilimumab (n=315). Median follow-up was 46·9 months (IQR 10·9-51·8) in the nivolumab plus ipilimumab group, 36·0 months (10·5-51·4) in the nivolumab group, and 18·6 months (7·6-49·5) in the ipilimumab group. At a minimum follow-up of 48 months from the date that the final patient was enrolled and randomised, median overall survival was not reached (95% CI 38·2-not reached) in the nivolumab plus ipilimumab group, 36·9 months (28·3-not reached) in the nivolumab group, and 19·9 months (16·9-24·6) in the ipilimumab group. The hazard ratio for death for the combination versus ipilimumab was 0·54 (95% CI 0·44-0·67; p<0·0001) and for nivolumab versus ipilimumab was 0·65 (0·53-0·79; p<0·0001). Median progression-free survival was 11·5 months (95% CI 8·7-19·3) in the nivolumab plus ipilimumab group, 6·9 months (5·1-10·2) in the nivolumab group, and 2·9 months (2·8-3·2) in the ipilimumab group. The hazard ratio for progression-free survival for the combination versus ipilimumab was 0·42 (95% CI 0·35-0·51; p<0·0001) and for nivolumab versus ipilimumab was 0·53 (0·44-0·64; p<0·0001). Treatment-related grade 3-4 adverse events were reported in 185 (59%) of 313 patients who received nivolumab plus ipilimumab, 70 (22%) of 313 who received nivolumab, and 86 (28%) of 311 who received ipilimumab. The most common treatment-related grade 3 adverse events were diarrhoea in the nivolumab plus ipilimumab group (29 [9%] of 313) and in the nivolumab group (nine [3%] of 313) and colitis in the ipilimumab group (23 [7%] of 311); the most common grade 4 adverse event in all three groups was increased lipase (15 [5%] of 313 in the combination group, ten [3%] of 313 in the nivolumab group, and four [1%] of 311 in the ipilimumab group). Serious adverse events were not analysed for the 4-year follow-up. In total for the study, there were four treatment-related deaths: two in the nivolumab plus ipilimumab group (one cardiomyopathy and one liver necrosis), one in the nivolumab group (neutropenia), and one in the ipilimumab group (colon perforation). No additional treatment-related deaths have occurred since the previous (3-year) analysis.",,,,
literature,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,"Patients were aged 18 years or older with previously untreated, unresectable, stage III or stage IV melanoma, known BRAFV600 mutation status, and an Eastern Cooperative Oncology Group performance status of 0 or 1",skin cancers,Phase 3,30361170,"Between July 3, 2013, and March 31, 2014, 945 patients were enrolled and randomly assigned to nivolumab plus ipilimumab (n=314), nivolumab (n=316), or ipilimumab (n=315). Median follow-up was 46·9 months (IQR 10·9-51·8) in the nivolumab plus ipilimumab group, 36·0 months (10·5-51·4) in the nivolumab group, and 18·6 months (7·6-49·5) in the ipilimumab group. At a minimum follow-up of 48 months from the date that the final patient was enrolled and randomised, median overall survival was not reached (95% CI 38·2-not reached) in the nivolumab plus ipilimumab group, 36·9 months (28·3-not reached) in the nivolumab group, and 19·9 months (16·9-24·6) in the ipilimumab group. The hazard ratio for death for the combination versus ipilimumab was 0·54 (95% CI 0·44-0·67; p<0·0001) and for nivolumab versus ipilimumab was 0·65 (0·53-0·79; p<0·0001). Median progression-free survival was 11·5 months (95% CI 8·7-19·3) in the nivolumab plus ipilimumab group, 6·9 months (5·1-10·2) in the nivolumab group, and 2·9 months (2·8-3·2) in the ipilimumab group. The hazard ratio for progression-free survival for the combination versus ipilimumab was 0·42 (95% CI 0·35-0·51; p<0·0001) and for nivolumab versus ipilimumab was 0·53 (0·44-0·64; p<0·0001). Treatment-related grade 3-4 adverse events were reported in 185 (59%) of 313 patients who received nivolumab plus ipilimumab, 70 (22%) of 313 who received nivolumab, and 86 (28%) of 311 who received ipilimumab. The most common treatment-related grade 3 adverse events were diarrhoea in the nivolumab plus ipilimumab group (29 [9%] of 313) and in the nivolumab group (nine [3%] of 313) and colitis in the ipilimumab group (23 [7%] of 311); the most common grade 4 adverse event in all three groups was increased lipase (15 [5%] of 313 in the combination group, ten [3%] of 313 in the nivolumab group, and four [1%] of 311 in the ipilimumab group). Serious adverse events were not analysed for the 4-year follow-up. In total for the study, there were four treatment-related deaths: two in the nivolumab plus ipilimumab group (one cardiomyopathy and one liver necrosis), one in the nivolumab group (neutropenia), and one in the ipilimumab group (colon perforation). No additional treatment-related deaths have occurred since the previous (3-year) analysis.",,,,
literature,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,patients with relapsed malignant pleural mesothelioma,lung cancers,Phase 2,30660609,"Between March 24 and August 25, 2016, 125 eligible patients were recruited and assigned to either nivolumab (n=63) or nivolumab plus ipilimumab (n=62). In the first 108 eligible patients, 12-week disease control was achieved by 24 (44%; 95% CI 31-58) of 54 patients in the nivolumab group and 27 (50%; 37-63) of 54 patients in the nivolumab plus ipilimumab group. In the intention-to-treat population, 12-week disease control was achieved by 25 (40%; 28-52) of 63 patients in the nivolumab group and 32 (52%; 39-64) of 62 patients in the combination group. Nine (14%) of 63 patients in the nivolumab group and 16 (26%) of 61 patients in the combination group had grade 3-4 toxicities. The most frequent grade 3 adverse events were asthenia (one [2%] in the nivolumab group vs three [5%] in the combination group), asymptomatic increase in aspartate aminotransferase or alanine aminotransferase (none vs four [7%] of each), and asymptomatic lipase increase (two [3%] vs one [2%]). No patients had toxicities leading to death in the nivolumab group, whereas three (5%) of 62 in the combination group did (one fulminant hepatitis, one encephalitis, and one acute kidney failure).",,,,
literature,nivolumab,,Q15116,,,,ipilimumab,1238537,P16410,,,,Patients With Advanced Melanoma,skin cancers,Phase 3b/4,30811280,"At a minimum follow-up of 12 months, incidence of treatment-related grade 3 to 5 AEs was 34% with NIVO3+IPI1 versus 48% with NIVO1+IPI3 ( P = .006). In descriptive analyses, objective response rate was 45.6% in the NIVO3+IPI1 group and 50.6% in the NIVO1+IPI3 group, with complete responses in 15.0% and 13.5% of patients, respectively. Median progression-free survival was 9.9 months in the NIVO3+IPI1 group and 8.9 months in the NIVO1+IPI3 group. Median overall survival was not reached in either group.",,,,
clinicaltrials.gov,panobinostat,523996,Q9BY41;Q969S8;O15379;P56524;Q8WUI4;Q9UQL6;Q9UKV0;Q13547;Q92769;Q9UBN7;Q96DB2,"InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+",FPOHNWQLNRZRFC-ZHACJKMWSA-N,Cc1[nH]c2ccccc2c1CCNCc3ccc(\C=C\C(=O)NO)cc3,ipilimumab,1238537,P16410,,,,,skin cancers,Phase 1,,,NCT02032810,Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma,,https://ClinicalTrials.gov/show/NCT02032810
clinicaltrials.gov,relatlimab,,,,,,ipilimumab,1238537,P16410,,,,,,,,,NCT03978611,A Study to Assess Safety and Efficacy of relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-PD-1 Treatment,,https://ClinicalTrials.gov/show/NCT03978611
clinicaltrials.gov,SGI-110,1311517,,"InChI=1S/C18H24N9O10P/c19-16-22-6-27(18(31)25-16)12-2-8(9(3-28)35-12)37-38(32,33)34-4-10-7(29)1-11(36-10)26-5-21-13-14(26)23-17(20)24-15(13)30/h5-12,28-29H,1-4H2,(H,32,33)(H2,19,25,31)(H3,20,23,24,30)/t7-,8-,9+,10+,11+,12+/m0/s1",GUWXKKAWLCENJA-WGWHJZDNSA-N,NC1=Nc2c(ncn2[C@H]3C[C@H](O)[C@@H](COP(=O)(O)O[C@H]4C[C@@H](O[C@@H]4CO)N5C=NC(=NC5=O)N)O3)C(=O)N1,ipilimumab,1238537,P16410,,,,,skin cancers,Phase 1,,,NCT02608437,A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients,NIBIT-M4,https://ClinicalTrials.gov/show/NCT02608437
clinicaltrials.gov,sipuleucel-T,,,,,,ipilimumab,1238537,P16410,,,,,prostate cancers,Phase 1,,,NCT01832870,Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer,,https://ClinicalTrials.gov/show/NCT01832870
clinicaltrials.gov,Vopratelimab,,,,,,ipilimumab,1238537,P16410,,,,,,,,,NCT03989362,Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer,EMERGE,https://ClinicalTrials.gov/show/NCT03989362
clinicaltrials.gov,romidepsin,761764,Q96DB2;Q9UBN7;Q92769;Q13547;Q9UKV0;Q9UQL6;Q8WUI4;P56524;O15379;Q969S8;Q9BY41,"InChI=1S/C25H39N3O6S2/c1-6-19-23(31)28-21(15(4)5)25(33)34-17(9-7-8-10-35)11-16(29)12-18(14(2)3)22(30)27-20(13-36)24(32)26-19/h6-7,9,14-15,17-18,20-21,35-36H,8,10-13H2,1-5H3,(H,26,32)(H,27,30)(H,28,31)/b9-7+,19-6-/t17-,18-,20-,21+/m1/s1",UPCFDQLGZODPFB-BXJZLCHMSA-N,C\C=C\1/NC(=O)[C@@H](CS)NC(=O)[C@H](CC(=O)C[C@H](OC(=O)[C@@H](NC1=O)C(C)C)\C=C\CCS)C(C)C,ixazomib,1069383,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C14H19BCl2N2O4/c1-8(2)5-12(15(22)23)19-13(20)7-18-14(21)10-6-9(16)3-4-11(10)17/h3-4,6,8,12,22-23H,5,7H2,1-2H3,(H,18,21)(H,19,20)/t12-/m0/s1",MXAYKZJJDUDWDS-LBPRGKRZSA-N,,,lymphoma,Phase 1/2,,,NCT03547700,Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL),,https://ClinicalTrials.gov/show/NCT03547700
clinicaltrials.gov,romidepsin,761764,Q96DB2;Q9UBN7;Q92769;Q13547;Q9UKV0;Q9UQL6;Q8WUI4;P56524;O15379;Q969S8;Q9BY41,"InChI=1S/C25H39N3O6S2/c1-6-19-23(31)28-21(15(4)5)25(33)34-17(9-7-8-10-35)11-16(29)12-18(14(2)3)22(30)27-20(13-36)24(32)26-19/h6-7,9,14-15,17-18,20-21,35-36H,8,10-13H2,1-5H3,(H,26,32)(H,27,30)(H,28,31)/b9-7+,19-6-/t17-,18-,20-,21+/m1/s1",UPCFDQLGZODPFB-BXJZLCHMSA-N,C\C=C\1/NC(=O)[C@@H](CS)NC(=O)[C@H](CC(=O)C[C@H](OC(=O)[C@@H](NC1=O)C(C)C)\C=C\CCS)C(C)C,ixazomib,1069383,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C14H19BCl2N2O4/c1-8(2)5-12(15(22)23)19-13(20)7-18-14(21)10-6-9(16)3-4-11(10)17/h3-4,6,8,12,22-23H,5,7H2,1-2H3,(H,18,21)(H,19,20)/t12-/m0/s1",MXAYKZJJDUDWDS-LBPRGKRZSA-N,CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,,lymphoma,Phase 1/2,,,NCT03547700,Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL),,https://ClinicalTrials.gov/show/NCT03547700
clinicaltrials.gov,CM082,,,,,,JS001,,,,,,,other,Phase 2,,,NCT03602547,Study of the Combination of CM082 With JS001 in Patients With Advanced Mucinous Melanoma.,,https://ClinicalTrials.gov/show/NCT03602547
clinicaltrials.gov,CM082,,,,,,JS001,,,,,,,other,Phase 2,,,NCT03602547,Study of the Combination of CM082 With JS001 in Patients With Advanced Mucinous Melanoma.,,https://ClinicalTrials.gov/show/NCT03602547
clinicaltrials.gov,CM082,,,,,,JS001,,,,,,Non-small Cell Lung Cancer,,Phase 2,,,NCT03848611,,,
clinicaltrials.gov,utomilumab,,,,,,KW-0761,,,,,,,advanced solid cancers,Phase 1,,,NCT02444793,A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT02444793
clinicaltrials.gov,PDR001,,,,,,LAG525,,,,,,,lung cancers;stomach cancers;oesophageal cancers;protsate cancers;soft tissue cancers;ovarian cancers;other;lymphoma,Phase 2,,,NCT03365791,PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies,,https://ClinicalTrials.gov/show/NCT03365791
clinicaltrials.gov,bevacizumab,11,P15692,,,,lapatinib,2195,O00750;O14733;O43353;O75747;O94804;P00533;P04626;P08684;P09619;P21860;Q13163;Q15303;Q9H2G2;Q9UBF8,"InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)",BCFGMOOMADDAQU-UHFFFAOYSA-N,CS(=O)(=O)CCNCc1oc(cc1)c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2,,brain cancers,Phase 2,,,NCT00883688,Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma,,https://ClinicalTrials.gov/show/NCT00883688
literature,buparlisib,962639,O00329;O00459;P27986;P42336;P42338;P48736;Q8WYR1;Q92569,"InChI=1S/C18H21F3N6O2/c19-18(20,21)13-9-15(22)23-11-12(13)14-10-16(26-1-5-28-6-2-26)25-17(24-14)27-3-7-29-8-4-27/h9-11H,1-8H2,(H2,22,23)",CWHUFRVAEUJCEF-UHFFFAOYSA-N,Nc1cc(c(cn1)c2cc(nc(n2)N3CCOCC3)N4CCOCC4)C(F)(F)F,lapatinib,2195,O00750;O14733;O43353;O75747;O94804;P00533;P04626;P08684;P09619;P21860;Q13163;Q15303;Q9H2G2;Q9UBF8,"InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)",BCFGMOOMADDAQU-UHFFFAOYSA-N,CS(=O)(=O)CCNCc1oc(cc1)c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2,HER2-positive advanced Breast_Cancer,breast cancers,Phase 1b,28950146,"A total of 24 patients were treated across five dose levels. Dose-limiting toxicities included transaminases elevation, vomiting, stomatitis, hyperglycemia and diarrhoea. MTD was declared at buparlisib 80_mg/d_+_lapatinib 1250_mg/d, but toxicities and early treatment discontinuation rate beyond cycle_1_led to select buparlisib 80_mg_+_lapatinib 1000_mg/d as the RP2D. Main drug-related adverse events included diarrhoea, nausea, skin rash, asthenia, depression, anxiety and transaminases increase. There was no significant evidence for drug-drug PK interaction. Disease control rate was 79% [95% confidence interval [CI] 57-92%], one patient obtained a complete remission, and six additional patients experienced stable disease for___24 weeks (clinical benefit rate of 29% [95% CI 12-51%]).",,,,
literature,cetuximab,9,P00533,,,,lapatinib,2195,O00750;O14733;O43353;O75747;O94804;P00533;P04626;P08684;P09619;P21860;Q13163;Q15303;Q9H2G2;Q9UBF8,"InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)",BCFGMOOMADDAQU-UHFFFAOYSA-N,CS(=O)(=O)CCNCc1oc(cc1)c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2,advanced solid tumor malignancies,advanced solid cancers,Phase 1,25641763,"Twenty-two patients were enrolled, and 18 patients each were evaluable for toxicity and response. Fifty-nine percent of patients had received prior anti-EGFR therapy. Common toxicities included rash and diarrhea. No patient experienced a DLT at the highest dose level, and no grade 4 toxicity was observed. Response included no complete responses, 3 partial responses, 9 patients with stable disease, and 6 patients with disease progression, for an overall response rate of 17% and a clinical benefit rate of 67%. The clinical benefit rate in patients who had previously received anti-EGFR therapy was 70%. The mean treatment duration was 4.7 cycles (range, 1-14 cycles). Decreased expression of EGFR/ErbB2 pathway components after treatment was correlated with response, whereas increased expression in the PI3K, Jak/Stat, and MAPK pathways occurred in nonresponders.",,,,
clinicaltrials.gov,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,lapatinib,2195,O00750;O14733;O43353;O75747;O94804;P00533;P04626;P08684;P09619;P21860;Q13163;Q15303;Q9H2G2;Q9UBF8,"InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)",BCFGMOOMADDAQU-UHFFFAOYSA-N,CS(=O)(=O)CCNCc1oc(cc1)c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2,,lymphoma,Phase 1,,,NCT00352443,S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma,,https://ClinicalTrials.gov/show/NCT00352443
clinicaltrials.gov,foretinib,753913,P08581;P09619;P16234;P10721;Q02763;P36888;P35968;P17948;P35916,"InChI=1S/C34H34F2N4O6/c1-43-30-20-25-27(21-31(30)45-16-2-13-40-14-17-44-18-15-40)37-12-9-28(25)46-29-8-7-24(19-26(29)36)39-33(42)34(10-11-34)32(41)38-23-5-3-22(35)4-6-23/h3-9,12,19-21H,2,10-11,13-18H2,1H3,(H,38,41)(H,39,42)",CXQHYVUVSFXTMY-UHFFFAOYSA-N,COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5)cc3F)ccnc2cc1OCCCN6CCOCC6,lapatinib,2195,O00750;O14733;O43353;O75747;O94804;P00533;P04626;P08684;P09619;P21860;Q13163;Q15303;Q9H2G2;Q9UBF8,"InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)",BCFGMOOMADDAQU-UHFFFAOYSA-N,CS(=O)(=O)CCNCc1oc(cc1)c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2,,breast cancers,Phase 1/2,,,NCT01138384,Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer,,https://ClinicalTrials.gov/show/NCT01138384
clinicaltrials.gov,pazopanib,200268,O00238;O00444;O14965;O14976;O15197;O43353;O60331;O60674;O75716;O94804;O95819;P00519;P04049;P06239;P06241;P07332;P07333;P07947;P07948;P07949;P08581;P08631;P08922;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P16591;P17948;P19525;P21127;P21802;P22455;P22607;P27448;P29376;P29597;P33981;P35590;P35916;P35968;P36888;P37173;P42681;P42684;P42685;P43405;P45983;P45985;P51451;P51617;P51955;P52333;P52564;P53667;P53671;P53779;P57059;P80192;Q00536;Q02763;Q02779;Q08345;Q12851;Q12866;Q13163;Q13233;Q13470;Q13546;Q13705;Q13882;Q14012;Q16584;Q16832;Q2M2I8;Q56UN5;Q6P3R8;Q7L7X3;Q8IVH8;Q8TBX8;Q92918;Q96NX5;Q9BVS4;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K8;Q9H3Y6;Q9NRP7;Q9NSY1;Q9UBE8;Q9UBF8;Q9UKE5;Q9UL54;Q9UM73;Q9UQ88;Q9UQB9;Q9Y2U5;Q9Y4K4;Q9Y616,"InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)",CUIHSIWYWATEQL-UHFFFAOYSA-N,CN(c1ccc2c(C)n(C)nc2c1)c3ccnc(Nc4ccc(C)c(c4)S(=O)(=O)N)n3,lapatinib,2195,O00750;O14733;O43353;O75747;O94804;P00533;P04626;P08684;P09619;P21860;Q13163;Q15303;Q9H2G2;Q9UBF8,"InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)",BCFGMOOMADDAQU-UHFFFAOYSA-N,CS(=O)(=O)CCNCc1oc(cc1)c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2,,cervical cancers,Phase 2,,,NCT00430781,Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer,,https://ClinicalTrials.gov/show/NCT00430781
clinicaltrials.gov,pazopanib,200268,O00238;O00444;O14965;O14976;O15197;O43353;O60331;O60674;O75716;O94804;O95819;P00519;P04049;P06239;P06241;P07332;P07333;P07947;P07948;P07949;P08581;P08631;P08922;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P16591;P17948;P19525;P21127;P21802;P22455;P22607;P27448;P29376;P29597;P33981;P35590;P35916;P35968;P36888;P37173;P42681;P42684;P42685;P43405;P45983;P45985;P51451;P51617;P51955;P52333;P52564;P53667;P53671;P53779;P57059;P80192;Q00536;Q02763;Q02779;Q08345;Q12851;Q12866;Q13163;Q13233;Q13470;Q13546;Q13705;Q13882;Q14012;Q16584;Q16832;Q2M2I8;Q56UN5;Q6P3R8;Q7L7X3;Q8IVH8;Q8TBX8;Q92918;Q96NX5;Q9BVS4;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K8;Q9H3Y6;Q9NRP7;Q9NSY1;Q9UBE8;Q9UBF8;Q9UKE5;Q9UL54;Q9UM73;Q9UQ88;Q9UQB9;Q9Y2U5;Q9Y4K4;Q9Y616,"InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)",CUIHSIWYWATEQL-UHFFFAOYSA-N,CN(c1ccc2c(C)n(C)nc2c1)c3ccnc(Nc4ccc(C)c(c4)S(=O)(=O)N)n3,lapatinib,2195,O00750;O14733;O43353;O75747;O94804;P00533;P04626;P08684;P09619;P21860;Q13163;Q15303;Q9H2G2;Q9UBF8,"InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)",BCFGMOOMADDAQU-UHFFFAOYSA-N,CS(=O)(=O)CCNCc1oc(cc1)c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2,,kidney cancers,Phase 1,,,NCT00516672,Phase I Study of Pazopanib Alone and In Combination With Lapatinib in Japanese Patients With Solid Tumors.,,https://ClinicalTrials.gov/show/NCT00516672
literature,pazopanib,200268,O00238;O00444;O14965;O14976;O15197;O43353;O60331;O60674;O75716;O94804;O95819;P00519;P04049;P06239;P06241;P07332;P07333;P07947;P07948;P07949;P08581;P08631;P08922;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P16591;P17948;P19525;P21127;P21802;P22455;P22607;P27448;P29376;P29597;P33981;P35590;P35916;P35968;P36888;P37173;P42681;P42684;P42685;P43405;P45983;P45985;P51451;P51617;P51955;P52333;P52564;P53667;P53671;P53779;P57059;P80192;Q00536;Q02763;Q02779;Q08345;Q12851;Q12866;Q13163;Q13233;Q13470;Q13546;Q13705;Q13882;Q14012;Q16584;Q16832;Q2M2I8;Q56UN5;Q6P3R8;Q7L7X3;Q8IVH8;Q8TBX8;Q92918;Q96NX5;Q9BVS4;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K8;Q9H3Y6;Q9NRP7;Q9NSY1;Q9UBE8;Q9UBF8;Q9UKE5;Q9UL54;Q9UM73;Q9UQ88;Q9UQB9;Q9Y2U5;Q9Y4K4;Q9Y616,"InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)",CUIHSIWYWATEQL-UHFFFAOYSA-N,CN(c1ccc2c(C)n(C)nc2c1)c3ccnc(Nc4ccc(C)c(c4)S(=O)(=O)N)n3,lapatinib,2195,O00750;O14733;O43353;O75747;O94804;P00533;P04626;P08684;P09619;P21860;Q13163;Q15303;Q9H2G2;Q9UBF8,"InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)",BCFGMOOMADDAQU-UHFFFAOYSA-N,CS(=O)(=O)CCNCc1oc(cc1)c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2,solid tumors,advanced solid cancers,Phase 1,24464355,"There was no dose-limiting toxicity during the study. In part A, most drug-related adverse events were grade 2 or lower, including neutropenia/neutrophil count decreased, thrombocytopenia/platelet count decreased, diarrhea, hypertension, aspartate aminotransferase increased, and lipase increased. In part B, rash, decreased appetite, and serum thyroid-stimulating hormone increased also occurred. In all dose groups, the plasma concentrations after multiple doses of pazopanib exceeded the target trough concentration for inhibition of vascular endothelial growth factor receptor-2 activity (20 _g/mL).",,,,
literature,pazopanib,200268,O00238;O00444;O14965;O14976;O15197;O43353;O60331;O60674;O75716;O94804;O95819;P00519;P04049;P06239;P06241;P07332;P07333;P07947;P07948;P07949;P08581;P08631;P08922;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P16591;P17948;P19525;P21127;P21802;P22455;P22607;P27448;P29376;P29597;P33981;P35590;P35916;P35968;P36888;P37173;P42681;P42684;P42685;P43405;P45983;P45985;P51451;P51617;P51955;P52333;P52564;P53667;P53671;P53779;P57059;P80192;Q00536;Q02763;Q02779;Q08345;Q12851;Q12866;Q13163;Q13233;Q13470;Q13546;Q13705;Q13882;Q14012;Q16584;Q16832;Q2M2I8;Q56UN5;Q6P3R8;Q7L7X3;Q8IVH8;Q8TBX8;Q92918;Q96NX5;Q9BVS4;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K8;Q9H3Y6;Q9NRP7;Q9NSY1;Q9UBE8;Q9UBF8;Q9UKE5;Q9UL54;Q9UM73;Q9UQ88;Q9UQB9;Q9Y2U5;Q9Y4K4;Q9Y616,"InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)",CUIHSIWYWATEQL-UHFFFAOYSA-N,CN(c1ccc2c(C)n(C)nc2c1)c3ccnc(Nc4ccc(C)c(c4)S(=O)(=O)N)n3,lapatinib,2195,O00750;O14733;O43353;O75747;O94804;P00533;P04626;P08684;P09619;P21860;Q13163;Q15303;Q9H2G2;Q9UBF8,"InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)",BCFGMOOMADDAQU-UHFFFAOYSA-N,CS(=O)(=O)CCNCc1oc(cc1)c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2,solid tumors,advanced solid cancers,Phase 1,26210681,"Twenty-four patients were treated. The most common drug-related adverse events were fatigue 7/24 (29%), skin rash 5/21 (21%), and diarrhea 3/24 (17%), with 4/24 (16%) patients experiencing grade _3 drug-related adverse events. Escalation to the FDA-approved dose (800 mg daily for pazopanib and 1500 mg every day for lapatinib) was not feasible due to toxicities. Pazopanib 200 mg every other day + lapatinib 500 mg daily was considered the maximum tolerated dose (MTD). No tumor response was observed, including in patients with the specific molecular genetic alterations tested.",,,,
literature,trastuzumab,4,P04626,,,,lapatinib,2195,O00750;O14733;O43353;O75747;O94804;P00533;P04626;P08684;P09619;P21860;Q13163;Q15303;Q9H2G2;Q9UBF8,"InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)",BCFGMOOMADDAQU-UHFFFAOYSA-N,CS(=O)(=O)CCNCc1oc(cc1)c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2,"treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer",bowel cancers,Phase 2,27108243,"Between Aug 27, 2012, and May 15, 2015, we screened 914 patients with KRAS exon 2 (codons 12 and 13) wild-type metastatic colorectal cancer and identified 48 (5%) patients with HER2-positive tumours, although two died before enrolment. Of these patients, 27 were eligible for the trial. All were evaluable for response. At the time of data cutoff on Oct 15, 2015, with a median follow-up of 94 weeks (IQR 51-127), eight (30%, 95% CI 14-50) of 27 patients had achieved an objective response, with one patient (4%, 95% CI -3 to 11) achieving a complete response, and seven (26%, 95% CI 9-43) achieving partial responses; 12 (44%, 95% CI 25-63) patients had stable disease. Six (22%) of 27 patients had grade 3 adverse events, which consisted of fatigue in four patients, skin rash in one patient, and increased bilirubin concentration in one patient. No grade 4 or 5 adverse events were reported. We detected no drug-related serious adverse events.",,,,
clinicaltrials.gov,vorinostat,260,O15379;O75376;P56524;Q13547;Q8WUI4;Q92769;Q969S8;Q96DB2;Q9BY41;Q9UBN7;Q9UKV0;Q9UQL6;Q9Y618,"InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)",WAEXFXRVDQXREF-UHFFFAOYSA-N,ONC(=O)CCCCCCC(=O)Nc1ccccc1,lapatinib,2195,O00750;O14733;O43353;O75747;O94804;P00533;P04626;P08684;P09619;P21860;Q13163;Q15303;Q9H2G2;Q9UBF8,"InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)",BCFGMOOMADDAQU-UHFFFAOYSA-N,CS(=O)(=O)CCNCc1oc(cc1)c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2,,breast cancers,Phase 1/2,,,NCT01118975,GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers,,https://ClinicalTrials.gov/show/NCT01118975
clinicaltrials.gov,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,LDE 225,,,,,,,oesophageal cancers,Phase 1,,,NCT02138929,LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma,,https://ClinicalTrials.gov/show/NCT02138929
clinicaltrials.gov,vemurafenib,754991,P15056,"InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)",GPXBXXGIAQBQNI-UHFFFAOYSA-N,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)c4ccc(Cl)cc4)c1F,leflunomide,437,Q02127,"InChI=1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18)",VHOGYURTWQBHIL-UHFFFAOYSA-N,Cc1oncc1C(=O)Nc2ccc(cc2)C(F)(F)F,,skin cancers,Phase 1,,,NCT01611675,Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma,,https://ClinicalTrials.gov/show/NCT01611675
clinicaltrials.gov,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,lenalidomide,718,O14920,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,Nc1cccc2C(=O)N(Cc12)C3CCC(=O)NC3=O,,multiple myeloma,Phase 1/2,,,NCT01460420,Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation,EMN-alloRIC,https://ClinicalTrials.gov/show/NCT01460420
clinicaltrials.gov,cetuximab,9,P00533,,,,lenalidomide,718,O14920,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,Nc1cccc2C(=O)N(Cc12)C3CCC(=O)NC3=O,,bowel cancers,Phase 2,,,NCT01032291,A Study to Assess the Efficacy and Safety of Lenalidomide in Combination With Cetuximab in Pre-treated Patients With KRAS Mutant Colorectal Cancer,,https://ClinicalTrials.gov/show/NCT01032291
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,lenalidomide,718,O14920,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,Nc1cccc2C(=O)N(Cc12)C3CCC(=O)NC3=O,,lymphoma,Phase 2,,,NCT03054532,Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell Lymphoma,,https://ClinicalTrials.gov/show/NCT03054532
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,lenalidomide,718,O14920,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,Nc1cccc2C(=O)N(Cc12)C3CCC(=O)NC3=O,,lymphoma,Phase 2,,,NCT03212807,"Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL",DuRIANS,https://ClinicalTrials.gov/show/NCT03212807
clinicaltrials.gov,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,lenalidomide,718,O14920,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,Nc1cccc2C(=O)N(Cc12)C3CCC(=O)NC3=O,,multiple myeloma,Phase 1,,,NCT00729638,RAD001 and Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma,,https://ClinicalTrials.gov/show/NCT00729638
literature,ezatiostat hydrochloride,,P09211,"InChI=1S/C27H35N3O6S.ClH/c1-3-35-26(33)21(28)15-16-23(31)29-22(18-37-17-19-11-7-5-8-12-19)25(32)30-24(27(34)36-4-2)20-13-9-6-10-14-20;/h5-14,21-22,24H,3-4,15-18,28H2,1-2H3,(H,29,31)(H,30,32);1H/t21-,22-,24+;/m0./s1",XJDYQYNYISTAMO-GFDYFVENSA-N,Cl.CCOC(=O)[C@@H](N)CCC(=O)N[C@@H](CSCc1ccccc1)C(=O)N[C@@H](C(=O)OCC)c2ccccc2,lenalidomide,718,O14920,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,Nc1cccc2C(=O)N(Cc12)C3CCC(=O)NC3=O,non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS),other,Phase 1,22546242,"Ezatiostat was administered to 19 patients with non-deletion(5q) myelodysplastic syndrome (MDS) at one of two doses (2000 mg or 2500 mg/day) in combination with 10 mg of lenalidomide on days 1-21 of a 28-day cycle. No unexpected toxicities occurred and the incidence and severity of adverse events (AEs) were consistent with that expected for each drug alone. The most common non-hematologic AEs related to ezatiostat in combination with lenalidomide were mostly grade 1 and 2 fatigue, anorexia, nausea, diarrhea, and vomiting; hematologic AEs due to lenalidomide were thrombocytopenia, neutropenia, and anemia. One of 4 evaluable patients (25%) in the 2500/10 mg dose group experienced an erythroid hematologic improvement (HI-E) response by 2006 MDS International Working Group (IWG) criteria. Four of 10 evaluable patients (40%) in the 2000 mg/10 mg dose group experienced an HI-E response. Three of 7 (43%) red blood cell (RBC) transfusion-dependent patients became RBC transfusion independent, including one patient for whom prior lenalidomide monotherapy was ineffective. Three of 5 (60%) thrombocytopenic patients had an HI-platelet (HI-P) response. Bilineage HI-E and HI-P responses occurred in 3 of 5 (60%), 1 of 3 with HI-E and HI-N (33%), and 1 of 3 with HI-N and HI-P (33%). One of 3 patients (33%) with pancytopenia experienced a complete trilineage response. All multilineage responses were observed in the 2000/10 mg doses recommended for future studies.",,,,
clinicaltrials.gov,gefitinib,701,O14578;O14976;O15197;O43293;O43353;O75676;O94768;O94804;O96017;P00519;P00533;P04626;P06239;P07948;P07949;P08581;P08631;P09769;P10721;P12931;P15735;P21709;P21860;P29320;P29322;P29376;P30530;P31152;P36888;P42681;P42684;P42685;P45984;P48730;P49674;P50613;P51451;P51617;P53779;P54756;P54760;P54762;Q09013;Q13163;Q15139;Q15303;Q16659;Q16816;Q52WX2;Q56UN5;Q86V86;Q8N4C8;Q8NE63;Q8TBX8;Q99759;Q9BUB5;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NWZ3;Q9UBE8;Q9UEE5;Q9UF33;Q9UKE5;Q9UNQ0;Q9Y2U5;Q9Y616,"InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)",XGALLCVXEZPNRQ-UHFFFAOYSA-N,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN4CCOCC4,lenalidomide,718,O14920,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,Nc1cccc2C(=O)N(Cc12)C3CCC(=O)NC3=O,,pancreatic cancers,Phase 1/2,,,NCT01547260,Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic Cancer,LENAGEM,https://ClinicalTrials.gov/show/NCT01547260
clinicaltrials.gov,ipilimumab,1238537,P16410,,,,lenalidomide,718,O14920,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,Nc1cccc2C(=O)N(Cc12)C3CCC(=O)NC3=O,,,Phase 1,,,NCT01750983,Ipilimumab and Lenalidomide in Advanced Cancer,,https://ClinicalTrials.gov/show/NCT01750983
clinicaltrials.gov,ixazomib,1069383,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C14H19BCl2N2O4/c1-8(2)5-12(15(22)23)19-13(20)7-18-14(21)10-6-9(16)3-4-11(10)17/h3-4,6,8,12,22-23H,5,7H2,1-2H3,(H,18,21)(H,19,20)/t12-/m0/s1",MXAYKZJJDUDWDS-LBPRGKRZSA-N,CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,lenalidomide,718,O14920,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,Nc1cccc2C(=O)N(Cc12)C3CCC(=O)NC3=O,,multiple myeloma,Phase 2,,,NCT03733691,Phase 2 Maintenance Trial: Ixazomib Compared to Ixazomib-Lenalidomide Combination as Maintenance Therapy for Frontline Multiple Myeloma Patients,,https://ClinicalTrials.gov/show/NCT03733691
clinicaltrials.gov,pembrolizumab,,Q15116,,,,lenalidomide,718,O14920,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,Nc1cccc2C(=O)N(Cc12)C3CCC(=O)NC3=O,,lymphoma,Phase 1/2,,,NCT02875067,"Safety & Efficacy Study of Combination of pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma",,https://ClinicalTrials.gov/show/NCT02875067
clinicaltrials.gov,rituximab,16,P11836,,,,lenalidomide,718,O14920,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,Nc1cccc2C(=O)N(Cc12)C3CCC(=O)NC3=O,,leukemia,Phase 2,,,NCT00096044,Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia,,https://ClinicalTrials.gov/show/NCT00096044
clinicaltrials.gov,rituximab,16,P11836,,,,lenalidomide,718,O14920,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,Nc1cccc2C(=O)N(Cc12)C3CCC(=O)NC3=O,,leukemia;lymphoma,Phase 2,,,NCT01446133,Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL),,https://ClinicalTrials.gov/show/NCT01446133
clinicaltrials.gov,romidepsin,761764,Q96DB2;Q9UBN7;Q92769;Q13547;Q9UKV0;Q9UQL6;Q8WUI4;P56524;O15379;Q969S8;Q9BY41,"InChI=1S/C25H39N3O6S2/c1-6-19-23(31)28-21(15(4)5)25(33)34-17(9-7-8-10-35)11-16(29)12-18(14(2)3)22(30)27-20(13-36)24(32)26-19/h6-7,9,14-15,17-18,20-21,35-36H,8,10-13H2,1-5H3,(H,26,32)(H,27,30)(H,28,31)/b9-7+,19-6-/t17-,18-,20-,21+/m1/s1",UPCFDQLGZODPFB-BXJZLCHMSA-N,C\C=C\1/NC(=O)[C@@H](CS)NC(=O)[C@H](CC(=O)C[C@H](OC(=O)[C@@H](NC1=O)C(C)C)\C=C\CCS)C(C)C,lenalidomide,718,O14920,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,Nc1cccc2C(=O)N(Cc12)C3CCC(=O)NC3=O,,multiple myeloma;lymphoma,Phase 1/2,,,NCT01755975,Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma,,https://ClinicalTrials.gov/show/NCT01755975
clinicaltrials.gov,ublituximab,,P11836,,,,lenalidomide,718,O14920,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,Nc1cccc2C(=O)N(Cc12)C3CCC(=O)NC3=O,,leukemia;lymphoma,Phase 1/2,,,NCT01744912,Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies,,https://ClinicalTrials.gov/show/NCT01744912
clinicaltrials.gov,E7386,,,,,,lenvatinib,802872,P35968;P17948;P35916,"InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)",WOSKHXYHFSIKNG-UHFFFAOYSA-N,,,,,,,NCT04008797,A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor,,https://ClinicalTrials.gov/show/NCT04008797
clinicaltrials.gov,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,lenvatinib,802872,P35968;P17948;P35916,"InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)",WOSKHXYHFSIKNG-UHFFFAOYSA-N,,,,,,,NCT03950609,"Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors",,https://ClinicalTrials.gov/show/NCT03950609
clinicaltrials.gov,pembrolizumab,,Q15116,,,,lenvatinib,802872,P35968;P17948;P35916,"InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)",WOSKHXYHFSIKNG-UHFFFAOYSA-N,,Non-small Cell Lung Cancer,,Phase 3,,,NCT03829332,,,
clinicaltrials.gov,EMLA,,,,,,Lidocaine,,,,,,,,,,,NCT04003012,Pain Control in Pediatric Oncology: Utility of EMLA Cream vs Lidocaine Injection in Lumbar Punctures,,https://ClinicalTrials.gov/show/NCT04003012
literature,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,linsitinib,678359,P06213;P08069,"InChI=1S/C26H23N5O/c1-26(32)14-19(15-26)25-30-22(23-24(27)28-11-12-31(23)25)18-8-7-17-9-10-20(29-21(17)13-18)16-5-3-2-4-6-16/h2-13,19,32H,14-15H2,1H3,(H2,27,28)/t19-,26+",PKCDDUHJAFVJJB-VLZXCDOPSA-N,C[C@@]1(O)C[C@@H](C1)c2nc(c3ccc4ccc(nc4c3)c5ccccc5)c6c(N)nccn26,Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations,lung cancers,Phase 2,27686971,"After randomization of 88 patients (44 each arm), the trial was unblinded early owing to inferiority in the linsitinib arm. The median progression-free survival for the linsitinib versus the placebo group was 8.4 months versus 12.4 months (hazard ratio, 1.37; P_= .29). Overall response rate (47.7% vs. 75.0%; P_= .02) and disease control rate (77.3% vs. 95.5%; P_= .03) were also inferior. Whereas most adverse events were__ grade 2, linsitinib plus erlotinib was associated with increased adverse events that led to decreased erlotinib exposure (median days, 228 vs. 305). No_drug-drug interaction was suggested by pharmacokinetic and pharmacodynamic results.",,,,
clinicaltrials.gov,nivolumab,,Q15116,,,,lirilumab,,P43626;P43627;P43628,,,,,head and neck cancers,Phase 2,,,NCT03341936,"Adjuvant Nivolumab and Lirilumab in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and Neck",,https://ClinicalTrials.gov/show/NCT03341936
clinicaltrials.gov,nivolumab,,Q15116,,,,lirilumab,,P43626;P43627;P43628,,,,,bladder cancers,Phase 1,,,NCT03532451,Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer,PrE0807,https://ClinicalTrials.gov/show/NCT03532451
clinicaltrials.gov,nivolumab,,Q15116,,,,lirilumab,,P43626;P43627;P43628,,,,,bladder cancers,Phase 1,,,NCT03532451,Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer,PrE0807,https://ClinicalTrials.gov/show/NCT03532451
clinicaltrials.gov,LXH254,,,,,,LTT462,,,,,,,lung cancers,Phase 1,,,NCT02974725,Study of LXH254 and LTT462 in NSCLC,,https://ClinicalTrials.gov/show/NCT02974725
clinicaltrials.gov,rucaparib,757098,P09874;Q9UGN5;Q9Y6F1,"InChI=1S/C19H18FN3O/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15/h2-5,8-9,21,23H,6-7,10H2,1H3,(H,22,24)",HMABYWSNWIZPAG-UHFFFAOYSA-N,CNCc1ccc(cc1)c2[nH]c3cc(F)cc4C(=O)NCCc2c34,Lucitanib,,,,,,,,,,,NCT03992131,A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR),,https://ClinicalTrials.gov/show/NCT03992131
clinicaltrials.gov,S-1,,,,,,LV,,,,,,,stomach cancers,Phase 2,,,NCT02090153,Study of S-1 Plus LV for Advanced Gastric Cancer,,https://ClinicalTrials.gov/show/NCT02090153
clinicaltrials.gov,enzalutamide,679762,P10275,"InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)",WXCXUHSOUPDCQV-UHFFFAOYSA-N,CNC(=O)c1ccc(cc1F)N2C(=S)N(C(=O)C2(C)C)c3ccc(C#N)c(c3)C(F)(F)F,LY2157299,,P36897,,,,,prostate cancers,Phase 2,,,NCT02452008,Study of TGF-__ Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer,,https://ClinicalTrials.gov/show/NCT02452008
clinicaltrials.gov,merestinib,1103571,P08581,"InChI=1S/C30H22F2N6O3/c1-17-3-9-23(30(40)38(17)22-7-4-20(31)5-8-22)29(39)36-21-6-10-27(25(32)12-21)41-28-11-18-16-35-37(2)26(18)13-24(28)19-14-33-34-15-19/h3-16H,1-2H3,(H,33,34)(H,36,39)",QHADVLVFMKEIIP-UHFFFAOYSA-N,CC1=CC=C(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3c5cn[nH]c5)c(F)c2)C(=O)N1c6ccc(F)cc6,LY2874455,,,,,,,leukemia,Phase 1,,,NCT03125239,Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia,,https://ClinicalTrials.gov/show/NCT03125239
clinicaltrials.gov,LY3321367,,,,,,LY3300054,,,,,,,advanced solid cancers,Phase 1,,,NCT03099109,A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors,,https://ClinicalTrials.gov/show/NCT03099109
clinicaltrials.gov,LY3381916,,,,,,LY3300054,,,,,,,lung cancers;head and neck cancers;bladder cancers;bladder cancers,Phase 1,,,NCT03343613,A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors,,https://ClinicalTrials.gov/show/NCT03343613
clinicaltrials.gov,cetuximab,9,P00533,,,,mannitol,127055,,"InChI=1S/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H2/t3-,4-,5-,6-/m1/s1",FBPFZTCFMRRESA-KVTDHHQDSA-N,OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,,brain cancers,Phase 1/2,,,NCT02861898,Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma,,https://ClinicalTrials.gov/show/NCT02861898
clinicaltrials.gov,pembrolizumab,,Q15116,,,,maraviroc,513,P51681,"InChI=1S/C29H41F2N5O/c1-19(2)27-34-33-20(3)36(27)25-17-23-9-10-24(18-25)35(23)16-13-26(21-7-5-4-6-8-21)32-28(37)22-11-14-29(30,31)15-12-22/h4-8,19,22-26H,9-18H2,1-3H3,(H,32,37)/t23-,24+,25-,26-/m0/s1",GSNHKUDZZFZSJB-QYOOZWMWSA-N,CC(C)c1nnc(C)n1[C@@H]2C[C@H]3CC[C@@H](C2)N3CC[C@H](NC(=O)C4CCC(F)(F)CC4)c5ccccc5,,colorectal cancers,Phase 1,,,NCT03274804,Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC,PICCASSO,https://ClinicalTrials.gov/show/NCT03274804
clinicaltrials.gov,ECX,132024,,"InChI=1S/C5H11NO2S/c1-2-9-3-4(6)5(7)8/h4H,2-3,6H2,1H3,(H,7,8)/t4-/m0/s1",ULXKXLZEOGLCRJ-BYPYZUCNSA-N,CCSC[C@H](N)C(=O)O,matuzumab,,P00533,,,,,oesophageal cancers;stomach cancers,Phase 2,,,NCT00215644,MATRIX EG (Matuzumab Treatment With ECX in Esophago-Gastric Cancer),,https://ClinicalTrials.gov/show/NCT00215644
clinicaltrials.gov,HDM201,,,,,,MBG453,,,,,,,,,,,NCT03940352,HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS),,https://ClinicalTrials.gov/show/NCT03940352
clinicaltrials.gov,PDR001,,,,,,MCS110,,,,,,,oesophageal cancers,Phase 2,,,NCT03785496,Phase II Study of PDR001 in Combination With MCS110 in Patients With Squamous Cell Carcinoma of the Esophagus.,,https://ClinicalTrials.gov/show/NCT03785496
clinicaltrials.gov,PDR001,,,,,,MCS110,,,,,,,oesophageal cancers,Phase 2,,,NCT03785496,Phase II Study of PDR001 in Combination With MCS110 in Patients With Squamous Cell Carcinoma of the Esophagus.,,https://ClinicalTrials.gov/show/NCT03785496
clinicaltrials.gov,cobimetinib,1055500,Q02750;P36507,"InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1",BSMCAPRUBJMWDF-KRWDZBQOSA-N,OC1(CN(C1)C(=O)c2ccc(F)c(F)c2Nc3ccc(I)cc3F)[C@@H]4CCCCN4,MEHD7945A,,,,,,,,Phase 1,,,NCT01986166,A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS,,https://ClinicalTrials.gov/show/NCT01986166
clinicaltrials.gov,bicalutamide,308,P10275,"InChI=1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)",LKJPYSCBVHEWIU-UHFFFAOYSA-N,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc2ccc(C#N)c(c2)C(F)(F)F,metformin,1855,P43304;P03923;O95299;O00217;P03901;P56556;P03886;O95139;O00483;Q86Y39;P17568;P03891;O75306;P03915;P51970;O43674;P03905;P03897;O14561;O15239;O43181;O43676;O43677;O43678;O43920;O75251;O75380;O75438;O75489;O95167;O95168;O95169;O95178;O95182;O95298;O96000;P19404;P28331;P49821;P56181;Q16718;Q16795;Q8N183;Q9BU61;Q9NRX3;Q9NX14;Q9P032;Q9P0J0;Q9UI09;Q9Y375;Q9Y6M9,"InChI=1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)",XZWYZXLIPXDOLR-UHFFFAOYSA-N,CN(C)C(=N)NC(=N)N,,prostate cancers,Phase 2,,,NCT02614859,Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients,BIMET-1,https://ClinicalTrials.gov/show/NCT02614859
clinicaltrials.gov,enzalutamide,679762,P10275,"InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)",WXCXUHSOUPDCQV-UHFFFAOYSA-N,CNC(=O)c1ccc(cc1F)N2C(=S)N(C(=O)C2(C)C)c3ccc(C#N)c(c3)C(F)(F)F,metformin,1855,P43304;P03923;O95299;O00217;P03901;P56556;P03886;O95139;O00483;Q86Y39;P17568;P03891;O75306;P03915;P51970;O43674;P03905;P03897;O14561;O15239;O43181;O43676;O43677;O43678;O43920;O75251;O75380;O75438;O75489;O95167;O95168;O95169;O95178;O95182;O95298;O96000;P19404;P28331;P49821;P56181;Q16718;Q16795;Q8N183;Q9BU61;Q9NRX3;Q9NX14;Q9P032;Q9P0J0;Q9UI09;Q9Y375;Q9Y6M9,"InChI=1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)",XZWYZXLIPXDOLR-UHFFFAOYSA-N,CN(C)C(=N)NC(=N)N,,prostate cancers,Phase 1,,,NCT02339168,Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer,,https://ClinicalTrials.gov/show/NCT02339168
clinicaltrials.gov,enzalutamide,679762,P10275,"InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)",WXCXUHSOUPDCQV-UHFFFAOYSA-N,CNC(=O)c1ccc(cc1F)N2C(=S)N(C(=O)C2(C)C)c3ccc(C#N)c(c3)C(F)(F)F,metformin,1855,P43304;P03923;O95299;O00217;P03901;P56556;P03886;O95139;O00483;Q86Y39;P17568;P03891;O75306;P03915;P51970;O43674;P03905;P03897;O14561;O15239;O43181;O43676;O43677;O43678;O43920;O75251;O75380;O75438;O75489;O95167;O95168;O95169;O95178;O95182;O95298;O96000;P19404;P28331;P49821;P56181;Q16718;Q16795;Q8N183;Q9BU61;Q9NRX3;Q9NX14;Q9P032;Q9P0J0;Q9UI09;Q9Y375;Q9Y6M9,"InChI=1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)",XZWYZXLIPXDOLR-UHFFFAOYSA-N,CN(C)C(=N)NC(=N)N,,prostate cancers,Phase 2,,,NCT02640534,Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone,,https://ClinicalTrials.gov/show/NCT02640534
clinicaltrials.gov,sintilimab,,,,,,metformin,1855,P43304;P03923;O95299;O00217;P03901;P56556;P03886;O95139;O00483;Q86Y39;P17568;P03891;O75306;P03915;P51970;O43674;P03905;P03897;O14561;O15239;O43181;O43676;O43677;O43678;O43920;O75251;O75380;O75438;O75489;O95167;O95168;O95169;O95178;O95182;O95298;O96000;P19404;P28331;P49821;P56181;Q16718;Q16795;Q8N183;Q9BU61;Q9NRX3;Q9NX14;Q9P032;Q9P0J0;Q9UI09;Q9Y375;Q9Y6M9,"InChI=1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)",XZWYZXLIPXDOLR-UHFFFAOYSA-N,CN(C)C(=N)NC(=N)N,Non Small Cell Lung Cancer,,Phase 2,,,NCT03874000,,,
clinicaltrials.gov,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,metformin,1855,P43304;P03923;O95299;O00217;P03901;P56556;P03886;O95139;O00483;Q86Y39;P17568;P03891;O75306;P03915;P51970;O43674;P03905;P03897;O14561;O15239;O43181;O43676;O43677;O43678;O43920;O75251;O75380;O75438;O75489;O95167;O95168;O95169;O95178;O95182;O95298;O96000;P19404;P28331;P49821;P56181;Q16718;Q16795;Q8N183;Q9BU61;Q9NRX3;Q9NX14;Q9P032;Q9P0J0;Q9UI09;Q9Y375;Q9Y6M9,"InChI=1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)",XZWYZXLIPXDOLR-UHFFFAOYSA-N,CN(C)C(=N)NC(=N)N,,liver cancers,Phase 2,,,NCT02672488,Metformin Plus Sorafenib for Advanced HCC,,https://ClinicalTrials.gov/show/NCT02672488
clinicaltrials.gov,temsirolimus,401,P42345,"InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1",CBPNZQVSJQDFBE-FUXHJELOSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO,metformin,1855,P43304;P03923;O95299;O00217;P03901;P56556;P03886;O95139;O00483;Q86Y39;P17568;P03891;O75306;P03915;P51970;O43674;P03905;P03897;O14561;O15239;O43181;O43676;O43677;O43678;O43920;O75251;O75380;O75438;O75489;O95167;O95168;O95169;O95178;O95182;O95298;O96000;P19404;P28331;P49821;P56181;Q16718;Q16795;Q8N183;Q9BU61;Q9NRX3;Q9NX14;Q9P032;Q9P0J0;Q9UI09;Q9Y375;Q9Y6M9,"InChI=1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)",XZWYZXLIPXDOLR-UHFFFAOYSA-N,CN(C)C(=N)NC(=N)N,,,Phase 1,,,NCT01529593,Temsirolimus in Combination With Metformin in Patients With Advanced Cancers,,https://ClinicalTrials.gov/show/NCT01529593
clinicaltrials.gov,vandetanib,551660,O00238;O00444;O14578;O14976;O15197;O43353;O75116;O94804;O95819;P00519;P00533;P04626;P06239;P06241;P07333;P07947;P07948;P07949;P08581;P08631;P09619;P09769;P10721;P11362;P12931;P15735;P16234;P17948;P21709;P21802;P21860;P22455;P22607;P23443;P29317;P29320;P29322;P29323;P29376;P30530;P35590;P35916;P35968;P36507;P36888;P37023;P41240;P42681;P42684;P42685;P49674;P50613;P51451;P51617;P54756;P54760;P54762;P54764;P57058;P57059;P57078;Q02750;Q02763;Q04771;Q04912;Q06187;Q06418;Q08345;Q12851;Q12866;Q13131;Q13163;Q13882;Q15303;Q15375;Q15418;Q15569;Q16659;Q16816;Q16832;Q56UN5;Q59H18;Q5VT25;Q6DT37;Q6PHR2;Q8IVH8;Q8N4C8;Q8NI60;Q8TDR2;Q8WU08;Q92918;Q96D53;Q9BUB5;Q9BYT3;Q9H0K1;Q9H2G2;Q9H3Y6;Q9HBH9;Q9NWZ3;Q9NYL2;Q9UF33;Q9UK32;Q9UKE5;Q9UM73;Q9UQB9;Q9Y2K2;Q9Y4K4;Q9Y5S2;Q9Y6R4,"InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)",UHTHHESEBZOYNR-UHFFFAOYSA-N,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC4CCN(C)CC4,metformin,1855,P43304;P03923;O95299;O00217;P03901;P56556;P03886;O95139;O00483;Q86Y39;P17568;P03891;O75306;P03915;P51970;O43674;P03905;P03897;O14561;O15239;O43181;O43676;O43677;O43678;O43920;O75251;O75380;O75438;O75489;O95167;O95168;O95169;O95178;O95182;O95298;O96000;P19404;P28331;P49821;P56181;Q16718;Q16795;Q8N183;Q9BU61;Q9NRX3;Q9NX14;Q9P032;Q9P0J0;Q9UI09;Q9Y375;Q9Y6M9,"InChI=1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)",XZWYZXLIPXDOLR-UHFFFAOYSA-N,CN(C)C(=N)NC(=N)N,,kidney cancers,Phase 1/2,,,NCT02495103,Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT02495103
clinicaltrials.gov,MGC018,,,,,,MGA012,,,,,,,advanced solid cancers,Phase 1/2,,,NCT03729596,MGC018 With or Without MGA012 in Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT03729596
clinicaltrials.gov,MGC018,,,,,,MGA012,,,,,,,advanced solid cancers,Phase 1/2,,,NCT03729596,MGC018 With or Without MGA012 in Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT03729596
clinicaltrials.gov,MGD007,,,,,,MGA012,,,,,,,colorectal cancers,Phase 1/2,,,NCT03531632,MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer,,https://ClinicalTrials.gov/show/NCT03531632
clinicaltrials.gov,MGD007,,,,,,MGA012,,,,,,,colorectal cancers,Phase 1/2,,,NCT03531632,MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer,,https://ClinicalTrials.gov/show/NCT03531632
clinicaltrials.gov,MGD009,,,,,,MGA012,,,,,,,advanced solid cancers,Phase 1,,,NCT03406949,MGD009/MGA012 Combination in Relapsed/Refractory Cancer,,https://ClinicalTrials.gov/show/NCT03406949
clinicaltrials.gov,tasisulam,1360191,,"InChI=1S/C11H6BrCl2NO3S2/c12-9-3-4-10(19-9)20(17,18)15-11(16)7-2-1-6(13)5-8(7)14/h1-5H,(H,15,16)",WWONFUQGBVOKOF-UHFFFAOYSA-N,Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1,midazolam,1248,Q9UN88;P28472;P14867;P48169;O14764;P31644;Q99928;P78334;Q8N1C3;P34903;O00591;P47870;P18507;P18505;Q16445;P47869,"InChI=1S/C18H13ClFN3/c1-11-21-9-13-10-22-18(14-4-2-3-5-16(14)20)15-8-12(19)6-7-17(15)23(11)13/h2-9H,10H2,1H3",DDLIGBOFAVUZHB-UHFFFAOYSA-N,Cc1ncc2CN=C(c3ccccc3F)c4cc(Cl)ccc4n12,,,Phase 1,,,NCT01209832,A Tasisulam and Midazolam Drug Interaction Study in Cancer Patients,,https://ClinicalTrials.gov/show/NCT01209832
clinicaltrials.gov,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,midostaurin,805428,P09619;P16234;Q05513;Q04759;Q02156;O94806;P17252;Q05655;P05129;P05771;P24723;P41743;Q15139;P10721;P36888;P35968,"InChI=1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16,25-26,32H,17-18H2,1-3H3,(H,36,40)/t25-,26-,32-,35+/m1/s1",BMGQWWVMWDBQGC-IIFHNQTCSA-N,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n3c4ccccc4c5c6CNC(=O)c6c7c8ccccc8n2c7c35)N(C)C(=O)c9ccccc9,,leukemia,Phase 1,,,NCT00819546,"RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS",,https://ClinicalTrials.gov/show/NCT00819546
clinicaltrials.gov,LGH447,,,,,,midostaurin,805428,P09619;P16234;Q05513;Q04759;Q02156;O94806;P17252;Q05655;P05129;P05771;P24723;P41743;Q15139;P10721;P36888;P35968,"InChI=1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16,25-26,32H,17-18H2,1-3H3,(H,36,40)/t25-,26-,32-,35+/m1/s1",BMGQWWVMWDBQGC-IIFHNQTCSA-N,CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n3c4ccccc4c5c6CNC(=O)c6c7c8ccccc8n2c7c35)N(C)C(=O)c9ccccc9,,leukemia,Phase 1,,,NCT02078609,A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS),,https://ClinicalTrials.gov/show/NCT02078609
clinicaltrials.gov,pembrolizumab,,Q15116,,,,mifepristone,119,P04150;P06401,"InChI=1S/C29H35NO2/c1-5-15-29(32)16-14-26-24-12-8-20-17-22(31)11-13-23(20)27(24)25(18-28(26,29)2)19-6-9-21(10-7-19)30(3)4/h6-7,9-10,17,24-26,32H,8,11-14,16,18H2,1-4H3/t24-,25+,26-,28-,29-/m0/s1",VKHAHZOOUSRJNA-GCNJZUOMSA-N,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@H](C[C@]12C)c5ccc(cc5)N(C)C,,breast cancers,Phase 2,,,NCT03225547,Study of pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer,,https://ClinicalTrials.gov/show/NCT03225547
clinicaltrials.gov,Quizartinib,,,,,,Milademetan,,,,,,,leukemia,Phase 1,,,NCT03552029,DS-3032b Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML),,https://ClinicalTrials.gov/show/NCT03552029
clinicaltrials.gov,Quizartinib,,,,,,Milademetan,,,,,,,leukemia,Phase 1,,,NCT03552029,DS-3032b Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML),,https://ClinicalTrials.gov/show/NCT03552029
literature,ridaforolimus,1020194,P42345,"InChI=1S/C53H84NO14P/c1-32-18-14-13-15-19-33(2)44(63-8)30-40-23-21-38(7)53(61,67-40)50(58)51(59)54-25-17-16-20-41(54)52(60)66-45(35(4)28-39-22-24-43(46(29-39)64-9)68-69(11,12)62)31-42(55)34(3)27-37(6)48(57)49(65-10)47(56)36(5)26-32/h13-15,18-19,27,32,34-36,38-41,43-46,48-49,57,61H,16-17,20-26,28-31H2,1-12H3/b15-13+,18-14+,33-19+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",BUROJSBIWGDYCN-GAUTUEMISA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OP(=O)(C)C,MK-0752,,,,,,advanced solid tumours,advanced solid cancers,Phase 1,26199039,"Twenty eight patients were treated on study. Ridaforolimus doses were escalated from 20 to 30 mg/day. Among 14 evaluable patients receiving ridaforolimus 20 mg, one DLT (grade 2 stomatitis, second episode) was reported. Among eight evaluable patients receiving ridaforolimus 30 mg, three DLTs were reported (one each grade 3 stomatitis, grade 3 diarrhoea, and grade 3 asthenia). The MTD was 20 mg daily ridaforolimus 5 days/week+1800 mg weekly MK-0752. The most common drug-related adverse events included stomatitis, diarrhoea, decreased appetite, hyperglycaemia, thrombocytopenia, asthenia and rash. Two of 15 (13%) patients with head and neck squamous cell carcinoma (HNSCC) had responses: one with complete response and one with partial response. In addition, one patient experienced stable disease _6 months.",,,,
clinicaltrials.gov,axitinib,600224,P35968;P17948;P35916,"InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+",RITAVMQDGBJQJZ-FMIVXFBMSA-N,CNC(=O)c1ccccc1Sc2ccc3c(\C=C\c4ccccn4)n[nH]c3c2,MK-3475,,,,,,,kidney cancers,Phase 1,,,NCT02133742,"A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer",,https://ClinicalTrials.gov/show/NCT02133742
clinicaltrials.gov,utomilumab,,,,,,MK-3475,,,,,,,advanced solid cancers,Phase 1,,,NCT02179918,A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036),,https://ClinicalTrials.gov/show/NCT02179918
clinicaltrials.gov,pembrolizumab,,Q15116,,,,MK-4280,,,,,,,lymphoma,Phase 1/2,,,NCT03598608,Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003),,https://ClinicalTrials.gov/show/NCT03598608
clinicaltrials.gov,pembrolizumab,,Q15116,,,,MK-4280,,,,,,,lymphoma,Phase 1/2,,,NCT03598608,Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003),,https://ClinicalTrials.gov/show/NCT03598608
clinicaltrials.gov,alisertib,,O14965,"InChI=1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33)",ZLHFILGSQDJULK-UHFFFAOYSA-N,COc1cccc(F)c1C2=NCc3cnc(Nc4ccc(C(=O)O)c(OC)c4)nc3c5ccc(Cl)cc25,MLN0128,,,,,,,breast cancers,Phase 1,,,NCT02719691,Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer,,https://ClinicalTrials.gov/show/NCT02719691
clinicaltrials.gov,MLN0128,,,,,,MLN1117,,,,,,,advanced solid cancers,Phase 1,,,NCT01899053,Phase 1b Study of MLN0128 in Combination With MLN1117 in Adult Patients With Advanced Nonhematologic Malignancies,,https://ClinicalTrials.gov/show/NCT01899053
clinicaltrials.gov,MM-151,,,,,,MM-121,,P21860,,,,,bowel cancers;lung cancers;head and neck cancers,Phase 1,,,NCT02538627,Phase 1 Combination Study of MM-151 and MM-121,,https://ClinicalTrials.gov/show/NCT02538627
clinicaltrials.gov,KHK2455,,,,,,mogamulizumab,,,,,,,advanced solid cancers,Phase 1,,,NCT02867007,KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors,,https://ClinicalTrials.gov/show/NCT02867007
clinicaltrials.gov,atezolizumab,,Q9NZQ7,,,,MOXR0916,,,,,,,advanced solid cancers,Phase 1,,,NCT02410512,A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors,,https://ClinicalTrials.gov/show/NCT02410512
clinicaltrials.gov,pilaralisib,1348813,Q92569;Q8WYR1;P48736;P42338;P42336;P27986;O00459;O00329,"InChI=1S/C25H25ClN6O4S/c1-25(2,27)24(33)28-15-7-6-8-17(13-15)37(34,35)32-23-22(29-19-9-4-5-10-20(19)30-23)31-21-14-16(36-3)11-12-18(21)26/h4-14H,27H2,1-3H3,(H,28,33)(H,29,31)(H,30,32)",QINPEPAQOBZPOF-UHFFFAOYSA-N,COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c4cccc(NC(=O)C(C)(C)N)c4)c1,MSC1936369B,,,,,,,advanced solid cancers,Phase 1,,,NCT01357330,Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid Tumors,,https://ClinicalTrials.gov/show/NCT01357330
clinicaltrials.gov,atezolizumab,,Q9NZQ7,,,,MTIG7192A,,,,,,,advanced solid cancers,Phase 1,,,NCT02794571,Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors,,https://ClinicalTrials.gov/show/NCT02794571
clinicaltrials.gov,MVT-1075,,,,,,MVT-5873,,,,,,,pancreatic cancers,Phase 1,,,NCT03118349,Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy,,https://ClinicalTrials.gov/show/NCT03118349
clinicaltrials.gov,MVT-2163,,,,,,MVT-5873,,,,,,,pancreatic cancers,Phase 1,,,NCT02687230,Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1,,https://ClinicalTrials.gov/show/NCT02687230
clinicaltrials.gov,LY3023414,,,,,,necitumumab,,P00533,,,,,lung cancers,Phase 2,,,NCT02443337,A Study of LY3023414 and Necitumumab in Squamous Lung Cancer,,https://ClinicalTrials.gov/show/NCT02443337
clinicaltrials.gov,cetuximab,9,P00533,,,,neratinib,29601,P00533;P04626,"InChI=1S/C30H29ClN6O3/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38)/b9-7+",JWNPDZNEKVCWMY-VQHVLOKHSA-N,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,,bowel cancers,Phase 1/2,,,NCT01960023,Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer,,https://ClinicalTrials.gov/show/NCT01960023
clinicaltrials.gov,temsirolimus,401,P42345,"InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1",CBPNZQVSJQDFBE-FUXHJELOSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO,neratinib,29601,P00533;P04626,"InChI=1S/C30H29ClN6O3/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38)/b9-7+",JWNPDZNEKVCWMY-VQHVLOKHSA-N,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,,breast cancers,Phase 1/2,,,NCT01111825,Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer,,https://ClinicalTrials.gov/show/NCT01111825
clinicaltrials.gov,avelumab,,Q9NZQ7,,,,NHS-IL12,,,,,,,advanced solid cancers,Phase 1,,,NCT02994953,"A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12)",COMBO,https://ClinicalTrials.gov/show/NCT02994953
clinicaltrials.gov,NOVE-HiDAC,,,,,,nilotinib,457827,O15197;O43570;O94804;P00519;P00915;P00918;P04049;P06239;P06241;P07333;P07451;P07947;P07948;P07949;P08631;P09619;P09769;P10721;P11274;P12931;P15056;P16234;P21709;P22748;P23280;P29317;P29320;P29322;P29323;P35218;P35590;P41240;P42684;P42685;P43166;P45983;P45984;P49759;P51451;P53779;P54753;P54756;P54760;P54762;P54764;Q02763;Q08345;Q13163;Q15759;Q16288;Q16539;Q16620;Q16790;Q16832;Q59H18;Q7L7X3;Q8TBX8;Q92918;Q9H2K8;Q9HAZ1;Q9NYL2;Q9UF33;Q9ULX7;Q9Y5S2,,,,,leukemia,Phase 1/2,,,NCT01222143,"Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia",,https://ClinicalTrials.gov/show/NCT01222143
clinicaltrials.gov,afatinib,755714,O14578;O14976;O15197;O43353;O94804;P00519;P00533;P04626;P06239;P08581;P08631;P12931;P15735;P21860;P30530;P36888;P42681;P42685;P45984;P49674;P51451;P51617;P53779;Q13163;Q13627;Q15303;Q16539;Q16816;Q52WX2;Q8NE63;Q92630;Q9BUB5;Q9H2G2;Q9HBH9;Q9UEE5;Q9UF33;Q9UK32;Q9Y463,"InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1",ULXXDDBFHOBEHA-CWDCEQMOSA-N,CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]4CCOC4,nintedanib,37936,P11362;P22455;P22607;P21802;P09619;P16234;P35968;P17948;P35916,"InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,32H,15-18,20H2,1-3H3,(H,33,38)/b29-28-",XZXHXSATPCNXJR-ZIADKAODSA-N,COC(=O)c1ccc2\C(=C(\Nc3ccc(cc3)N(C)C(=O)CN4CCN(C)CC4)/c5ccccc5)\C(=O)Nc2c1,,advanced solid cancers,Phase 1,,,NCT00998296,Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.,,https://ClinicalTrials.gov/show/NCT00998296
clinicaltrials.gov,afatinib,755714,O14578;O14976;O15197;O43353;O94804;P00519;P00533;P04626;P06239;P08581;P08631;P12931;P15735;P21860;P30530;P36888;P42681;P42685;P45984;P49674;P51451;P51617;P53779;Q13163;Q13627;Q15303;Q16539;Q16816;Q52WX2;Q8NE63;Q92630;Q9BUB5;Q9H2G2;Q9HBH9;Q9UEE5;Q9UF33;Q9UK32;Q9Y463,"InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1",ULXXDDBFHOBEHA-CWDCEQMOSA-N,CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]4CCOC4,nintedanib,37936,P11362;P22455;P22607;P21802;P09619;P16234;P35968;P17948;P35916,"InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,32H,15-18,20H2,1-3H3,(H,33,38)/b29-28-",XZXHXSATPCNXJR-ZIADKAODSA-N,COC(=O)c1ccc2\C(=C(\Nc3ccc(cc3)N(C)C(=O)CN4CCN(C)CC4)/c5ccccc5)\C(=O)Nc2c1,,,Phase 1,,,NCT00730821,Phase I of BIBW 2992/BIBF 1120 Combination Therapy in Solid Tumors,,https://ClinicalTrials.gov/show/NCT00730821
clinicaltrials.gov,BI-6727,749220,P53350,"InChI=1S/C34H50N8O3/c1-6-28-33(44)39(4)29-20-35-34(38-31(29)42(28)22(2)3)37-27-14-9-24(19-30(27)45-5)32(43)36-25-10-12-26(13-11-25)41-17-15-40(16-18-41)21-23-7-8-23/h9,14,19-20,22-23,25-26,28H,6-8,10-13,15-18,21H2,1-5H3,(H,36,43)(H,35,37,38)/t25-,26-,28-/m1/s1",SXNJFOWDRLKDSF-STROYTFGSA-N,CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@@H]4CC[C@H](CC4)N5CCN(CC6CC6)CC5)ncc2N(C)C1=O,nintedanib,37936,P11362;P22455;P22607;P21802;P09619;P16234;P35968;P17948;P35916,"InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,32H,15-18,20H2,1-3H3,(H,33,38)/b29-28-",XZXHXSATPCNXJR-ZIADKAODSA-N,COC(=O)c1ccc2\C(=C(\Nc3ccc(cc3)N(C)C(=O)CN4CCN(C)CC4)/c5ccccc5)\C(=O)Nc2c1,,,Phase 1,,,NCT01022853,Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors,,https://ClinicalTrials.gov/show/NCT01022853
clinicaltrials.gov,enzalutamide,679762,P10275,"InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)",WXCXUHSOUPDCQV-UHFFFAOYSA-N,CNC(=O)c1ccc(cc1F)N2C(=S)N(C(=O)C2(C)C)c3ccc(C#N)c(c3)C(F)(F)F,niraparib,919241,Q9UGN5;P09874,"InChI=1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)/t14-/m1/s1",PCHKPVIQAHNQLW-CQSZACIVSA-N,NC(=O)c1cccc2cn(nc12)c3ccc(cc3)[C@@H]4CCCNC4,,prostate cancers,Phase 1,,,NCT02500901,Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC),,https://ClinicalTrials.gov/show/NCT02500901
clinicaltrials.gov,ABBV-368,,,,,,nivolumab,,Q15116,,,,,advanced solid cancers,Phase 1,,,NCT03071757,"A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors",,https://ClinicalTrials.gov/show/NCT03071757
clinicaltrials.gov,ABBV-428,,,,,,nivolumab,,Q15116,,,,,advanced solid cancers,Phase 1,,,NCT02955251,"A Study Evaluating Safety and Pharmacokinetics, and the Recommended Phase 2 Dose (RPTD) of ABBV-428 in Participants With Advanced Solid Tumors",,https://ClinicalTrials.gov/show/NCT02955251
clinicaltrials.gov,abemaciclib,1211300,P11802;Q00534,"InChI=1S/C27H32F2N8/c1-5-35-8-10-36(11-9-35)16-19-6-7-24(30-14-19)33-27-31-15-22(29)25(34-27)20-12-21(28)26-23(13-20)37(17(2)3)18(4)32-26/h6-7,12-15,17H,5,8-11,16H2,1-4H3,(H,30,31,33,34)",UZWDCWONPYILKI-UHFFFAOYSA-N,CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)c4cc(F)c5nc(C)n(C(C)C)c5c4)nc2)CC1,nivolumab,,Q15116,,,,,liver cancers,Phase 2,,,NCT03781960,Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma,,https://ClinicalTrials.gov/show/NCT03781960
clinicaltrials.gov,abemaciclib,1211300,P11802;Q00534,"InChI=1S/C27H32F2N8/c1-5-35-8-10-36(11-9-35)16-19-6-7-24(30-14-19)33-27-31-15-22(29)25(34-27)20-12-21(28)26-23(13-20)37(17(2)3)18(4)32-26/h6-7,12-15,17H,5,8-11,16H2,1-4H3,(H,30,31,33,34)",UZWDCWONPYILKI-UHFFFAOYSA-N,CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)c4cc(F)c5nc(C)n(C(C)C)c5c4)nc2)CC1,nivolumab,,Q15116,,,,,liver cancers,Phase 2,,,NCT03781960,Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma,,https://ClinicalTrials.gov/show/NCT03781960
clinicaltrials.gov,aldesleukin,,,,,,nivolumab,,Q15116,,,,Metastatic Melanoma,,Phase 2,,,NCT03850691,,,
clinicaltrials.gov,AM0010,,,,,,nivolumab,,Q15116,,,,,lung cancers,Phase 2,,,NCT03382912,Study of AM0010 With Nivolumab Compared to Nivolumab Alone Second-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer,Cypress 2,https://ClinicalTrials.gov/show/NCT03382912
clinicaltrials.gov,apatinib,1384455,P35968,"InChI=1S/C24H23N5O.CH4O3S/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18;1-5(2,3)4/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30);1H3,(H,2,3,4)",FYJROXRIVQPKRY-UHFFFAOYSA-N,CS(=O)(=O)O.O=C(Nc1ccc(cc1)C2(CCCC2)C#N)c3cccnc3NCc4ccncc4,nivolumab,,Q15116,,,,,,Phase 1,,,NCT03396211,Study to Evaluate Apatinib Plus Nivolumab in Patients With Unresectable or Metastatic Cancer,,https://ClinicalTrials.gov/show/NCT03396211
clinicaltrials.gov,APX005M,,,,,,nivolumab,,Q15116,,,,,lung cancers,Phase 1/2,,,NCT03123783,CD40 Agonistic Antibody APX005M in Combination With Nivolumab,,https://ClinicalTrials.gov/show/NCT03123783
clinicaltrials.gov,axitinib,600224,P35968;P17948;P35916,"InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+",RITAVMQDGBJQJZ-FMIVXFBMSA-N,CNC(=O)c1ccccc1Sc2ccc3c(\C=C\c4ccccn4)n[nH]c3c2,nivolumab,,Q15116,,,,,kidney cancers,Phase 2,,,NCT03595124,Axitinib and Nivolumab in Treating Participants With Unresectable or Metastatic TFE/Translocation Renal Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT03595124
clinicaltrials.gov,axitinib,600224,P35968;P17948;P35916,"InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+",RITAVMQDGBJQJZ-FMIVXFBMSA-N,CNC(=O)c1ccccc1Sc2ccc3c(\C=C\c4ccccn4)n[nH]c3c2,nivolumab,,Q15116,,,,,kidney cancers,Phase 2,,,NCT03595124,Axitinib and Nivolumab in Treating Participants With Unresectable or Metastatic TFE/Translocation Renal Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT03595124
clinicaltrials.gov,bevacizumab,11,P15692,,,,nivolumab,,Q15116,,,,,ovarian cancers;female cancers,Phase 2,,,NCT02873962,A Phase II Study Of Nivolumab/ Bevacizumab,,https://ClinicalTrials.gov/show/NCT02873962
clinicaltrials.gov,BMS-986012,,,,,,nivolumab,,Q15116,,,,,lung cancers,Phase 1/2,,,NCT02247349,BMS-986012 in Relapsed/Refractory SCLC,,https://ClinicalTrials.gov/show/NCT02247349
clinicaltrials.gov,BMS-986016,,,,,,nivolumab,,Q15116,,,,,advanced solid cancers,Phase 1,,,NCT02966548,Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT02966548
clinicaltrials.gov,BMS-986016,,,,,,nivolumab,,Q15116,,,,,advanced solid cancers,Phase 1/2,,,NCT01968109,Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors,,https://ClinicalTrials.gov/show/NCT01968109
clinicaltrials.gov,BMS-986016,,,,,,nivolumab,,Q15116,,,,,,Phase 1/2,,,NCT02061761,Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies,,https://ClinicalTrials.gov/show/NCT02061761
clinicaltrials.gov,BMS-986148,,,,,,nivolumab,,Q15116,,,,,advanced solid cancers,Phase 1/2,,,NCT02341625,A Study of BMS-986148 in Patients With Select Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT02341625
clinicaltrials.gov,BMS-986156,,,,,,nivolumab,,Q15116,,,,,advanced solid cancers,Phase 1/2,,,NCT02598960,"An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.",,https://ClinicalTrials.gov/show/NCT02598960
clinicaltrials.gov,BMS-986179,,,,,,nivolumab,,Q15116,,,,,advanced solid cancers,Phase 1/2,,,NCT02754141,An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread,,https://ClinicalTrials.gov/show/NCT02754141
clinicaltrials.gov,BMS-986205,,,,,,nivolumab,,Q15116,,,,,advanced solid cancers,Phase 1,,,NCT03192943,A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors,,https://ClinicalTrials.gov/show/NCT03192943
clinicaltrials.gov,BMS-986207,,,,,,nivolumab,,Q15116,,,,,advanced solid cancers,Phase 1/2,,,NCT02913313,An Investigational Immuno-therapy Study to Evaluate the Safety and Effectiveness of Experimental Medication BMS-986207 by Itself and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread,,https://ClinicalTrials.gov/show/NCT02913313
clinicaltrials.gov,BMS-986242,,,,,,nivolumab,,Q15116,,,,,,Phase 1/2,,,NCT03351231,An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer,,https://ClinicalTrials.gov/show/NCT03351231
clinicaltrials.gov,BMS-986249,,,,,,nivolumab,,Q15116,,,,,,Phase 1/2,,,NCT03369223,An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread,,https://ClinicalTrials.gov/show/NCT03369223
clinicaltrials.gov,BMS-986253,,,,,,nivolumab,,Q15116,,,,,,Phase 1/2,,,NCT03400332,An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination With Nivolumab in Patients With Advanced Cancers,,https://ClinicalTrials.gov/show/NCT03400332
clinicaltrials.gov,BMS-986258,,,,,,nivolumab,,Q15116,,,,,,Phase 1/2,,,NCT03446040,An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread,,https://ClinicalTrials.gov/show/NCT03446040
clinicaltrials.gov,BMS-986277,,,,,,nivolumab,,Q15116,,,,,,Phase 1/2,,,NCT03363776,An Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers,,https://ClinicalTrials.gov/show/NCT03363776
clinicaltrials.gov,BMS-986288,,,,,,nivolumab,,Q15116,,,,,,,,,NCT03994601,An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers,,https://ClinicalTrials.gov/show/NCT03994601
clinicaltrials.gov,BMS-986301,,,,,,nivolumab,,Q15116,,,,,,,,,NCT03956680,"An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers",,https://ClinicalTrials.gov/show/NCT03956680
clinicaltrials.gov,BMS-986310,,,,,,nivolumab,,Q15116,,,,,advanced solid cancers,Phase 1/2,,,NCT03661632,An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT03661632
clinicaltrials.gov,BMS-986310,,,,,,nivolumab,,Q15116,,,,,advanced solid cancers,Phase 1/2,,,NCT03661632,An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT03661632
clinicaltrials.gov,cabiralizumab,,,,,,nivolumab,,Q15116,,,,,advanced solid cancers,Phase 1,,,NCT03158272,A Study to of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread,,https://ClinicalTrials.gov/show/NCT03158272
clinicaltrials.gov,cabozantinib,1081506,P08581,"InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)",ONIQOQHATWINJY-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5)cc3)c2cc1OC,nivolumab,,Q15116,,,,,liver cancers,Phase 1,,,NCT03299946,Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC),,https://ClinicalTrials.gov/show/NCT03299946
clinicaltrials.gov,cabozantinib,1081506,P08581,"InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)",ONIQOQHATWINJY-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5)cc3)c2cc1OC,nivolumab,,Q15116,,,,,kidney cancers,Phase 2,,,NCT03635892,A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT03635892
clinicaltrials.gov,cabozantinib,1081506,P08581,"InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)",ONIQOQHATWINJY-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5)cc3)c2cc1OC,nivolumab,,Q15116,,,,,kidney cancers,Phase 2,,,NCT03635892,A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT03635892
clinicaltrials.gov,cabozantinib,1081506,P08581,"InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)",ONIQOQHATWINJY-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5)cc3)c2cc1OC,nivolumab,,Q15116,,,,,,,,,NCT03937219,Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma,COSMIC-313,https://ClinicalTrials.gov/show/NCT03937219
clinicaltrials.gov,carotuximab,,,,,,nivolumab,,Q15116,,,,,lung cancers,Phase 1,,,NCT03181308,Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC,,https://ClinicalTrials.gov/show/NCT03181308
clinicaltrials.gov,CB-1158,,,,,,nivolumab,,Q15116,,,,,lung cancers;bowel cancers;stomach cancers;kidney cancers;head and neck cancers,Phase 1,,,NCT02903914,Arginase Inhibitor CB-1158 in Patients With Solid Tumors,,https://ClinicalTrials.gov/show/NCT02903914
clinicaltrials.gov,CB-839,,,,,,nivolumab,,Q15116,,,,,skin cancers;lung cancers;kidney cancers,Phase 1/2,,,NCT02771626,Study CB-839 in Combination With Nivolumab in Patients With ccRCC and Other Solid Tumors,,https://ClinicalTrials.gov/show/NCT02771626
clinicaltrials.gov,CC-122,,,,,,nivolumab,,Q15116,,,,Melanoma,,Phase 2,,,NCT03834623,,,
clinicaltrials.gov,ceritinib,1135147,O60674;O75116;P00519;P00533;P04629;P06213;P06239;P07948;P07949;P08069;P08581;P08922;P09769;P10721;P11802;P12931;P16234;P21802;P22455;P22607;P23458;P24941;P35968;P36888;P41212;P43403;P43405;P52333;Q06187;Q16620;Q9BXA7;Q9HBH9;Q9UM73,"InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34)",VERWOWGGCGHDQE-UHFFFAOYSA-N,CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)C(C)C)n3,nivolumab,,Q15116,,,,,lung cancers,Phase 1,,,NCT02393625,Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT02393625
clinicaltrials.gov,CMP-001,,,,,,nivolumab,,Q15116,,,,,skin cancers;lymphoma,Phase 2,,,NCT03618641,CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease,,https://ClinicalTrials.gov/show/NCT03618641
clinicaltrials.gov,CMP-001,,,,,,nivolumab,,Q15116,,,,,skin cancers;lymphoma,Phase 2,,,NCT03618641,CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease,,https://ClinicalTrials.gov/show/NCT03618641
clinicaltrials.gov,COM701,,,,,,nivolumab,,Q15116,,,,,advanced solid cancers;female cancers;breast cancers;lung cancers,Phase 1,,,NCT03667716,COM701 in Subjects With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT03667716
clinicaltrials.gov,COM701,,,,,,nivolumab,,Q15116,,,,,advanced solid cancers;female cancers;breast cancers;lung cancers,Phase 1,,,NCT03667716,COM701 in Subjects With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT03667716
clinicaltrials.gov,copanlisib,1212464,O00329;O00459;P27986;P42336;P42338;P48736;Q8WYR1;Q92569,"InChI=1S/C23H28N8O4/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15/h3-4,13-14H,2,5-12H2,1H3,(H2,24,26,27)(H,28,29,32)",PZBCKZWLPGJMAO-UHFFFAOYSA-N,COc1c(OCCCN2CCOCC2)ccc3C4=NCCN4C(=Nc13)NC(=O)c5cnc(N)nc5,nivolumab,,Q15116,,,,,lung cancers;head and neck cancers;colorectal cancers;liver cancers,Phase 1/2,,,NCT03735628,An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT03735628
clinicaltrials.gov,copanlisib,1212464,O00329;O00459;P27986;P42336;P42338;P48736;Q8WYR1;Q92569,"InChI=1S/C23H28N8O4/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15/h3-4,13-14H,2,5-12H2,1H3,(H2,24,26,27)(H,28,29,32)",PZBCKZWLPGJMAO-UHFFFAOYSA-N,COc1c(OCCCN2CCOCC2)ccc3C4=NCCN4C(=Nc13)NC(=O)c5cnc(N)nc5,nivolumab,,Q15116,,,,,lung cancers;head and neck cancers;colorectal cancers;liver cancers,Phase 1/2,,,NCT03735628,An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT03735628
clinicaltrials.gov,CV301,,,,,,nivolumab,,Q15116,,,,,lung cancers,Phase 1/2,,,NCT02840994,A Trial of CV301 in Combination With Nivolumab Versus Nivolumab in Subjects With Previously Treated Non-Small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT02840994
clinicaltrials.gov,CXD101,,,,,,nivolumab,,Q15116,,,,,,,,,NCT03993626,A Trial of CXD101 in Combination With Nivolumab in Patients With Metastatic Microsatellite-Stable Colorectal Cancer,CAROSELL,https://ClinicalTrials.gov/show/NCT03993626
clinicaltrials.gov,Denenicokin,,,,,,nivolumab,,Q15116,,,,,,Phase 1,,,NCT01629758,Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors,,https://ClinicalTrials.gov/show/NCT01629758
clinicaltrials.gov,denosumab,,,,,,nivolumab,,Q15116,,,,,lung cancers,Phase 2,,,NCT03669523,denosumab and Nivolumab Combination as 2d-line Therapy in Stage IV NSC Lung Cancer With Bone Metastases (DENIVOS),DENIVOS,https://ClinicalTrials.gov/show/NCT03669523
clinicaltrials.gov,denosumab,,,,,,nivolumab,,Q15116,,,,,lung cancers,Phase 2,,,NCT03669523,denosumab and Nivolumab Combination as 2d-line Therapy in Stage IV NSC Lung Cancer With Bone Metastases (DENIVOS),DENIVOS,https://ClinicalTrials.gov/show/NCT03669523
clinicaltrials.gov,enadenotucirev,,,,,,nivolumab,,Q15116,,,,,bowel cancers;bladder cancers;head and neck cancers;salivary gland cancer,Phase 1,,,NCT02636036,Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors,SPICE,https://ClinicalTrials.gov/show/NCT02636036
clinicaltrials.gov,entinostat,312087,Q96DB2;Q9UBN7;Q92769;Q13547;Q9UKV0;Q9UQL6;Q8WUI4;P56524;O15379;Q969S8;Q9BY41,"InChI=1S/C21H20N4O3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-24-21(27)28-14-16-4-3-11-23-12-16/h1-12H,13-14,22H2,(H,24,27)(H,25,26)",INVTYAOGFAGBOE-UHFFFAOYSA-N,Nc1ccccc1NC(=O)c2ccc(CNC(=O)OCc3cccnc3)cc2,nivolumab,,Q15116,,,,,other; pancreatic cancers,Phase 2,,,NCT03250273,A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma,,https://ClinicalTrials.gov/show/NCT03250273
clinicaltrials.gov,ESK981,,,,,,nivolumab,,Q15116,,,,,kidney cancers,Phase 2,,,NCT03562507,Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma,ERICA,https://ClinicalTrials.gov/show/NCT03562507
clinicaltrials.gov,ESK981,,,,,,nivolumab,,Q15116,,,,,kidney cancers,Phase 2,,,NCT03562507,Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma,ERICA,https://ClinicalTrials.gov/show/NCT03562507
clinicaltrials.gov,FPA008,,,,,,nivolumab,,Q15116,,,,,head and neck cancers;pancreatic cancers;ovarian cancers;kidney cancers;central nervous system cancers,Phase 1,,,NCT02526017,Study of FPA008 in Combination With Nivolumab in Patients With Selected Advanced Cancers,FPA008-003,https://ClinicalTrials.gov/show/NCT02526017
clinicaltrials.gov,galunisertib,1096122,P36897,"InChI=1S/C22H19N5O/c1-13-4-2-5-18(25-13)21-20(19-6-3-11-27(19)26-21)15-9-10-24-17-8-7-14(22(23)28)12-16(15)17/h2,4-5,7-10,12H,3,6,11H2,1H3,(H2,23,28)",IVRXNBXKWIJUQB-UHFFFAOYSA-N,Cc1cccc(n1)c2nn3CCCc3c2c4ccnc5ccc(cc45)C(=O)N,nivolumab,,Q15116,,,,,lung cancers;liver cancers,Phase 1/2,,,NCT02423343,"A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma",,https://ClinicalTrials.gov/show/NCT02423343
clinicaltrials.gov,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,nivolumab,,Q15116,,,,,lung cancers,Phase 2,,,NCT02950038,Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC),,https://ClinicalTrials.gov/show/NCT02950038
clinicaltrials.gov,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,nivolumab,,Q15116,,,,,,Phase 1/2,,,NCT02329847,"A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies",,https://ClinicalTrials.gov/show/NCT02329847
literature,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,nivolumab,,Q15116,,,,Patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia,lymphoma;leukemia,Phase 1/2a,30642819,"Between March 12, 2015, and April 11, 2017, 144 patients were enrolled in the study. Three patients died before receiving study treatment; thus, 141 patients were included in the analysis, 14 in part A and 127 in part B. One dose-limiting toxicity (grade 3 hyperbilirubinaemia) was reported at the 420 mg dose in the diffuse large B-cell lymphoma cohort, which resolved after 5 days. The combination of ibrutinib and nivolumab led to overall responses in 22 (61%) of 36 patients with high-risk chronic lymphocytic leukaemia or small lymphocytic lymphoma, 13 (33%) of 40 patients with follicular lymphoma, 16 (36%) of 45 patients with diffuse large B-cell lymphoma, and 13 (65%) of 20 patients with Richter's transformation. The most common all-grade adverse events were diarrhoea (47 [33%] of 141 patients), neutropenia (44 [31%]), and fatigue (37 [26%]). 11 (8%) of 141 patients had adverse events leading to death; none were reported as drug-related. The most common grade 3-4 adverse events were neutropenia (40 [28%] of 141 patients) and anaemia (32 [23%]). The incidence of grade 3-4 neutropenia ranged from eight (18%) of 45 patients with diffuse large B-cell lymphoma to 19 (53%) of 36 patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma; incidence of grade 3-4 anaemia ranged from five (13%) of 40 patients with follicular lymphoma to seven (35%) of 20 patients with Richter's transformation. The most common serious adverse events included anaemia (six [4%] of 141 patients) and pneumonia (five [4%]). The most common grade 3-4 immune-related adverse events were rash (11 [8%] of 141 patients) and increased alanine aminotransferase (three [2%]).",NCT02329847,,,
clinicaltrials.gov,INCB081776,,,,,,nivolumab,,Q15116,,,,,advanced solid cancers,Phase 1,,,NCT03522142,A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT03522142
clinicaltrials.gov,INCB081776,,,,,,nivolumab,,Q15116,,,,,advanced solid cancers,Phase 1,,,NCT03522142,A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT03522142
clinicaltrials.gov,IPI-549,,,,,,nivolumab,,Q15116,,,,,advanced solid cancers;lung cancers;skin cancers;head and neck cancers,Phase 1,,,NCT02637531,"A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549",,https://ClinicalTrials.gov/show/NCT02637531
clinicaltrials.gov,IPI-549,,,,,,nivolumab,,Q15116,,,,,,,,,NCT03980041,Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275),,https://ClinicalTrials.gov/show/NCT03980041
clinicaltrials.gov,ipilimumab,1238537,P16410,,,,nivolumab,,Q15116,,,,,bladder cancers,Phase 1,,,NCT03387761,Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy,NABUCCO,https://ClinicalTrials.gov/show/NCT03387761
clinicaltrials.gov,ipilimumab,1238537,P16410,,,,nivolumab,,Q15116,,,,,bladder cancers;male cancers;prostate cancers;other,Phase 2,,,NCT03333616,Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors,,https://ClinicalTrials.gov/show/NCT03333616
clinicaltrials.gov,ipilimumab,1238537,P16410,,,,nivolumab,,Q15116,,,,,lung cancers,Phase 2,,,NCT03091491,Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT03091491
clinicaltrials.gov,ipilimumab,1238537,P16410,,,,nivolumab,,Q15116,,,,,nasopharyngeal cancers,Phase 2,,,NCT03097939,Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma,,https://ClinicalTrials.gov/show/NCT03097939
clinicaltrials.gov,ipilimumab,1238537,P16410,,,,nivolumab,,Q15116,,,,,skin cancers,Phase 2,,,NCT02626962,Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma,GEM1402,https://ClinicalTrials.gov/show/NCT02626962
clinicaltrials.gov,ipilimumab,1238537,P16410,,,,nivolumab,,Q15116,,,,,stomach cancers;other;female cancers,Phase 2,,,NCT02923934,A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers,,https://ClinicalTrials.gov/show/NCT02923934
clinicaltrials.gov,ipilimumab,1238537,P16410,,,,nivolumab,,Q15116,,,,,liver cancers,Phase 1/2,,,NCT03682276,Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma,PRIME-HCC,https://ClinicalTrials.gov/show/NCT03682276
clinicaltrials.gov,ipilimumab,1238537,P16410,,,,nivolumab,,Q15116,,,,,liver cancers,Phase 1/2,,,NCT03682276,Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma,PRIME-HCC,https://ClinicalTrials.gov/show/NCT03682276
clinicaltrials.gov,ipilimumab,1238537,P16410,,,,nivolumab,,Q15116,,,,,,,,,NCT03999749,A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma,,https://ClinicalTrials.gov/show/NCT03999749
literature,ipilimumab,1238537,P16410,,,,nivolumab,,Q15116,,,,recurrent malignant pleural mesothelioma ,lung cancers,Phase 2,30660511,"Between Oct 5, 2016, and Aug 3, 2017, 38 patients were enrolled in the study, of which two patients were excluded because they were not eligible for a biopsy. Of 36 eligible patients, one deteriorated before the start of the study so was not included in any analyses and one withdrew consent after one treatment cycle before radiological assessment so was included in the safety population only. 34 patients were evaluable for response assessment at 12 weeks. Of these, ten (29%) patients had a partial response and 13 (38%) patients had stable disease; thus, disease control was achieved by 23 (68%, 95% CI 50-83) of 34 patients. Treatment-related adverse events were reported in 33 (94%) patients. The most common adverse events were infusion-related reactions, skin disorders, and fatigue. Grade 3 treatment-related adverse events were reported in 12 (34%) of 35 patients.",NCT03048474,,,
literature,ipilimumab,1238537,P16410,,,,nivolumab,,Q15116,,,,macroscopic stage III melanoma,skin cancers,Phase 2,31160251,"Between Nov 24, 2016 and June 28, 2018, 105 patients were screened for eligibility, of whom 89 (85%) eligible patients were enrolled and randomly assigned to one of the three groups. Three patients were excluded after randomisation because they were found to be ineligible, and 86 received at least one dose of study drug; 30 patients in group A, 30 in group B, and 26 in group C (accrual to this group was closed early upon advice of the Data Safety Monitoring Board on June 4, 2018 because of severe adverse events). Within the first 12 weeks, grade 3-4 immune-related adverse events were observed in 12 (40%) of 30 patients in group A, six (20%) of 30 in group B, and 13 (50%) of 26 in group C. The difference in grade 3-4 toxicity between group B and A was -20% (95% CI -46 to 6; p=0·158) and between group C and group A was 10% (-20 to 40; p=0·591). The most common grade 3-4 adverse events were elevated liver enzymes in group A (six [20%)]) and colitis in group C (five [19%]); in group B, none of the grade 3-4 adverse events were seen in more than one patient. One patient (in group A) died 9·5 months after the start of treatment due to the consequences of late-onset immune-related encephalitis, which was possibly treatment-related. 19 (63% [95% CI 44-80]) of 30 patients in group A, 17 (57% [37-75]) of 30 in group B, and nine (35% [17-56]) of 26 in group C achieved a radiological objective response, while pathological responses occurred in 24 (80% [61-92]) patients in group A, 23 (77% [58-90]) in group B, and 17 (65% [44-83]) in group C.",NCT02977052,,,
clinicaltrials.gov,IRX 2,,,,,,nivolumab,,Q15116,,,,,advanced solid cancers,Phase 1,,,NCT03758781,IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors,,https://ClinicalTrials.gov/show/NCT03758781
clinicaltrials.gov,IRX 2,,,,,,nivolumab,,Q15116,,,,,advanced solid cancers,Phase 1,,,NCT03758781,IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors,,https://ClinicalTrials.gov/show/NCT03758781
clinicaltrials.gov,ISA 101,,,,,,nivolumab,,Q15116,,,,,advanced solid cancers,Phase 2,,,NCT02426892,Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors,,https://ClinicalTrials.gov/show/NCT02426892
clinicaltrials.gov,JNJ-64041757,,,,,,nivolumab,,Q15116,,,,,lung cancers,Phase 1/2,,,NCT03371381,"An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung",,https://ClinicalTrials.gov/show/NCT03371381
clinicaltrials.gov,JTX-2011,,,,,,nivolumab,,Q15116,,,,,advanced solid cancers,Phase 1/2,,,NCT02904226,Dose Escalation and Expansion of JTX-2011 Alone or in Combination With Anti-PD-1 in Subjects With Advanced Solid Tumors,ICONIC,https://ClinicalTrials.gov/show/NCT02904226
clinicaltrials.gov,lenvatinib,802872,P35968;P17948;P35916,"InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)",WOSKHXYHFSIKNG-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(=O)N,nivolumab,,Q15116,,,,,liver cancers,Phase 1,,,NCT03418922,A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma,,https://ClinicalTrials.gov/show/NCT03418922
clinicaltrials.gov,lenvatinib,802872,P35968;P17948;P35916,"InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)",WOSKHXYHFSIKNG-UHFFFAOYSA-N,,nivolumab,,Q15116,,,,Advanced Hepatocellular Carcinoma,,Phase 2,,,NCT03841201,,,
clinicaltrials.gov,MGCD516,,,,,,nivolumab,,Q15116,,,,,kidney cancers,Phase 1/2,,,NCT03015740,MGCD516 Combined With Nivolumab in Renal Cell Cancer (RCC),,https://ClinicalTrials.gov/show/NCT03015740
clinicaltrials.gov,mogamulizumab,,,,,,nivolumab,,Q15116,,,,,stomach cancers;oesophageal cancers;lung cancers;kidney cancers,Phase 1,,,NCT02946671,Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients,,https://ClinicalTrials.gov/show/NCT02946671
clinicaltrials.gov,MTG201,,,,,,nivolumab,,Q15116,,,,,,,,,NCT04013334,MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma,,https://ClinicalTrials.gov/show/NCT04013334
clinicaltrials.gov,NKTR-214,,,,,,nivolumab,,Q15116,,,,,soft tissue cancers,Phase 2,,,NCT03282344,A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma,,https://ClinicalTrials.gov/show/NCT03282344
clinicaltrials.gov,NKTR-214,,,,,,nivolumab,,Q15116,,,,,advanced solid cancers,Phase 1,,,NCT03745807,An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT03745807
clinicaltrials.gov,NKTR-214,,,,,,nivolumab,,Q15116,,,,,skin cancers,Phase 3,,,NCT03635983,A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma,,https://ClinicalTrials.gov/show/NCT03635983
clinicaltrials.gov,NKTR-214,,,,,,nivolumab,,Q15116,,,,,advanced solid cancers,Phase 1,,,NCT03745807,An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT03745807
clinicaltrials.gov,NKTR-214,,,,,,nivolumab,,Q15116,,,,,skin cancers,Phase 3,,,NCT03635983,A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma,,https://ClinicalTrials.gov/show/NCT03635983
clinicaltrials.gov,ONO-4578,,,,,,nivolumab,,Q15116,,,,,advanced solid cancers,Phase 1,,,NCT03155061,Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors,,https://ClinicalTrials.gov/show/NCT03155061
clinicaltrials.gov,ramucirumab,,P35968,,,,nivolumab,,Q15116,,,,,stomach cancers,Phase 1/2,,,NCT02999295,A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer,,https://ClinicalTrials.gov/show/NCT02999295
clinicaltrials.gov,regorafenib,998226,P15056;P34913,"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)",FNHKPVJBJVTLMP-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1,nivolumab,,Q15116,,,,,advanced solid cancers,Phase 1/2,,,NCT03406871,Regorafenib and Nivolumab Simultaneous Combination Therapy,REGONIVO,https://ClinicalTrials.gov/show/NCT03406871
clinicaltrials.gov,regorafenib,998226,P15056;P34913,"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)",FNHKPVJBJVTLMP-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1,nivolumab,,Q15116,,,,,colorectal cancers,Phase 1,,,NCT03712943,Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer,,https://ClinicalTrials.gov/show/NCT03712943
clinicaltrials.gov,regorafenib,998226,P15056;P34913,"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)",FNHKPVJBJVTLMP-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1,nivolumab,,Q15116,,,,,colorectal cancers,Phase 1,,,NCT03712943,Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer,,https://ClinicalTrials.gov/show/NCT03712943
clinicaltrials.gov,relatlimab,,,,,,nivolumab,,Q15116,,,,,skin cancers,Phase 2,,,NCT03743766,"Nivolumab, BMS-936558 in Combination With relatlimab, BMS-986016 in Patients With Metastatic Melanoma Na√Øve to Prior Immunotherapy in the Metastatic Setting",,https://ClinicalTrials.gov/show/NCT03743766
clinicaltrials.gov,relatlimab,,,,,,nivolumab,,Q15116,,,,,skin cancers,Phase 2,,,NCT03743766,"Nivolumab, BMS-936558 in Combination With relatlimab, BMS-986016 in Patients With Metastatic Melanoma Na√Øve to Prior Immunotherapy in the Metastatic Setting",,https://ClinicalTrials.gov/show/NCT03743766
clinicaltrials.gov,RP1,,,,,,nivolumab,,Q15116,,,,,,Phase 1/2,,,NCT03767348,Study of RP1 Monotherapy and RP1 in Combination With Nivolumab,,https://ClinicalTrials.gov/show/NCT03767348
clinicaltrials.gov,RP1,,,,,,nivolumab,,Q15116,,,,,,Phase 1/2,,,NCT03767348,Study of RP1 Monotherapy and RP1 in Combination With Nivolumab,,https://ClinicalTrials.gov/show/NCT03767348
clinicaltrials.gov,rucaparib,757098,P09874;Q9UGN5;Q9Y6F1,"InChI=1S/C19H18FN3O/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15/h2-5,8-9,21,23H,6-7,10H2,1H3,(H,22,24)",HMABYWSNWIZPAG-UHFFFAOYSA-N,CNCc1ccc(cc1)c2[nH]c3cc(F)cc4C(=O)NCCc2c34,nivolumab,,Q15116,,,,,prostate cancers;female cancers,Phase 1/2,,,NCT03572478,Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer,,https://ClinicalTrials.gov/show/NCT03572478
clinicaltrials.gov,rucaparib,757098,P09874;Q9UGN5;Q9Y6F1,"InChI=1S/C19H18FN3O/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15/h2-5,8-9,21,23H,6-7,10H2,1H3,(H,22,24)",HMABYWSNWIZPAG-UHFFFAOYSA-N,CNCc1ccc(cc1)c2[nH]c3cc(F)cc4C(=O)NCCc2c34,nivolumab,,Q15116,,,,,other,Phase 2,,,NCT03639935,Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy,,https://ClinicalTrials.gov/show/NCT03639935
clinicaltrials.gov,rucaparib,757098,P09874;Q9UGN5;Q9Y6F1,"InChI=1S/C19H18FN3O/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15/h2-5,8-9,21,23H,6-7,10H2,1H3,(H,22,24)",HMABYWSNWIZPAG-UHFFFAOYSA-N,CNCc1ccc(cc1)c2[nH]c3cc(F)cc4C(=O)NCCc2c34,nivolumab,,Q15116,,,,,prostate cancers;female cancers,Phase 1/2,,,NCT03572478,Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer,,https://ClinicalTrials.gov/show/NCT03572478
clinicaltrials.gov,rucaparib,757098,P09874;Q9UGN5;Q9Y6F1,"InChI=1S/C19H18FN3O/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15/h2-5,8-9,21,23H,6-7,10H2,1H3,(H,22,24)",HMABYWSNWIZPAG-UHFFFAOYSA-N,CNCc1ccc(cc1)c2[nH]c3cc(F)cc4C(=O)NCCc2c34,nivolumab,,Q15116,,,,,other,Phase 2,,,NCT03639935,Rucaparib in Combination With Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy,,https://ClinicalTrials.gov/show/NCT03639935
clinicaltrials.gov,rucaparib,757098,P09874;Q9UGN5;Q9Y6F1,"InChI=1S/C19H18FN3O/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15/h2-5,8-9,21,23H,6-7,10H2,1H3,(H,22,24)",HMABYWSNWIZPAG-UHFFFAOYSA-N,CNCc1ccc(cc1)c2[nH]c3cc(F)cc4C(=O)NCCc2c34,nivolumab,,Q15116,,,,,,,,,NCT03958045,Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma,,https://ClinicalTrials.gov/show/NCT03958045
clinicaltrials.gov,ruxolitinib,974392,O00238;O00444;O00506;O14730;O14920;O14936;O14976;O15075;O15197;O43293;O43318;O60674;O75116;O75385;O75460;O75582;O75676;O75716;O94768;O95747;O96013;P00519;P04629;P07949;P0C264;P10721;P15056;P15735;P19784;P23458;P29320;P29376;P29597;P32298;P33981;P36507;P45983;P45985;P46734;P48729;P49760;P50613;P51617;P51956;P52333;P53350;P53355;P57078;P68400;Q02156;Q02750;Q07912;Q09013;Q12851;Q13233;Q13237;Q13464;Q13554;Q13555;Q13557;Q13627;Q13873;Q14012;Q14164;Q14680;Q15349;Q15418;Q15746;Q15835;Q16288;Q16620;Q16816;Q2M2I8;Q52WX2;Q56UN5;Q5S007;Q6PHR2;Q6ZN16;Q7KZI7;Q7L7X3;Q86Y07;Q86Z02;Q8IU85;Q8IYT8;Q8N568;Q8NFD2;Q8TDX7;Q8WTQ7;Q92630;Q96NX5;Q96SB4;Q99759;Q9BRS2;Q9BVS4;Q9C098;Q9H093;Q9H2K8;Q9H2X6;Q9H422;Q9H4B4;Q9HAZ1;Q9HBH9;Q9NQU5;Q9NSY1;Q9NYY3;Q9P286;Q9P289;Q9UBF8;Q9UEE5;Q9UEW8;Q9UHD2;Q9UIK4;Q9UK32;Q9UL54;Q9UM73;Q9UPE1;Q9UQB9;Q9UQM7;Q9Y2H9;Q9Y2K2;Q9Y2U5,"InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1",HFNKQEVNSGCOJV-OAHLLOKOSA-N,N#CC[C@H](C1CCCC1)n2cc(cn2)c3ncnc4[nH]ccc34,nivolumab,,Q15116,,,,,lymphoma,Phase 1/2,,,NCT03681561,Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma,,https://ClinicalTrials.gov/show/NCT03681561
clinicaltrials.gov,ruxolitinib,974392,O00238;O00444;O00506;O14730;O14920;O14936;O14976;O15075;O15197;O43293;O43318;O60674;O75116;O75385;O75460;O75582;O75676;O75716;O94768;O95747;O96013;P00519;P04629;P07949;P0C264;P10721;P15056;P15735;P19784;P23458;P29320;P29376;P29597;P32298;P33981;P36507;P45983;P45985;P46734;P48729;P49760;P50613;P51617;P51956;P52333;P53350;P53355;P57078;P68400;Q02156;Q02750;Q07912;Q09013;Q12851;Q13233;Q13237;Q13464;Q13554;Q13555;Q13557;Q13627;Q13873;Q14012;Q14164;Q14680;Q15349;Q15418;Q15746;Q15835;Q16288;Q16620;Q16816;Q2M2I8;Q52WX2;Q56UN5;Q5S007;Q6PHR2;Q6ZN16;Q7KZI7;Q7L7X3;Q86Y07;Q86Z02;Q8IU85;Q8IYT8;Q8N568;Q8NFD2;Q8TDX7;Q8WTQ7;Q92630;Q96NX5;Q96SB4;Q99759;Q9BRS2;Q9BVS4;Q9C098;Q9H093;Q9H2K8;Q9H2X6;Q9H422;Q9H4B4;Q9HAZ1;Q9HBH9;Q9NQU5;Q9NSY1;Q9NYY3;Q9P286;Q9P289;Q9UBF8;Q9UEE5;Q9UEW8;Q9UHD2;Q9UIK4;Q9UK32;Q9UL54;Q9UM73;Q9UPE1;Q9UQB9;Q9UQM7;Q9Y2H9;Q9Y2K2;Q9Y2U5,"InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1",HFNKQEVNSGCOJV-OAHLLOKOSA-N,N#CC[C@H](C1CCCC1)n2cc(cn2)c3ncnc4[nH]ccc34,nivolumab,,Q15116,,,,,lymphoma,Phase 1/2,,,NCT03681561,Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma,,https://ClinicalTrials.gov/show/NCT03681561
clinicaltrials.gov,Sitravatinib,,,,,,nivolumab,,Q15116,,,,,bladder cancers,Phase 2,,,NCT03606174,Sitravatinib and Nivolumab in Urothelial Carcinoma Study,,https://ClinicalTrials.gov/show/NCT03606174
clinicaltrials.gov,Sitravatinib,,,,,,nivolumab,,Q15116,,,,,kidney cancers,Phase 2,,,NCT03680521,Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT03680521
clinicaltrials.gov,Sitravatinib,,,,,,nivolumab,,Q15116,,,,,bladder cancers,Phase 2,,,NCT03606174,Sitravatinib and Nivolumab in Urothelial Carcinoma Study,,https://ClinicalTrials.gov/show/NCT03606174
clinicaltrials.gov,Sitravatinib,,,,,,nivolumab,,Q15116,,,,,kidney cancers,Phase 2,,,NCT03680521,Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT03680521
clinicaltrials.gov,Sym004,,,,,,nivolumab,,Q15116,,,,,lung cancers,Phase 1/2,,,NCT02924233,Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT02924233
clinicaltrials.gov,TAK-659,,P43405,,,,nivolumab,,Q15116,,,,,breast cancers;lung cancers;head and neck cancers;advanced solid cancers,Phase 1,,,NCT02834247,A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT02834247
clinicaltrials.gov,tivozanib,,P35968;P17948;P35916,"InChI=1S/C22H19ClN4O5/c1-12-8-21(27-32-12)26-22(28)25-16-5-4-13(9-15(16)23)31-18-6-7-24-17-11-20(30-3)19(29-2)10-14(17)18/h4-11H,1-3H3,(H2,25,26,27,28)",SPMVMDHWKHCIDT-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,nivolumab,,Q15116,,,,,kidney cancers,Phase 1/2,,,NCT03136627,Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC,,https://ClinicalTrials.gov/show/NCT03136627
clinicaltrials.gov,trabectedin,748449,,"InChI=1S/C39H43N3O11S/c1-16-9-20-10-22-37(46)42-23-13-50-38(47)39(21-12-25(48-5)24(44)11-19(21)7-8-40-39)14-54-36(30(42)29(41(22)4)26(20)31(45)32(16)49-6)28-27(23)35-34(51-15-52-35)17(2)33(28)53-18(3)43/h9,11-12,22-23,29-30,36-37,40,44-46H,7-8,10,13-15H2,1-6H3/t22-,23+,29+,30+,36-,37-,39+/m0/s1",PKVRCIRHQMSYJX-PYDRXBSSSA-N,COc1cc2c(CCN[C@]23CS[C@@H]4[C@H]5[C@@H]6N(C)[C@@H](Cc7cc(C)c(OC)c(O)c67)[C@H](O)N5[C@H](COC3=O)c8c9OCOc9c(C)c(OC(=O)C)c48)cc1O,nivolumab,,Q15116,,,,,soft tissue cancers,Phase 2,,,NCT03590210,Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas,NiTraSarc,https://ClinicalTrials.gov/show/NCT03590210
clinicaltrials.gov,trabectedin,748449,,"InChI=1S/C39H43N3O11S/c1-16-9-20-10-22-37(46)42-23-13-50-38(47)39(21-12-25(48-5)24(44)11-19(21)7-8-40-39)14-54-36(30(42)29(41(22)4)26(20)31(45)32(16)49-6)28-27(23)35-34(51-15-52-35)17(2)33(28)53-18(3)43/h9,11-12,22-23,29-30,36-37,40,44-46H,7-8,10,13-15H2,1-6H3/t22-,23+,29+,30+,36-,37-,39+/m0/s1",PKVRCIRHQMSYJX-PYDRXBSSSA-N,COc1cc2c(CCN[C@]23CS[C@@H]4[C@H]5[C@@H]6N(C)[C@@H](Cc7cc(C)c(OC)c(O)c67)[C@H](O)N5[C@H](COC3=O)c8c9OCOc9c(C)c(OC(=O)C)c48)cc1O,nivolumab,,Q15116,,,,,soft tissue cancers,Phase 2,,,NCT03590210,Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas,NiTraSarc,https://ClinicalTrials.gov/show/NCT03590210
clinicaltrials.gov,trastuzumab,4,P04626,,,,nivolumab,,Q15116,,,,,breast cancers,Phase 1,,,NCT03523572,Trastuzumab Deruxtecan (DS-8201a) With Nivolumab in Advanced Breast and Urothelial Cancer,,https://ClinicalTrials.gov/show/NCT03523572
clinicaltrials.gov,trastuzumab,4,P04626,,,,nivolumab,,Q15116,,,,,breast cancers,Phase 1,,,NCT03523572,Trastuzumab Deruxtecan (DS-8201a) With Nivolumab in Advanced Breast and Urothelial Cancer,,https://ClinicalTrials.gov/show/NCT03523572
clinicaltrials.gov,ulocuplumab,,,,,,nivolumab,,Q15116,,,,,,Phase 1/2,,,NCT02472977,Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors,CXCessoR4,https://ClinicalTrials.gov/show/NCT02472977
clinicaltrials.gov,urelumab,,Q07011,,,,nivolumab,,Q15116,,,,,advanced solid cancers;lymphoma,Phase 1/2,,,NCT02253992,An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma,,https://ClinicalTrials.gov/show/NCT02253992
clinicaltrials.gov,urelumab,,Q07011,,,,nivolumab,,Q15116,,,,,,Phase 1,,,NCT02534506,Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors,,https://ClinicalTrials.gov/show/NCT02534506
clinicaltrials.gov,Viagenpumatucel-L,,,,,,nivolumab,,Q15116,,,,,lung cancers,Phase 1/2,,,NCT02439450,A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT02439450
clinicaltrials.gov,X82,,,,,,nivolumab,,Q15116,,,,,other,Phase 1/2,,,NCT03583086,Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors,,https://ClinicalTrials.gov/show/NCT03583086
clinicaltrials.gov,X82,,,,,,nivolumab,,Q15116,,,,,other,Phase 1/2,,,NCT03583086,Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors,,https://ClinicalTrials.gov/show/NCT03583086
clinicaltrials.gov,TAK-659,,P43405,,,,NKTR-214,,,,,,,lymphoma,Phase 1,,,NCT03772288,A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL),,https://ClinicalTrials.gov/show/NCT03772288
clinicaltrials.gov,TAK-659,,P43405,,,,NKTR-214,,,,,,,lymphoma,Phase 1,,,NCT03772288,A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL),,https://ClinicalTrials.gov/show/NCT03772288
clinicaltrials.gov,ceritinib,1135147,O60674;O75116;P00519;P00533;P04629;P06213;P06239;P07948;P07949;P08069;P08581;P08922;P09769;P10721;P11802;P12931;P16234;P21802;P22455;P22607;P23458;P24941;P35968;P36888;P41212;P43403;P43405;P52333;Q06187;Q16620;Q9BXA7;Q9HBH9;Q9UM73,"InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34)",VERWOWGGCGHDQE-UHFFFAOYSA-N,CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)C(C)C)n3,NVP-AUY922,480574,,"InChI=1S/C26H31N3O5/c1-4-27-26(32)24-23(18-7-5-17(6-8-18)15-29-9-11-33-12-10-29)25(34-28-24)20-13-19(16(2)3)21(30)14-22(20)31/h5-8,13-14,16,30-31H,4,9-12,15H2,1-3H3,(H,27,32)",NDAZATDQFDPQBD-UHFFFAOYSA-N,CCNC(=O)c1noc(c2cc(C(C)C)c(O)cc2O)c1c3ccc(CN4CCOCC4)cc3,,lung cancers,Phase 1,,,NCT01772797,Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT01772797
clinicaltrials.gov,BGB-3111,,,,,,obinutuzumab,,P11836,,,,,lymphoma,Phase 2,,,NCT03332017,A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma,,https://ClinicalTrials.gov/show/NCT03332017
clinicaltrials.gov,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,obinutuzumab,,P11836,,,,,leukemia,Phase 1,,,NCT02611908,Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.,,https://ClinicalTrials.gov/show/NCT02611908
literature,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,obinutuzumab,,P11836,,,,chronic lymphocytic leukaemia or small lymphocytic lymphoma,lymphoma;leukemia,Phase 3,30522969,,NCT02264574,,,
clinicaltrials.gov,lenalidomide,718,O14920,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,Nc1cccc2C(=O)N(Cc12)C3CCC(=O)NC3=O,obinutuzumab,,P11836,,,,,leukemia,Phase 2,,,NCT02225275,Combination of Lenalidomide and Obinutuzumab (GA101) in Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL),,https://ClinicalTrials.gov/show/NCT02225275
clinicaltrials.gov,lenalidomide,718,O14920,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,Nc1cccc2C(=O)N(Cc12)C3CCC(=O)NC3=O,obinutuzumab,,P11836,,,,,leukemia,Phase 2,,,NCT02371590,Lenalidomide and Obinutuzumab for Previously Untreated CLL,,https://ClinicalTrials.gov/show/NCT02371590
clinicaltrials.gov,vemurafenib,754991,P15056,"InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)",GPXBXXGIAQBQNI-UHFFFAOYSA-N,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)c4ccc(Cl)cc4)c1F,obinutuzumab,,P11836,,,,,leukemia,Phase 2,,,NCT03410875,"A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia",,https://ClinicalTrials.gov/show/NCT03410875
clinicaltrials.gov,idelalisib,1059065,O00329,"InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1",IFSDAJWBUCMOAH-HNNXBMFYSA-N,CC[C@H](Nc1ncnc2[nH]cnc12)C3=Nc4cccc(F)c4C(=O)N3c5ccccc5,ofatumumab,,P11836,,,,,leukemia;lymphoma,Phase 2,,,NCT02135133,"A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL",,https://ClinicalTrials.gov/show/NCT02135133
clinicaltrials.gov,lenalidomide,718,O14920,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,Nc1cccc2C(=O)N(Cc12)C3CCC(=O)NC3=O,ofatumumab,,P11836,,,,,leukemia;lymphoma,Phase 2,,,NCT01002755,Lenalidomide and Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL),,https://ClinicalTrials.gov/show/NCT01002755
clinicaltrials.gov,ARQ761,,,,,,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,,lymphoma,Phase 1,,,NCT03575078,ARQ761 + PARP Inhibitor in Refractory Solid Tumors,,https://ClinicalTrials.gov/show/NCT03575078
clinicaltrials.gov,ARQ761,,,,,,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,,lymphoma,Phase 1,,,NCT03575078,ARQ761 + PARP Inhibitor in Refractory Solid Tumors,,https://ClinicalTrials.gov/show/NCT03575078
clinicaltrials.gov,AZD0156,,,,,,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,,advanced solid cancers,Phase 1,,,NCT02588105,Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer,AToM,https://ClinicalTrials.gov/show/NCT02588105
clinicaltrials.gov,AZD1775,,,,,,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,,ovarian cancers;breast cancers;lung cancers,Phase 1,,,NCT02511795,AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors,,https://ClinicalTrials.gov/show/NCT02511795
clinicaltrials.gov,AZD6738,,,,,,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,,head and neck cancers,Phase 1,,,NCT03022409,A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC),,https://ClinicalTrials.gov/show/NCT03022409
clinicaltrials.gov,AZD6738,,,,,,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,,lung cancers,Phase 2,,,NCT03428607,Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2],,https://ClinicalTrials.gov/show/NCT03428607
clinicaltrials.gov,AZD6738,,,,,,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,,,Phase 2,,,NCT03682289,Phase II Trial of AZD6738 Alone and in Combination With Olaparib,,https://ClinicalTrials.gov/show/NCT03682289
clinicaltrials.gov,AZD6738,,,,,,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,,,Phase 2,,,NCT03682289,Phase II Trial of AZD6738 Alone and in Combination With Olaparib,,https://ClinicalTrials.gov/show/NCT03682289
clinicaltrials.gov,cediranib,106760,O00444;O14976;O15197;O43353;O75460;O94804;O95819;P00519;P00533;P04626;P06239;P06241;P07333;P07947;P07948;P07949;P08581;P08631;P09619;P09769;P10721;P11362;P12931;P16234;P17948;P21709;P21802;P21860;P22455;P22607;P29320;P29322;P29376;P30530;P35590;P35916;P35968;P36507;P36888;P36896;P36897;P42684;P42685;P49674;P51451;P54760;Q02763;Q04771;Q04912;Q06187;Q06418;Q08345;Q12851;Q12866;Q13043;Q13163;Q13882;Q15303;Q15375;Q16832;Q56UN5;Q8IVH8;Q8N4C8;Q8TDR2;Q92918;Q96GD4;Q9BQI3;Q9BYT3;Q9H0K1;Q9H2G2;Q9H2K8;Q9P289;Q9UF33;Q9UKE5;Q9UL54;Q9UM73;Q9UQB9;Q9Y4K4,"InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3",XXJWYDDUDKYVKI-UHFFFAOYSA-N,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN5CCCC5,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,,ovarian cancers,not specified,,,NCT02681237,A Study of Cediranib and Olaparib at Disease Worsening in ovarian Cancers,,https://ClinicalTrials.gov/show/NCT02681237
literature,cediranib,106760,O00444;O14976;O15197;O43353;O75460;O94804;O95819;P00519;P00533;P04626;P06239;P06241;P07333;P07947;P07948;P07949;P08581;P08631;P09619;P09769;P10721;P11362;P12931;P16234;P17948;P21709;P21802;P21860;P22455;P22607;P29320;P29322;P29376;P30530;P35590;P35916;P35968;P36507;P36888;P36896;P36897;P42684;P42685;P49674;P51451;P54760;Q02763;Q04771;Q04912;Q06187;Q06418;Q08345;Q12851;Q12866;Q13043;Q13163;Q13882;Q15303;Q15375;Q16832;Q56UN5;Q8IVH8;Q8N4C8;Q8TDR2;Q92918;Q96GD4;Q9BQI3;Q9BYT3;Q9H0K1;Q9H2G2;Q9H2K8;Q9P289;Q9UF33;Q9UKE5;Q9UL54;Q9UM73;Q9UQB9;Q9Y4K4,"InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3",XXJWYDDUDKYVKI-UHFFFAOYSA-N,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN5CCCC5,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,recurrent ovarian cancer,ovarian cancers,Phase 2,25218906,"Between Oct 26, 2011, and June 3, 2013, we randomly allocated 46 women to receive olaparib alone and 44 to receive the combination of olaparib and cediranib. Median PFS was 17à7 months (95% CI 14à7-not reached) for the women treated with cediranib plus olaparib compared with 9à0 months (95% CI 5à7-16à5) for those treated with olaparib monotherapy (hazard ratio 0à42, 95% CI 0à23-0à76; p=0à005). Grade 3 and 4 adverse events were more common with combination therapy than with monotherapy, including fatigue (12 patients in the cediranib plus olaparib group vs five patients in the olaparib monotherapy group), diarrhoea (ten vs none), and hypertension (18 vs none).",,,,
clinicaltrials.gov,CRLX101,,,,,,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,,lung cancers,Phase 1/2,,,NCT02769962,"Trial of CRLX101, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer",,https://ClinicalTrials.gov/show/NCT02769962
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,,breast cancers,Phase 1,,,NCT03544125,Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer,,https://ClinicalTrials.gov/show/NCT03544125
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,,bladder cancers,Phase 2,,,NCT03534492,Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB),NEODURVARIB,https://ClinicalTrials.gov/show/NCT03534492
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,,breast cancers,Phase 1,,,NCT03544125,Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer,,https://ClinicalTrials.gov/show/NCT03544125
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,,bladder cancers,Phase 2,,,NCT03534492,Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB),NEODURVARIB,https://ClinicalTrials.gov/show/NCT03534492
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,,,,,,NCT03951415,Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer,DOMEC,https://ClinicalTrials.gov/show/NCT03951415
literature,durvalumab,,Q9NZQ7,,,,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,recurrent women's cancers,female cancers,Phase 1,28471727,"Between June 2015 and May 2016, 26 women were enrolled. The RP2D was durvalumab_1,500 mg every 4 weeks with olaparib 300 mg twice a day, or cediranib 20 mg, 5 days on/2 days off. No dose-limiting toxicity was recorded with durvalumab plus olaparib. The cediranib intermittent schedule (n = 6) was examined because of recurrent grade 2 and non-dose-limiting toxicity grade 3 and 4 adverse events (AEs) on the daily schedule (n = 8). Treatment-emergent AEs included hypertension (two of eight), diarrhea (two of eight), pulmonary embolism (two of eight), pulmonary hypertension (one of eight), and lymphopenia (one of eight). Durvalumab plus intermittent cediranib grade 3 and 4 AEs were hypertension (one of six) and fatigue (one of six). Exposure to durvalumab increased cediranib area under the curve and maximum plasma concentration on the daily, but not intermittent, schedules. Two partial responses (_15 months and _ 11 months) and eight stable diseases _ 4 months (median, 8 months [4 to 14.5 months]) were seen in patients who received durvalumab plus olaparib, yielding an 83% disease control rate. Six partial responses (_ 5 to _ 8 months) and three stable diseases _ 4 months (4 to _ 8 months) were seen in 12 evaluable patients who received durvalumab plus cediranib, for a 50% response rate and a 75% disease control rate. Response to therapy was independent of PD-L1 expression.",,,,
clinicaltrials.gov,gefitinib,701,O14578;O14976;O15197;O43293;O43353;O75676;O94768;O94804;O96017;P00519;P00533;P04626;P06239;P07948;P07949;P08581;P08631;P09769;P10721;P12931;P15735;P21709;P21860;P29320;P29322;P29376;P30530;P31152;P36888;P42681;P42684;P42685;P45984;P48730;P49674;P50613;P51451;P51617;P53779;P54756;P54760;P54762;Q09013;Q13163;Q15139;Q15303;Q16659;Q16816;Q52WX2;Q56UN5;Q86V86;Q8N4C8;Q8NE63;Q8TBX8;Q99759;Q9BUB5;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NWZ3;Q9UBE8;Q9UEE5;Q9UF33;Q9UKE5;Q9UNQ0;Q9Y2U5;Q9Y616,"InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)",XGALLCVXEZPNRQ-UHFFFAOYSA-N,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN4CCOCC4,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,,lung cancers,Phase 1/2,,,NCT01513174,Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone,GOAL,https://ClinicalTrials.gov/show/NCT01513174
clinicaltrials.gov,prexasertib,,O14757;O96017,"InChI=1S/C18H19N7O2/c1-26-14-4-2-5-15(27-7-3-6-19)18(14)13-8-16(25-24-13)23-17-11-21-12(9-20)10-22-17/h2,4-5,8,10-11H,3,6-7,19H2,1H3,(H2,22,23,24,25)",DOTGPNHGTYJDEP-UHFFFAOYSA-N,COc1cccc(OCCCN)c1c2cc(Nc3cnc(cn3)C#N)n[nH]2,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,,advanced solid cancers,Phase 1,,,NCT03057145,Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT03057145
clinicaltrials.gov,selumetinib,646570,Q02750;P36507,"InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)",CYOHGALHFOKKQC-UHFFFAOYSA-N,Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,,breast cancers;stomach cancers;bowel cancers;female cancers;male cancers;thyroid cancers,Phase 1,,,NCT03162627,Selumetinib and Olaparib in Solid Tumors,,https://ClinicalTrials.gov/show/NCT03162627
clinicaltrials.gov,trabectedin,748449,,"InChI=1S/C39H43N3O11S/c1-16-9-20-10-22-37(46)42-23-13-50-38(47)39(21-12-25(48-5)24(44)11-19(21)7-8-40-39)14-54-36(30(42)29(41(22)4)26(20)31(45)32(16)49-6)28-27(23)35-34(51-15-52-35)17(2)33(28)53-18(3)43/h9,11-12,22-23,29-30,36-37,40,44-46H,7-8,10,13-15H2,1-6H3/t22-,23+,29+,30+,36-,37-,39+/m0/s1",PKVRCIRHQMSYJX-PYDRXBSSSA-N,COc1cc2c(CCN[C@]23CS[C@@H]4[C@H]5[C@@H]6N(C)[C@@H](Cc7cc(C)c(OC)c(O)c67)[C@H](O)N5[C@H](COC3=O)c8c9OCOc9c(C)c(OC(=O)C)c48)cc1O,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,,soft tissue cancers;bone cancers,Phase 1,,,NCT02398058,Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS),TOMAS,https://ClinicalTrials.gov/show/NCT02398058
clinicaltrials.gov,trabectedin,748449,,"InChI=1S/C39H43N3O11S/c1-16-9-20-10-22-37(46)42-23-13-50-38(47)39(21-12-25(48-5)24(44)11-19(21)7-8-40-39)14-54-36(30(42)29(41(22)4)26(20)31(45)32(16)49-6)28-27(23)35-34(51-15-52-35)17(2)33(28)53-18(3)43/h9,11-12,22-23,29-30,36-37,40,44-46H,7-8,10,13-15H2,1-6H3/t22-,23+,29+,30+,36-,37-,39+/m0/s1",PKVRCIRHQMSYJX-PYDRXBSSSA-N,COc1cc2c(CCN[C@]23CS[C@@H]4[C@H]5[C@@H]6N(C)[C@@H](Cc7cc(C)c(OC)c(O)c67)[C@H](O)N5[C@H](COC3=O)c8c9OCOc9c(C)c(OC(=O)C)c48)cc1O,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,Advanced Soft Tissue Sarcoma,,Phase 2,,,NCT03838744,,,
clinicaltrials.gov,tremelimumab,,P16410,,,,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,,other,Phase 1/2,,,NCT02485990,"Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)",,https://ClinicalTrials.gov/show/NCT02485990
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,Oleclumab,,,,,,,bladder cancers,Phase 1,,,NCT03773666,A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2),,https://ClinicalTrials.gov/show/NCT03773666
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,Oleclumab,,,,,,,bladder cancers,Phase 1,,,NCT03773666,A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2),,https://ClinicalTrials.gov/show/NCT03773666
clinicaltrials.gov,Palonosetron,,,,,,ondansetron,2228,P46098,"InChI=1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3",FELGMEQIXOGIFQ-UHFFFAOYSA-N,Cc1nccn1CC2CCc3c(C2=O)c4ccccc4n3C,,breast cancers,Phase 2/3,,,NCT03606369,Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.,,https://ClinicalTrials.gov/show/NCT03606369
clinicaltrials.gov,Palonosetron,,,,,,ondansetron,2228,P46098,"InChI=1S/C18H19N3O/c1-12-19-9-10-21(12)11-13-7-8-16-17(18(13)22)14-5-3-4-6-15(14)20(16)2/h3-6,9-10,13H,7-8,11H2,1-2H3",FELGMEQIXOGIFQ-UHFFFAOYSA-N,Cc1nccn1CC2CCc3c(C2=O)c4ccccc4n3C,,breast cancers,Phase 2/3,,,NCT03606369,Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.,,https://ClinicalTrials.gov/show/NCT03606369
clinicaltrials.gov,ONO-7475,,,,,,ONO-4538,,,,,,,advanced solid cancers,Phase 1,,,NCT03730337,Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors,,https://ClinicalTrials.gov/show/NCT03730337
clinicaltrials.gov,ONO-7475,,,,,,ONO-4538,,,,,,,advanced solid cancers,Phase 1,,,NCT03730337,Phase 1 Study of ONO-7475 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors,,https://ClinicalTrials.gov/show/NCT03730337
clinicaltrials.gov,nivolumab,,Q15116,,,,oregovomab,,Q8WXI7,,,,,ovarian cancers,Phase 1/2,,,NCT03100006,"Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin",ORION-01,https://ClinicalTrials.gov/show/NCT03100006
clinicaltrials.gov,APG-1252,,,,,,osimertinib,1371518,P00533;P04626;P21860;Q15303;P00533,"InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)",DUYJMQONPNNFPI-UHFFFAOYSA-N,COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2nccc(n2)c3cn(C)c4ccccc34,,,,,,NCT04001777,A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients,,https://ClinicalTrials.gov/show/NCT04001777
clinicaltrials.gov,dasatinib,375,O00238;O00506;O14965;O14976;O15197;O15264;O43283;O43318;O43353;O60674;O94804;O95819;P00519;P00533;P04049;P04626;P06239;P06241;P07333;P07947;P07948;P07949;P08631;P08684;P09619;P09769;P0C1S8;P10721;P11274;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P21860;P22607;P27037;P29317;P29320;P29322;P29323;P29597;P30291;P35968;P36507;P36888;P36894;P36896;P36897;P37023;P37173;P41240;P42680;P42681;P42684;P42685;P43405;P49674;P51451;P51813;P51955;P52333;P53667;P53671;P53778;P54753;P54756;P54760;P54762;P54764;P57059;Q01538;Q02750;Q04771;Q06187;Q07912;Q08345;Q09013;Q12851;Q13043;Q13163;Q13705;Q13882;Q15303;Q15569;Q15759;Q16539;Q16832;Q52WX2;Q56UN5;Q59H18;Q5VT25;Q6DT37;Q6PHR2;Q86Y07;Q8IVH8;Q8N4C8;Q8NG66;Q8NI60;Q8TDR2;Q92918;Q96GD4;Q99640;Q99759;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K8;Q9H3Y6;Q9NRP7;Q9NYL2;Q9P289;Q9P2K8;Q9UBE8;Q9UF33;Q9UKE5;Q9UL54;Q9Y2K2;Q9Y2U5;Q9Y4K4;Q9Y5S2;Q9Y6R4,"InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)",ZBNZXTGUTAYRHI-UHFFFAOYSA-N,Cc1nc(Nc2ncc(s2)C(=O)Nc3c(C)cccc3Cl)cc(n1)N4CCN(CCO)CC4,osimertinib,1371518,P00533;P04626;P21860;Q15303;P00533,"InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)",DUYJMQONPNNFPI-UHFFFAOYSA-N,COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2nccc(n2)c3cn(C)c4ccccc34,,lung cancers,Phase 1/2,,,NCT02954523,Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations,,https://ClinicalTrials.gov/show/NCT02954523
clinicaltrials.gov,DS-1205c,,,,,,osimertinib,1371518,P00533;P04626;P21860;Q15303;P00533,"InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)",DUYJMQONPNNFPI-UHFFFAOYSA-N,COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2nccc(n2)c3cn(C)c4ccccc34,,lung cancers,Phase 1,,,NCT03255083,DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT03255083
clinicaltrials.gov,fexofenadine,1714,P35367,"InChI=1S/C32H39NO4/c1-31(2,30(35)36)25-17-15-24(16-18-25)29(34)14-9-21-33-22-19-28(20-23-33)32(37,26-10-5-3-6-11-26)27-12-7-4-8-13-27/h3-8,10-13,15-18,28-29,34,37H,9,14,19-23H2,1-2H3,(H,35,36)",RWTNPBWLLIMQHL-UHFFFAOYSA-N,CC(C)(C(=O)O)c1ccc(cc1)C(O)CCCN2CCC(CC2)C(O)(c3ccccc3)c4ccccc4,osimertinib,1371518,P00533;P04626;P21860;Q15303;P00533,"InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)",DUYJMQONPNNFPI-UHFFFAOYSA-N,COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2nccc(n2)c3cn(C)c4ccccc34,,lung cancers,Phase 1,,,NCT02908750,Study to Assess the Effect of Osimertinib (TAGRISSO__¢ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC,,https://ClinicalTrials.gov/show/NCT02908750
clinicaltrials.gov,G1T38,,,,,,osimertinib,1371518,P00533;P04626;P21860;Q15303;P00533,"InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)",DUYJMQONPNNFPI-UHFFFAOYSA-N,COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2nccc(n2)c3cn(C)c4ccccc34,,lung cancers,Phase 1/2,,,NCT03455829,"G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer",,https://ClinicalTrials.gov/show/NCT03455829
clinicaltrials.gov,gefitinib,701,O14578;O14976;O15197;O43293;O43353;O75676;O94768;O94804;O96017;P00519;P00533;P04626;P06239;P07948;P07949;P08581;P08631;P09769;P10721;P12931;P15735;P21709;P21860;P29320;P29322;P29376;P30530;P31152;P36888;P42681;P42684;P42685;P45984;P48730;P49674;P50613;P51451;P51617;P53779;P54756;P54760;P54762;Q09013;Q13163;Q15139;Q15303;Q16659;Q16816;Q52WX2;Q56UN5;Q86V86;Q8N4C8;Q8NE63;Q8TBX8;Q99759;Q9BUB5;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NWZ3;Q9UBE8;Q9UEE5;Q9UF33;Q9UKE5;Q9UNQ0;Q9Y2U5;Q9Y616,"InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)",XGALLCVXEZPNRQ-UHFFFAOYSA-N,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN4CCOCC4,osimertinib,1371518,P00533;P04626;P21860;Q15303;P00533,"InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)",DUYJMQONPNNFPI-UHFFFAOYSA-N,COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2nccc(n2)c3cn(C)c4ccccc34,,lung cancers,Phase 1,,,NCT03122717,Osimertinib and Gefitinib in EGFR Inhibitor naêève Advanced EGFR Mutant Lung Cancer,,https://ClinicalTrials.gov/show/NCT03122717
clinicaltrials.gov,Glutaminase Inhibitor CB-839,,,,,,osimertinib,1371518,P00533;P04626;P21860;Q15303;P00533,"InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)",DUYJMQONPNNFPI-UHFFFAOYSA-N,COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2nccc(n2)c3cn(C)c4ccccc34,Advanced Lung Carcinoma|EGFR Activating Mutation|EGFR Exon 19 Deletion Mutation|EGFR NP_005219.2:p.L858R|EGFR T790M Mutation Negative|Lung Non-Small Cell Carcinoma|Metastatic Lung Carcinoma|Stage IV Lung Cancer AJCC v8|Stage IVA Lung Cancer AJCC v8|Stage IVB Lung Cancer AJCC v8,,Phase 1/2,,,NCT03831932,,,
clinicaltrials.gov,INCB039110,1947652,P23458,"InChI=1S/C26H23F4N9O/c27-20-18(1-7-32-22(20)26(28,29)30)24(40)37-9-3-17(4-10-37)38-13-25(14-38,5-6-31)39-12-16(11-36-39)21-19-2-8-33-23(19)35-15-34-21/h1-2,7-8,11-12,15,17H,3-5,9-10,13-14H2,(H,33,34,35)",KTBSXLIQKWEBRB-UHFFFAOYSA-N,Fc1c(ccnc1C(F)(F)F)C(=O)N2CCC(CC2)N3CC(CC#N)(C3)n4cc(cn4)c5ncnc6[nH]ccc56,osimertinib,1371518,P00533;P04626;P21860;Q15303;P00533,"InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)",DUYJMQONPNNFPI-UHFFFAOYSA-N,COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2nccc(n2)c3cn(C)c4ccccc34,,lung cancers,Phase 1/2,,,NCT02917993,An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT02917993
clinicaltrials.gov,Tepotinib,,,,,,osimertinib,1371518,P00533;P04626;P21860;Q15303;P00533,"InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)",DUYJMQONPNNFPI-UHFFFAOYSA-N,COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2nccc(n2)c3cn(C)c4ccccc34,,,,,,NCT03940703,A Study of Tepotinib Plus Osimertinib in Epidermal Growth Factor Receptor (EGFR ) Tyrosine Kinase Inhibitor (TKI) Relapsed Mesenchymal-epithelial Transition Factor (MET) Amplified Non-small Cell Lung Cancer (NSCLC),,https://ClinicalTrials.gov/show/NCT03940703
clinicaltrials.gov,trastuzumab,4,P04626,,,,osimertinib,1371518,P00533;P04626;P21860;Q15303;P00533,"InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)",DUYJMQONPNNFPI-UHFFFAOYSA-N,COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2nccc(n2)c3cn(C)c4ccccc34,,lung cancers,Phase 2,,,NCT03784599,T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC,TRAEMOS,https://ClinicalTrials.gov/show/NCT03784599
clinicaltrials.gov,trastuzumab,4,P04626,,,,osimertinib,1371518,P00533;P04626;P21860;Q15303;P00533,"InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)",DUYJMQONPNNFPI-UHFFFAOYSA-N,COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2nccc(n2)c3cn(C)c4ccccc34,,lung cancers,Phase 2,,,NCT03784599,T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC,TRAEMOS,https://ClinicalTrials.gov/show/NCT03784599
clinicaltrials.gov,AZD9833,,,,,,palbociclib,149415,P11802;P20248;P24385;P24941;P30279;P30281;P36888;P50750;P52333;Q00534,"InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)",AHJRHEGDXFFMBM-UHFFFAOYSA-N,CC(=O)C1=C(C)c2cnc(Nc3ccc(cn3)N4CCNCC4)nc2N(C5CCCC5)C1=O,,breast cancers,Phase 1,,,NCT03616587,Study of AZD9833 Alone or in Combination With Palbociclib in Women With Advanced Breast Cancer,,https://ClinicalTrials.gov/show/NCT03616587
clinicaltrials.gov,AZD9833,,,,,,palbociclib,149415,P11802;P20248;P24385;P24941;P30279;P30281;P36888;P50750;P52333;Q00534,"InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)",AHJRHEGDXFFMBM-UHFFFAOYSA-N,CC(=O)C1=C(C)c2cnc(Nc3ccc(cn3)N4CCNCC4)nc2N(C5CCCC5)C1=O,,breast cancers,Phase 1,,,NCT03616587,Study of AZD9833 Alone or in Combination With Palbociclib in Women With Advanced Breast Cancer,,https://ClinicalTrials.gov/show/NCT03616587
clinicaltrials.gov,binimetinib,1222391,Q02750;P36507,"InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)",ACWZRVQXLIRSDF-UHFFFAOYSA-N,Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO,palbociclib,149415,P11802;P20248;P24385;P24941;P30279;P30281;P36888;P50750;P52333;Q00534,"InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)",AHJRHEGDXFFMBM-UHFFFAOYSA-N,CC(=O)C1=C(C)c2cnc(Nc3ccc(cn3)N4CCNCC4)nc2N(C5CCCC5)C1=O,,lung cancers,Phase 1/2,,,NCT03170206,Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor Binimetinib (MEK162) for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT03170206
clinicaltrials.gov,binimetinib,1222391,Q02750;P36507,"InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)",ACWZRVQXLIRSDF-UHFFFAOYSA-N,Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO,palbociclib,149415,P11802;P20248;P24385;P24941;P30279;P30281;P36888;P50750;P52333;Q00534,"InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)",AHJRHEGDXFFMBM-UHFFFAOYSA-N,CC(=O)C1=C(C)c2cnc(Nc3ccc(cn3)N4CCNCC4)nc2N(C5CCCC5)C1=O,,,,,,NCT03981614,Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer,,https://ClinicalTrials.gov/show/NCT03981614
clinicaltrials.gov,cetuximab,9,P00533,,,,palbociclib,149415,P11802;P20248;P24385;P24941;P30279;P30281;P36888;P50750;P52333;Q00534,"InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)",AHJRHEGDXFFMBM-UHFFFAOYSA-N,CC(=O)C1=C(C)c2cnc(Nc3ccc(cn3)N4CCNCC4)nc2N(C5CCCC5)C1=O,,colorectal cancers,Phase 2,,,NCT03446157,Palbociclib and Cetuximab in Metastatic Colorectal Cancer,,https://ClinicalTrials.gov/show/NCT03446157
clinicaltrials.gov,SAR439859,,,,,,palbociclib,149415,P11802;P20248;P24385;P24941;P30279;P30281;P36888;P50750;P52333;Q00534,"InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)",AHJRHEGDXFFMBM-UHFFFAOYSA-N,CC(=O)C1=C(C)c2cnc(Nc3ccc(cn3)N4CCNCC4)nc2N(C5CCCC5)C1=O,,breast cancers,Phase 1/2,,,NCT03284957,Phase 1 / 2 Study of SAR439859 Single Agent and in Combination With Palbociclib in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer,,https://ClinicalTrials.gov/show/NCT03284957
clinicaltrials.gov,Telaglenestat,,,,,,palbociclib,149415,P11802;P20248;P24385;P24941;P30279;P30281;P36888;P50750;P52333;Q00534,"InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)",AHJRHEGDXFFMBM-UHFFFAOYSA-N,CC(=O)C1=C(C)c2cnc(Nc3ccc(cn3)N4CCNCC4)nc2N(C5CCCC5)C1=O,,,,,,NCT03965845,A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors,,https://ClinicalTrials.gov/show/NCT03965845
clinicaltrials.gov,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,palbociclib,149415,P11802;P20248;P24385;P24941;P30279;P30281;P36888;P50750;P52333;Q00534,"InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)",AHJRHEGDXFFMBM-UHFFFAOYSA-N,CC(=O)C1=C(C)c2cnc(Nc3ccc(cn3)N4CCNCC4)nc2N(C5CCCC5)C1=O,,,Phase 1,,,NCT02065063,"A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors",,https://ClinicalTrials.gov/show/NCT02065063
clinicaltrials.gov,ulixertinib,,P27361;P28482,,,,palbociclib,149415,P11802;P20248;P24385;P24941;P30279;P30281;P36888;P50750;P52333;Q00534,"InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)",AHJRHEGDXFFMBM-UHFFFAOYSA-N,CC(=O)C1=C(C)c2cnc(Nc3ccc(cn3)N4CCNCC4)nc2N(C5CCCC5)C1=O,,pancreatic cancers,Phase 1,,,NCT03454035,Phase I Trial of Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors,,https://ClinicalTrials.gov/show/NCT03454035
clinicaltrials.gov,binimetinib,1222391,Q02750;P36507,"InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)",ACWZRVQXLIRSDF-UHFFFAOYSA-N,Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO,panitumumab,1238534,P00533,,,,,bowel cancers,Phase 1/2,,,NCT01927341,"Phase Ib/II Study of Efficacy and Safety of MEK162 and panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors",,https://ClinicalTrials.gov/show/NCT01927341
clinicaltrials.gov,buparlisib,962639,O00329;O00459;P27986;P42336;P42338;P48736;Q8WYR1;Q92569,"InChI=1S/C18H21F3N6O2/c19-18(20,21)13-9-15(22)23-11-12(13)14-10-16(26-1-5-28-6-2-26)25-17(24-14)27-3-7-29-8-4-27/h9-11H,1-8H2,(H2,22,23)",CWHUFRVAEUJCEF-UHFFFAOYSA-N,Nc1cc(c(cn1)c2cc(nc(n2)N3CCOCC3)N4CCOCC4)C(F)(F)F,panitumumab,1238534,P00533,,,,,bowel cancers,Phase 1/2,,,NCT01591421,P13Kinase Inhibitor BKM120 in Combination With panitumumab in Patients With Metastatic or Advanced RAS-Wild Type Colorectal Cancer.,,https://ClinicalTrials.gov/show/NCT01591421
literature,motesanib,199235,P09619;P16234;P10721;P07949;P35968;P17948;P35916,"InChI=1S/C22H23N5O/c1-22(2)14-26-19-12-16(5-6-18(19)22)27-21(28)17-4-3-9-24-20(17)25-13-15-7-10-23-11-8-15/h3-12,26H,13-14H2,1-2H3,(H,24,25)(H,27,28)",RAHBGWKEPAQNFF-UHFFFAOYSA-N,CC1(C)CNc2cc(NC(=O)c3cccnc3NCc4ccncc4)ccc12,panitumumab,1238534,P00533,,,,advanced non-small cell lung cancer,lung cancers,Phase 1b,20028752,"Forty-five patients received motesanib. Three dose-limiting toxicities occurred: grade 4 pulmonary embolism (n = 1; arm A, 50 mg once daily) and grade 3 deep vein thrombosis (n = 2; arm A, 125 mg once daily; arm C). The MTD was 125 mg once daily. Common motesanib-related adverse events were fatigue (60% of patients), diarrhea (53%), hypertension, (38%), anorexia (27%), and nausea (22%). Three cases of cholecystitis occurred but only in the 75-mg twice-daily schedule, which was subsequently discontinued. At 125 mg once daily, motesanib pharmacokinetics were not markedly changed with carboplatin/paclitaxel coadministration; however, exposure to paclitaxel was moderately increased. The objective response rates were 17%, 0%, and 17% in arms A, B, and C, respectively.",,,,
clinicaltrials.gov,niraparib,919241,Q9UGN5;P09874,"InChI=1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)/t14-/m1/s1",PCHKPVIQAHNQLW-CQSZACIVSA-N,NC(=O)c1cccc2cn(nc12)c3ccc(cc3)[C@@H]4CCCNC4,panitumumab,,,,,,,,,,,NCT03983993,Niraparib and panitumumab in Patients With Advanced or Metastatic Colorectal Cancer,NIPAVect,https://ClinicalTrials.gov/show/NCT03983993
clinicaltrials.gov,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,panitumumab,1238534,P00533,,,,,bowel cancers,Phase 2,,,NCT02399943,A Trial of Trametinib and panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer,,https://ClinicalTrials.gov/show/NCT02399943
clinicaltrials.gov,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,panobinostat,523996,Q9BY41;Q969S8;O15379;P56524;Q8WUI4;Q9UQL6;Q9UKV0;Q13547;Q92769;Q9UBN7;Q96DB2,"InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+",FPOHNWQLNRZRFC-ZHACJKMWSA-N,Cc1[nH]c2ccccc2c1CCNCc3ccc(\C=C\C(=O)NO)cc3,,multiple myeloma,Phase 1,,,NCT00891033,Panobinostat/Velcade in Multiple Myeloma,,https://ClinicalTrials.gov/show/NCT00891033
clinicaltrials.gov,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,panobinostat,523996,Q9BY41;Q969S8;O15379;P56524;Q8WUI4;Q9UQL6;Q9UKV0;Q13547;Q92769;Q9UBN7;Q96DB2,"InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+",FPOHNWQLNRZRFC-ZHACJKMWSA-N,Cc1[nH]c2ccccc2c1CCNCc3ccc(\C=C\C(=O)NO)cc3,,pancreatic cancers,Phase 2,,,NCT01056601,Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy,,https://ClinicalTrials.gov/show/NCT01056601
literature,carfilzomib,134643,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436,"InChI=1S/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1",BLMPQMFVWMYDKT-NZTKNTHTSA-N,CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN2CCOCC2)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]4(C)CO4,panobinostat,523996,Q9BY41;Q969S8;O15379;P56524;Q8WUI4;Q9UQL6;Q9UKV0;Q13547;Q92769;Q9UBN7;Q96DB2,"InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+",FPOHNWQLNRZRFC-ZHACJKMWSA-N,Cc1[nH]c2ccccc2c1CCNCc3ccc(\C=C\C(=O)NO)cc3,relapsed/refractory multiple myeloma,multiple myeloma,Phase 1,30610196," Thirty-two patients (median of 4 prior lines of therapy) were enrolled. The MTD was carfilzomib 36_mg/m2 (on days 1, 2, 8, 9, 15, and 16) and panobinostat 20_mg (TIW, 3 weeks on/1 week off, every 28 days), administered until progression. At the MTD, the most common grade 3/4, treatment-related adverse events were thrombocytopenia (41%), fatigue (17%), and nausea/vomiting (12%). The objective response rate (ORR) and clinical benefit rate were 63% and 68%, respectively. Median progression-free survival (PFS) and overall survival (OS) for the entire population were 8 and 23 months, respectively. No differences in terms of ORR (55% vs. 57%), median PFS (months 8 vs. 7 months) and OS (24 vs. 22 months) were observed between bortezomib-sensitive and -refractory patients. CarPan proved to be a safe and effective steroid-sparing regimen in a heavily pre-treated population of MM patients.",NCT01549431,,,
clinicaltrials.gov,PDR001,,,,,,panobinostat,523996,Q9BY41;Q969S8;O15379;P56524;Q8WUI4;Q9UQL6;Q9UKV0;Q13547;Q92769;Q9UBN7;Q96DB2,"InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+",FPOHNWQLNRZRFC-ZHACJKMWSA-N,Cc1[nH]c2ccccc2c1CCNCc3ccc(\C=C\C(=O)NO)cc3,,,,,,NCT03982134,PDR001 + Panobinostat for Melanoma and NSCLC,,https://ClinicalTrials.gov/show/NCT03982134
clinicaltrials.gov,alisertib,,O14965,"InChI=1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33)",ZLHFILGSQDJULK-UHFFFAOYSA-N,COc1cccc(F)c1C2=NCc3cnc(Nc4ccc(C(=O)O)c(OC)c4)nc3c5ccc(Cl)cc25,pazopanib,200268,O00238;O00444;O14965;O14976;O15197;O43353;O60331;O60674;O75716;O94804;O95819;P00519;P04049;P06239;P06241;P07332;P07333;P07947;P07948;P07949;P08581;P08631;P08922;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P16591;P17948;P19525;P21127;P21802;P22455;P22607;P27448;P29376;P29597;P33981;P35590;P35916;P35968;P36888;P37173;P42681;P42684;P42685;P43405;P45983;P45985;P51451;P51617;P51955;P52333;P52564;P53667;P53671;P53779;P57059;P80192;Q00536;Q02763;Q02779;Q08345;Q12851;Q12866;Q13163;Q13233;Q13470;Q13546;Q13705;Q13882;Q14012;Q16584;Q16832;Q2M2I8;Q56UN5;Q6P3R8;Q7L7X3;Q8IVH8;Q8TBX8;Q92918;Q96NX5;Q9BVS4;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K8;Q9H3Y6;Q9NRP7;Q9NSY1;Q9UBE8;Q9UBF8;Q9UKE5;Q9UL54;Q9UM73;Q9UQ88;Q9UQB9;Q9Y2U5;Q9Y4K4;Q9Y616,"InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)",CUIHSIWYWATEQL-UHFFFAOYSA-N,CN(c1ccc2c(C)n(C)nc2c1)c3ccnc(Nc4ccc(C)c(c4)S(=O)(=O)N)n3,,breast cancers;central nervous system cancers;stomach cancers;bowel cancers;bladder cancers;head and neck cancers;skin cancers,Phase 1,,,NCT01639911,Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors,,https://ClinicalTrials.gov/show/NCT01639911
clinicaltrials.gov,AR-42,,,,,,pazopanib,200268,O00238;O00444;O14965;O14976;O15197;O43353;O60331;O60674;O75716;O94804;O95819;P00519;P04049;P06239;P06241;P07332;P07333;P07947;P07948;P07949;P08581;P08631;P08922;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P16591;P17948;P19525;P21127;P21802;P22455;P22607;P27448;P29376;P29597;P33981;P35590;P35916;P35968;P36888;P37173;P42681;P42684;P42685;P43405;P45983;P45985;P51451;P51617;P51955;P52333;P52564;P53667;P53671;P53779;P57059;P80192;Q00536;Q02763;Q02779;Q08345;Q12851;Q12866;Q13163;Q13233;Q13470;Q13546;Q13705;Q13882;Q14012;Q16584;Q16832;Q2M2I8;Q56UN5;Q6P3R8;Q7L7X3;Q8IVH8;Q8TBX8;Q92918;Q96NX5;Q9BVS4;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K8;Q9H3Y6;Q9NRP7;Q9NSY1;Q9UBE8;Q9UBF8;Q9UKE5;Q9UL54;Q9UM73;Q9UQ88;Q9UQB9;Q9Y2U5;Q9Y4K4;Q9Y616,"InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)",CUIHSIWYWATEQL-UHFFFAOYSA-N,CN(c1ccc2c(C)n(C)nc2c1)c3ccnc(Nc4ccc(C)c(c4)S(=O)(=O)N)n3,,kidney cancers;soft tissue cancers,Phase 1,,,NCT02795819,Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer,,https://ClinicalTrials.gov/show/NCT02795819
clinicaltrials.gov,lapatinib,2195,O00750;O14733;O43353;O75747;O94804;P00533;P04626;P08684;P09619;P21860;Q13163;Q15303;Q9H2G2;Q9UBF8,"InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)",BCFGMOOMADDAQU-UHFFFAOYSA-N,CS(=O)(=O)CCNCc1oc(cc1)c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2,pazopanib,200268,O00238;O00444;O14965;O14976;O15197;O43353;O60331;O60674;O75716;O94804;O95819;P00519;P04049;P06239;P06241;P07332;P07333;P07947;P07948;P07949;P08581;P08631;P08922;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P16591;P17948;P19525;P21127;P21802;P22455;P22607;P27448;P29376;P29597;P33981;P35590;P35916;P35968;P36888;P37173;P42681;P42684;P42685;P43405;P45983;P45985;P51451;P51617;P51955;P52333;P52564;P53667;P53671;P53779;P57059;P80192;Q00536;Q02763;Q02779;Q08345;Q12851;Q12866;Q13163;Q13233;Q13470;Q13546;Q13705;Q13882;Q14012;Q16584;Q16832;Q2M2I8;Q56UN5;Q6P3R8;Q7L7X3;Q8IVH8;Q8TBX8;Q92918;Q96NX5;Q9BVS4;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K8;Q9H3Y6;Q9NRP7;Q9NSY1;Q9UBE8;Q9UBF8;Q9UKE5;Q9UL54;Q9UM73;Q9UQ88;Q9UQB9;Q9Y2U5;Q9Y4K4;Q9Y616,"InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)",CUIHSIWYWATEQL-UHFFFAOYSA-N,CN(c1ccc2c(C)n(C)nc2c1)c3ccnc(Nc4ccc(C)c(c4)S(=O)(=O)N)n3,,breast cancers,Phase 2,,,NCT00558103,Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer,,https://ClinicalTrials.gov/show/NCT00558103
clinicaltrials.gov,nivolumab,,Q15116,,,,pazopanib,200268,O00238;O00444;O14965;O14976;O15197;O43353;O60331;O60674;O75716;O94804;O95819;P00519;P04049;P06239;P06241;P07332;P07333;P07947;P07948;P07949;P08581;P08631;P08922;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P16591;P17948;P19525;P21127;P21802;P22455;P22607;P27448;P29376;P29597;P33981;P35590;P35916;P35968;P36888;P37173;P42681;P42684;P42685;P43405;P45983;P45985;P51451;P51617;P51955;P52333;P52564;P53667;P53671;P53779;P57059;P80192;Q00536;Q02763;Q02779;Q08345;Q12851;Q12866;Q13163;Q13233;Q13470;Q13546;Q13705;Q13882;Q14012;Q16584;Q16832;Q2M2I8;Q56UN5;Q6P3R8;Q7L7X3;Q8IVH8;Q8TBX8;Q92918;Q96NX5;Q9BVS4;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K8;Q9H3Y6;Q9NRP7;Q9NSY1;Q9UBE8;Q9UBF8;Q9UKE5;Q9UL54;Q9UM73;Q9UQ88;Q9UQB9;Q9Y2U5;Q9Y4K4;Q9Y616,"InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)",CUIHSIWYWATEQL-UHFFFAOYSA-N,CN(c1ccc2c(C)n(C)nc2c1)c3ccnc(Nc4ccc(C)c(c4)S(=O)(=O)N)n3,,soft tissue cancers,Phase 2,,,NCT03149120,Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas,,https://ClinicalTrials.gov/show/NCT03149120
clinicaltrials.gov,palbociclib,149415,P11802;P20248;P24385;P24941;P30279;P30281;P36888;P50750;P52333;Q00534,"InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)",AHJRHEGDXFFMBM-UHFFFAOYSA-N,CC(=O)C1=C(C)c2cnc(Nc3ccc(cn3)N4CCNCC4)nc2N(C5CCCC5)C1=O,PD0325901,,Q02750;P36507,,,,,lung cancers,Phase 1/2,,,NCT02022982,PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors,,https://ClinicalTrials.gov/show/NCT02022982
clinicaltrials.gov,apatinib,1384455,P35968,"InChI=1S/C24H23N5O.CH4O3S/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18;1-5(2,3)4/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30);1H3,(H,2,3,4)",FYJROXRIVQPKRY-UHFFFAOYSA-N,CS(=O)(=O)O.O=C(Nc1ccc(cc1)C2(CCCC2)C#N)c3cccnc3NCc4ccncc4,PD1,,,,,,,,,,,NCT03954756,Exploratory Clinical Study of Apatinib and PD-1 in Treating Advanced Gastric Cancer,,https://ClinicalTrials.gov/show/NCT03954756
clinicaltrials.gov,TAI,,,,,,PD1,,,,,,Hepatocellular Carcinoma,,Phase 2,,,NCT03869034,,,
clinicaltrials.gov,BLZ945,,,,,,PDR001,,,,,,,advanced solid cancers,Phase 1/2,,,NCT02829723,Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT02829723
clinicaltrials.gov,FAZ053,,,,,,PDR001,,,,,,,advanced solid cancers;lung cancers;breast cancers;female cancers;thyroid cancers,Phase 1,,,NCT02936102,A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.,,https://ClinicalTrials.gov/show/NCT02936102
clinicaltrials.gov,FGF401,,P22455,,,,PDR001,,,,,,,liver cancers,Phase 1/2,,,NCT02325739,FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression,,https://ClinicalTrials.gov/show/NCT02325739
clinicaltrials.gov,GWN323,,,,,,PDR001,,,,,,,lymphoma,Phase 1,,,NCT02740270,Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas,,https://ClinicalTrials.gov/show/NCT02740270
clinicaltrials.gov,LAG525,,,,,,PDR001,,,,,,,advanced solid cancers,Phase 1/2,,,NCT02460224,Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.,,https://ClinicalTrials.gov/show/NCT02460224
clinicaltrials.gov,LGK974,,,,,,PDR001,,,,,,,pancreatic cancers;bowel cancers;skin cancers;breast cancers;head and neck cancers,Phase 1,,,NCT01351103,A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands,,https://ClinicalTrials.gov/show/NCT01351103
clinicaltrials.gov,LHC165,,,,,,PDR001,,,,,,,,Phase 1,,,NCT03301896,Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies,,https://ClinicalTrials.gov/show/NCT03301896
clinicaltrials.gov,LXH254,,,,,,PDR001,,,,,,,lung cancers;ovarian cancers;skin cancers,Phase 1,,,NCT02607813,Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations,,https://ClinicalTrials.gov/show/NCT02607813
clinicaltrials.gov,MBG453,,,,,,PDR001,,,,,,,,Phase 1/2,,,NCT02608268,Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.,,https://ClinicalTrials.gov/show/NCT02608268
clinicaltrials.gov,MCS110,,,,,,PDR001,,,,,,,breast cancers;pancreatic cancers;skin cancers;female cancers,Phase 1/2,,,NCT02807844,Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies,,https://ClinicalTrials.gov/show/NCT02807844
clinicaltrials.gov,MCS110,,,,,,PDR001,,,,,,,stomach cancers,Phase 2,,,NCT03694977,Biomarker Study of PDR001 in Combination With MCS110 in Gastric Cancer,,https://ClinicalTrials.gov/show/NCT03694977
clinicaltrials.gov,MCS110,,,,,,PDR001,,,,,,,stomach cancers,Phase 2,,,NCT03694977,Biomarker Study of PDR001 in Combination With MCS110 in Gastric Cancer,,https://ClinicalTrials.gov/show/NCT03694977
clinicaltrials.gov,MIW815,,,,,,PDR001,,,,,,,lymphoma,Phase 1,,,NCT03172936,Study of the Safety and Efficacy of MIW815 With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas,,https://ClinicalTrials.gov/show/NCT03172936
clinicaltrials.gov,NIR178,,,,,,PDR001,,,,,,,lung cancers;kidney cancers;pancreatic cancers;bladder cancers;head and neck cancers;lymphoma;bowel cancers;breast cancers;skin cancers,Phase 2,,,NCT03207867,A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma,,https://ClinicalTrials.gov/show/NCT03207867
clinicaltrials.gov,NIS793,,,,,,PDR001,,,,,,,breast cancers;lung cancers;liver cancers;bowel cancers;pancreatic cancers;prostate cancers;kidney cancers,Phase 1,,,NCT02947165,Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.,,https://ClinicalTrials.gov/show/NCT02947165
clinicaltrials.gov,NIZ985,,,,,,PDR001,,,,,,,advanced solid cancers,Phase 1,,,NCT02452268,A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers,,https://ClinicalTrials.gov/show/NCT02452268
clinicaltrials.gov,atezolizumab,,Q9NZQ7,,,,PEGPH20,,,,,,,,,,,NCT03979066,Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma,NEOiPANC,https://ClinicalTrials.gov/show/NCT03979066
clinicaltrials.gov,4SC-202,,,,,,pembrolizumab,,Q15116,,,,,multiple myeloma,Phase 1/2,,,NCT03278665,4SC-202 in Combination With pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy,SENSITIZE,https://ClinicalTrials.gov/show/NCT03278665
clinicaltrials.gov,abemaciclib,1211300,P11802;Q00534,"InChI=1S/C27H32F2N8/c1-5-35-8-10-36(11-9-35)16-19-6-7-24(30-14-19)33-27-31-15-22(29)25(34-27)20-12-21(28)26-23(13-20)37(17(2)3)18(4)32-26/h6-7,12-15,17H,5,8-11,16H2,1-4H3,(H,30,31,33,34)",UZWDCWONPYILKI-UHFFFAOYSA-N,CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)c4cc(F)c5nc(C)n(C(C)C)c5c4)nc2)CC1,pembrolizumab,,Q15116,,,,,lung cancers;breast cancers,Phase 1,,,NCT02779751,A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer,,https://ClinicalTrials.gov/show/NCT02779751
clinicaltrials.gov,abexinostat,,,,,,pembrolizumab,,Q15116,,,,,skin cancers;head and neck cancers,Phase 1,,,NCT03590054,A Phase 1b Dose Escalation/Expansion Study of abexinostat in Combination With pembrolizumab in Patients With Advanced Solid Tumor Malignancies,,https://ClinicalTrials.gov/show/NCT03590054
clinicaltrials.gov,abexinostat,,,,,,pembrolizumab,,Q15116,,,,,skin cancers;head and neck cancers,Phase 1,,,NCT03590054,A Phase 1b Dose Escalation/Expansion Study of abexinostat in Combination With pembrolizumab in Patients With Advanced Solid Tumor Malignancies,,https://ClinicalTrials.gov/show/NCT03590054
clinicaltrials.gov,acalabrutinib,2014063,,"InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1",WDENQIQQYWYTPO-IBGZPJMESA-N,CC#CC(=O)N1CCC[C@H]1c2nc(c3ccc(cc3)C(=O)Nc4ccccn4)c5c(N)nccn25,pembrolizumab,,Q15116,,,,,multiple myeloma;lymphoma,Phase 1/2,,,NCT02362035,"ACP-196 (Acalabrutinib) in Combination With pembrolizumab, for Treatment of Hematologic Malignancies",KEYNOTE145,https://ClinicalTrials.gov/show/NCT02362035
clinicaltrials.gov,acalabrutinib,2014063,,"InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1",WDENQIQQYWYTPO-IBGZPJMESA-N,CC#CC(=O)N1CCC[C@H]1c2nc(c3ccc(cc3)C(=O)Nc4ccccn4)c5c(N)nccn25,pembrolizumab,,Q15116,,,,,ovarian cancers,Phase 2,,,NCT02537444,Acalabrutinib (ACP-196) Alone and in Combination With pembrolizumab in ovarian Cancers (KEYNOTE191),,https://ClinicalTrials.gov/show/NCT02537444
clinicaltrials.gov,acalabrutinib,2014063,,"InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1",WDENQIQQYWYTPO-IBGZPJMESA-N,CC#CC(=O)N1CCC[C@H]1c2nc(c3ccc(cc3)C(=O)Nc4ccccn4)c5c(N)nccn25,pembrolizumab,,Q15116,,,,,pancreatic cancers,Phase 2,,,NCT02362048,ACP-196 Alone and in Combination With pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer,KEYNOTE144,https://ClinicalTrials.gov/show/NCT02362048
clinicaltrials.gov,ADI PEG20,,,,,,pembrolizumab,,Q15116,,,,,advanced solid cancers,Phase 1,,,NCT03254732,Study ADI-PEG 20 Plus pembrolizumab in Advanced Solid Cancers,,https://ClinicalTrials.gov/show/NCT03254732
clinicaltrials.gov,ADXS-503,,,,,,pembrolizumab,,Q15116,,,,"Lung Cancer, Non-Small Cell|Metastatic Squamous Cell Carcinoma|Metastatic Non-Squamous Cell Carcinoma",,Phase 1/2,,,NCT03847519,,,
clinicaltrials.gov,ADXS31-142,,,,,,pembrolizumab,,Q15116,,,,,prostate cancers,Phase 1/2,,,NCT02325557,ADXS31-142 Alone and in Combination With pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046,,https://ClinicalTrials.gov/show/NCT02325557
clinicaltrials.gov,afatinib,755714,O14578;O14976;O15197;O43353;O94804;P00519;P00533;P04626;P06239;P08581;P08631;P12931;P15735;P21860;P30530;P36888;P42681;P42685;P45984;P49674;P51451;P51617;P53779;Q13163;Q13627;Q15303;Q16539;Q16816;Q52WX2;Q8NE63;Q92630;Q9BUB5;Q9H2G2;Q9HBH9;Q9UEE5;Q9UF33;Q9UK32;Q9Y463,"InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1",ULXXDDBFHOBEHA-CWDCEQMOSA-N,CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]4CCOC4,pembrolizumab,,Q15116,,,,,lung cancers,Phase 1,,,NCT02364609,pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib,,https://ClinicalTrials.gov/show/NCT02364609
clinicaltrials.gov,afatinib,755714,O14578;O14976;O15197;O43353;O94804;P00519;P00533;P04626;P06239;P08581;P08631;P12931;P15735;P21860;P30530;P36888;P42681;P42685;P45984;P49674;P51451;P51617;P53779;Q13163;Q13627;Q15303;Q16539;Q16816;Q52WX2;Q8NE63;Q92630;Q9BUB5;Q9H2G2;Q9HBH9;Q9UEE5;Q9UF33;Q9UK32;Q9Y463,"InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1",ULXXDDBFHOBEHA-CWDCEQMOSA-N,CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]4CCOC4,pembrolizumab,,Q15116,,,,,lung cancers,Phase 2,,,NCT03157089,Testing Afatinib in Combination With pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung,LUX-Lung IO,https://ClinicalTrials.gov/show/NCT03157089
clinicaltrials.gov,AGEN1884,,,,,,pembrolizumab,,Q15116,,,,,lung cancers,Phase 2,,,NCT03411473,Study of AGEN1884 With pembrolizumab in 1L NSCLC,,https://ClinicalTrials.gov/show/NCT03411473
clinicaltrials.gov,AGI-134,,,,,,pembrolizumab,,Q15116,,,,,advanced solid cancers;colorectal cancers;head and neck cancers,Phase 1/2,,,NCT03593226,Study to Evaluate Safety & Tolerability of AGI-134 in Solid Tumour,,https://ClinicalTrials.gov/show/NCT03593226
clinicaltrials.gov,AGI-134,,,,,,pembrolizumab,,Q15116,,,,,advanced solid cancers;colorectal cancers;head and neck cancers,Phase 1/2,,,NCT03593226,Study to Evaluate Safety & Tolerability of AGI-134 in Solid Tumour,,https://ClinicalTrials.gov/show/NCT03593226
clinicaltrials.gov,ALKS 4230,,,,,,pembrolizumab,,Q15116,,,,Advanced Solid Tumors,,Phase 1,,,NCT03861793,,,
clinicaltrials.gov,ALT-803,,,,,,pembrolizumab,,Q15116,,,,,lung cancers,Phase 2,,,NCT03520686,"QUILT-2.023: A Study of ALT-803, a Fusion Protein Activator of Natural Killer and T-Cells, in Combination With pembrolizumab vs pembrolizumab Alone as First-Line Treatment for Patients With Metastatic NSCLC.",,https://ClinicalTrials.gov/show/NCT03520686
clinicaltrials.gov,ALT-803,,,,,,pembrolizumab,,Q15116,,,,,lung cancers,Phase 2,,,NCT03520686,"QUILT-2.023: A Study of ALT-803, a Fusion Protein Activator of Natural Killer and T-Cells, in Combination With pembrolizumab vs pembrolizumab Alone as First-Line Treatment for Patients With Metastatic NSCLC.",,https://ClinicalTrials.gov/show/NCT03520686
clinicaltrials.gov,AM0010,,,,,,pembrolizumab,,Q15116,,,,,lung cancers,Phase 2,,,NCT03382899,Study of AM0010 With pembrolizumab Compared to pembrolizumab Alone First-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer,Cypress 1,https://ClinicalTrials.gov/show/NCT03382899
clinicaltrials.gov,amcasertib,1896288,,"InChI=1S/C31H33N5O2S/c1-5-36(6-2)15-14-32-30(38)28-19(3)26(33-20(28)4)17-24-23-16-22(12-13-25(23)34-29(24)37)27-18-39-31(35-27)21-10-8-7-9-11-21/h7-13,16-18,33H,5-6,14-15H2,1-4H3,(H,32,38)(H,34,37)/b24-17-",QDWKGEFGLQMDAM-ULJHMMPZSA-N,CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C\2/C(=O)Nc3ccc(cc23)c4csc(n4)c5ccccc5)c1C,pembrolizumab,,Q15116,,,,,bowel cancers,Phase 1/2,,,NCT02851004,Special Combination of BBI608 and pembrolizumab,,https://ClinicalTrials.gov/show/NCT02851004
clinicaltrials.gov,apatinib,1384455,P35968,"InChI=1S/C24H23N5O.CH4O3S/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18;1-5(2,3)4/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30);1H3,(H,2,3,4)",FYJROXRIVQPKRY-UHFFFAOYSA-N,CS(=O)(=O)O.O=C(Nc1ccc(cc1)C2(CCCC2)C#N)c3cccnc3NCc4ccncc4,pembrolizumab,,Q15116,,,,,bladder cancers;stomach cancers,Phase 1/2,,,NCT03407976,Apatinib With pembrolizumab in Previously Treated Advanced Malignancies,APPEASE,https://ClinicalTrials.gov/show/NCT03407976
clinicaltrials.gov,APG-115,,,,,,pembrolizumab,,Q15116,,,,,skin cancers;advanced solid cancers,Phase 1/2,,,NCT03611868,A Study of APG-115 in Combination With pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT03611868
clinicaltrials.gov,APG-115,,,,,,pembrolizumab,,Q15116,,,,,skin cancers;advanced solid cancers,Phase 1/2,,,NCT03611868,A Study of APG-115 in Combination With pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT03611868
clinicaltrials.gov,APX005M,,,,,,pembrolizumab,,Q15116,,,,,skin cancers,Phase 1/2,,,NCT02706353,APX005M in Combination With Systemic pembrolizumab in Patients With Metastatic Melanoma,,https://ClinicalTrials.gov/show/NCT02706353
clinicaltrials.gov,ARRx,,,,,,pembrolizumab,,Q15116,,,,,prostate cancers,Phase 2,,,NCT03300505,ARRx Followed by pembrolizumab in Metastatic Castration Resistant Prostate Cancer,,https://ClinicalTrials.gov/show/NCT03300505
clinicaltrials.gov,ARRY-382,,P07333,,,,pembrolizumab,,Q15116,,,,,advanced solid cancers,Phase 1/2,,,NCT02880371,A Study of ARRY-382 in Combination With pembrolizumab for the Treatment of Patients With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT02880371
clinicaltrials.gov,AST-008,,,,,,pembrolizumab,,Q15116,,,,,skin cancers;head and neck cancers,Phase 1/2,,,NCT03684785,Intratumoral AST-008 Combined With pembrolizumab in Patients With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT03684785
clinicaltrials.gov,AST-008,,,,,,pembrolizumab,,Q15116,,,,,skin cancers;head and neck cancers,Phase 1/2,,,NCT03684785,Intratumoral AST-008 Combined With pembrolizumab in Patients With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT03684785
clinicaltrials.gov,Ataluren,,,,,,pembrolizumab,,Q15116,,,,,,,,,NCT04014530,pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study,ATAPEMBRO,https://ClinicalTrials.gov/show/NCT04014530
clinicaltrials.gov,B-701,,,,,,pembrolizumab,,Q15116,,,,,bladder cancers,Phase 1,,,NCT02925533,Ph 1B B-701 in Combination With pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract,,https://ClinicalTrials.gov/show/NCT02925533
clinicaltrials.gov,B-701,,,,,,pembrolizumab,,Q15116,,,,,bladder cancers,Phase 1,,,NCT03123055,A Study of B-701 in Combination With pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma,U22,https://ClinicalTrials.gov/show/NCT03123055
clinicaltrials.gov,BAY1834942,,,,,,pembrolizumab,,Q15116,,,,,advanced solid cancers,Phase 1,,,NCT03596372,Study of BAY1834942 in Patients With Solid Tumors,,https://ClinicalTrials.gov/show/NCT03596372
clinicaltrials.gov,BAY1834942,,,,,,pembrolizumab,,Q15116,,,,,advanced solid cancers,Phase 1,,,NCT03596372,Study of BAY1834942 in Patients With Solid Tumors,,https://ClinicalTrials.gov/show/NCT03596372
clinicaltrials.gov,BGB324,,P30530,,,,pembrolizumab,,Q15116,,,,,breast cancers,Phase 2,,,NCT03184558,BGB324 in Combination With pembrolizumab in Patients With TNBC,,https://ClinicalTrials.gov/show/NCT03184558
clinicaltrials.gov,BGB324,,P30530,,,,pembrolizumab,,Q15116,,,,,lung cancers,Phase 2,,,NCT03184571,BGB324 in Combination With pembrolizumab in Patients With Advanced NSCLC,,https://ClinicalTrials.gov/show/NCT03184571
clinicaltrials.gov,binimetinib,1222391,Q02750;P36507,"InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)",ACWZRVQXLIRSDF-UHFFFAOYSA-N,Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO,pembrolizumab,,Q15116,,,,,,,,,NCT03991819,Study of Binimetinib in Combination With pembrolizumab in Advanced Non-Small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT03991819
clinicaltrials.gov,birinapant,1106473,Q13490;Q13489,"InChI=1S/C42H56F2N8O6/c1-7-33(49-39(55)21(3)45-5)41(57)51-19-27(53)15-25(51)17-31-29-11-9-23(43)13-35(29)47-37(31)38-32(30-12-10-24(44)14-36(30)48-38)18-26-16-28(54)20-52(26)42(58)34(8-2)50-40(56)22(4)46-6/h9-14,21-22,25-28,33-34,45-48,53-54H,7-8,15-20H2,1-6H3,(H,49,55)(H,50,56)/t21-,22-,25-,26-,27-,28-,33-,34-/m0/s1",PKWRMUKBEYJEIX-DXXQBUJASA-N,CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc2c([nH]c3cc(F)ccc23)c4[nH]c5cc(F)ccc5c4C[C@@H]6C[C@H](O)CN6C(=O)[C@H](CC)NC(=O)[C@H](C)NC,pembrolizumab,,Q15116,,,,,,Phase 1/2,,,NCT02587962,Dose-escalation Study of Birinapant and pembrolizumab in Solid Tumors,,https://ClinicalTrials.gov/show/NCT02587962
clinicaltrials.gov,BL-8040,,P61073,,,,pembrolizumab,,Q15116,,,,,pancreatic cancers,Phase 2,,,NCT02826486,Study Assessing Safety and Efficacy of Combination of BL-8040 and pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202),COMBAT,https://ClinicalTrials.gov/show/NCT02826486
clinicaltrials.gov,blinatumomab,,P15391;P07766;P09693;P04234,,,,pembrolizumab,,Q15116,,,,,leukemia,Phase 1/2,,,NCT03160079,Blinatumomab and pembrolizumab for Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia With High Marrow Lymphoblasts,,https://ClinicalTrials.gov/show/NCT03160079
clinicaltrials.gov,blinatumomab,,P15391;P07766;P09693;P04234,,,,pembrolizumab,,Q15116,,,,,lymphoma,Phase 1,,,NCT03340766,Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With pembrolizumab (KEYNOTE-348),,https://ClinicalTrials.gov/show/NCT03340766
clinicaltrials.gov,blinatumomab,,P15391;P07766;P09693;P04234,,,,pembrolizumab,,Q15116,,,,,leukemia;lymphoma,Phase 1,,,NCT03605589,Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma,,https://ClinicalTrials.gov/show/NCT03605589
clinicaltrials.gov,blinatumomab,,P15391;P07766;P09693;P04234,,,,pembrolizumab,,Q15116,,,,,leukemia;lymphoma,Phase 1,,,NCT03605589,Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma,,https://ClinicalTrials.gov/show/NCT03605589
clinicaltrials.gov,cabozantinib,1081506,P08581,"InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)",ONIQOQHATWINJY-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5)cc3)c2cc1OC,pembrolizumab,,Q15116,,,,,kidney cancers,Phase 1/2,,,NCT03149822,Study of pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT03149822
clinicaltrials.gov,cabozantinib,1081506,P08581,"InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)",ONIQOQHATWINJY-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5)cc3)c2cc1OC,pembrolizumab,,Q15116,,,,,bladder cancers,Phase 2,,,NCT03534804,Cabozantinib Plus pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma,PemCab,https://ClinicalTrials.gov/show/NCT03534804
clinicaltrials.gov,cabozantinib,1081506,P08581,"InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)",ONIQOQHATWINJY-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5)cc3)c2cc1OC,pembrolizumab,,Q15116,,,,,bladder cancers,Phase 2,,,NCT03534804,Cabozantinib Plus pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma,PemCab,https://ClinicalTrials.gov/show/NCT03534804
clinicaltrials.gov,cabozantinib,1081506,P08581,"InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)",ONIQOQHATWINJY-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5)cc3)c2cc1OC,pembrolizumab,,Q15116,,,,,,,,,NCT03957551,Cabozantinib and pembrolizumab for Advanced Metastatic Melanoma,,https://ClinicalTrials.gov/show/NCT03957551
clinicaltrials.gov,canakinumab,,,,,,pembrolizumab,,Q15116,,,,,,,,,NCT03968419,This Study Will Evaluate the Effect of Canakinumab or pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.,CANOPY-N,https://ClinicalTrials.gov/show/NCT03968419
clinicaltrials.gov,CC-486,,,,,,pembrolizumab,,Q15116,,,,,ovarian cancers,Phase 2,,,NCT02900560,Study of pembrolizumab With or Without CC-486 in Patients With Platinum-resistant ovarian Cancers,,https://ClinicalTrials.gov/show/NCT02900560
clinicaltrials.gov,CM-24,,,,,,pembrolizumab,,Q15116,,,,,lung cancers;skin cancers;bladder cancers;bowel cancers;stomach cancers;ovarian cancers,Phase 1,,,NCT02346955,Study of CM-24 (MK-6018) Alone and In Combination With pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001),,https://ClinicalTrials.gov/show/NCT02346955
clinicaltrials.gov,CMP-001,,,,,,pembrolizumab,,Q15116,,,,,,,,,NCT03983668,CMP-001 for Relapsed and Refractory Lymphoma,,https://ClinicalTrials.gov/show/NCT03983668
clinicaltrials.gov,crizotinib,652583,O00238;O00444;O14730;O14920;O14936;O14965;O15075;O15146;O15197;O43283;O43318;O43353;O60674;O75116;O75385;O94804;O94806;P00519;P00533;P04629;P06213;P06239;P06241;P06748;P07332;P07333;P07947;P07948;P07949;P08069;P08581;P08922;P09769;P0C264;P10721;P12931;P14616;P16591;P17948;P19525;P21127;P21709;P22607;P23443;P23458;P29317;P29320;P29322;P29376;P29597;P30530;P32298;P35590;P36888;P36896;P36897;P42681;P42684;P42685;P43403;P43405;P46734;P50613;P51451;P51617;P51813;P52333;P53667;P53671;P54756;P54760;P54762;P54764;P57078;Q02763;Q04771;Q04912;Q05397;Q06187;Q06418;Q07912;Q08345;Q08881;Q09013;Q12851;Q12852;Q12866;Q13043;Q13131;Q13164;Q13188;Q13233;Q13464;Q13470;Q13546;Q14164;Q14289;Q15139;Q15375;Q15569;Q16288;Q16620;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q6PHR2;Q6XUX3;Q6ZN16;Q7L7X3;Q8IVH8;Q8IY84;Q8IYT8;Q8N4C8;Q8N568;Q8NE63;Q8NFD2;Q8TD19;Q8TDR2;Q8TDX7;Q92630;Q92772;Q92918;Q96D53;Q96GD4;Q96RR4;Q96SB4;Q99755;Q99759;Q9BRS2;Q9H093;Q9H0K1;Q9H2G2;Q9H2K8;Q9NSY1;Q9NWZ3;Q9P289;Q9UF33;Q9UHD2;Q9UL54;Q9UM73;Q9UPE1;Q9UQ88;Q9UQB9;Q9Y2U5;Q9Y4K4;Q9Y616,"InChI=1S/C21H22Cl2FN5O/c1-12(19-16(22)2-3-17(24)20(19)23)30-18-8-13(9-27-21(18)25)14-10-28-29(11-14)15-4-6-26-7-5-15/h2-3,8-12,15,26H,4-7H2,1H3,(H2,25,27)/t12-/m1/s1",KTEIFNKAUNYNJU-GFCCVEGCSA-N,C[C@@H](Oc1cc(cnc1N)c2cnn(c2)C3CCNCC3)c4c(Cl)ccc(F)c4Cl,pembrolizumab,,Q15116,,,,,lung cancers,Phase 1,,,NCT02511184,Crizotinib Plus pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients,,https://ClinicalTrials.gov/show/NCT02511184
clinicaltrials.gov,CRS-207,,,,,,pembrolizumab,,Q15116,,,,,oesophageal cancers;stomach cancers,Phase 2,,,NCT03122548,"Safety and Efficacy of CRS-207 With pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers",,https://ClinicalTrials.gov/show/NCT03122548
clinicaltrials.gov,dasatinib,375,O00238;O00506;O14965;O14976;O15197;O15264;O43283;O43318;O43353;O60674;O94804;O95819;P00519;P00533;P04049;P04626;P06239;P06241;P07333;P07947;P07948;P07949;P08631;P08684;P09619;P09769;P0C1S8;P10721;P11274;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P21860;P22607;P27037;P29317;P29320;P29322;P29323;P29597;P30291;P35968;P36507;P36888;P36894;P36896;P36897;P37023;P37173;P41240;P42680;P42681;P42684;P42685;P43405;P49674;P51451;P51813;P51955;P52333;P53667;P53671;P53778;P54753;P54756;P54760;P54762;P54764;P57059;Q01538;Q02750;Q04771;Q06187;Q07912;Q08345;Q09013;Q12851;Q13043;Q13163;Q13705;Q13882;Q15303;Q15569;Q15759;Q16539;Q16832;Q52WX2;Q56UN5;Q59H18;Q5VT25;Q6DT37;Q6PHR2;Q86Y07;Q8IVH8;Q8N4C8;Q8NG66;Q8NI60;Q8TDR2;Q92918;Q96GD4;Q99640;Q99759;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K8;Q9H3Y6;Q9NRP7;Q9NYL2;Q9P289;Q9P2K8;Q9UBE8;Q9UF33;Q9UKE5;Q9UL54;Q9Y2K2;Q9Y2U5;Q9Y4K4;Q9Y5S2;Q9Y6R4,"InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)",ZBNZXTGUTAYRHI-UHFFFAOYSA-N,Cc1nc(Nc2ncc(s2)C(=O)Nc3c(C)cccc3Cl)cc(n1)N4CCN(CCO)CC4,pembrolizumab,,Q15116,,,,,lung cancers;mesothelioma;pancreatic cancers,Phase 1/2,,,NCT02758587,Study of FAK (Defactinib) and PD-1 (pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1),,https://ClinicalTrials.gov/show/NCT02758587
clinicaltrials.gov,demcizumab,,Q9NR61,,,,pembrolizumab,,Q15116,,,,,advanced solid cancers,Phase 1,,,NCT02722954,A Phase 1b Study of Demcizumab Plus pembrolizumab in Locally Advanced or Metastatic Solid Tumors,,https://ClinicalTrials.gov/show/NCT02722954
clinicaltrials.gov,denosumab,,,,,,pembrolizumab,,Q15116,,,,,skin cancers,Phase 2,,,NCT03620019,denosumab + pembrolizumab in Patients With Stage IV Melanoma,,https://ClinicalTrials.gov/show/NCT03620019
clinicaltrials.gov,denosumab,,,,,,pembrolizumab,,Q15116,,,,,skin cancers,Phase 2,,,NCT03620019,denosumab + pembrolizumab in Patients With Stage IV Melanoma,,https://ClinicalTrials.gov/show/NCT03620019
clinicaltrials.gov,DNX-2401,,,,,,pembrolizumab,,Q15116,,,,,brain cancers,Phase 2,,,NCT02798406,Combination Adenovirus + pembrolizumab to Trigger Immune Virus Effects,CAPTIVE,https://ClinicalTrials.gov/show/NCT02798406
clinicaltrials.gov,enoblituzumab,,,,,,pembrolizumab,,Q15116,,,,,skin cancers;head and neck cancers;lung cancers;bladder cancers,Phase 1,,,NCT02475213,Safety Study of Enoblituzumab (MGA271) in Combination With pembrolizumab in Refractory Cancer,,https://ClinicalTrials.gov/show/NCT02475213
clinicaltrials.gov,entinostat,312087,Q96DB2;Q9UBN7;Q92769;Q13547;Q9UKV0;Q9UQL6;Q8WUI4;P56524;O15379;Q969S8;Q9BY41,"InChI=1S/C21H20N4O3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-24-21(27)28-14-16-4-3-11-23-12-16/h1-12H,13-14,22H2,(H,24,27)(H,25,26)",INVTYAOGFAGBOE-UHFFFAOYSA-N,Nc1ccccc1NC(=O)c2ccc(CNC(=O)OCc3cccnc3)cc2,pembrolizumab,,Q15116,,,,,lung cancers;skin cancers;bowel cancers,Phase 1/2,,,NCT02437136,"Ph1b/2 Dose-Escalation Study of Entinostat With pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer",,https://ClinicalTrials.gov/show/NCT02437136
clinicaltrials.gov,entinostat,312087,Q96DB2;Q9UBN7;Q92769;Q13547;Q9UKV0;Q9UQL6;Q8WUI4;P56524;O15379;Q969S8;Q9BY41,"InChI=1S/C21H20N4O3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-24-21(27)28-14-16-4-3-11-23-12-16/h1-12H,13-14,22H2,(H,24,27)(H,25,26)",INVTYAOGFAGBOE-UHFFFAOYSA-N,Nc1ccccc1NC(=O)c2ccc(CNC(=O)OCc3cccnc3)cc2,pembrolizumab,,Q15116,,,,,lung cancers;stomach cancers;bowel cancers;other;lung cancers;breast cancers;kidney cancers,Phase 1,,,NCT02909452,Continuation Study of Entinostat in Combination With pembrolizumab in Patients With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT02909452
clinicaltrials.gov,entinostat,312087,Q96DB2;Q9UBN7;Q92769;Q13547;Q9UKV0;Q9UQL6;Q8WUI4;P56524;O15379;Q969S8;Q9BY41,"InChI=1S/C21H20N4O3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-24-21(27)28-14-16-4-3-11-23-12-16/h1-12H,13-14,22H2,(H,24,27)(H,25,26)",INVTYAOGFAGBOE-UHFFFAOYSA-N,Nc1ccccc1NC(=O)c2ccc(CNC(=O)OCc3cccnc3)cc2,pembrolizumab,,Q15116,,,,,lymphoma,Phase 2,,,NCT03179930,Combination Therapy With Entinostat and pembrolizumab in Relapsed and Refractory Lymphomas,,https://ClinicalTrials.gov/show/NCT03179930
clinicaltrials.gov,epacadostat,1265058,P14902,"InChI=1S/C11H13BrFN7O4S/c12-7-5-6(1-2-8(7)13)17-11(18-21)9-10(20-24-19-9)15-3-4-16-25(14,22)23/h1-2,5,16,21H,3-4H2,(H,15,20)(H,17,18)(H2,14,22,23)",FBKMWOJEPMPVTQ-UHFFFAOYSA-N,NS(=O)(=O)NCCNc1nonc1\C(=N\O)\Nc2ccc(F)c(Br)c2,pembrolizumab,,Q15116,,,,,female cancers,Phase 2,,,NCT03310567,A Study of pembrolizumab in Combination With Epacadostat in Women With Recurrent/Metastatic Endometrial Carcinoma,,https://ClinicalTrials.gov/show/NCT03310567
clinicaltrials.gov,epacadostat,1265058,P14902,"InChI=1S/C11H13BrFN7O4S/c12-7-5-6(1-2-8(7)13)17-11(18-21)9-10(20-24-19-9)15-3-4-16-25(14,22)23/h1-2,5,16,21H,3-4H2,(H,15,20)(H,17,18)(H2,14,22,23)",FBKMWOJEPMPVTQ-UHFFFAOYSA-N,NS(=O)(=O)NCCNc1nonc1\C(=N\O)\Nc2ccc(F)c(Br)c2,pembrolizumab,,Q15116,,,,,soft tissue cancers,Phase 2,,,NCT03414229,"A Study of Epacadostat, an IDO1 Inhibitor, in Combination With pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma",,https://ClinicalTrials.gov/show/NCT03414229
literature,epacadostat,1265058,P14902,"InChI=1S/C11H13BrFN7O4S/c12-7-5-6(1-2-8(7)13)17-11(18-21)9-10(20-24-19-9)15-3-4-16-25(14,22)23/h1-2,5,16,21H,3-4H2,(H,15,20)(H,17,18)(H2,14,22,23)",FBKMWOJEPMPVTQ-UHFFFAOYSA-N,NS(=O)(=O)NCCNc1nonc1\C(=N\O)\Nc2ccc(F)c(Br)c2,pembrolizumab,,Q15116,,,,patients with unresectable or metastatic melanoma,skin cancers,Phase 3,31221619,"Between June 21, 2016, and Aug 7, 2017, 928 patients were screened and 706 patients were randomly assigned to receive epacadostat plus pembrolizumab (n=354) or placebo plus pembrolizumab (n=352). Median follow-up was 12·4 months (IQR 10·3-14·5). No significant differences were found between the treatment groups for progression-free survival (median 4·7 months, 95% CI 2·9-6·8, for epacadostat plus pembrolizumab vs 4·9 months, 2·9-6·8, for placebo plus pembrolizumab; hazard ratio [HR] 1·00, 95% CI 0·83-1·21; one-sided p=0·52) or overall survival (median not reached in either group; epacadostat plus pembrolizumab vs placebo plus pembrolizumab: HR 1·13, 0·86-1·49; one-sided p=0·81). The most common grade 3 or worse treatment-related adverse event was lipase increase, which occurred in 14 (4%) of 353 patients receiving epacadostat plus pembrolizumab and 11 (3%) of 352 patients receiving placebo plus pembrolizumab. Treatment-related serious adverse events were reported in 37 (10%) of 353 patients receiving epacadostat plus pembrolizumab and 32 (9%) of 352 patients receiving placebo plus pembrolizumab. There were no treatment-related deaths in either treatment group.",NCT02752074,,,
clinicaltrials.gov,FLX475,,,,,,pembrolizumab,,Q15116,,,,,advanced solid cancers,Phase 1/2,,,NCT03674567,Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With pembrolizumab,,https://ClinicalTrials.gov/show/NCT03674567
clinicaltrials.gov,FLX475,,,,,,pembrolizumab,,Q15116,,,,,advanced solid cancers,Phase 1/2,,,NCT03674567,Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With pembrolizumab,,https://ClinicalTrials.gov/show/NCT03674567
clinicaltrials.gov,grapiprant,,,,,,pembrolizumab,,Q15116,,,,,colorectal cancers,Phase 1,,,NCT03658772,Grapiprant and pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer,,https://ClinicalTrials.gov/show/NCT03658772
clinicaltrials.gov,grapiprant,,,,,,pembrolizumab,,Q15116,,,,,lung cancers,Phase 1/2,,,NCT03696212,Grapiprant (ARY-007) and pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma,,https://ClinicalTrials.gov/show/NCT03696212
clinicaltrials.gov,grapiprant,,,,,,pembrolizumab,,Q15116,,,,,colorectal cancers,Phase 1,,,NCT03658772,Grapiprant and pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer,,https://ClinicalTrials.gov/show/NCT03658772
clinicaltrials.gov,grapiprant,,,,,,pembrolizumab,,Q15116,,,,,lung cancers,Phase 1/2,,,NCT03696212,Grapiprant (ARY-007) and pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma,,https://ClinicalTrials.gov/show/NCT03696212
clinicaltrials.gov,GRN-1201 ,,,,,,pembrolizumab,,Q15116,,,,,lung cancers,Phase 2,,,NCT03417882,GRN-1201 With pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC,,https://ClinicalTrials.gov/show/NCT03417882
clinicaltrials.gov,GSK2636771,1268958,,"InChI=1S/C22H22F3N3O3/c1-13-15(4-3-5-18(13)22(23,24)25)12-28-14(2)26-20-17(21(29)30)10-16(11-19(20)28)27-6-8-31-9-7-27/h3-5,10-11H,6-9,12H2,1-2H3,(H,29,30)",XTKLTGBKIDQGQL-UHFFFAOYSA-N,Cc1c(Cn2c(C)nc3c(cc(cc23)N4CCOCC4)C(=O)O)cccc1C(F)(F)F,pembrolizumab,,Q15116,,,,,skin cancers,Phase 1/2,,,NCT03131908,Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss,,https://ClinicalTrials.gov/show/NCT03131908
clinicaltrials.gov,GSK2857916,,,,,,pembrolizumab,,Q15116,,,,Multiple Myeloma,,Phase 2,,,NCT03848845,,,
clinicaltrials.gov,GSK3145095,,,,,,pembrolizumab,,Q15116,,,,,pancreatic cancers,Phase 2,,,NCT03681951,First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT03681951
clinicaltrials.gov,GSK3145095,,,,,,pembrolizumab,,Q15116,,,,,pancreatic cancers,Phase 2,,,NCT03681951,First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT03681951
clinicaltrials.gov,GSK3174998,,,,,,pembrolizumab,,Q15116,,,,,advanced solid cancers,Phase 1,,,NCT02528357,GSK3174998 Alone or With pembrolizumab in Subjects With Advanced Solid Tumors (ENGAGE-1),,https://ClinicalTrials.gov/show/NCT02528357
clinicaltrials.gov,GSK3359609,,,,,,pembrolizumab,,Q15116,,,,,advanced solid cancers,Phase 1,,,NCT02723955,Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1),,https://ClinicalTrials.gov/show/NCT02723955
clinicaltrials.gov,GSK3377794,,,,,,pembrolizumab,,Q15116,,,,,lung cancers,Phase 2,,,NCT03709706,Pilot Immunotherapy With Autologous T-cells Specific for New York Esophageal Antigen-1 (NY-ESO-1)/ Cancer-testis Antigen-2 (LAGE-1a)-Positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With pembrolizumab,,https://ClinicalTrials.gov/show/NCT03709706
clinicaltrials.gov,GSK3377794,,,,,,pembrolizumab,,Q15116,,,,,lung cancers,Phase 2,,,NCT03709706,Pilot Immunotherapy With Autologous T-cells Specific for New York Esophageal Antigen-1 (NY-ESO-1)/ Cancer-testis Antigen-2 (LAGE-1a)-Positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With pembrolizumab,,https://ClinicalTrials.gov/show/NCT03709706
clinicaltrials.gov,GSK3745417,,,,,,pembrolizumab,,Q15116,,,,Neoplasms,,Phase 1,,,NCT03843359,,,
clinicaltrials.gov,GX-I7,,,,,,pembrolizumab,,Q15116,,,,,breast cancers,Phase 1/2,,,NCT03752723,Study of GX-I7 in Combination With pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899),,https://ClinicalTrials.gov/show/NCT03752723
clinicaltrials.gov,GX-I7,,,,,,pembrolizumab,,Q15116,,,,,breast cancers,Phase 1/2,,,NCT03752723,Study of GX-I7 in Combination With pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899),,https://ClinicalTrials.gov/show/NCT03752723
clinicaltrials.gov,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,pembrolizumab,,Q15116,,,,,leukemia;lymphoma,Phase 1/2,,,NCT03153202,Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL),,https://ClinicalTrials.gov/show/NCT03153202
clinicaltrials.gov,ilixadencel,,,,,,pembrolizumab,,Q15116,,,,,advanced solid cancers,Phase 1/2,,,NCT03735290,A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer,ILIAD,https://ClinicalTrials.gov/show/NCT03735290
clinicaltrials.gov,ilixadencel,,,,,,pembrolizumab,,Q15116,,,,,advanced solid cancers,Phase 1/2,,,NCT03735290,A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer,ILIAD,https://ClinicalTrials.gov/show/NCT03735290
clinicaltrials.gov,ipilimumab,1238537,P16410,,,,pembrolizumab,,Q15116,,,,Clinical Stage IV Cutaneous Melanoma|Metastatic Malignant Neoplasm in the Brain|Metastatic Melanoma|Pathologic Stage IV Cutaneous Melanoma,,Phase 2,,,NCT03873818,,,
clinicaltrials.gov,itacitinib,1947652,P23458,"InChI=1S/C26H23F4N9O/c27-20-18(1-7-32-22(20)26(28,29)30)24(40)37-9-3-17(4-10-37)38-13-25(14-38,5-6-31)39-12-16(11-36-39)21-19-2-8-33-23(19)35-15-34-21/h1-2,7-8,11-12,15,17H,3-5,9-10,13-14H2,(H,33,34,35)",KTBSXLIQKWEBRB-UHFFFAOYSA-N,Fc1c(ccnc1C(F)(F)F)C(=O)N2CCC(CC2)N3CC(CC#N)(C3)n4cc(cn4)c5ncnc6[nH]ccc56,pembrolizumab,,Q15116,,,,,lung cancers,Phase 2,,,NCT03425006,pembrolizumab and Itacitinib (INCB039110) for NSCLC,,https://ClinicalTrials.gov/show/NCT03425006
clinicaltrials.gov,L-NMMA,,,,,,pembrolizumab,,Q15116,,,,,lung cancers;skin cancers;head and neck cancers;lymphoma;bladder cancers,Phase 1,,,NCT03236935,Phase Ib of L-NMMA and pembrolizumab,,https://ClinicalTrials.gov/show/NCT03236935
clinicaltrials.gov,lenalidomide,718,O14920,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,Nc1cccc2C(=O)N(Cc12)C3CCC(=O)NC3=O,pembrolizumab,,Q15116,,,,,advanced solid cancers;lung cancers,Phase 1/2,,,NCT02963610,Phase I/II Study of Lenalidomide Plus pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT02963610
clinicaltrials.gov,lenvatinib,802872,P35968;P17948;P35916,"InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)",WOSKHXYHFSIKNG-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(=O)N,pembrolizumab,,Q15116,,,,,advanced solid cancers,Phase 1/2,,,NCT02501096,Phase 1b/2 Trial of Lenvatinib (E7080) Plus pembrolizumab in Subjects With Selected Solid Tumors,,https://ClinicalTrials.gov/show/NCT02501096
clinicaltrials.gov,lenvatinib,802872,P35968;P17948;P35916,"InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)",WOSKHXYHFSIKNG-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(=O)N,pembrolizumab,,Q15116,,,,,oesophageal cancers;stomach cancers,Phase 2,,,NCT03321630,"A Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies",,https://ClinicalTrials.gov/show/NCT03321630
clinicaltrials.gov,lenvatinib,802872,P35968;P17948;P35916,"InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)",WOSKHXYHFSIKNG-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(=O)N,pembrolizumab,,Q15116,,,,,,Phase 1,,,NCT03006887,Phase 1b Trial of Lenvatinib Plus pembrolizumab in Subjects With Selected Solid Tumors,,https://ClinicalTrials.gov/show/NCT03006887
clinicaltrials.gov,lenvatinib,802872,P35968;P17948;P35916,"InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)",WOSKHXYHFSIKNG-UHFFFAOYSA-N,,pembrolizumab,,Q15116,,,,,skin cancers,Phase 2,,,NCT03776136,Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004),,https://ClinicalTrials.gov/show/NCT03776136
clinicaltrials.gov,lenvatinib,802872,P35968;P17948;P35916,"InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)",WOSKHXYHFSIKNG-UHFFFAOYSA-N,,pembrolizumab,,Q15116,,,,,stomach cancers,Phase 2,,,NCT03609359,Lenvatinib and pembrolizumab Simultaneous Combination Study,Lenva+Pembro,https://ClinicalTrials.gov/show/NCT03609359
clinicaltrials.gov,lenvatinib,802872,P35968;P17948;P35916,"InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)",WOSKHXYHFSIKNG-UHFFFAOYSA-N,,pembrolizumab,,Q15116,,,,,skin cancers,Phase 2,,,NCT03776136,Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004),,https://ClinicalTrials.gov/show/NCT03776136
clinicaltrials.gov,lenvatinib,802872,P35968;P17948;P35916,"InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)",WOSKHXYHFSIKNG-UHFFFAOYSA-N,,pembrolizumab,,Q15116,,,,,stomach cancers,Phase 2,,,NCT03609359,Lenvatinib and pembrolizumab Simultaneous Combination Study,Lenva+Pembro,https://ClinicalTrials.gov/show/NCT03609359
literature,lenvatinib,802872,P35968;P17948;P35916,"InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)",WOSKHXYHFSIKNG-UHFFFAOYSA-N,,pembrolizumab,,Q15116,,,,patients with advanced endometrial cancer,female cancers,Phase 2,30922731,"Between Sept 10, 2015, and July 24, 2017, 54 patients were enrolled, 53 of whom were included in the analysis. At the cutoff date for anti-tumour activity data (Dec 15, 2017), median study follow-up was 13·3 months (IQR 6·7-20·1). 21 (39·6% [95% CI 26·5-54·0]) patients had an objective response at week 24. Serious treatment-related adverse events occurred in 16 (30%) patients, and one treatment-related death was reported (intracranial haemorrhage). The most frequently reported any-grade treatment-related adverse events were hypertension (31 [58%]), fatigue (29 [55%]), diarrhoea (27 [51%]), and hypothyroidism (25 [47%]). The most common grade 3 treatment-related adverse events were hypertension (18 [34%]) and diarrhoea (four [8%]). No grade 4 treatment-related adverse events were reported. Five (9%) patients discontinued study treatment because of treatment-related adverse events.",NCT02501096,,,
clinicaltrials.gov,LYC-55716,,,,,,pembrolizumab,,Q15116,,,,,lung cancers,Phase 1,,,NCT03396497,Study of LYC-55716 With pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT03396497
clinicaltrials.gov,MK-1308,,,,,,pembrolizumab,,Q15116,,,,,advanced solid cancers,Phase 1,,,NCT03179436,"Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With pembrolizumab in Advanced Solid Tumors (MK-1308-001)",,https://ClinicalTrials.gov/show/NCT03179436
clinicaltrials.gov,MK-1454,,,,,,pembrolizumab,,Q15116,,,,,lymphoma,Phase 1,,,NCT03010176,Study of MK-1454 Alone or in Combination With pembrolizumab in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001),,https://ClinicalTrials.gov/show/NCT03010176
clinicaltrials.gov,MK-2118,,,,,,pembrolizumab,,Q15116,,,,,lymphoma,Phase 1,,,NCT03249792,Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With pembrolizumab (MK-3475) in the Treatment of Adults With Advance/Metastatic Solid Tumors or Lymphomas (MK-2118-001),,https://ClinicalTrials.gov/show/NCT03249792
clinicaltrials.gov,MK-4166,,,,,,pembrolizumab,,Q15116,,,,,advanced solid cancers,Phase 1,,,NCT02132754,Study of MK-4166 and MK-4166 in Combination With pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001),,https://ClinicalTrials.gov/show/NCT02132754
clinicaltrials.gov,MK-4280,,,,,,pembrolizumab,,Q15116,,,,,advanced solid cancers,Phase 1,,,NCT02720068,Study of MK-4280 as Monotherapy and in Combination With pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-4280-001),,https://ClinicalTrials.gov/show/NCT02720068
clinicaltrials.gov,MK-4621/JetPEI‚Ñ¢,,,,,,pembrolizumab,,Q15116,,,,,advanced solid cancers,Phase 1,,,NCT03739138,Intratumoral/Intralesional Administration of MK-4621/JetPEI‚Ñ¢ With or Without pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002),,https://ClinicalTrials.gov/show/NCT03739138
clinicaltrials.gov,MK-4621/JetPEI‚Ñ¢,,,,,,pembrolizumab,,Q15116,,,,,advanced solid cancers,Phase 1,,,NCT03739138,Intratumoral/Intralesional Administration of MK-4621/JetPEI‚Ñ¢ With or Without pembrolizumab in Participants With Advanced/Metastatic or Recurrent Solid Tumors (MK-4621-002),,https://ClinicalTrials.gov/show/NCT03739138
clinicaltrials.gov,MK-4830,,,,,,pembrolizumab,,Q15116,,,,,advanced solid cancers,Phase 1,,,NCT03564691,Study of MK-4830 as Monotherapy and in Combination With pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001),,https://ClinicalTrials.gov/show/NCT03564691
clinicaltrials.gov,MK-4830,,,,,,pembrolizumab,,Q15116,,,,,advanced solid cancers,Phase 1,,,NCT03564691,Study of MK-4830 as Monotherapy and in Combination With pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001),,https://ClinicalTrials.gov/show/NCT03564691
clinicaltrials.gov,MK-5890,,,,,,pembrolizumab,,Q15116,,,,,,Phase 1,,,NCT03396445,Safety and Pharmacokinetics Study of MK-5890 as Monotherapy and in Combination With pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001),,https://ClinicalTrials.gov/show/NCT03396445
clinicaltrials.gov,MK-7162,,,,,,pembrolizumab,,Q15116,,,,,,Phase 1,,,NCT03364049,Study of MK-7162 in Combination With pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002),,https://ClinicalTrials.gov/show/NCT03364049
clinicaltrials.gov,MK-7684,,,,,,pembrolizumab,,Q15116,,,,,lung cancers;head and neck cancers;bladder cancers;stomach cancers,Phase 1,,,NCT02964013,Study of MK-7684 Alone and in Combination With pembrolizumab in Advanced Solid Tumors (MK-7684-001),,https://ClinicalTrials.gov/show/NCT02964013
clinicaltrials.gov,MK-8353,,,,,,pembrolizumab,,Q15116,,,,,bowel cancers,Phase 1,,,NCT02972034,Study of MK-8353 in Combination With pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013),,https://ClinicalTrials.gov/show/NCT02972034
clinicaltrials.gov,MRx0518,,,,,,pembrolizumab,,Q15116,,,,,lung cancers;kidney cancers;skin cancers;bladder cancers,Phase 1,,,NCT03637803,MRx0518 and pembrolizumab Combination Study,,https://ClinicalTrials.gov/show/NCT03637803
clinicaltrials.gov,MRx0518,,,,,,pembrolizumab,,Q15116,,,,,lung cancers;kidney cancers;skin cancers;bladder cancers,Phase 1,,,NCT03637803,MRx0518 and pembrolizumab Combination Study,,https://ClinicalTrials.gov/show/NCT03637803
clinicaltrials.gov,NC-6004,,,,,,pembrolizumab,,Q15116,,,,,head and neck cancers,Phase 2,,,NCT03771820,Combination Therapy With NC-6004 and pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen,,https://ClinicalTrials.gov/show/NCT03771820
clinicaltrials.gov,NC-6004,,,,,,pembrolizumab,,Q15116,,,,,head and neck cancers,Phase 2,,,NCT03771820,Combination Therapy With NC-6004 and pembrolizumab in Head and Neck Cancer Subjects Who Have Failed Platinum Regimen,,https://ClinicalTrials.gov/show/NCT03771820
clinicaltrials.gov,necitumumab,,P00533,,,,pembrolizumab,,Q15116,,,,,lung cancers,Phase 1,,,NCT02451930,A Study of the Combination of Necitumumab (LY3012211) and pembrolizumab (MK3475) in Participants With NSCLC,,https://ClinicalTrials.gov/show/NCT02451930
clinicaltrials.gov,niraparib,919241,Q9UGN5;P09874,"InChI=1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)/t14-/m1/s1",PCHKPVIQAHNQLW-CQSZACIVSA-N,NC(=O)c1cccc2cn(nc12)c3ccc(cc3)[C@@H]4CCCNC4,pembrolizumab,,Q15116,,,,,breast cancers;ovarian cancers;female cancers;other,Phase 1/2,,,NCT02657889,Study of Niraparib in Combination With pembrolizumab (MK-3475) in Patients With Triple-negative Breast Cancer or ovarian Cancers,TOPACIO,https://ClinicalTrials.gov/show/NCT02657889
literature,niraparib,919241,Q9UGN5;P09874,"InChI=1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)/t14-/m1/s1",PCHKPVIQAHNQLW-CQSZACIVSA-N,NC(=O)c1cccc2cn(nc12)c3ccc(cc3)[C@@H]4CCCNC4,pembrolizumab,,Q15116,,,,Patients With Recurrent Platinum-Resistant Ovarian Carcinoma,ovarian cancers,Phase 1/2,31194228,"Fourteen patients (9 with ovarian carcinoma and 5 with TNBC) in phase 1 and 53 patients with ovarian carcinoma in phase 2 were enrolled, for a pooled ovarian carcinoma cohort of 62 patients (median age, 60 years [range, 46-83 years]). In the integrated efficacy phases 1 and 2 ovarian carcinoma population (60 of 62 evaluable patients), ORR was 18% (90% CI, 11%-29%), with a disease control rate of 65% (90% CI, 54%-75%), including 3 (5%) with confirmed complete responses, 8 (13%) with confirmed partial responses, 28 (47%) with stable disease, and 20 (33%) with progressive disease. The ORRs were consistent across subgroups based on platinum-based chemotherapy sensitivity, previous bevacizumab treatment, or tumor BRCA or homologous recombination deficiency (HRD) biomarker status. Median duration of response was not reached (range, 4.2 to ≥14.5 months). At data cutoff, 2 patients with a response and 1 patient with stable disease continued to receive treatment.",NCT02657889,,,
literature,niraparib,919241,Q9UGN5;P09874,"InChI=1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)/t14-/m1/s1",PCHKPVIQAHNQLW-CQSZACIVSA-N,NC(=O)c1cccc2cn(nc12)c3ccc(cc3)[C@@H]4CCCNC4,pembrolizumab,,Q15116,,,,Advanced or Metastatic Triple-Negative Breast Cancer,breast cancers,Phase 2,31194225,"Within the full study population of 55 women (median age, 54 years [range, 32-90 years]), 5 patients had confirmed complete responses, 5 had confirmed partial responses, 13 had stable disease, and 24 had progressive disease. In the efficacy-evaluable population (n_=_47), ORR included 10 patients (21%; 90% CI, 12%-33%) and DCR included 23 (49%; 90% CI, 36%-62%). Median DOR was not reached at the time of the data cutoff, with 7 patients still receiving treatment at the time of analysis. In 15 evaluable patients with tumor BRCA mutations, ORR included 7 patients(47%; 90% CI, 24%-70%), DCR included 12 (80%; 90% CI, 56%-94%), and median PFS was 8.3 months (95% CI, 2.1 months to not estimable). In 27 evaluable patients with BRCA wild-type tumors, ORR included 3 patients (11%; 90% CI, 3%-26%), DCR included 9 (33%; 90% CI, 19%-51%), and median PFS was 2.1 months (95% CI, 1.4-2.5 months). The most common treatment-related adverse events of grade 3 or higher were anemia (10 [18%]), thrombocytopenia (8 [15%]), and fatigue (4 [7%]). Immune-related adverse events were reported in 8 patients (15%) and were grade 3 in 2 patients (4%); no new safety signals were detected.",NCT02657889,,,
clinicaltrials.gov,OBP-301,,,,,,pembrolizumab,,Q15116,,,,,advanced solid cancers,Phase 1,,,NCT03172819,Special Combination of OBP-301 and pembrolizumab,,https://ClinicalTrials.gov/show/NCT03172819
clinicaltrials.gov,olaratumab,,P16234,,,,pembrolizumab,,Q15116,,,,,soft tissue cancers,Phase 1,,,NCT03126591,A Study of Olaratumab (LY3012207) Plus pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma,,https://ClinicalTrials.gov/show/NCT03126591
clinicaltrials.gov,Oraxol,,,,,,pembrolizumab,,Q15116,,,,,advanced solid cancers,Phase 1,,,NCT03588039,Study of Oraxol and pembrolizumab in Subjects With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT03588039
clinicaltrials.gov,Oraxol,,,,,,pembrolizumab,,Q15116,,,,,advanced solid cancers,Phase 1,,,NCT03588039,Study of Oraxol and pembrolizumab in Subjects With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT03588039
clinicaltrials.gov,PEGPH20,,,,,,pembrolizumab,,Q15116,,,,,pancreatic cancers,Phase 2,,,NCT03634332,Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC,,https://ClinicalTrials.gov/show/NCT03634332
clinicaltrials.gov,PEGPH20,,,,,,pembrolizumab,,Q15116,,,,,pancreatic cancers,Phase 2,,,NCT03634332,Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC,,https://ClinicalTrials.gov/show/NCT03634332
clinicaltrials.gov,PLX3397,,,,,,pembrolizumab,,Q15116,,,,,skin cancers;lung cancers;head and neck cancers;soft tissue cancers;ovarian cancers,Phase 1/2,,,NCT02452424,A Combination Clinical Study of PLX3397 and pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors,,https://ClinicalTrials.gov/show/NCT02452424
clinicaltrials.gov,preladenant,534038,P29274,"InChI=1S/C25H29N9O3/c1-35-15-16-36-19-6-4-18(5-7-19)32-11-8-31(9-12-32)10-13-33-23-20(17-27-33)24-28-22(21-3-2-14-37-21)30-34(24)25(26)29-23/h2-7,14,17H,8-13,15-16H2,1H3,(H2,26,29)",DTYWJKSSUANMHD-UHFFFAOYSA-N,COCCOc1ccc(cc1)N2CCN(CCn3ncc4c3nc(N)n5nc(nc45)c6occc6)CC2,pembrolizumab,,Q15116,,,,,advanced solid cancers,Phase 1,,,NCT03099161,Study of Preladenant (MK-3814) Alone and With pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062),,https://ClinicalTrials.gov/show/NCT03099161
clinicaltrials.gov,ramucirumab,,P35968,,,,pembrolizumab,,Q15116,,,,,stomach cancers;oesophageal cancers;lung cancers;bile duct cancers,Phase 1,,,NCT02443324,"A Study of Ramucirumab Plus pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer",,https://ClinicalTrials.gov/show/NCT02443324
clinicaltrials.gov,regorafenib,998226,P15056;P34913,"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)",FNHKPVJBJVTLMP-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1,pembrolizumab,,Q15116,,,,,liver cancers,Phase 1,,,NCT03347292,Regorafenib Plus pembrolizumab in First Line Systemic Treatment of HCC,,https://ClinicalTrials.gov/show/NCT03347292
clinicaltrials.gov,RO6874281,,,,,,pembrolizumab,,Q15116,,,,Metastatic Melanoma,,Phase 1,,,NCT03875079,,,
clinicaltrials.gov,SEA-CD40,,,,,,pembrolizumab,,Q15116,,,,,lung cancers;lymphoma;skin cancers;head and neck cancers,Phase 1,,,NCT02376699,Safety Study of SEA-CD40 in Cancer Patients,,https://ClinicalTrials.gov/show/NCT02376699
clinicaltrials.gov,selumetinib,646570,Q02750;P36507,"InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)",CYOHGALHFOKKQC-UHFFFAOYSA-N,Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO,pembrolizumab,,Q15116,,,,Advanced/Metastatic Solid Tumors,,Phase 1,,,NCT03833427,,,
clinicaltrials.gov,SGN-LIV1A,,,,,,pembrolizumab,,Q15116,,,,,breast cancers,Phase 1/2,,,NCT03310957,Safety and Efficacy of SGN-LIV1A Plus pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer,,https://ClinicalTrials.gov/show/NCT03310957
clinicaltrials.gov,somatuline depot,1405,P30874;P35346,"InChI=1S/C54H69N11O10S2.C2H4O2/c1-29(2)45-54(75)63-44(53(74)65-46(30(3)66)47(57)68)28-77-76-27-43(62-48(69)38(56)23-32-15-18-33-10-4-5-11-34(33)22-32)52(73)60-41(24-31-16-19-36(67)20-17-31)50(71)61-42(25-35-26-58-39-13-7-6-12-37(35)39)51(72)59-40(49(70)64-45)14-8-9-21-55;1-2(3)4/h4-7,10-13,15-20,22,26,29-30,38,40-46,58,66-67H,8-9,14,21,23-25,27-28,55-56H2,1-3H3,(H2,57,68)(H,59,72)(H,60,73)(H,61,71)(H,62,69)(H,63,75)(H,64,70)(H,65,74);1H3,(H,3,4)/t30-,38-,40+,41+,42-,43+,44+,45+,46+;/m1./s1",DEXPIBGCLCPUHE-UISHROKMSA-N,CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc4ccc(O)cc4)NC(=O)[C@H](CSSC[C@H](NC1=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N)NC(=O)[C@H](N)Cc5ccc6ccccc6c5.CC(=O)O,pembrolizumab,,Q15116,,,,,other,Phase 1/2,,,NCT03043664,Study of pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors,PLANET,https://ClinicalTrials.gov/show/NCT03043664
clinicaltrials.gov,SX-682,,,,,,pembrolizumab,,Q15116,,,,,skin cancers,Phase 1,,,NCT03161431,SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With pembrolizumab,,https://ClinicalTrials.gov/show/NCT03161431
clinicaltrials.gov,T-DM1,,,,,,pembrolizumab,,Q15116,,,,,breast cancers,Phase 1,,,NCT03032107,A Study Of pembrolizumab In Combination With Trastuzumab-DM1,,https://ClinicalTrials.gov/show/NCT03032107
clinicaltrials.gov,TG02,993309,P06493;P50750;P24941;P50613;O60674;P36888,"InChI=1S/C23H24N4O/c1-27-13-3-2-4-14-28-21-10-6-8-19(16-21)22-11-12-24-23(26-22)25-20-9-5-7-18(15-20)17-27/h2-3,5-12,15-16H,4,13-14,17H2,1H3,(H,24,25,26)/b3-2+",VXBAJLGYBMTJCY-NSCUHMNNSA-N,CN1C\C=C\CCOc2cccc(c2)c3ccnc(Nc4cccc(C1)c4)n3,pembrolizumab,,Q15116,,,,,bowel cancers,Phase 1,,,NCT02933944,Exploratory Study of TG02-treatment as Monotherapy or in Combination With pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Recurrent Oncogenic RAS Exon 2 Mutant Rectal Cancer,,https://ClinicalTrials.gov/show/NCT02933944
clinicaltrials.gov,TGR-1202,,O00329,,,,pembrolizumab,,Q15116,,,,,leukemia;lymphoma,Phase 1,,,NCT03283137,Combination of pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL,,https://ClinicalTrials.gov/show/NCT03283137
clinicaltrials.gov,TJ011133,,,,,,pembrolizumab,,Q15116,,,,,,,,,NCT03934814,Study of TJ011133 Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma,,https://ClinicalTrials.gov/show/NCT03934814
clinicaltrials.gov,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,pembrolizumab,,Q15116,,,,,lung cancers,Phase 1/2,,,NCT03225664,BATTLE-2 Program - A Biomarker-Integrated Targeted Therapy in Non-Small Cell Lung Cancer (NSCLC),,https://ClinicalTrials.gov/show/NCT03225664
clinicaltrials.gov,TTAC-0001,,,,,,pembrolizumab,,Q15116,,,,,breast cancers,Phase 1,,,NCT03720431,TTAC-0001 and pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer,,https://ClinicalTrials.gov/show/NCT03720431
clinicaltrials.gov,TTAC-0001,,,,,,pembrolizumab,,Q15116,,,,,brain cancers,Phase 1,,,NCT03722342,TTAC-0001 and pembrolizumab Phase Ib Combination Trial in Recurrent Glioblastoma,,https://ClinicalTrials.gov/show/NCT03722342
clinicaltrials.gov,TTAC-0001,,,,,,pembrolizumab,,Q15116,,,,,breast cancers,Phase 1,,,NCT03720431,TTAC-0001 and pembrolizumab Phase Ib Combination Trial in Metastatic Triple-negative Breast Cancer,,https://ClinicalTrials.gov/show/NCT03720431
clinicaltrials.gov,TTAC-0001,,,,,,pembrolizumab,,Q15116,,,,,brain cancers,Phase 1,,,NCT03722342,TTAC-0001 and pembrolizumab Phase Ib Combination Trial in Recurrent Glioblastoma,,https://ClinicalTrials.gov/show/NCT03722342
clinicaltrials.gov,Vicriviroc,,,,,,pembrolizumab,,Q15116,,,,,colorectal cancers,Phase 2,,,NCT03631407,Safety and Efficacy of Vicriviroc (MK-7690) in Combination With pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046),,https://ClinicalTrials.gov/show/NCT03631407
clinicaltrials.gov,Vicriviroc,,,,,,pembrolizumab,,Q15116,,,,,colorectal cancers,Phase 2,,,NCT03631407,Safety and Efficacy of Vicriviroc (MK-7690) in Combination With pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046),,https://ClinicalTrials.gov/show/NCT03631407
clinicaltrials.gov,vorinostat,260,O15379;O75376;P56524;Q13547;Q8WUI4;Q92769;Q969S8;Q96DB2;Q9BY41;Q9UBN7;Q9UKV0;Q9UQL6;Q9Y618,"InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)",WAEXFXRVDQXREF-UHFFFAOYSA-N,ONC(=O)CCCCCCC(=O)Nc1ccccc1,pembrolizumab,,Q15116,,,,,lung cancers,Phase 1/2,,,NCT02638090,Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC),,https://ClinicalTrials.gov/show/NCT02638090
clinicaltrials.gov,VSV-IFNŒ≤-NIS,,,,,,pembrolizumab,,Q15116,,,,,advanced solid cancers;liver cancers;lung cancers,Phase 1,,,NCT03647163,Combination Therapy With Intravenous VSV-IFNŒ≤-NIS and pembrolizumab in Refractory NSCLC and HCC,,https://ClinicalTrials.gov/show/NCT03647163
clinicaltrials.gov,VSV-IFNŒ≤-NIS,,,,,,pembrolizumab,,Q15116,,,,,advanced solid cancers;liver cancers;lung cancers,Phase 1,,,NCT03647163,Combination Therapy With Intravenous VSV-IFNŒ≤-NIS and pembrolizumab in Refractory NSCLC and HCC,,https://ClinicalTrials.gov/show/NCT03647163
clinicaltrials.gov,X4P-001,,,,,,pembrolizumab,,Q15116,,,,,skin cancers,Phase 1,,,NCT02823405,X4P-001 and pembrolizumab in Patients With Advanced Melanoma,X4P-001-MELA,https://ClinicalTrials.gov/show/NCT02823405
clinicaltrials.gov,XL888,,,,,,pembrolizumab,,Q15116,,,,,liver cancers;pancreatic cancers;bowel cancers,Phase 1,,,NCT03095781,pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer,,https://ClinicalTrials.gov/show/NCT03095781
clinicaltrials.gov,XmAb¬Æ22841,,,,,,pembrolizumab,,Q15116,,,,Melanoma|Cervical Carcinoma|Pancreatic Carcinoma|Triple Negative Breast Cancer|Hepatocellular Carcinoma|Urothelial Carcinoma|Squamous Cell Carcinoma of the Head and Neck|Nasopharyngeal Carcinoma|Renal Cell Carcinoma|Colorectal Carcinoma|Endometrial Carcinoma|Non-small Cell Lung Carcinoma|Small Cell Lung Carcinoma|Gastric or Gastroesophageal Junction Adenocarcinoma|Advanced or Metastatic Solid Tumors,,Phase 1,,,NCT03849469,,,
clinicaltrials.gov,regorafenib,998226,P15056;P34913,"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)",FNHKPVJBJVTLMP-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1,perindopril,1261,P12821,"InChI=1S/C19H32N2O5/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24/h12-16,20H,4-11H2,1-3H3,(H,23,24)/t12-,13-,14-,15-,16-/m0/s1",IPVQLZZIHOAWMC-QXKUPLGCSA-N,CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O)C(=O)OCC,,bowel cancers,Phase 2,,,NCT02651415,Phase II Study of Perindopril and Regorafenib in mCRC,PARICCA,https://ClinicalTrials.gov/show/NCT02651415
literature,cetuximab,9,P00533,,,,pertuzumab,1238538,P04626,,,,cetuximab-refractory colorectal cancer,bowel cancers,Phase 1/2,23568716,"Six of the thirteen patients (46 %) experienced DLTs, therefore the study was terminated early. Grade 3 or higher DLTs included dermatitis with desquamation and/or acneiform rash (n_=_6), mucositis or stomatitis (n_=_5), and diarrhea (n_=_2). There was one Grade 5 event (myocardial infarction) attributed to underlying disease. Among the 13 patients, seven (54 %) were evaluable for response. The objective response rate was 14 %: one patient had a partial response lasting 6 months. Two patients had stable disease (29 %), and four had progressive disease (57 %). Median progression free survival was 2.1 months (95 % CI, 1.5-4.9) and median overall survival was 3.7 months (95 % CI, 1.6-7.9).",,,,
clinicaltrials.gov,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,pertuzumab,1238538,P04626,,,,,lung cancers,Phase 1,,,NCT02507375,A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC),,https://ClinicalTrials.gov/show/NCT02507375
literature,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,pertuzumab,1238538,P04626,,,,advanced non-small-cell lung cancer,lung cancers,Phase 1b,22609229,"No dose-limiting toxicities were observed. Adverse events were generally grade 1/2 and manageable. The objective response rate was 20% (3/15 patients; 2 responders had mutant HER1, 1 responder had wild-type HER1), median overall progression-free survival was 9.3 weeks. High HER1, HER2, and HER3 messenger RNA expression correlated with increased progression-free survival. Combination therapy did not affect erlotinib's pharmacokinetics; however, pertuzumab mean exposures (maximum concentration, 231 mg/L; area under the concentration-time curve from 0 to 21 days, 1780 mg*d/L) were slightly higher than in previous studies.",,,,
clinicaltrials.gov,trastuzumab,4,P04626,,,,pertuzumab,1238538,P04626,,,,,breast cancers,Phase 1,,,NCT02738970,A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC),,https://ClinicalTrials.gov/show/NCT02738970
clinicaltrials.gov,belinostat,73864,Q9BY41;Q969S8;O15379;P56524;Q8WUI4;Q9UQL6;Q9UKV0;Q13547;Q92769;Q9UBN7;Q96DB2,"InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+",NCNRHFGMJRPRSK-MDZDMXLPSA-N,ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc2ccccc2,Pevonedistat,,,,,,,leukemia,Phase 1,,,NCT03772925,Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome,,https://ClinicalTrials.gov/show/NCT03772925
clinicaltrials.gov,belinostat,73864,Q9BY41;Q969S8;O15379;P56524;Q8WUI4;Q9UQL6;Q9UKV0;Q13547;Q92769;Q9UBN7;Q96DB2,"InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+",NCNRHFGMJRPRSK-MDZDMXLPSA-N,ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc2ccccc2,Pevonedistat,,,,,,,leukemia,Phase 1,,,NCT03772925,Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome,,https://ClinicalTrials.gov/show/NCT03772925
clinicaltrials.gov,binimetinib,1222391,Q02750;P36507,"InChI=1S/C17H15BrF2N4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)",ACWZRVQXLIRSDF-UHFFFAOYSA-N,Cn1cnc2c(F)c(Nc3ccc(Br)cc3F)c(cc12)C(=O)NOCCO,pexidartinib,,,,,,,stomach cancers,Phase 1,,,NCT03158103,A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST),,https://ClinicalTrials.gov/show/NCT03158103
clinicaltrials.gov,cobimetinib,1055500,Q02750;P36507,"InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1",BSMCAPRUBJMWDF-KRWDZBQOSA-N,OC1(CN(C1)C(=O)c2ccc(F)c(F)c2Nc3ccc(I)cc3F)[C@@H]4CCCCN4,pictilisib,70473,O00329;O00459;P27986;P42336;P42338;P48736;Q8WYR1;Q92569,"InChI=1S/C23H27N7O3S2/c1-35(31,32)30-7-5-28(6-8-30)15-16-13-20-21(34-16)23(29-9-11-33-12-10-29)26-22(25-20)17-3-2-4-19-18(17)14-24-27-19/h2-4,13-14H,5-12,15H2,1H3,(H,24,27)",LHNIIDJUOCFXAP-UHFFFAOYSA-N,CS(=O)(=O)N1CCN(Cc2cc3nc(nc(N4CCOCC4)c3s2)c5cccc6[nH]ncc56)CC1,,advanced solid cancers,Phase 1,,,NCT00996892,"Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors",,https://ClinicalTrials.gov/show/NCT00996892
clinicaltrials.gov,MM-121,,P21860,,,,pilaralisib,1348813,Q92569;Q8WYR1;P48736;P42338;P42336;P27986;O00459;O00329,"InChI=1S/C25H25ClN6O4S/c1-25(2,27)24(33)28-15-7-6-8-17(13-15)37(34,35)32-23-22(29-19-9-4-5-10-20(19)30-23)31-21-14-16(36-3)11-12-18(21)26/h4-14H,27H2,1-3H3,(H,28,33)(H,29,31)(H,30,32)",QINPEPAQOBZPOF-UHFFFAOYSA-N,COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c4cccc(NC(=O)C(C)(C)N)c4)c1,,advanced solid cancers,Phase 1,,,NCT01436565,A Study of Investigational SAR256212 in Combination With SAR245408 in Patients With Solid Tumor Cancers,,https://ClinicalTrials.gov/show/NCT01436565
clinicaltrials.gov,XL647,,,,,,pilaralisib,1348813,Q92569;Q8WYR1;P48736;P42338;P42336;P27986;O00459;O00329,"InChI=1S/C25H25ClN6O4S/c1-25(2,27)24(33)28-15-7-6-8-17(13-15)37(34,35)32-23-22(29-19-9-4-5-10-20(19)30-23)31-21-14-16(36-3)11-12-18(21)26/h4-14H,27H2,1-3H3,(H,28,33)(H,29,31)(H,30,32)",QINPEPAQOBZPOF-UHFFFAOYSA-N,COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c4cccc(NC(=O)C(C)(C)N)c4)c1,,lung cancers;breast cancers,Phase 1,,,NCT00704392,Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid Tumors,,https://ClinicalTrials.gov/show/NCT00704392
clinicaltrials.gov,SAR405838,,,,,,pimasertib,1025752,Q02750; P36507,"InChI=1S/C15H15FIN3O3/c16-12-5-9(17)1-2-13(12)20-14-7-18-4-3-11(14)15(23)19-6-10(22)8-21/h1-5,7,10,20-22H,6,8H2,(H,19,23)/t10-/m0/s1",VIUAUNHCRHHYNE-JTQLQIEISA-N,OC[C@@H](O)CNC(=O)c1ccncc1Nc2ccc(I)cc2F,,,Phase 1,,,NCT01985191,A Safety and Efficacy Study of SAR405838 and Pimasertib in Cancer Patients,,https://ClinicalTrials.gov/show/NCT01985191
literature,SAR405838,,,,,,pimasertib,1025752,Q02750; P36507,"InChI=1S/C15H15FIN3O3/c16-12-5-9(17)1-2-13(12)20-14-7-18-4-3-11(14)15(23)19-6-10(22)8-21/h1-5,7,10,20-22H,6,8H2,(H,19,23)/t10-/m0/s1",VIUAUNHCRHHYNE-JTQLQIEISA-N,OC[C@@H](O)CNC(=O)c1ccncc1Nc2ccc(I)cc2F,Patients with locally advanced or metastatic solid tumours with documented wild-type TP53 and RAS or RAF mutations,advanced solid tumours,Phase 1,30585255,"Twenty-six patients were treated with SAR405838 200 or 300_mg QD plus pimasertib 60_mg QD or 45_mg BID. The MTD was SAR405838 200_mg QD plus pimasertib 45_mg BID. The most common dose-limiting toxicity was thrombocytopenia. The most frequently occurring treatment-related adverse events were diarrhoea (81%), increased blood creatine phosphokinase (77%), nausea (62%) and vomiting (62%). No significant drug-drug interactions were observed. The biomarkers MIC-1 and pERK were, respectively, upregulated and downregulated in response to study treatment. In 24 efficacy-evaluable patients, one patient (4%) had a partial response and 63% had stable disease.",,,,
literature,SAR405838,,,,,,pimasertib,1025752,Q02750; P36507,"InChI=1S/C15H15FIN3O3/c16-12-5-9(17)1-2-13(12)20-14-7-18-4-3-11(14)15(23)19-6-10(22)8-21/h1-5,7,10,20-22H,6,8H2,(H,19,23)/t10-/m0/s1",VIUAUNHCRHHYNE-JTQLQIEISA-N,OC[C@@H](O)CNC(=O)c1ccncc1Nc2ccc(I)cc2F,Patients with locally advanced or metastatic solid tumours with documented wild-type TP53 and RAS or RAF mutations,advanced solid tumours,Phase 1,30585255,"Twenty-six patients were treated with SAR405838 200 or 300_mg QD plus pimasertib 60_mg QD or 45_mg BID. The MTD was SAR405838 200_mg QD plus pimasertib 45_mg BID. The most common dose-limiting toxicity was thrombocytopenia. The most frequently occurring treatment-related adverse events were diarrhoea (81%), increased blood creatine phosphokinase (77%), nausea (62%) and vomiting (62%). No significant drug-drug interactions were observed. The biomarkers MIC-1 and pERK were, respectively, upregulated and downregulated in response to study treatment. In 24 efficacy-evaluable patients, one patient (4%) had a partial response and 63% had stable disease.",,,,
clinicaltrials.gov,avelumab,,Q9NZQ7,,,,PLD,962505,,,,,,ovarian cancers,Phase 3,,,NCT02580058,A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory ovarian Cancers (JAVELIN Ovarian 200),,https://ClinicalTrials.gov/show/NCT02580058
clinicaltrials.gov,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,,ponatinib,,,,,,,lung cancers,Phase 1/2,,,NCT03704688,Trial of Trametinib and ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT03704688
clinicaltrials.gov,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,,ponatinib,,,,,,,lung cancers,Phase 1/2,,,NCT03704688,Trial of Trametinib and ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT03704688
clinicaltrials.gov,Gemtuzumab Ozogamicin,,,,,,Pracinostat,,,,,,Relapsed Adult AML,,Phase 1,,,NCT03848754,,,
clinicaltrials.gov,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,pravastatin,2024,P04035,"InChI=1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1",TUZYXOIXSAXUGO-PZAWKZKUSA-N,CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@@H]12,,leukemia,Phase 1,,,NCT02484261,Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children,,https://ClinicalTrials.gov/show/NCT02484261
clinicaltrials.gov,abiraterone,181093,P05093,"InChI=1S/C24H31NO/c1-23-11-9-18(26)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22,26H,6,8-12,14H2,1-2H3/t18-,19-,21-,22-,23-,24+/m0/s1",GZOSMCIZMLWJML-VJLLXTKPSA-N,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c5cccnc5,prednisone,656,P04150,"InChI=1S/C21H26O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-15,18,22,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1",XOFYZVNMUHMLCC-ZPOLXVRWSA-N,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,,prostate cancers,Phase 1,,,NCT02405858,A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy,,https://ClinicalTrials.gov/show/NCT02405858
clinicaltrials.gov,abiraterone,181093,P05093,"InChI=1S/C24H31NO/c1-23-11-9-18(26)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22,26H,6,8-12,14H2,1-2H3/t18-,19-,21-,22-,23-,24+/m0/s1",GZOSMCIZMLWJML-VJLLXTKPSA-N,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c5cccnc5,prednisone,656,P04150,"InChI=1S/C21H26O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-15,18,22,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1",XOFYZVNMUHMLCC-ZPOLXVRWSA-N,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,,prostate cancers,Phase 2,,,NCT01637402,A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer,,https://ClinicalTrials.gov/show/NCT01637402
clinicaltrials.gov,abiraterone,181093,P05093,"InChI=1S/C24H31NO/c1-23-11-9-18(26)14-17(23)5-6-19-21-8-7-20(16-4-3-13-25-15-16)24(21,2)12-10-22(19)23/h3-5,7,13,15,18-19,21-22,26H,6,8-12,14H2,1-2H3/t18-,19-,21-,22-,23-,24+/m0/s1",GZOSMCIZMLWJML-VJLLXTKPSA-N,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CC=C2c5cccnc5,prednisone,656,P04150,"InChI=1S/C21H26O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-15,18,22,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1",XOFYZVNMUHMLCC-ZPOLXVRWSA-N,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@]34C)[C@@H]1CC[C@]2(O)C(=O)CO,,prostate cancers,not specified,,,NCT01961843,Abiraterone Acetate for Castrate Resistant Prostate Cancer,,https://ClinicalTrials.gov/show/NCT01961843
clinicaltrials.gov,pembrolizumab,,Q15116,,,,PVX-410,,,,,,,breast cancers,Phase 1,,,NCT03362060,PVX-410 Vaccine Plus pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer,,https://ClinicalTrials.gov/show/NCT03362060
clinicaltrials.gov,prexasertib,,O14757;O96017,"InChI=1S/C18H19N7O2/c1-26-14-4-2-5-15(27-7-3-6-19)18(14)13-8-16(25-24-13)23-17-11-21-12(9-20)10-22-17/h2,4-5,8,10-11H,3,6-7,19H2,1H3,(H2,22,23,24,25)",DOTGPNHGTYJDEP-UHFFFAOYSA-N,COc1cccc(OCCCN)c1c2cc(Nc3cnc(cn3)C#N)n[nH]2,ralimetinib,1355533,Q16539,"InChI=1S/C24H29FN6/c1-23(2,3)13-31-20-17(28-22(31)26)12-11-16(27-20)19-18(14-7-9-15(25)10-8-14)29-21(30-19)24(4,5)6/h7-12H,13H2,1-6H3,(H2,26,28)(H,29,30)",XPPBBJCBDOEXDN-UHFFFAOYSA-N,CC(C)(C)Cn1c(N)nc2ccc(nc12)c3[nH]c(nc3c4ccc(F)cc4)C(C)(C)C,,bowel cancers;lung cancers,Phase 1,,,NCT02860780,A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer,,https://ClinicalTrials.gov/show/NCT02860780
clinicaltrials.gov,tamoxifen,1059,P00533;P03372;P04626;P06239;P06241;P08172;P08173;P08684;P08912;P08913;P11229;P11474;P13945;P14416;P18089;P20309;P20813;P21452;P21728;P21917;P23219;P23975;P24557;P25021;P25100;P28223;P28335;P29274;P31645;P33765;P35462;P41143;P41595;P50406;Q01959;Q12809;Q15125;Q92731;Q99720;Q9BY08;Q9UBM7,"InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-",NKANXQFJJICGDU-QPLCGJKRSA-N,CC\C(=C(/c1ccccc1)\c2ccc(OCCN(C)C)cc2)\c3ccccc3,ralimetinib,1355533,Q16539,"InChI=1S/C24H29FN6/c1-23(2,3)13-31-20-17(28-22(31)26)12-11-16(27-20)19-18(14-7-9-15(25)10-8-14)29-21(30-19)24(4,5)6/h7-12H,13H2,1-6H3,(H2,26,28)(H,29,30)",XPPBBJCBDOEXDN-UHFFFAOYSA-N,CC(C)(C)Cn1c(N)nc2ccc(nc12)c3[nH]c(nc3c4ccc(F)cc4)C(C)(C)C,,breast cancers,Phase 2,,,NCT02322853,A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors,OLYMPE,https://ClinicalTrials.gov/show/NCT02322853
literature,abemaciclib,1211300,P11802;Q00534,"InChI=1S/C27H32F2N8/c1-5-35-8-10-36(11-9-35)16-19-6-7-24(30-14-19)33-27-31-15-22(29)25(34-27)20-12-21(28)26-23(13-20)37(17(2)3)18(4)32-26/h6-7,12-15,17H,5,8-11,16H2,1-4H3,(H,30,31,33,34)",UZWDCWONPYILKI-UHFFFAOYSA-N,CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)c4cc(F)c5nc(C)n(C(C)C)c5c4)nc2)CC1,ramucirumab,,P35968,,,,patients with metastatic NSCLC,lung cancers,Phase 1b,30082474,"The three study parts enrolled 86 patients; all received ≥1 dose of combination therapy. Across arms, the most common treatment-emergent adverse events were fatigue, diarrhea, neutropenia, decreased appetite, and nausea. The trial did not identify an abemaciclib MTD for the combination with pemetrexed or gemcitabine but did so for the combination of abemaciclib with days 1 and 8 ramucirumab (8 mg/kg). Plasma sample analysis showed that abemaciclib did not influence the pharmacokinetics of the combination agents and the combination agents did not affect abemaciclib exposure. The disease control rate was 57% for patients treated with abemaciclib-pemetrexed, 25% for abemaciclib-gemcitabine, and 54% for abemaciclib-ramucirumab. Median progression-free survival was 5.55, 1.58, and 4.83 months, respectively.",,,,
literature,abemaciclib,1211300,P11802;Q00534,"InChI=1S/C27H32F2N8/c1-5-35-8-10-36(11-9-35)16-19-6-7-24(30-14-19)33-27-31-15-22(29)25(34-27)20-12-21(28)26-23(13-20)37(17(2)3)18(4)32-26/h6-7,12-15,17H,5,8-11,16H2,1-4H3,(H,30,31,33,34)",UZWDCWONPYILKI-UHFFFAOYSA-N,CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)c4cc(F)c5nc(C)n(C(C)C)c5c4)nc2)CC1,ramucirumab,,P35968,,,,patients with metastatic NSCLC,lung cancers,Phase 1b,30082474,"The three study parts enrolled 86 patients; all received ≥1 dose of combination therapy. Across arms, the most common treatment-emergent adverse events were fatigue, diarrhea, neutropenia, decreased appetite, and nausea. The trial did not identify an abemaciclib MTD for the combination with pemetrexed or gemcitabine but did so for the combination of abemaciclib with days 1 and 8 ramucirumab (8 mg/kg). Plasma sample analysis showed that abemaciclib did not influence the pharmacokinetics of the combination agents and the combination agents did not affect abemaciclib exposure. The disease control rate was 57% for patients treated with abemaciclib-pemetrexed, 25% for abemaciclib-gemcitabine, and 54% for abemaciclib-ramucirumab. Median progression-free survival was 5.55, 1.58, and 4.83 months, respectively.",,,,
clinicaltrials.gov,emibetuzumab,,,,,,ramucirumab,,P35968,,,,,stomach cancers;lung cancers;kidney cancers;lung cancers,Phase 1/2,,,NCT02082210,A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer,,https://ClinicalTrials.gov/show/NCT02082210
clinicaltrials.gov,nivolumab,,Q15116,,,,ramucirumab,,P35968,,,,,lung cancers,Phase 2,,,NCT03527108,"Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC",,https://ClinicalTrials.gov/show/NCT03527108
clinicaltrials.gov,nivolumab,,Q15116,,,,ramucirumab,,P35968,,,,,lung cancers,Phase 2,,,NCT03527108,"Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC",,https://ClinicalTrials.gov/show/NCT03527108
clinicaltrials.gov,pembrolizumab,,Q15116,,,,ramucirumab,,P35968,,,,,oesophageal cancers;stomach cancers,Phase 1,,,NCT03395847,A Study of pembrolizumab Monotherapy or in Combination With Other Agents in Patients With Previously Treated Advanced Gastroesophageal Adenocarcinoma,,https://ClinicalTrials.gov/show/NCT03395847
clinicaltrials.gov,rucaparib,757098,P09874;Q9UGN5;Q9Y6F1,"InChI=1S/C19H18FN3O/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15/h2-5,8-9,21,23H,6-7,10H2,1H3,(H,22,24)",HMABYWSNWIZPAG-UHFFFAOYSA-N,CNCc1ccc(cc1)c2[nH]c3cc(F)cc4C(=O)NCCc2c34,ramucirumab,,P35968,,,,,,,,,NCT03995017,"Rucaparib, Ramucirumab and Nivolumab in Patients Who Have Had Treatment for Gastric and Esophageal Adenocarcinoma",RiME,https://ClinicalTrials.gov/show/NCT03995017
clinicaltrials.gov,TAS 102,,,,,,ramucirumab,,P35968,,,,,stomach cancers,Phase 2,,,NCT03686488,"TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma",,https://ClinicalTrials.gov/show/NCT03686488
clinicaltrials.gov,TAS 102,,,,,,ramucirumab,,P35968,,,,,stomach cancers,Phase 2,,,NCT03686488,"TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma",,https://ClinicalTrials.gov/show/NCT03686488
clinicaltrials.gov,copanlisib,1212464,O00329;O00459;P27986;P42336;P42338;P48736;Q8WYR1;Q92569,"InChI=1S/C23H28N8O4/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15/h3-4,13-14H,2,5-12H2,1H3,(H2,24,26,27)(H,28,29,32)",PZBCKZWLPGJMAO-UHFFFAOYSA-N,COc1c(OCCCN2CCOCC2)ccc3C4=NCCN4C(=Nc13)NC(=O)c5cnc(N)nc5,refametinib,1285727,Q02750;P36507,"InChI=1S/C19H20F3IN2O5S/c1-30-15-7-13(21)16(22)18(24-14-3-2-10(23)6-12(14)20)17(15)25-31(28,29)19(4-5-19)8-11(27)9-26/h2-3,6-7,11,24,26-27H,4-5,8-9H2,1H3,(H-,25,28,29)",QXLZZQSWYQRQEM-UHFFFAOYSA-N,COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1N[S+](=O)([O-])C3(CC(O)CO)CC3,,,Phase 1,,,NCT01392521,Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor Copanlisib With MEK (Mitogen-activated Protein Kinase) Inhibitor Refametinib (BAY86-9766) in Patients With Advanced Cancer,,https://ClinicalTrials.gov/show/NCT01392521
clinicaltrials.gov,isatuximab,,,,,,REGN2810,,,,,,,multiple myeloma,Phase 1/2,,,NCT03194867,Isatuximab in Combination With REGN2810 in Relapsed/Refractory Multiple Myeloma (RRMM) Patients,,https://ClinicalTrials.gov/show/NCT03194867
clinicaltrials.gov,isatuximab,,,,,,REGN2810,,,,,,,prostate cancers;lung cancers,Phase 1/2,,,NCT03367819,Isatuximab in Combination With REGN2810 in Patients With Advanced Malignancies,,https://ClinicalTrials.gov/show/NCT03367819
clinicaltrials.gov,REGN3767,,,,,,REGN2810,,,,,,,,Phase 1,,,NCT03005782,Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers,,https://ClinicalTrials.gov/show/NCT03005782
clinicaltrials.gov,SAR439459,,,,,,REGN2810,,,,,,,advanced solid cancers,Phase 1,,,NCT03192345,"A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and REGN2810 in Patients With Advanced Solid Tumors",,https://ClinicalTrials.gov/show/NCT03192345
clinicaltrials.gov,PDR001,,,,,,regorafenib,998226,P15056;P34913,"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)",FNHKPVJBJVTLMP-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1,,bowel cancers,Phase 1,,,NCT03081494,Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer,,https://ClinicalTrials.gov/show/NCT03081494
clinicaltrials.gov,PF-03446962,,P37023,,,,regorafenib,998226,P15056;P34913,"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)",FNHKPVJBJVTLMP-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1,,bowel cancers,Phase 1,,,NCT02116894,Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer,REGAL-1,https://ClinicalTrials.gov/show/NCT02116894
clinicaltrials.gov,refametinib,1285727,Q02750;P36507,"InChI=1S/C19H20F3IN2O5S/c1-30-15-7-13(21)16(22)18(24-14-3-2-10(23)6-12(14)20)17(15)25-31(28,29)19(4-5-19)8-11(27)9-26/h2-3,6-7,11,24,26-27H,4-5,8-9H2,1H3,(H-,25,28,29)",QXLZZQSWYQRQEM-UHFFFAOYSA-N,COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1N[S+](=O)([O-])C3(CC(O)CO)CC3,regorafenib,998226,P15056;P34913,"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)",FNHKPVJBJVTLMP-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1,,,Phase 1,,,NCT02168777,"Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer",,https://ClinicalTrials.gov/show/NCT02168777
clinicaltrials.gov,sunitinib,1055,O00238;O00444;O00506;O14578;O14730;O14757;O14965;O14976;O15075;O15111;O15146;O15197;O15530;O43172;O43283;O43293;O43318;O60285;O60674;O75116;O75385;O75460;O75582;O75676;O75716;O75914;O94768;O94804;O94806;O94921;O95747;O95819;O95835;O96013;O96017;P00519;P04629;P06213;P06239;P06241;P07332;P07333;P07947;P07948;P07949;P08069;P08581;P08631;P09619;P09769;P0C264;P10721;P11362;P11802;P12931;P14616;P15735;P16234;P16591;P17252;P17948;P19525;P19784;P21802;P22455;P22607;P23443;P23458;P27448;P29320;P29376;P29597;P30291;P30530;P31751;P32298;P33981;P35590;P35916;P35968;P36507;P36888;P42679;P42684;P42685;P45984;P45985;P46734;P48729;P48730;P49674;P49759;P49760;P50613;P51451;P51617;P51812;P51955;P52333;P52564;P53355;P53779;P54646;P54756;P54760;P54762;P57058;P57059;P57078;P68400;P78356;P78362;P78368;P80192;P80370;Q00535;Q00536;Q00537;Q02750;Q04759;Q05397;Q06187;Q06418;Q07002;Q07912;Q08345;Q08881;Q12809;Q12851;Q12852;Q12866;Q13043;Q13131;Q13163;Q13164;Q13188;Q13464;Q13470;Q13523;Q13546;Q13554;Q13555;Q13557;Q13627;Q13873;Q13882;Q14012;Q14164;Q14289;Q14680;Q15139;Q15208;Q15349;Q15375;Q15418;Q15746;Q15831;Q15835;Q16288;Q16512;Q16513;Q16566;Q16584;Q16620;Q16816;Q16832;Q2M2I8;Q32MK0;Q52WX2;Q56UN5;Q5S007;Q6PHR2;Q6XUX3;Q6ZN16;Q7KZI7;Q7L7X3;Q86UE8;Q86V86;Q86YV6;Q86Z02;Q8IU85;Q8IVH8;Q8IWQ3;Q8IY84;Q8IYT8;Q8N4C8;Q8N568;Q8N5S9;Q8N752;Q8NE63;Q8NEV4;Q8NFD2;Q8TDC3;Q8TDR2;Q8TDX7;Q8WTQ7;Q8WXR4;Q92630;Q92772;Q92918;Q96BR1;Q96GD4;Q96L34;Q96NX5;Q96RR4;Q96SB4;Q99755;Q99759;Q9BRS2;Q9BUB5;Q9BVS4;Q9BXA7;Q9BYT3;Q9BZL6;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K2;Q9H2K8;Q9H2X6;Q9H422;Q9HAZ1;Q9HBH9;Q9HCP0;Q9NQU5;Q9NRH2;Q9NRM7;Q9NSY1;Q9NWZ3;Q9NYY3;Q9P0L2;Q9P1W9;Q9P286;Q9P289;Q9P2K8;Q9UEE5;Q9UEW8;Q9UF33;Q9UHD2;Q9UIK4;Q9UK32;Q9UKE5;Q9UKI8;Q9UM73;Q9UPE1;Q9UPZ9;Q9UQB9;Q9UQM7;Q9Y2H1;Q9Y2H9;Q9Y2U5;Q9Y463;Q9Y4K4;Q9Y616;Q9Y6E0;Q9Y6M4;Q9Y6R4,"InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-",WINHZLLDWRZWRT-ATVHPVEESA-N,CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C\2/C(=O)Nc3ccc(F)cc23)c1C,regorafenib,998226,P15056;P34913,"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)",FNHKPVJBJVTLMP-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1,,stomach cancers,Phase 1,,,NCT02164240,Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST,SURE,https://ClinicalTrials.gov/show/NCT02164240
clinicaltrials.gov,TAS 102,,,,,,regorafenib,998226,P15056;P34913,"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)",FNHKPVJBJVTLMP-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1,,colorectal cancers,Phase 1,,,NCT03305913,Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy,REMETY,https://ClinicalTrials.gov/show/NCT03305913
clinicaltrials.gov,JS001,,,,,,regorafenib,998226,P15056;P34913,"InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)",FNHKPVJBJVTLMP-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1,,,,,,NCT03946917,JS001 Combined With Regorafenib in Patients With Advanced Colorectal Cancer,,https://ClinicalTrials.gov/show/NCT03946917
clinicaltrials.gov,enzalutamide,679762,P10275,"InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)",WXCXUHSOUPDCQV-UHFFFAOYSA-N,CNC(=O)c1ccc(cc1F)N2C(=S)N(C(=O)C2(C)C)c3ccc(C#N)c(c3)C(F)(F)F,Relacorilant,,,,,,,prostate cancers,Phase 1,,,NCT03674814,Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer,,https://ClinicalTrials.gov/show/NCT03674814
clinicaltrials.gov,enzalutamide,679762,P10275,"InChI=1S/C21H16F4N4O2S/c1-20(2)18(31)28(12-5-4-11(10-26)15(8-12)21(23,24)25)19(32)29(20)13-6-7-14(16(22)9-13)17(30)27-3/h4-9H,1-3H3,(H,27,30)",WXCXUHSOUPDCQV-UHFFFAOYSA-N,CNC(=O)c1ccc(cc1F)N2C(=S)N(C(=O)C2(C)C)c3ccc(C#N)c(c3)C(F)(F)F,Relacorilant,,,,,,,prostate cancers,Phase 1,,,NCT03674814,Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer,,https://ClinicalTrials.gov/show/NCT03674814
clinicaltrials.gov,nivolumab,,Q15116,,,,relatlimab,,,,,,,oesophageal cancers,Phase 1/2,,,NCT03610711,REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer,REACTION,https://ClinicalTrials.gov/show/NCT03610711
clinicaltrials.gov,nivolumab,,Q15116,,,,relatlimab,,,,,,,colorectal cancers,Phase 2,,,NCT03642067,Study of Nivolumab and relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer,,https://ClinicalTrials.gov/show/NCT03642067
clinicaltrials.gov,nivolumab,,Q15116,,,,relatlimab,,,,,,,oesophageal cancers,Phase 1/2,,,NCT03610711,REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer,REACTION,https://ClinicalTrials.gov/show/NCT03610711
clinicaltrials.gov,nivolumab,,Q15116,,,,relatlimab,,,,,,,colorectal cancers,Phase 2,,,NCT03642067,Study of Nivolumab and relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer,,https://ClinicalTrials.gov/show/NCT03642067
clinicaltrials.gov,sirolimus,344,P06730;P08183;P08684;P11712;P33261;P42345;P62942;Q13451;Q53EL6;Q9Y6L6,"InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1",QFJCIRLUMZQUOT-HPLJOQBZSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1O,resveratrol,511498,,"InChI=1S/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1+",LUKBXSAWLPMMSZ-OWOJBTEDSA-N,Oc1ccc(\C=C\c2cc(O)cc(O)c2)cc1,,lymphoma,Phase 2,,,NCT03253913,Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial,RESULT,https://ClinicalTrials.gov/show/NCT03253913
clinicaltrials.gov,vandetanib,551660,O00238;O00444;O14578;O14976;O15197;O43353;O75116;O94804;O95819;P00519;P00533;P04626;P06239;P06241;P07333;P07947;P07948;P07949;P08581;P08631;P09619;P09769;P10721;P11362;P12931;P15735;P16234;P17948;P21709;P21802;P21860;P22455;P22607;P23443;P29317;P29320;P29322;P29323;P29376;P30530;P35590;P35916;P35968;P36507;P36888;P37023;P41240;P42681;P42684;P42685;P49674;P50613;P51451;P51617;P54756;P54760;P54762;P54764;P57058;P57059;P57078;Q02750;Q02763;Q04771;Q04912;Q06187;Q06418;Q08345;Q12851;Q12866;Q13131;Q13163;Q13882;Q15303;Q15375;Q15418;Q15569;Q16659;Q16816;Q16832;Q56UN5;Q59H18;Q5VT25;Q6DT37;Q6PHR2;Q8IVH8;Q8N4C8;Q8NI60;Q8TDR2;Q8WU08;Q92918;Q96D53;Q9BUB5;Q9BYT3;Q9H0K1;Q9H2G2;Q9H3Y6;Q9HBH9;Q9NWZ3;Q9NYL2;Q9UF33;Q9UK32;Q9UKE5;Q9UM73;Q9UQB9;Q9Y2K2;Q9Y4K4;Q9Y5S2;Q9Y6R4,"InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)",UHTHHESEBZOYNR-UHFFFAOYSA-N,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC4CCN(C)CC4,retinoic Acid,,,,,,,neuroblastoma,Phase 1,,,NCT00533169,ZD6474 Alone and in Combination With Retinoic Acid in Pediatric Neuroblastoma,,https://ClinicalTrials.gov/show/NCT00533169
clinicaltrials.gov,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,RG1507,,,,,,,advanced solid cancers,Phase 1,,,NCT00985374,A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT00985374
clinicaltrials.gov,rh IL-12,,,,,,rh IL-2,,,,,,,kidney cancers;lung cancers;soft tissue cancers;breast cancers,Phase 1,,,NCT00005655,Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer,,https://ClinicalTrials.gov/show/NCT00005655
clinicaltrials.gov,HDM201,,,,,,ribociclib,,P11802;Q00534,"InChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28)",RHXHGRAEPCAFML-UHFFFAOYSA-N,CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N4CCNCC4)nc2n1C5CCCC5,,soft tissue cancers,Phase 1/2,,,NCT02343172,Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma,,https://ClinicalTrials.gov/show/NCT02343172
clinicaltrials.gov,navitoclax,1081596,Q07817,"InChI=1S/C47H55ClF3N5O6S3/c1-46(2)20-18-42(34-8-12-37(48)13-9-34)36(31-46)32-55-22-24-56(25-23-55)39-14-10-35(11-15-39)45(57)53-65(60,61)41-16-17-43(44(30-41)64(58,59)47(49,50)51)52-38(19-21-54-26-28-62-29-27-54)33-63-40-6-4-3-5-7-40/h3-17,30,38,52H,18-29,31-33H2,1-2H3,(H,53,57)/t38-/m1/s1",JLYAXFNOILIKPP-KXQOOQHDSA-N,CC1(C)CCC(=C(CN2CCN(CC2)c3ccc(cc3)C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc6ccccc6)c(c4)S(=O)(=O)C(F)(F)F)C1)c7ccc(Cl)cc7,rifampin,779,"P0A8V2,P00575","InChI=1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1",JQXXHWHPUNPDRT-WLSIYKJHSA-N,CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)\C(=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(=O)C)[C@@H]1C)\C)c(\C=N\N5CCN(C)CC5)c(O)c4c3C2=O,,lymphoma,Phase 1,,,NCT01121133,A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax,,https://ClinicalTrials.gov/show/NCT01121133
clinicaltrials.gov,ABT-263,1081596,Q07817,"InChI=1S/C47H55ClF3N5O6S3/c1-46(2)20-18-42(34-8-12-37(48)13-9-34)36(31-46)32-55-22-24-56(25-23-55)39-14-10-35(11-15-39)45(57)53-65(60,61)41-16-17-43(44(30-41)64(58,59)47(49,50)51)52-38(19-21-54-26-28-62-29-27-54)33-63-40-6-4-3-5-7-40/h3-17,30,38,52H,18-29,31-33H2,1-2H3,(H,53,57)/t38-/m1/s1",JLYAXFNOILIKPP-KXQOOQHDSA-N,CC1(C)CCC(=C(CN2CCN(CC2)c3ccc(cc3)C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc6ccccc6)c(c4)S(=O)(=O)C(F)(F)F)C1)c7ccc(Cl)cc7,rituximab,16,P11836,,,,,lymphoma,Phase 1,,,NCT00788684,Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers,,https://ClinicalTrials.gov/show/NCT00788684
clinicaltrials.gov,ACTR707,,,,,,rituximab,16,P11836,,,,,lymphoma,Phase 1,,,NCT03189836,Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma,,https://ClinicalTrials.gov/show/NCT03189836
literature,alisertib,,O14965,"InChI=1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33)",ZLHFILGSQDJULK-UHFFFAOYSA-N,COc1cccc(F)c1C2=NCc3cnc(Nc4ccc(C(=O)O)c(OC)c4)nc3c5ccc(Cl)cc25,rituximab,16,P11836,,,,Patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma,lymphoma,Phase 1,30082475,"Forty-five patients participated. The alisertib RP2D for MR was 50 mg b.i.d. For MRV (n = 32), the RP2D was determined as 40 mg b.i.d. [1 dose-limiting toxicity (DLT) at 40 mg; 2 DLTs at 50 mg]. Drug-related adverse events were reported in 89% of patients, the most common was neutropenia (47%). Seven patients had complete responses (CR), 7 had partial responses (PRs); 9 of 20 (45%) patients at the MRV RP2D responded (4 CRs, 5 PRs), all with non-germinal center B-cell (GCB) diffuse large B-cell lymphoma (DLBCL).",,,,
literature,alisertib,,O14965,"InChI=1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33)",ZLHFILGSQDJULK-UHFFFAOYSA-N,COc1cccc(F)c1C2=NCc3cnc(Nc4ccc(C(=O)O)c(OC)c4)nc3c5ccc(Cl)cc25,rituximab,16,P11836,,,,Patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma,lymphoma,Phase 1,30082475,"Forty-five patients participated. The alisertib RP2D for MR was 50 mg b.i.d. For MRV (n = 32), the RP2D was determined as 40 mg b.i.d. [1 dose-limiting toxicity (DLT) at 40 mg; 2 DLTs at 50 mg]. Drug-related adverse events were reported in 89% of patients, the most common was neutropenia (47%). Seven patients had complete responses (CR), 7 had partial responses (PRs); 9 of 20 (45%) patients at the MRV RP2D responded (4 CRs, 5 PRs), all with non-germinal center B-cell (GCB) diffuse large B-cell lymphoma (DLBCL).",,,,
clinicaltrials.gov,apolizumab,,,,,,rituximab,16,P11836,,,,,lymphoma,Phase 1,,,NCT00022971,Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia,,https://ClinicalTrials.gov/show/NCT00022971
clinicaltrials.gov,BI1206,,,,,,rituximab,16,P11836,,,,,lymphoma,Phase 1/2,,,NCT03571568,A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma,,https://ClinicalTrials.gov/show/NCT03571568
clinicaltrials.gov,BI1206,,,,,,rituximab,16,P11836,,,,,lymphoma,Phase 1/2,,,NCT03571568,A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma,,https://ClinicalTrials.gov/show/NCT03571568
clinicaltrials.gov,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,rituximab,16,P11836,,,,,lymphoma,Phase 2,,,NCT00422799,Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia,,https://ClinicalTrials.gov/show/NCT00422799
literature,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,rituximab,16,P11836,,,,"relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma",lymphoma,Phase 3,21724462,"Between April 10, 2006, and Aug 12, 2008, 676 patients were randomised to receive rituximab (n=340) or bortezomib plus rituximab (n=336). After a median follow-up of 33à9 months (IQR 26à4-39à7), median progression-free survival was 11à0 months (95% CI 9à1-12à0) in the rituximab group and 12à8 months (11à5-15à0) in the bortezomib plus rituximab group (hazard ratio 0à82, 95% CI 0à68-0à99; p=0à039). The magnitude of clinical benefit was not as large as the anticipated prespecified improvement of 33% in progression-free survival. Patients in both groups received a median of five treatment cycles (range 1-5); 245 of 339 (72%) and 237 of 334 (71%) patients in the rituximab and bortezomib plus rituximab groups, respectively, completed five cycles. Of patients who did not complete five cycles, most discontinued early because of disease progression (77 [23%] patients in the rituximab group, and 56 [17%] patients in the bortezomib plus rituximab group). Rates of adverse events of grade 3 or higher (70 [21%] of 339 rituximab-treated patients vs 152 [46%] of 334 bortezomib plus rituximab treated patients), and serious adverse events (37 [11%] patients vs 59 [18%] patients) were lower in the rituximab group than in the combination group. The most common adverse events of grade 3 or higher were neutropenia (15 [4%] patients in the rituximab group and 37 [11%] patients in the bortezomib plus rituximab group), infection (15 [4%] patients and 36 [11%] patients, respectively), diarrhoea (no patients and 25 [7%] patients, respectively), herpes zoster (one [<1%] patient and 12 [4%] patients, respectively), nausea or vomiting (two [<1%] patients and 10 [3%] patients, respectively) and thrombocytopenia (two [<1%] patients and 10 [3%] patients, respectively). No individual serious adverse event was reported by more than three patients in the rituximab group; in the bortezomib plus rituximab group, only pneumonia (seven patients [2%]) and pyrexia (six patients [2%]) were reported in more than five patients. In the bortezomib plus rituximab group 57 (17%) of 334 patients had peripheral neuropathy (including sensory, motor, and sensorimotor neuropathy), including nine (3%) with grade 3 or higher, compared with three (1%) of 339 patients in the rituximab group (no events of grade _3). No patients in the rituximab group but three (1%) patients in the bortezomib plus rituximab group died of adverse events considered at least possibly related to treatment.",,,,
clinicaltrials.gov,CC-90002,,,,,,rituximab,16,P11836,,,,,,Phase 1,,,NCT02367196,"A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers",,https://ClinicalTrials.gov/show/NCT02367196
clinicaltrials.gov,CT-011,,,,,,rituximab,16,P11836,,,,,lymphoma,Phase 2,,,NCT00904722,Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma,,https://ClinicalTrials.gov/show/NCT00904722
literature,dulanermin,,O00220;O14763,,,,rituximab,16,P11836,,,,relapsed indolent B-cell lymphoma,lymphoma,Phase 1b/2,26687959,"Between June 6, 2006, and Feb 15, 2007, 12 patients were enrolled in phase 1b, and between April 4, 2007, and April 20, 2009, 60 patients were enrolled in phase 2, of whom 59 were included in safety analyses and 58 in efficacy analyses. No dose-limiting toxic effects were noted in phase 1b. The most common grade 1-2 adverse events in phase 1b were fatigue (nine; 75%), rash (five; 42%), and chills, decreased appetite, diarrhoea, and nausea (four each; 33%). 19 grade 3 or higher adverse effects were noted in five (42%) patients, with 14 occurring in one patient. After treatment with 8 mg/kg of dulanermin, in six patients the mean serum peak concentration was 80 _g/mL, dropping below the minimum detectable concentration (2 ng/mL) within 24 h after the dose. The mean steady state peak and trough concentrations of rituximab were 461 _g/mL (SD 97.5) and 303 _g/mL (92.8), respectively. In phase 2, eight (14%) of 59 patients experienced 12 grade 3 or higher adverse events. In phase 2, objective responses were noted in 14 of 22 (63.6%, 95% CI 41.8-81.3) patients treated with rituximab only, 16 of 25 (64.0%, 43.1-81.5) treated with dulanermin and rituximab, and one of 11 (9.1%, 0.5-39.0) treated with dulanermin only. The study was terminated early, on May 5, 2010, because of an absence of efficacy in the combination group.",,,,
literature,epratuzumab,,,,,,rituximab,16,P11836,,,,previously untreated follicular lymphoma,lymphoma,Phase 2,23922187,"Therapy was well-tolerated, with toxicities similar to expected with rituximab monotherapy. Fifty-two (88.2%) evaluable patients responded, including 25 complete responses (42.4%) and 27 partial responses (45.8%). At 3 years follow-up, 60% of patients remain in remission. Follicular Lymphoma International Prognostic Index (FLIPI) risk strongly predicted progression-free survival (P = .022).",,,,
clinicaltrials.gov,Hu5F9-G4,,,,,,rituximab,16,P11836,,,,,lymphoma,Phase 1/2,,,NCT02953509,Trial of Hu5F9-G4 in Combination With Rituximab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma,,https://ClinicalTrials.gov/show/NCT02953509
clinicaltrials.gov,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,rituximab,16,P11836,,,,,lymphoma,Phase 2,,,NCT01880567,Phase 2 Ibrutinib + Rituximab in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL),,https://ClinicalTrials.gov/show/NCT01880567
clinicaltrials.gov,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,rituximab,16,P11836,,,,,lymphoma,Phase 2,,,NCT03697512,MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas,MALIBU,https://ClinicalTrials.gov/show/NCT03697512
clinicaltrials.gov,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,rituximab,16,P11836,,,,,lymphoma,Phase 2,,,NCT03697512,MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas,MALIBU,https://ClinicalTrials.gov/show/NCT03697512
literature,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,rituximab,16,P11836,,,,high-risk chronic lymphocytic leukaemia,leukemia,Phase 4,25150798,"Between Feb 28, 2012, and Sept 11, 2012, we enrolled 40 patients with CLL with high-risk disease features, 20 of whom had deletion 17p (del[17p]) or TP53 mutations (16 previously treated, four untreated), 13 had relapsed CLL with deletion 11q (del[11q]), and seven a PFS less than 36 months after first-line chemoimmunotherapy. 18-month PFS in all patients was 78à0% (95% CI 60à6-88à5), whereas in those with a del(17p) or TP53 mutation it was 72à4% (45à6-87à6) Toxicity was mainly mild to moderate in severity (grade 1-2). Diarrhoea occurred in ten (25%) patients (grade 1 in nine patients and grade 2 in one), bleeding events in 14 (33%) patients (eight grade 1 and five grade 2), nausea or vomiting in 15 patients (38%) (ten grade 1 and five grade 2), and fatigue in seven (18%) patients (four grade 1 and three grade 2). Five patients (13%) had grade 3 infections (two lung infections, one upper respiratory tract infection, one sepsis, and one mucositis), and no grade 4 or 5 infections occurred. One patient had grade 4 neutropenia.",,,,
literature,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,rituximab,16,P11836,,,,relapsed or refractory mantle cell lymphoma,lymphoma,Phase 2,26640039,"Between July 15, 2013, and June 30, 2014, 50 patients were enrolled. Median age was 67 years (range 45-86), and the median number of previous regimens was three (range 1-9). At a median follow-up of 16à5 months (IQR 12à09-19à28), 44 (88%, 95% CI 75à7-95à5) patients achieved an objective response, with 22 (44%, 30à0-58à7) patients achieving a complete response, and 22 (44%, 30à0-58à7) a partial response. The only grade 3 adverse event in >=10% of patients was atrial fibrillation, which was noted in six (12%) patients. Grade 4 diarrhoea and neutropenia occurred in one patient each. Adverse events led to discontinuation of therapy in five (10%) patients (atrial fibrillation in three [6%] patients, liver infection in one [2%], and bleeding in one [2%]). Two patients died while on-study from cardiac arrest and septic shock; the latter was deemed possibly related to treatment.",,,,
literature,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,rituximab,16,P11836,,,,younger patients with chronic lymphocytic leukaemia,leukemia,Phase 2,31208944,"Between Oct 23, 2014, and April 23, 2018, 85 patients with chronic lymphocytic leukaemia were enrolled. del(17p) was detected in four (5%) of 83 patients and TP53 mutations were noted in three (4%) of 81 patients; two patients had both del(17p) and TP53 mutations. Median patients' age was 55 years (IQR 50-58). At data cutoff, median follow-up was 16·5 months (IQR 10·6-34·1). A complete response and undetectable minimal residual disease in bone marrow 2 months after the last cycle of ibrutinib plus FCR was achieved by 28 (33%, 95% CI 0·23-0·44) of 85 patients (p=0·0035 compared with a 20% historical value with FCR alone). A best response of undetectable minimal residual disease in bone marrow was achieved by 71 (84%) of 85 patients during the study. One patient had disease progression and one patient died (sudden cardiac death after 17 months of ibrutinib maintenance, assessed as possibly related to ibrutinib). The most common all-grade toxic effects were haematological, including thrombocytopenia in 63 (74%) patients, neutropenia in 53 (62%), and anaemia in 41 (49%). Grade 3 or 4 non-haematological serious adverse events included grade 3 atrial fibrillation in three (4%) patients and grade 3 Pneumocystis jirovecii pneumonia in two (2%).",NCT02251548,,,
clinicaltrials.gov,idelalisib,1059065,O00329,"InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1",IFSDAJWBUCMOAH-HNNXBMFYSA-N,CC[C@H](Nc1ncnc2[nH]cnc12)C3=Nc4cccc(F)c4C(=O)N3c5ccccc5,rituximab,16,P11836,,,,,lymphoma,Phase 2,,,NCT02258529,Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma,,https://ClinicalTrials.gov/show/NCT02258529
literature,idelalisib,1059065,O00329,"InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1",IFSDAJWBUCMOAH-HNNXBMFYSA-N,CC[C@H](Nc1ncnc2[nH]cnc12)C3=Nc4cccc(F)c4C(=O)N3c5ccccc5,rituximab,16,P11836,,,,relapsed chronic lymphocytic leukemia,leukemia,Phase 3,24450857,"The median progression-free survival was 5.5 months in the placebo group and was not reached in the idelalisib group (hazard ratio for progression or death in the idelalisib group, 0.15; P<0.001). Patients receiving idelalisib versus those receiving placebo had improved rates of overall response (81% vs. 13%; odds ratio, 29.92; P<0.001) and overall survival at 12 months (92% vs. 80%; hazard ratio for death, 0.28; P=0.02). Serious adverse events occurred in 40% of the patients receiving idelalisib and rituximab and in 35% of those receiving placebo and rituximab.",,,,
literature,idelalisib,1059065,O00329,"InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1",IFSDAJWBUCMOAH-HNNXBMFYSA-N,CC[C@H](Nc1ncnc2[nH]cnc12)C3=Nc4cccc(F)c4C(=O)N3c5ccccc5,rituximab,16,P11836,,,, treatment-na_ve older patients with chronic lymphocytic leukemia,leukemia,Phase 2,26472751,"The overall response rate (ORR) was 97%, including 19% complete responses. The ORR was 100% in patients with del(17p)/TP53 mutations and 97% in those with unmutated IGHV. Progression-free survival was 83% at 36 months. The most frequent (>30%) adverse events (any grade) were diarrhea (including colitis) (64%), rash (58%), pyrexia (42%), nausea (38%), chills (36%), cough (33%), and fatigue (31%). Elevated alanine transaminase/aspartate transaminase was seen in 67% of patients (23% grade _3). The combination of idelalisib and rituximab was highly active, resulting in durable disease control in treatment-na´ve older patients with CLL. These results support the further development of idelalisib as initial treatment of CLL.",,,,
clinicaltrials.gov,JHL1101,,,,,,rituximab,16,P11836,,,,,lymphoma,Phase 3,,,NCT03670901,A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL),,https://ClinicalTrials.gov/show/NCT03670901
clinicaltrials.gov,JHL1101,,,,,,rituximab,16,P11836,,,,,lymphoma,Phase 3,,,NCT03670901,A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL),,https://ClinicalTrials.gov/show/NCT03670901
clinicaltrials.gov,lenalidomide,718,O14920,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,Nc1cccc2C(=O)N(Cc12)C3CCC(=O)NC3=O,rituximab,16,P11836,,,,,leukemia;lymphoma,Phase 2,,,NCT00759603,Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia,,https://ClinicalTrials.gov/show/NCT00759603
clinicaltrials.gov,lenalidomide,718,O14920,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,Nc1cccc2C(=O)N(Cc12)C3CCC(=O)NC3=O,rituximab,16,P11836,,,,,leukemia;lymphoma,Phase 2,,,NCT00609869,Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab,,https://ClinicalTrials.gov/show/NCT00609869
clinicaltrials.gov,lenalidomide,718,O14920,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,Nc1cccc2C(=O)N(Cc12)C3CCC(=O)NC3=O,rituximab,16,P11836,,,,,lymphoma,Phase 1/2,,,NCT00294632,Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell Lymphoma,,https://ClinicalTrials.gov/show/NCT00294632
literature,lenalidomide,718,O14920,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,Nc1cccc2C(=O)N(Cc12)C3CCC(=O)NC3=O,rituximab,16,P11836,,,,elderly patients with relapsed or refractory diffuse large B-cell lymphoma,lymphoma,Phase 2,21859554,"A total of 23 patients with a median of three prior treatments (range, 2 to 8) were included. The overall response rate (CR + PR) at the end of the induction phase was 35% (n = 8). Ten patients (7 CR, 1 PR, and 2 SD patients) were eligible for lenalidomide maintenance and 8 of these patients achieved a CR. Adverse events were manageable and the most common included neutropenia and thrombocytopenia.",,,,
literature,lenalidomide,718,O14920,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,Nc1cccc2C(=O)N(Cc12)C3CCC(=O)NC3=O,rituximab,16,P11836,,,,elapsed or refractory mantle-cell lymphoma,lymphoma,Phase 1/2,22677155,"52 patients were enrolled between Feb 10, 2006 and July 30, 2009, 14 in phase 1 and 44 (including six patients who received the MTD of lenalidomide in the phase 1 portion) in phase 2. The MTD was 20 mg lenalidomide. One patient who was treated with 25 mg lenalidomide developed a grade 4 non-neutropenic infection and died. In the phase 2 portion of the study, grade 3-4 haematological toxicities included neutropenia (29 patients), lymphopenia (16 patients), leucopenia (13 patients), and thrombocytopenia (ten patients). There were only two episodes of febrile neutropenia. Among 44 patients in phase 2, 25 (57%) had an overall response: 16 (36%) had a complete response and nine (20%) had a partial response. The median response duration was 18à9 months (95% CI 17à0 months to not reached [NR]). The median progression-free survival was 11à1 months (95% CI 8à3 to 24à9 months), and the median overall survival was 24à3 months (19à8 months to NR). Five of 14 patients who had received bortezomib treatment before enrolment achieved an overall response.",,,,
literature,lenalidomide,718,O14920,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,Nc1cccc2C(=O)N(Cc12)C3CCC(=O)NC3=O,rituximab,16,P11836,,,,Initial Treatment for Mantle-Cell Lymphoma,lymphoma,Phase 2,26535512,"A total of 38 participants were enrolled at four centers from July 2011 through April 2014. The median age was 65 years. On the basis of the Mantle Cell Lymphoma International Prognostic Index scores, the proportions of participants with low-risk, intermediate-risk, and high-risk disease at baseline were similar (34%, 34%, and 32%, respectively). The most common grade 3 or 4 adverse events were neutropenia (in 50% of the patients), rash (in 29%), thrombocytopenia (in 13%), an inflammatory syndrome (""tumor flare"") (in 11%), anemia (in 11%), serum sickness (in 8%), and fatigue (in 8%). At the median follow-up of 30 months (through February 2015), the overall response rate among the participants who could be evaluated was 92% (95% confidence interval [CI], 78 to 98), and the complete response rate was 64% (95% CI, 46 to 79); median progression-free survival had not been reached. The 2-year progression-free survival was estimated to be 85% (95% CI, 67 to 94), and the 2-year overall survival 97% (95% CI, 79 to 99). A response to treatment was associated with improvement in quality of life.",,,,
clinicaltrials.gov,lirilumab,,P43626;P43627;P43628,,,,rituximab,16,P11836,,,,,leukemia,Phase 2,,,NCT02481297,"Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients",,https://ClinicalTrials.gov/show/NCT02481297
literature,navitoclax,1081596,Q07817,"InChI=1S/C47H55ClF3N5O6S3/c1-46(2)20-18-42(34-8-12-37(48)13-9-34)36(31-46)32-55-22-24-56(25-23-55)39-14-10-35(11-15-39)45(57)53-65(60,61)41-16-17-43(44(30-41)64(58,59)47(49,50)51)52-38(19-21-54-26-28-62-29-27-54)33-63-40-6-4-3-5-7-40/h3-17,30,38,52H,18-29,31-33H2,1-2H3,(H,53,57)/t38-/m1/s1",JLYAXFNOILIKPP-KXQOOQHDSA-N,CC1(C)CCC(=C(CN2CCN(CC2)c3ccc(cc3)C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc6ccccc6)c(c4)S(=O)(=O)C(F)(F)F)C1)c7ccc(Cl)cc7,rituximab,16,P11836,,,,previously untreated B-cell chronic lymphocytic leukemia,leukemia,Phase 2,25797560,"One hundred and eighteen patients with chronic lymphocytic leukemia (CLL) were randomized to receive eight weekly doses of rituximab (arm A), eight weekly doses of rituximab plus daily navitoclax for 12 weeks (arm B) or eight weekly doses of rituximab plus daily navitoclax until disease progression or unacceptable toxicity (arm C). Investigator-assessed overall response rates (complete [CR] and partial [PR]) were 35% (arm A), 55% (arm B, p = 0.19 vs. A) and 70% (arm C, p = 0.0034 vs. A). Patients with del(17p) or high levels of BCL2 had significantly better clinical responses when treated with navitoclax. Navitoclax in combination with rituximab was well tolerated as initial therapy for patients with CLL, yielded higher response rates than rituximab alone and resulted in prolonged progression-free survival with treatment beyond 12 weeks.",,,,
literature,navitoclax,1081596,Q07817,"InChI=1S/C47H55ClF3N5O6S3/c1-46(2)20-18-42(34-8-12-37(48)13-9-34)36(31-46)32-55-22-24-56(25-23-55)39-14-10-35(11-15-39)45(57)53-65(60,61)41-16-17-43(44(30-41)64(58,59)47(49,50)51)52-38(19-21-54-26-28-62-29-27-54)33-63-40-6-4-3-5-7-40/h3-17,30,38,52H,18-29,31-33H2,1-2H3,(H,53,57)/t38-/m1/s1",JLYAXFNOILIKPP-KXQOOQHDSA-N,CC1(C)CCC(=C(CN2CCN(CC2)c3ccc(cc3)C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc6ccccc6)c(c4)S(=O)(=O)C(F)(F)F)C1)c7ccc(Cl)cc7,rituximab,16,P11836,,,,relapsed or refractory CD20+ lymphoid malignancies,lymphoma,Phase 1,25942994,"Twenty-nine patients were enrolled across three dose-escalation cohorts and a safety expansion cohort (250_mg/d navitoclax). The combination was well tolerated. Common toxicities were mild diarrhoea (79%) and nausea (72%). Grade 4 thrombocytopenia occurred in 17% of patients (dose limiting at 325_mg/d). CD19(+) counts were severely reduced, while CD3(+) cells (~ 20%) and serum immunoglobulin M levels (~ 33%) were also reduced during the first year. The maximum tolerated dose for navitoclax in combination was 250_mg/d. Pharmacokinetic analyses revealed no apparent interactions between the drugs. The response rate in patients with follicular lymphoma was 9/12, including five complete responses. All five patients with CLL/small lymphocytic leukaemia achieved partial responses. One of nine patients with aggressive lymphoma responded. The addition of rituximab to navitoclax 250_mg/d is safe; the combination demonstrates higher response rates for low-grade lymphoid cancers than observed for either agent alone in previous Phase 1 trials.",,,,
clinicaltrials.gov,obatoclax,58297,P10415;Q92843;Q07817;Q9HD36;Q16548;Q07820,"InChI=1S/C20H19N3O/c1-12-8-13(2)21-16(12)10-19-20(24-3)11-18(23-19)17-9-14-6-4-5-7-15(14)22-17/h4-11,21-22H,1-3H3/b19-10-",RFTSSZJZXOSICM-GRSHGNNSSA-N,COC1=CC(=N/C/1=C\c2[nH]c(C)cc2C)c3cc4ccccc4[nH]3,rituximab,16,P11836,,,,,lymphoma,Phase 2,,,NCT00427856,Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL),,https://ClinicalTrials.gov/show/NCT00427856
clinicaltrials.gov,pembrolizumab,,Q15116,,,,rituximab,16,P11836,,,,,lymphoma,Phase 2,,,NCT03630042,Investigating the Safety and Efficacy of Rituximab and pembrolizumab in Relapsed/Refractory Waldenstr√∂m's Macroglobulinaemia,PembroWM,https://ClinicalTrials.gov/show/NCT03630042
clinicaltrials.gov,pembrolizumab,,Q15116,,,,rituximab,16,P11836,,,,,lymphoma,Phase 2,,,NCT03630042,Investigating the Safety and Efficacy of Rituximab and pembrolizumab in Relapsed/Refractory Waldenstr√∂m's Macroglobulinaemia,PembroWM,https://ClinicalTrials.gov/show/NCT03630042
literature,pentostatin,615,P00813,"InChI=1S/C11H16N4O4/c16-3-8-6(17)1-9(19-8)15-5-14-10-7(18)2-12-4-13-11(10)15/h4-9,16-18H,1-3H2,(H,12,13)/t6-,7+,8+,9+/m0/s1",FPVKHBSQESCIEP-JQCXWYLXSA-N,OC[C@H]1O[C@H](C[C@@H]1O)n2cnc3[C@H](O)CNC=Nc23,rituximab,16,P11836,,,,previously untreated patients with B-cell chronic lymphocytic leukemia,leukemia,Phase 2,20187101,"The OR rate was 76%, with 9 CRs (27%), 5 nodular partial responses, and 11 partial responses (PRs) reported. At the time of last follow-up, 29 of 33 patients were still alive at a median follow-up of 14 months (range, 1-34.8 months). Four (12%) patients experienced grade 3 or higher hematologic toxicity, and 5 (15%) experienced grade 3 or higher nonhematologic toxicity. Comparison of this trial with the previous PCR trial demonstrated that patients treated with PCR had a higher OR rate (91% vs 76%) and CR rate (41% vs 27%) compared with patients treated with PR. The median treatment-free survival for all accrued patients was notably longer in patients treated with PCR compared with PR (30 months vs 16 months).",,,,
literature,pidilizumab,,,,,,rituximab,16,P11836,,,,relapsed follicular lymphoma,lymphoma,Phase 2,24332512,"We enrolled 32 patients between Jan 13, 2010, and Jan 20, 2012. Median follow-up was 15.4 months (IQR 10.1-21.0). The combination of pidilizumab and rituximab was well tolerated, with no autoimmune or treatment-related adverse events of grade 3 or 4. The most common adverse events of grade 1 were anaemia (14 patients) and fatigue (13 patients), and the most common adverse event of grade 2 was respiratory infection (five patients). Of the 29 patients evaluable for activity, 19 (66%) achieved an objective response: complete responses were noted in 15 (52%) patients and partial responses in four (14%).",,,,
clinicaltrials.gov,rituximab,16,P11836,,,,rituximab,16,P11836,,,,"Kaposi Sarcoma|Castleman's Disease, Multicentric",,Phase 1,,,NCT03864419,,,
clinicaltrials.gov,TQB2303,,,,,,rituximab,16,P11836,,,,,lymphoma,Phase 3,,,NCT03777085,Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL),,https://ClinicalTrials.gov/show/NCT03777085
clinicaltrials.gov,TQB2303,,,,,,rituximab,16,P11836,,,,,lymphoma,Phase 3,,,NCT03777085,Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL),,https://ClinicalTrials.gov/show/NCT03777085
clinicaltrials.gov,urelumab,,Q07011,,,,rituximab,16,P11836,,,,,lymphoma,Phase 1,,,NCT01775631,Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma,,https://ClinicalTrials.gov/show/NCT01775631
clinicaltrials.gov,venetoclax,1150189,P10415,"InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)",LQBVNQSMGBZMKD-UHFFFAOYSA-N,CC1(C)CCC(=C(C1)c2ccc(Cl)cc2)CN3CCN(CC3)c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c(c5)N(=O)=O)c(Oc7cnc8[nH]ccc8c7)c4,rituximab,16,P11836,,,,,leukemia,Phase 2,,,NCT03455517,Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia,VeRitAs,https://ClinicalTrials.gov/show/NCT03455517
literature,venetoclax,1150189,P10415,"InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)",LQBVNQSMGBZMKD-UHFFFAOYSA-N,CC1(C)CCC(=C(C1)c2ccc(Cl)cc2)CN3CCN(CC3)c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c(c5)N(=O)=O)c(Oc7cnc8[nH]ccc8c7)c4,rituximab,16,P11836,,,,relapsed or refractory chronic lymphocytic leukaemia,leukemia,Phase 1b,28089635,"Between Aug 6, 2012, and May 28, 2014, we enrolled 49 patients. Common grade 1-2 toxicities included upper respiratory tract infections (in 28 [57%] of 49 patients), diarrhoea (27 [55%]), and nausea (25 [51%]). Grade 3-4 adverse events occurred in 37 (76%) of 49 patients; most common were neutropenia (26 [53%]), thrombocytopenia (eight [16%]), anaemia (seven [14%]), febrile neutropenia (six [12%]), and leucopenia (six [12%]). The most common serious adverse events were pyrexia (six [12%]), febrile neutropenia (five [10%]), lower respiratory tract infection, and pneumonia (each three [6%]). Clinical tumour lysis syndrome occurred in two patients (resulting in one death) who initiated venetoclax at 50 mg. After enhancing tumour lysis syndrome prophylaxis measures and commencing venetoclax at 20 mg, clinical tumour lysis syndrome did not occur. The maximum tolerated dose was not identified; the recommended phase 2 dose of venetoclax in combination with rituximab was 400 mg. Overall, 42 (86%) of 49 patients achieved a response, including a complete response in 25 (51%) of 49 patients. 2 year estimates for progression-free survival and ongoing response were 82% (95% CI 66-91) and 89% (95% CI 72-96), respectively. Negative marrow minimal residual disease was attained in 20 (80%) of 25 complete responders and 28 (57%) of 49 patients overall. 13 responders ceased all therapy; among these all 11 minimal residual disease-negative responders remain progression-free off therapy. Two with minimal residual disease-positive complete response progressed after 24 months off therapy and re-attained response after re-initiation of venetoclax.",,,,
clinicaltrials.gov,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,RO5452802,,,,,,,lung cancers,Phase 2,,,NCT01801111,A Study of RO5424802 in Patients With Non-Small Cell Lung Cancer Who Have ALK Mutation and Failed Crizotinib Treatment,,https://ClinicalTrials.gov/show/NCT01801111
clinicaltrials.gov,atezolizumab,,Q9NZQ7,,,,RO6870810,,,,,,,ovarian cancers;breast cancers,Phase 1,,,NCT03292172,"A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer",,https://ClinicalTrials.gov/show/NCT03292172
clinicaltrials.gov,atezolizumab,,Q9NZQ7,,,,RO6958688,,,,,,,advanced solid cancers,Phase 1,,,NCT02650713,"A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors",,https://ClinicalTrials.gov/show/NCT02650713
clinicaltrials.gov,atezolizumab,,Q9NZQ7,,,,RO7009789,,,,,,,advanced solid cancers,Phase 1,,,NCT02304393,A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and Metastatic Solid Tumors,,https://ClinicalTrials.gov/show/NCT02304393
clinicaltrials.gov,emactuzumab,,,,,,RO7009789,,,,,,,advanced solid cancers,Phase 1,,,NCT02760797,A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT02760797
clinicaltrials.gov,pembrolizumab,,Q15116,,,,romidepsin,761764,Q96DB2;Q9UBN7;Q92769;Q13547;Q9UKV0;Q9UQL6;Q8WUI4;P56524;O15379;Q969S8;Q9BY41,"InChI=1S/C25H39N3O6S2/c1-6-19-23(31)28-21(15(4)5)25(33)34-17(9-7-8-10-35)11-16(29)12-18(14(2)3)22(30)27-20(13-36)24(32)26-19/h6-7,9,14-15,17-18,20-21,35-36H,8,10-13H2,1-5H3,(H,26,32)(H,27,30)(H,28,31)/b9-7+,19-6-/t17-,18-,20-,21+/m1/s1",UPCFDQLGZODPFB-BXJZLCHMSA-N,C\C=C\1/NC(=O)[C@@H](CS)NC(=O)[C@H](CC(=O)C[C@H](OC(=O)[C@@H](NC1=O)C(C)C)\C=C\CCS)C(C)C,,lymphoma,Phase 1/2,,,NCT03278782,Study of pembrolizumab (MK-3475) in Combination With Romidepsin,,https://ClinicalTrials.gov/show/NCT03278782
clinicaltrials.gov,Tenalisib,,,,,,romidepsin,761764,Q96DB2;Q9UBN7;Q92769;Q13547;Q9UKV0;Q9UQL6;Q8WUI4;P56524;O15379;Q969S8;Q9BY41,"InChI=1S/C25H39N3O6S2/c1-6-19-23(31)28-21(15(4)5)25(33)34-17(9-7-8-10-35)11-16(29)12-18(14(2)3)22(30)27-20(13-36)24(32)26-19/h6-7,9,14-15,17-18,20-21,35-36H,8,10-13H2,1-5H3,(H,26,32)(H,27,30)(H,28,31)/b9-7+,19-6-/t17-,18-,20-,21+/m1/s1",UPCFDQLGZODPFB-BXJZLCHMSA-N,C\C=C\1/NC(=O)[C@@H](CS)NC(=O)[C@H](CC(=O)C[C@H](OC(=O)[C@@H](NC1=O)C(C)C)\C=C\CCS)C(C)C,,lymphoma,Phase 1/2,,,NCT03770000,Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma,,https://ClinicalTrials.gov/show/NCT03770000
clinicaltrials.gov,Tenalisib,,,,,,romidepsin,761764,Q96DB2;Q9UBN7;Q92769;Q13547;Q9UKV0;Q9UQL6;Q8WUI4;P56524;O15379;Q969S8;Q9BY41,"InChI=1S/C25H39N3O6S2/c1-6-19-23(31)28-21(15(4)5)25(33)34-17(9-7-8-10-35)11-16(29)12-18(14(2)3)22(30)27-20(13-36)24(32)26-19/h6-7,9,14-15,17-18,20-21,35-36H,8,10-13H2,1-5H3,(H,26,32)(H,27,30)(H,28,31)/b9-7+,19-6-/t17-,18-,20-,21+/m1/s1",UPCFDQLGZODPFB-BXJZLCHMSA-N,C\C=C\1/NC(=O)[C@@H](CS)NC(=O)[C@H](CC(=O)C[C@H](OC(=O)[C@@H](NC1=O)C(C)C)\C=C\CCS)C(C)C,,lymphoma,Phase 1/2,,,NCT03770000,Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma,,https://ClinicalTrials.gov/show/NCT03770000
clinicaltrials.gov,ABBV-181,,,,,,rovalpituzumab,,,,,,,advanced solid cancers,Phase 1,,,NCT03000257,A Study of ABBV-181 in Participants With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT03000257
clinicaltrials.gov,atezolizumab,,Q9NZQ7,,,,rucaparib,757098,P09874;Q9UGN5;Q9Y6F1,"InChI=1S/C19H18FN3O/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15/h2-5,8-9,21,23H,6-7,10H2,1H3,(H,22,24)",HMABYWSNWIZPAG-UHFFFAOYSA-N,CNCc1ccc(cc1)c2[nH]c3cc(F)cc4C(=O)NCCc2c34,,female cancers;ovarian cancers,Phase 1,,,NCT03101280,"A Combination Study of Rucaparib and Atezolizumab in Participants With Solid Tumors and Advanced Gynecologic Cancers, With a Focus on ovarian Cancers",,https://ClinicalTrials.gov/show/NCT03101280
clinicaltrials.gov,ipatasertib,1017408,P31751;Q9Y243;P31749,"InChI=1S/C24H32ClN5O2/c1-15(2)26-13-19(17-4-6-18(25)7-5-17)24(32)30-10-8-29(9-11-30)23-21-16(3)12-20(31)22(21)27-14-28-23/h4-7,14-16,19-20,26,31H,8-13H2,1-3H3/t16-,19-,20-/m1/s1",GRZXWCHAXNAUHY-NSISKUIASA-N,CC(C)NC[C@@H](C(=O)N1CCN(CC1)c2ncnc3[C@H](O)C[C@@H](C)c23)c4ccc(Cl)cc4,rucaparib,757098,P09874;Q9UGN5;Q9Y6F1,"InChI=1S/C19H18FN3O/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15/h2-5,8-9,21,23H,6-7,10H2,1H3,(H,22,24)",HMABYWSNWIZPAG-UHFFFAOYSA-N,CNCc1ccc(cc1)c2[nH]c3cc(F)cc4C(=O)NCCc2c34,Breast Cancer|Prostate Cancer|Ovarian Cancer,,Phase 1/2,,,NCT03840200,,,
clinicaltrials.gov,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,ruxolitinib,974392,O00238;O00444;O00506;O14730;O14920;O14936;O14976;O15075;O15197;O43293;O43318;O60674;O75116;O75385;O75460;O75582;O75676;O75716;O94768;O95747;O96013;P00519;P04629;P07949;P0C264;P10721;P15056;P15735;P19784;P23458;P29320;P29376;P29597;P32298;P33981;P36507;P45983;P45985;P46734;P48729;P49760;P50613;P51617;P51956;P52333;P53350;P53355;P57078;P68400;Q02156;Q02750;Q07912;Q09013;Q12851;Q13233;Q13237;Q13464;Q13554;Q13555;Q13557;Q13627;Q13873;Q14012;Q14164;Q14680;Q15349;Q15418;Q15746;Q15835;Q16288;Q16620;Q16816;Q2M2I8;Q52WX2;Q56UN5;Q5S007;Q6PHR2;Q6ZN16;Q7KZI7;Q7L7X3;Q86Y07;Q86Z02;Q8IU85;Q8IYT8;Q8N568;Q8NFD2;Q8TDX7;Q8WTQ7;Q92630;Q96NX5;Q96SB4;Q99759;Q9BRS2;Q9BVS4;Q9C098;Q9H093;Q9H2K8;Q9H2X6;Q9H422;Q9H4B4;Q9HAZ1;Q9HBH9;Q9NQU5;Q9NSY1;Q9NYY3;Q9P286;Q9P289;Q9UBF8;Q9UEE5;Q9UEW8;Q9UHD2;Q9UIK4;Q9UK32;Q9UL54;Q9UM73;Q9UPE1;Q9UQB9;Q9UQM7;Q9Y2H9;Q9Y2K2;Q9Y2U5,"InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1",HFNKQEVNSGCOJV-OAHLLOKOSA-N,N#CC[C@H](C1CCCC1)n2cc(cn2)c3ncnc4[nH]ccc34,,lymphoma,Phase 1,,,NCT02613598,Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma,,https://ClinicalTrials.gov/show/NCT02613598
clinicaltrials.gov,itacitinib,1947652,P23458,"InChI=1S/C26H23F4N9O/c27-20-18(1-7-32-22(20)26(28,29)30)24(40)37-9-3-17(4-10-37)38-13-25(14-38,5-6-31)39-12-16(11-36-39)21-19-2-8-33-23(19)35-15-34-21/h1-2,7-8,11-12,15,17H,3-5,9-10,13-14H2,(H,33,34,35)",KTBSXLIQKWEBRB-UHFFFAOYSA-N,Fc1c(ccnc1C(F)(F)F)C(=O)N2CCC(CC2)N3CC(CC#N)(C3)n4cc(cn4)c5ncnc6[nH]ccc56,ruxolitinib,974392,O00238;O00444;O00506;O14730;O14920;O14936;O14976;O15075;O15197;O43293;O43318;O60674;O75116;O75385;O75460;O75582;O75676;O75716;O94768;O95747;O96013;P00519;P04629;P07949;P0C264;P10721;P15056;P15735;P19784;P23458;P29320;P29376;P29597;P32298;P33981;P36507;P45983;P45985;P46734;P48729;P49760;P50613;P51617;P51956;P52333;P53350;P53355;P57078;P68400;Q02156;Q02750;Q07912;Q09013;Q12851;Q13233;Q13237;Q13464;Q13554;Q13555;Q13557;Q13627;Q13873;Q14012;Q14164;Q14680;Q15349;Q15418;Q15746;Q15835;Q16288;Q16620;Q16816;Q2M2I8;Q52WX2;Q56UN5;Q5S007;Q6PHR2;Q6ZN16;Q7KZI7;Q7L7X3;Q86Y07;Q86Z02;Q8IU85;Q8IYT8;Q8N568;Q8NFD2;Q8TDX7;Q8WTQ7;Q92630;Q96NX5;Q96SB4;Q99759;Q9BRS2;Q9BVS4;Q9C098;Q9H093;Q9H2K8;Q9H2X6;Q9H422;Q9H4B4;Q9HAZ1;Q9HBH9;Q9NQU5;Q9NSY1;Q9NYY3;Q9P286;Q9P289;Q9UBF8;Q9UEE5;Q9UEW8;Q9UHD2;Q9UIK4;Q9UK32;Q9UL54;Q9UM73;Q9UPE1;Q9UQB9;Q9UQM7;Q9Y2H9;Q9Y2K2;Q9Y2U5,"InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1",HFNKQEVNSGCOJV-OAHLLOKOSA-N,N#CC[C@H](C1CCCC1)n2cc(cn2)c3ncnc4[nH]ccc34,,,Phase 2,,,NCT03144687,A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis,,https://ClinicalTrials.gov/show/NCT03144687
clinicaltrials.gov,nilotinib,457827,O15197;O43570;O94804;P00519;P00915;P00918;P04049;P06239;P06241;P07333;P07451;P07947;P07948;P07949;P08631;P09619;P09769;P10721;P11274;P12931;P15056;P16234;P21709;P22748;P23280;P29317;P29320;P29322;P29323;P35218;P35590;P41240;P42684;P42685;P43166;P45983;P45984;P49759;P51451;P53779;P54753;P54756;P54760;P54762;P54764;Q02763;Q08345;Q13163;Q15759;Q16288;Q16539;Q16620;Q16790;Q16832;Q59H18;Q7L7X3;Q8TBX8;Q92918;Q9H2K8;Q9HAZ1;Q9NYL2;Q9UF33;Q9ULX7;Q9Y5S2,"InChI=1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37)",HHZIURLSWUIHRB-UHFFFAOYSA-N,Cc1cn(cn1)c2cc(NC(=O)c3ccc(C)c(Nc4nccc(n4)c5cccnc5)c3)cc(c2)C(F)(F)F,ruxolitinib,974392,O00238;O00444;O00506;O14730;O14920;O14936;O14976;O15075;O15197;O43293;O43318;O60674;O75116;O75385;O75460;O75582;O75676;O75716;O94768;O95747;O96013;P00519;P04629;P07949;P0C264;P10721;P15056;P15735;P19784;P23458;P29320;P29376;P29597;P32298;P33981;P36507;P45983;P45985;P46734;P48729;P49760;P50613;P51617;P51956;P52333;P53350;P53355;P57078;P68400;Q02156;Q02750;Q07912;Q09013;Q12851;Q13233;Q13237;Q13464;Q13554;Q13555;Q13557;Q13627;Q13873;Q14012;Q14164;Q14680;Q15349;Q15418;Q15746;Q15835;Q16288;Q16620;Q16816;Q2M2I8;Q52WX2;Q56UN5;Q5S007;Q6PHR2;Q6ZN16;Q7KZI7;Q7L7X3;Q86Y07;Q86Z02;Q8IU85;Q8IYT8;Q8N568;Q8NFD2;Q8TDX7;Q8WTQ7;Q92630;Q96NX5;Q96SB4;Q99759;Q9BRS2;Q9BVS4;Q9C098;Q9H093;Q9H2K8;Q9H2X6;Q9H422;Q9H4B4;Q9HAZ1;Q9HBH9;Q9NQU5;Q9NSY1;Q9NYY3;Q9P286;Q9P289;Q9UBF8;Q9UEE5;Q9UEW8;Q9UHD2;Q9UIK4;Q9UK32;Q9UL54;Q9UM73;Q9UPE1;Q9UQB9;Q9UQM7;Q9Y2H9;Q9Y2K2;Q9Y2U5,"InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1",HFNKQEVNSGCOJV-OAHLLOKOSA-N,N#CC[C@H](C1CCCC1)n2cc(cn2)c3ncnc4[nH]ccc34,,leukemia,Phase 1/2,,,NCT02973711,A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML,,https://ClinicalTrials.gov/show/NCT02973711
clinicaltrials.gov,apatinib,1384455,P35968,"InChI=1S/C24H23N5O.CH4O3S/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18;1-5(2,3)4/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30);1H3,(H,2,3,4)",FYJROXRIVQPKRY-UHFFFAOYSA-N,CS(=O)(=O)O.O=C(Nc1ccc(cc1)C2(CCCC2)C#N)c3cccnc3NCc4ccncc4,S-1,,,,,,,head and neck cancers,Phase 2,,,NCT02943252,The Clinical Study of Apatinib Plus S1 for Patients With Advanced Non-squamous Head and Neck Cancer,,https://ClinicalTrials.gov/show/NCT02943252
clinicaltrials.gov,apatinib,1384455,P35968,"InChI=1S/C24H23N5O.CH4O3S/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18;1-5(2,3)4/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30);1H3,(H,2,3,4)",FYJROXRIVQPKRY-UHFFFAOYSA-N,CS(=O)(=O)O.O=C(Nc1ccc(cc1)C2(CCCC2)C#N)c3cccnc3NCc4ccncc4,S-1,,,,,,,stomach cancers,Phase 2,,,NCT02525237,Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric Cancer,,https://ClinicalTrials.gov/show/NCT02525237
clinicaltrials.gov,apatinib,1384455,P35968,"InChI=1S/C24H23N5O.CH4O3S/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18;1-5(2,3)4/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30);1H3,(H,2,3,4)",FYJROXRIVQPKRY-UHFFFAOYSA-N,CS(=O)(=O)O.O=C(Nc1ccc(cc1)C2(CCCC2)C#N)c3cccnc3NCc4ccncc4,S-1,,,,,,,pancreatic cancers,Phase 2,,,NCT03662035,Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer,ASPC,https://ClinicalTrials.gov/show/NCT03662035
clinicaltrials.gov,apatinib,1384455,P35968,"InChI=1S/C24H23N5O.CH4O3S/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18;1-5(2,3)4/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30);1H3,(H,2,3,4)",FYJROXRIVQPKRY-UHFFFAOYSA-N,CS(=O)(=O)O.O=C(Nc1ccc(cc1)C2(CCCC2)C#N)c3cccnc3NCc4ccncc4,S-1,,,,,,,pancreatic cancers,Phase 2,,,NCT03662035,Apatinib Combined With S-1 in the Second-line Treatment of Advanced Pancreatic Cancer,ASPC,https://ClinicalTrials.gov/show/NCT03662035
clinicaltrials.gov,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,S-1,,,,,,,advanced solid cancers,Phase 1,,,NCT01128998,Sorafenib Plus S-1 in Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT01128998
clinicaltrials.gov,TAS-114,,,,,,S-1,,,,,,,advanced solid cancers,Phase 1,,,NCT02454062,A Trial of TAS-114 in Combination With S-1,,https://ClinicalTrials.gov/show/NCT02454062
clinicaltrials.gov,TAS-114,,,,,,S-1,,,,,,,lung cancers,Phase 2,,,NCT02855125,A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1,,https://ClinicalTrials.gov/show/NCT02855125
clinicaltrials.gov,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,Sandostatin LAR Depot,,,,,,,,Phase 4,,,NCT01789281,Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.,,https://ClinicalTrials.gov/show/NCT01789281
clinicaltrials.gov,pilaralisib,1348813,Q92569;Q8WYR1;P48736;P42338;P42336;P27986;O00459;O00329,"InChI=1S/C25H25ClN6O4S/c1-25(2,27)24(33)28-15-7-6-8-17(13-15)37(34,35)32-23-22(29-19-9-4-5-10-20(19)30-23)31-21-14-16(36-3)11-12-18(21)26/h4-14H,27H2,1-3H3,(H,28,33)(H,29,31)(H,30,32)",QINPEPAQOBZPOF-UHFFFAOYSA-N,COc1ccc(Cl)c(Nc2nc3ccccc3nc2NS(=O)(=O)c4cccc(NC(=O)C(C)(C)N)c4)c1,SAR245409,,,,,,,,Phase 1/2,,,NCT01587040,Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen,,https://ClinicalTrials.gov/show/NCT01587040
clinicaltrials.gov,cediranib,106760,O00444;O14976;O15197;O43353;O75460;O94804;O95819;P00519;P00533;P04626;P06239;P06241;P07333;P07947;P07948;P07949;P08581;P08631;P09619;P09769;P10721;P11362;P12931;P16234;P17948;P21709;P21802;P21860;P22455;P22607;P29320;P29322;P29376;P30530;P35590;P35916;P35968;P36507;P36888;P36896;P36897;P42684;P42685;P49674;P51451;P54760;Q02763;Q04771;Q04912;Q06187;Q06418;Q08345;Q12851;Q12866;Q13043;Q13163;Q13882;Q15303;Q15375;Q16832;Q56UN5;Q8IVH8;Q8N4C8;Q8TDR2;Q92918;Q96GD4;Q9BQI3;Q9BYT3;Q9H0K1;Q9H2G2;Q9H2K8;Q9P289;Q9UF33;Q9UKE5;Q9UL54;Q9UM73;Q9UQB9;Q9Y4K4,"InChI=1S/C25H27FN4O3/c1-16-12-17-19(29-16)6-7-21(24(17)26)33-25-18-13-22(31-2)23(14-20(18)27-15-28-25)32-11-5-10-30-8-3-4-9-30/h6-7,12-15,29H,3-5,8-11H2,1-2H3",XXJWYDDUDKYVKI-UHFFFAOYSA-N,COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN5CCCC5,saracatinib,503045,P00519;P12931,"InChI=1S/C27H32ClN5O5/c1-32-6-8-33(9-7-32)10-13-35-19-14-21-24(23(15-19)38-18-4-11-34-12-5-18)27(30-16-29-21)31-25-20(28)2-3-22-26(25)37-17-36-22/h2-3,14-16,18H,4-13,17H2,1H3,(H,29,30,31)",OUKYUETWWIPKQR-UHFFFAOYSA-N,CN1CCN(CCOc2cc(OC3CCOCC3)c4c(Nc5c(Cl)ccc6OCOc56)ncnc4c2)CC1,,advanced solid cancers,Phase 1,,,NCT00475956,Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours,,https://ClinicalTrials.gov/show/NCT00475956
clinicaltrials.gov,entinostat,312087,Q96DB2;Q9UBN7;Q92769;Q13547;Q9UKV0;Q9UQL6;Q8WUI4;P56524;O15379;Q969S8;Q9BY41,"InChI=1S/C21H20N4O3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-24-21(27)28-14-16-4-3-11-23-12-16/h1-12H,13-14,22H2,(H,24,27)(H,25,26)",INVTYAOGFAGBOE-UHFFFAOYSA-N,Nc1ccccc1NC(=O)c2ccc(CNC(=O)OCc3cccnc3)cc2,sargramostim,,P15509;P32927,,,,,leukemia,Phase 2,,,NCT00462605,MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia,,https://ClinicalTrials.gov/show/NCT00462605
clinicaltrials.gov,pembrolizumab,,Q15116,,,,sargramostim,,P15509;P32927,,,,,other,Phase 2,,,NCT02703714,pembrolizumab and GM-CSF in Biliary Cancer,,https://ClinicalTrials.gov/show/NCT02703714
clinicaltrials.gov,osimertinib,1371518,P00533;P04626;P21860;Q15303;P00533,"InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)",DUYJMQONPNNFPI-UHFFFAOYSA-N,COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2nccc(n2)c3cn(C)c4ccccc34,savolitinib,,,,,,,lung cancers,Phase 2,,,NCT03778229,Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib,SAVANNAH,https://ClinicalTrials.gov/show/NCT03778229
clinicaltrials.gov,osimertinib,1371518,P00533;P04626;P21860;Q15303;P00533,"InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)",DUYJMQONPNNFPI-UHFFFAOYSA-N,COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2nccc(n2)c3cn(C)c4ccccc34,savolitinib,,,,,,,lung cancers,Phase 2,,,NCT03778229,Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib,SAVANNAH,https://ClinicalTrials.gov/show/NCT03778229
clinicaltrials.gov,MK-1966,,,,,,SD-101,,,,,,,,Phase 1,,,NCT02731742,Dose Evaluation of MK-1966 in Combination With SD-101 in Participants With Advanced Malignancies (MK-1966-001),,https://ClinicalTrials.gov/show/NCT02731742
clinicaltrials.gov,ACTR087,,,,,,SEA-BCMA,,,,,,,multiple myeloma,Phase 1,,,NCT03266692,Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma,,https://ClinicalTrials.gov/show/NCT03266692
clinicaltrials.gov,LMB-100,,,,,,SEL-110,,,,,,,mesothelioma,Phase 1,,,NCT03436732,Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma,,https://ClinicalTrials.gov/show/NCT03436732
clinicaltrials.gov,venetoclax,1150189,P10415,"InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)",LQBVNQSMGBZMKD-UHFFFAOYSA-N,CC1(C)CCC(=C(C1)c2ccc(Cl)cc2)CN3CCN(CC3)c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c(c5)N(=O)=O)c(Oc7cnc8[nH]ccc8c7)c4,Selinexor,,,,,,,,,,,NCT03955783,Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies,,https://ClinicalTrials.gov/show/NCT03955783
clinicaltrials.gov,AZD-2014,,P42345,"InChI=1S/C25H31N5O4/c1-16-13-30(14-17(2)34-16)25-27-23-20(24(28-25)29-8-10-33-11-9-29)5-6-21(26-23)18-4-7-22(32-3)19(12-18)15-31/h4-7,12,16-17,31H,8-11,13-15H2,1-3H3/t16-,17+",RFSMUFRPPYDYRD-CALCHBBNSA-N,COc1ccc(cc1CO)c2ccc3c(nc(nc3n2)N4C[C@@H](C)O[C@@H](C)C4)N5CCOCC5,selumetinib,646570,Q02750;P36507,"InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)",CYOHGALHFOKKQC-UHFFFAOYSA-N,Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO,,breast cancers;lung cancers,Phase 1/2,,,NCT02583542,A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers,TORCMEK,https://ClinicalTrials.gov/show/NCT02583542
clinicaltrials.gov,cetuximab,9,P00533,,,,selumetinib,646570,Q02750;P36507,"InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)",CYOHGALHFOKKQC-UHFFFAOYSA-N,Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO,,bowel cancers,Phase 1,,,NCT01287130,AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer,,https://ClinicalTrials.gov/show/NCT01287130
literature,MK-2206,,P31751;Q9Y243;P31749,"InChI=1S/C25H21N5O/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31)",ULDXWLCXEDXJGE-UHFFFAOYSA-N,NC1(CCC1)c2ccc(cc2)c3nc4C=CN5C(=O)NN=C5c4cc3c6ccccc6,selumetinib,646570,Q02750;P36507,"InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)",CYOHGALHFOKKQC-UHFFFAOYSA-N,Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO,colorectal cancer,bowel cancers,Phase 2,25637165,"Common toxicities were gastrointestinal, hepatic, dermatologic, and hematologic. Of 21 patients enrolled, there were no objective responses. Target modulation did not achieve the pre-specified criteria of dual 70 % inhibition of pERK and pAKT levels in paired tumor biopsies.",,,,
clinicaltrials.gov,MK-8353,,,,,,selumetinib,646570,Q02750;P36507,"InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)",CYOHGALHFOKKQC-UHFFFAOYSA-N,Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO,,advanced solid cancers,Phase 1,,,NCT03745989,Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014),,https://ClinicalTrials.gov/show/NCT03745989
clinicaltrials.gov,MK-8353,,,,,,selumetinib,646570,Q02750;P36507,"InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)",CYOHGALHFOKKQC-UHFFFAOYSA-N,Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO,,advanced solid cancers,Phase 1,,,NCT03745989,Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014),,https://ClinicalTrials.gov/show/NCT03745989
clinicaltrials.gov,osimertinib,1371518,P00533;P04626;P21860;Q15303;P00533,"InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)",DUYJMQONPNNFPI-UHFFFAOYSA-N,COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc2nccc(n2)c3cn(C)c4ccccc34,selumetinib,646570,Q02750;P36507,"InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)",CYOHGALHFOKKQC-UHFFFAOYSA-N,Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO,,lung cancers,Phase 2,,,NCT03392246,A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naêève Advanced EGFR Mutant Lung Cancer,,https://ClinicalTrials.gov/show/NCT03392246
clinicaltrials.gov,apatinib,1384455,P35968,"InChI=1S/C24H23N5O.CH4O3S/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18;1-5(2,3)4/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30);1H3,(H,2,3,4)",FYJROXRIVQPKRY-UHFFFAOYSA-N,CS(=O)(=O)O.O=C(Nc1ccc(cc1)C2(CCCC2)C#N)c3cccnc3NCc4ccncc4,SHR-1210,841778,,"InChI=1S/C23H27FN4O2/c1-4-27(5-2)10-11-28-9-8-19-21(23(28)30)14(3)20(25-19)13-17-16-12-15(24)6-7-18(16)26-22(17)29/h6-7,12-13,25H,4-5,8-11H2,1-3H3,(H,26,29)/b17-13-",GKEYKDOLBLYGRB-LGMDPLHJSA-N,CCN(CC)CCN1CCc2[nH]c(\C=C\3/C(=O)Nc4ccc(F)cc34)c(C)c2C1=O,,stomach cancers;liver cancers,Phase 1/2,,,NCT02942329,Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer,,https://ClinicalTrials.gov/show/NCT02942329
clinicaltrials.gov,ipilimumab,1238537,P16410,,,,SHR-1210,841778,,"InChI=1S/C23H27FN4O2/c1-4-27(5-2)10-11-28-9-8-19-21(23(28)30)14(3)20(25-19)13-17-16-12-15(24)6-7-18(16)26-22(17)29/h6-7,12-13,25H,4-5,8-11H2,1-3H3,(H,26,29)/b17-13-",GKEYKDOLBLYGRB-LGMDPLHJSA-N,CCN(CC)CCN1CCc2[nH]c(\C=C\3/C(=O)Nc4ccc(F)cc34)c(C)c2C1=O,,lung cancers,Phase 1,,,NCT03527251,Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC,SEQUENCE,https://ClinicalTrials.gov/show/NCT03527251
clinicaltrials.gov,ipilimumab,1238537,P16410,,,,SHR-1210,841778,,"InChI=1S/C23H27FN4O2/c1-4-27(5-2)10-11-28-9-8-19-21(23(28)30)14(3)20(25-19)13-17-16-12-15(24)6-7-18(16)26-22(17)29/h6-7,12-13,25H,4-5,8-11H2,1-3H3,(H,26,29)/b17-13-",GKEYKDOLBLYGRB-LGMDPLHJSA-N,CCN(CC)CCN1CCc2[nH]c(\C=C\3/C(=O)Nc4ccc(F)cc34)c(C)c2C1=O,,lung cancers,Phase 1,,,NCT03527251,Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC,SEQUENCE,https://ClinicalTrials.gov/show/NCT03527251
clinicaltrials.gov,nimotuzumab,,,,,,SHR-1210,841778,,"InChI=1S/C23H27FN4O2/c1-4-27(5-2)10-11-28-9-8-19-21(23(28)30)14(3)20(25-19)13-17-16-12-15(24)6-7-18(16)26-22(17)29/h6-7,12-13,25H,4-5,8-11H2,1-3H3,(H,26,29)/b17-13-",GKEYKDOLBLYGRB-LGMDPLHJSA-N,CCN(CC)CCN1CCc2[nH]c(\C=C\3/C(=O)Nc4ccc(F)cc34)c(C)c2C1=O,,oesophageal cancers,Phase 2,,,NCT03766178,Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT03766178
clinicaltrials.gov,nimotuzumab,,,,,,SHR-1210,841778,,"InChI=1S/C23H27FN4O2/c1-4-27(5-2)10-11-28-9-8-19-21(23(28)30)14(3)20(25-19)13-17-16-12-15(24)6-7-18(16)26-22(17)29/h6-7,12-13,25H,4-5,8-11H2,1-3H3,(H,26,29)/b17-13-",GKEYKDOLBLYGRB-LGMDPLHJSA-N,CCN(CC)CCN1CCc2[nH]c(\C=C\3/C(=O)Nc4ccc(F)cc34)c(C)c2C1=O,,oesophageal cancers,Phase 2,,,NCT03766178,Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT03766178
clinicaltrials.gov,SHR7390,,,,,,SHR-1210,841778,,"InChI=1S/C23H27FN4O2/c1-4-27(5-2)10-11-28-9-8-19-21(23(28)30)14(3)20(25-19)13-17-16-12-15(24)6-7-18(16)26-22(17)29/h6-7,12-13,25H,4-5,8-11H2,1-3H3,(H,26,29)/b17-13-",GKEYKDOLBLYGRB-LGMDPLHJSA-N,CCN(CC)CCN1CCc2[nH]c(\C=C\3/C(=O)Nc4ccc(F)cc34)c(C)c2C1=O,,advanced solid cancers,Phase 1,,,NCT03182673,The Study of SHR7390 in Combination With SHR-1210 in Patients With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT03182673
clinicaltrials.gov,SHR-1501,,,,,,SHR-1316,,,,,,,,,,,NCT03995472,A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors,,https://ClinicalTrials.gov/show/NCT03995472
clinicaltrials.gov,SHR3680,,,,,,SHR2554,,,,,,,prostate cancers,Phase 1/2,,,NCT03741712,A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC,,https://ClinicalTrials.gov/show/NCT03741712
clinicaltrials.gov,SHR3680,,,,,,SHR2554,,,,,,,prostate cancers,Phase 1/2,,,NCT03741712,A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC,,https://ClinicalTrials.gov/show/NCT03741712
clinicaltrials.gov,Pyrotinib,,,,,,SHR6390,,,,,,,,,,,NCT03993964,Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer,,https://ClinicalTrials.gov/show/NCT03993964
clinicaltrials.gov,SHR-1210,841778,,"InChI=1S/C23H27FN4O2/c1-4-27(5-2)10-11-28-9-8-19-21(23(28)30)14(3)20(25-19)13-17-16-12-15(24)6-7-18(16)26-22(17)29/h6-7,12-13,25H,4-5,8-11H2,1-3H3,(H,26,29)/b17-13-",GKEYKDOLBLYGRB-LGMDPLHJSA-N,CCN(CC)CCN1CCc2[nH]c(\C=C\3/C(=O)Nc4ccc(F)cc34)c(C)c2C1=O,SHR6390,,,,,,,colorectal cancers;liver cancers;lung cancers,Phase 1/2,,,NCT03601598,"A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC",,https://ClinicalTrials.gov/show/NCT03601598
clinicaltrials.gov,SHR-1210,841778,,"InChI=1S/C23H27FN4O2/c1-4-27(5-2)10-11-28-9-8-19-21(23(28)30)14(3)20(25-19)13-17-16-12-15(24)6-7-18(16)26-22(17)29/h6-7,12-13,25H,4-5,8-11H2,1-3H3,(H,26,29)/b17-13-",GKEYKDOLBLYGRB-LGMDPLHJSA-N,CCN(CC)CCN1CCc2[nH]c(\C=C\3/C(=O)Nc4ccc(F)cc34)c(C)c2C1=O,SHR6390,,,,,,,colorectal cancers;liver cancers;lung cancers,Phase 1/2,,,NCT03601598,"A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC",,https://ClinicalTrials.gov/show/NCT03601598
clinicaltrials.gov,metformin,1855,P43304;P03923;O95299;O00217;P03901;P56556;P03886;O95139;O00483;Q86Y39;P17568;P03891;O75306;P03915;P51970;O43674;P03905;P03897;O14561;O15239;O43181;O43676;O43677;O43678;O43920;O75251;O75380;O75438;O75489;O95167;O95168;O95169;O95178;O95182;O95298;O96000;P19404;P28331;P49821;P56181;Q16718;Q16795;Q8N183;Q9BU61;Q9NRX3;Q9NX14;Q9P032;Q9P0J0;Q9UI09;Q9Y375;Q9Y6M9,"InChI=1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)",XZWYZXLIPXDOLR-UHFFFAOYSA-N,CN(C)C(=N)NC(=N)N,simvastatin,370,P04035,"InChI=1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1",RYMZZMVNJRMUDD-HGQWONQESA-N,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12,,bladder cancers,Phase 2,,,NCT02360618,Metformin and Simvastatin Use in Bladder Cancer,,https://ClinicalTrials.gov/show/NCT02360618
clinicaltrials.gov,metformin,1855,P43304;P03923;O95299;O00217;P03901;P56556;P03886;O95139;O00483;Q86Y39;P17568;P03891;O75306;P03915;P51970;O43674;P03905;P03897;O14561;O15239;O43181;O43676;O43677;O43678;O43920;O75251;O75380;O75438;O75489;O95167;O95168;O95169;O95178;O95182;O95298;O96000;P19404;P28331;P49821;P56181;Q16718;Q16795;Q8N183;Q9BU61;Q9NRX3;Q9NX14;Q9P032;Q9P0J0;Q9UI09;Q9Y375;Q9Y6M9,"InChI=1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)",XZWYZXLIPXDOLR-UHFFFAOYSA-N,CN(C)C(=N)NC(=N)N,simvastatin,370,P04035,"InChI=1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1",RYMZZMVNJRMUDD-HGQWONQESA-N,CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@@H]12,,prostate cancers,Phase 2,,,NCT01561482,Study of Metformin With Simvastatin for Men With Prostate Carcinoma,,https://ClinicalTrials.gov/show/NCT01561482
clinicaltrials.gov,IBI101,,,,,,sintilimab,,,,,,,advanced solid cancers,Phase 1,,,NCT03758001,First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT03758001
clinicaltrials.gov,IBI101,,,,,,sintilimab,,,,,,,advanced solid cancers,Phase 1,,,NCT03758001,First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT03758001
clinicaltrials.gov,IBI310,,,,,,sintilimab,,,,,,,advanced solid cancers,Phase 1,,,NCT03545971,A Study of IBI310 in Treatment of Patients With Advanced Solid Tumors.,,https://ClinicalTrials.gov/show/NCT03545971
clinicaltrials.gov,IBI310,,,,,,sintilimab,,,,,,,advanced solid cancers,Phase 1,,,NCT03545971,A Study of IBI310 in Treatment of Patients With Advanced Solid Tumors.,,https://ClinicalTrials.gov/show/NCT03545971
clinicaltrials.gov,afatinib,755714,O14578;O14976;O15197;O43353;O94804;P00519;P00533;P04626;P06239;P08581;P08631;P12931;P15735;P21860;P30530;P36888;P42681;P42685;P45984;P49674;P51451;P51617;P53779;Q13163;Q13627;Q15303;Q16539;Q16816;Q52WX2;Q8NE63;Q92630;Q9BUB5;Q9H2G2;Q9HBH9;Q9UEE5;Q9UF33;Q9UK32;Q9Y463,"InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1",ULXXDDBFHOBEHA-CWDCEQMOSA-N,CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]4CCOC4,sirolimus,344,P06730;P08183;P08684;P11712;P33261;P42345;P62942;Q13451;Q53EL6;Q9Y6L6,"InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1",QFJCIRLUMZQUOT-HPLJOQBZSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1O,,lung cancers,Phase 1,,,NCT00993499,Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune__) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib,,https://ClinicalTrials.gov/show/NCT00993499
clinicaltrials.gov,epacadostat,1265058,P14902,"InChI=1S/C11H13BrFN7O4S/c12-7-5-6(1-2-8(7)13)17-11(18-21)9-10(20-24-19-9)15-3-4-16-25(14,22)23/h1-2,5,16,21H,3-4H2,(H,15,20)(H,17,18)(H2,14,22,23)",FBKMWOJEPMPVTQ-UHFFFAOYSA-N,NS(=O)(=O)NCCNc1nonc1\C(=N\O)\Nc2ccc(F)c(Br)c2,sirolimus,344,P06730;P08183;P08684;P11712;P33261;P42345;P62942;Q13451;Q53EL6;Q9Y6L6,"InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1",QFJCIRLUMZQUOT-HPLJOQBZSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1O,,advanced solid cancers;lung cancers,Phase 1,,,NCT03217669,Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy,,https://ClinicalTrials.gov/show/NCT03217669
clinicaltrials.gov,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,sirolimus,344,P06730;P08183;P08684;P11712;P33261;P42345;P62942;Q13451;Q53EL6;Q9Y6L6,"InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1",QFJCIRLUMZQUOT-HPLJOQBZSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1O,,,Phase 2,,,NCT01962896,A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors,,https://ClinicalTrials.gov/show/NCT01962896
clinicaltrials.gov,ganetespib,,P07900;P08238,"InChI=1S/C20H20N4O3/c1-11(2)14-9-15(18(26)10-17(14)25)19-21-22-20(27)24(19)13-4-5-16-12(8-13)6-7-23(16)3/h4-11,25-26H,1-3H3,(H,22,27)",RVAQIUULWULRNW-UHFFFAOYSA-N,CC(C)c1cc(C2=NNC(=O)N2c3ccc4c(ccn4C)c3)c(O)cc1O,sirolimus,344,P06730;P08183;P08684;P11712;P33261;P42345;P62942;Q13451;Q53EL6;Q9Y6L6,"InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1",QFJCIRLUMZQUOT-HPLJOQBZSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1O,,soft tissue cancers,Phase 1/2,,,NCT02008877,SARC023: Ganetespib and Sirolimos in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors),,https://ClinicalTrials.gov/show/NCT02008877
literature,gefitinib,701,O14578;O14976;O15197;O43293;O43353;O75676;O94768;O94804;O96017;P00519;P00533;P04626;P06239;P07948;P07949;P08581;P08631;P09769;P10721;P12931;P15735;P21709;P21860;P29320;P29322;P29376;P30530;P31152;P36888;P42681;P42684;P42685;P45984;P48730;P49674;P50613;P51451;P51617;P53779;P54756;P54760;P54762;Q09013;Q13163;Q15139;Q15303;Q16659;Q16816;Q52WX2;Q56UN5;Q86V86;Q8N4C8;Q8NE63;Q8TBX8;Q99759;Q9BUB5;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NWZ3;Q9UBE8;Q9UEE5;Q9UF33;Q9UKE5;Q9UNQ0;Q9Y2U5;Q9Y616,"InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)",XGALLCVXEZPNRQ-UHFFFAOYSA-N,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN4CCOCC4,sirolimus,344,P06730;P08183;P08684;P11712;P33261;P42345;P62942;Q13451;Q53EL6;Q9Y6L6,"InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1",QFJCIRLUMZQUOT-HPLJOQBZSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1O,adults with recurrent malignant glioma,brain cancers,Phase 1,16467100,"Thirty-four patients with progressive disease after prior radiation therapy and chemotherapy were enrolled, including 29 (85%) with glioblastoma multiforme and 5 (15%) with anaplastic glioma. The MTD was 500 mg of gefitinib plus 5 mg of sirolimus for patients not on EIAEDs and 1,000 mg of gefitinib plus 10 mg of sirolimus for patients on EIAEDs. DLTs included mucositis, diarrhea, rash, thrombocytopenia, and hypertriglyceridemia. Gefitinib exposure was not affected by sirolimus administration but was significantly lowered by concurrent EIAED use. Two patients (6%) achieved a partial radiographic response, and 13 patients (38%) achieved stable disease.",,,,
clinicaltrials.gov,PLX3397,,,,,,sirolimus,344,P06730;P08183;P08684;P11712;P33261;P42345;P62942;Q13451;Q53EL6;Q9Y6L6,"InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1",QFJCIRLUMZQUOT-HPLJOQBZSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1O,,soft tissue cancers,Phase 1/2,,,NCT02584647,PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors,PLX3397,https://ClinicalTrials.gov/show/NCT02584647
clinicaltrials.gov,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,sirolimus,344,P06730;P08183;P08684;P11712;P33261;P42345;P62942;Q13451;Q53EL6;Q9Y6L6,"InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1",QFJCIRLUMZQUOT-HPLJOQBZSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1O,,advanced solid cancers,Phase 1,,,NCT00509613,Phase 1 Study With Sorafenib and Sirolimus,,https://ClinicalTrials.gov/show/NCT00509613
clinicaltrials.gov,sunitinib,1055,O00238;O00444;O00506;O14578;O14730;O14757;O14965;O14976;O15075;O15111;O15146;O15197;O15530;O43172;O43283;O43293;O43318;O60285;O60674;O75116;O75385;O75460;O75582;O75676;O75716;O75914;O94768;O94804;O94806;O94921;O95747;O95819;O95835;O96013;O96017;P00519;P04629;P06213;P06239;P06241;P07332;P07333;P07947;P07948;P07949;P08069;P08581;P08631;P09619;P09769;P0C264;P10721;P11362;P11802;P12931;P14616;P15735;P16234;P16591;P17252;P17948;P19525;P19784;P21802;P22455;P22607;P23443;P23458;P27448;P29320;P29376;P29597;P30291;P30530;P31751;P32298;P33981;P35590;P35916;P35968;P36507;P36888;P42679;P42684;P42685;P45984;P45985;P46734;P48729;P48730;P49674;P49759;P49760;P50613;P51451;P51617;P51812;P51955;P52333;P52564;P53355;P53779;P54646;P54756;P54760;P54762;P57058;P57059;P57078;P68400;P78356;P78362;P78368;P80192;P80370;Q00535;Q00536;Q00537;Q02750;Q04759;Q05397;Q06187;Q06418;Q07002;Q07912;Q08345;Q08881;Q12809;Q12851;Q12852;Q12866;Q13043;Q13131;Q13163;Q13164;Q13188;Q13464;Q13470;Q13523;Q13546;Q13554;Q13555;Q13557;Q13627;Q13873;Q13882;Q14012;Q14164;Q14289;Q14680;Q15139;Q15208;Q15349;Q15375;Q15418;Q15746;Q15831;Q15835;Q16288;Q16512;Q16513;Q16566;Q16584;Q16620;Q16816;Q16832;Q2M2I8;Q32MK0;Q52WX2;Q56UN5;Q5S007;Q6PHR2;Q6XUX3;Q6ZN16;Q7KZI7;Q7L7X3;Q86UE8;Q86V86;Q86YV6;Q86Z02;Q8IU85;Q8IVH8;Q8IWQ3;Q8IY84;Q8IYT8;Q8N4C8;Q8N568;Q8N5S9;Q8N752;Q8NE63;Q8NEV4;Q8NFD2;Q8TDC3;Q8TDR2;Q8TDX7;Q8WTQ7;Q8WXR4;Q92630;Q92772;Q92918;Q96BR1;Q96GD4;Q96L34;Q96NX5;Q96RR4;Q96SB4;Q99755;Q99759;Q9BRS2;Q9BUB5;Q9BVS4;Q9BXA7;Q9BYT3;Q9BZL6;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K2;Q9H2K8;Q9H2X6;Q9H422;Q9HAZ1;Q9HBH9;Q9HCP0;Q9NQU5;Q9NRH2;Q9NRM7;Q9NSY1;Q9NWZ3;Q9NYY3;Q9P0L2;Q9P1W9;Q9P286;Q9P289;Q9P2K8;Q9UEE5;Q9UEW8;Q9UF33;Q9UHD2;Q9UIK4;Q9UK32;Q9UKE5;Q9UKI8;Q9UM73;Q9UPE1;Q9UPZ9;Q9UQB9;Q9UQM7;Q9Y2H1;Q9Y2H9;Q9Y2U5;Q9Y463;Q9Y4K4;Q9Y616;Q9Y6E0;Q9Y6M4;Q9Y6R4,"InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-",WINHZLLDWRZWRT-ATVHPVEESA-N,CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C\2/C(=O)Nc3ccc(F)cc23)c1C,sirolimus,344,P06730;P08183;P08684;P11712;P33261;P42345;P62942;Q13451;Q53EL6;Q9Y6L6,"InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1",QFJCIRLUMZQUOT-HPLJOQBZSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1O,,advanced solid cancers,Phase 1,,,NCT00402415,Study of Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors Non-Curable With Standard Therapy,,https://ClinicalTrials.gov/show/NCT00402415
clinicaltrials.gov,sunitinib,1055,O00238;O00444;O00506;O14578;O14730;O14757;O14965;O14976;O15075;O15111;O15146;O15197;O15530;O43172;O43283;O43293;O43318;O60285;O60674;O75116;O75385;O75460;O75582;O75676;O75716;O75914;O94768;O94804;O94806;O94921;O95747;O95819;O95835;O96013;O96017;P00519;P04629;P06213;P06239;P06241;P07332;P07333;P07947;P07948;P07949;P08069;P08581;P08631;P09619;P09769;P0C264;P10721;P11362;P11802;P12931;P14616;P15735;P16234;P16591;P17252;P17948;P19525;P19784;P21802;P22455;P22607;P23443;P23458;P27448;P29320;P29376;P29597;P30291;P30530;P31751;P32298;P33981;P35590;P35916;P35968;P36507;P36888;P42679;P42684;P42685;P45984;P45985;P46734;P48729;P48730;P49674;P49759;P49760;P50613;P51451;P51617;P51812;P51955;P52333;P52564;P53355;P53779;P54646;P54756;P54760;P54762;P57058;P57059;P57078;P68400;P78356;P78362;P78368;P80192;P80370;Q00535;Q00536;Q00537;Q02750;Q04759;Q05397;Q06187;Q06418;Q07002;Q07912;Q08345;Q08881;Q12809;Q12851;Q12852;Q12866;Q13043;Q13131;Q13163;Q13164;Q13188;Q13464;Q13470;Q13523;Q13546;Q13554;Q13555;Q13557;Q13627;Q13873;Q13882;Q14012;Q14164;Q14289;Q14680;Q15139;Q15208;Q15349;Q15375;Q15418;Q15746;Q15831;Q15835;Q16288;Q16512;Q16513;Q16566;Q16584;Q16620;Q16816;Q16832;Q2M2I8;Q32MK0;Q52WX2;Q56UN5;Q5S007;Q6PHR2;Q6XUX3;Q6ZN16;Q7KZI7;Q7L7X3;Q86UE8;Q86V86;Q86YV6;Q86Z02;Q8IU85;Q8IVH8;Q8IWQ3;Q8IY84;Q8IYT8;Q8N4C8;Q8N568;Q8N5S9;Q8N752;Q8NE63;Q8NEV4;Q8NFD2;Q8TDC3;Q8TDR2;Q8TDX7;Q8WTQ7;Q8WXR4;Q92630;Q92772;Q92918;Q96BR1;Q96GD4;Q96L34;Q96NX5;Q96RR4;Q96SB4;Q99755;Q99759;Q9BRS2;Q9BUB5;Q9BVS4;Q9BXA7;Q9BYT3;Q9BZL6;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K2;Q9H2K8;Q9H2X6;Q9H422;Q9HAZ1;Q9HBH9;Q9HCP0;Q9NQU5;Q9NRH2;Q9NRM7;Q9NSY1;Q9NWZ3;Q9NYY3;Q9P0L2;Q9P1W9;Q9P286;Q9P289;Q9P2K8;Q9UEE5;Q9UEW8;Q9UF33;Q9UHD2;Q9UIK4;Q9UK32;Q9UKE5;Q9UKI8;Q9UM73;Q9UPE1;Q9UPZ9;Q9UQB9;Q9UQM7;Q9Y2H1;Q9Y2H9;Q9Y2U5;Q9Y463;Q9Y4K4;Q9Y616;Q9Y6E0;Q9Y6M4;Q9Y6R4,"InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-",WINHZLLDWRZWRT-ATVHPVEESA-N,CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C\2/C(=O)Nc3ccc(F)cc23)c1C,sirolimus,344,P06730;P08183;P08684;P11712;P33261;P42345;P62942;Q13451;Q53EL6;Q9Y6L6,"InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1",QFJCIRLUMZQUOT-HPLJOQBZSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1O,,advanced solid cancers,Phase 1,,,NCT00583063,Interaction Study of Rapamycin and Sunitinib in Patients With Advanced Cancers,,https://ClinicalTrials.gov/show/NCT00583063
clinicaltrials.gov,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,SOM230,1054651,P30872;P30874;P32745;P35346,"InChI=1S/C58H66N10O9/c59-27-13-12-22-46-52(69)64-47(30-38-23-25-42(26-24-38)76-36-39-16-6-2-7-17-39)53(70)66-49(31-37-14-4-1-5-15-37)57(74)68-35-43(77-58(75)61-29-28-60)33-50(68)55(72)67-51(40-18-8-3-9-19-40)56(73)65-48(54(71)63-46)32-41-34-62-45-21-11-10-20-44(41)45/h1-11,14-21,23-26,34,43,46-51,62H,12-13,22,27-33,35-36,59-60H2,(H,61,75)(H,63,71)(H,64,69)(H,65,73)(H,66,70)(H,67,72)/t43-,46+,47-,48-,49-,50+,51-/m0/s1",,,,other,Phase 1,,,NCT01590199,Evaluate Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs,MACS2002,https://ClinicalTrials.gov/show/NCT01590199
clinicaltrials.gov,buparlisib,962639,O00329;O00459;P27986;P42336;P42338;P48736;Q8WYR1;Q92569,"InChI=1S/C18H21F3N6O2/c19-18(20,21)13-9-15(22)23-11-12(13)14-10-16(26-1-5-28-6-2-26)25-17(24-14)27-3-7-29-8-4-27/h9-11H,1-8H2,(H2,22,23)",CWHUFRVAEUJCEF-UHFFFAOYSA-N,Nc1cc(c(cn1)c2cc(nc(n2)N3CCOCC3)N4CCOCC4)C(F)(F)F,sonidegib,1835744,Q99835,"InChI=1S/C26H26F3N3O3.2H3O4P/c1-16-14-32(15-17(2)34-16)24-12-9-20(13-30-24)31-25(33)23-6-4-5-22(18(23)3)19-7-10-21(11-8-19)35-26(27,28)29;2*1-5(2,3)4/h4-13,16-17H,14-15H2,1-3H3,(H,31,33);2*(H3,1,2,3,4)/t16-,17+;;",RWIVSVMMGFFZIJ-VWDRLOGHSA-N,C[C@@H]1CN(C[C@H](C)O1)c2ccc(NC(=O)c3cccc(c3C)c4ccc(OC(F)(F)F)cc4)cn2.OP(=O)(O)O.OP(=O)(O)O,,skin cancers,not specified,,,NCT02303041,Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT02303041
clinicaltrials.gov,pembrolizumab,,Q15116,,,,sonidegib,1835744,Q99835,"InChI=1S/C26H26F3N3O3.2H3O4P/c1-16-14-32(15-17(2)34-16)24-12-9-20(13-30-24)31-25(33)23-6-4-5-22(18(23)3)19-7-10-21(11-8-19)35-26(27,28)29;2*1-5(2,3)4/h4-13,16-17H,14-15H2,1-3H3,(H,31,33);2*(H3,1,2,3,4)/t16-,17+;;",RWIVSVMMGFFZIJ-VWDRLOGHSA-N,C[C@@H]1CN(C[C@H](C)O1)c2ccc(NC(=O)c3cccc(c3C)c4ccc(OC(F)(F)F)cc4)cn2.OP(=O)(O)O.OP(=O)(O)O,,,,,,NCT04007744,Sonidegib and pembrolizumab in Treating Patients With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT04007744
literature,AMG 386,,Q15389;O15123,,,,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,metastatic clear cell carcinoma of the kidney,kidney cancers,Phase 2,22692704,"A total of 152 patients were randomized. Median PFS was 9.0, 8.5, and 9.0 months in arms A, B, and C, respectively (hazard ratio for arms A and B vs arm C, 0.88; 95% confidence interval [CI], 0.60-1.30; P = .523). The objective response rate (95% CI) for arms A, B, and C, respectively, was 38% (25%-53%), 37% (24%-52%), and 25% (14%-40%). Among 30 patients in arm C who had disease progression and subsequently received open-label AMG 386 at 10 mg/kg qw, the objective response rate was 3% (95% CI, 0%-17%). Frequently occurring adverse events (AEs) included diarrhea (arms A/B/C, 70%/67%/56%), palmar-plantar erythrodysesthesia syndrome (52%/47%/54%), alopecia (50%/45%/50%), and hypertension (42%/49%/46%). Fifteen patients had grade 4 AEs (arms A/B/C, n = 3/7/5); 4 had fatal AEs (n = 2/1/1), with 1 (abdominal pain, arm B) considered possibly related to AMG 386.",,,,
clinicaltrials.gov,ascorbic acid,49811,,"InChI=1S/C6H8O6/c7-1-2(8)5-3(9)4(10)6(11)12-5/h2,5,7-10H,1H2/t2-,5+/m0/s1",CIWBSHSKHKDKBQ-JLAZNSOCSA-N,OC[C@H](O)[C@H]1OC(=O)C(=C1O)O,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,,liver cancers,Phase 1/2,,,NCT01754987,A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective,,https://ClinicalTrials.gov/show/NCT01754987
clinicaltrials.gov,BBI503,,,,,,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,,liver cancers;advanced solid cancers,Phase 1,,,NCT02354898,"A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma",,https://ClinicalTrials.gov/show/NCT02354898
clinicaltrials.gov,bevacizumab,11,P15692,,,,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,,brain cancers;central nervous system cancers,Phase 2,,,NCT00621686,Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme,,https://ClinicalTrials.gov/show/NCT00621686
clinicaltrials.gov,bevacizumab,11,P15692,,,,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,,ovarian cancers;female cancers,Phase 2,,,NCT00436215,"Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer",,https://ClinicalTrials.gov/show/NCT00436215
clinicaltrials.gov,CC-122,,,,,,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,,liver cancers,Phase 1,,,NCT02323906,Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer,,https://ClinicalTrials.gov/show/NCT02323906
clinicaltrials.gov,cetuximab,9,P00533,,,,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,,bowel cancers,Phase 2,,,NCT00326495,BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer,,https://ClinicalTrials.gov/show/NCT00326495
literature,cetuximab,9,P00533,,,,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,Metastatic colorectal cancer,bowel cancers,not specified,21248446,"Partial response was higher in cetuximab-sorafenib (EN), which constituted 33.3% compared to 17.6% in the cetuximab group (P = 0.44). Progression-free survival had a statistically higher significant difference in wild K-ras compared to mutant K-ras cases (P = .0001). Median overall survival was seven and five months in the (EN) and (E) groups respectively (P = 0.49).",,,,
clinicaltrials.gov,DKN-01,,,,,,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,,liver cancers,Phase 1/2,,,NCT03645980,DKN-01 Inhibition in Advanced Liver Cancer,,https://ClinicalTrials.gov/show/NCT03645980
clinicaltrials.gov,DKN-01,,,,,,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,,liver cancers,Phase 1/2,,,NCT03645980,DKN-01 Inhibition in Advanced Liver Cancer,,https://ClinicalTrials.gov/show/NCT03645980
literature,entinostat,312087,Q96DB2;Q9UBN7;Q92769;Q13547;Q9UKV0;Q9UQL6;Q8WUI4;P56524;O15379;Q969S8;Q9BY41,"InChI=1S/C21H20N4O3/c22-18-5-1-2-6-19(18)25-20(26)17-9-7-15(8-10-17)13-24-21(27)28-14-16-4-3-11-23-12-16/h1-12H,13-14,22H2,(H,24,27)(H,25,26)",INVTYAOGFAGBOE-UHFFFAOYSA-N,Nc1ccccc1NC(=O)c2ccc(CNC(=O)OCc3cccnc3)cc2,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,advanced solid tumors,advanced solid cancers,Phase 1,25371323,"The three dose-limiting toxicities (DLTs) observed were grade 3 hand-foot syndrome, nausea/vomiting, and fatigue. MTD was not reached. The recommended phase II dose was defined as the full dose of the respective drugs administered individually. The most common grade 3-4 toxicities were muscle weakness (13 %), skin rash (10 %), fatigue (6 %), diarrhea (6 %), and hand-foot syndrome (3 %). One NSCLC patient achieved a partial response. Two patients (adenocarcinoma of GE junction and Hurthle cell carcinoma of the thyroid) were on the study for more than 9 months with stable disease. The combination of entinostat and sorafenib was well tolerated. Entinostat 10 mg orally once every 2 weeks in combination with sorafenib 400 mg orally twice daily, representing full single agent doses of each drug was identified as the recommended phase 2 dose (RP2D).",,,,
clinicaltrials.gov,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,,advanced solid cancers,Phase 1,,,NCT00759928,PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors,,https://ClinicalTrials.gov/show/NCT00759928
clinicaltrials.gov,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,,advanced solid cancers,Phase 1,,,NCT00126620,Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors,,https://ClinicalTrials.gov/show/NCT00126620
clinicaltrials.gov,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,,lung cancers,Phase 2,,,NCT00600015,Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC),,https://ClinicalTrials.gov/show/NCT00600015
clinicaltrials.gov,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,,brain cancers,Phase 1/2,,,NCT01434602,Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas,,https://ClinicalTrials.gov/show/NCT01434602
clinicaltrials.gov,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,,kidney cancers,Phase 1/2,,,NCT00448149,Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer,,https://ClinicalTrials.gov/show/NCT00448149
clinicaltrials.gov,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,,liver cancers,Phase 1,,,NCT00828594,Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma,,https://ClinicalTrials.gov/show/NCT00828594
clinicaltrials.gov,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,,liver cancers,Phase 2,,,NCT01005199,"Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer",,https://ClinicalTrials.gov/show/NCT01005199
clinicaltrials.gov,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,,multiple myeloma;lymphoma,Phase 1/2,,,NCT00474929,Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma,,https://ClinicalTrials.gov/show/NCT00474929
literature,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,metastatic clear cell renal cell carcinoma,kidney cancers,Phase 1,21387258,"Twenty patients with a median age of 65 years received therapy in 3 cohorts. Dose level 1 was comprised of everolimus at a dose of 2.5 mg daily and sorafenib at a dose of 400 mg twice daily (6 patients), dose level 2 was comprised of everolimus at a dose of 5 mg daily and sorafenib at a dose of 400 mg twice daily (8 patients), and dose level 3 was comprised of everolimus at a dose of 10 mg daily and sorafenib at a dose of 200 mg twice daily (6 patients). DLTs included grade 4 (according to National Cancer Institute Common Terminology Criteria for Adverse Events [version 3.0]) hyperuricemia with grade 2 gout and grade 3 lipase associated with grade 2 pancreatitis at dose level 2, and grade 3 rash in 2 patients at dose level 3. Dose level 2 (everolimus at a dose of 5 mg daily and sorafenib at a dose of 400 mg twice daily) was established as the maximum tolerated dose. Treatment-related adverse events occurring in >20% of patients included diarrhea, hand-foot syndrome, hypertension, hypophosphatemia, hypothyroidism, and rash. Five of 20 patients achieved Response Evaluation Criteria In Solid Tumors (RECIST)-defined partial responses, all of which occurred in patients without a history of prior systemic therapy. Seven of 8 patients treated at dose level 2 experienced a partial response or stable disease. Pharmacokinetic analysis revealed no interaction between everolimus and sorafenib.",,,,
clinicaltrials.gov,GC33(RO5137382),,,,,,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,,liver cancers,Phase 1,,,NCT00976170,Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma),,https://ClinicalTrials.gov/show/NCT00976170
clinicaltrials.gov,lenalidomide,718,O14920,"InChI=1S/C13H13N3O3/c14-9-3-1-2-7-8(9)6-16(13(7)19)10-4-5-11(17)15-12(10)18/h1-3,10H,4-6,14H2,(H,15,17,18)",GOTYRUGSSMKFNF-UHFFFAOYSA-N,Nc1cccc2C(=O)N(Cc12)C3CCC(=O)NC3=O,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,,liver cancers,Phase 1,,,NCT01348503,Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma,,https://ClinicalTrials.gov/show/NCT01348503
clinicaltrials.gov,LY2157299,,P36897,,,,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,,liver cancers,Phase 1,,,NCT02240433,A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC),,https://ClinicalTrials.gov/show/NCT02240433
clinicaltrials.gov,mapatumumab,,O00220,,,,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,,liver cancers,Phase 1,,,NCT00712855,A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma,HCC,https://ClinicalTrials.gov/show/NCT00712855
clinicaltrials.gov,MEDI-573,,P05019;P01344,,,,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,,liver cancers,Phase 1,,,NCT01498952,MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.,MEDI-573-1028,https://ClinicalTrials.gov/show/NCT01498952
clinicaltrials.gov,panobinostat,523996,Q9BY41;Q969S8;O15379;P56524;Q8WUI4;Q9UQL6;Q9UKV0;Q13547;Q92769;Q9UBN7;Q96DB2,"InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+",FPOHNWQLNRZRFC-ZHACJKMWSA-N,Cc1[nH]c2ccccc2c1CCNCc3ccc(\C=C\C(=O)NO)cc3,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,,liver cancers,Phase 1,,,NCT00873002,Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and/or Cannot Be Removed by Surgery,,https://ClinicalTrials.gov/show/NCT00873002
clinicaltrials.gov,PDR001,,,,,,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,,liver cancers,Phase 1,,,NCT02988440,Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients,,https://ClinicalTrials.gov/show/NCT02988440
clinicaltrials.gov,perifosine,12580,P31749,"InChI=1S/C25H52NO4P/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-24-29-31(27,28)30-25-20-22-26(2,3)23-21-25/h25H,4-24H2,1-3H3",SZFPYBIJACMNJV-UHFFFAOYSA-N,CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](C)(C)CC1,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,,kidney cancers,Phase 1,,,NCT00398814,Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers,,https://ClinicalTrials.gov/show/NCT00398814
clinicaltrials.gov,RDEA119,,,,,,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,,,Phase 1/2,,,NCT00785226,RDEA119 and Sorafenib Combination Dose Escalation Study,,https://ClinicalTrials.gov/show/NCT00785226
clinicaltrials.gov,refametinib,1285727,Q02750;P36507,"InChI=1S/C19H20F3IN2O5S/c1-30-15-7-13(21)16(22)18(24-14-3-2-10(23)6-12(14)20)17(15)25-31(28,29)19(4-5-19)8-11(27)9-26/h2-3,6-7,11,24,26-27H,4-5,8-9H2,1H3,(H-,25,28,29)",QXLZZQSWYQRQEM-UHFFFAOYSA-N,COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1N[S+](=O)([O-])C3(CC(O)CO)CC3,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,,liver cancers,Phase 2,,,NCT01915602,Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC),,https://ClinicalTrials.gov/show/NCT01915602
literature,resminostat,,,,,,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,advanced hepatocellular carcinoma,liver cancers,Phase 1/2,26952006,"57 patients received treatment. Most common adverse events were gastrointestinal disorders, thrombocytopenia and fatigue. Median maximal histone deacetylase inhibition and highest increase in H4-acetylation matched Tmax of resminostat. Sorafenib or the Child-Pugh score did not affect typical pharmacokinetics characteristics of resminostat. Efficacy assessment as progression-free survival-rate after 6 treatment cycles (12weeks, primary endpoint) was 12.5% for resminostat and 62.5% for resminostat plus sorafenib. Median time to progression and overall survival were 1.8 and 4.1months for resminostat and 6.5 and 8.0months for the combination, respectively. Zinc finger protein 64 (ZFP64) baseline expression in blood cells was found to correlate with overall survival.",,,,
literature,S-1,,,,,,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,advanced hepatocellular carcinoma,liver cancers,Phase 1,21695438,"From August 2009 to July 2010, 20 patients with advanced HCC were enrolled. The median age was 48 years (range, 29-74). Eighteen (90%) patients had hepatitis B viral infection and 19 (95%) patients were rated as Child-Pugh class A. The dose-limiting toxicities were grade 4 infection and thrombocytopenia. After a median follow-up duration of 8.6 months (range, 3.7-14.2 months), median PFS was 3.9 months (95% CI, 0.8-7.0 months) and median OS was 10.4 months (95% CI, 0-22.4 months). In pharmacokinetic analysis, there was no statistically significant drug interaction between sorafenib and S-1.",,,,
clinicaltrials.gov,selinexor,1347824,O14980,"InChI=1S/C17H11F6N7O/c18-16(19,20)11-5-10(6-12(7-11)17(21,22)23)15-26-9-30(29-15)4-1-14(31)28-27-13-8-24-2-3-25-13/h1-9H,(H,25,27)(H,28,31)/b4-1-",DEVSOMFAQLZNKR-RJRFIUFISA-N,FC(F)(F)c1cc(cc(c1)C(F)(F)F)c2ncn(\C=C/C(=O)NNc3cnccn3)n2,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,,leukemia,Phase 1/2,,,NCT02530476,"Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia",,https://ClinicalTrials.gov/show/NCT02530476
clinicaltrials.gov,tigatuzumab,,O14763,,,,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,,liver cancers,Phase 2,,,NCT01033240,CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer,,https://ClinicalTrials.gov/show/NCT01033240
literature,tigatuzumab,,O14763,,,,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,advanced hepatocellular carcinoma,liver cancers,Phase 2,26071796,"163 subjects were randomized to treatment. Median time to progression was 3.0 months in the tigatuzumab 6/2 mg/kg combination group (p=0.988 vs. sorafenib), 3.9 months in the tigatuzumab 6/6 mg/kg combination group (p=0.586 vs. sorafenib), and 2.8 months in the sorafenib alone group. Median overall survival was 12.2 months in the tigatuzumab 6/6 mg/kg combination group (p=0.659 vs. sorafenib), vs. 8.2 months in both other treatment groups (p=0.303, tigatuzumab 6/2 mg/kg combination vs. sorafenib). The most common treatment-emergent adverse events were palmar-plantar erythrodysesthesia syndrome, diarrhea, and decreased appetite.",,,,
literature,tivantinib,1026778,P08581,"InChI=1S/C23H19N3O2/c27-22-19(16-11-24-18-9-2-1-7-14(16)18)20(23(28)25-22)17-12-26-10-4-6-13-5-3-8-15(17)21(13)26/h1-3,5,7-9,11-12,19-20,24H,4,6,10H2,(H,25,27,28)/t19-,20-/m0/s1",UCEQXRCJXIVODC-PMACEKPBSA-N,O=C1NC(=O)[C@H]([C@@H]1c2c[nH]c3ccccc23)c4cn5CCCc6cccc4c56,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,advanced solid tumors,advanced solid cancers,Phase 1,25294187,"Eighty-seven patients received the study treatment. The combination had no unexpected toxicities. The most common treatment-related adverse events (AE) were rash (40 %), diarrhea (38 %), and anorexia (33 %). The RP2D was tivantinib 360 mg BID and sorafenib 400 mg BID for all cancer histologies, except in hepatocellular carcinoma (HCC) patients tivantinib was 240 mg BID plus sorafenib 400 mg BID. The overall response rate was 12 % in all patients, 26 % in melanoma, 15 % in renal cell carcinoma (RCC), 10 % in HCC, and 0 % in other patients. Disease control rate (CR, PR and SD _8 weeks) was 58 % in all patients, 90 % in RCC, 65 % in HCC, 63 % in melanoma, 40 % in breast cancer, and 8 % in NSCLC patients.",,,,
clinicaltrials.gov,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,,liver cancers,Phase 1,,,NCT02292173,Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer,,https://ClinicalTrials.gov/show/NCT02292173
clinicaltrials.gov,TRC105,,,,,,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,,liver cancers,Phase 1/2,,,NCT01306058,Sorafenib and TRC105 in Hepatocellular Cancer,,https://ClinicalTrials.gov/show/NCT01306058
clinicaltrials.gov,TNO155,,,,,,Spartalizumab,,,,,,,,,,,NCT04000529,Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies,,https://ClinicalTrials.gov/show/NCT04000529
clinicaltrials.gov,difluoromethylornithine,1631221,P11926,"InChI=1S/C6H12F2N2O2.ClH/c7-4(8)6(10,5(11)12)2-1-3-9;/h4H,1-3,9-10H2,(H,11,12);1H",VKDGNNYJFSHYKD-UHFFFAOYSA-N,Cl.NCCCC(N)(C(F)F)C(=O)O,sulindac,586,P23219;P35354,,,,,,Phase 2,,,NCT01636128,Urinary Biomarker Study With Sulindac and Difluoromethylornithine,,https://ClinicalTrials.gov/show/NCT01636128
clinicaltrials.gov,AGS-003,,,,,,sunitinib,1055,O00238;O00444;O00506;O14578;O14730;O14757;O14965;O14976;O15075;O15111;O15146;O15197;O15530;O43172;O43283;O43293;O43318;O60285;O60674;O75116;O75385;O75460;O75582;O75676;O75716;O75914;O94768;O94804;O94806;O94921;O95747;O95819;O95835;O96013;O96017;P00519;P04629;P06213;P06239;P06241;P07332;P07333;P07947;P07948;P07949;P08069;P08581;P08631;P09619;P09769;P0C264;P10721;P11362;P11802;P12931;P14616;P15735;P16234;P16591;P17252;P17948;P19525;P19784;P21802;P22455;P22607;P23443;P23458;P27448;P29320;P29376;P29597;P30291;P30530;P31751;P32298;P33981;P35590;P35916;P35968;P36507;P36888;P42679;P42684;P42685;P45984;P45985;P46734;P48729;P48730;P49674;P49759;P49760;P50613;P51451;P51617;P51812;P51955;P52333;P52564;P53355;P53779;P54646;P54756;P54760;P54762;P57058;P57059;P57078;P68400;P78356;P78362;P78368;P80192;P80370;Q00535;Q00536;Q00537;Q02750;Q04759;Q05397;Q06187;Q06418;Q07002;Q07912;Q08345;Q08881;Q12809;Q12851;Q12852;Q12866;Q13043;Q13131;Q13163;Q13164;Q13188;Q13464;Q13470;Q13523;Q13546;Q13554;Q13555;Q13557;Q13627;Q13873;Q13882;Q14012;Q14164;Q14289;Q14680;Q15139;Q15208;Q15349;Q15375;Q15418;Q15746;Q15831;Q15835;Q16288;Q16512;Q16513;Q16566;Q16584;Q16620;Q16816;Q16832;Q2M2I8;Q32MK0;Q52WX2;Q56UN5;Q5S007;Q6PHR2;Q6XUX3;Q6ZN16;Q7KZI7;Q7L7X3;Q86UE8;Q86V86;Q86YV6;Q86Z02;Q8IU85;Q8IVH8;Q8IWQ3;Q8IY84;Q8IYT8;Q8N4C8;Q8N568;Q8N5S9;Q8N752;Q8NE63;Q8NEV4;Q8NFD2;Q8TDC3;Q8TDR2;Q8TDX7;Q8WTQ7;Q8WXR4;Q92630;Q92772;Q92918;Q96BR1;Q96GD4;Q96L34;Q96NX5;Q96RR4;Q96SB4;Q99755;Q99759;Q9BRS2;Q9BUB5;Q9BVS4;Q9BXA7;Q9BYT3;Q9BZL6;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K2;Q9H2K8;Q9H2X6;Q9H422;Q9HAZ1;Q9HBH9;Q9HCP0;Q9NQU5;Q9NRH2;Q9NRM7;Q9NSY1;Q9NWZ3;Q9NYY3;Q9P0L2;Q9P1W9;Q9P286;Q9P289;Q9P2K8;Q9UEE5;Q9UEW8;Q9UF33;Q9UHD2;Q9UIK4;Q9UK32;Q9UKE5;Q9UKI8;Q9UM73;Q9UPE1;Q9UPZ9;Q9UQB9;Q9UQM7;Q9Y2H1;Q9Y2H9;Q9Y2U5;Q9Y463;Q9Y4K4;Q9Y616;Q9Y6E0;Q9Y6M4;Q9Y6R4,"InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-",WINHZLLDWRZWRT-ATVHPVEESA-N,CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C\2/C(=O)Nc3ccc(F)cc23)c1C,,kidney cancers,Phase 2,,,NCT00678119,Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment,,https://ClinicalTrials.gov/show/NCT00678119
literature,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,sunitinib,1055,O00238;O00444;O00506;O14578;O14730;O14757;O14965;O14976;O15075;O15111;O15146;O15197;O15530;O43172;O43283;O43293;O43318;O60285;O60674;O75116;O75385;O75460;O75582;O75676;O75716;O75914;O94768;O94804;O94806;O94921;O95747;O95819;O95835;O96013;O96017;P00519;P04629;P06213;P06239;P06241;P07332;P07333;P07947;P07948;P07949;P08069;P08581;P08631;P09619;P09769;P0C264;P10721;P11362;P11802;P12931;P14616;P15735;P16234;P16591;P17252;P17948;P19525;P19784;P21802;P22455;P22607;P23443;P23458;P27448;P29320;P29376;P29597;P30291;P30530;P31751;P32298;P33981;P35590;P35916;P35968;P36507;P36888;P42679;P42684;P42685;P45984;P45985;P46734;P48729;P48730;P49674;P49759;P49760;P50613;P51451;P51617;P51812;P51955;P52333;P52564;P53355;P53779;P54646;P54756;P54760;P54762;P57058;P57059;P57078;P68400;P78356;P78362;P78368;P80192;P80370;Q00535;Q00536;Q00537;Q02750;Q04759;Q05397;Q06187;Q06418;Q07002;Q07912;Q08345;Q08881;Q12809;Q12851;Q12852;Q12866;Q13043;Q13131;Q13163;Q13164;Q13188;Q13464;Q13470;Q13523;Q13546;Q13554;Q13555;Q13557;Q13627;Q13873;Q13882;Q14012;Q14164;Q14289;Q14680;Q15139;Q15208;Q15349;Q15375;Q15418;Q15746;Q15831;Q15835;Q16288;Q16512;Q16513;Q16566;Q16584;Q16620;Q16816;Q16832;Q2M2I8;Q32MK0;Q52WX2;Q56UN5;Q5S007;Q6PHR2;Q6XUX3;Q6ZN16;Q7KZI7;Q7L7X3;Q86UE8;Q86V86;Q86YV6;Q86Z02;Q8IU85;Q8IVH8;Q8IWQ3;Q8IY84;Q8IYT8;Q8N4C8;Q8N568;Q8N5S9;Q8N752;Q8NE63;Q8NEV4;Q8NFD2;Q8TDC3;Q8TDR2;Q8TDX7;Q8WTQ7;Q8WXR4;Q92630;Q92772;Q92918;Q96BR1;Q96GD4;Q96L34;Q96NX5;Q96RR4;Q96SB4;Q99755;Q99759;Q9BRS2;Q9BUB5;Q9BVS4;Q9BXA7;Q9BYT3;Q9BZL6;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K2;Q9H2K8;Q9H2X6;Q9H422;Q9HAZ1;Q9HBH9;Q9HCP0;Q9NQU5;Q9NRH2;Q9NRM7;Q9NSY1;Q9NWZ3;Q9NYY3;Q9P0L2;Q9P1W9;Q9P286;Q9P289;Q9P2K8;Q9UEE5;Q9UEW8;Q9UF33;Q9UHD2;Q9UIK4;Q9UK32;Q9UKE5;Q9UKI8;Q9UM73;Q9UPE1;Q9UPZ9;Q9UQB9;Q9UQM7;Q9Y2H1;Q9Y2H9;Q9Y2U5;Q9Y463;Q9Y4K4;Q9Y616;Q9Y6E0;Q9Y6M4;Q9Y6R4,"InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-",WINHZLLDWRZWRT-ATVHPVEESA-N,CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C\2/C(=O)Nc3ccc(F)cc23)c1C,refractory solid tumor malignancies,advanced solid cancers,Phase 1,23322195,"Thirty patients were evaluable. During sunitinib escalation, DLTs of grade 4 thrombocytopenia (14%) and neutropenia (6%) at sunitinib 50_mg and bortezomib 1.3_mg_m(-2) were seen. Subsequent experience showed tolerability and activity for sunitinib 37.5_mg and bortezomib 1.9_mg_m(-2). Common grade 3/4 toxicities were neutropenia, thrombocytopenia, hypertension, and diarrhoea. The recommended doses for further study are bortezomib 1.9_mg_m(-2) and sunitinib 37.5_mg. Four partial responses were seen. Stable disease >6 months was noted in an additional six patients.",,,,
literature,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,sunitinib,1055,O00238;O00444;O00506;O14578;O14730;O14757;O14965;O14976;O15075;O15111;O15146;O15197;O15530;O43172;O43283;O43293;O43318;O60285;O60674;O75116;O75385;O75460;O75582;O75676;O75716;O75914;O94768;O94804;O94806;O94921;O95747;O95819;O95835;O96013;O96017;P00519;P04629;P06213;P06239;P06241;P07332;P07333;P07947;P07948;P07949;P08069;P08581;P08631;P09619;P09769;P0C264;P10721;P11362;P11802;P12931;P14616;P15735;P16234;P16591;P17252;P17948;P19525;P19784;P21802;P22455;P22607;P23443;P23458;P27448;P29320;P29376;P29597;P30291;P30530;P31751;P32298;P33981;P35590;P35916;P35968;P36507;P36888;P42679;P42684;P42685;P45984;P45985;P46734;P48729;P48730;P49674;P49759;P49760;P50613;P51451;P51617;P51812;P51955;P52333;P52564;P53355;P53779;P54646;P54756;P54760;P54762;P57058;P57059;P57078;P68400;P78356;P78362;P78368;P80192;P80370;Q00535;Q00536;Q00537;Q02750;Q04759;Q05397;Q06187;Q06418;Q07002;Q07912;Q08345;Q08881;Q12809;Q12851;Q12852;Q12866;Q13043;Q13131;Q13163;Q13164;Q13188;Q13464;Q13470;Q13523;Q13546;Q13554;Q13555;Q13557;Q13627;Q13873;Q13882;Q14012;Q14164;Q14289;Q14680;Q15139;Q15208;Q15349;Q15375;Q15418;Q15746;Q15831;Q15835;Q16288;Q16512;Q16513;Q16566;Q16584;Q16620;Q16816;Q16832;Q2M2I8;Q32MK0;Q52WX2;Q56UN5;Q5S007;Q6PHR2;Q6XUX3;Q6ZN16;Q7KZI7;Q7L7X3;Q86UE8;Q86V86;Q86YV6;Q86Z02;Q8IU85;Q8IVH8;Q8IWQ3;Q8IY84;Q8IYT8;Q8N4C8;Q8N568;Q8N5S9;Q8N752;Q8NE63;Q8NEV4;Q8NFD2;Q8TDC3;Q8TDR2;Q8TDX7;Q8WTQ7;Q8WXR4;Q92630;Q92772;Q92918;Q96BR1;Q96GD4;Q96L34;Q96NX5;Q96RR4;Q96SB4;Q99755;Q99759;Q9BRS2;Q9BUB5;Q9BVS4;Q9BXA7;Q9BYT3;Q9BZL6;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K2;Q9H2K8;Q9H2X6;Q9H422;Q9HAZ1;Q9HBH9;Q9HCP0;Q9NQU5;Q9NRH2;Q9NRM7;Q9NSY1;Q9NWZ3;Q9NYY3;Q9P0L2;Q9P1W9;Q9P286;Q9P289;Q9P2K8;Q9UEE5;Q9UEW8;Q9UF33;Q9UHD2;Q9UIK4;Q9UK32;Q9UKE5;Q9UKI8;Q9UM73;Q9UPE1;Q9UPZ9;Q9UQB9;Q9UQM7;Q9Y2H1;Q9Y2H9;Q9Y2U5;Q9Y463;Q9Y4K4;Q9Y616;Q9Y6E0;Q9Y6M4;Q9Y6R4,"InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-",WINHZLLDWRZWRT-ATVHPVEESA-N,CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C\2/C(=O)Nc3ccc(F)cc23)c1C,metastatic renal cell carcinoma,kidney cancers,Phase 1,21898375,"Twenty patients (13 clear cell and 7 nonclear cell RCC) were enrolled in 5 cohorts. Daily everolimus was not tolerated when combined with sunitinib; the first 2 patients on the second cohort suffered DLTs. With weekly everolimus, the MTD was 30 mg everolimus on days 7, 14, 21, and 28, plus 37.5 mg sunitinib on days 1 to 28 of a 42-day cycle; however, chronic treatment was associated with grade 3 and 4 toxicities. A schedule of 20 mg everolimus weekly/37.5 mg sunitinib was tolerated as chronic therapy. Five patients (25%) had confirmed partial responses, and 3 had nonclear cell RCC. No unexpected accumulation of everolimus, sunitinib, or N-desethyl sunitinib was observed.",,,,
literature,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,sunitinib,1055,O00238;O00444;O00506;O14578;O14730;O14757;O14965;O14976;O15075;O15111;O15146;O15197;O15530;O43172;O43283;O43293;O43318;O60285;O60674;O75116;O75385;O75460;O75582;O75676;O75716;O75914;O94768;O94804;O94806;O94921;O95747;O95819;O95835;O96013;O96017;P00519;P04629;P06213;P06239;P06241;P07332;P07333;P07947;P07948;P07949;P08069;P08581;P08631;P09619;P09769;P0C264;P10721;P11362;P11802;P12931;P14616;P15735;P16234;P16591;P17252;P17948;P19525;P19784;P21802;P22455;P22607;P23443;P23458;P27448;P29320;P29376;P29597;P30291;P30530;P31751;P32298;P33981;P35590;P35916;P35968;P36507;P36888;P42679;P42684;P42685;P45984;P45985;P46734;P48729;P48730;P49674;P49759;P49760;P50613;P51451;P51617;P51812;P51955;P52333;P52564;P53355;P53779;P54646;P54756;P54760;P54762;P57058;P57059;P57078;P68400;P78356;P78362;P78368;P80192;P80370;Q00535;Q00536;Q00537;Q02750;Q04759;Q05397;Q06187;Q06418;Q07002;Q07912;Q08345;Q08881;Q12809;Q12851;Q12852;Q12866;Q13043;Q13131;Q13163;Q13164;Q13188;Q13464;Q13470;Q13523;Q13546;Q13554;Q13555;Q13557;Q13627;Q13873;Q13882;Q14012;Q14164;Q14289;Q14680;Q15139;Q15208;Q15349;Q15375;Q15418;Q15746;Q15831;Q15835;Q16288;Q16512;Q16513;Q16566;Q16584;Q16620;Q16816;Q16832;Q2M2I8;Q32MK0;Q52WX2;Q56UN5;Q5S007;Q6PHR2;Q6XUX3;Q6ZN16;Q7KZI7;Q7L7X3;Q86UE8;Q86V86;Q86YV6;Q86Z02;Q8IU85;Q8IVH8;Q8IWQ3;Q8IY84;Q8IYT8;Q8N4C8;Q8N568;Q8N5S9;Q8N752;Q8NE63;Q8NEV4;Q8NFD2;Q8TDC3;Q8TDR2;Q8TDX7;Q8WTQ7;Q8WXR4;Q92630;Q92772;Q92918;Q96BR1;Q96GD4;Q96L34;Q96NX5;Q96RR4;Q96SB4;Q99755;Q99759;Q9BRS2;Q9BUB5;Q9BVS4;Q9BXA7;Q9BYT3;Q9BZL6;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K2;Q9H2K8;Q9H2X6;Q9H422;Q9HAZ1;Q9HBH9;Q9HCP0;Q9NQU5;Q9NRH2;Q9NRM7;Q9NSY1;Q9NWZ3;Q9NYY3;Q9P0L2;Q9P1W9;Q9P286;Q9P289;Q9P2K8;Q9UEE5;Q9UEW8;Q9UF33;Q9UHD2;Q9UIK4;Q9UK32;Q9UKE5;Q9UKI8;Q9UM73;Q9UPE1;Q9UPZ9;Q9UQB9;Q9UQM7;Q9Y2H1;Q9Y2H9;Q9Y2U5;Q9Y463;Q9Y4K4;Q9Y616;Q9Y6E0;Q9Y6M4;Q9Y6R4,"InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-",WINHZLLDWRZWRT-ATVHPVEESA-N,CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C\2/C(=O)Nc3ccc(F)cc23)c1C,Advanced Renal Cell Carcinoma,kidney cancers,Phase 1b,26174223,"A total of 4 out of a planned 30 subjects were enrolled onto this study (M:F_= 2:2; mean age 52 years, 50% with Karnofsky performance status_< 80). The first 3 patients were enrolled onto a 4_+ 2 dosing schedule of daily sunitinib 50 mg and weekly everolimus 30 mg. Mean time receiving drug was 99 days. One partial response was seen. Toxicities included mucositis, thrombocytopenia, anemia, fatigue, dehydration, and hypoglycemia. Because of multiple grade 3 to 4 toxicities, the protocol was amended to 2_+ 1 dosing of sunitinib 37.5 mg and daily everolimus 5_mg. The first patient on this schedule died from multiorgan failure with septic shock after 1 cycle of treatment. Subsequently, the study was closed. Pharmacokinetic results inconclusively suggest that toxicities could be attributed to the drug exposure.",,,,
clinicaltrials.gov,figitumumab,,P08069,,,,sunitinib,1055,O00238;O00444;O00506;O14578;O14730;O14757;O14965;O14976;O15075;O15111;O15146;O15197;O15530;O43172;O43283;O43293;O43318;O60285;O60674;O75116;O75385;O75460;O75582;O75676;O75716;O75914;O94768;O94804;O94806;O94921;O95747;O95819;O95835;O96013;O96017;P00519;P04629;P06213;P06239;P06241;P07332;P07333;P07947;P07948;P07949;P08069;P08581;P08631;P09619;P09769;P0C264;P10721;P11362;P11802;P12931;P14616;P15735;P16234;P16591;P17252;P17948;P19525;P19784;P21802;P22455;P22607;P23443;P23458;P27448;P29320;P29376;P29597;P30291;P30530;P31751;P32298;P33981;P35590;P35916;P35968;P36507;P36888;P42679;P42684;P42685;P45984;P45985;P46734;P48729;P48730;P49674;P49759;P49760;P50613;P51451;P51617;P51812;P51955;P52333;P52564;P53355;P53779;P54646;P54756;P54760;P54762;P57058;P57059;P57078;P68400;P78356;P78362;P78368;P80192;P80370;Q00535;Q00536;Q00537;Q02750;Q04759;Q05397;Q06187;Q06418;Q07002;Q07912;Q08345;Q08881;Q12809;Q12851;Q12852;Q12866;Q13043;Q13131;Q13163;Q13164;Q13188;Q13464;Q13470;Q13523;Q13546;Q13554;Q13555;Q13557;Q13627;Q13873;Q13882;Q14012;Q14164;Q14289;Q14680;Q15139;Q15208;Q15349;Q15375;Q15418;Q15746;Q15831;Q15835;Q16288;Q16512;Q16513;Q16566;Q16584;Q16620;Q16816;Q16832;Q2M2I8;Q32MK0;Q52WX2;Q56UN5;Q5S007;Q6PHR2;Q6XUX3;Q6ZN16;Q7KZI7;Q7L7X3;Q86UE8;Q86V86;Q86YV6;Q86Z02;Q8IU85;Q8IVH8;Q8IWQ3;Q8IY84;Q8IYT8;Q8N4C8;Q8N568;Q8N5S9;Q8N752;Q8NE63;Q8NEV4;Q8NFD2;Q8TDC3;Q8TDR2;Q8TDX7;Q8WTQ7;Q8WXR4;Q92630;Q92772;Q92918;Q96BR1;Q96GD4;Q96L34;Q96NX5;Q96RR4;Q96SB4;Q99755;Q99759;Q9BRS2;Q9BUB5;Q9BVS4;Q9BXA7;Q9BYT3;Q9BZL6;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K2;Q9H2K8;Q9H2X6;Q9H422;Q9HAZ1;Q9HBH9;Q9HCP0;Q9NQU5;Q9NRH2;Q9NRM7;Q9NSY1;Q9NWZ3;Q9NYY3;Q9P0L2;Q9P1W9;Q9P286;Q9P289;Q9P2K8;Q9UEE5;Q9UEW8;Q9UF33;Q9UHD2;Q9UIK4;Q9UK32;Q9UKE5;Q9UKI8;Q9UM73;Q9UPE1;Q9UPZ9;Q9UQB9;Q9UQM7;Q9Y2H1;Q9Y2H9;Q9Y2U5;Q9Y463;Q9Y4K4;Q9Y616;Q9Y6E0;Q9Y6M4;Q9Y6R4,"InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-",WINHZLLDWRZWRT-ATVHPVEESA-N,CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C\2/C(=O)Nc3ccc(F)cc23)c1C,,advanced solid cancers,Phase 1,,,NCT00729833,"Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors",,https://ClinicalTrials.gov/show/NCT00729833
clinicaltrials.gov,LY573636-sodium,,,,,,sunitinib,1055,O00238;O00444;O00506;O14578;O14730;O14757;O14965;O14976;O15075;O15111;O15146;O15197;O15530;O43172;O43283;O43293;O43318;O60285;O60674;O75116;O75385;O75460;O75582;O75676;O75716;O75914;O94768;O94804;O94806;O94921;O95747;O95819;O95835;O96013;O96017;P00519;P04629;P06213;P06239;P06241;P07332;P07333;P07947;P07948;P07949;P08069;P08581;P08631;P09619;P09769;P0C264;P10721;P11362;P11802;P12931;P14616;P15735;P16234;P16591;P17252;P17948;P19525;P19784;P21802;P22455;P22607;P23443;P23458;P27448;P29320;P29376;P29597;P30291;P30530;P31751;P32298;P33981;P35590;P35916;P35968;P36507;P36888;P42679;P42684;P42685;P45984;P45985;P46734;P48729;P48730;P49674;P49759;P49760;P50613;P51451;P51617;P51812;P51955;P52333;P52564;P53355;P53779;P54646;P54756;P54760;P54762;P57058;P57059;P57078;P68400;P78356;P78362;P78368;P80192;P80370;Q00535;Q00536;Q00537;Q02750;Q04759;Q05397;Q06187;Q06418;Q07002;Q07912;Q08345;Q08881;Q12809;Q12851;Q12852;Q12866;Q13043;Q13131;Q13163;Q13164;Q13188;Q13464;Q13470;Q13523;Q13546;Q13554;Q13555;Q13557;Q13627;Q13873;Q13882;Q14012;Q14164;Q14289;Q14680;Q15139;Q15208;Q15349;Q15375;Q15418;Q15746;Q15831;Q15835;Q16288;Q16512;Q16513;Q16566;Q16584;Q16620;Q16816;Q16832;Q2M2I8;Q32MK0;Q52WX2;Q56UN5;Q5S007;Q6PHR2;Q6XUX3;Q6ZN16;Q7KZI7;Q7L7X3;Q86UE8;Q86V86;Q86YV6;Q86Z02;Q8IU85;Q8IVH8;Q8IWQ3;Q8IY84;Q8IYT8;Q8N4C8;Q8N568;Q8N5S9;Q8N752;Q8NE63;Q8NEV4;Q8NFD2;Q8TDC3;Q8TDR2;Q8TDX7;Q8WTQ7;Q8WXR4;Q92630;Q92772;Q92918;Q96BR1;Q96GD4;Q96L34;Q96NX5;Q96RR4;Q96SB4;Q99755;Q99759;Q9BRS2;Q9BUB5;Q9BVS4;Q9BXA7;Q9BYT3;Q9BZL6;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K2;Q9H2K8;Q9H2X6;Q9H422;Q9HAZ1;Q9HBH9;Q9HCP0;Q9NQU5;Q9NRH2;Q9NRM7;Q9NSY1;Q9NWZ3;Q9NYY3;Q9P0L2;Q9P1W9;Q9P286;Q9P289;Q9P2K8;Q9UEE5;Q9UEW8;Q9UF33;Q9UHD2;Q9UIK4;Q9UK32;Q9UKE5;Q9UKI8;Q9UM73;Q9UPE1;Q9UPZ9;Q9UQB9;Q9UQM7;Q9Y2H1;Q9Y2H9;Q9Y2U5;Q9Y463;Q9Y4K4;Q9Y616;Q9Y6E0;Q9Y6M4;Q9Y6R4,"InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-",WINHZLLDWRZWRT-ATVHPVEESA-N,CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C\2/C(=O)Nc3ccc(F)cc23)c1C,,kidney cancers,Phase 1,,,NCT01258348,A Phase 1b Trial in Patients With Renal Cell Cancer,,https://ClinicalTrials.gov/show/NCT01258348
clinicaltrials.gov,Panzema NCD,,,,,,sunitinib,1055,O00238;O00444;O00506;O14578;O14730;O14757;O14965;O14976;O15075;O15111;O15146;O15197;O15530;O43172;O43283;O43293;O43318;O60285;O60674;O75116;O75385;O75460;O75582;O75676;O75716;O75914;O94768;O94804;O94806;O94921;O95747;O95819;O95835;O96013;O96017;P00519;P04629;P06213;P06239;P06241;P07332;P07333;P07947;P07948;P07949;P08069;P08581;P08631;P09619;P09769;P0C264;P10721;P11362;P11802;P12931;P14616;P15735;P16234;P16591;P17252;P17948;P19525;P19784;P21802;P22455;P22607;P23443;P23458;P27448;P29320;P29376;P29597;P30291;P30530;P31751;P32298;P33981;P35590;P35916;P35968;P36507;P36888;P42679;P42684;P42685;P45984;P45985;P46734;P48729;P48730;P49674;P49759;P49760;P50613;P51451;P51617;P51812;P51955;P52333;P52564;P53355;P53779;P54646;P54756;P54760;P54762;P57058;P57059;P57078;P68400;P78356;P78362;P78368;P80192;P80370;Q00535;Q00536;Q00537;Q02750;Q04759;Q05397;Q06187;Q06418;Q07002;Q07912;Q08345;Q08881;Q12809;Q12851;Q12852;Q12866;Q13043;Q13131;Q13163;Q13164;Q13188;Q13464;Q13470;Q13523;Q13546;Q13554;Q13555;Q13557;Q13627;Q13873;Q13882;Q14012;Q14164;Q14289;Q14680;Q15139;Q15208;Q15349;Q15375;Q15418;Q15746;Q15831;Q15835;Q16288;Q16512;Q16513;Q16566;Q16584;Q16620;Q16816;Q16832;Q2M2I8;Q32MK0;Q52WX2;Q56UN5;Q5S007;Q6PHR2;Q6XUX3;Q6ZN16;Q7KZI7;Q7L7X3;Q86UE8;Q86V86;Q86YV6;Q86Z02;Q8IU85;Q8IVH8;Q8IWQ3;Q8IY84;Q8IYT8;Q8N4C8;Q8N568;Q8N5S9;Q8N752;Q8NE63;Q8NEV4;Q8NFD2;Q8TDC3;Q8TDR2;Q8TDX7;Q8WTQ7;Q8WXR4;Q92630;Q92772;Q92918;Q96BR1;Q96GD4;Q96L34;Q96NX5;Q96RR4;Q96SB4;Q99755;Q99759;Q9BRS2;Q9BUB5;Q9BVS4;Q9BXA7;Q9BYT3;Q9BZL6;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K2;Q9H2K8;Q9H2X6;Q9H422;Q9HAZ1;Q9HBH9;Q9HCP0;Q9NQU5;Q9NRH2;Q9NRM7;Q9NSY1;Q9NWZ3;Q9NYY3;Q9P0L2;Q9P1W9;Q9P286;Q9P289;Q9P2K8;Q9UEE5;Q9UEW8;Q9UF33;Q9UHD2;Q9UIK4;Q9UK32;Q9UKE5;Q9UKI8;Q9UM73;Q9UPE1;Q9UPZ9;Q9UQB9;Q9UQM7;Q9Y2H1;Q9Y2H9;Q9Y2U5;Q9Y463;Q9Y4K4;Q9Y616;Q9Y6E0;Q9Y6M4;Q9Y6R4,"InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-",WINHZLLDWRZWRT-ATVHPVEESA-N,CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C\2/C(=O)Nc3ccc(F)cc23)c1C,,kidney cancers,Phase 2,,,NCT00444314,Phase 2 Study of Panzem__ NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT00444314
clinicaltrials.gov,perifosine,12580,P31749,"InChI=1S/C25H52NO4P/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-24-29-31(27,28)30-25-20-22-26(2,3)23-21-25/h25H,4-24H2,1-3H3",SZFPYBIJACMNJV-UHFFFAOYSA-N,CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](C)(C)CC1,sunitinib,1055,O00238;O00444;O00506;O14578;O14730;O14757;O14965;O14976;O15075;O15111;O15146;O15197;O15530;O43172;O43283;O43293;O43318;O60285;O60674;O75116;O75385;O75460;O75582;O75676;O75716;O75914;O94768;O94804;O94806;O94921;O95747;O95819;O95835;O96013;O96017;P00519;P04629;P06213;P06239;P06241;P07332;P07333;P07947;P07948;P07949;P08069;P08581;P08631;P09619;P09769;P0C264;P10721;P11362;P11802;P12931;P14616;P15735;P16234;P16591;P17252;P17948;P19525;P19784;P21802;P22455;P22607;P23443;P23458;P27448;P29320;P29376;P29597;P30291;P30530;P31751;P32298;P33981;P35590;P35916;P35968;P36507;P36888;P42679;P42684;P42685;P45984;P45985;P46734;P48729;P48730;P49674;P49759;P49760;P50613;P51451;P51617;P51812;P51955;P52333;P52564;P53355;P53779;P54646;P54756;P54760;P54762;P57058;P57059;P57078;P68400;P78356;P78362;P78368;P80192;P80370;Q00535;Q00536;Q00537;Q02750;Q04759;Q05397;Q06187;Q06418;Q07002;Q07912;Q08345;Q08881;Q12809;Q12851;Q12852;Q12866;Q13043;Q13131;Q13163;Q13164;Q13188;Q13464;Q13470;Q13523;Q13546;Q13554;Q13555;Q13557;Q13627;Q13873;Q13882;Q14012;Q14164;Q14289;Q14680;Q15139;Q15208;Q15349;Q15375;Q15418;Q15746;Q15831;Q15835;Q16288;Q16512;Q16513;Q16566;Q16584;Q16620;Q16816;Q16832;Q2M2I8;Q32MK0;Q52WX2;Q56UN5;Q5S007;Q6PHR2;Q6XUX3;Q6ZN16;Q7KZI7;Q7L7X3;Q86UE8;Q86V86;Q86YV6;Q86Z02;Q8IU85;Q8IVH8;Q8IWQ3;Q8IY84;Q8IYT8;Q8N4C8;Q8N568;Q8N5S9;Q8N752;Q8NE63;Q8NEV4;Q8NFD2;Q8TDC3;Q8TDR2;Q8TDX7;Q8WTQ7;Q8WXR4;Q92630;Q92772;Q92918;Q96BR1;Q96GD4;Q96L34;Q96NX5;Q96RR4;Q96SB4;Q99755;Q99759;Q9BRS2;Q9BUB5;Q9BVS4;Q9BXA7;Q9BYT3;Q9BZL6;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K2;Q9H2K8;Q9H2X6;Q9H422;Q9HAZ1;Q9HBH9;Q9HCP0;Q9NQU5;Q9NRH2;Q9NRM7;Q9NSY1;Q9NWZ3;Q9NYY3;Q9P0L2;Q9P1W9;Q9P286;Q9P289;Q9P2K8;Q9UEE5;Q9UEW8;Q9UF33;Q9UHD2;Q9UIK4;Q9UK32;Q9UKE5;Q9UKI8;Q9UM73;Q9UPE1;Q9UPZ9;Q9UQB9;Q9UQM7;Q9Y2H1;Q9Y2H9;Q9Y2U5;Q9Y463;Q9Y4K4;Q9Y616;Q9Y6E0;Q9Y6M4;Q9Y6R4,"InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-",WINHZLLDWRZWRT-ATVHPVEESA-N,CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C\2/C(=O)Nc3ccc(F)cc23)c1C,,kidney cancers,Phase 1,,,NCT00399152,Perifosine + Sunitinib Malate for Patients With Advanced Cancers,,https://ClinicalTrials.gov/show/NCT00399152
clinicaltrials.gov,propranolol,1210,P08588;P07550,"InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3",AQHHHDLHHXJYJD-UHFFFAOYSA-N,CC(C)NCC(O)COc1cccc2ccccc12,sunitinib,1055,O00238;O00444;O00506;O14578;O14730;O14757;O14965;O14976;O15075;O15111;O15146;O15197;O15530;O43172;O43283;O43293;O43318;O60285;O60674;O75116;O75385;O75460;O75582;O75676;O75716;O75914;O94768;O94804;O94806;O94921;O95747;O95819;O95835;O96013;O96017;P00519;P04629;P06213;P06239;P06241;P07332;P07333;P07947;P07948;P07949;P08069;P08581;P08631;P09619;P09769;P0C264;P10721;P11362;P11802;P12931;P14616;P15735;P16234;P16591;P17252;P17948;P19525;P19784;P21802;P22455;P22607;P23443;P23458;P27448;P29320;P29376;P29597;P30291;P30530;P31751;P32298;P33981;P35590;P35916;P35968;P36507;P36888;P42679;P42684;P42685;P45984;P45985;P46734;P48729;P48730;P49674;P49759;P49760;P50613;P51451;P51617;P51812;P51955;P52333;P52564;P53355;P53779;P54646;P54756;P54760;P54762;P57058;P57059;P57078;P68400;P78356;P78362;P78368;P80192;P80370;Q00535;Q00536;Q00537;Q02750;Q04759;Q05397;Q06187;Q06418;Q07002;Q07912;Q08345;Q08881;Q12809;Q12851;Q12852;Q12866;Q13043;Q13131;Q13163;Q13164;Q13188;Q13464;Q13470;Q13523;Q13546;Q13554;Q13555;Q13557;Q13627;Q13873;Q13882;Q14012;Q14164;Q14289;Q14680;Q15139;Q15208;Q15349;Q15375;Q15418;Q15746;Q15831;Q15835;Q16288;Q16512;Q16513;Q16566;Q16584;Q16620;Q16816;Q16832;Q2M2I8;Q32MK0;Q52WX2;Q56UN5;Q5S007;Q6PHR2;Q6XUX3;Q6ZN16;Q7KZI7;Q7L7X3;Q86UE8;Q86V86;Q86YV6;Q86Z02;Q8IU85;Q8IVH8;Q8IWQ3;Q8IY84;Q8IYT8;Q8N4C8;Q8N568;Q8N5S9;Q8N752;Q8NE63;Q8NEV4;Q8NFD2;Q8TDC3;Q8TDR2;Q8TDX7;Q8WTQ7;Q8WXR4;Q92630;Q92772;Q92918;Q96BR1;Q96GD4;Q96L34;Q96NX5;Q96RR4;Q96SB4;Q99755;Q99759;Q9BRS2;Q9BUB5;Q9BVS4;Q9BXA7;Q9BYT3;Q9BZL6;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K2;Q9H2K8;Q9H2X6;Q9H422;Q9HAZ1;Q9HBH9;Q9HCP0;Q9NQU5;Q9NRH2;Q9NRM7;Q9NSY1;Q9NWZ3;Q9NYY3;Q9P0L2;Q9P1W9;Q9P286;Q9P289;Q9P2K8;Q9UEE5;Q9UEW8;Q9UF33;Q9UHD2;Q9UIK4;Q9UK32;Q9UKE5;Q9UKI8;Q9UM73;Q9UPE1;Q9UPZ9;Q9UQB9;Q9UQM7;Q9Y2H1;Q9Y2H9;Q9Y2U5;Q9Y463;Q9Y4K4;Q9Y616;Q9Y6E0;Q9Y6M4;Q9Y6R4,"InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-",WINHZLLDWRZWRT-ATVHPVEESA-N,CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C\2/C(=O)Nc3ccc(F)cc23)c1C,,kidney cancers,Phase 2,,,NCT03323710,Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT03323710
literature,tremelimumab,,P16410,,,,sunitinib,1055,O00238;O00444;O00506;O14578;O14730;O14757;O14965;O14976;O15075;O15111;O15146;O15197;O15530;O43172;O43283;O43293;O43318;O60285;O60674;O75116;O75385;O75460;O75582;O75676;O75716;O75914;O94768;O94804;O94806;O94921;O95747;O95819;O95835;O96013;O96017;P00519;P04629;P06213;P06239;P06241;P07332;P07333;P07947;P07948;P07949;P08069;P08581;P08631;P09619;P09769;P0C264;P10721;P11362;P11802;P12931;P14616;P15735;P16234;P16591;P17252;P17948;P19525;P19784;P21802;P22455;P22607;P23443;P23458;P27448;P29320;P29376;P29597;P30291;P30530;P31751;P32298;P33981;P35590;P35916;P35968;P36507;P36888;P42679;P42684;P42685;P45984;P45985;P46734;P48729;P48730;P49674;P49759;P49760;P50613;P51451;P51617;P51812;P51955;P52333;P52564;P53355;P53779;P54646;P54756;P54760;P54762;P57058;P57059;P57078;P68400;P78356;P78362;P78368;P80192;P80370;Q00535;Q00536;Q00537;Q02750;Q04759;Q05397;Q06187;Q06418;Q07002;Q07912;Q08345;Q08881;Q12809;Q12851;Q12852;Q12866;Q13043;Q13131;Q13163;Q13164;Q13188;Q13464;Q13470;Q13523;Q13546;Q13554;Q13555;Q13557;Q13627;Q13873;Q13882;Q14012;Q14164;Q14289;Q14680;Q15139;Q15208;Q15349;Q15375;Q15418;Q15746;Q15831;Q15835;Q16288;Q16512;Q16513;Q16566;Q16584;Q16620;Q16816;Q16832;Q2M2I8;Q32MK0;Q52WX2;Q56UN5;Q5S007;Q6PHR2;Q6XUX3;Q6ZN16;Q7KZI7;Q7L7X3;Q86UE8;Q86V86;Q86YV6;Q86Z02;Q8IU85;Q8IVH8;Q8IWQ3;Q8IY84;Q8IYT8;Q8N4C8;Q8N568;Q8N5S9;Q8N752;Q8NE63;Q8NEV4;Q8NFD2;Q8TDC3;Q8TDR2;Q8TDX7;Q8WTQ7;Q8WXR4;Q92630;Q92772;Q92918;Q96BR1;Q96GD4;Q96L34;Q96NX5;Q96RR4;Q96SB4;Q99755;Q99759;Q9BRS2;Q9BUB5;Q9BVS4;Q9BXA7;Q9BYT3;Q9BZL6;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K2;Q9H2K8;Q9H2X6;Q9H422;Q9HAZ1;Q9HBH9;Q9HCP0;Q9NQU5;Q9NRH2;Q9NRM7;Q9NSY1;Q9NWZ3;Q9NYY3;Q9P0L2;Q9P1W9;Q9P286;Q9P289;Q9P2K8;Q9UEE5;Q9UEW8;Q9UF33;Q9UHD2;Q9UIK4;Q9UK32;Q9UKE5;Q9UKI8;Q9UM73;Q9UPE1;Q9UPZ9;Q9UQB9;Q9UQM7;Q9Y2H1;Q9Y2H9;Q9Y2U5;Q9Y463;Q9Y4K4;Q9Y616;Q9Y6E0;Q9Y6M4;Q9Y6R4,"InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-",WINHZLLDWRZWRT-ATVHPVEESA-N,CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C\2/C(=O)Nc3ccc(F)cc23)c1C,metastatic renal cell carcinoma,liver cancers,Phase 1,20922784,"Twenty-eight patients were enrolled. Two of 5 patients who received 50 mg sunitinib plus tremelimumab 6 mg/kg experienced dose-limiting toxicities (DLTs), and no further enrollment to the combination with sunitinib 50 mg dosing was pursued. Among patients who received continuous sunitinib 37.5 mg daily, 1 of 7 patients who received tremelimumab 10 mg/kg plus sunitinib suffered a sudden death, and 3 of 6 patients who received tremelimumab 15 mg/kg plus sunitinib experienced DLTs. An expansion cohort (n = 7) was enrolled at tremelimumab 10 mg/kg plus sunitinib 37.5 mg daily; 3 of those patients experienced DLTs. Overall, rapid-onset renal failure was the most common DLT. Nine of 21 patients who were evaluable for response achieved partial responses (43%; 95% confidence interval, 22%-66%), and 4 of those responses were ongoing at the time of the current report.",,,,
clinicaltrials.gov,pembrolizumab,,Q15116,,,,Sylatron,,,,,,,other,Phase 2,,,NCT02982720,Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With pembrolizumab and PEG-Intron,,https://ClinicalTrials.gov/show/NCT02982720
clinicaltrials.gov,neratinib,29601,P00533;P04626,"InChI=1S/C30H29ClN6O3/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38)/b9-7+",JWNPDZNEKVCWMY-VQHVLOKHSA-N,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,T-DM1,,,,,,,breast cancers,Phase 1/2,,,NCT02236000,A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer,,https://ClinicalTrials.gov/show/NCT02236000
clinicaltrials.gov,palbociclib,149415,P11802;P20248;P24385;P24941;P30279;P30281;P36888;P50750;P52333;Q00534,"InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)",AHJRHEGDXFFMBM-UHFFFAOYSA-N,CC(=O)C1=C(C)c2cnc(Nc3ccc(cn3)N4CCNCC4)nc2N(C5CCCC5)C1=O,T-DM1,,,,,,,breast cancers,Phase 2,,,NCT03530696,T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer,T-DM1,https://ClinicalTrials.gov/show/NCT03530696
clinicaltrials.gov,palbociclib,149415,P11802;P20248;P24385;P24941;P30279;P30281;P36888;P50750;P52333;Q00534,"InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)",AHJRHEGDXFFMBM-UHFFFAOYSA-N,CC(=O)C1=C(C)c2cnc(Nc3ccc(cn3)N4CCNCC4)nc2N(C5CCCC5)C1=O,T-DM1,,,,,,,breast cancers,Phase 2,,,NCT03530696,T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer,T-DM1,https://ClinicalTrials.gov/show/NCT03530696
clinicaltrials.gov,tucatinib,,,,,,T-DM1,,,,,,,breast cancers,Phase 1,,,NCT01983501,A Phase 1b Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer,,https://ClinicalTrials.gov/show/NCT01983501
literature,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,tabalumab,,Q9Y275,,,,relapsed/refractory multiple myeloma,multiple myeloma,Phase 1,27287072,"The most common grade 3/4 toxicities included thrombocytopenia, neutropenia, pneumonia, and peripheral sensory neuropathy. There were no dose-limiting toxicities, and the maximum tolerated dose was not reached. Pharmacokinetic data suggested serum exposure increased in a greater than dose-proportional manner up to a dose of 100 mg. Out of 46 evaluable patients, 20 had confirmed responses. The median time to progression (9 patients censored) was 4.8 months, and the median response duration (4 patients censored) was 7.2 months.",,,,
clinicaltrials.gov,mycophenolate mofetil,1304,P12268;P20839 ,"InChI=1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+",RTGDFNSFWBGLEC-SYZQJQIISA-N,COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)\CCC(=O)OCCN3CCOCC3,tacrolimus,282060,P62942,,,,,leukemia;multiple myeloma,Phase 2,,,NCT00096096,Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation,,https://ClinicalTrials.gov/show/NCT00096096
clinicaltrials.gov,sirolimus,344,P06730;P08183;P08684;P11712;P33261;P42345;P62942;Q13451;Q53EL6;Q9Y6L6,"InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1",QFJCIRLUMZQUOT-HPLJOQBZSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1O,tacrolimus,282060,P62942,,,,,leukemia,Phase 2,,,NCT00144703,Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Related Stem Cell Transplantation,,https://ClinicalTrials.gov/show/NCT00144703
clinicaltrials.gov,pembrolizumab,,Q15116,,,,Tadalafil,,,,,,,,,,,NCT03993353,Tadalafil and pembrolizumab in Recurrent or Metastatic Head and Neck Cancer,,https://ClinicalTrials.gov/show/NCT03993353
clinicaltrials.gov,alisertib,,O14965,"InChI=1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33)",ZLHFILGSQDJULK-UHFFFAOYSA-N,COc1cccc(F)c1C2=NCc3cnc(Nc4ccc(C(=O)O)c(OC)c4)nc3c5ccc(Cl)cc25,TAK-228,,,,,,,stomach cancers; female cancers;male cancers;mouth and oropharyngeal cancers,Phase 1,,,NCT02812056,Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies,,https://ClinicalTrials.gov/show/NCT02812056
clinicaltrials.gov,metformin,1855,P43304;P03923;O95299;O00217;P03901;P56556;P03886;O95139;O00483;Q86Y39;P17568;P03891;O75306;P03915;P51970;O43674;P03905;P03897;O14561;O15239;O43181;O43676;O43677;O43678;O43920;O75251;O75380;O75438;O75489;O95167;O95168;O95169;O95178;O95182;O95298;O96000;P19404;P28331;P49821;P56181;Q16718;Q16795;Q8N183;Q9BU61;Q9NRX3;Q9NX14;Q9P032;Q9P0J0;Q9UI09;Q9Y375;Q9Y6M9,"InChI=1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)",XZWYZXLIPXDOLR-UHFFFAOYSA-N,CN(C)C(=N)NC(=N)N,TAK-228,,,,,,,advanced solid cancers,Phase 1,,,NCT03017833,Study of TAK-228 (MLN0128) in Combination With Metformin in Patients With Advanced Cancers,,https://ClinicalTrials.gov/show/NCT03017833
clinicaltrials.gov,avelumab,,Q9NZQ7,,,,talazoparib,,Q9UGN5;P09874,,,Cn1ncnc1[C@@H]2[C@H](Nc3cc(F)cc4C(=O)NN=C2c34)c5ccc(F)cc5,,,Phase 2,,,NCT03565991,Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors,,https://ClinicalTrials.gov/show/NCT03565991
clinicaltrials.gov,avelumab,,Q9NZQ7,,,,talazoparib,,Q9UGN5;P09874,,,Cn1ncnc1[C@@H]2[C@H](Nc3cc(F)cc4C(=O)NN=C2c34)c5ccc(F)cc5,,,Phase 2,,,NCT03565991,Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors,,https://ClinicalTrials.gov/show/NCT03565991
clinicaltrials.gov,CB-839,,,,,,talazoparib,,Q9UGN5;P09874,,,Cn1ncnc1[C@@H]2[C@H](Nc3cc(F)cc4C(=O)NN=C2c34)c5ccc(F)cc5,Solid Tumor|Clear Cell Renal Cell Carcinoma|TNBC - Triple-Negative Breast Cancer|Colorectal Cancer|CRC|RCC|ccRCC,,Phase 1/2,,,NCT03875313,,,
clinicaltrials.gov,pembrolizumab,,Q15116,,,,Talimogene Laherparepvec,,,,,,Cutaneous Melanoma,,Phase 2,,,NCT03842943,,,
clinicaltrials.gov,buparlisib,962639,O00329;O00459;P27986;P42336;P42338;P48736;Q8WYR1;Q92569,"InChI=1S/C18H21F3N6O2/c19-18(20,21)13-9-15(22)23-11-12(13)14-10-16(26-1-5-28-6-2-26)25-17(24-14)27-3-7-29-8-4-27/h9-11H,1-8H2,(H2,22,23)",CWHUFRVAEUJCEF-UHFFFAOYSA-N,Nc1cc(c(cn1)c2cc(nc(n2)N3CCOCC3)N4CCOCC4)C(F)(F)F,tamoxifen,1059,P00533;P03372;P04626;P06239;P06241;P08172;P08173;P08684;P08912;P08913;P11229;P11474;P13945;P14416;P18089;P20309;P20813;P21452;P21728;P21917;P23219;P23975;P24557;P25021;P25100;P28223;P28335;P29274;P31645;P33765;P35462;P41143;P41595;P50406;Q01959;Q12809;Q15125;Q92731;Q99720;Q9BY08;Q9UBM7,"InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-",NKANXQFJJICGDU-QPLCGJKRSA-N,CC\C(=C(/c1ccccc1)\c2ccc(OCCN(C)C)cc2)\c3ccccc3,,breast cancers,Phase 2,,,NCT02404844,"Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer",PIKTAM,https://ClinicalTrials.gov/show/NCT02404844
clinicaltrials.gov,GDC-0032,,O00329;O00459;P27986;P42336;P42338;P48736;Q8WYR1;Q92569,,,,tamoxifen,1059,P00533;P03372;P04626;P06239;P06241;P08172;P08173;P08684;P08912;P08913;P11229;P11474;P13945;P14416;P18089;P20309;P20813;P21452;P21728;P21917;P23219;P23975;P24557;P25021;P25100;P28223;P28335;P29274;P31645;P33765;P35462;P41143;P41595;P50406;Q01959;Q12809;Q15125;Q92731;Q99720;Q9BY08;Q9UBM7,"InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-",NKANXQFJJICGDU-QPLCGJKRSA-N,CC\C(=C(/c1ccccc1)\c2ccc(OCCN(C)C)cc2)\c3ccccc3,,breast cancers;ovarian cancers;female cancers,Phase 1,,,NCT02285179,Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen,Poseidon,https://ClinicalTrials.gov/show/NCT02285179
clinicaltrials.gov,gefitinib,701,O14578;O14976;O15197;O43293;O43353;O75676;O94768;O94804;O96017;P00519;P00533;P04626;P06239;P07948;P07949;P08581;P08631;P09769;P10721;P12931;P15735;P21709;P21860;P29320;P29322;P29376;P30530;P31152;P36888;P42681;P42684;P42685;P45984;P48730;P49674;P50613;P51451;P51617;P53779;P54756;P54760;P54762;Q09013;Q13163;Q15139;Q15303;Q16659;Q16816;Q52WX2;Q56UN5;Q86V86;Q8N4C8;Q8NE63;Q8TBX8;Q99759;Q9BUB5;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NWZ3;Q9UBE8;Q9UEE5;Q9UF33;Q9UKE5;Q9UNQ0;Q9Y2U5;Q9Y616,"InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)",XGALLCVXEZPNRQ-UHFFFAOYSA-N,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN4CCOCC4,tamoxifen,1059,P00533;P03372;P04626;P06239;P06241;P08172;P08173;P08684;P08912;P08913;P11229;P11474;P13945;P14416;P18089;P20309;P20813;P21452;P21728;P21917;P23219;P23975;P24557;P25021;P25100;P28223;P28335;P29274;P31645;P33765;P35462;P41143;P41595;P50406;Q01959;Q12809;Q15125;Q92731;Q99720;Q9BY08;Q9UBM7,"InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-",NKANXQFJJICGDU-QPLCGJKRSA-N,CC\C(=C(/c1ccccc1)\c2ccc(OCCN(C)C)cc2)\c3ccccc3,,breast cancers,Phase 2,,,NCT00229697,Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study,,https://ClinicalTrials.gov/show/NCT00229697
clinicaltrials.gov,gefitinib,701,O14578;O14976;O15197;O43293;O43353;O75676;O94768;O94804;O96017;P00519;P00533;P04626;P06239;P07948;P07949;P08581;P08631;P09769;P10721;P12931;P15735;P21709;P21860;P29320;P29322;P29376;P30530;P31152;P36888;P42681;P42684;P42685;P45984;P48730;P49674;P50613;P51451;P51617;P53779;P54756;P54760;P54762;Q09013;Q13163;Q15139;Q15303;Q16659;Q16816;Q52WX2;Q56UN5;Q86V86;Q8N4C8;Q8NE63;Q8TBX8;Q99759;Q9BUB5;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NWZ3;Q9UBE8;Q9UEE5;Q9UF33;Q9UKE5;Q9UNQ0;Q9Y2U5;Q9Y616,"InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)",XGALLCVXEZPNRQ-UHFFFAOYSA-N,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN4CCOCC4,tamoxifen,1059,P00533;P03372;P04626;P06239;P06241;P08172;P08173;P08684;P08912;P08913;P11229;P11474;P13945;P14416;P18089;P20309;P20813;P21452;P21728;P21917;P23219;P23975;P24557;P25021;P25100;P28223;P28335;P29274;P31645;P33765;P35462;P41143;P41595;P50406;Q01959;Q12809;Q15125;Q92731;Q99720;Q9BY08;Q9UBM7,"InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-",NKANXQFJJICGDU-QPLCGJKRSA-N,CC\C(=C(/c1ccccc1)\c2ccc(OCCN(C)C)cc2)\c3ccccc3,,ovarian cancers;female cancers,Phase 2,,,NCT00189358,"A Phase II Study of ZD1839 and Tamoxifen in Patients With Epithelial Ovarian Carcinoma, Cancer of the Fallopian Tube or the Peritoneum Refractory to Platinum- and Taxane-based Therapy",,https://ClinicalTrials.gov/show/NCT00189358
literature,lapatinib,2195,O00750;O14733;O43353;O75747;O94804;P00533;P04626;P08684;P09619;P21860;Q13163;Q15303;Q9H2G2;Q9UBF8,"InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)",BCFGMOOMADDAQU-UHFFFAOYSA-N,CS(=O)(=O)CCNCc1oc(cc1)c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2,tamoxifen,1059,P00533;P03372;P04626;P06239;P06241;P08172;P08173;P08684;P08912;P08913;P11229;P11474;P13945;P14416;P18089;P20309;P20813;P21452;P21728;P21917;P23219;P23975;P24557;P25021;P25100;P28223;P28335;P29274;P31645;P33765;P35462;P41143;P41595;P50406;Q01959;Q12809;Q15125;Q92731;Q99720;Q9BY08;Q9UBM7,"InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-",NKANXQFJJICGDU-QPLCGJKRSA-N,CC\C(=C(/c1ccccc1)\c2ccc(OCCN(C)C)cc2)\c3ccccc3,metastatic breast_cancer,breast cancers,Phase 1,25065668,"Twenty-five pts were enrolled of which 23 started treatment, five (22%) of them were HER-2 positive. Median age was 59 years and 96% had PS _1. Eleven (91.7%) pts in the T _ T + L group and 10 (76.9%) in L _ T + L group received at least 2 cycles of treatment. The most frequently reported drug-related adverse events (>25% of patients) were diarrhoea (62%), anaemia (56%), rash (52%), fatigue (52%), dermatology other (34%) and leukopenia (28%). Grade 3-4 drug-related toxicities were infrequent (<10%). No cardiotoxicity was observed. T plasma concentrations did not appeared to be affected by the presence of lapatinib. L steady-state plasma concentrations were 20% lower after 28 days of co-administration with T. Eight (36.4%) patients experienced stable disease and median progression free survival was 2.7 months.",,,,
clinicaltrials.gov,octreotide acetate,2126,P30874;P31391;P32745;P35346;P30872,"InChI=1S/C49H66N10O10S2.C2H4O2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41;1-2(3)4/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64);1H3,(H,3,4)/t28-,29-,34-,36+,37+,38-,39-,40+,41+,42+;/m1./s1",XQEJFZYLWPSJOV-XJQYZYIXSA-N,C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](N)Cc2ccccc2)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@H](Cc4c[nH]c5ccccc45)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1.CC(=O)O,tamoxifen,1059,P00533;P03372;P04626;P06239;P06241;P08172;P08173;P08684;P08912;P08913;P11229;P11474;P13945;P14416;P18089;P20309;P20813;P21452;P21728;P21917;P23219;P23975;P24557;P25021;P25100;P28223;P28335;P29274;P31645;P33765;P35462;P41143;P41595;P50406;Q01959;Q12809;Q15125;Q92731;Q99720;Q9BY08;Q9UBM7,"InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-",NKANXQFJJICGDU-QPLCGJKRSA-N,CC\C(=C(/c1ccccc1)\c2ccc(OCCN(C)C)cc2)\c3ccccc3,,breast cancers,Phase 3,,,NCT00002864,"Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer",,https://ClinicalTrials.gov/show/NCT00002864
clinicaltrials.gov,palbociclib,149415,P11802;P20248;P24385;P24941;P30279;P30281;P36888;P50750;P52333;Q00534,"InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)",AHJRHEGDXFFMBM-UHFFFAOYSA-N,CC(=O)C1=C(C)c2cnc(Nc3ccc(cn3)N4CCNCC4)nc2N(C5CCCC5)C1=O,tamoxifen,1059,P00533;P03372;P04626;P06239;P06241;P08172;P08173;P08684;P08912;P08913;P11229;P11474;P13945;P14416;P18089;P20309;P20813;P21452;P21728;P21917;P23219;P23975;P24557;P25021;P25100;P28223;P28335;P29274;P31645;P33765;P35462;P41143;P41595;P50406;Q01959;Q12809;Q15125;Q92731;Q99720;Q9BY08;Q9UBM7,"InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-",NKANXQFJJICGDU-QPLCGJKRSA-N,CC\C(=C(/c1ccccc1)\c2ccc(OCCN(C)C)cc2)\c3ccccc3,,breast cancers,Phase 2,,,NCT02668666,Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer,,https://ClinicalTrials.gov/show/NCT02668666
clinicaltrials.gov,pembrolizumab,,Q15116,,,,tamoxifen,1059,P00533;P03372;P04626;P06239;P06241;P08172;P08173;P08684;P08912;P08913;P11229;P11474;P13945;P14416;P18089;P20309;P20813;P21452;P21728;P21917;P23219;P23975;P24557;P25021;P25100;P28223;P28335;P29274;P31645;P33765;P35462;P41143;P41595;P50406;Q01959;Q12809;Q15125;Q92731;Q99720;Q9BY08;Q9UBM7,"InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-",NKANXQFJJICGDU-QPLCGJKRSA-N,CC\C(=C(/c1ccccc1)\c2ccc(OCCN(C)C)cc2)\c3ccccc3,Breast Cancer Female,,Phase 2,,,NCT03879174,,,
clinicaltrials.gov,vorinostat,260,O15379;O75376;P56524;Q13547;Q8WUI4;Q92769;Q969S8;Q96DB2;Q9BY41;Q9UBN7;Q9UKV0;Q9UQL6;Q9Y618,"InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)",WAEXFXRVDQXREF-UHFFFAOYSA-N,ONC(=O)CCCCCCC(=O)Nc1ccccc1,tamoxifen,1059,P00533;P03372;P04626;P06239;P06241;P08172;P08173;P08684;P08912;P08913;P11229;P11474;P13945;P14416;P18089;P20309;P20813;P21452;P21728;P21917;P23219;P23975;P24557;P25021;P25100;P28223;P28335;P29274;P31645;P33765;P35462;P41143;P41595;P50406;Q01959;Q12809;Q15125;Q92731;Q99720;Q9BY08;Q9UBM7,"InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-",NKANXQFJJICGDU-QPLCGJKRSA-N,CC\C(=C(/c1ccccc1)\c2ccc(OCCN(C)C)cc2)\c3ccccc3,,breast cancers,Phase 2,,,NCT00365599,Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer,,https://ClinicalTrials.gov/show/NCT00365599
clinicaltrials.gov,ramucirumab,,P35968,,,,TAS 102,,,,,,,colorectal cancers,Phase 2,,,NCT03520946,RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients,RAMTAS,https://ClinicalTrials.gov/show/NCT03520946
clinicaltrials.gov,ramucirumab,,P35968,,,,TAS 102,,,,,,,colorectal cancers,Phase 2,,,NCT03520946,RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients,RAMTAS,https://ClinicalTrials.gov/show/NCT03520946
clinicaltrials.gov,Sym004,,,,,,TAS 102,,,,,,,colorectal cancers,Phase 3,,,NCT03717038,Sym004 Versus TAS-102 in Patients With mCRC,,https://ClinicalTrials.gov/show/NCT03717038
clinicaltrials.gov,Sym004,,,,,,TAS 102,,,,,,,colorectal cancers,Phase 3,,,NCT03717038,Sym004 Versus TAS-102 in Patients With mCRC,,https://ClinicalTrials.gov/show/NCT03717038
clinicaltrials.gov,axitinib,600224,P35968;P17948;P35916,"InChI=1S/C22H18N4OS/c1-23-22(27)18-7-2-3-8-21(18)28-16-10-11-17-19(25-26-20(17)14-16)12-9-15-6-4-5-13-24-15/h2-14H,1H3,(H,23,27)(H,25,26)/b12-9+",RITAVMQDGBJQJZ-FMIVXFBMSA-N,CNC(=O)c1ccccc1Sc2ccc3c(\C=C\c4ccccn4)n[nH]c3c2,temsirolimus,401,P42345,"InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1",CBPNZQVSJQDFBE-FUXHJELOSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO,,,Phase 1,,,NCT01529138,Study of Axitinib and Temsirolimus in Solid Tumors,,https://ClinicalTrials.gov/show/NCT01529138
clinicaltrials.gov,bevacizumab,11,P15692,,,,temsirolimus,401,P42345,"InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1",CBPNZQVSJQDFBE-FUXHJELOSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO,,female cancers,Phase 2,,,NCT00723255,Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer,,https://ClinicalTrials.gov/show/NCT00723255
clinicaltrials.gov,bevacizumab,11,P15692,,,,temsirolimus,401,P42345,"InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1",CBPNZQVSJQDFBE-FUXHJELOSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO,,kidney cancers,Phase 2,,,NCT00782275,Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT00782275
clinicaltrials.gov,bevacizumab,11,P15692,,,,temsirolimus,401,P42345,"InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1",CBPNZQVSJQDFBE-FUXHJELOSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO,,kidney cancers,Phase 2,,,NCT01264341,Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT01264341
literature,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,temsirolimus,401,P42345,"InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1",CBPNZQVSJQDFBE-FUXHJELOSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO,relapsed or relapsed and refractory multiple myeloma,multiple myeloma,Phase 1/2,21345726,"20 patients were enrolled into the phase 1 study and 43 into phase 2. All patients were heavily pretreated (median five lines in the phase 1 cohort, and four lines in the phase 2 cohort). The MTD was determined to be 1à6 mg/m(2) bortezomib on days 1, 8, 15, and 22 in combination with 25 mg temsirolimus on days 1, 8, 15, 22, and 29, for a cycle of 35 days. In the phase 2 study, the proportion of patients with a partial response or better was 33% (14 of 43; 90% CI 21-47). Long-term follow-up of patients is ongoing. There were three deaths during treatment in the phase 1 and 2 studies: one patient died of septic shock in the phase 1 study; one patient died with H1N1 influenza infection and one died with cardiac amyloid and ventricular arrhythmia unrelated to treatment in the phase 2 study. In the phase 1 study, the most common treatment-related grade 3-4 adverse events were thrombocytopenia (13 patients), lymphopenia (ten), neutropenia (nine), leucopenia (seven), and anaemia (five). In the phase 2 study, the most common treatment-related grade 3-4 adverse events were thrombocytopenia (25 patients), lymphopenia (24), neutropenia (17), leucopenia (ten), anaemia (seven), and diarrhoea (five). Four patients in the phase 1 study had sensory peripheral neuropathy (grade 2 or less); in the phase 2 study, 11 had sensory peripheral neuropathy (all grade 2 or less) and seven motor peripheral neuropathy (one grade 3, six grade 2 or less).",,,,
clinicaltrials.gov,bryostatin,829168,,"InChI=1S/C47H68O17/c1-10-11-12-13-14-15-39(51)62-43-31(22-41(53)58-9)21-34-25-37(28(2)48)61-42(54)24-32(50)23-35-26-38(59-29(3)49)45(6,7)46(55,63-35)27-36-19-30(20-40(52)57-8)18-33(60-36)16-17-44(4,5)47(43,56)64-34/h12-17,20,22,28,32-38,43,48,50,55-56H,10-11,18-19,21,23-27H2,1-9H3/b13-12+,15-14+,17-16+,30-20+,31-22+/t28-,32-,33+,34+,35-,36+,37-,38+,43+,46+,47-/m1/s1",MJQUEDHRCUIRLF-TVIXENOKSA-N,CCC\C=C\C=C\C(=O)O[C@H]1\C(=C\C(=O)OC)\C[C@H]2C[C@@H](OC(=O)C[C@H](O)C[C@@H]3C[C@H](OC(=O)C)C(C)(C)[C@](O)(C[C@@H]4C\C(=C\C(=O)OC)\C[C@@H](O4)\C=C\C(C)(C)[C@]1(O)O2)O3)[C@@H](C)O,temsirolimus,401,P42345,"InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1",CBPNZQVSJQDFBE-FUXHJELOSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO,,skin cancers;kidney cancers,Phase 1,,,NCT00112476,Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors,,https://ClinicalTrials.gov/show/NCT00112476
clinicaltrials.gov,cetuximab,9,P00533,,,,temsirolimus,401,P42345,"InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1",CBPNZQVSJQDFBE-FUXHJELOSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO,,advanced solid cancers,Phase 1,,,NCT02215720,Temsirolimus and Cetuximab in Patients With Advanced or Metastatic Solid Tumors,TORERO,https://ClinicalTrials.gov/show/NCT02215720
clinicaltrials.gov,cixutumumab,,P08069,,,,temsirolimus,401,P42345,"InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1",CBPNZQVSJQDFBE-FUXHJELOSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO,,brain cancers,Phase 1,,,NCT01182883,A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors,,https://ClinicalTrials.gov/show/NCT01182883
literature,cixutumumab,,P08069,,,,temsirolimus,401,P42345,"InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1",CBPNZQVSJQDFBE-FUXHJELOSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO,bone and soft-tissue sarcoma,bone cancers;soft tissue cancers,Phase 2,23477833,"Between Nov 18, 2009, and April 11, 2012, 388 patients were screened for IGF-1R expression and 54 were assigned to each arm. 17 of 54 patients in the IGF-1R-positive soft-tissue sarcoma group (31%; one-sided 95% CI lower bound 21%; two-sided 90% CI 21-43), 19 of 54 in IGF-1R-positive bone sarcoma group (35%; one-sided 95% CI lower bound 24%; two-sided 90% CI 24-47), and 21 of 54 in the IGF-1R-negative group (39%, one-sided 95% CI lower bound 28%; two-sided 90% CI 28-51) were progression free at 12 weeks. On April 6, 2011, the protocol was amended to include three additional patients in the IGF-1R-positive soft-tissue sarcoma group (total of 57 patients) and nine more in the IGF-1R-negative group (total of 63 patients). There were 2546 adverse events reported during the study, 214 (8%) of which were grade 3-4. The most common grade 3-4 toxicities in the 174 treated patients were anaemia in 16 (9%) patients, hyperglycaemia in 18 (10%), hypophosphataemia in 16 (9%), lymphopenia in 25 (14%), oral mucositis in 19 (11%), and thrombocytopenia in 19 (11%).",,,,
clinicaltrials.gov,erlotinib,1012,O00444;O14578;O14965;O14976;O15197;O43293;O43353;O60674;O75676;O94768;O94804;O94956;P00519;P00533;P04626;P06239;P07947;P07948;P07949;P08581;P08631;P08684;P09769;P10721;P12931;P16234;P17948;P19525;P21802;P21860;P29320;P29322;P29376;P29597;P30530;P31152;P32298;P33981;P35590;P35916;P36888;P41240;P42681;P42684;P42685;P45984;P48730;P49674;P51451;P52333;P53779;P54756;P54760;P54762;P57078;Q06418;Q08345;Q09013;Q12866;Q13163;Q13470;Q13557;Q15303;Q15375;Q2M2I8;Q52WX2;Q56UN5;Q59H18;Q5S007;Q6DT37;Q6PHR2;Q8N4C8;Q8NE63;Q8NI60;Q8TBX8;Q92630;Q96D53;Q96GD4;Q99759;Q9BUB5;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NSY1;Q9P2K8;Q9UEE5;Q9UF33;Q9UHD2;Q9UKE5;Q9UM73;Q9UPE1;Q9UQB9;Q9Y2U5,"InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)",AAKJLRGGTJKAMG-UHFFFAOYSA-N,COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC,temsirolimus,401,P42345,"InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1",CBPNZQVSJQDFBE-FUXHJELOSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO,,,Phase 1,,,NCT00770263,Erlotinib and Temsirolimus for Solid Tumors,,https://ClinicalTrials.gov/show/NCT00770263
clinicaltrials.gov,metformin,1855,P43304;P03923;O95299;O00217;P03901;P56556;P03886;O95139;O00483;Q86Y39;P17568;P03891;O75306;P03915;P51970;O43674;P03905;P03897;O14561;O15239;O43181;O43676;O43677;O43678;O43920;O75251;O75380;O75438;O75489;O95167;O95168;O95169;O95178;O95182;O95298;O96000;P19404;P28331;P49821;P56181;Q16718;Q16795;Q8N183;Q9BU61;Q9NRX3;Q9NX14;Q9P032;Q9P0J0;Q9UI09;Q9Y375;Q9Y6M9,"InChI=1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)",XZWYZXLIPXDOLR-UHFFFAOYSA-N,CN(C)C(=N)NC(=N)N,temsirolimus,401,P42345,"InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1",CBPNZQVSJQDFBE-FUXHJELOSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO,,breast cancers;female cancers;kidney cancers;lung cancers;lymphoma,Phase 1,,,NCT00659568,Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma,,https://ClinicalTrials.gov/show/NCT00659568
clinicaltrials.gov,neratinib,29601,P00533;P04626,"InChI=1S/C30H29ClN6O3/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38)/b9-7+",JWNPDZNEKVCWMY-VQHVLOKHSA-N,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,temsirolimus,401,P42345,"InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1",CBPNZQVSJQDFBE-FUXHJELOSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO,,lung cancers,Phase 2,,,NCT01827267,Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer,,https://ClinicalTrials.gov/show/NCT01827267
clinicaltrials.gov,neratinib,29601,P00533;P04626,"InChI=1S/C30H29ClN6O3/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38)/b9-7+",JWNPDZNEKVCWMY-VQHVLOKHSA-N,CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,temsirolimus,401,P42345,"InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1",CBPNZQVSJQDFBE-FUXHJELOSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO,,,Phase 1,,,NCT00838539,Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors,,https://ClinicalTrials.gov/show/NCT00838539
clinicaltrials.gov,pelitinib,597321,P00533,"InChI=1S/C24H23ClFN5O2/c1-4-33-22-12-20-17(11-21(22)30-23(32)6-5-9-31(2)3)24(15(13-27)14-28-20)29-16-7-8-19(26)18(25)10-16/h5-8,10-12,14H,4,9H2,1-3H3,(H,28,29)(H,30,32)/b6-5+",WVUNYSQLFKLYNI-AATRIKPKSA-N,CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C,temsirolimus,401,P42345,"InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1",CBPNZQVSJQDFBE-FUXHJELOSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO,,advanced solid cancers,Phase 1,,,NCT00098501,CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT00098501
literature,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,temsirolimus,401,P42345,"InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1",CBPNZQVSJQDFBE-FUXHJELOSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO,"Patients with recurrent and/or metastatic, radioactive iodine-refractory thyroid carcinoma",thyroid cancers,Phase 2,28662274,"The best response was a partial response in 8 patients (22%), stable disease in 21 (58%), and progressive disease in_1_(3%). Six patients were not evaluable for a response. Patients who had received any prior systemic treatment had a response rate of 10% compared with 38% of those who had not received prior systemic treatment. One of 2 patients with anaplastic thyroid_cancer_had an objective response. The progression-free survival rate at_1_year was 30.5%. The most common grade 3 and 4 toxicities associated with sorafenib and temsirolimus included hyperglycemia, fatigue, anemia, and oral mucositis.",,,,
clinicaltrials.gov,sunitinib,1055,O00238;O00444;O00506;O14578;O14730;O14757;O14965;O14976;O15075;O15111;O15146;O15197;O15530;O43172;O43283;O43293;O43318;O60285;O60674;O75116;O75385;O75460;O75582;O75676;O75716;O75914;O94768;O94804;O94806;O94921;O95747;O95819;O95835;O96013;O96017;P00519;P04629;P06213;P06239;P06241;P07332;P07333;P07947;P07948;P07949;P08069;P08581;P08631;P09619;P09769;P0C264;P10721;P11362;P11802;P12931;P14616;P15735;P16234;P16591;P17252;P17948;P19525;P19784;P21802;P22455;P22607;P23443;P23458;P27448;P29320;P29376;P29597;P30291;P30530;P31751;P32298;P33981;P35590;P35916;P35968;P36507;P36888;P42679;P42684;P42685;P45984;P45985;P46734;P48729;P48730;P49674;P49759;P49760;P50613;P51451;P51617;P51812;P51955;P52333;P52564;P53355;P53779;P54646;P54756;P54760;P54762;P57058;P57059;P57078;P68400;P78356;P78362;P78368;P80192;P80370;Q00535;Q00536;Q00537;Q02750;Q04759;Q05397;Q06187;Q06418;Q07002;Q07912;Q08345;Q08881;Q12809;Q12851;Q12852;Q12866;Q13043;Q13131;Q13163;Q13164;Q13188;Q13464;Q13470;Q13523;Q13546;Q13554;Q13555;Q13557;Q13627;Q13873;Q13882;Q14012;Q14164;Q14289;Q14680;Q15139;Q15208;Q15349;Q15375;Q15418;Q15746;Q15831;Q15835;Q16288;Q16512;Q16513;Q16566;Q16584;Q16620;Q16816;Q16832;Q2M2I8;Q32MK0;Q52WX2;Q56UN5;Q5S007;Q6PHR2;Q6XUX3;Q6ZN16;Q7KZI7;Q7L7X3;Q86UE8;Q86V86;Q86YV6;Q86Z02;Q8IU85;Q8IVH8;Q8IWQ3;Q8IY84;Q8IYT8;Q8N4C8;Q8N568;Q8N5S9;Q8N752;Q8NE63;Q8NEV4;Q8NFD2;Q8TDC3;Q8TDR2;Q8TDX7;Q8WTQ7;Q8WXR4;Q92630;Q92772;Q92918;Q96BR1;Q96GD4;Q96L34;Q96NX5;Q96RR4;Q96SB4;Q99755;Q99759;Q9BRS2;Q9BUB5;Q9BVS4;Q9BXA7;Q9BYT3;Q9BZL6;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K2;Q9H2K8;Q9H2X6;Q9H422;Q9HAZ1;Q9HBH9;Q9HCP0;Q9NQU5;Q9NRH2;Q9NRM7;Q9NSY1;Q9NWZ3;Q9NYY3;Q9P0L2;Q9P1W9;Q9P286;Q9P289;Q9P2K8;Q9UEE5;Q9UEW8;Q9UF33;Q9UHD2;Q9UIK4;Q9UK32;Q9UKE5;Q9UKI8;Q9UM73;Q9UPE1;Q9UPZ9;Q9UQB9;Q9UQM7;Q9Y2H1;Q9Y2H9;Q9Y2U5;Q9Y463;Q9Y4K4;Q9Y616;Q9Y6E0;Q9Y6M4;Q9Y6R4,"InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-",WINHZLLDWRZWRT-ATVHPVEESA-N,CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C\2/C(=O)Nc3ccc(F)cc23)c1C,temsirolimus,401,P42345,"InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1",CBPNZQVSJQDFBE-FUXHJELOSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO,,kidney cancers,Phase 1,,,NCT01122615,Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC),,https://ClinicalTrials.gov/show/NCT01122615
literature,trebaninib,,,,,,temsirolimus,401,P42345,"InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1",CBPNZQVSJQDFBE-FUXHJELOSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OC(=O)C(C)(CO)CO,advanced solid tumors,advanced solid cancers,Phase 1,26686201,"Twenty-one patients were enrolled, 6 at dose level (DL) 1, 7 at DL -1, and 8 at DL -2. No effect of temsirolimus on trebananib PK was observed. The most common treatment-related adverse events (AEs) were: fatigue (81 %), edema (62 %), anorexia (57 %), nausea (52 %), rash (43 %) and mucositis (43 %). The most common grade _ 3 AEs included lymphopenia (28 %) and fatigue (28 %). The MTD was exceeded at DL-2. Of 18 response evaluable patients, 1 partial response was observed (ER+/HER2-/PIK3CA mutant breast cancer) and 4 patients had prolonged SD _ 24 weeks. No correlation with clinical benefit was observed with change in number TEMs or TP expression in TEMs with treatment.",,,,
clinicaltrials.gov,Conmana,,,,,,thalidomide,123,O14920,"InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)",UEJJHQNACJXSKW-UHFFFAOYSA-N,O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,,lung cancers,Phase 4,,,NCT02778893,Conmana Combined With Thalidomide to Treat NSCLC,,https://ClinicalTrials.gov/show/NCT02778893
clinicaltrials.gov,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,tipifarnib,197794,P49356;P49354,"InChI=1S/C27H22Cl2N4O/c1-32-16-31-15-25(32)27(30,18-6-9-20(28)10-7-18)19-8-11-24-23(13-19)22(14-26(34)33(24)2)17-4-3-5-21(29)12-17/h3-16H,30H2,1-2H3/t27-/m1/s1",PLHJCIYEEKOWNM-HHHXNRCGSA-N,CN1C(=O)C=C(c2cccc(Cl)c2)c3cc(ccc13)[C@](N)(c4ccc(Cl)cc4)c5cncn5C,,multiple myeloma,Phase 1/2,,,NCT00361088,A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma,,https://ClinicalTrials.gov/show/NCT00361088
literature,imatinib,1561,O00444;O14976;O15244;O43570;P00519;P00533;P00915;P00918;P04049;P06239;P06241;P07333;P07451;P07948;P09619;P09769;P10721;P11274;P15056;P16083;P16234;P22748;P23280;P24557;P25021;P28223;P29322;P29597;P31645;P36888;P42684;P42685;P43166;P43405;P45983;P45984;P49759;P51451;P51617;P53779;Q08345;Q14680;Q15046;Q16790;Q16832;Q59H18;Q86VL8;Q8NE63;Q8TBX8;Q96FL8;Q9BWU1;Q9HAZ1;Q9NYL2;Q9UEE5;Q9ULX7;Q9UNQ0,"InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)",KTUFNOKKBVMGRW-UHFFFAOYSA-N,CN1CCN(Cc2ccc(cc2)C(=O)Nc3ccc(C)c(Nc4nccc(n4)c5cccnc5)c3)CC1,tipifarnib,197794,P49356;P49354,"InChI=1S/C27H22Cl2N4O/c1-32-16-31-15-25(32)27(30,18-6-9-20(28)10-7-18)19-8-11-24-23(13-19)22(14-26(34)33(24)2)17-4-3-5-21(29)12-17/h3-16H,30H2,1-2H3/t27-/m1/s1",PLHJCIYEEKOWNM-HHHXNRCGSA-N,CN1C(=O)C=C(c2cccc(Cl)c2)c3cc(ccc13)[C@](N)(c4ccc(Cl)cc4)c5cncn5C,chronic myelogenous leukemia in chronic phase after imatinib failure,leukemia,Phase 1,17849425,"Adverse events included diarrhea in 21 patients (81%) and nausea in 18 patients (69%), but were generally grade 2 or less (using the revised National Cancer Institute Common Toxicity Criteria). Grade 3-4 neutropenia and thrombocytopenia occurred in 11 patients (42%) and 8 patients (31%), respectively. Sixteen patients discontinued therapy (5 due to toxicity and 11 due to lack of response or disease progression). Hematologic responses were attained by 17 (68%) of 25 assessable patients. Nine patients (36%) also achieved a cytogenetic response (3 complete responses, 4 partial responses, and 2 minimal responses), including 4 patients harboring mutant Bcr-Abl tyrosine kinases. One patient bearing the highly imatinib-resistant T315I mutant achieved a partial cytogenetic response. The median response duration was 3 months (range, 2-30+ months).",,,,
literature,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,tipifarnib,197794,P49356;P49354,"InChI=1S/C27H22Cl2N4O/c1-32-16-31-15-25(32)27(30,18-6-9-20(28)10-7-18)19-8-11-24-23(13-19)22(14-26(34)33(24)2)17-4-3-5-21(29)12-17/h3-16H,30H2,1-2H3/t27-/m1/s1",PLHJCIYEEKOWNM-HHHXNRCGSA-N,CN1C(=O)C=C(c2cccc(Cl)c2)c3cc(ccc13)[C@](N)(c4ccc(Cl)cc4)c5cncn5C,advanced malignancies,advanced solid cancers,Phase 1,19903778,"Fifty patients were treated; 43 reached restaging evaluation after cycle 2. The most common side effects were grade 1 to 2 rash, hyperglycemia, and diarrhea. Dose-limiting toxicity was rash, and the recommended phase II dose is sorafenib 400 mg p.o. qam/200 mg p.o. qpm and tipifarnib p.o. 100 mg bd. Despite the low doses of tipifarnib, one quarter of patients had > or =50% reduction in farnesyltransferase levels. Interestingly, six of eight patients with medullary thyroid cancer had durable stable disease (n = 3) or partial remissions (n = 3), lasting 12 to 26+ months. Five of the six responders had available tissue, and RET gene mutations were identified in them. Prolonged (> or =6 months) stable disease was also seen in nine patients as follows: papillary thyroid cancer (n = 4; 18+ to 27+ months), adrenocortical cancer (n = 2; 7 and 11 months), and one each of melanoma (platelet-derived growth factor receptor mutation positive; 14 months), renal (6 months), and pancreatic cancer (6 months).",,,,
clinicaltrials.gov,tamoxifen,1059,P00533;P03372;P04626;P06239;P06241;P08172;P08173;P08684;P08912;P08913;P11229;P11474;P13945;P14416;P18089;P20309;P20813;P21452;P21728;P21917;P23219;P23975;P24557;P25021;P25100;P28223;P28335;P29274;P31645;P33765;P35462;P41143;P41595;P50406;Q01959;Q12809;Q15125;Q92731;Q99720;Q9BY08;Q9UBM7,"InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-",NKANXQFJJICGDU-QPLCGJKRSA-N,CC\C(=C(/c1ccccc1)\c2ccc(OCCN(C)C)cc2)\c3ccccc3,tipifarnib,197794,P49356;P49354,"InChI=1S/C27H22Cl2N4O/c1-32-16-31-15-25(32)27(30,18-6-9-20(28)10-7-18)19-8-11-24-23(13-19)22(14-26(34)33(24)2)17-4-3-5-21(29)12-17/h3-16H,30H2,1-2H3/t27-/m1/s1",PLHJCIYEEKOWNM-HHHXNRCGSA-N,CN1C(=O)C=C(c2cccc(Cl)c2)c3cc(ccc13)[C@](N)(c4ccc(Cl)cc4)c5cncn5C,,breast cancers,Phase 2,,,NCT00210028,Study Assessing Efficacy of ZARNESTRA__¢ Combined With Tamoxifen in Patients With Advanced or Metastatic Breast Cancer,,https://ClinicalTrials.gov/show/NCT00210028
clinicaltrials.gov,BGB-A425,,,,,,tislelizumab,,,,,,,advanced solid cancers,Phase 1/2,,,NCT03744468,Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT03744468
clinicaltrials.gov,BGB-A425,,,,,,tislelizumab,,,,,,,advanced solid cancers,Phase 1/2,,,NCT03744468,Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT03744468
clinicaltrials.gov,Sitravatinib,,,,,,tislelizumab,,,,,,,lung cancers;kidney cancers; female cancers,Phase 1,,,NCT03666143,A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors.,,https://ClinicalTrials.gov/show/NCT03666143
clinicaltrials.gov,Sitravatinib,,,,,,tislelizumab,,,,,,,,,,,NCT03941873,A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Patients With Unresectable Locally Advanced or Metastatic HCC or GC/GEJC,,https://ClinicalTrials.gov/show/NCT03941873
clinicaltrials.gov,Sitravatinib,,,,,,tislelizumab,,,,,,,lung cancers;kidney cancers; female cancers,Phase 1,,,NCT03666143,A Phase 1b Study to Assess Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors.,,https://ClinicalTrials.gov/show/NCT03666143
clinicaltrials.gov,pazopanib,200268,O00238;O00444;O14965;O14976;O15197;O43353;O60331;O60674;O75716;O94804;O95819;P00519;P04049;P06239;P06241;P07332;P07333;P07947;P07948;P07949;P08581;P08631;P08922;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P16591;P17948;P19525;P21127;P21802;P22455;P22607;P27448;P29376;P29597;P33981;P35590;P35916;P35968;P36888;P37173;P42681;P42684;P42685;P43405;P45983;P45985;P51451;P51617;P51955;P52333;P52564;P53667;P53671;P53779;P57059;P80192;Q00536;Q02763;Q02779;Q08345;Q12851;Q12866;Q13163;Q13233;Q13470;Q13546;Q13705;Q13882;Q14012;Q16584;Q16832;Q2M2I8;Q56UN5;Q6P3R8;Q7L7X3;Q8IVH8;Q8TBX8;Q92918;Q96NX5;Q9BVS4;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K8;Q9H3Y6;Q9NRP7;Q9NSY1;Q9UBE8;Q9UBF8;Q9UKE5;Q9UL54;Q9UM73;Q9UQ88;Q9UQB9;Q9Y2U5;Q9Y4K4;Q9Y616,"InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)",CUIHSIWYWATEQL-UHFFFAOYSA-N,CN(c1ccc2c(C)n(C)nc2c1)c3ccnc(Nc4ccc(C)c(c4)S(=O)(=O)N)n3,tivantinib,1026778,P08581,,,,,soft tissue cancers;stomach cancers,Phase 1,,,NCT01468922,Pazopanib and ARQ 197 for Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT01468922
clinicaltrials.gov,Anti-OX40 Antibody BMS 986178,,,,,,TLR9 Agonist SD-101,,,,,,Advanced Malignant Solid Neoplasm|Extracranial Solid Neoplasm|Metastatic Malignant Solid Neoplasm,,Phase 1,,,NCT03831295,,,
clinicaltrials.gov,gatipotuzumab,,,,,,tomuzotuximab,,,,,,,,Phase 1,,,NCT03360734,Combination of Gatipotuzumab and Tomuzotuximab in Patients With Solid Tumors,GATTO,https://ClinicalTrials.gov/show/NCT03360734
clinicaltrials.gov,anlotinib,,,,,,TQB2450,,,,,,,,,,,NCT03991975,Study of TQB2450 Combined With anlotinib in Subjects With Advanced Acral Malignant Melanoma,,https://ClinicalTrials.gov/show/NCT03991975
clinicaltrials.gov,anlotinib,,,,,,TQB2450,,,,,,,,,,,NCT03996408,Study of TQB2450 Combined With anlotinib in Subjects With Advanced Cholangiocarcinoma,,https://ClinicalTrials.gov/show/NCT03996408
clinicaltrials.gov,olaratumab,,P16234,,,,trabectedin,748449,,"InChI=1S/C39H43N3O11S/c1-16-9-20-10-22-37(46)42-23-13-50-38(47)39(21-12-25(48-5)24(44)11-19(21)7-8-40-39)14-54-36(30(42)29(41(22)4)26(20)31(45)32(16)49-6)28-27(23)35-34(51-15-52-35)17(2)33(28)53-18(3)43/h9,11-12,22-23,29-30,36-37,40,44-46H,7-8,10,13-15H2,1-6H3/t22-,23+,29+,30+,36-,37-,39+/m0/s1",PKVRCIRHQMSYJX-PYDRXBSSSA-N,COc1cc2c(CCN[C@]23CS[C@@H]4[C@H]5[C@@H]6N(C)[C@@H](Cc7cc(C)c(OC)c(O)c67)[C@H](O)N5[C@H](COC3=O)c8c9OCOc9c(C)c(OC(=O)C)c48)cc1O,,,,,,NCT03985722,Olaratumab Plus Trabectedin in Advanced Soft-tissue Sarcoma Patients Soft-tissue Sarcoma Patients,OLATRASTS,https://ClinicalTrials.gov/show/NCT03985722
clinicaltrials.gov,AMG 232,,,,,,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,leukemia,Phase 1,,,NCT02016729,A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia,,https://ClinicalTrials.gov/show/NCT02016729
clinicaltrials.gov,buparlisib,962639,O00329;O00459;P27986;P42336;P42338;P48736;Q8WYR1;Q92569,"InChI=1S/C18H21F3N6O2/c19-18(20,21)13-9-15(22)23-11-12(13)14-10-16(26-1-5-28-6-2-26)25-17(24-14)27-3-7-29-8-4-27/h9-11H,1-8H2,(H2,22,23)",CWHUFRVAEUJCEF-UHFFFAOYSA-N,Nc1cc(c(cn1)c2cc(nc(n2)N3CCOCC3)N4CCOCC4)C(F)(F)F,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,advanced solid cancers,Phase 1,,,NCT01155453,"A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients",,https://ClinicalTrials.gov/show/NCT01155453
clinicaltrials.gov,ceritinib,1135147,O60674;O75116;P00519;P00533;P04629;P06213;P06239;P07948;P07949;P08069;P08581;P08922;P09769;P10721;P11802;P12931;P16234;P21802;P22455;P22607;P23458;P24941;P35968;P36888;P41212;P43403;P43405;P52333;Q06187;Q16620;Q9BXA7;Q9HBH9;Q9UM73,"InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34)",VERWOWGGCGHDQE-UHFFFAOYSA-N,CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)C(C)C)n3,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,lung cancers,Phase 1/2,,,NCT03087448,Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC),,https://ClinicalTrials.gov/show/NCT03087448
clinicaltrials.gov,dabrafenib,1929355,P15056,"InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)",BFSMGDJOXZAERB-UHFFFAOYSA-N,CC(C)(C)c1nc(c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(s1)c4ccnc(N)n4,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,advanced solid cancers;skin cancers,Phase 2,,,NCT01928940,Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part),,https://ClinicalTrials.gov/show/NCT01928940
clinicaltrials.gov,dabrafenib,1929355,P15056,"InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)",BFSMGDJOXZAERB-UHFFFAOYSA-N,CC(C)(C)c1nc(c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(s1)c4ccnc(N)n4,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,central nervous system cancers,Phase 2,,,NCT02684058,Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG,,https://ClinicalTrials.gov/show/NCT02684058
clinicaltrials.gov,dabrafenib,1929355,P15056,"InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)",BFSMGDJOXZAERB-UHFFFAOYSA-N,CC(C)(C)c1nc(c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(s1)c4ccnc(N)n4,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,lung cancers,Phase 2,,,NCT02672358,Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC,,https://ClinicalTrials.gov/show/NCT02672358
clinicaltrials.gov,dabrafenib,1929355,P15056,"InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)",BFSMGDJOXZAERB-UHFFFAOYSA-N,CC(C)(C)c1nc(c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(s1)c4ccnc(N)n4,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,lung cancers,Phase 2,,,NCT01336634,Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.,,https://ClinicalTrials.gov/show/NCT01336634
clinicaltrials.gov,dabrafenib,1929355,P15056,"InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)",BFSMGDJOXZAERB-UHFFFAOYSA-N,CC(C)(C)c1nc(c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(s1)c4ccnc(N)n4,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,skin cancers,Phase 2,,,NCT02314143,Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib,,https://ClinicalTrials.gov/show/NCT02314143
clinicaltrials.gov,dabrafenib,1929355,P15056,"InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)",BFSMGDJOXZAERB-UHFFFAOYSA-N,CC(C)(C)c1nc(c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(s1)c4ccnc(N)n4,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,skin cancers,Phase 2,,,NCT01972347,Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma,,https://ClinicalTrials.gov/show/NCT01972347
clinicaltrials.gov,dabrafenib,1929355,P15056,"InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)",BFSMGDJOXZAERB-UHFFFAOYSA-N,CC(C)(C)c1nc(c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(s1)c4ccnc(N)n4,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,skin cancers,Phase 2,,,NCT02974803,Concurrent Dabrafenib and Trametinib With Sterotactic Radiation in Patients With BRAF Mutation-Positive Malignant Melanoma and Brain Metastases,,https://ClinicalTrials.gov/show/NCT02974803
clinicaltrials.gov,dabrafenib,1929355,P15056,"InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)",BFSMGDJOXZAERB-UHFFFAOYSA-N,CC(C)(C)c1nc(c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(s1)c4ccnc(N)n4,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,skin cancers,Phase 2,,,NCT01978236,"Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites",,https://ClinicalTrials.gov/show/NCT01978236
clinicaltrials.gov,dabrafenib,1929355,P15056,"InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)",BFSMGDJOXZAERB-UHFFFAOYSA-N,CC(C)(C)c1nc(c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(s1)c4ccnc(N)n4,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,skin cancers,Phase 2,,,NCT01619774,An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor,,https://ClinicalTrials.gov/show/NCT01619774
clinicaltrials.gov,dabrafenib,1929355,P15056,"InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)",BFSMGDJOXZAERB-UHFFFAOYSA-N,CC(C)(C)c1nc(c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(s1)c4ccnc(N)n4,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,skin cancers,Phase 2,,,NCT02083354,Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma,,https://ClinicalTrials.gov/show/NCT02083354
clinicaltrials.gov,dabrafenib,1929355,P15056,"InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)",BFSMGDJOXZAERB-UHFFFAOYSA-N,CC(C)(C)c1nc(c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(s1)c4ccnc(N)n4,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,skin cancers,Phase 2,,,NCT03352947,Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma,INTERIM,https://ClinicalTrials.gov/show/NCT03352947
clinicaltrials.gov,dabrafenib,1929355,P15056,"InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)",BFSMGDJOXZAERB-UHFFFAOYSA-N,CC(C)(C)c1nc(c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(s1)c4ccnc(N)n4,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,skin cancers;lung cancers;others;brain cancers,Phase 4,,,NCT03340506,Dabrafenib and/or Trametinib Rollover Study,,https://ClinicalTrials.gov/show/NCT03340506
clinicaltrials.gov,dabrafenib,1929355,P15056,"InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)",BFSMGDJOXZAERB-UHFFFAOYSA-N,CC(C)(C)c1nc(c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(s1)c4ccnc(N)n4,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,,Phase 2,,,NCT02034110,Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers,,https://ClinicalTrials.gov/show/NCT02034110
clinicaltrials.gov,dabrafenib,1929355,P15056,"InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)",BFSMGDJOXZAERB-UHFFFAOYSA-N,CC(C)(C)c1nc(c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(s1)c4ccnc(N)n4,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,,Phase 2,,,NCT01072175,"Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212",,https://ClinicalTrials.gov/show/NCT01072175
clinicaltrials.gov,dabrafenib,1929355,P15056,"InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)",BFSMGDJOXZAERB-UHFFFAOYSA-N,CC(C)(C)c1nc(c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(s1)c4ccnc(N)n4,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,lung cancers,Phase 2,,,NCT03543306,Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation,,https://ClinicalTrials.gov/show/NCT03543306
clinicaltrials.gov,dabrafenib,1929355,P15056,"InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)",BFSMGDJOXZAERB-UHFFFAOYSA-N,CC(C)(C)c1nc(c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(s1)c4ccnc(N)n4,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,skin cancers,Phase 3,,,NCT03551626,Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes,COMBI-APlus,https://ClinicalTrials.gov/show/NCT03551626
clinicaltrials.gov,dabrafenib,1929355,P15056,"InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)",BFSMGDJOXZAERB-UHFFFAOYSA-N,CC(C)(C)c1nc(c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(s1)c4ccnc(N)n4,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,lung cancers,Phase 2,,,NCT03543306,Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation,,https://ClinicalTrials.gov/show/NCT03543306
clinicaltrials.gov,dabrafenib,1929355,P15056,"InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)",BFSMGDJOXZAERB-UHFFFAOYSA-N,CC(C)(C)c1nc(c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(s1)c4ccnc(N)n4,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,skin cancers,Phase 3,,,NCT03551626,Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes,COMBI-APlus,https://ClinicalTrials.gov/show/NCT03551626
clinicaltrials.gov,dabrafenib,1929355,P15056,"InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)",BFSMGDJOXZAERB-UHFFFAOYSA-N,CC(C)(C)c1nc(c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(s1)c4ccnc(N)n4,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,,,,,NCT03975829,Pediatric Long-Term Follow-up and Rollover Study,,https://ClinicalTrials.gov/show/NCT03975829
literature,dabrafenib,1929355,P15056,"InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)",BFSMGDJOXZAERB-UHFFFAOYSA-N,CC(C)(C)c1nc(c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(s1)c4ccnc(N)n4,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,melanoma with BRAF V600 mutations,skin cancers,Phase 1/2,23020132,"Dose-limiting toxic effects were infrequently observed in patients receiving combination therapy with 150 mg of dabrafenib and 2 mg of trametinib (combination 150/2). Cutaneous squamous-cell carcinoma was seen in 7% of patients receiving combination 150/2 and in 19% receiving monotherapy (P=0.09), whereas pyrexia was more common in the combination 150/2 group than in the monotherapy group (71% vs. 26%). Median progression-free survival in the combination 150/2 group was 9.4 months, as compared with 5.8 months in the monotherapy group (hazard ratio for progression or death, 0.39; 95% confidence interval, 0.25 to 0.62; P<0.001). The rate of complete or partial response with combination 150/2 therapy was 76%, as compared with 54% with monotherapy (P=0.03).",,,,
literature,dabrafenib,1929355,P15056,"InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)",BFSMGDJOXZAERB-UHFFFAOYSA-N,CC(C)(C)c1nc(c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(s1)c4ccnc(N)n4,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,unresectable stage IIIC or stage IV melanoma with a BRAF V600E or V600K mutation,skin cancers,Phase 3,25265492,"The median progression-free survival was 9.3 months in the dabrafenib-trametinib group and 8.8 months in the dabrafenib-only group (hazard ratio for progression or death in the dabrafenib-trametinib group, 0.75; 95% confidence interval [CI], 0.57 to 0.99; P=0.03). The overall response rate was 67% in the dabrafenib-trametinib group and 51% in the dabrafenib-only group (P=0.002). At 6 months, the interim overall survival rate was 93% with dabrafenib-trametinib and 85% with dabrafenib alone (hazard ratio for death, 0.63; 95% CI, 0.42 to 0.94; P=0.02). However, a specified efficacy-stopping boundary (two-sided P=0.00028) was not crossed. Rates of adverse events were similar in the two groups, although more dose modifications occurred in the dabrafenib-trametinib group. The rate of cutaneous squamous-cell carcinoma was lower in the dabrafenib-trametinib group than in the dabrafenib-only group (2% vs. 9%), whereas pyrexia occurred in more patients (51% vs. 28%) and was more often severe (grade 3, 6% vs. 2%) in the dabrafenib-trametinib group.",,,,
literature,dabrafenib,1929355,P15056,"InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)",BFSMGDJOXZAERB-UHFFFAOYSA-N,CC(C)(C)c1nc(c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(s1)c4ccnc(N)n4,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,previously untreated metastatic melanoma with BRAF V600E or V600K mutations,skin cancers,Phase 3,25399551,"At the preplanned interim overall survival analysis, which was performed after 77% of the total number of expected events occurred, the overall survival rate at 12 months was 72% (95% confidence interval [CI], 67 to 77) in the combination-therapy group and 65% (95% CI, 59 to 70) in the vemurafenib group (hazard ratio for death in the combination-therapy group, 0.69; 95% CI, 0.53 to 0.89; P=0.005). The prespecified interim stopping boundary was crossed, and the study was stopped for efficacy in July 2014. Median progression-free survival was 11.4 months in the combination-therapy group and 7.3 months in the vemurafenib group (hazard ratio, 0.56; 95% CI, 0.46 to 0.69; P<0.001). The objective response rate was 64% in the combination-therapy group and 51% in the vemurafenib group (P<0.001). Rates of severe adverse events and study-drug discontinuations were similar in the two groups. Cutaneous squamous-cell carcinoma and keratoacanthoma occurred in 1% of patients in the combination-therapy group and 18% of those in the vemurafenib group.",,,,
literature,dabrafenib,1929355,P15056,"InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)",BFSMGDJOXZAERB-UHFFFAOYSA-N,CC(C)(C)c1nc(c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(s1)c4ccnc(N)n4,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,Val600 BRAF-mutant melanoma,skin cancers,Phase 3,26037941,"Between May 4, 2012, and Nov 30, 2012, we screened 947 patients for eligibility, of whom 423 were randomly assigned to receive dabrafenib and trametinib (n=211) or dabrafenib only (n=212). The final data cutoff was Jan 12, 2015, at which time 222 patients had died. Median overall survival was 25à1 months (95% CI 19à2-not reached) in the dabrafenib and trametinib group versus 18à7 months (15à2-23à7) in the dabrafenib only group (hazard ratio [HR] 0à71, 95% CI 0à55-0à92; p=0à0107). Overall survival was 74% at 1 year and 51% at 2 years in the dabrafenib and trametinib group versus 68% and 42%, respectively, in the dabrafenib only group. Based on 301 events, median progression-free survival was 11à0 months (95% CI 8à0-13à9) in the dabrafenib and trametinib group and 8à8 months (5à9-9à3) in the dabrafenib only group (HR 0à67, 95% CI 0à53-0à84; p=0à0004; unadjusted for multiple testing). Treatment-related adverse events occurred in 181 (87%) of 209 patients in the dabrafenib and trametinib group and 189 (90%) of 211 patients in the dabrafenib only group; the most common was pyrexia (108 patients, 52%) in the dabrafenib and trametinib group, and hyperkeratosis (70 patients, 33%) in the dabrafenib only group. Grade 3 or 4 adverse events occurred in 67 (32%) patients in the dabrafenib and trametinib group and 66 (31%) patients in the dabrafenib only group.",,,,
literature,dabrafenib,1929355,P15056,"InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)",BFSMGDJOXZAERB-UHFFFAOYSA-N,CC(C)(C)c1nc(c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(s1)c4ccnc(N)n4,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma ,skin cancers,Phase 3,26433819,"From June 4, 2012, to Oct 7, 2013, 1645 patients at 193 centres worldwide were screened for eligibility, and 704 patients were randomly assigned to dabrafenib plus trametinib (n=352) or vemurafenib (n=352). Questionnaire completion rates for both groups were high (>95% at baseline, >80% at follow-up assessments, and >70% at disease progression) with similar HRQoL and symptom scores reported at baseline in both treatment groups for all questionnaires. Differences in mean scores between treatment groups were significant and clinically meaningful in favour of the combination compared with vemurafenib monotherapy for most domains across all three questionnaires during study treatment and at disease progression, including EORTC QLQ-C30 global health (7à92, 7à62, 6à86, 7à47, 5à16, 7à56, and 7à57 at weeks 8, 16, 24, 32, 40, 48, and disease progression, respectively; p<0à001 for all assessments except p=0à005 at week 40), EORTC QLQ-C30 pain (-13à20, -8à05, -8à82, -12à69, -12à46, -11à41, and -10à57 at weeks 8, 16, 24, 32, 40, 48, and disease progression, respectively; all p<0à001), EQ-5D thermometer scores (7à96, 8à05, 6à83, 11à53, 7à41, 9à08, and 10à51 at weeks 8, 16, 24, 32, 40, 48, and disease progression, respectively; p<0à001 for all assessments except p=0à006 at week 32), and FACT-M Melanoma Subscale score (3à62, 2à93, 2à45, 3à39, 2à85, 3à00, and 3à68 at weeks 8, 16, 24, 32, 40, 48, and disease progression, respectively; all p<0à001).",,,,
literature,dabrafenib,1929355,P15056,"InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)",BFSMGDJOXZAERB-UHFFFAOYSA-N,CC(C)(C)c1nc(c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(s1)c4ccnc(N)n4,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,BRAF-mutated melanoma,skin cancers,Phase 3,28648698,"Long-term pooled outcomes were consistent with individual trial results (N_=_563; 3-year PFS, 23%; 3-year OS, 44%). Baseline LDH level and number of organ sites remained strongly associated with and/or predictive of PFS and OS. In addition, baseline sum of lesion diameters (SLD) was identified as a predictor for progression. In the most favourable prognostic group (normal LDH, SLD <66_mm, <3 organ sites; n_=_183/563 [33%]), 3-year PFS was 42%. Baseline number of organ sites was also predictive of outcomes in patients with PFS___6 months.",,,,
literature,dabrafenib,1929355,P15056,"InChI=1S/C23H20F3N5O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25/h4-11,31H,1-3H3,(H2,27,28,29)",BFSMGDJOXZAERB-UHFFFAOYSA-N,CC(C)(C)c1nc(c2cccc(NS(=O)(=O)c3c(F)cccc3F)c2F)c(s1)c4ccnc(N)n4,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,patients with melanoma who previously have received programmed cell death protein 1-based therapy,skin cancers,Phase 3,30521084,"A total of 78 patients were identified as having received a BRAF-MEK regimen at a median of 34 days after the last dose of PD-1-based therapy. The majority of patients (86%) received the combination of dabrafenib and trametinib. Approximately 80% of patients had American Joint Committee on Cancer M1c or M1d disease. Sixty-five regimens (83%) had ≥1 dose modification. The median time to the first dose modification was 14 days; 86% occurred within 90 days and 71% involved pyrexia. Dose modifications were more common in patients receiving BRAF-MEK <90 days after the last dose of PD-1 and who were not receiving steroids. Of the dose modifications, 25 (31%) led to an AE-related hospitalization. Among 55 BRAF-naive patients, the median time receiving BRAF-MEK therapy was 5.8 months and the median OS was 15.6 months.",,,,
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,colorectal cancers,Phase 2,,,NCT03428126,Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer,,https://ClinicalTrials.gov/show/NCT03428126
clinicaltrials.gov,EGF816,,,,,,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,lung cancers,Phase 1,,,NCT03516214,EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer and T790M-positive Resistance to EGFR TKI Therapy,EATON,https://ClinicalTrials.gov/show/NCT03516214
clinicaltrials.gov,EGF816,,,,,,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,lung cancers,Phase 1,,,NCT03516214,EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer and T790M-positive Resistance to EGFR TKI Therapy,EATON,https://ClinicalTrials.gov/show/NCT03516214
clinicaltrials.gov,GSK2256098,,,,,,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,advanced solid cancers,Phase 1,,,NCT01938443,A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT01938443
clinicaltrials.gov,GSK2256098,,,,,,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,pancreatic cancers,Phase 2,,,NCT02428270,A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer,,https://ClinicalTrials.gov/show/NCT02428270
clinicaltrials.gov,GSK525762,763777,,"InChI=1S/C22H22ClN5O2/c1-4-24-20(29)12-18-22-27-26-13(2)28(22)19-10-9-16(30-3)11-17(19)21(25-18)14-5-7-15(23)8-6-14/h5-11,18H,4,12H2,1-3H3,(H,24,29)/t18-/m0/s1",AAAQFGUYHFJNHI-SFHVURJKSA-N,CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c3cc(OC)ccc3n4c(C)nnc14,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,,Phase 2,,,NCT03266159,"A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors",,https://ClinicalTrials.gov/show/NCT03266159
clinicaltrials.gov,HDM201,,,,,,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,colorectal cancers,Phase 1,,,NCT03714958,Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type,TRAHD,https://ClinicalTrials.gov/show/NCT03714958
clinicaltrials.gov,HDM201,,,,,,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,colorectal cancers,Phase 1,,,NCT03714958,Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type,TRAHD,https://ClinicalTrials.gov/show/NCT03714958
clinicaltrials.gov,lapatinib,2195,O00750;O14733;O43353;O75747;O94804;P00533;P04626;P08684;P09619;P21860;Q13163;Q15303;Q9H2G2;Q9UBF8,"InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)",BCFGMOOMADDAQU-UHFFFAOYSA-N,CS(=O)(=O)CCNCc1oc(cc1)c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,bowel cancers,Phase 1/2,,,NCT02230553,Lapatinib Plus Trametinib in KRAS Mutant Malignancies,M14LTK,https://ClinicalTrials.gov/show/NCT02230553
clinicaltrials.gov,MMB,754222,,"InChI=1S/C25H28N2O5/c1-4-14-31-27-17(2)22(25(28)29)15-19-10-12-21(13-11-19)30-16-23-18(3)32-24(26-23)20-8-6-5-7-9-20/h5-13,22H,4,14-16H2,1-3H3,(H,28,29)/b27-17+/t22-/m1/s1",,,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,lung cancers,Phase 1,,,NCT02258607,Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase,,https://ClinicalTrials.gov/show/NCT02258607
clinicaltrials.gov,panitumumab,1238534,P00533,,,,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,bowel cancers,Phase 2,,,NCT03087071,panitumumab in Combination With Trametinib in Cetuximab-Refractory Stage IV Colorectal Cancer,,https://ClinicalTrials.gov/show/NCT03087071
clinicaltrials.gov,pazopanib,200268,O00238;O00444;O14965;O14976;O15197;O43353;O60331;O60674;O75716;O94804;O95819;P00519;P04049;P06239;P06241;P07332;P07333;P07947;P07948;P07949;P08581;P08631;P08922;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P16591;P17948;P19525;P21127;P21802;P22455;P22607;P27448;P29376;P29597;P33981;P35590;P35916;P35968;P36888;P37173;P42681;P42684;P42685;P43405;P45983;P45985;P51451;P51617;P51955;P52333;P52564;P53667;P53671;P53779;P57059;P80192;Q00536;Q02763;Q02779;Q08345;Q12851;Q12866;Q13163;Q13233;Q13470;Q13546;Q13705;Q13882;Q14012;Q16584;Q16832;Q2M2I8;Q56UN5;Q6P3R8;Q7L7X3;Q8IVH8;Q8TBX8;Q92918;Q96NX5;Q9BVS4;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K8;Q9H3Y6;Q9NRP7;Q9NSY1;Q9UBE8;Q9UBF8;Q9UKE5;Q9UL54;Q9UM73;Q9UQ88;Q9UQB9;Q9Y2U5;Q9Y4K4;Q9Y616,"InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)",CUIHSIWYWATEQL-UHFFFAOYSA-N,CN(c1ccc2c(C)n(C)nc2c1)c3ccnc(Nc4ccc(C)c(c4)S(=O)(=O)N)n3,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,soft tissue cancers,Phase 2,,,NCT02342600,SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor),,https://ClinicalTrials.gov/show/NCT02342600
clinicaltrials.gov,pazopanib,200268,O00238;O00444;O14965;O14976;O15197;O43353;O60331;O60674;O75716;O94804;O95819;P00519;P04049;P06239;P06241;P07332;P07333;P07947;P07948;P07949;P08581;P08631;P08922;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P16591;P17948;P19525;P21127;P21802;P22455;P22607;P27448;P29376;P29597;P33981;P35590;P35916;P35968;P36888;P37173;P42681;P42684;P42685;P43405;P45983;P45985;P51451;P51617;P51955;P52333;P52564;P53667;P53671;P53779;P57059;P80192;Q00536;Q02763;Q02779;Q08345;Q12851;Q12866;Q13163;Q13233;Q13470;Q13546;Q13705;Q13882;Q14012;Q16584;Q16832;Q2M2I8;Q56UN5;Q6P3R8;Q7L7X3;Q8IVH8;Q8TBX8;Q92918;Q96NX5;Q9BVS4;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K8;Q9H3Y6;Q9NRP7;Q9NSY1;Q9UBE8;Q9UBF8;Q9UKE5;Q9UL54;Q9UM73;Q9UQ88;Q9UQB9;Q9Y2U5;Q9Y4K4;Q9Y616,"InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)",CUIHSIWYWATEQL-UHFFFAOYSA-N,CN(c1ccc2c(C)n(C)nc2c1)c3ccnc(Nc4ccc(C)c(c4)S(=O)(=O)N)n3,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,thyroid cancers;soft tissue cancers;other,Phase 1,,,NCT01438554,"Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma",,https://ClinicalTrials.gov/show/NCT01438554
clinicaltrials.gov,ribociclib,,P11802;Q00534,"InChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28)",RHXHGRAEPCAFML-UHFFFAOYSA-N,CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N4CCNCC4)nc2n1C5CCCC5,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,pancreatic cancers;bowel cancers,Phase 1/2,,,NCT02703571,Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT02703571
clinicaltrials.gov,rociletinib,1271035,P00533,"InChI=1S/C27H28F3N7O3/c1-4-24(39)32-18-6-5-7-19(14-18)33-25-21(27(28,29)30)16-31-26(35-25)34-22-9-8-20(15-23(22)40-3)37-12-10-36(11-13-37)17(2)38/h4-9,14-16H,1,10-13H2,2-3H3,(H,32,39)(H2,31,33,34,35)",HUFOZJXAKZVRNJ-UHFFFAOYSA-N,COc1cc(ccc1Nc2ncc(c(Nc3cccc(NC(=O)C=C)c3)n2)C(F)(F)F)N4CCN(CC4)C(=O)C,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,,lung cancers,Phase 1/2,,,NCT02580708,A Phase 1/2 Study of the Safety and Efficacy of Rociletinib When Administered in Combination With Trametinib in Patients With Activating EGFR Mutation-positive Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC),,https://ClinicalTrials.gov/show/NCT02580708
clinicaltrials.gov,BMS-754807,,P06213;P08069,"InChI=1S/C23H24FN9O/c1-23(21(34)26-15-7-8-18(24)25-13-15)9-3-10-32(23)22-28-20(17-4-2-11-33(17)31-22)27-19-12-16(29-30-19)14-5-6-14/h2,4,7-8,11-14H,3,5-6,9-10H2,1H3,(H,26,34)(H2,27,28,29,30,31)/t23-/m0/s1",LQVXSNNAFNGRAH-QHCPKHFHSA-N,C[C@]1(CCCN1c2nc(Nc3cc([nH]n3)C4CC4)c5cccn5n2)C(=O)Nc6ccc(F)nc6,trastuzumab,4,P04626,,,,,breast cancers,Phase 1/2,,,NCT00788333,Combination Study of BMS-754807 and Herceptin__ in Patients With Advanced or Metastatic Her-2-positive Breast Cancer,,https://ClinicalTrials.gov/show/NCT00788333
clinicaltrials.gov,cabozantinib,1081506,P08581,"InChI=1S/C28H24FN3O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34)",ONIQOQHATWINJY-UHFFFAOYSA-N,COc1cc2nccc(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc5ccc(F)cc5)cc3)c2cc1OC,trastuzumab,4,P04626,,,,,breast cancers,Phase 2,,,NCT02260531,Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases,,https://ClinicalTrials.gov/show/NCT02260531
clinicaltrials.gov,cetuximab,9,P00533,,,,trastuzumab,4,P04626,,,,,breast cancers,Phase 1,,,NCT00367250,Safety Study of Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast Cancer,,https://ClinicalTrials.gov/show/NCT00367250
literature,cetuximab,9,P00533,,,,trastuzumab,4,P04626,,,,metastatic pancreatic_cancer_after gemcitabine failure,pancreatic cancers,Phase 1/2,25918250,"Endpoints were the objective response rate, safety, progression-free (PFS) and overall survival (OS). During phase 1 (n=10 patients), toxicities were evenly distributed except for skin toxicities that frequently caused compliance issues. The higher dose level was defined as the trastuzumab recommended dose. During phase 2 (n=39 patients), toxicities were mainly cutaneous reactions and asthenia. No objective response was observed. Nine patients were stabilized but arrested treatment due to toxicity. Median PFS was 1.8 months (95%CI: 1.7-2.0 months) and median OS was 4.6 months (95%CI: 2.7-6.6 months). Both were positively correlated with skin toxicity severity (P=0.027 and P=0.001, respectively). Conventional phase 1 dose-escalation schedules are unsuitable for targeted therapies because most cutaneous toxicities are not considered dose-limiting toxicities. The compliance issues caused by skin toxicities were particularly detrimental because of the toxicity-response correlation.",,,,
clinicaltrials.gov,CNF2024,,,,,,trastuzumab,4,P04626,,,,,breast cancers,Phase 1,,,NCT00412412,CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD Study,,https://ClinicalTrials.gov/show/NCT00412412
clinicaltrials.gov,copanlisib,1212464,O00329;O00459;P27986;P42336;P42338;P48736;Q8WYR1;Q92569,"InChI=1S/C23H28N8O4/c1-33-19-17(35-10-2-6-30-8-11-34-12-9-30)4-3-16-18(19)28-23(31-7-5-25-20(16)31)29-21(32)15-13-26-22(24)27-14-15/h3-4,13-14H,2,5-12H2,1H3,(H2,24,26,27)(H,28,29,32)",PZBCKZWLPGJMAO-UHFFFAOYSA-N,COc1c(OCCCN2CCOCC2)ccc3C4=NCCN4C(=Nc13)NC(=O)c5cnc(N)nc5,trastuzumab,4,P04626,,,,,breast cancers,Phase 1,,,NCT02705859,Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study),Panther,https://ClinicalTrials.gov/show/NCT02705859
clinicaltrials.gov,EG12014,,,,,,trastuzumab,4,P04626,,,,,breast cancers,Phase 3,,,NCT03433313,Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer,,https://ClinicalTrials.gov/show/NCT03433313
clinicaltrials.gov,epothilone D,,,"InChI=1S/C27H41NO5S/c1-16-9-8-10-17(2)25(31)19(4)26(32)27(6,7)23(29)14-24(30)33-22(12-11-16)18(3)13-21-15-34-20(5)28-21/h11,13,15,17,19,22-23,25,29,31H,8-10,12,14H2,1-7H3/b16-11-,18-13+/t17-,19+,22-,23-,25-/m0/s1",XOZIUKBZLSUILX-GIQCAXHBSA-N,C[C@H]1CCC\C(=C/C[C@H](OC(=O)C[C@H](O)C(C)(C)C(=O)[C@H](C)[C@H]1O)\C(=C\c2csc(C)n2)\C)\C,trastuzumab,4,P04626,,,,,breast cancers,Phase 2,,,NCT00337649,A Study of Epothilone D in Combination With Herceptin (Trastuzumab) in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer.,,https://ClinicalTrials.gov/show/NCT00337649
clinicaltrials.gov,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,trastuzumab,4,P04626,,,,,breast cancers,Phase 1/2,,,NCT00458237,Dose Escalation Followed by Study of RAD001 in Combination With Trastuzumab in HER2-Positive Metastatic Breast Cancer,,https://ClinicalTrials.gov/show/NCT00458237
clinicaltrials.gov,everolimus,1005231,P62942,"InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",HKVAMNSJSFKALM-GKUWKFKPSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OCCO,trastuzumab,4,P04626,,,,,breast cancers,Phase 2,,,NCT00912340,Phase II Trial of EVEROLIMUS _± Trastuzumab in Hormone-Refractory Metastatic Breast Cancer,,https://ClinicalTrials.gov/show/NCT00912340
clinicaltrials.gov,ganitumab,,P08069,,,,trastuzumab,4,P04626,,,,,breast cancers,Phase 1/2,,,NCT01479179,Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab,,https://ClinicalTrials.gov/show/NCT01479179
clinicaltrials.gov,IPI-504,747696,P07900;P08238,"InChI=1S/C31H45N3O8/c1-8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30(38)34-22(28(21)37)16-23(26)35/h8-11,15-17,19,24-25,27,29,33,35-37H,1,12-14H2,2-7H3,(H2,32,39)(H,34,38)/b11-9-,18-10+,20-15+/t17-,19+,24+,25+,27-,29+/m1/s1",OAKGNIRUXAZDQF-TXHRRWQRSA-N,CO[C@H]1C[C@H](C)Cc2c(O)c(NC(=O)\C(=C\C=C/[C@H](OC)[C@@H](OC(=O)N)\C(=C\[C@H](C)[C@H]1O)\C)\C)cc(O)c2NCC=C,trastuzumab,4,P04626,,,,,breast cancers,Phase 2,,,NCT00817362,"Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer",,https://ClinicalTrials.gov/show/NCT00817362
literature,IPI-504,747696,P07900;P08238,"InChI=1S/C31H45N3O8/c1-8-12-33-26-21-13-17(2)14-25(41-7)27(36)19(4)15-20(5)29(42-31(32)39)24(40-6)11-9-10-18(3)30(38)34-22(28(21)37)16-23(26)35/h8-11,15-17,19,24-25,27,29,33,35-37H,1,12-14H2,2-7H3,(H2,32,39)(H,34,38)/b11-9-,18-10+,20-15+/t17-,19+,24+,25+,27-,29+/m1/s1",OAKGNIRUXAZDQF-TXHRRWQRSA-N,CO[C@H]1C[C@H](C)Cc2c(O)c(NC(=O)\C(=C\C=C/[C@H](OC)[C@@H](OC(=O)N)\C(=C\[C@H](C)[C@H]1O)\C)\C)cc(O)c2NCC=C,trastuzumab,4,P04626,,,,advanced or metastatic HER2-positive breast cancer,breast cancers,Phase 2,23580070,"No DLTs were observed. Most adverse events (AEs) were grade 1 or 2; common treatment-related AEs included fatigue (46 %), nausea (31 %), and diarrhea (23 %). One patient had treatment-related serious AEs of grade 1 diarrhea and grade 3 hypokalemia. grade 3 transaminase elevation occurred in one patient (4 %) who also had metastatic liver disease. Sixteen patients (62 %) had stable disease, with a median on-study duration of 2.4 months (range 1.1-8.2). No confirmed responses were observed. Retaspimycin HCl at 300 mg/m_ weekly in combination with trastuzumab was well tolerated and without significant toxicities. Modest clinical activity was observed, but did not meet criteria for trial expansion. The safety profile for patients on study raises the possibility of retaspimycin HCl underdosing that limited efficacy. Studies employing higher doses are ongoing.",,,,
clinicaltrials.gov,lapatinib,2195,O00750;O14733;O43353;O75747;O94804;P00533;P04626;P08684;P09619;P21860;Q13163;Q15303;Q9H2G2;Q9UBF8,"InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)",BCFGMOOMADDAQU-UHFFFAOYSA-N,CS(=O)(=O)CCNCc1oc(cc1)c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2,trastuzumab,4,P04626,,,,,breast cancers,Phase 2,,,NCT00470704,"Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer",,https://ClinicalTrials.gov/show/NCT00470704
clinicaltrials.gov,lapatinib,2195,O00750;O14733;O43353;O75747;O94804;P00533;P04626;P08684;P09619;P21860;Q13163;Q15303;Q9H2G2;Q9UBF8,"InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)",BCFGMOOMADDAQU-UHFFFAOYSA-N,CS(=O)(=O)CCNCc1oc(cc1)c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2,trastuzumab,4,P04626,,,,,breast cancers,Phase 2,,,NCT02238509,Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies,,https://ClinicalTrials.gov/show/NCT02238509
clinicaltrials.gov,lapatinib,2195,O00750;O14733;O43353;O75747;O94804;P00533;P04626;P08684;P09619;P21860;Q13163;Q15303;Q9H2G2;Q9UBF8,"InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)",BCFGMOOMADDAQU-UHFFFAOYSA-N,CS(=O)(=O)CCNCc1oc(cc1)c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2,trastuzumab,4,P04626,,,,,breast cancers,Phase 2,,,NCT02213042,Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer,,https://ClinicalTrials.gov/show/NCT02213042
clinicaltrials.gov,lapatinib,2195,O00750;O14733;O43353;O75747;O94804;P00533;P04626;P08684;P09619;P21860;Q13163;Q15303;Q9H2G2;Q9UBF8,"InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)",BCFGMOOMADDAQU-UHFFFAOYSA-N,CS(=O)(=O)CCNCc1oc(cc1)c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2,trastuzumab,4,P04626,,,,,breast cancers,Phase 2,,,NCT01557764,Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast Cancer,,https://ClinicalTrials.gov/show/NCT01557764
clinicaltrials.gov,lapatinib,2195,O00750;O14733;O43353;O75747;O94804;P00533;P04626;P08684;P09619;P21860;Q13163;Q15303;Q9H2G2;Q9UBF8,"InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)",BCFGMOOMADDAQU-UHFFFAOYSA-N,CS(=O)(=O)CCNCc1oc(cc1)c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2,trastuzumab,4,P04626,,,,,breast cancers,Phase 3,,,NCT00490139,ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D,ALTTO,https://ClinicalTrials.gov/show/NCT00490139
clinicaltrials.gov,lapatinib,2195,O00750;O14733;O43353;O75747;O94804;P00533;P04626;P08684;P09619;P21860;Q13163;Q15303;Q9H2G2;Q9UBF8,"InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)",BCFGMOOMADDAQU-UHFFFAOYSA-N,CS(=O)(=O)CCNCc1oc(cc1)c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2,trastuzumab,4,P04626,,,,,breast cancers,Phase 3,,,NCT00320385,Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer,,https://ClinicalTrials.gov/show/NCT00320385
clinicaltrials.gov,lapatinib,2195,O00750;O14733;O43353;O75747;O94804;P00533;P04626;P08684;P09619;P21860;Q13163;Q15303;Q9H2G2;Q9UBF8,"InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)",BCFGMOOMADDAQU-UHFFFAOYSA-N,CS(=O)(=O)CCNCc1oc(cc1)c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2,trastuzumab,4,P04626,,,,,,Phase 3,,,NCT00968968,Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone,,https://ClinicalTrials.gov/show/NCT00968968
literature,lapatinib,2195,O00750;O14733;O43353;O75747;O94804;P00533;P04626;P08684;P09619;P21860;Q13163;Q15303;Q9H2G2;Q9UBF8,"InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)",BCFGMOOMADDAQU-UHFFFAOYSA-N,CS(=O)(=O)CCNCc1oc(cc1)c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2,trastuzumab,4,P04626,,,,HER2-positive early breast cancer,breast cancers,Phase 3,22257673,"154 patients received lapatinib, 149 trastuzumab, and 152 the combination. pCR rate was significantly higher in the group given lapatinib and trastuzumab (78 of 152 patients [51à3%; 95% CI 43à1-59à5]) than in the group given trastuzumab alone (44 of 149 patients [29à5%; 22à4-37à5]; difference 21à1%, 9à1-34à2, p=0à0001). We recorded no significant difference in pCR between the lapatinib (38 of 154 patients [24à7%, 18à1-32à3]) and the trastuzumab (difference -4à8%, -17à6 to 8à2, p=0à34) groups. No major cardiac dysfunctions occurred. Frequency of grade 3 diarrhoea was higher with lapatinib (36 patients [23à4%]) and lapatinib plus trastuzumab (32 [21à1%]) than with trastuzumab (three [2à0%]). Similarly, grade 3 liver-enzyme alterations were more frequent with lapatinib (27 [17à5%]) and lapatinib plus trastuzumab (15 [9à9%]) than with trastuzumab (11 [7à4%]).",,,,
literature,lapatinib,2195,O00750;O14733;O43353;O75747;O94804;P00533;P04626;P08684;P09619;P21860;Q13163;Q15303;Q9H2G2;Q9UBF8,"InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)",BCFGMOOMADDAQU-UHFFFAOYSA-N,CS(=O)(=O)CCNCc1oc(cc1)c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2,trastuzumab,4,P04626,,,,HER2-positive early breast cancer,breast cancers,Phase 3,25130998,"455 patients were enrolled: 154 (34%) were assigned to the lapatinib group, 149 (33%) to the trastuzumab group, and 152 (33%) to the lapatinib plus trastuzumab group. At an event follow-up of 3à77 years (IQR 3à50-4à22), 3-year event-free survival was 78% (95% CI 70-84) in the lapatinib group, 76% (68-82) in the trastuzumab group, and 84% (77-89) in the combination group. Event-free survival did not differ between the lapatinib and trastuzumab groups (HR 1à06, 95% CI 0à66-1à69, p=0à81), nor between the combination and trastuzumab groups (0à78, 0à47-1à28, p=0à33). Median survival follow-up was 3à84 years (IQR 3à60-4à24), and 3-year overall survival was 93% (95% CI 87-96) for lapatinib, 90% (84-94) for trastuzumab, and 95% (90-98) for combination therapy. Overall survival did not significantly differ between the lapatinib and trastuzumab groups (HR 0à86, 95% CI 0à45-1à63, p=0à65), nor between the combination and trastuzumab groups (0à62, 0à30-1à25, p=0à19). Landmark analyses showed that 3-year event-free survival was significantly improved for women who achieved pathological complete response compared with those who did not (HR 0à38, 95% CI 0à22-0à63, p=0à0003), as was 3-year overall survival (0à35, 0à15-0à70, p=0à005). Adverse events occurred in 149 (99%) patients receiving lapatinib, 142 (96%) patients receiving trastuzumab, and 147 (99%) patients receiving combination therapy. The most common adverse events were diarrhoea, rash or erythema, hepatic adverse events, and neutropenia (not related to FEC administration), and were consistent with known safety profiles of lapatinib and trastuzumab. Three primary and eight secondary cardiac events occurred, with no significant difference in incidence between treatment groups for primary or any cardiac events.",,,,
clinicaltrials.gov,LJM716,,,,,,trastuzumab,4,P04626,,,,,breast cancers;stomach cancers,Phase 1,,,NCT01602406,Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer,,https://ClinicalTrials.gov/show/NCT01602406
literature,MK-2206,,P31751;Q9Y243;P31749,"InChI=1S/C25H21N5O/c26-25(12-4-13-25)18-9-7-17(8-10-18)22-19(16-5-2-1-3-6-16)15-20-21(27-22)11-14-30-23(20)28-29-24(30)31/h1-3,5-11,14-15H,4,12-13,26H2,(H,29,31)",ULDXWLCXEDXJGE-UHFFFAOYSA-N,NC1(CCC1)c2ccc(cc2)c3nc4C=CN5C(=O)NN=C5c4cc3c6ccccc6,trastuzumab,4,P04626,,,,HER2-positive solid tumours,advanced solid cancers,Phase 1,24252402,"A total of 34 patients with HER2+ disease were enrolled; 31 received study-drug. The maximum tolerated dose (MTD) for MK-2206 in combination with trastuzumab was 60 mg for the QOD schedule and 135 mg for the QW schedule, although a true MTD was not established due to early termination of the trial. The most common treatment-emergent toxicities included fatigue, hyperglycemia, and dermatologic rash, consistent with prior experience; one death unrelated to treatment was reported. There was one complete response in a patient with metastatic breast cancer, one patient achieved a partial response, and 5 patients had stable disease for at least 4 months, despite progression on multiple prior trastuzumab- and lapatinib-based therapies. Results also indicate that trastuzumab does not affect the pharmacokinetics of MK-2206.",,,,
clinicaltrials.gov,MM-302,,P11388;P04626,,,,trastuzumab,4,P04626,,,,,advanced solid cancers,Phase 1,,,NCT02735798,64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain Mets,,https://ClinicalTrials.gov/show/NCT02735798
clinicaltrials.gov,niraparib,919241,Q9UGN5;P09874,"InChI=1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)/t14-/m1/s1",PCHKPVIQAHNQLW-CQSZACIVSA-N,NC(=O)c1cccc2cn(nc12)c3ccc(cc3)[C@@H]4CCCNC4,trastuzumab,4,P04626,,,,,breast cancers,Phase 1/2,,,NCT03368729,Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer,,https://ClinicalTrials.gov/show/NCT03368729
clinicaltrials.gov,NVP-AUY922,480574,,"InChI=1S/C26H31N3O5/c1-4-27-26(32)24-23(18-7-5-17(6-8-18)15-29-9-11-33-12-10-29)25(34-28-24)20-13-19(16(2)3)21(30)14-22(20)31/h5-8,13-14,16,30-31H,4,9-12,15H2,1-3H3,(H,27,32)",NDAZATDQFDPQBD-UHFFFAOYSA-N,CCNC(=O)c1noc(c2cc(C(C)C)c(O)cc2O)c1c3ccc(CN4CCOCC4)cc3,trastuzumab,4,P04626,,,,,breast cancers,Phase 2,,,NCT01271920,Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab,,https://ClinicalTrials.gov/show/NCT01271920
clinicaltrials.gov,panobinostat,523996,Q9BY41;Q969S8;O15379;P56524;Q8WUI4;Q9UQL6;Q9UKV0;Q13547;Q92769;Q9UBN7;Q96DB2,"InChI=1S/C21H23N3O2/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26/h2-11,22-23,26H,12-14H2,1H3,(H,24,25)/b11-10+",FPOHNWQLNRZRFC-ZHACJKMWSA-N,Cc1[nH]c2ccccc2c1CCNCc3ccc(\C=C\C(=O)NO)cc3,trastuzumab,4,P04626,,,,,breast cancers,Phase 1/2,,,NCT00567879,A Trial of Panobinostat and Trastuzumab for Adult Female Patients With HER2 Positive Metastatic Breast Cancer (MBC) Whose Disease Has Progressed on or After Trastuzumab,,https://ClinicalTrials.gov/show/NCT00567879
clinicaltrials.gov,Pertuzuma,,,,,,trastuzumab,4,P04626,,,,,breast cancers,Phase 2,,,NCT03674112,A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer,,https://ClinicalTrials.gov/show/NCT03674112
clinicaltrials.gov,Pertuzuma,,,,,,trastuzumab,4,P04626,,,,,breast cancers,Phase 2,,,NCT03674112,A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer,,https://ClinicalTrials.gov/show/NCT03674112
clinicaltrials.gov,pertuzumab,1238538,P04626,,,,trastuzumab,4,P04626,,,,,breast cancers,Phase 2,,,NCT01674062,A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast Cancer,,https://ClinicalTrials.gov/show/NCT01674062
clinicaltrials.gov,pertuzumab,1238538,P04626,,,,trastuzumab,4,P04626,,,,,breast cancers,Phase 2,,,NCT02536339,Pertuzumab With High-Dose Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy,,https://ClinicalTrials.gov/show/NCT02536339
clinicaltrials.gov,pertuzumab,1238538,P04626,,,,trastuzumab,4,P04626,,,,,breast cancers,Phase 2,,,NCT00943670,Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression,,https://ClinicalTrials.gov/show/NCT00943670
clinicaltrials.gov,pertuzumab,1238538,P04626,,,,trastuzumab,4,P04626,,,,,breast cancers,Phase 3,,,NCT02625441,"Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer",BOLD-1,https://ClinicalTrials.gov/show/NCT02625441
literature,pertuzumab,1238538,P04626,,,,trastuzumab,4,P04626,,,,"locally advanced, inflammatory, or early HER2-positive breast cancer",breast cancers,Phase 2,22153890,"Of 417 eligible patients, 107 were randomly assigned to group A, 107 to group B, 107 to group C, and 96 to group D. Patients given pertuzumab and trastuzumab plus docetaxel (group B) had a significantly improved pathological complete response rate (49 of 107 patients; 45à8% [95% CI 36à1-55à7]) compared with those given trastuzumab plus docetaxel (group A; 31 of 107; 29à0% [20à6-38à5]; p=0à0141). 23 of 96 (24à0% [15à8-33à7]) women given pertuzumab plus docetaxel (group D) had a pathological complete response, as did 18 of 107 (16à8% [10à3-25à3]) given pertuzumab and trastuzumab (group C). The most common adverse events of grade 3 or higher were neutropenia (61 of 107 women in group A, 48 of 107 in group B, one of 108 in group C, and 52 of 94 in group D), febrile neutropenia (eight, nine, none, and seven, respectively), and leucopenia (13, five, none, and seven, respectively). The number of serious adverse events was similar in groups A, B, and D (15-20 serious adverse events per group in 10-17% of patients) but lower in group C (four serious adverse events in 4% of patients).",,,,
clinicaltrials.gov,ridaforolimus,1020194,P42345,"InChI=1S/C53H84NO14P/c1-32-18-14-13-15-19-33(2)44(63-8)30-40-23-21-38(7)53(61,67-40)50(58)51(59)54-25-17-16-20-41(54)52(60)66-45(35(4)28-39-22-24-43(46(29-39)64-9)68-69(11,12)62)31-42(55)34(3)27-37(6)48(57)49(65-10)47(56)36(5)26-32/h13-15,18-19,27,32,34-36,38-41,43-46,48-49,57,61H,16-17,20-26,28-31H2,1-12H3/b15-13+,18-14+,33-19+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",BUROJSBIWGDYCN-GAUTUEMISA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OP(=O)(C)C,trastuzumab,4,P04626,,,,,breast cancers,Phase 2,,,NCT00736970,Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009),,https://ClinicalTrials.gov/show/NCT00736970
clinicaltrials.gov,ruxolitinib,974392,O00238;O00444;O00506;O14730;O14920;O14936;O14976;O15075;O15197;O43293;O43318;O60674;O75116;O75385;O75460;O75582;O75676;O75716;O94768;O95747;O96013;P00519;P04629;P07949;P0C264;P10721;P15056;P15735;P19784;P23458;P29320;P29376;P29597;P32298;P33981;P36507;P45983;P45985;P46734;P48729;P49760;P50613;P51617;P51956;P52333;P53350;P53355;P57078;P68400;Q02156;Q02750;Q07912;Q09013;Q12851;Q13233;Q13237;Q13464;Q13554;Q13555;Q13557;Q13627;Q13873;Q14012;Q14164;Q14680;Q15349;Q15418;Q15746;Q15835;Q16288;Q16620;Q16816;Q2M2I8;Q52WX2;Q56UN5;Q5S007;Q6PHR2;Q6ZN16;Q7KZI7;Q7L7X3;Q86Y07;Q86Z02;Q8IU85;Q8IYT8;Q8N568;Q8NFD2;Q8TDX7;Q8WTQ7;Q92630;Q96NX5;Q96SB4;Q99759;Q9BRS2;Q9BVS4;Q9C098;Q9H093;Q9H2K8;Q9H2X6;Q9H422;Q9H4B4;Q9HAZ1;Q9HBH9;Q9NQU5;Q9NSY1;Q9NYY3;Q9P286;Q9P289;Q9UBF8;Q9UEE5;Q9UEW8;Q9UHD2;Q9UIK4;Q9UK32;Q9UL54;Q9UM73;Q9UPE1;Q9UQB9;Q9UQM7;Q9Y2H9;Q9Y2K2;Q9Y2U5,"InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1",HFNKQEVNSGCOJV-OAHLLOKOSA-N,N#CC[C@H](C1CCCC1)n2cc(cn2)c3ncnc4[nH]ccc34,trastuzumab,4,P04626,,,,,breast cancers,Phase 1/2,,,NCT02066532,Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer,,https://ClinicalTrials.gov/show/NCT02066532
literature,S-1,,,,,,trastuzumab,4,P04626,,,,HER2-positive Metastatic Breast_Cancer,breast cancers,Phase 2,29374719,"Between December 2008 and March 2013, 10 patients were enrolled and received a median of 17 (range=3-76) cycles of treatment. Overall response and clinical benefit rates were 60.0% and 90.0%, respectively. Progression-free survival was 15.8 (95% confidence interval=9.4-29.6) months and overall survival was 45.5 (95% confidence interval=37.1-62.2) months. Grade 3/4 adverse events included were neutropenia and hyperglycemia in one patient each (10.0%). There was no clinically significant cardiotoxicity.",,,,
clinicaltrials.gov,SGN-LIV1A,,,,,,trastuzumab,4,P04626,,,,,breast cancers,Phase 1,,,NCT01969643,A Safety Study of SGN-LIV1A in Breast Cancer Patients,,https://ClinicalTrials.gov/show/NCT01969643
clinicaltrials.gov,sirolimus,344,P06730;P08183;P08684;P11712;P33261;P42345;P62942;Q13451;Q53EL6;Q9Y6L6,"InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1",QFJCIRLUMZQUOT-HPLJOQBZSA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1O,trastuzumab,4,P04626,,,,,breast cancers,Phase 2,,,NCT00411788,A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer,,https://ClinicalTrials.gov/show/NCT00411788
literature,sunitinib,1055,O00238;O00444;O00506;O14578;O14730;O14757;O14965;O14976;O15075;O15111;O15146;O15197;O15530;O43172;O43283;O43293;O43318;O60285;O60674;O75116;O75385;O75460;O75582;O75676;O75716;O75914;O94768;O94804;O94806;O94921;O95747;O95819;O95835;O96013;O96017;P00519;P04629;P06213;P06239;P06241;P07332;P07333;P07947;P07948;P07949;P08069;P08581;P08631;P09619;P09769;P0C264;P10721;P11362;P11802;P12931;P14616;P15735;P16234;P16591;P17252;P17948;P19525;P19784;P21802;P22455;P22607;P23443;P23458;P27448;P29320;P29376;P29597;P30291;P30530;P31751;P32298;P33981;P35590;P35916;P35968;P36507;P36888;P42679;P42684;P42685;P45984;P45985;P46734;P48729;P48730;P49674;P49759;P49760;P50613;P51451;P51617;P51812;P51955;P52333;P52564;P53355;P53779;P54646;P54756;P54760;P54762;P57058;P57059;P57078;P68400;P78356;P78362;P78368;P80192;P80370;Q00535;Q00536;Q00537;Q02750;Q04759;Q05397;Q06187;Q06418;Q07002;Q07912;Q08345;Q08881;Q12809;Q12851;Q12852;Q12866;Q13043;Q13131;Q13163;Q13164;Q13188;Q13464;Q13470;Q13523;Q13546;Q13554;Q13555;Q13557;Q13627;Q13873;Q13882;Q14012;Q14164;Q14289;Q14680;Q15139;Q15208;Q15349;Q15375;Q15418;Q15746;Q15831;Q15835;Q16288;Q16512;Q16513;Q16566;Q16584;Q16620;Q16816;Q16832;Q2M2I8;Q32MK0;Q52WX2;Q56UN5;Q5S007;Q6PHR2;Q6XUX3;Q6ZN16;Q7KZI7;Q7L7X3;Q86UE8;Q86V86;Q86YV6;Q86Z02;Q8IU85;Q8IVH8;Q8IWQ3;Q8IY84;Q8IYT8;Q8N4C8;Q8N568;Q8N5S9;Q8N752;Q8NE63;Q8NEV4;Q8NFD2;Q8TDC3;Q8TDR2;Q8TDX7;Q8WTQ7;Q8WXR4;Q92630;Q92772;Q92918;Q96BR1;Q96GD4;Q96L34;Q96NX5;Q96RR4;Q96SB4;Q99755;Q99759;Q9BRS2;Q9BUB5;Q9BVS4;Q9BXA7;Q9BYT3;Q9BZL6;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K2;Q9H2K8;Q9H2X6;Q9H422;Q9HAZ1;Q9HBH9;Q9HCP0;Q9NQU5;Q9NRH2;Q9NRM7;Q9NSY1;Q9NWZ3;Q9NYY3;Q9P0L2;Q9P1W9;Q9P286;Q9P289;Q9P2K8;Q9UEE5;Q9UEW8;Q9UF33;Q9UHD2;Q9UIK4;Q9UK32;Q9UKE5;Q9UKI8;Q9UM73;Q9UPE1;Q9UPZ9;Q9UQB9;Q9UQM7;Q9Y2H1;Q9Y2H9;Q9Y2U5;Q9Y463;Q9Y4K4;Q9Y616;Q9Y6E0;Q9Y6M4;Q9Y6R4,"InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-",WINHZLLDWRZWRT-ATVHPVEESA-N,CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C\2/C(=O)Nc3ccc(F)cc23)c1C,trastuzumab,4,P04626,,,,grade III ductal carcinoma,breast cancers,not specified,20110783,"In September 2007, the patient joined a phase II trial with sunitinib (37.5 mg once a day in 28 days cycles) and trastuzumab (6 mg/kg every 3 weeks), after having verified a normal cardiac function. After two courses, a partial cutaneous response and a complete radiological response were obtained. The most relevant toxicities included cutaneous hyperpigmentation, dysgeusia, mucositis, grade II diarrhea and hypertension. The development of grade III diarrhea led to sunitinib dose reduction (25mg/day). In January 2008, the patient developed hypothyroidism and a significant drop in the left ventricular ejection fraction that led to treatment interruption. In March 2008, once cardiac function was recovered, treatment at the same dose was reinitiated. After two months of treatment, a new descent in cardiac function was noted which led to the suspension of sunitinib, and the interruption of the trastuzumab treatment until recovery of normal cardiac function. In July 2008, trastuzumab monotherapy was resumed and since then no cardiac events have been reported, while maintaining a radiological and clinical response",,,,
literature,sunitinib,1055,O00238;O00444;O00506;O14578;O14730;O14757;O14965;O14976;O15075;O15111;O15146;O15197;O15530;O43172;O43283;O43293;O43318;O60285;O60674;O75116;O75385;O75460;O75582;O75676;O75716;O75914;O94768;O94804;O94806;O94921;O95747;O95819;O95835;O96013;O96017;P00519;P04629;P06213;P06239;P06241;P07332;P07333;P07947;P07948;P07949;P08069;P08581;P08631;P09619;P09769;P0C264;P10721;P11362;P11802;P12931;P14616;P15735;P16234;P16591;P17252;P17948;P19525;P19784;P21802;P22455;P22607;P23443;P23458;P27448;P29320;P29376;P29597;P30291;P30530;P31751;P32298;P33981;P35590;P35916;P35968;P36507;P36888;P42679;P42684;P42685;P45984;P45985;P46734;P48729;P48730;P49674;P49759;P49760;P50613;P51451;P51617;P51812;P51955;P52333;P52564;P53355;P53779;P54646;P54756;P54760;P54762;P57058;P57059;P57078;P68400;P78356;P78362;P78368;P80192;P80370;Q00535;Q00536;Q00537;Q02750;Q04759;Q05397;Q06187;Q06418;Q07002;Q07912;Q08345;Q08881;Q12809;Q12851;Q12852;Q12866;Q13043;Q13131;Q13163;Q13164;Q13188;Q13464;Q13470;Q13523;Q13546;Q13554;Q13555;Q13557;Q13627;Q13873;Q13882;Q14012;Q14164;Q14289;Q14680;Q15139;Q15208;Q15349;Q15375;Q15418;Q15746;Q15831;Q15835;Q16288;Q16512;Q16513;Q16566;Q16584;Q16620;Q16816;Q16832;Q2M2I8;Q32MK0;Q52WX2;Q56UN5;Q5S007;Q6PHR2;Q6XUX3;Q6ZN16;Q7KZI7;Q7L7X3;Q86UE8;Q86V86;Q86YV6;Q86Z02;Q8IU85;Q8IVH8;Q8IWQ3;Q8IY84;Q8IYT8;Q8N4C8;Q8N568;Q8N5S9;Q8N752;Q8NE63;Q8NEV4;Q8NFD2;Q8TDC3;Q8TDR2;Q8TDX7;Q8WTQ7;Q8WXR4;Q92630;Q92772;Q92918;Q96BR1;Q96GD4;Q96L34;Q96NX5;Q96RR4;Q96SB4;Q99755;Q99759;Q9BRS2;Q9BUB5;Q9BVS4;Q9BXA7;Q9BYT3;Q9BZL6;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K2;Q9H2K8;Q9H2X6;Q9H422;Q9HAZ1;Q9HBH9;Q9HCP0;Q9NQU5;Q9NRH2;Q9NRM7;Q9NSY1;Q9NWZ3;Q9NYY3;Q9P0L2;Q9P1W9;Q9P286;Q9P289;Q9P2K8;Q9UEE5;Q9UEW8;Q9UF33;Q9UHD2;Q9UIK4;Q9UK32;Q9UKE5;Q9UKI8;Q9UM73;Q9UPE1;Q9UPZ9;Q9UQB9;Q9UQM7;Q9Y2H1;Q9Y2H9;Q9Y2U5;Q9Y463;Q9Y4K4;Q9Y616;Q9Y6E0;Q9Y6M4;Q9Y6R4,"InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-",WINHZLLDWRZWRT-ATVHPVEESA-N,CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C\2/C(=O)Nc3ccc(F)cc23)c1C,trastuzumab,4,P04626,,,,advanced HER2+ breast cancer,breast cancers,Phase 2,24606768,"Sixty patients were enrolled and evaluable for safety; 57 were evaluable for efficacy. The majority of patients (58%) had received no prior chemotherapy in the metastatic setting. The ORR was 37%; the clinical benefit rate (CBR; percent objective response plus stable disease _ 24 weeks) was 56%. Among patients who were treatment-na´ve or had received only adjuvant therapy, the ORR was 44% and the CBR was 59%. Overall, median overall survival had not been reached and the 1-year survival rate was 91%. The majority of adverse events (AEs) were mild to moderate in severity. Forty percent of patients experienced AEs related to measured left ventricular ejection fraction (LVEF) declines, which occurred more frequently in patients who had received prior anthracycline treatment. Ten percent of patients exhibited symptoms related to LVEF declines. One patient died on study from cardiogenic shock. Antitumor response and several safety parameters appeared to correlate with sunitinib exposure.",,,,
clinicaltrials.gov,tucatinib,,,,,,trastuzumab,4,P04626,,,,,bowel cancers,Phase 2,,,NCT03043313,Tucatinib (ONT-380) and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer (MOUNTAINEER),MOUNTAINEER,https://ClinicalTrials.gov/show/NCT03043313
clinicaltrials.gov,vatalanib,535503,O14578;P00533;P07333;P07949;P09619;P10721;P16234;P17948;P35916;P35968;P42685;P49336;Q08345;Q13882;Q56UN5;Q9BWU1;Q9NYL2,"InChI=1S/C20H15ClN4/c21-15-5-7-16(8-6-15)23-20-18-4-2-1-3-17(18)19(24-25-20)13-14-9-11-22-12-10-14/h1-12H,13H2,(H,23,25)",YCOYDOIWSSHVCK-UHFFFAOYSA-N,Clc1ccc(Nc2nnc(Cc3ccncc3)c4ccccc24)cc1,trastuzumab,4,P04626,,,,,breast cancers,Phase 1/2,,,NCT00216047,PTK787 + Trastuzumab for HER2 Overexpressing Metastatic Breast Cancer,,https://ClinicalTrials.gov/show/NCT00216047
clinicaltrials.gov,vorinostat,260,O15379;O75376;P56524;Q13547;Q8WUI4;Q92769;Q969S8;Q96DB2;Q9BY41;Q9UBN7;Q9UKV0;Q9UQL6;Q9Y618,"InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)",WAEXFXRVDQXREF-UHFFFAOYSA-N,ONC(=O)CCCCCCC(=O)Nc1ccccc1,trastuzumab,4,P04626,,,,,breast cancers,Phase 1/2,,,NCT00258349,Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer,,https://ClinicalTrials.gov/show/NCT00258349
clinicaltrials.gov,pembrolizumab,,Q15116,,,,Trastuzumab Biosimilar ABP 980,,,,,,,,,,,NCT03988036,A Study With pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1),Keyriched-1,https://ClinicalTrials.gov/show/NCT03988036
clinicaltrials.gov,pembrolizumab,,Q15116,,,,trebaninib,,,,,,,advanced solid cancers,Phase 1,,,NCT03239145,pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor,,https://ClinicalTrials.gov/show/NCT03239145
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,tremelimumab,,P16410,,,,,advanced solid cancers,Phase 1,,,NCT02261220,A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors,,https://ClinicalTrials.gov/show/NCT02261220
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,tremelimumab,,P16410,,,,,advanced solid cancers,Phase 1,,,NCT01938612,"A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours",,https://ClinicalTrials.gov/show/NCT01938612
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,tremelimumab,,P16410,,,,,advanced solid cancers,Phase 1,,,NCT02537418,Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens,,https://ClinicalTrials.gov/show/NCT02537418
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,tremelimumab,,P16410,,,,,advanced solid cancers,Phase 1/2,,,NCT02978482,A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies,,https://ClinicalTrials.gov/show/NCT02978482
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,tremelimumab,,P16410,,,,,advanced solid cancers,Phase 2,,,NCT02938793,Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors,,https://ClinicalTrials.gov/show/NCT02938793
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,tremelimumab,,P16410,,,,,advanced solid cancers,Phase 3,,,NCT03084471,"An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.",STRONG,https://ClinicalTrials.gov/show/NCT03084471
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,tremelimumab,,P16410,,,,,bladder cancers,Phase 2,,,NCT03234153,Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin,NITIMIB,https://ClinicalTrials.gov/show/NCT03234153
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,tremelimumab,,P16410,,,,,bladder cancers,Phase 2,,,NCT03430895,"Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract",,https://ClinicalTrials.gov/show/NCT03430895
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,tremelimumab,,P16410,,,,,bowel cancers,Phase 2,,,NCT03007407,Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy,,https://ClinicalTrials.gov/show/NCT03007407
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,tremelimumab,,P16410,,,,,breast cancers;ovarian cancers;bowel cancers;cervical cancers;kidney cancers,Phase 1,,,NCT01975831,A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab,,https://ClinicalTrials.gov/show/NCT01975831
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,tremelimumab,,P16410,,,,,head and neck cancers,Phase 2,,,NCT03450967,Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC,,https://ClinicalTrials.gov/show/NCT03450967
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,tremelimumab,,P16410,,,,,kidney cancers,Phase 3,,,NCT03288532,Renal Adjuvant MultiPle Arm Randomised Trial,RAMPART,https://ClinicalTrials.gov/show/NCT03288532
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,tremelimumab,,P16410,,,,,lung cancers,Phase 2,,,NCT03319316,Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC),SOLUTION,https://ClinicalTrials.gov/show/NCT03319316
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,tremelimumab,,P16410,,,,,pancreatic cancers,Phase 2,,,NCT02558894,Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma,,https://ClinicalTrials.gov/show/NCT02558894
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,tremelimumab,,P16410,,,,,prostate cancers,Phase 2,,,NCT03204812,Tremelimumab + Durvalumab Chemotherapy Naive CRPC,,https://ClinicalTrials.gov/show/NCT03204812
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,tremelimumab,,P16410,,,,,prostate cancers,Phase 2,,,NCT02788773,Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer,,https://ClinicalTrials.gov/show/NCT02788773
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,tremelimumab,,P16410,,,,,soft tissue cancers,Phase 2,,,NCT02815995,Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes,,https://ClinicalTrials.gov/show/NCT02815995
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,tremelimumab,,P16410,,,,,,Phase 2,,,NCT03081923,Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors,APACHE,https://ClinicalTrials.gov/show/NCT03081923
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,tremelimumab,,P16410,,,,,head and neck cancers,Phase 1/2,,,NCT03784066,Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity,DUTRELASCO,https://ClinicalTrials.gov/show/NCT03784066
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,tremelimumab,,P16410,,,,,head and neck cancers,Phase 2,,,NCT03737968,Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.,,https://ClinicalTrials.gov/show/NCT03737968
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,tremelimumab,,P16410,,,,,head and neck cancers,Phase 1/2,,,NCT03784066,Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity,DUTRELASCO,https://ClinicalTrials.gov/show/NCT03784066
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,tremelimumab,,P16410,,,,,head and neck cancers,Phase 2,,,NCT03737968,Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.,,https://ClinicalTrials.gov/show/NCT03737968
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,tremelimumab,,P16410,,,,Pediatric Cancer|Solid Tumor Pediatric|Hematological Malignancies,,Phase 1/2,,,NCT03837899,,,
literature,durvalumab,,Q9NZQ7,,,,tremelimumab,,P16410,,,,advanced squamous or non-squamous non-small cell lung cancer,lung cancers,Phase 1b,26858122,"Between Oct 28, 2013, and April 1, 2015, 102 patients were enrolled into the dose-escalation phase and received treatment. At the time of this analysis (June 1, 2015), median follow-up was 18à8 weeks (IQR 11-33). The maximum tolerated dose was exceeded in the cohort receiving durvalumab 20 mg/kg every 4 weeks plus tremelimumab 3 mg/kg, with two (30%) of six patients having a dose-limiting toxicity (one grade 3 increased aspartate aminotransferase and alanine aminotransferase and one grade 4 increased lipase). The most frequent treatment-related grade 3 and 4 adverse events were diarrhoea (11 [11%]), colitis (nine [9%]), and increased lipase (eight [8%]). Discontinuations attributable to treatment-related adverse events occurred in 29 (28%) of 102 patients. Treatment-related serious adverse events occurred in 37 (36%) of 102 patients. 22 patients died during the study, and three deaths were related to treatment. The treatment-related deaths were due to complications arising from myasthenia gravis (durvalumab 10 mg/kg every 4 weeks plus tremelimumab 1 mg/kg), pericardial effusion (durvalumab 20 mg/kg every 4 weeks plus tremelimumab 1 mg/kg), and neuromuscular disorder (durvalumab 20 mg/kg every 4 weeks plus tremelimumab 3 mg/kg). Evidence of clinical activity was noted both in patients with PD-L1-positive tumours and in those with PD-L1-negative tumours. Investigator-reported confirmed objective responses were achieved by six (23%, 95% CI 9-44) of 26 patients in the combined tremelimumab 1 mg/kg cohort, comprising two (22%, 95% CI 3-60) of nine patients with PD-L1-positive tumours and four (29%, 95% CI 8-58) of 14 patients with PD-L1-negative tumours, including those with no PD-L1 staining (four [40%, 95% CI 12-74] of ten patients).",,,,
clinicaltrials.gov,gefitinib,701,O14578;O14976;O15197;O43293;O43353;O75676;O94768;O94804;O96017;P00519;P00533;P04626;P06239;P07948;P07949;P08581;P08631;P09769;P10721;P12931;P15735;P21709;P21860;P29320;P29322;P29376;P30530;P31152;P36888;P42681;P42684;P42685;P45984;P48730;P49674;P50613;P51451;P51617;P53779;P54756;P54760;P54762;Q09013;Q13163;Q15139;Q15303;Q16659;Q16816;Q52WX2;Q56UN5;Q86V86;Q8N4C8;Q8NE63;Q8TBX8;Q99759;Q9BUB5;Q9C098;Q9H093;Q9H0K1;Q9H1R3;Q9H2G2;Q9HBH9;Q9NRP7;Q9NWZ3;Q9UBE8;Q9UEE5;Q9UF33;Q9UKE5;Q9UNQ0;Q9Y2U5;Q9Y616,"InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)",XGALLCVXEZPNRQ-UHFFFAOYSA-N,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN4CCOCC4,tremelimumab,,P16410,,,,,lung cancers,Phase 1,,,NCT02040064,Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients,GEFTREM,https://ClinicalTrials.gov/show/NCT02040064
clinicaltrials.gov,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,tremelimumab,,P16410,,,,,ovarian cancers;female cancers,Phase 1/2,,,NCT02571725,PARP-inhibition and CTLA-4 Blockade in BRCA-deficient ovarian Cancers,,https://ClinicalTrials.gov/show/NCT02571725
clinicaltrials.gov,niraparib,919241,Q9UGN5;P09874,"InChI=1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)/t14-/m1/s1",PCHKPVIQAHNQLW-CQSZACIVSA-N,NC(=O)c1cccc2cn(nc12)c3ccc(cc3)[C@@H]4CCCNC4,TSR-042,,,,,,,,,,,NCT03955471,"A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients With Platinum Resistant Ovarian Cancer",MOONSTONE,https://ClinicalTrials.gov/show/NCT03955471
clinicaltrials.gov,TSR-022,,,,,,TSR-042,,,,,,,liver cancers,Phase 2,,,NCT03680508,TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer,,https://ClinicalTrials.gov/show/NCT03680508
clinicaltrials.gov,TSR-022,,,,,,TSR-042,,,,,,,liver cancers,Phase 2,,,NCT03680508,TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer,,https://ClinicalTrials.gov/show/NCT03680508
clinicaltrials.gov,TGR-1202,,O00329,,,,ublituximab,,P11836,,,,,leukemia;lymphoma,Phase 2,,,NCT03207256,Compassionate Use Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials,,https://ClinicalTrials.gov/show/NCT03207256
clinicaltrials.gov,ublituximab,,P11836,,,,umbralisib,,,,,,Follicular Lymphoma|Small Lymphocytic Lymphoma,,Phase 2,,,NCT03828448,,,
clinicaltrials.gov,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,uprosertib,1197714,P31751;Q9Y243;P31749,"InChI=1S/C18H16Cl2F2N4O2/c1-26-16(12(19)8-24-26)11-6-15(28-17(11)20)18(27)25-10(7-23)4-9-2-3-13(21)14(22)5-9/h2-3,5-6,8,10H,4,7,23H2,1H3,(H,25,27)/t10-/m0/s1",AXTAPYRUEKNRBA-JTQLQIEISA-N,Cn1ncc(Cl)c1c2cc(oc2Cl)C(=O)N[C@H](CN)Cc3ccc(F)c(F)c3,,cervical cancers,Phase 2,,,NCT01958112,GSK1120212+GSK2141795 for Cervical Cancer,,https://ClinicalTrials.gov/show/NCT01958112
clinicaltrials.gov,trametinib,1081334,O00329;P42336;P42338;P42345;P48736;P52333,"InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34)",LIRYPHYGHXZJBZ-UHFFFAOYSA-N,CN1C(=O)C(=C2N(C(=O)N(C3CC3)C(=O)C2=C1Nc4ccc(I)cc4F)c5cccc(NC(=O)C)c5)C,uprosertib,1197714,P31751;Q9Y243;P31749,"InChI=1S/C18H16Cl2F2N4O2/c1-26-16(12(19)8-24-26)11-6-15(28-17(11)20)18(27)25-10(7-23)4-9-2-3-13(21)14(22)5-9/h2-3,5-6,8,10H,4,7,23H2,1H3,(H,25,27)/t10-/m0/s1",AXTAPYRUEKNRBA-JTQLQIEISA-N,Cn1ncc(Cl)c1c2cc(oc2Cl)C(=O)N[C@H](CN)Cc3ccc(F)c(F)c3,,,Phase 1,,,NCT01138085,"Safety, Pharmacokinetics (PK) of AKT and MEK Combination",,https://ClinicalTrials.gov/show/NCT01138085
clinicaltrials.gov,nivolumab,,Q15116,,,,urelumab,,Q07011,,,,,bladder cancers,Phase 2,,,NCT02845323,Neoadjuvant Nivolumab With and Without Urelumab in Patients With Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder,,https://ClinicalTrials.gov/show/NCT02845323
clinicaltrials.gov,rituximab,16,P11836,,,,urelumab,,Q07011,,,,,leukemia,Phase 2,,,NCT02420938,"Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients",,https://ClinicalTrials.gov/show/NCT02420938
clinicaltrials.gov,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,vandetanib,551660,O00238;O00444;O14578;O14976;O15197;O43353;O75116;O94804;O95819;P00519;P00533;P04626;P06239;P06241;P07333;P07947;P07948;P07949;P08581;P08631;P09619;P09769;P10721;P11362;P12931;P15735;P16234;P17948;P21709;P21802;P21860;P22455;P22607;P23443;P29317;P29320;P29322;P29323;P29376;P30530;P35590;P35916;P35968;P36507;P36888;P37023;P41240;P42681;P42684;P42685;P49674;P50613;P51451;P51617;P54756;P54760;P54762;P54764;P57058;P57059;P57078;Q02750;Q02763;Q04771;Q04912;Q06187;Q06418;Q08345;Q12851;Q12866;Q13131;Q13163;Q13882;Q15303;Q15375;Q15418;Q15569;Q16659;Q16816;Q16832;Q56UN5;Q59H18;Q5VT25;Q6DT37;Q6PHR2;Q8IVH8;Q8N4C8;Q8NI60;Q8TDR2;Q8WU08;Q92918;Q96D53;Q9BUB5;Q9BYT3;Q9H0K1;Q9H2G2;Q9H3Y6;Q9HBH9;Q9NWZ3;Q9NYL2;Q9UF33;Q9UK32;Q9UKE5;Q9UM73;Q9UQB9;Q9Y2K2;Q9Y4K4;Q9Y5S2;Q9Y6R4,"InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)",UHTHHESEBZOYNR-UHFFFAOYSA-N,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC4CCN(C)CC4,,thyroid cancers,Phase 1/2,,,NCT00923247,"A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)",,https://ClinicalTrials.gov/show/NCT00923247
literature,dasatinib,375,O00238;O00506;O14965;O14976;O15197;O15264;O43283;O43318;O43353;O60674;O94804;O95819;P00519;P00533;P04049;P04626;P06239;P06241;P07333;P07947;P07948;P07949;P08631;P08684;P09619;P09769;P0C1S8;P10721;P11274;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P21860;P22607;P27037;P29317;P29320;P29322;P29323;P29597;P30291;P35968;P36507;P36888;P36894;P36896;P36897;P37023;P37173;P41240;P42680;P42681;P42684;P42685;P43405;P49674;P51451;P51813;P51955;P52333;P53667;P53671;P53778;P54753;P54756;P54760;P54762;P54764;P57059;Q01538;Q02750;Q04771;Q06187;Q07912;Q08345;Q09013;Q12851;Q13043;Q13163;Q13705;Q13882;Q15303;Q15569;Q15759;Q16539;Q16832;Q52WX2;Q56UN5;Q59H18;Q5VT25;Q6DT37;Q6PHR2;Q86Y07;Q8IVH8;Q8N4C8;Q8NG66;Q8NI60;Q8TDR2;Q92918;Q96GD4;Q99640;Q99759;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K8;Q9H3Y6;Q9NRP7;Q9NYL2;Q9P289;Q9P2K8;Q9UBE8;Q9UF33;Q9UKE5;Q9UL54;Q9Y2K2;Q9Y2U5;Q9Y4K4;Q9Y5S2;Q9Y6R4,"InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)",ZBNZXTGUTAYRHI-UHFFFAOYSA-N,Cc1nc(Nc2ncc(s2)C(=O)Nc3c(C)cccc3Cl)cc(n1)N4CCN(CCO)CC4,vandetanib,551660,O00238;O00444;O14578;O14976;O15197;O43353;O75116;O94804;O95819;P00519;P00533;P04626;P06239;P06241;P07333;P07947;P07948;P07949;P08581;P08631;P09619;P09769;P10721;P11362;P12931;P15735;P16234;P17948;P21709;P21802;P21860;P22455;P22607;P23443;P29317;P29320;P29322;P29323;P29376;P30530;P35590;P35916;P35968;P36507;P36888;P37023;P41240;P42681;P42684;P42685;P49674;P50613;P51451;P51617;P54756;P54760;P54762;P54764;P57058;P57059;P57078;Q02750;Q02763;Q04771;Q04912;Q06187;Q06418;Q08345;Q12851;Q12866;Q13131;Q13163;Q13882;Q15303;Q15375;Q15418;Q15569;Q16659;Q16816;Q16832;Q56UN5;Q59H18;Q5VT25;Q6DT37;Q6PHR2;Q8IVH8;Q8N4C8;Q8NI60;Q8TDR2;Q8WU08;Q92918;Q96D53;Q9BUB5;Q9BYT3;Q9H0K1;Q9H2G2;Q9H3Y6;Q9HBH9;Q9NWZ3;Q9NYL2;Q9UF33;Q9UK32;Q9UKE5;Q9UM73;Q9UQB9;Q9Y2K2;Q9Y4K4;Q9Y5S2;Q9Y6R4,"InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)",UHTHHESEBZOYNR-UHFFFAOYSA-N,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC4CCN(C)CC4,Paediatric diffuse Intrinsic Pontine Glioma,brain cancers,Phase 1,23536435,"Twenty-five patients were treated. Treatment was well tolerated. The median duration of treatment was 184 days. Diarrhea was the most significant toxicity. Three patients experienced substantial myelosuppression. The steady-state plasma pharmacokinetics of vandetanib was comparable with previous studies. Although the plasma exposure to dasatinib decreased from days 8 to 42, it remained similar to adult studies. CSF to plasma exposure of vandetanib and dasatinib were approximately 2% in 2 patients. Phosphorylated 70S6K decreased during therapy in PBMCs",,,,
clinicaltrials.gov,atezolizumab,,Q9NZQ7,,,,vanucizumab,,,,,,,advanced solid cancers,Phase 1,,,NCT01688206,A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors,,https://ClinicalTrials.gov/show/NCT01688206
clinicaltrials.gov,RO7009789,,,,,,vanucizumab,,,,,,,advanced solid cancers,Phase 1,,,NCT02665416,"Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Participants With Metastatic Solid Tumors",,https://ClinicalTrials.gov/show/NCT02665416
clinicaltrials.gov,imatinib,1561,O00444;O14976;O15244;O43570;P00519;P00533;P00915;P00918;P04049;P06239;P06241;P07333;P07451;P07948;P09619;P09769;P10721;P11274;P15056;P16083;P16234;P22748;P23280;P24557;P25021;P28223;P29322;P29597;P31645;P36888;P42684;P42685;P43166;P43405;P45983;P45984;P49759;P51451;P51617;P53779;Q08345;Q14680;Q15046;Q16790;Q16832;Q59H18;Q86VL8;Q8NE63;Q8TBX8;Q96FL8;Q9BWU1;Q9HAZ1;Q9NYL2;Q9UEE5;Q9ULX7;Q9UNQ0,"InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)",KTUFNOKKBVMGRW-UHFFFAOYSA-N,CN1CCN(Cc2ccc(cc2)C(=O)Nc3ccc(C)c(Nc4nccc(n4)c5cccnc5)c3)CC1,vatalanib,535503,O14578;P00533;P07333;P07949;P09619;P10721;P16234;P17948;P35916;P35968;P42685;P49336;Q08345;Q13882;Q56UN5;Q9BWU1;Q9NYL2,"InChI=1S/C20H15ClN4/c21-15-5-7-16(8-6-15)23-20-18-4-2-1-3-17(18)19(24-25-20)13-14-9-11-22-12-10-14/h1-12H,13H2,(H,23,25)",YCOYDOIWSSHVCK-UHFFFAOYSA-N,Clc1ccc(Nc2nnc(Cc3ccncc3)c4ccccc24)cc1,,leukemia,Phase 1/2,,,NCT00088231,"PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP",,https://ClinicalTrials.gov/show/NCT00088231
literature,imatinib,1561,O00444;O14976;O15244;O43570;P00519;P00533;P00915;P00918;P04049;P06239;P06241;P07333;P07451;P07948;P09619;P09769;P10721;P11274;P15056;P16083;P16234;P22748;P23280;P24557;P25021;P28223;P29322;P29597;P31645;P36888;P42684;P42685;P43166;P43405;P45983;P45984;P49759;P51451;P51617;P53779;Q08345;Q14680;Q15046;Q16790;Q16832;Q59H18;Q86VL8;Q8NE63;Q8TBX8;Q96FL8;Q9BWU1;Q9HAZ1;Q9NYL2;Q9UEE5;Q9ULX7;Q9UNQ0,"InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34)",KTUFNOKKBVMGRW-UHFFFAOYSA-N,CN1CCN(Cc2ccc(cc2)C(=O)Nc3ccc(C)c(Nc4nccc(n4)c5cccnc5)c3)CC1,vatalanib,535503,O14578;P00533;P07333;P07949;P09619;P10721;P16234;P17948;P35916;P35968;P42685;P49336;Q08345;Q13882;Q56UN5;Q9BWU1;Q9NYL2,"InChI=1S/C20H15ClN4/c21-15-5-7-16(8-6-15)23-20-18-4-2-1-3-17(18)19(24-25-20)13-14-9-11-22-12-10-14/h1-12H,13H2,(H,23,25)",YCOYDOIWSSHVCK-UHFFFAOYSA-N,Clc1ccc(Nc2nnc(Cc3ccncc3)c4ccccc24)cc1,Advanced malignancies,advanced solid cancers,Phase 1,21469980,"Forty-five patients were enrolled between September 2004 and November 2007. As of September 2009, a total of 247 cycles of treatment had been administered (range: 1 -44+, median = 2 ). The MTD was determined to be vatalanib 1250 mg daily and imatinib 400 mg daily. Thirty-five patients (78%) were evaluable for response; 2 patients achieved PR, while 14 patients had SD ( 10 had stable disease _ 6 cycles). The combination of vatalanib and imatinib was well tolerated. Twice-daily vatalanib dosing improved tolerability and ease of full-dose administration. These results suggest that vatalanib-containing combinations may be active and tolerable, warranting further study.",,,,
clinicaltrials.gov,cobimetinib,1055500,Q02750;P36507,"InChI=1S/C21H21F3IN3O2/c22-14-6-5-13(19(18(14)24)27-16-7-4-12(25)9-15(16)23)20(29)28-10-21(30,11-28)17-3-1-2-8-26-17/h4-7,9,17,26-27,30H,1-3,8,10-11H2/t17-/m0/s1",BSMCAPRUBJMWDF-KRWDZBQOSA-N,OC1(CN(C1)C(=O)c2ccc(F)c(F)c2Nc3ccc(I)cc3F)[C@@H]4CCCCN4,vemurafenib,754991,P15056,"InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)",GPXBXXGIAQBQNI-UHFFFAOYSA-N,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)c4ccc(Cl)cc4)c1F,,skin cancers,Phase 2,,,NCT02230306,Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases,CoBRIM-B,https://ClinicalTrials.gov/show/NCT02230306
clinicaltrials.gov,ipilimumab,1238537,P16410,,,,vemurafenib,754991,P15056,"InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)",GPXBXXGIAQBQNI-UHFFFAOYSA-N,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)c4ccc(Cl)cc4)c1F,,skin cancers,Phase 1,,,NCT01400451,Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF),,https://ClinicalTrials.gov/show/NCT01400451
clinicaltrials.gov,KTN3379,,,,,,vemurafenib,754991,P15056,"InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)",GPXBXXGIAQBQNI-UHFFFAOYSA-N,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)c4ccc(Cl)cc4)c1F,,thyroid cancers,Phase 1,,,NCT02456701,Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379,,https://ClinicalTrials.gov/show/NCT02456701
clinicaltrials.gov,PX-866,398788,O00329;O00459;P27986;P42336;P42338;P48736;Q8WYR1;Q92569,"InChI=1S/C29H35NO8/c1-7-11-30(12-8-2)14-17-23-26(34)25(33)22-18-9-10-20(32)28(18,4)13-19(37-16(3)31)24(22)29(23,5)21(15-36-6)38-27(17)35/h7-8,14,18-19,21,34H,1-2,9-13,15H2,3-6H3/b17-14+/t18-,19+,21+,28-,29-/m0/s1",QIUASFSNWYMDFS-NILGECQDSA-N,COC[C@H]1OC(=O)\C(=C\N(CC=C)CC=C)\C2=C(O)C(=O)C3=C([C@@H](C[C@@]4(C)[C@H]3CCC4=O)OC(=O)C)[C@@]12C,vemurafenib,754991,P15056,"InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)",GPXBXXGIAQBQNI-UHFFFAOYSA-N,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)c4ccc(Cl)cc4)c1F,,skin cancers,Phase 1/2,,,NCT01616199,Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma,,https://ClinicalTrials.gov/show/NCT01616199
clinicaltrials.gov,SAR260301,,,,,,vemurafenib,754991,P15056,"InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28)",GPXBXXGIAQBQNI-UHFFFAOYSA-N,CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)c4ccc(Cl)cc4)c1F,,advanced solid cancers,Phase 1,,,NCT01673737,A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer,,https://ClinicalTrials.gov/show/NCT01673737
clinicaltrials.gov,ABBV-075,,,,,,venetoclax,1150189,P10415,"InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)",LQBVNQSMGBZMKD-UHFFFAOYSA-N,CC1(C)CCC(=C(C1)c2ccc(Cl)cc2)CN3CCN(CC3)c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c(c5)N(=O)=O)c(Oc7cnc8[nH]ccc8c7)c4,,breast cancers;lung cancers;leukemia;multiple myeloma;prostate cancers;lung cancers;lymphoma,Phase 1,,,NCT02391480,A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer,,https://ClinicalTrials.gov/show/NCT02391480
clinicaltrials.gov,CYC065,,,,,,venetoclax,1150189,P10415,"InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)",LQBVNQSMGBZMKD-UHFFFAOYSA-N,CC1(C)CCC(=C(C1)c2ccc(Cl)cc2)CN3CCN(CC3)c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c(c5)N(=O)=O)c(Oc7cnc8[nH]ccc8c7)c4,,leukemia,Phase 1,,,NCT03739554,CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL,,https://ClinicalTrials.gov/show/NCT03739554
clinicaltrials.gov,CYC065,,,,,,venetoclax,1150189,P10415,"InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)",LQBVNQSMGBZMKD-UHFFFAOYSA-N,CC1(C)CCC(=C(C1)c2ccc(Cl)cc2)CN3CCN(CC3)c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c(c5)N(=O)=O)c(Oc7cnc8[nH]ccc8c7)c4,,leukemia,Phase 1,,,NCT03739554,CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL,,https://ClinicalTrials.gov/show/NCT03739554
clinicaltrials.gov,Duvelisib,,,,,,venetoclax,1150189,P10415,"InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)",LQBVNQSMGBZMKD-UHFFFAOYSA-N,CC1(C)CCC(=C(C1)c2ccc(Cl)cc2)CN3CCN(CC3)c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c(c5)N(=O)=O)c(Oc7cnc8[nH]ccc8c7)c4,,leukemia,Phase 1/2,,,NCT03534323,Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL,,https://ClinicalTrials.gov/show/NCT03534323
clinicaltrials.gov,Duvelisib,,,,,,venetoclax,1150189,P10415,"InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)",LQBVNQSMGBZMKD-UHFFFAOYSA-N,CC1(C)CCC(=C(C1)c2ccc(Cl)cc2)CN3CCN(CC3)c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c(c5)N(=O)=O)c(Oc7cnc8[nH]ccc8c7)c4,,leukemia,Phase 1/2,,,NCT03534323,Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL,,https://ClinicalTrials.gov/show/NCT03534323
clinicaltrials.gov,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,venetoclax,1150189,P10415,"InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)",LQBVNQSMGBZMKD-UHFFFAOYSA-N,CC1(C)CCC(=C(C1)c2ccc(Cl)cc2)CN3CCN(CC3)c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c(c5)N(=O)=O)c(Oc7cnc8[nH]ccc8c7)c4,,leukemia;lymphoma,Phase 2,,,NCT02756897,Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL),,https://ClinicalTrials.gov/show/NCT02756897
clinicaltrials.gov,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,venetoclax,1150189,P10415,"InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)",LQBVNQSMGBZMKD-UHFFFAOYSA-N,CC1(C)CCC(=C(C1)c2ccc(Cl)cc2)CN3CCN(CC3)c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c(c5)N(=O)=O)c(Oc7cnc8[nH]ccc8c7)c4,,leukemia,Phase 2,,,NCT03708003,Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL,,https://ClinicalTrials.gov/show/NCT03708003
clinicaltrials.gov,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,venetoclax,1150189,P10415,"InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)",LQBVNQSMGBZMKD-UHFFFAOYSA-N,CC1(C)CCC(=C(C1)c2ccc(Cl)cc2)CN3CCN(CC3)c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c(c5)N(=O)=O)c(Oc7cnc8[nH]ccc8c7)c4,,leukemia,Phase 2,,,NCT03708003,Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL,,https://ClinicalTrials.gov/show/NCT03708003
clinicaltrials.gov,ibrutinib,1010435,P00533;P07948;P07949;P51451;P51813;Q06187,"InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1",XYFPWWZEPKGCCK-GOSISDBHSA-N,Nc1ncnc2c1c(nn2[C@@H]3CCCN(C3)C(=O)C=C)c4ccc(Oc5ccccc5)cc4,venetoclax,1150189,P10415,"InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)",LQBVNQSMGBZMKD-UHFFFAOYSA-N,CC1(C)CCC(=C(C1)c2ccc(Cl)cc2)CN3CCN(CC3)c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c(c5)N(=O)=O)c(Oc7cnc8[nH]ccc8c7)c4,,,,,,NCT03943342,Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance,,https://ClinicalTrials.gov/show/NCT03943342
clinicaltrials.gov,MIK665,,,,,,venetoclax,1150189,P10415,"InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)",LQBVNQSMGBZMKD-UHFFFAOYSA-N,CC1(C)CCC(=C(C1)c2ccc(Cl)cc2)CN3CCN(CC3)c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c(c5)N(=O)=O)c(Oc7cnc8[nH]ccc8c7)c4,,leukemia,Phase 1,,,NCT03672695,Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia,,https://ClinicalTrials.gov/show/NCT03672695
clinicaltrials.gov,MIK665,,,,,,venetoclax,1150189,P10415,"InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)",LQBVNQSMGBZMKD-UHFFFAOYSA-N,CC1(C)CCC(=C(C1)c2ccc(Cl)cc2)CN3CCN(CC3)c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c(c5)N(=O)=O)c(Oc7cnc8[nH]ccc8c7)c4,,leukemia,Phase 1,,,NCT03672695,Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia,,https://ClinicalTrials.gov/show/NCT03672695
clinicaltrials.gov,obinutuzumab,,P11836,,,,venetoclax,1150189,P10415,"InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)",LQBVNQSMGBZMKD-UHFFFAOYSA-N,CC1(C)CCC(=C(C1)c2ccc(Cl)cc2)CN3CCN(CC3)c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c(c5)N(=O)=O)c(Oc7cnc8[nH]ccc8c7)c4,,lymphoma,Phase 1,,,NCT02877550,Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients,,https://ClinicalTrials.gov/show/NCT02877550
clinicaltrials.gov,Quizartinib,,,,,,venetoclax,1150189,P10415,"InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)",LQBVNQSMGBZMKD-UHFFFAOYSA-N,CC1(C)CCC(=C(C1)c2ccc(Cl)cc2)CN3CCN(CC3)c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c(c5)N(=O)=O)c(Oc7cnc8[nH]ccc8c7)c4,,leukemia,Phase 1/2,,,NCT03735875,Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia,,https://ClinicalTrials.gov/show/NCT03735875
clinicaltrials.gov,Quizartinib,,,,,,venetoclax,1150189,P10415,"InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)",LQBVNQSMGBZMKD-UHFFFAOYSA-N,CC1(C)CCC(=C(C1)c2ccc(Cl)cc2)CN3CCN(CC3)c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c(c5)N(=O)=O)c(Oc7cnc8[nH]ccc8c7)c4,,leukemia,Phase 1/2,,,NCT03735875,Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia,,https://ClinicalTrials.gov/show/NCT03735875
clinicaltrials.gov,ruxolitinib,974392,O00238;O00444;O00506;O14730;O14920;O14936;O14976;O15075;O15197;O43293;O43318;O60674;O75116;O75385;O75460;O75582;O75676;O75716;O94768;O95747;O96013;P00519;P04629;P07949;P0C264;P10721;P15056;P15735;P19784;P23458;P29320;P29376;P29597;P32298;P33981;P36507;P45983;P45985;P46734;P48729;P49760;P50613;P51617;P51956;P52333;P53350;P53355;P57078;P68400;Q02156;Q02750;Q07912;Q09013;Q12851;Q13233;Q13237;Q13464;Q13554;Q13555;Q13557;Q13627;Q13873;Q14012;Q14164;Q14680;Q15349;Q15418;Q15746;Q15835;Q16288;Q16620;Q16816;Q2M2I8;Q52WX2;Q56UN5;Q5S007;Q6PHR2;Q6ZN16;Q7KZI7;Q7L7X3;Q86Y07;Q86Z02;Q8IU85;Q8IYT8;Q8N568;Q8NFD2;Q8TDX7;Q8WTQ7;Q92630;Q96NX5;Q96SB4;Q99759;Q9BRS2;Q9BVS4;Q9C098;Q9H093;Q9H2K8;Q9H2X6;Q9H422;Q9H4B4;Q9HAZ1;Q9HBH9;Q9NQU5;Q9NSY1;Q9NYY3;Q9P286;Q9P289;Q9UBF8;Q9UEE5;Q9UEW8;Q9UHD2;Q9UIK4;Q9UK32;Q9UL54;Q9UM73;Q9UPE1;Q9UQB9;Q9UQM7;Q9Y2H9;Q9Y2K2;Q9Y2U5,"InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1",HFNKQEVNSGCOJV-OAHLLOKOSA-N,N#CC[C@H](C1CCCC1)n2cc(cn2)c3ncnc4[nH]ccc34,venetoclax,1150189,P10415,"InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)",LQBVNQSMGBZMKD-UHFFFAOYSA-N,CC1(C)CCC(=C(C1)c2ccc(Cl)cc2)CN3CCN(CC3)c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c(c5)N(=O)=O)c(Oc7cnc8[nH]ccc8c7)c4,"Acute Myeloid Leukemia|Acute Myeloid Leukemia, in Relapse",,Phase 1,,,NCT03874052,,,
clinicaltrials.gov,TAK-659,,P43405,,,,venetoclax,1150189,P10415,"InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)",LQBVNQSMGBZMKD-UHFFFAOYSA-N,CC1(C)CCC(=C(C1)c2ccc(Cl)cc2)CN3CCN(CC3)c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c(c5)N(=O)=O)c(Oc7cnc8[nH]ccc8c7)c4,,lymphoma,Phase 1,,,NCT03357627,A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma,,https://ClinicalTrials.gov/show/NCT03357627
clinicaltrials.gov,Vyxeos,,,,,,venetoclax,1150189,P10415,"InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)",LQBVNQSMGBZMKD-UHFFFAOYSA-N,CC1(C)CCC(=C(C1)c2ccc(Cl)cc2)CN3CCN(CC3)c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c(c5)N(=O)=O)c(Oc7cnc8[nH]ccc8c7)c4,Leukemia,leukemia,Phase 1,,,NCT03826992,,,
clinicaltrials.gov,hydroxyurea,185,P31350,"InChI=1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)",VSNHCAURESNICA-UHFFFAOYSA-N,NC(=O)NO,verapamil,1761,Q13936;Q01668;Q13698;O60840,,,,,brain cancers,Phase 2,,,NCT00706810,Combination of Hydroxyurea and Verapamil for Refractory Meningiomas,,https://ClinicalTrials.gov/show/NCT00706810
clinicaltrials.gov,durvalumab,,Q9NZQ7,,,,vicinium,,P16422,,,,,bladder cancers,Phase 1,,,NCT03258593,Durvalumab and Vicinium in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG),,https://ClinicalTrials.gov/show/NCT03258593
clinicaltrials.gov,acalabrutinib,2014063,,"InChI=1S/C26H23N7O2/c1-2-6-21(34)32-15-5-7-19(32)25-31-22(23-24(27)29-14-16-33(23)25)17-9-11-18(12-10-17)26(35)30-20-8-3-4-13-28-20/h3-4,8-14,16,19H,5,7,15H2,1H3,(H2,27,29)(H,28,30,35)/t19-/m0/s1",WDENQIQQYWYTPO-IBGZPJMESA-N,CC#CC(=O)N1CCC[C@H]1c2nc(c3ccc(cc3)C(=O)Nc4ccccn4)c5c(N)nccn25,vistusertib,1095122,,"InChI=1S/C25H30N6O3/c1-16-14-33-11-9-30(16)23-20-7-8-21(18-5-4-6-19(13-18)24(32)26-3)27-22(20)28-25(29-23)31-10-12-34-15-17(31)2/h4-8,13,16-17H,9-12,14-15H2,1-3H3,(H,26,32)/t16-,17-/m0/s1",JUSFANSTBFGBAF-IRXDYDNUSA-N,CNC(=O)c1cccc(c1)c2ccc3c(nc(nc3n2)N4CCOC[C@@H]4C)N5CCOC[C@@H]5C,,lymphoma,Phase 1/2,,,NCT03205046,A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies,,https://ClinicalTrials.gov/show/NCT03205046
clinicaltrials.gov,selumetinib,646570,Q02750;P36507,"InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26)",CYOHGALHFOKKQC-UHFFFAOYSA-N,Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO,vistusertib,1095122,,"InChI=1S/C25H30N6O3/c1-16-14-33-11-9-30(16)23-20-7-8-21(18-5-4-6-19(13-18)24(32)26-3)27-22(20)28-25(29-23)31-10-12-34-15-17(31)2/h4-8,13,16-17H,9-12,14-15H2,1-3H3,(H,26,32)/t16-,17-/m0/s1",JUSFANSTBFGBAF-IRXDYDNUSA-N,CNC(=O)c1cccc(c1)c2ccc3c(nc(nc3n2)N4CCOC[C@@H]4C)N5CCOC[C@@H]5C,,other,Phase 2,,,NCT03433183,SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the Dual mTOR Kinase Inhibitor Vistusertib (AZD2014) for Patients With Malignant Peripheral Nerve Sheath Tumors,,https://ClinicalTrials.gov/show/NCT03433183
clinicaltrials.gov,bortezomib,303268,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m0/s1",GXJABQQUPOEUTA-RDJZCZTQSA-N,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c2cnccn2)B(O)O,vorinostat,260,O15379;O75376;P56524;Q13547;Q8WUI4;Q92769;Q969S8;Q96DB2;Q9BY41;Q9UBN7;Q9UKV0;Q9UQL6;Q9Y618,"InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)",WAEXFXRVDQXREF-UHFFFAOYSA-N,ONC(=O)CCCCCCC(=O)Nc1ccccc1,,advanced solid cancers,Phase 1,,,NCT00227513,Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors,,https://ClinicalTrials.gov/show/NCT00227513
clinicaltrials.gov,ixazomib,1069383,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436;Q99460;O00487;Q16186;P35998;P62191;P43686;P62333;P17980;P62195;Q13200;O43242;O00232;O00231;Q15008;P51665;Q9UNM6;P55036;P48556;P60896,"InChI=1S/C14H19BCl2N2O4/c1-8(2)5-12(15(22)23)19-13(20)7-18-14(21)10-6-9(16)3-4-11(10)17/h3-4,6,8,12,22-23H,5,7H2,1-2H3,(H,18,21)(H,19,20)/t12-/m0/s1",MXAYKZJJDUDWDS-LBPRGKRZSA-N,CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,vorinostat,260,O15379;O75376;P56524;Q13547;Q8WUI4;Q92769;Q969S8;Q96DB2;Q9BY41;Q9UBN7;Q9UKV0;Q9UQL6;Q9Y618,"InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)",WAEXFXRVDQXREF-UHFFFAOYSA-N,ONC(=O)CCCCCCC(=O)Nc1ccccc1,,,Phase 1,,,NCT02042989,MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies,,https://ClinicalTrials.gov/show/NCT02042989
literature,marizomib,263086,P49721;P20618;P28074;P28062;P28065;P28072;P25786;P25787;P25788;P25789;P28066;P60900;O14818;Q8TAA3;P40306;A5LHX3;P49720;P28070;Q99436,"InChI=1S/C15H20ClNO4/c1-14-10(7-8-16)12(19)17-15(14,13(20)21-14)11(18)9-5-3-2-4-6-9/h3,5,9-11,18H,2,4,6-8H2,1H3,(H,17,19)/t9-,10+,11+,14+,15+/m1/s1",NGWSFRIPKNWYAO-SHTIJGAHSA-N,C[C@@]12OC(=O)[C@@]1(NC(=O)[C@@H]2CCCl)[C@@H](O)[C@H]3CCCC=C3,vorinostat,260,O15379;O75376;P56524;Q13547;Q8WUI4;Q92769;Q969S8;Q96DB2;Q9BY41;Q9UBN7;Q9UKV0;Q9UQL6;Q9Y618,"InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)",WAEXFXRVDQXREF-UHFFFAOYSA-N,ONC(=O)CCCCCCC(=O)Nc1ccccc1,"melanoma, pancreatic and lung cancer",skin cancers;male cancers;lung cancers,Phase 1,22080430,"Marked synergy of marizomib and vorinostat was seen in tumor cell lines derived from patients with NSCLC, melanoma and pancreatic carcinoma. In the clinical trial, 22 patients were enrolled. Increased toxicity was not seen with the combination. Co-administration did not appear to affect the PK or PD of either drug in comparison to historical data. Although no responses were demonstrated using RECIST criteria, 61% of evaluable patients demonstrated stable disease with 39% having decreases in tumor measurements.",,,,
clinicaltrials.gov,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,vorinostat,260,O15379;O75376;P56524;Q13547;Q8WUI4;Q92769;Q969S8;Q96DB2;Q9BY41;Q9UBN7;Q9UKV0;Q9UQL6;Q9Y618,"InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)",WAEXFXRVDQXREF-UHFFFAOYSA-N,ONC(=O)CCCCCCC(=O)Nc1ccccc1,,breast cancers,Phase 1,,,NCT03742245,Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer,,https://ClinicalTrials.gov/show/NCT03742245
clinicaltrials.gov,olaparib,26590,O95271;P09874;Q9UGN5,"InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)",FDLYAMZZIXQODN-UHFFFAOYSA-N,Fc1ccc(CC2=NNC(=O)c3ccccc23)cc1C(=O)N4CCN(CC4)C(=O)C5CC5,vorinostat,260,O15379;O75376;P56524;Q13547;Q8WUI4;Q92769;Q969S8;Q96DB2;Q9BY41;Q9UBN7;Q9UKV0;Q9UQL6;Q9Y618,"InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)",WAEXFXRVDQXREF-UHFFFAOYSA-N,ONC(=O)CCCCCCC(=O)Nc1ccccc1,,breast cancers,Phase 1,,,NCT03742245,Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer,,https://ClinicalTrials.gov/show/NCT03742245
clinicaltrials.gov,pazopanib,200268,O00238;O00444;O14965;O14976;O15197;O43353;O60331;O60674;O75716;O94804;O95819;P00519;P04049;P06239;P06241;P07332;P07333;P07947;P07948;P07949;P08581;P08631;P08922;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P16591;P17948;P19525;P21127;P21802;P22455;P22607;P27448;P29376;P29597;P33981;P35590;P35916;P35968;P36888;P37173;P42681;P42684;P42685;P43405;P45983;P45985;P51451;P51617;P51955;P52333;P52564;P53667;P53671;P53779;P57059;P80192;Q00536;Q02763;Q02779;Q08345;Q12851;Q12866;Q13163;Q13233;Q13470;Q13546;Q13705;Q13882;Q14012;Q16584;Q16832;Q2M2I8;Q56UN5;Q6P3R8;Q7L7X3;Q8IVH8;Q8TBX8;Q92918;Q96NX5;Q9BVS4;Q9H0K1;Q9H1R3;Q9H2G2;Q9H2K8;Q9H3Y6;Q9NRP7;Q9NSY1;Q9UBE8;Q9UBF8;Q9UKE5;Q9UL54;Q9UM73;Q9UQ88;Q9UQB9;Q9Y2U5;Q9Y4K4;Q9Y616,"InChI=1S/C21H23N7O2S/c1-13-5-6-15(11-19(13)31(22,29)30)24-21-23-10-9-20(25-21)27(3)16-7-8-17-14(2)28(4)26-18(17)12-16/h5-12H,1-4H3,(H2,22,29,30)(H,23,24,25)",CUIHSIWYWATEQL-UHFFFAOYSA-N,CN(c1ccc2c(C)n(C)nc2c1)c3ccnc(Nc4ccc(C)c(c4)S(=O)(=O)N)n3,vorinostat,260,O15379;O75376;P56524;Q13547;Q8WUI4;Q92769;Q969S8;Q96DB2;Q9BY41;Q9UBN7;Q9UKV0;Q9UQL6;Q9Y618,"InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)",WAEXFXRVDQXREF-UHFFFAOYSA-N,ONC(=O)CCCCCCC(=O)Nc1ccccc1,,,Phase 1,,,NCT01339871,Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies,,https://ClinicalTrials.gov/show/NCT01339871
clinicaltrials.gov,pembrolizumab,,Q15116,,,,vorinostat,260,O15379;O75376;P56524;Q13547;Q8WUI4;Q92769;Q969S8;Q96DB2;Q9BY41;Q9UBN7;Q9UKV0;Q9UQL6;Q9Y618,"InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)",WAEXFXRVDQXREF-UHFFFAOYSA-N,ONC(=O)CCCCCCC(=O)Nc1ccccc1,,kidney cancers;bladder cancers,Phase 1,,,NCT02619253,Phase I/Ib Study of pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma,,https://ClinicalTrials.gov/show/NCT02619253
literature,ridaforolimus,1020194,P42345,"InChI=1S/C53H84NO14P/c1-32-18-14-13-15-19-33(2)44(63-8)30-40-23-21-38(7)53(61,67-40)50(58)51(59)54-25-17-16-20-41(54)52(60)66-45(35(4)28-39-22-24-43(46(29-39)64-9)68-69(11,12)62)31-42(55)34(3)27-37(6)48(57)49(65-10)47(56)36(5)26-32/h13-15,18-19,27,32,34-36,38-41,43-46,48-49,57,61H,16-17,20-26,28-31H2,1-12H3/b15-13+,18-14+,33-19+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1",BUROJSBIWGDYCN-GAUTUEMISA-N,CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(/C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(/C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N4CCCC[C@H]4C(=O)O2)OC)CC[C@H]1OP(=O)(C)C,vorinostat,260,O15379;O75376;P56524;Q13547;Q8WUI4;Q92769;Q969S8;Q96DB2;Q9BY41;Q9UBN7;Q9UKV0;Q9UQL6;Q9Y618,"InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)",WAEXFXRVDQXREF-UHFFFAOYSA-N,ONC(=O)CCCCCCC(=O)Nc1ccccc1,advanced renal cell carcinoma and other solid tumors,kidney cancers;advanced solid cancers,Phase 1,26091915,"Fifteen patients were treated at one of three dose levels, thirteen with RCC (10 clear cell, 3 papillary). Dosing was limited by thrombocytopenia. The MTD was determined to be ridaforolimus 20 mg daily days 1-5 with vorinostat 100 mg BID days 1-3 weekly, however late onset thrombocytopenia led to a lower recommended phase II dose: ridaforolimus 20 mg daily days 1-5 with vorinostat 100 mg daily days 1-3 weekly. Two patients, both with papillary RCC, maintained disease control for 54 and 80 weeks, respectively.",,,,
clinicaltrials.gov,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,vorinostat,260,O15379;O75376;P56524;Q13547;Q8WUI4;Q92769;Q969S8;Q96DB2;Q9BY41;Q9UBN7;Q9UKV0;Q9UQL6;Q9Y618,"InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)",WAEXFXRVDQXREF-UHFFFAOYSA-N,ONC(=O)CCCCCCC(=O)Nc1ccccc1,,kidney cancers;lung cancers,Phase 1,,,NCT00635791,Phase I Study of Vorinostat and Sorafenib in Advanced Cancer,,https://ClinicalTrials.gov/show/NCT00635791
clinicaltrials.gov,sorafenib,1857,O00444;O14578;O14965;O15146;O15197;O15264;O43318;O43353;O94804;O94921;O95819;P00519;P04049;P04629;P06213;P06239;P06241;P07333;P07948;P07949;P08631;P08908;P09619;P09769;P10721;P11362;P12931;P15056;P16234;P17948;P21709;P21802;P22607;P24941;P28223;P28335;P29317;P29320;P29322;P29323;P30530;P33981;P34913;P34969;P35590;P35916;P35968;P36888;P37173;P41240;P41595;P42684;P42685;P45984;P47898;P48729;P49336;P49759;P50406;P50613;P52333;P53667;P53671;P53778;P54756;P54760;P54762;P54764;Q00526;Q00535;Q00537;Q02750;Q02763;Q08345;Q12866;Q13163;Q13470;Q15375;Q15759;Q16288;Q16539;Q16620;Q16832;Q32MK0;Q56UN5;Q59H18;Q7L7X3;Q86Z02;Q8IVW4;Q8NE63;Q8TD08;Q8WXR4;Q92772;Q92918;Q96GD4;Q96Q40;Q9BUB5;Q9BWU1;Q9BYT3;Q9H1R3;Q9H2G2;Q9H2K8;Q9H2X6;Q9H3Y6;Q9H422;Q9HBH9;Q9NRP7;Q9NYL2;Q9UBE8;Q9UF33;Q9UK32;Q9UKE5;Q9UL54;Q9UQB9;Q9Y4K4,"InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)",MLDQJTXFUGDVEO-UHFFFAOYSA-N,CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1,vorinostat,260,O15379;O75376;P56524;Q13547;Q8WUI4;Q92769;Q969S8;Q96DB2;Q9BY41;Q9UBN7;Q9UKV0;Q9UQL6;Q9Y618,"InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)",WAEXFXRVDQXREF-UHFFFAOYSA-N,ONC(=O)CCCCCCC(=O)Nc1ccccc1,,liver cancers,Phase 1,,,NCT01075113,Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer,,https://ClinicalTrials.gov/show/NCT01075113
clinicaltrials.gov,RO5126766,,,,,,VS-6063,,,,,,NSCLC|Solid Tumor,,Phase 1,,,NCT03875820,,,
clinicaltrials.gov,WX-037,,Q92569;Q8WYR1;P48736;P42338;P42336;P27986;O00459;O00329,,,,WX-554,,Q02750;P36507,,,,,advanced solid cancers,Phase 1,,,NCT01859351,Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours,,https://ClinicalTrials.gov/show/NCT01859351
clinicaltrials.gov,Xgeva,,,,,,Xtandi,,,,,,Castration-resistant Prostate Cancer|Metastatic Cancer|Bone Metastases,,Phase 2,,,NCT03869762,,,